<SEC-DOCUMENT>0001628280-24-047102.txt : 20241112
<SEC-HEADER>0001628280-24-047102.hdr.sgml : 20241112
<ACCEPTANCE-DATETIME>20241112160233
ACCESSION NUMBER:		0001628280-24-047102
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241112
DATE AS OF CHANGE:		20241112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		241447827

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94084
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94084

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sgmo-20240930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:71d79187-a2e4-4f72-bd61-283a5977d997,g:6e5f68a8-3875-4e0a-8723-d2906a1af0a5,d:2ce39f749ac4424b8fd01e23f7902cf4-->
<html xmlns:sgmo="http://www.sangamo.com/20240930" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sgmo-20240930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-25">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-26">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-27">Q3</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-28">0001001233</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-29">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-243" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="f-745">5.5</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sgmo-20240930.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="performance_obligation"><xbrli:measure>sgmo:performance_obligation</xbrli:measure></xbrli:unit><xbrli:unit id="milestone"><xbrli:measure>sgmo:milestone</xbrli:measure></xbrli:unit><xbrli:unit id="product"><xbrli:measure>sgmo:product</xbrli:measure></xbrli:unit><xbrli:unit id="employee"><xbrli:measure>sgmo:employee</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInAgreementEstimateMarch2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInAgreementEstimateSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInAgreementEstimateSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:LicenseTechnologyTransferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherCollaborationAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherCollaborationAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherCollaborationAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherCollaborationAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:EquipmentFurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:LeaseholdImprovementsAndConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-05</xbrli:startDate><xbrli:endDate>2024-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-05</xbrli:startDate><xbrli:endDate>2024-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-26</xbrli:startDate><xbrli:endDate>2024-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-26</xbrli:startDate><xbrli:endDate>2024-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:CommonWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:CommonWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-21</xbrli:startDate><xbrli:endDate>2024-03-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-21</xbrli:startDate><xbrli:endDate>2024-03-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-08</xbrli:startDate><xbrli:endDate>2024-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-26</xbrli:startDate><xbrli:endDate>2023-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sgmo:FullTimeEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sgmo:ContractedEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_1"></div><div style="min-height:36pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.527%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="15" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">September 30, 2024</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.262%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-30171</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">SANGAMO THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:30.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">68-0359556</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">501 Canal Blvd.</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Richmond</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">California</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">94804</ix:nonNumeric></span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices) (Zip Code)</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">510</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">970-6000</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.722%"><tr><td style="width:1.0%"/><td style="width:38.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">SGMO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:2pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.722%"><tr><td style="width:1.0%"/><td style="width:21.773%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-21">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#9744;</span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;&#9744;&#160;&#160;&#160;&#160;&#160;No&#160;&#160; <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9746;</ix:nonNumeric></span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of November&#160;7, 2024, <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">208,646,870</ix:nonFraction> shares of the issuer&#8217;s common stock, par value $0.01 per share, were outstanding.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.527%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="15" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"/><td style="width:13.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.180%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i2ce39f749ac4424b8fd01e23f7902cf4_16">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_19">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_19">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_22">Condensed Consolidated Balance Sheets at </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_22">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_22"> 30, 2024 and December 31, 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_25">Condensed Consolidated Statements of Operations for the Three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_25">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_25"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_25">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_25"> 30, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_28">Condensed Consolidated Statements of Comprehensive</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_28"> Income (</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_28">L</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_28">oss</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_28">)</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_28"> for the Three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_28">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_28"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_28">Se</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_28">ptember</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_28"> 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_28">, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_31">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_31">Ni</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_31">ne</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_31"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_31">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_31"> 30, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_34">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_34">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_34"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_34">September </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_34">30, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_34">11</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_37">12</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_94">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_94">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_94">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_115">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_115">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_115">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_118">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_118">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_118">41</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i2ce39f749ac4424b8fd01e23f7902cf4_121">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_124">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_124">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_124">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_127">Item&#160;1A</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_127">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_127">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_130">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_130">Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_130">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_133">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_133">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_133">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_136">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_136">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_136">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_139">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_139">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_139">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_142">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_142">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_142">48</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i2ce39f749ac4424b8fd01e23f7902cf4_145">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_145">49</a></span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated or the context suggests otherwise, references in this Quarterly Report on Form 10-Q, or Quarterly Report, to &#8220;Sangamo,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Sangamo Therapeutics, Inc. and our subsidiaries, including Sangamo Therapeutics France S.A.S. and Sangamo Therapeutics UK Ltd.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any third-party trade names, trademarks and service marks appearing in this Quarterly Report are the property of their respective holders. Solely for convenience, trademarks and trade names referred to in this Quarterly Report may appear without the &#174; or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">symbols, but such references are not intended to indicate in any way that the Company will not assert, to the fullest extent under applicable law, its rights or the rights of the applicable licensor to these trademarks and trade names. The Company does not intend its use or display of other entities&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of the Company by, any other entity.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some statements contained in this report are &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements relate to our future events, including our anticipated operations, research, development, manufacturing and commercialization activities, clinical trials, operating results and financial condition. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding the sufficiency of our cash resources and our expenses, capital requirements and need for substantial additional financing, and our ability to obtain additional financing, including the impact of business development and clinical advancements on our cash runway;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to continue to operate as a going concern, including our estimate that our available cash and cash equivalents as of September&#160;30, 2024 will not be sufficient to fund our planned operations for one year from the issuance date of the Condensed Consolidated Financial Statements included in Part I, Item 1, &#8220;Financial Statements and Supplementary Data&#8221; of this Quarterly Report on Form&#160;10-Q;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our projected operating and financial performance;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans for advancing our development programs and the plans of our collaboration partners for advancing our partnered programs, and the expected charges and cost savings associated with our restructurings and facility closures;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated research and development of product candidates and potential commercialization of any resulting approved products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, scope, rate of progress, enrollment, dosing, anticipated results and timing of our preclinical studies and clinical trials and those of our collaborators or strategic partners;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the therapeutic and commercial potential of our product candidates, including the durability of therapeutic effects;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the therapeutic and commercial potential of technologies used by us in our product candidates, including our gene therapy and gene editing technologies, zinc finger, or ZF, technology platform, and zinc finger transcriptional regulators, or ZF-transcriptional regulators, which include zinc finger repressors, or ZFRs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to realize the expected benefits of the global epigenetic regulation and capsid delivery license agreement with Genentech, a member of the Roche group, the potential for Genentech to complete clinical development, regulatory interactions, manufacturing and global commercialization of any resulting products, and the potential for us to receive milestone payments and royalties from Genentech;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated investigational new drug, or IND, and clinical trial application, or CTA, submissions and potential acceptance thereof by the U.S. Food and Drug Administration, or FDA and regulatory authorities outside the United States;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential for isaralgagene civaparvovec to qualify for the FDA&#8217;s Accelerated Approval program, including the adequacy of data generated in the Phase 1/2 STAAR study to support any such approval; expectations concerning the availability of additional data to support a potential Biologics License Application, or BLA, submission for isaralgagene civaparvovec and the timing of such submission;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations and strategic partnerships and realize the expected benefits of such arrangements, including our ability to find a collaboration partner for our Fabry disease program and to engage in additional transactions with respect to our STAC-BBB capsid delivery program and epigenetic regulation capabilities, and Pfizer&#8217;s continued advancements of the giroctocogene fitelparvovec program, including the potential for Pfizer to complete clinical development, regulatory interactions, manufacturing and global commercialization of any resulting products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated revenues from existing and new collaborations and the timing thereof;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our and our collaborators&#8217; anticipated plans and timelines in conducting our ongoing and potential future clinical trials and presenting clinical data from such clinical trials, and the anticipated advancement of our product candidates to late-stage development;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding the impact of the macroeconomic environment on our business and operations and the business and operations of our collaborators, including preclinical studies, clinical trials and manufacturing, and our ability to manage such impacts;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our research and development and other expenses;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain adequate preclinical and clinical supplies of our product candidates from current and potential new suppliers and manufacturers;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability, and the ability of our collaborators and strategic partners to obtain and maintain regulatory approvals for product candidates and the timing and costs associated with obtaining regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with, and the impact of, regulatory requirements, obligations and restrictions on our business and operations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, including our ability to obtain and maintain rights to the technologies required to develop and commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive developments, including the impact on our competitive position of rival products and product candidates and our ability to meet such competition;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our operational and legal risks; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans, objectives, expectations and intentions and any other statements that are not historical facts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by use of future dates or by terms such as: &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;continues,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;will&#8221; and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, without limitation:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There is substantial doubt about our ability to continue to operate as a going concern. We need substantial additional funding to execute our operating plan and to continue to operate as a going concern. If adequate funds are not available to us on a timely basis, or at all, we will be required to take additional actions to address our liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering our research and development activities, which would have a material adverse effect on our business and prospects, or we may be required to cease operations entirely, liquidate all or a portion of our assets, and/or seek protection under the U.S. Bankruptcy Code, and you may lose all or part of your investment. Future sales and issuances of equity securities would also result in substantial dilution to our stockholders.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a biotechnology company with no approved products or product revenues. Our success depends substantially on results of preclinical studies and clinical trials demonstrating safety and efficacy of our product candidates to the satisfaction of applicable regulatory authorities. Obtaining positive clinical trial results and regulatory approvals is expensive, lengthy, challenging and unpredictable and may never occur for any product candidates.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are early in our research and development efforts for our core preclinical neurology programs that are the current focus of our business. We may encounter difficulties in advancing product candidates from research programs to preclinical and clinical development.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Success in research and preclinical studies or early clinical trial results may not be indicative of results obtained in later trials. Likewise, preliminary, initial or interim data from clinical trials may be materially different from final data.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Many of our product candidates are based on novel ZF technologies that have yet to yield any approved commercially viable therapeutic products.  </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have historically incurred significant operating losses since inception and anticipate continued losses for the foreseeable future. We may never become profitable. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biotechnology and genomic medicine are highly competitive businesses. Our competitors may develop rival technologies and products that are superior to or are commercialized more quickly than our technologies and product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacturing genomic medicines is complex, expensive, highly regulated and risky. We are currently substantially reliant on third&#8209;party manufacturers. Manufacturing challenges may result in unexpected costs, supply interruptions and harm and delay to our product development efforts.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we obtain regulatory approvals for our product candidates, our approved products may not gain market acceptance among physicians and patients and adequate coverage and reimbursement from third-party payors and may not demonstrate commercial viability.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to obtain, maintain and enforce necessary and desirable intellectual property protections for our technologies and product candidates in all desired jurisdictions, which could adversely affect the value of our technologies and our product development efforts and could increase the risks of costly, lengthy and distracting litigation with unpredictable results.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third parties, who may or may not be competitors, may allege that we are infringing, misappropriating, or otherwise practicing in an unauthorized manner their patents or other proprietary rights. Such allegations may result in infringement actions, other misappropriation actions or threats of such actions, all of which could increase the risks of costly, lengthy and distracting litigation with unpredictable results.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our recent restructurings may not result in anticipated savings or operational efficiencies and could result in total costs and expenses that are greater than expected.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends on hiring, integrating and retaining additional highly qualified skilled employees and retaining current key executives and employees, which may be challenging given the uncertainty regarding our ability to obtain sufficient additional funding and to continue to operate as a going concern as well as the competition among numerous biopharmaceutical companies and academic institutions for individuals with these skills. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable global economic conditions could have a negative impact on our operations, which could materially and adversely affect our ability to continue to operate as a going concern and otherwise have a material adverse effect on our business, financial condition, results of operations, prospects and market price of our common stock.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market price of our common stock has been and will likely continue to be volatile, and you could lose all or part of any investment in our common stock.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have fully impaired our goodwill and indefinite-lived intangible assets, have recorded significant impairment of our right-of-use and other long-lived assets, and may be required to record significant additional charges if our long-lived assets become further impaired in the future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional discussion of the risks, uncertainties and other factors described above, as well as other risks and uncertainties material to our business, can be found under &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023 as filed with the Securities and Exchange Commission on March 13, 2024, as supplemented by the risks described under &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q, and we encourage you to refer to that additional discussion. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our plans, objectives, estimates, expectations and intentions only as of the date of this filing. You should read this report completely and with the understanding that our actual future results and the timing of events may be materially different from what we expect, and we cannot otherwise guarantee that any forward-looking statement will be realized. We hereby qualify all of our forward-looking statements by these cautionary statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as required by law, we undertake no obligation to update or supplement any forward-looking statements publicly, or to update or supplement the reasons that actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. You are advised, however, to consult any further disclosures we make on related subjects. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes discussion of certain clinical studies and trials relating to various product candidates. These studies typically are part of a larger body of clinical data relating to such product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical data are subject to differing interpretations, and even if we view data as sufficient to support the safety and/or effectiveness of a product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_19"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS</span></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_22"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:74.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-30">39,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">45,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="f-32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-33">35,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">10,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="f-35">923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">8,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">12,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">58,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">94,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-40">19,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-41">26,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-42">17,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-43">25,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refundable research income tax credits and other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="sgmo:IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-44">14,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="sgmo:IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-45">16,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-48">111,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-49">165,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">19,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">15,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">10,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">8,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">11,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">23,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-56">774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">43,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">47,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">27,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">33,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">1,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">1,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-64">72,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-65">82,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-66"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-67"/></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-70">2,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-71">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-72">1,522,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-73">1,492,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-74">1,480,921</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-75">1,406,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-76">4,223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-77">4,595</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-78">39,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-79">82,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-80">111,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-81">165,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands, except per share amounts)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:50.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-82">49,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-83">9,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-84">50,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-85">174,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-86">27,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-87">57,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-88">87,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-89">183,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-90">11,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-91">13,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-92">34,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-93">48,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="3" id="f-94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="3" id="f-95">44,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="3" id="f-96">5,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="3" id="f-97">65,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill and indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="f-101">89,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-102">38,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-103">115,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-104">128,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-105">386,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-106">10,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-107">106,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-108">77,979</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-109">211,946</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestAndOtherIncome" scale="3" id="f-110">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-111">3,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-112">3,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-113">9,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-114">10,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-115">102,893</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-116">74,285</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-117">202,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-118">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-119">1,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-120">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-121">4,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-122">10,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-123">104,163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-124">74,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-125">197,536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income allocated to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:num-dot-decimal" scale="3" id="f-126">1,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="3" id="f-127">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="3" id="f-128">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="3" id="f-129">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-130">9,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-131">104,163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-132">74,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-133">197,536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-134">0.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-135">0.59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-136">0.37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-137">1.14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-138">0.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-139">0.59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-140">0.37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-141">1.14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-142">208,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-143">177,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-144">198,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-145">173,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-146">214,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-147">177,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-148">198,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-149">173,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-150">10,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-151">104,163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-152">74,545</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-153">197,536</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-154">1,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-155">1,144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-156">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-157">981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net pension (loss) gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-158">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-159">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-160">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-161">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="f-162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-163">494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-164">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-165">840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-166">12,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-167">104,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-168">74,173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-169">195,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.563%"><tr><td style="width:1.0%"/><td style="width:30.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.421%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at June 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-170">208,201,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-171">2,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-172">1,519,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-173">1,491,593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-174">5,883</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-175">23,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-176">418,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-177">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-178">207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-179">203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-180">3,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-181">3,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" format="ixt:num-dot-decimal" scale="3" id="f-182">1,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" format="ixt:num-dot-decimal" scale="3" id="f-183">1,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net pension loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-184">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-185">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-186">10,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-187">10,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at September 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-188">208,619,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-189">2,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-190">1,522,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-191">1,480,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-192">4,223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-193">39,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.706%"><tr><td style="width:1.0%"/><td style="width:30.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.405%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2024</span></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-194">178,133,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-195">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-196">1,492,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-197">1,406,376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-198">4,595</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-199">82,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-200">24,761,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-201">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-202">21,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-203">21,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of pre-funded warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-204">3,809,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-205">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-206">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-207">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-208">1,535,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-209">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-210">699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-211">684</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-212">379,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-213">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-214">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-215">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-216">9,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-217">9,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="f-218">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="f-219">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net pension gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-220">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-221">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net unrealized loss on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-222">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-223">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-224">74,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-225">74,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at September 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-226">208,619,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-227">2,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-228">1,522,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-229">1,480,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-230">4,223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-231">39,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands, except share amounts)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.563%"><tr><td style="width:1.0%"/><td style="width:30.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.421%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-232">177,074,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-233">1,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-234">1,479,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-235">1,241,918</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-236">5,936</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-237">233,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-238">205,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-239">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-240">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-241">101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-242">6,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-243">6,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" format="ixt:num-dot-decimal" scale="3" id="f-244">1,144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" format="ixt:num-dot-decimal" scale="3" id="f-245">1,144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net pension gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-246">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-247">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net unrealized gain on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-248">494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-249">494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-250">104,163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-251">104,163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-252">177,279,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-253">1,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-254">1,485,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-255">1,346,081</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-256">6,581</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-257">134,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.706%"><tr><td style="width:1.0%"/><td style="width:30.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.399%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.405%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-258">166,793,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-259">1,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-260">1,450,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-261">1,148,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-262">8,404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-263">294,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock in at-the-market offering, net of offering expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-264">8,249,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-265">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-266">15,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-267">15,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-268">1,481,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-269">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-270">1,419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-271">1,404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-272">755,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-273">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-274">712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-275">719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-276">21,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-277">21,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="f-278">981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="f-279">981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net pension gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-280">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-281">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net unrealized gain on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-282">840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-283">840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-284">197,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-285">197,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-286">177,279,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-287">1,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-288">1,485,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-289">1,346,081</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-290">6,581</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-291">134,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:74.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-292">74,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-293">197,536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="3" id="f-294">5,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="3" id="f-295">65,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-296">3,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-297">13,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of discount and impairment on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-298">273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-299">2,031</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization in operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-300">3,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-301">5,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-302">9,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-303">21,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-304">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-305">1,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill and indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="f-307">89,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-308">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-309">6,195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="3" id="f-310">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="3" id="f-311">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-312">9,573</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-313">2,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-314">6,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-315">5,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-316">6,851</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-317">5,220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-318">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-319">4,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-320">4,081</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-321">3,737</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-322">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-323">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-324">774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-325">159,671</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-326">63,788</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-327">174,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:fixed-zero" scale="3" id="f-328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-329">59,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-330">1,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-331">193,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-332">34,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="f-333">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of assets classified as held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="3" id="f-334">475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:fixed-zero" scale="3" id="f-335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-336">115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-337">18,484</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-338">36,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-339">115,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of offering expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="f-340">21,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:fixed-zero" scale="3" id="f-341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from at-the-market offering, net of offering expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-343">15,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-344">684</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-345">1,404</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-346">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-347">719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-348">21,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-349">14,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-350">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-351">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-352">6,003</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-353">43,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-354">46,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-355">101,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-356">40,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-357">58,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment included in unpaid liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-358">389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-359">2,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_40"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-360" continuedAt="f-360-1" escape="true">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-360-1" continuedAt="f-360-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or &#8220;the Company&#8221;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. The Company believes its zinc finger (&#8220;ZF&#8221;) epigenetic regulators are ideally suited to potentially address devastating neurology disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system (&#8220;CNS&#8221;), in preclinical studies.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, the Company announced its strategic transformation into a neurology-focused genomic medicine company focused on developing epigenetic regulation therapies designed to address serious neurological diseases and novel adeno-associated virus (&#8220;AAV&#8221;) capsid delivery technology. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-361" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three and nine months ended September&#160;30, 2024 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024. The Condensed Consolidated Balance Sheet data at December&#160;31, 2023 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2023 (the &#8220;2023 Annual Report&#8221;) as filed with the SEC on March 13,&#160;2024.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-362" escape="true">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements.</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2023, included in the 2023 Annual Report.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity, Going Concern, and Capital Resources</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects will require several years and substantial expenditures to complete and ultimately may be unsuccessful. In recent years, the Company&#8217;s operations have been funded primarily through collaborations and strategic partnerships, research grants and from the issuance of equity securities. As of September&#160;30, 2024, the Company had capital resources of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-363">39.2</ix:nonFraction>&#160;million consisting of cash and cash equivalents. On August 2, 2024, the Company entered into a global epigenetic regulation and capsid delivery license agreement (the &#8220;Genentech Agreement&#8221;) with Genentech, Inc., a member of the Roche Group (&#8220;Genentech&#8221;), under which the Company received a $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-364">40.0</ix:nonFraction>&#160;million upfront license fee in August 2024 and a $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-365">10.0</ix:nonFraction>&#160;million milestone payment in October 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Accounting Standard Codification (&#8220;ASC&#8221;) Topic 205-40, Presentation of Financial Statements&#8212;Going Concern (&#8220;ASC Topic 205-40&#8221;), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the Condensed Consolidated Financial Statements are issued. As required under ASC Topic 205-40, management&#8217;s evaluation should initially not take into consideration the potential mitigating effects of management&#8217;s plans that have not been fully implemented as of the date the Condensed Consolidated Financial Statements are issued. When substantial doubt exists, management evaluates whether the mitigating effects of its plans sufficiently alleviates the substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effects of management&#8217;s plans, however, are only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (ii) it is probable that the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><ix:continuation id="f-360-2" continuedAt="f-360-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans must have been approved by the Company&#8217;s board of directors before the date that the financial statements are issued.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s history of significant losses, its negative cash flows from operations, its limited liquidity resources currently on hand, and its dependence on additional financing to fund its operations after the current resources are exhausted raise substantial doubt about its ability to continue to operate as a going concern within one year after the date that the Condensed Consolidated Financial Statements are issued. Based on the Company&#8217;s current operating plan, its cash and cash equivalents as of September&#160;30, 2024, together with the $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-366">10.0</ix:nonFraction>&#160;million milestone payment that the Company received from Genentech in October&#160;2024, is expected to allow the Company to meet its liquidity requirements only into the first quarter of 2025, which is less than one year following the date these Condensed Consolidated Financial Statements are issued. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company&#8217;s cost structure and operating plan. Management&#8217;s plans include, among other things, pursuing one or more of the following steps to raise additional capital, none of which can be guaranteed or are entirely within the Company&#8217;s control:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">raise funding through the sale of the Company&#8217;s common stock, including sales under the at-the-market offering program with Jefferies LLC;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">raise funding through debt or royalty financing; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish collaborations with potential partners to advance the Company&#8217;s product pipeline.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is unable to raise capital on acceptable terms, or at all, or if it is unable to procure collaboration arrangements or external direct investments to advance its programs, the Company would be required to discontinue some or all of its operations or develop and implement a plan to further extend payables, reduce overhead or scale back its current operating plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan would be successful. Additional capital may not be available to the Company on a timely basis, on terms that are acceptable or at all. In particular, the perception of the Company&#8217;s ability to continue to operate as a going concern may make it more difficult to obtain financing for the continuation of its operations, particularly in light of currently challenging macroeconomic and market conditions. Further, the Company may be unable to attract new investments as a result of the speculative nature of its newly reprioritized core neurology preclinical programs. If adequate funds are not available to the Company on a timely basis, or at all, the Company will be required to take additional actions to address its liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering its research and development activities, which would have a material adverse effect on its business and prospects, or the Company may be required to cease operations entirely, liquidate all or a portion of its assets, and/or seek protection under the U.S. Bankruptcy Code.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-367" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, useful lives and impairment of long-lived assets, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company recorded additional revenue related to a change in estimate in connection with the collaboration agreement with Kite Pharma, Inc., a Gilead Sciences, Inc. subsidiary (&#8220;Kite&#8221;). This adjustment was driven by a reduction in the estimated future level of the Company&#8217;s research and development services and as a result, future project costs. This resulted in an increase in proportional cumulative performance on this collaboration and an increase in revenue of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><ix:continuation id="f-360-3" continuedAt="f-360-4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="sgmo:IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-368">8.9</ix:nonFraction>&#160;million, a decrease in net loss of $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" sign="-" name="sgmo:IncreaseDecreaseInNetIncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="f-369">8.9</ix:nonFraction>&#160;million, and a decrease in the Company&#8217;s basic and diluted net loss per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="2" sign="-" name="sgmo:IncreaseDecreaseInEarningsPerShareDiluted" scale="0" id="f-370"><ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="2" sign="-" name="sgmo:IncreaseDecreaseInEarningsPerShareBasic" scale="0" id="f-371">0.05</ix:nonFraction></ix:nonFraction> for the nine months ended September 30, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Company recorded additional revenue related to a change in estimate in connection with the collaboration agreement with Kite. This adjustment was driven by a further reduction in the estimated future level of the Company&#8217;s research and development services and as a result, future project costs. This resulted in an increase in proportional cumulative performance on this collaboration and an increase in revenue by $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="sgmo:IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-372">4.9</ix:nonFraction>&#160;million, a decrease in net loss by $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" sign="-" name="sgmo:IncreaseDecreaseInNetIncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="f-373">4.9</ix:nonFraction>&#160;million, and a decrease in the Company&#8217;s basic and diluted net loss per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-55" decimals="2" sign="-" name="sgmo:IncreaseDecreaseInEarningsPerShareDiluted" scale="0" id="f-374"><ix:nonFraction unitRef="usdPerShare" contextRef="c-56" decimals="2" sign="-" name="sgmo:IncreaseDecreaseInEarningsPerShareDiluted" scale="0" id="f-375"><ix:nonFraction unitRef="usdPerShare" contextRef="c-56" decimals="2" sign="-" name="sgmo:IncreaseDecreaseInEarningsPerShareBasic" scale="0" id="f-376"><ix:nonFraction unitRef="usdPerShare" contextRef="c-55" decimals="2" sign="-" name="sgmo:IncreaseDecreaseInEarningsPerShareBasic" scale="0" id="f-377">0.03</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> for the three and nine months ended September 30, 2023.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-378" continuedAt="f-378-1" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research services. Research and license agreements typically include nonrefundable upfront signing or license fees, payments at negotiated rates for time incurred by Company researchers, third-party cost reimbursements, additional target selection fees, sublicense fees, milestone payments tied to ongoing development and product commercialization, and royalties on future licensees&#8217; product sales. All funds received from the Company&#8217;s collaboration partners are generally not refundable. Non-refundable upfront fees are fixed at the commencement of the contract. All other fees represent variable consideration in contracts. For contracts that contain a provision where the Company reimburses its customer for certain costs they incur and where the Company does not acquire any distinct goods or services in exchange for such payments, the Company accounts for it as a reduction to the contract transaction price. Deferred revenue primarily represents the portion of nonrefundable upfront fees or milestone payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s performance obligations in its collaboration agreements frequently represent distinct bundles of licenses of intellectual property and research and development services, with these components being individually non-distinct as the customer cannot benefit from the licenses independently from the research and development activities. In some instances, the Company has determined that the customer can benefit from the licensed intellectual property separately from the research and development activities, and the licenses of intellectual property and research and development services are individual distinct performance obligations. Options to license the Company&#8217;s intellectual property and/or acquire research and development services also represent performance obligations when they grant customers a material right, e.g. a right to a discount the customer would not have received if they did not purchase the Company&#8217;s services under the existing contract. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from grants of licenses to intellectual property that are distinct and therefore separate performance obligations are recognized at the point in time when the license is effective and the Company has completed the transfer of a copy of the licensed intellectual property to the customer. Revenues from distinct research and development services as well as from distinct bundles of licenses of intellectual property and research and development services, are recognized over time using a proportional performance method. Under this method, revenue is recognized by measuring progress towards satisfaction of the relevant performance obligation using a measure that best depicts the progress towards satisfaction of the relevant performance obligation. For most of the Company&#8217;s agreements the measure of progress is an input measure based on a level of effort incurred, which includes the value of actual time by Company researchers plus third-party cost reimbursements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration allocated to options that include material rights is deferred until the options are exercised or expire. The exercise of such options is accounted for as contract continuation, with target selection fees and estimated variable consideration included in the transaction price at that time and allocated specifically to the respective target&#8217;s performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. For variable consideration, the amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. A cumulative catch-up is then recorded in the current period to reflect the updated transaction price and the updated measure of progress. The estimated period </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><ix:continuation id="f-360-4" continuedAt="f-360-5"><ix:continuation id="f-378-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of performance and level of effort, including the value of Company researchers&#8217; time and third-party costs, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current expectations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, discount rates and probabilities of exercise of technical and regulatory success, and the expected level of effort for research and development services. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract modifications occur when the price and/or scope of an arrangement changes. If the modification consists of adding new distinct goods or services in exchange for consideration that reflects standalone selling prices of these goods and services, the modification is accounted for as a separate contract with the customer. Otherwise, if the remaining goods and services are distinct from those previously provided, the existing contract is considered terminated, and the remaining consideration is allocated to the remaining goods and services as if this was a newly signed contract. If the remaining goods and services are not distinct from those previously provided, the effects of the modification are accounted for in a manner similar to the effect of a change in the estimated measure of progress, with cumulative catch-up in revenue recorded at the time of the modification. If some of the remaining goods and services are distinct from those previously provided and others are not, to account for the effects of the modification the Company applies principles consistent with the objectives of the modification accounting.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" id="f-379" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from collaboration and license agreements as a percentage of total revenues were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.529%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genentech, Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-57" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-380">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-58" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="f-381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-59" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-382">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-60" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="f-383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-61" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="f-384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-62" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-385">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-63" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="f-386">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-64" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-387">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-65" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="f-388">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-66" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-389">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-67" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="f-390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-68" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-391">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-69" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="f-392">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-70" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="f-393">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-71" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="f-394">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-72" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-395">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other license agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-73" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="f-396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-74" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-397">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-75" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-398">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-76" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-399">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-400" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable. If a change in circumstance occurs that indicates long-lived assets may be impaired, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. The long-lived asset evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. The Company reassesses the composition of its asset groups whenever there are changes in its operations that affect whether the cash flows associated with assets included in asset groups are largely independent. If the impairment review indicates that the carrying amount of an asset group is not recoverable, an impairment loss is measured as the amount by which the carrying amount of an asset group exceeds its fair value. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, general macroeconomic conditions, conditions specific to the industry and market, an adverse change in legal factors, business climate or operational performance of the business, and sustained decline in the stock price and market capitalization compared to the net book value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calculating the fair value of a reporting unit, an asset group and an individual asset involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During a portion of the nine months ended September 30, 2023, the Company had goodwill and indefinite-lived intangible assets (IPR&amp;D). These assets were written off in full as the Company recognized impairment losses during the nine months ended September&#160;30,&#160;2023, see&#160;Note&#160;6&#160;&#8211;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment and Write-Down of Assets Held For Sale</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><ix:continuation id="f-360-5" continuedAt="f-360-6"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-401" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo considers all highly liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in money market accounts and U.S. government-sponsored entity debt securities. Restricted cash consisted of a letter of credit for $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="f-402">1.5</ix:nonFraction>&#160;million, representing a deposit for the lease of office and research and development laboratory facilities in Brisbane, California.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-404" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-403" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-405">39,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-406">45,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-407">56,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-408">100,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-409">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-410">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-411">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-412">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-413">40,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-414">46,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-415">58,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-416">101,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-417" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. Right-of-use assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases, calculated as the sum of the amortization of the right of use asset and accretion of the lease liability, is recognized on a straight-line basis over the lease term, unless the right of use asset was previously written down due to impairment. The Company evaluates the lease arrangement for impairment whenever events or changes in circumstances indicate that the carrying amounts of the right-of-use asset may not be fully recoverable. To the extent an impairment of the right-of-use asset is identified, the Company will recognize the impairment expense and subsequently amortize the remaining right of use asset into rent expense on a straight-line basis (unless another systematic basis is more representative of the pattern in which the Company expects to consume the future economic benefits from the asset) from the date of impairment to the earlier of the end of the right-of-use asset&#8217;s useful life or the end of the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there is a change to the terms and conditions of a contract that results in a change in the scope of or the consideration for a lease, the Company determines if the lease modification results in a separate contract or a change in the accounting for the existing lease and not a separate contract. For lease modifications that result in a separate contract, the Company accounts for the new contract in the same manner as other new leases. For lease modifications that do not result in a separate contract, the Company reassesses the classification of the lease at the effective date of the modification, remeasures and reallocates the remaining consideration in the contract, and remeasures the lease liability using the discount rate determined at the effective date of the modification.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected not to apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants to Purchase Shares of Company Stock </span></div><ix:nonNumeric contextRef="c-1" name="sgmo:WarrantOrRightPolicyPolicyTextBlock" id="f-418" continuedAt="f-418-1" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the accounting classification of warrants to purchase shares of its stock as either liability or equity by first assessing whether the warrants meet liability classification criteria in accordance with ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 480&#8221;). Under ASC 480, a financial instrument other than an outstanding share that embodies an obligation to repurchase the entity&#8217;s shares or is indexed to such an obligation, and that requires or may require the entity to settle it by transferring assets, is classified as a liability. In addition, a financial instrument that embodies an unconditional obligation, or </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><ix:continuation id="f-360-6"><ix:continuation id="f-418-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares must be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception, (b) variations in something other than the fair value of the issuer&#8217;s equity shares, or (c) variations inversely related to changes in the fair value of the issuer&#8217;s equity shares. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If financial instruments, such as warrants, are not required to be classified as liabilities under ASC 480, the Company assesses whether such instruments are indexed to the Company&#8217;s own stock under ASC 815-40. In order for an instrument to be considered indexed to an entity&#8217;s own stock, its settlement amount must always equal the difference between the following: (a)&#160;the fair value of a fixed number of the Company&#8217;s equity shares, and (b) a fixed monetary amount or a fixed amount of a debt instrument issued by the Company. Certain adjustments to this amount are allowed, if they are based on non-levered inputs into the fair value of a fixed price/fixed consideration-option.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants are also required to meet equity classification criteria to be classified in stockholders&#8217; equity. Under these criteria, warrants have to provide for settlement in shares, or cash or shares at the entity&#8217;s option. With limited exceptions, a possibility of net cash settlement under any circumstances will result in the warrants being classified as liabilities. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants classified as equity are generally measured using the Black-Scholes valuation model on the date of issuance. Warrants classified as liabilities are remeasured at any reporting date using valuation models consistent with their terms, with changes recognized in earnings.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" id="f-419" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records employee severance costs based on whether the termination benefits are provided under an on-going benefit arrangement or under a one-time benefit arrangement. The Company accounts for on-going termination benefit arrangements, such as those arising from employment agreements, applicable regulations or past practices, in accordance with ASC Topic 712, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Nonretirement Postemployment Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 712&#8221;). Under ASC 712, liabilities for post-employment benefits related to past services and that vest or are accumulated over time are recorded at the time the obligations are probable of being incurred and can be reasonably estimated. The Company accounts for one-time employment benefit arrangements in accordance with ASC Topic 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 420&#8221;). One-time termination benefits are expensed at the date the entity notifies the employee, unless the employee must provide future service over a period extending past the minimum notification period, in which case the benefits are expensed ratably over the future service period. Other associated costs are recognized in the period in which the liability is incurred.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred to terminate contracts are recognized upon their termination, e.g., when notice of termination is provided to the counterparty. Costs related to contracts without future benefit are recognized at the cease-use date. Other exit-related costs are recognized as incurred.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-420" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2023-07&#8221;), which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2023-09&#8221;), which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.</span></div></ix:nonNumeric></ix:continuation><div id="i2ce39f749ac4424b8fd01e23f7902cf4_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-421" continuedAt="f-421-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-422" continuedAt="f-422-1" escape="true"><ix:continuation id="f-421-1" continuedAt="f-421-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and marketable securities. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><ix:continuation id="f-421-2"><ix:continuation id="f-422-1"><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).</span></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="usd" contextRef="c-77" decimals="INF" name="us-gaap:AssetsFairValueDisclosure" format="ixt-sec:numwordsen" id="f-423">no</ix:nonFraction> cash equivalents or marketable securities as of September&#160;30, 2024. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="f-424" continuedAt="f-424-1" escape="true">The fair value measurements of the Company&#8217;s cash equivalents and marketable securities as of December&#160;31, 2023 are identified at the following levels within the fair value hierarchy (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-424-1"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-425">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-426">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-427">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-428">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-429">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-430">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-432">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-433">22,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="f-434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-435">22,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="f-436">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-437">2,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="f-438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-439">2,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="f-440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-441">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="f-442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-443">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="f-444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-445">2,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="f-446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-447">2,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="f-448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-449">5,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="f-450">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-451">5,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="f-452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-453">1,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="f-454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-455">1,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="f-456">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-457">35,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="f-458">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-459">35,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:fixed-zero" scale="3" id="f-460">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-461">38,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-462">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-463">35,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally classifies its marketable securities as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-465" continuedAt="f-465-1" escape="true">CASH EQUIVALENTS AND MARKETABLE SECURITIES</ix:nonNumeric></span></div><ix:continuation id="f-465-1"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent" format="ixt-sec:numwordsen" id="f-466">no</ix:nonFraction> cash equivalents or marketable securities as of September&#160;30, 2024. <ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesTextBlock" id="f-467" continuedAt="f-467-1" escape="true">The table below summarizes the Company&#8217;s cash equivalents and marketable securities as of December&#160;31, 2023 (in thousands):</ix:nonNumeric></span><ix:continuation id="f-467-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-468">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-471">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-472">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-475">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-476">22,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-477">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-479">22,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-480">2,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-481">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-482">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-483">2,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-484">1,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-485">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-486">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-487">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-488">2,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-489">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-490">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-491">2,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-492">5,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-493">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-494">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-495">5,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-496">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-497">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-498">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-499">1,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-500">35,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-501">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-502">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-503">35,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="f-504">38,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" scale="3" id="f-505">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" scale="3" id="f-506">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-507">38,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></ix:continuation></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="f-508" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.687%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-509">10,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="f-510">24,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" format="ixt:num-dot-decimal" scale="3" id="f-511">35,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="0" id="f-512"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="0" id="f-513">no</ix:nonFraction></ix:nonFraction>t material during the three and nine months ended September&#160;30, 2024. There were <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt-sec:numwordsen" id="f-514"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="INF" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt-sec:numwordsen" id="f-515">no</ix:nonFraction></ix:nonFraction> realized gains and losses on the sales of investments during the three and nine months ended September&#160;30, 2023. Total unrealized gains for securities with net gains in accumulated other comprehensive loss were not material during the three and nine months ended September&#160;30, 2024 and 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company did <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" format="ixt:fixed-zero" scale="0" id="f-516"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" format="ixt:fixed-zero" scale="0" id="f-517"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" format="ixt:fixed-zero" scale="0" id="f-518"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" format="ixt:fixed-zero" scale="0" id="f-519">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t record an allowance for credit losses related to its marketable securities for the three and nine months ended September&#160;30, 2024 and 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt-sec:numwordsen" id="f-520">no</ix:nonFraction> unrealized losses related to its marketable securities for the three and nine months ended September&#160;30, 2024. The Company had no material unrealized losses related to its marketable securities for the three and nine months ended September&#160;30, 2023. The Company had no material unrealized losses, individually and in the aggregate, for marketable securities that were in a continuous unrealized loss position for greater than 12 months as of September&#160;30, 2024 and December&#160;31, 2023. These unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews its marketable securities for indications of credit losses. No significant facts or circumstances had arisen to indicate that there had been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#8217;s review of these securities, the Company determined that <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="0" id="f-521"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="0" id="f-522">no</ix:nonFraction></ix:nonFraction> allowance for credit losses related to its marketable securities was required at either September&#160;30, 2024 or December&#160;31, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods the Company had investment in debt securities, the Company also considered whether it was more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis. No impairment charges were recorded during the three and nine months ended September&#160;30, 2024.</span></div></ix:continuation><div id="i2ce39f749ac4424b8fd01e23f7902cf4_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-523" continuedAt="f-523-1" escape="true">BASIC AND DILUTED NET INCOME (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="f-523-1" continuedAt="f-523-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share has been computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is calculated by dividing net income </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><ix:continuation id="f-523-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(loss) by the weighted-average number of shares of common stock plus potentially dilutive securities outstanding during the period. Potential shares of common stock exercisable for little or no consideration are included in both basic and diluted weighted-average number of shares of common stock outstanding. During the three months ended September&#160;30, 2024, basic and diluted weighted-average number of shares outstanding were <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-524">208.3</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-525">214.3</ix:nonFraction>&#160;million shares, respectively. During the nine months ended September&#160;30, 2024, both basic and diluted weighted-average number of shares outstanding were <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="f-526"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-527">198.8</ix:nonFraction></ix:nonFraction>&#160;million shares, and included pre-funded warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-528">3,809,523</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-118" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-529">0.01</ix:nonFraction> per share. These warrants were exercised during the three months ended June 30, 2024.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-530" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of basic and diluted net income (loss) per share are as follows (in thousands, except per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-531">10,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-532">104,163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-533">74,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-534">197,536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income allocated to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:num-dot-decimal" scale="3" id="f-535">1,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="3" id="f-536">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="3" id="f-537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="3" id="f-538">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-539">9,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-540">104,163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-541">74,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-542">197,536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-543">208,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-544">177,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-545">198,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-546">173,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-547">208,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-548">177,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-549">198,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-550">173,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-119" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-551">5,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-120" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-552">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-121" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-553">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-122" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-554">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of common stock pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-123" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-555">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-556">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - diluted</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-559">214,325</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-560">177,171</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-561">198,849</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-562">173,375</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareBasic" id="f-563">0.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="f-564">0.59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="f-565">0.37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="f-566">1.14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="f-567">0.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="f-568">0.59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="f-569">0.37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="f-570">1.14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase shares of common stock, with the exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-118" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-571">1.00</ix:nonFraction> per share, entitle holders to participate in dividends but are not required to absorb losses incurred. As a result, for the three months ended September&#160;30, 2024, the Company applied the two-class method to allocate net income to shares of common stock and these warrants for purposes of calculating basic and diluted net income per share. The warrants were excluded from basic net loss per share calculations during the nine months ended September&#160;30, 2024. No warrants were outstanding during the three and nine months ended September&#160;30, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computation of diluted net income per share for the three months ended September&#160;30, 2024 excluded <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-572">12.7</ix:nonFraction>&#160;million shares subject to stock options and restricted stock units outstanding because their inclusion would have had an anti-dilutive effect on diluted net income per share. The computation of diluted net loss per share for the nine months ended September&#160;30, 2024 excluded <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-573">51.6</ix:nonFraction>&#160;million shares subject to stock options, restricted stock units outstanding, warrants to purchase common stock, and the employee stock purchase plan shares reserved for issuance because their inclusion would have had an anti-dilutive effect on diluted net loss per share. The computation of diluted net loss per share for the three and nine months ended September&#160;30, 2023 excluded <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-574"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-575">22.1</ix:nonFraction></ix:nonFraction>&#160;million shares subject to stock options, restricted stock units outstanding, and the employee stock purchase plan shares reserved for issuance because their inclusion would have had an anti-dilutive effect on diluted net loss per share.</span></div></ix:continuation><div id="i2ce39f749ac4424b8fd01e23f7902cf4_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-576" continuedAt="f-576-1" escape="true">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</ix:nonNumeric></span></div><ix:continuation id="f-576-1" continuedAt="f-576-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, the Company entered into a global epigenetic regulation and capsid delivery license agreement with Genentech to develop intravenously administered genomic medicines to treat certain neurodegenerative diseases. Under the terms of the agreement, the Company granted an exclusive license to Genentech for the Company&#8217;s proprietary zinc finger repressors (&#8220;ZFRs&#8221;) that are directed to tau and a second undisclosed neurology target. The Company also granted an exclusive license to Genentech to the Company&#8217;s proprietary, neurotropic adeno-associated virus capsid, STAC-BBB, for use with therapies directed to tau and to the second neurology target. The Company is prohibited from exploiting (for itself or with or for a third party) </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><ix:continuation id="f-576-2" continuedAt="f-576-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products directed to tau and to the second neurology target during the applicable exclusivity periods set forth in the agreement. The Company was responsible for completing the technology transfer and certain preclinical activities, and Genentech is solely responsible for all clinical development, regulatory interactions, manufacturing and global commercialization of resulting products. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, the Company received a $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-577">40.0</ix:nonFraction>&#160;million upfront license payment from Genentech. In October 2024, the Company received a $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-578">10.0</ix:nonFraction>&#160;million milestone payment related to the technology transfer which was completed in September 2024. Under the terms of the agreement, the Company is also eligible to earn up to $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-8" name="sgmo:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="9" id="f-579">1.9</ix:nonFraction>&#160;billion in development and commercial milestones spread across multiple potential products. In addition, the Company is also entitled to receive escalating, tiered mid-single digit to sub-teen double digit royalty payments on the net sales of such products, subject to adjustments for patent expiration, entry of competitive products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will continue, on a product-by-product and country-by-country basis, until the date when there is no remaining royalty payment obligation in such country with respect to such product, at which time the agreement will expire with respect to such product in such country. Royalty obligations cease upon the later of expiry of the last valid patent claim covering the product in the country or <ix:nonNumeric contextRef="c-127" name="sgmo:RoyaltyObligationTerm" format="ixt-sec:duryear" id="f-580">10</ix:nonNumeric> years from the date of the first commercial sale of the product in such country. Genentech has the right to terminate the agreement for convenience. Each party has the right to terminate the agreement on account of the other party&#8217;s uncured material breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Genentech in accordance with ASC Topic 606 and concluded that Genentech is a customer. The initial transaction price of $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-581">50.0</ix:nonFraction>&#160;million includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-582">40.0</ix:nonFraction>&#160;million and the $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-583">10.0</ix:nonFraction>&#160;million technology transfer milestone payment. None of the development milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price as uncertain events are resolved or other changes in circumstances occur. Potential sales-based milestones and royalty payments are not estimated as they meet the sales-or usage-based royalty exception under ASC 606 and are recognized in the period they are earned, provided the related performance obligations have been completed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified <ix:nonFraction unitRef="performance_obligation" contextRef="c-52" decimals="0" name="sgmo:RevenueFromContractsWithCustomerNumberOfPerformanceObligations" format="ixt-sec:numwordsen" id="f-584">two</ix:nonFraction> performance obligations within the Genentech Agreement. All licenses were accounted for as a performance obligation to provide functional IP that is satisfied at a point in time that was satisfied upon completion of the technology transfer in September 2024. The preclinical activities represent research and development services and are satisfied over time as the Company conducts and Genentech benefits from the associated activities. Revenue related to the preclinical activities is recognized using an input method of cumulative actual costs incurred relative to total estimated costs. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the initial transaction price to the performance obligations based on the relative standalone selling price of each performance obligation. In the absence of an observable standalone selling price, the Company used a methodology that maximized the use of observable inputs. This included a cost plus margin approach for the preclinical activities, which required the estimation of total costs and an expected margin. The standalone selling price of the licenses was determined based on the analysis of the probability-adjusted discounted cash flows and potential sales of licensed products. Significant estimates and assumptions were used that include but are not limited to, expected market opportunity and pricing, timelines, and likelihood of success of clinical, regulatory and commercialization activities. The Company expects to allocate variable consideration payable upon achievement of future milestones and royalty payments to the specific performance obligation to which they relate, i.e. the license performance obligation, as such allocation would meet the allocation objective in ASC&#160;Topic&#160;606.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, the Company had a receivable of $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-585">10.0</ix:nonFraction>&#160;million related to the milestone payment which had been earned but not yet received, and deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-586">0.8</ix:nonFraction>&#160;million related to this agreement which is expected to be recognized over approximately the next three months. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-587" continuedAt="f-587-1" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.103%"><tr><td style="width:1.0%"/><td style="width:47.202%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.250%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Genentech agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-588">48,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-589">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-590">48,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-591">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-592">547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-593">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-594">547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-595">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-596">49,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-597">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-598">49,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-599">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><ix:continuation id="f-576-3" continuedAt="f-576-4"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer Inc. (&#8220;Pfizer&#8221;), pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia A, and closely related products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, the Company was responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty-free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#8217;s products that utilize the AAV delivery system.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i) the expiration of patent claims that cover the product in a country, (ii) the expiration of regulatory exclusivity for a product in a country, and (iii) <ix:nonNumeric contextRef="c-142" name="sgmo:AgreementTerminationTerm" format="ixt-sec:duryear" id="f-600">15</ix:nonNumeric> years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the agreement, the Company received an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="f-601">70.0</ix:nonFraction>&#160;million and was eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="f-602">208.5</ix:nonFraction>&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="f-603">266.5</ix:nonFraction>&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and potentially other products. To date, <ix:nonFraction unitRef="milestone" contextRef="c-145" decimals="INF" name="sgmo:CollaborativeArrangementNumberOfMilestonesAchieved" format="ixt-sec:numwordsen" scale="0" id="f-604">two</ix:nonFraction> milestones of $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="sgmo:MilestonePaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="f-605">55.0</ix:nonFraction>&#160;million in aggregate have been earned and received. The Company is eligible to earn from Pfizer up to $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="sgmo:MilestoneRevenueReceivable" format="ixt:num-dot-decimal" scale="6" id="f-606">220.0</ix:nonFraction>&#160;million in remaining milestone payments for giroctocogene fitelparvovec, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are <ix:nonFraction unitRef="number" contextRef="c-147" decimals="2" name="sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" scale="-2" id="f-607">14</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-148" decimals="2" name="sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" scale="-2" id="f-608">20</ix:nonFraction>% of the annual worldwide net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer was a customer. The Company completed its performance obligations and recognized the amounts included in the transaction price of $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="sgmo:CollaborativeArrangementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-609">134.0</ix:nonFraction>&#160;million during the periods through December 31, 2020. <ix:nonFraction unitRef="usd" contextRef="c-150" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt-sec:numwordsen" id="f-610"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt-sec:numwordsen" id="f-611"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt-sec:numwordsen" id="f-612"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt-sec:numwordsen" id="f-613">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> revenue was recognized during the three and nine months ended September&#160;30, 2024 and 2023. The remaining development, intellectual property and regulatory milestone amounts have not been included in the transaction price and have not been recognized as their achievement is dependent on the progress and outcomes of Pfizer&#8217;s development activities and is therefore uncertain. If and when these milestones become probable of being achieved, they will be recognized in full at that time. Sales milestones and royalties are not recognized until triggered based on the contractual terms.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into an exclusive, global collaboration and license agreement with Pfizer, subsequently assigned to Alexion, AstraZeneca Rare Disease (&#8220;Alexion&#8221;) in September 2023, for the development and commercialization of potential gene therapy products that use zinc finger transcriptional regulators (&#8220;ZF-transcriptional regulators&#8221;) to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZF-transcriptional regulators that bind to and specifically reduce expression of the mutant form of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Pfizer (now Alexion) an exclusive, royalty-bearing, worldwide license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZF-transcriptional regulators that satisfy pre-agreed criteria. During a specified period, neither the Company nor Alexion are permitted to research, develop, manufacture or commercialize outside of the collaboration any zinc finger proteins (&#8220;ZFPs&#8221;) that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i) the expiration of patent claims that cover the licensed product in a country, (ii) the expiration of regulatory </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><ix:continuation id="f-576-4" continuedAt="f-576-5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exclusivity for a licensed product in a country, and (iii) <ix:nonNumeric contextRef="c-154" name="sgmo:AgreementTerminationTerm" format="ixt-sec:duryear" id="f-614">15</ix:nonNumeric> years after the first commercial sale of a licensed product in a major market country. Alexion also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Alexion to develop, manufacture and commercialize licensed products under the agreement would automatically terminate. Upon termination by the Company for cause or by Alexion without cause for any licensed product or licensed products in any country or countries, the Company would have the right to negotiate with Alexion to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Alexion to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following any termination by the Company for Alexion&#8217;s material breach, Alexion would not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time. Following any termination by Alexion for the Company&#8217;s material breach, the Company would not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="sgmo:MilestonePaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="f-615">12.0</ix:nonFraction>&#160;million upfront payment from Pfizer and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="f-616">60.0</ix:nonFraction>&#160;million in development milestone payments from Alexion contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="f-617">90.0</ix:nonFraction>&#160;million in commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Alexion will pay the Company royalties of <ix:nonFraction unitRef="number" contextRef="c-158" decimals="2" name="sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" scale="-2" id="f-618">14</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-159" decimals="2" name="sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" scale="-2" id="f-619">20</ix:nonFraction>% of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party is responsible for the cost of its performance of the research program. Alexion is operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="sgmo:MilestonePaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="f-620">5.0</ix:nonFraction>&#160;million has been earned and paid, however <ix:nonFraction unitRef="product" contextRef="c-160" decimals="INF" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" format="ixt:fixed-zero" scale="0" id="f-621">no</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="milestone" contextRef="c-160" decimals="INF" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" format="ixt:fixed-zero" scale="0" id="f-622">no</ix:nonFraction> royalty fees have been earned under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Alexion in accordance with ASC Topic 606 and concluded that Alexion was a customer. The Company completed its performance obligations and recognized the amounts included in the transaction price of $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="sgmo:CollaborativeArrangementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-623">17.0</ix:nonFraction>&#160;million during the periods through December 31, 2020. <ix:nonFraction unitRef="usd" contextRef="c-162" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt-sec:numwordsen" id="f-624"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt-sec:numwordsen" id="f-625"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt-sec:numwordsen" id="f-626"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt-sec:numwordsen" id="f-627">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> revenue was recognized during the three and nine months ended September&#160;30, 2024 and 2023. The remaining development milestone amounts have not been included in the transaction price and have not been recognized as their achievement is dependent on the progress and outcomes of Alexion&#8217;s development activities and is therefore uncertain. If and when these milestones become probable of being achieved, they would be recognized in full at that time. Sales related milestones and royalties are not recognized until triggered based on the contractual terms. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, Pfizer notified the Company of Pfizer&#8217;s assignment of the collaboration and license agreement to Alexion, AstraZeneca Rare Disease, pursuant to a definitive purchase and license agreement for preclinical gene therapy assets and enabling technologies that closed on September 20, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Collaboration and License Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, the Company had a collaboration and license agreement with Kite and certain other license agreements. In 2023, in addition to the agreement with Kite, the Company had collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc. (&#8220;Novartis&#8221;), and Biogen MA, Inc. (&#8220;Biogen&#8221;). These collaboration agreements were designed for the research, development, and commercialization of various potential therapy products, including potential engineered cell therapies for cancer and gene regulation therapies to treat neurodevelopmental disorders and diseases. The collaboration agreements with Novartis and Biogen were both terminated effective June 2023. The Company&#8217;s services under the Kite collaboration agreement were completed during the year ended December 31, 2023, and the agreement expired pursuant to its terms in April 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed each of these collaboration agreements in accordance with ASC Topic 606, concluding Kite, Novartis and Biogen were customers. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><ix:continuation id="f-576-5"><ix:continuation id="f-587-1"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under these agreements were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.477%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.477%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.477%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license fee fixed consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-628">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-629">5,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-630">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-631">17,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services variable consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-632">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-633">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-634">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-635">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-636">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-637">5,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-639">19,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Novartis agreement:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront license fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-642">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-643">9,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-644">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-645">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-646">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-647">2,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-648">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-649">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-650">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-651">12,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Biogen agreement:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and other fixed consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-652">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-653">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-654">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-655">132,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost-sharing payments for research services, net variable consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-656">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-657">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-658">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-659">2,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-661">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-662">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-663">134,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from other license agreements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-664">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-665">3,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-666">1,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-667">8,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-668">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-669">9,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-670">1,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-671">174,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024 and December&#160;31, 2023, the Company had no material receivables, no deferred revenue, and no amounts included in transaction price remaining to be recognized related to these license and collaboration agreements.</span></div></ix:continuation><div id="i2ce39f749ac4424b8fd01e23f7902cf4_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:AssetImpairmentChargesTextBlock" id="f-672" continuedAt="f-672-1" escape="true">IMPAIRMENT AND WRITE-DOWN OF ASSETS HELD FOR SALE</ix:nonNumeric></span></div><ix:continuation id="f-672-1" continuedAt="f-672-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company experienced a sustained decline in stock price and related market capitalization, the collaboration agreements with Biogen and Novartis were terminated, and actions were initiated including deferral and reprioritization of certain research and development programs, announcement and execution of restructuring of operations and reductions in force. As a result, throughout the year the Company tested various long-lived and indefinite-life intangible assets for impairment and recognized a pre-tax goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-673">38.1</ix:nonFraction>&#160;million, a pre-tax indefinite-lived intangible asset impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-674">51.4</ix:nonFraction>&#160;million along with the income tax benefit from the reduction of the associated deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" name="sgmo:EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" format="ixt:num-dot-decimal" scale="6" id="f-675">6.3</ix:nonFraction>&#160;million, and a pre-tax long-lived assets impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-676">65.5</ix:nonFraction>&#160;million during the year ended December 31, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nine months ended September 30, 2024</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024, the Company&#8217;s Board of Directors approved the wind-down of operations in France and corresponding reduction in workforce, including closure of the Company&#8217;s cell therapy manufacturing facility and research labs in Valbonne, France (the &#8220;France Restructuring&#8221;), and also initiated several actions aimed at reducing costs, including actions to commence the closure of its facility in Brisbane, California. As such, the Company reassessed its long-lived assets for impairment as of March 31, 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the France Restructuring, the Company concluded its equipment, furniture and fixtures located in France met the held for sale criteria as of March 31, 2024. The Company wrote down the carrying value of these assets to their estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-677">1.0</ix:nonFraction>&#160;million, net of the estimated costs to sell, recognizing a loss of $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-678">1.8</ix:nonFraction>&#160;million. The fair value measurement represents a level 3 nonrecurring fair value measurement. The loss is included in impairment of long-lived assets in the accompanying Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also reassessed whether its remaining long-lived assets continued to represent a single asset group for purposes of impairment assessment. After considering changes in the manner in which the right-of-use assets and leasehold improvements related to the Company&#8217;s Brisbane and Valbonne, France, facilities are used, costs incurred to cease use of these assets, the France Restructuring, and the Company&#8217;s activities to market these facilities for sublease, the Company concluded the identifiable operations and cash flows of these assets are now largely independent of the operations and the cash flows of each other, as well as of the remainder of the Company. Accordingly, the Company assessed impairment of the resulting asset groups separately.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><ix:continuation id="f-672-2" continuedAt="f-672-3"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the changes in the use of assets related to the Brisbane and Valbonne facility leases, the Company concluded there were indicators of impairment for these asset groups, and further established that the carrying values of these asset groups were not recoverable. The Company proceeded to determine their fair values using a discounted cash flow method, which represents a level 3 nonrecurring fair value measurement. As a result, the Company recognized pre-tax long-lived asset impairment charges of $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-679">2.0</ix:nonFraction>&#160;million on the right-of-use assets and $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:ImpairmentOfLeasehold" format="ixt:num-dot-decimal" scale="6" id="f-680">0.5</ix:nonFraction>&#160;million on the related leasehold improvements during the three months ended March 31, 2024. No impairment was recognized on the remaining long-lived assets, as their carrying values were not in excess of their fair values.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2024, the Company faced a sustained decline in its stock price and related market capitalization, and continued the France Restructuring and activities related to the closure of its facility in Brisbane, California. There was also a decline in the market rates for facility subleases in Brisbane, California, indicating the carrying values of right of use and leasehold improvement assets could be impaired. As such, the Company reassessed its long-lived assets for impairment as of June 30, 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded there were indicators of impairment for the Brisbane and Valbonne facility lease asset groups, and further established that the carrying values of these asset groups were not recoverable. The Company proceeded to determine their fair values using a discounted cash flow method, which represents a level 3 nonrecurring fair value measurement. As a result, the Company recognized pre-tax long-lived asset impairment charges of $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-681">0.9</ix:nonFraction>&#160;million on the right-of-use assets and $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="us-gaap:ImpairmentOfLeasehold" format="ixt:num-dot-decimal" scale="6" id="f-682">0.1</ix:nonFraction>&#160;million on the related leasehold improvements during the three months ended June 30, 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also reassessed the fair value of assets held for sale as of June 30, 2024 and recorded an additional charge to write-down the carrying value of these assets by $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="f-683">0.1</ix:nonFraction>&#160;million. Assets held for sale are included within prepaid expenses and other current assets on the Company&#8217;s Condensed Consolidated Balance Sheet as of June 30, 2024. The fair value measurement represents a level 3 nonrecurring fair value measurement. The loss is included in impairment of long-lived assets in the accompanying Condensed Consolidated Statements of Operations. The sale of these assets is expected to occur within one year, either collectively or separately.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2024, no additional impairment was recorded.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will continue to assess whether its long-lived assets are impaired in future periods. As the Company finalizes the wind-down of its France operations and corresponding reduction in force of all France employees, as well as the closure of its Brisbane facility, it is reasonably possible that additional impairment charges will be recognized, for example, if sublease rates of leased facilities or selling prices of the assets held for sale are less than those estimated.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nine months ended September 30, 2023</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, as a result of the sustained decline in the Company&#8217;s stock price and related market capitalization, and termination of the collaboration agreements with Biogen and Novartis, the Company performed an impairment assessment of goodwill, indefinite-lived intangible assets, and other long-lived assets. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operated as a single reporting unit based on its business and reporting structure. For goodwill, a quantitative impairment assessment was performed using a market approach, whereby the Company&#8217;s fair value of equity was compared to its carrying value. The fair value of equity was derived using both the market capitalization of the Company and an estimate of a reasonable range of values of a control premium applied to the Company&#8217;s implied business enterprise value. The control premium was estimated based upon control premiums observed in comparable market transactions. This represented a level&#160;2 nonrecurring fair value measurement. Based on this analysis, the Company recognized a pre-tax goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-684">38.1</ix:nonFraction>&#160;million during the three months ended March 31, 2023. As a result, the goodwill was fully impaired as of March&#160;31, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before completing the goodwill impairment assessment, the Company also tested its indefinite-lived intangible assets and then its long-lived assets for impairment. Based on the qualitative assessment, the Company determined it was more likely than not that its indefinite-lived intangible assets were not impaired. The Company determined all of its long-lived assets represented one asset group for purposes of long-lived asset impairment assessment. The Company concluded that the carrying value of the asset group was not recoverable as it exceeded the future undiscounted cash flows the assets were expected to generate from the use and eventual disposition. To allocate and recognize the impairment loss, the Company determined individual fair values of its long-lived assets. The Company applied a discounted cash flow method to estimate fair values of its leasehold improvements and right-of-use assets, including leasehold improvements in the process of construction and a cost replacement method to estimate the fair value of its furniture, fixtures and laboratory and manufacturing equipment. These represented level&#160;3 nonrecurring fair value measurements. Based on this analysis, the Company recognized pre-tax long-lived asset impairment charges of $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-685">11.2</ix:nonFraction>&#160;million on the right-of-use assets, $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:ImpairmentOfLeasehold" format="ixt:num-dot-decimal" scale="6" id="f-686">5.0</ix:nonFraction>&#160;million on the related leasehold improvements, and $<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-687">4.2</ix:nonFraction>&#160;million on construction-in-progress, during the three months ended March 31, 2023. No impairment was recognized on the remaining long-lived assets as their carrying values were not in excess of their fair values.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><ix:continuation id="f-672-3"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2023, the Company&#8217;s stock price and the related market capitalization continued to decline. In April 2023, the Company announced a restructuring of operations and a corresponding reduction in force. The Company also initiated discussions around several actions aimed at reducing costs, preserving liquidity and improving operational performance metrics, including deferral and reprioritization of certain research and development programs, further reduction in force, and closing or downsizing its facilities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reassessed its indefinite-lived and long-lived assets for impairment as of June 30, 2023. Given the actions contemplated above, the Company determined that it was more likely than not that its indefinite-lived intangible assets were impaired. Accordingly, the Company developed an estimate of the fair value of its indefinite-lived intangible assets using the multi-period excess earnings model (income approach) and concluded the carrying value of its indefinite-lived intangible assets were fully impaired. This represents a level 3 nonrecurring fair value measurement. As a result, an indefinite-lived intangible assets impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-688"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-689">51.3</ix:nonFraction></ix:nonFraction>&#160;million, as well as the related income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="sgmo:EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" format="ixt:num-dot-decimal" scale="6" id="f-690"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="sgmo:EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" format="ixt:num-dot-decimal" scale="6" id="f-691">6.3</ix:nonFraction></ix:nonFraction>&#160;million due to the reversal of a deferred tax liability associated with the indefinite-lived intangible assets was recognized during the three and six months ended June 30, 2023. The impairment charge was primarily driven by a higher discount rate applied to future cash flows based on market participants&#8217; view of increased risk related to the asset.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that there were indicators of impairment in its long-lived asset group as of June 30, 2023, based on the same factors above as well as the impairment of its indefinite-lived intangible assets. As the estimated fair value of this asset group, based on a market approach, exceeded its carrying value, no impairment loss was recognized. This represented a level 3 nonrecurring fair value measurement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2023, the Company&#8217;s stock price and the related market capitalization continued to decline, and as such, the Company reassessed its long-lived assets for impairment as of September 30, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined all of its long-lived assets continued to represent one asset group for purposes of long-lived asset impairment assessment. The Company concluded that the carrying value of the asset group was not recoverable and the estimated fair value of this asset group was below its carrying value. The lower fair value of the asset group was mainly driven by the sustained decline in the Company&#8217;s stock price and the related market capitalization. To recognize the impairment loss, the Company determined individual fair values of its long-lived assets. The Company applied a discounted cash flow method to estimate fair values of its leasehold improvements and right-of-use assets, including leasehold improvements in the process of construction, and a market approach to estimate the fair value of its furniture, fixtures and laboratory and manufacturing equipment. These represented level 3 nonrecurring fair value measurements. Based on this analysis, the Company concluded the fair values of the long-lived assets were lower than their net book values due to declines in the market prices for leases, furniture, fixtures, and equipment. The Company recognized pre-tax long-lived asset impairment charges of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-692">17.6</ix:nonFraction>&#160;million on the right-of-use assets, $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-693">13.7</ix:nonFraction>&#160;million on the related leasehold improvements and construction-in-progress, and $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-694">13.5</ix:nonFraction>&#160;million on furniture, fixtures, and laboratory and manufacturing equipment during the three months ended September 30, 2023.</span></div></ix:continuation><div id="i2ce39f749ac4424b8fd01e23f7902cf4_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-695" continuedAt="f-695-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-695-1"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 5, 2024, the Company entered into an amendment to the operating lease of office and research and development laboratory facilities in Brisbane, California. The amendment established early termination rights for the landlord upon <ix:nonNumeric contextRef="c-221" name="sgmo:LesseeOperatingLeaseRequiredNoticeOfTermination" format="ixt-sec:durwordsen" id="f-696">thirty days</ix:nonNumeric>&#8217; notice to the Company, with the earliest date the landlord may terminate the lease being September 30, 2024. Additionally, the amendment authorized the landlord to draw on the existing letter of credit to satisfy the majority of the Company&#8217;s February 2024 through April 2024 rent payments and obligated the Company to provide a cash security deposit or replenish the letter of credit back to $<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="sgmo:LesseeRequiredLetterOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="f-697">1.5</ix:nonFraction>&#160;million by June 1, 2024. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the amendment represented a lease modification to be accounted for as a single contract with the existing lease under ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and remeasured its lease liability using the current incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="c-222" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="f-698">9.6</ix:nonFraction>%, and recorded an adjustment to reduce both the lease liability and the corresponding right-of-use asset by $<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-5" name="sgmo:OperatingLeaseRightOfUseAssetModificationReduction" format="ixt:num-dot-decimal" scale="6" id="f-699"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-700">1.9</ix:nonFraction></ix:nonFraction>&#160;million as of the lease modification date.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2024, the Company entered into another amendment to extend the deadline for replenishing the letter of credit to September&#160;30,&#160;2024, the effect of which had no material impact to the Company&#8217;s financial statements. The letter of credit was replenished during the three months ended September 30, 2024.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-701" continuedAt="f-701-1" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-702" escape="true"><ix:continuation id="f-701-1"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense recognized in the accompanying Condensed Consolidated Statements of Operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-703">1,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-704">3,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-705">4,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-706">11,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-707">1,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-708">2,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-709">4,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-710">9,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-711">3,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-712">6,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-713">9,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-714">21,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i2ce39f749ac4424b8fd01e23f7902cf4_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-715" continuedAt="f-715-1" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="f-715-1" continuedAt="f-715-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s common stock authorized for issuance was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-716">960,000,000</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-717">640,000,000</ix:nonFraction> shares as of September&#160;30, 2024 and December 31, 2023, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Offering Program</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into an Open Market Sale Agreement&#8480; with Jefferies LLC (&#8220;Jefferies&#8221;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#8217;s common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-5" name="sgmo:StockOfferingProgramMaximumValue" format="ixt:num-dot-decimal" scale="6" id="f-718">150.0</ix:nonFraction>&#160;million through Jefferies as the Company&#8217;s sales agent or principal. The Company is not obligated to sell any shares under the sales agreement. In December 2022, the Company entered into an amendment to the Open Market Sale Agreement&#8480; which increased the aggregate offering price under the at-the-market offering program by an additional $<ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-5" name="sgmo:SaleOfStockIncreaseToAggregateOfferingPrice" scale="6" id="f-719">175.0</ix:nonFraction> million. <ix:nonFraction unitRef="shares" contextRef="c-234" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt-sec:numwordsen" id="f-720">No</ix:nonFraction> shares were sold under the sales agreement during the three months ended September&#160;30, 2023. During the nine months ended September&#160;30, 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-235" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-721">8,249,261</ix:nonFraction> shares of its common stock for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-722">15.1</ix:nonFraction> million. <ix:nonFraction unitRef="shares" contextRef="c-236" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="f-723"><ix:nonFraction unitRef="shares" contextRef="c-237" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="f-724">No</ix:nonFraction></ix:nonFraction> shares were sold under the sales agreement during the three and nine months ended September&#160;30, 2024. Approximately $<ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-5" name="sgmo:SaleOfStockOutstandingAmountAvailable" format="ixt:num-dot-decimal" scale="6" id="f-725">194.5</ix:nonFraction>&#160;million remained available under the sales agreement as of September&#160;30, 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance and Sale of Common Stock and Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 21, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional investors (collectively, the &#8220;Investors&#8221;). On March 26, 2024 the Company issued and sold in a registered direct offering (the &#8220;Registered Direct Offering&#8221;) an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-239" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-726">24,761,905</ix:nonFraction> shares of common stock of the Company, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-240" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-727">0.01</ix:nonFraction> per share, and pre-funded warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-241" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-728">3,809,523</ix:nonFraction> shares of common stock, together with accompanying warrants (&#8220;Common Warrants&#8221;) to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-242" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-729">28,571,428</ix:nonFraction> shares of common stock. The combined offering price of a unit consisting of <ix:nonFraction unitRef="shares" contextRef="c-243" decimals="INF" name="sgmo:SaleOfStockNumberOfSharesIssuedInTransactionPerUnit" format="ixt-sec:numwordsen" id="f-730">one</ix:nonFraction> share of common stock and the accompanying Common Warrant to purchase <ix:nonFraction unitRef="shares" contextRef="c-243" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" id="f-731">one</ix:nonFraction> share of common stock was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-243" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-732">0.84</ix:nonFraction>. The combined offering price of a unit consisting of a pre-funded warrant to purchase <ix:nonFraction unitRef="shares" contextRef="c-244" decimals="INF" name="sgmo:SaleOfStockNumberOfSharesIssuedInTransactionPerUnit" format="ixt-sec:numwordsen" id="f-733">one</ix:nonFraction> share of common stock and the accompanying Common Warrant to purchase <ix:nonFraction unitRef="shares" contextRef="c-244" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" id="f-734">one</ix:nonFraction> share of common stock was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-244" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-735">0.83</ix:nonFraction>. The pre-funded warrants are immediately exercisable at any time, until exercised in full, at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-244" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-736">0.01</ix:nonFraction> per share of common stock. The Common Warrants are exercisable <ix:nonNumeric contextRef="c-245" name="sgmo:WarrantOrRightOutstandingExercisablePeriodAfterIssuance" format="ixt-sec:durwordsen" id="f-737">six months</ix:nonNumeric> from issuance, expire five and a half years from the issuance date and have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-244" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-738">1.00</ix:nonFraction> per share. Both pre-funded warrants and Common Warrants can be exercised net in limited circumstances and entitle holders to dividends if and when paid by the Company.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Barclays Capital Inc. and Cantor Fitzgerald &amp; Co. (the &#8220;Placement Agents&#8221;) acted as the placement agents for the offering, pursuant to a Placement Agency Agreement, dated March 21, 2024 (the &#8220;Placement Agreement&#8221;). Pursuant to the Placement Agreement, the Company paid the Placement Agents a cash placement fee equal to <ix:nonFraction unitRef="number" contextRef="c-246" decimals="2" name="sgmo:SaleOfStockPlacementFeePercentageOfGrossProceeds" scale="-2" id="f-739">6.0</ix:nonFraction>% of the aggregate gross proceeds raised in the Registered Direct Offering. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received aggregate net proceeds from the Registered Direct Offering of $<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-740">21.9</ix:nonFraction>&#160;million, net of the Placement Agents&#8217; fees of $<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="sgmo:SaleOfStockAgentPlacementFees" format="ixt:num-dot-decimal" scale="6" id="f-741">1.4</ix:nonFraction>&#160;million and other offering costs of $<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="sgmo:SaleOfStockOtherOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="f-742">0.7</ix:nonFraction>&#160;million. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common Warrants and pre-funded warrants were determined to be equity-classified and proceeds received from their issuance were recorded as a component of stockholders&#8217; equity within additional paid-in capital. The Company determined that the warrants should be equity classified because they are freestanding financial instruments, do not embody an obligation for the Company to repurchase its shares, do not contain exercise contingencies tied to observable markets or indices, permit the holders to receive a fixed number of shares of common stock upon exercise in exchange for a fixed amount of consideration, subject only to adjustments that are inputs to the fair value of a fixed price/fixed consideration-option, and meet the equity classification criteria. The pre-funded warrants were exercised in full on April 8, 2024 and the Company issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-247" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-743">3,809,523</ix:nonFraction> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><ix:continuation id="f-715-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-248" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-744">0.01</ix:nonFraction>. The Common Warrants had not been exercised and remained outstanding as of September&#160;30, 2024.</span></div></ix:continuation><div id="i2ce39f749ac4424b8fd01e23f7902cf4_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-746" continuedAt="f-746-1" escape="true">RESTRUCTURING CHARGES</ix:nonNumeric></span></div><ix:continuation id="f-746-1" continuedAt="f-746-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">April 2023 Restructuring</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2023, the Company executed a restructuring of operations and a corresponding reduction in workforce (the &#8220;April 2023 Restructuring&#8221;), designed to reduce costs and increase focus on certain strategic priorities. The April 2023 Restructuring resulted in the elimination of approximately <ix:nonFraction unitRef="employee" contextRef="c-249" decimals="-1" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="f-747">110</ix:nonFraction> roles in the United States, or approximately 23% of the total United States workforce. The April 2023 Restructuring resulted in the incurrence of one-time severance payments and other employee-related costs, including additional vesting of service-based stock compensation awards. The Company had estimated that it will incur $<ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="f-748">5.0</ix:nonFraction>&#160;million in expenses related to employee severance and notice period payments, benefits and related restructuring charges for the April 2023 Restructuring. <ix:nonFraction unitRef="usd" contextRef="c-251" decimals="INF" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="0" id="f-749"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="INF" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="0" id="f-750">No</ix:nonFraction></ix:nonFraction> expenses related to the April 2023 Restructuring were incurred during the three and nine months ended September&#160;30, 2024. <ix:nonFraction unitRef="usd" contextRef="c-251" decimals="INF" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="0" id="f-751"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="INF" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="0" id="f-752">No</ix:nonFraction></ix:nonFraction> expenses related to the April 2023 Restructuring were incurred during the three months ended September 30, 2023.The Company incurred approximately $<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-753">5.0</ix:nonFraction>&#160;million of expenses related to the April 2023 Restructuring during the nine months ended September&#160;30,&#160;2023, of which $<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-754">3.8</ix:nonFraction>&#160;million is included in research and development expense and $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-755">1.2</ix:nonFraction>&#160;million is included in general and administrative expense in the accompanying Condensed Consolidated Statements of Operations. The April 2023 Restructuring and the cash payments related thereto are complete as of September 30, 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">November 2023 Restructuring</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2023, the Company executed a restructuring of operations and a corresponding reduction in workforce (the &#8220;November 2023 Restructuring&#8221;), designed to reduce costs and advance its strategic transformation into a neurology-focused genomic medicine company. The November 2023 Restructuring resulted in the elimination of approximately <ix:nonFraction unitRef="employee" contextRef="c-256" decimals="0" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="f-756">162</ix:nonFraction> roles, including <ix:nonFraction unitRef="employee" contextRef="c-257" decimals="0" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" id="f-757">108</ix:nonFraction> full-time employees and <ix:nonFraction unitRef="employee" contextRef="c-258" decimals="0" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="f-758">54</ix:nonFraction> contracted employees and eliminated open positions, in the United States, or approximately <ix:nonFraction unitRef="number" contextRef="c-256" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="f-759">40</ix:nonFraction>% of the total United States workforce, and included one-time severance payments and other employee-related costs, including additional vesting of service-based stock compensation awards. The total restructuring expenses are estimated to be approximately $<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="f-760">8.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="f-761">9.0</ix:nonFraction> million, related to employee severance and notice period payments, benefits, Brisbane facility close-out costs, and other related restructuring charges for the November 2023 Restructuring. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-762">6.7</ix:nonFraction> million of expenses relating to the November 2023 Restructuring in the fourth quarter of 2023. The expense adjustments recorded during the three and nine months ended September&#160;30, 2024 were not material. The cash payments relating to employee severance and notice period payments, benefits, other employee-related costs for the November 2023 Restructuring are complete as of September&#160;30, 2024. The Company expects the Brisbane facility close-out costs to be complete by second quarter of 2025, which were previously estimated to be complete by third quarter of 2024. The Company expects to incur estimated costs of $<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:num-dot-decimal" scale="6" id="f-763">0.9</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:num-dot-decimal" scale="6" id="f-764">1.9</ix:nonFraction>&#160;million on Brisbane facility close-out costs through the second quarter of 2025.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">France Restructuring</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2024, the Company&#8217;s Board of Directors approved the France Restructuring which will result in the elimination of all <ix:nonFraction unitRef="employee" contextRef="c-264" decimals="0" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="f-765">93</ix:nonFraction> roles in France, or approximately <ix:nonFraction unitRef="number" contextRef="c-264" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="f-766">24</ix:nonFraction>% of the total global workforce. As a result, the Company has terminated its research and development activities in France and is in the process of disposing of its France-based assets and settling the associated liabilities. The Company is also making severance payments as required by French law and the terms of the applicable collective bargaining agreements, and incurring other employee-related costs. The total restructuring expenses are estimated to be approximately $<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="f-767">5.3</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="f-768">5.6</ix:nonFraction> million, related to employee severance and notice period payments, benefits, contract termination costs, and other related restructuring charges for the France Restructuring. The Company had recorded $<ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-769">4.7</ix:nonFraction> million of expenses relating to the France restructuring in the fourth quarter of 2023. The expenses incurred during the three and nine months ended September&#160;30, 2024 related to employee severance and notice period payments, benefits, other employee-related costs, and facility shutdown costs were not material. During the three months ended June 30, 2024, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="f-770">2.4</ix:nonFraction>&#160;million as expense relating to a manufacturing agreement for costs that will be incurred without economic benefit to the Company, included in general and administrative expense in the accompanying Condensed Consolidated Statements of Operations. During the three months ended September&#160;30, 2024, the Company reached a settlement relating to the terminated manufacturing agreement and recognized $<ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="f-771">2.2</ix:nonFraction>&#160;million as a reduction to general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations. The Company expects to incur other additional estimated costs of $<ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" scale="6" id="f-772">0.2</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" scale="6" id="f-773">0.5</ix:nonFraction> million related to the France Restructuring through the fourth quarter of 2024. The Company expects the France Restructuring and its related cash payments to be substantially complete by the fourth quarter of 2024. See&#160;Note&#160;6&#160;&#8211;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment and Write-Down of Assets Held For Sale </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for impairment considerations related to the France Restructuring.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><ix:continuation id="f-746-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-774" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of accrued April 2023 Restructuring, November 2023 Restructuring and France Restructuring charges included within other accrued liabilities on the Company&#8217;s Condensed Consolidated Balance Sheet as of September&#160;30, 2024 (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="f-775">11,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="f-776">603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="f-777">10,683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="f-778">1,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo may also incur other cash expenses or charges not currently contemplated or estimable due to events that may occur as a result of, or associated with, the November 2023 Restructuring and France Restructuring.</span></div></ix:continuation><div id="i2ce39f749ac4424b8fd01e23f7902cf4_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11&#8212;<ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-779" continuedAt="f-779-1" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span><ix:continuation id="f-779-1" continuedAt="f-779-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></ix:continuation></div><ix:continuation id="f-779-2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transfer to Nasdaq Capital Markets and Compliance with Bid Price Requirement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo&#8217;s common stock was transferred from Nasdaq Global Market to the Nasdaq Capital Market effective as of the opening of business on October 26, 2024 and has continued to trade under the symbol &#8220;SGMO.&#8221;  The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Select Market, and listed companies must meet certain financial requirements and comply with Nasdaq&#8217;s corporate governance requirements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the transfer, Sangamo was granted an additional 180-day grace period, or until April 21, 2025, or the Compliance Date, to regain compliance with the bid price requirement set forth in the continued listing requirements of Nasdaq Listing Rule 5450(a)(1) (the &#8220;Bid Price Requirement&#8221;). To regain compliance with the Bid Price Requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of Sangamo&#8217;s common stock must be at least $1.00 for at least ten consecutive business days during the additional 180-day compliance period. On November 5, 2024, Sangamo received a letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC that Sangamo has regained compliance with the Bid Price Requirement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contains trend analysis, estimates and other forward-looking statements within the meaning of Section&#160;27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements include, without limitation, statements containing the words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;continues,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; and other words of similar import or the negative of those terms or expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties, estimates and other factors that may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially from those set forth in such forward-looking statements as a result of, but not limited to, the &#8220;Risk Factors&#8221; described in Part I, Item 1A our Annual Report on Form 10-K for the year ended December&#160;31,&#160;2023 as filed with the Securities and Exchange Commission on March 13,&#160;2024, or the 2023 Annual Report, as supplemented by the risks described under &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q. You should also read the following discussion and analysis in conjunction with our Condensed Consolidated Financial Statements and accompanying notes included in this Quarterly Report and the Consolidated Financial Statements and accompanying notes thereto included in our 2023 Annual Report.</span></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_97"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. We believe our zinc finger epigenetic regulators are ideally suited to potentially address devastating neurology disorders and our capsid engineering platform has demonstrated the ability to expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system, or CNS, in preclinical studies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Updates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Epigenetic Regulation and Capsid Delivery License Agreement with Genentech</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2024, we entered into a global epigenetic regulation and capsid delivery license agreement, or the Genentech Agreement, with Genentech, Inc., a member of the Roche Group, or Genentech, to develop intravenously administered genomic medicines to treat certain neurodegenerative diseases. Under the Genentech Agreement, we granted an exclusive license to Genentech for our proprietary zinc finger repressors, or ZFRs, that are directed to tau and a second undisclosed neurology target. We also granted an exclusive license to Genentech to our proprietary, neurotropic adeno-associated virus capsid, STAC-BBB, for use with therapies directed to tau or to the second neurology target. Under the terms of the Genentech Agreement, we were responsible for completing a technology transfer and certain preclinical activities, and Genentech is solely responsible for all clinical development, regulatory interactions, manufacturing and global commercialization of resulting products. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Genentech Agreement, we have received from Genentech a $40.0 million upfront license fee and a $10.0 million milestone payment, or the Genentech Payments. In addition, we are eligible to earn up to $1.9 billion in development and commercial milestones spread across multiple potential products under the Genentech Agreement and tiered mid-single digit to sub-teen double digit royalties on the net sales of such products, subject to certain specified reductions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Position &#8211; Going Concern</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, our cash and cash equivalents as of September&#160;30, 2024, together with the $10.0&#160;million milestone payment that we received from Genentech in October&#160;2024, are expected to allow us to meet our liquidity requirements only into the first quarter of 2025. Our history of significant losses, negative cash flows from operations, limited liquidity resources currently on hand and dependence on our ability to obtain additional financing to fund our operations have resulted in management&#8217;s assessment that there is substantial doubt about our ability to continue as a going concern for at least the next 12 months from the date the financial statements included in this Quarterly Report are issued. Our ability to continue to operate as a going concern is dependent upon our ability to raise substantial additional capital to fund our operations and support our research and development endeavors, including to progress our preclinical and clinical programs as described in our 2023 Annual Report and in this Quarterly Report. Although we received the Genentech Payments, and raised capital via a registered direct offering to institutional investors of common stock and accompanying warrants in March 2024, we will still need substantial additional capital in order to continue to operate as a going concern and fund our operations. We have been actively seeking, and continue to actively seek, substantial additional capital, including through additional strategic collaborations and other direct investments in our programs, public or private equity or debt financing, royalty financing and other sources. We may be unable to attract new investments as a result of the speculative nature of our newly reprioritized core neurology preclinical programs and additional capital may not be available on acceptable terms or at all. If adequate funds are not available to us on a timely basis, or at all, we will be required to take additional actions to address our liquidity needs, including additional cost </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering our research and development activities, which would have a material adverse effect on our business and prospects, or we may be required to cease operations entirely, liquidate all or a portion of our assets, and/or seek protection under the U.S. Bankruptcy Code, and you may lose all or part of your investment. We have explored, and will continue to explore, whether filing for bankruptcy protection is in the best interest of our Company and our stakeholders.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Core Neurology Programs and Technologies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our neurology pipeline is focused on two innovative areas aligned with our strategic transformation: (i) development of epigenetic regulation therapies treating serious neurological diseases and (ii) development of novel engineered adeno-associated virus, or AAV, capsids to deliver our therapies to the intended neurological targets. Indications for our wholly-owned neurology programs include idiopathic small fiber neuropathy, or iSFN, a type of chronic neuropathic pain, and prion disease.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurology Epigenetic Regulation Programs</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have submitted an investigational new drug, or IND, application to the U.S. Food and Drug Administration, or FDA, for ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to iSFN.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Subject to clearance of this IND application by the FDA, we would expect to start the Phase 1/2 study of ST-503 in the middle of 2025, subject to our ability to secure adequate funding.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In September 2024, we published a manuscript in bioRxiv titled, &#8220;Potent and selective repression of SCN9A by engineered ZFRs for the treatment of neuropathic pain,&#8221; demonstrating that ZFRs can selectively and potently reduce the expression of Nav1.7 sodium channels in sensory neurons, following a single intrathecal administration of ST-503, an AAV encoding a ZFR targeting the SCN9A gene.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trial authorization, or CTA, enabling activities continue to advance for our epigenetic regulation program to treat prion disease, leveraging our novel proprietary neurotropic AAV capsid variant, known as STAC-BBB, which demonstrated industry-leading blood-brain barrier, or BBB, penetration in nonhuman primates, or NHPs, following intravenous administration.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We presented updated data at the Prion 2024 Conference in October 2024, showing the potency of Sangamo&#8217;s ZFR in a disease mouse model at multiple dose levels. The ZFR significantly reduced expression of prion mRNA and protein in the brain, extended mouse survival and limited the formation of toxic prion aggregates. Additionally, we presented NHP data at the Prion 2024 Conference, showing that a single intravenous administration of the prion ZFR, delivered via STAC-BBB, resulted in potent and widespread repression of the prion gene in transduced neurons.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A CTA submission for the prion program is expected in the fourth quarter of 2025, subject to our ability to secure adequate funding.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novel AAV Capsid Delivery Technology</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We continue to engage in business development discussions with new potential collaborators for STAC-BBB for use in delivering intravenously administered genomic medicines to treat certain specified neurological diseases.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Programs</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fabry Disease</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In October 2024, we announced the outcome of a successful interaction with the FDA, providing a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec, or ST-920, our investigational gene therapy for the treatment of Fabry disease. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The FDA has agreed in a Type B interaction that data from the ongoing Phase 1/2 STAAR study can serve as the primary basis for approval under the Accelerated Approval Program, using estimated glomerular filtration rate, or eGFR, slope at 52 weeks across all patients as an intermediate clinical endpoint. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We engaged with the FDA on alternative pathways to potential approval following analysis of clinical data from the Phase 1/2 STAAR study showing encouraging safety and efficacy data, including promising preliminary evidence of improved kidney function. In the 18 male and female patients treated with isaralgagene civaparvovec with more than one year of follow-up data, a statistically significant positive mean annualized eGFR slope was observed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Based on these latest data, the FDA agreed that eGFR slope at 52 weeks can serve as an intermediate clinical endpoint to support a potential Accelerated Approval. The FDA also advised that eGFR slope at 104 weeks may be assessed to verify clinical benefit.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The complete dataset to support an Accelerated Approval pathway will be available in the first half of 2025. This approach enables a potential Biologics License Application, or BLA, submission in the second half of 2025, three years ahead of previous estimates, and avoids the requirement for an additional, costly registrational study to establish clinical efficacy.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dosing was completed in the Phase 1/2 STAAR study in April 2024, with 33 patients dosed in the study. The longest treated patient recently achieved four years of follow-up.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In September 2024, the 18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and final patient who started the study on enzyme replacement therapy, or ERT, was withdrawn from ERT. All 18 patients remain off ERT as of November 12, 2024. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have begun to execute BLA readiness activities for isaralgagene civaparvovec, while continuing to advance ongoing business development discussions with potential collaboration partners.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnered Program</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hemophilia A</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pfizer plans to present detailed data from the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy that we have co-developed with and licensed to Pfizer for the treatment of adults with moderately severe to severe hemophilia A, in an oral presentation at the 66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> American Society for Hematology Annual Meeting and Exposition on December 9, 2024 and in a poster presentation. Summaries of the accepted abstracts are more fully described below.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pfizer is discussing these data with regulatory authorities.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are eligible to earn from Pfizer up to $220.0 million in potential milestone payments upon the achievement of certain regulatory and commercial milestones for giroctocogene fitelparvovec and product sales royalties of 14% - 20% if giroctocogene fitelparvovec is approved and commercialized, subject to reductions due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:9pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Summary of Results from the Hemophilia &#913; Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia &#913; Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Giroctocogene fitelparvovec (PF-07055480) is a liver-directed recombinant adeno-associated virus serotype 6, or AAV6, gene therapy vector encoding a B-domain-deleted variant of human factor VIII, or FVIII, that enables sustained endogenous FVIII expression. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">AFFINE (NCT04370054) is an ongoing, pivotal phase 3 trial to evaluate the efficacy and safety of giroctocogene fitelparvovec in individuals with hemophilia A. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The primary endpoint of the AFFINE trial is to demonstrate non-inferiority in total (treated and untreated) annualized bleeding rate, or ABR, compared with routine prophylactic FVIII replacement therapy collected prospectively in a separate lead-in trial. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The lead-in trial was initiated to establish prospective bleeding and infusion rates while on FVIII prophylaxis replacement therapy in the usual care setting of participants with hemophilia A. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The baseline data obtained in this trial will be used for comparison with data collected post gene therapy for those participants who subsequently enrolled in the giroctocogene fitelparvovec phase 3 AFFINE trial.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">This study (NCT03587116) is a prospective, noninterventional, phase 3 lead-in trial that enrolled adult men &#8805;18 to &lt;65 years old with moderately severe to severe hemophilia A (FVIII &#8804;1%) on stable prophylaxis FVIII replacement therapy who tested negative for neutralizing antibodies, or nAb, to AAV6. The trial is multi-regional in 18 countries in North America, South America, Asia Pacific, Europe, and the Middle East. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Participants were instructed to record infusions and bleeding events in an electronic diary, with most participants providing &#8805;6 months of data prior to entry in the phase 3 AFFINE trial. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Selected safety data (serious adverse events, or SAEs, and medically important events of FVIII inhibitor, thrombotic events, and factor hypersensitivity reactions) of FVIII replacement therapy were also collected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In all, 241 patients with hemophilia A were screened and 101 were enrolled in the hemophilia A cohort of this lead-in trial. The most common reason for screen failure was nAb positivity at screening in 115 (82.1%) of the 140 screen failures. The mean (range) age of those enrolled was 31.8 (18 to 64) years. Most participants were 18-44 years of age (84 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">[83.2%]), White (78 [77.2%]), and not Hispanic or Latino (76 [75.2%]). Target joints were identified in 47 (46.5%) participants. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Overall, 84 (83.2%) participants had &#8805;180 days of follow-up; the mean (SD) follow-up duration of these participants was 351.3 (197.32) days and 23 (22.8%) had &#8805;1 year of follow-up. Overall, 17 (16.8%) participants had &lt;180 days of follow-up; the mean (SD) follow-up duration of these participants was 84.8 (43.64) days. The overall mean (SD) follow-up duration was 306.5 (206.55) days. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The mean (SD) total ABR was 6.1 (10.6), mean (SD) treated ABR was 4.87 (7.2), and mean (SD) annualized infusion rate, or AIR, was 127.1 (51.8). The mean (SD) annualized total FVIII replacement therapy consumption was 304,998 (153,932) IU. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Of the 101 participants, four (4.0%) experienced four SAEs (hemorrhoidal hemorrhage, upper gastrointestinal hemorrhage, wound infection, and B-cell lymphoma; n=1 [1.0%] each); all SAEs were severe except upper gastrointestinal hemorrhage, which was moderate in severity. No adverse events of special interest were reported, and no safety signals were identified for FVIII replacement therapy.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ABR and AIR collected in this lead-in trial are representative of FVIII prophylaxis in hemophilia A populations. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Although FVIII prophylaxis was well tolerated, with no emerging safety signals, a total ABR of 6.1 illustrates the limitations of current standard of care prophylaxis. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The total ABR reported in a subset of participants who went on to enroll in the phase 3 AFFINE trial of giroctocogene fitelparvovec will be used as the comparator for the primary endpoint evaluating noninferiority post gene therapy, in accordance with the AFFINE trial protocol.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Summary of Primary Analysis Results from Phase 3 AFFINE Trial</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Giroctocogene fitelparvovec (PF-07055480), a hepatocyte-directed recombinant AAV serotype 6 vector encoding a B-domain&#8211;deleted variant of human FVIII, is a single-dose gene therapy aimed at enabling sustained endogenous FVIII expression in individuals with hemophilia A, or HA.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">AFFINE (NCT04370054) is a phase 3, open-label, single-arm trial that enrolled adult men with HA (FVIII:C &#8804;1%) who had completed a lead-in study while on exogenous FVIII prophylaxis therapy prior to administration of a single infusion of 3e13 vg/kg giroctocogene fitelparvovec. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Primary and secondary endpoints were assessed in the efficacy population corresponding to participants with &#8805;15 months follow-up post-infusion and at least six months follow-up in the lead-in study (n=50). </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The primary endpoint was ABR for total (treated and untreated) bleeds from Week 12 (onset of clinically meaningful transgene-derived FVIII levels) through &#8805;15 months post-infusion compared to the pre-infusion prophylaxis period. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Key secondary endpoints were the percentage of participants with FVIII activity &gt;5%, as assessed via chromogenic assay, at 15 months and ABR for treated bleeds. AIR of exogenous FVIII replacement from Week 12 to &#8805;15 months post-infusion was a secondary endpoint. Additional secondary endpoints, including the incidence and severity of adverse events, or AEs, were assessed for all dosed participants (n=75).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As of June 2024, 75 participants (median age, 30 [range 19&#8211;59] years) were dosed with giroctocogene fitelparvovec (median duration of follow-up, 16.8 [range 7.8&#8211;44.4] months). Of those 75 participants, 50 were included in the efficacy population (median duration of follow-up, 33.6 [range 14.5&#8211;44.4] months). </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Within this efficacy population, the study met its primary endpoint with a statistically significant decrease (non-inferiority and superiority; one-sided p-value=0.004) in total ABR from Week 12 through &#8805;15 months post-infusion compared to pre-infusion prophylaxis (mean total ABR, 1.2 vs 4.7; treatment difference, -3.49 [95% CI: -6.06, -0.91]). At Month 15, 84% of participants (95% CI: 70.9%, 92.8%; one-sided p-value=0.0086 vs null hypothesis of &#8804;68%) had FVIII activity &gt;5%. Participants continued to maintain FVIII activity &gt;5%, with 82.8% of participants [n=29] continuing to maintain FVIII activity &gt;5% at 2-years post-infusion and 63% of participants [n=8] at 3-years post-infusion respectively. Treated ABR during Week 12 through &#8805;15 months post-infusion was significantly reduced compared to prophylaxis (mean treated ABR, 0.07 vs 4.1; treatment difference, -4.01 [95% CI: -5.57, -2.45; one-sided p-value&lt;0.0001]), also demonstrating superiority. During the same period, 64% of participants had no bleeds, and 88% of participants had no treated bleeds. AIR post-infusion was reduced by 99.8% compared to the pre-infusion period (mean AIR, 0.2 vs 124.4). </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As of the June 2024 cutoff date, one (1.3%) dosed participant had resumed prophylaxis (at 16.1 months post-infusion). A total of 624 AEs, mostly mild or moderate, were reported in 74 (98.7%) participants. There were 26 serious AEs, or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SAEs, in 15 (20%) participants, with pyrexia most common (5 [6.7%] participants). The most common treatment-related AEs were pyrexia (54.7% of participants), alanine aminotransferase, or ALT, increased (46.7%), and headache (38.7%). There have been no study discontinuations. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Post-infusion, 62.7% of participants received at least one dose of corticosteroids due to ALT elevations or decreases in FVIII activity (median time to initiation, 84 [range 7&#8211;193] days; mean total time on corticosteroids, 114.6 [11&#8211;296] days). AEs related to corticosteroids were reported in 19 (25.3%) participants. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Transient FVIII activity &gt;150% (defined as &#8805;1 central chromogenic assay measurement &gt;150%) was reached in 37 (49.3%) participants, with 23 (30.7%) treated with prophylactic direct oral anticoagulants based on protocol and investigator&#8217;s recommendation, which was well tolerated.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Giroctocogene fitelparvovec yielded endogenous FVIII expression in the mild to normal range in most participants, resulting in superior bleed protection versus routine FVIII prophylaxis and significant reductions in bleeding. A single infusion was well tolerated and demonstrated durable efficacy on all primary and key secondary endpoints.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaborations with biopharmaceutical companies bring us important financial and strategic benefits and reinforce the potential of our research and development efforts and our zinc finger, or ZF, technology platform. They leverage our collaborators&#8217; therapeutic and clinical expertise and commercial resources with the goal of bringing our medicines more rapidly to patients. We believe these collaborations will potentially expand the addressable markets of our product candidates. To date, we have received approximately $867.0 million in upfront licensing fees, milestone payments and proceeds from sale of our common stock to collaborators and have the opportunity to earn up to $3.8 billion in potential future milestone payments from our ongoing collaborations, in addition to potential product royalties.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing &amp; Process Development</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following restructuring of our operations initiated in 2023, we expect to be substantially reliant on external partners to manufacture clinical supply for our neurology portfolio. We are retaining our in-house analytical and process development capabilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Macroeconomic Conditions</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and operations and those of our collaborators may be affected by financial instability and declining economic conditions in the United States and other countries caused by political instability and conflict, including the ongoing conflict between Russia and Ukraine and conflicts in the Middle East, or by general health crises, which have in the past led to market disruptions, including significant volatility in commodity prices, credit and capital markets instability, including disruptions in access to bank deposits and lending commitments, supply chain interruptions, rising interest rates and global inflationary pressures. These macroeconomic factors could materially and adversely affect our ability to continue to operate as a going concern and could otherwise have a material adverse effect on our business, operations, operating results and financial condition as well as the price of our common stock. In particular, our ability to raise the substantial additional capital we need in order to fund our business and to continue to operate as a going concern may be adversely impacted by these macroeconomic factors, and we cannot be certain that we will be able to obtain financing on terms acceptable to us, or at all. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Components of Results of Operations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues have consisted primarily of revenues from collaboration agreements, which included upfront licensing fees, reimbursements for research services, and milestone achievements, and research grant funding. In 2023, our collaboration agreements with Biogen MA, Inc. and Biogen International GmbH, which we refer to together as Biogen, and Novartis Institutes for BioMedical Research, Inc., or Novartis, were terminated, and the collaboration agreement with Kite Pharma, Inc., a Gilead Sciences, Inc. subsidiary, or Kite, expired pursuant to its terms in April 2024. We expect revenues to continue to fluctuate from period to period and there can be no assurance that new collaborations or partner reimbursements will continue beyond their initial terms or that we are able to meet the milestones specified in these agreements. For additional information concerning the terms of our ongoing collaboration agreements, see Note 5 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Major Customers, Partnerships and Strategic Alliances</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the accompanying notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since inception and expect to incur losses for at least the next several years as we continue our research and development activities. To date, we have funded our operations primarily through the issuance of equity securities and revenues from collaborations and research grants.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we expect research and development expenses to decrease in the near-term in connection with the restructuring of operations and reduction in workforce and significant reduction in our internal manufacturing and allogeneic research </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">footprints in California announced in April 2023, or the April 2023 Restructuring, the further restructuring of operations and corresponding reduction in workforce announced in November 2023, or the November 2023 Restructuring, and the wind-down of operations in France and corresponding reduction in workforce, including closure of our cell therapy manufacturing facility and research labs in Valbonne, France, or the France Restructuring, we expect to continue to devote substantial resources to research and development in the future and expect research and development expenses to increase in the next several years if we are successful in advancing our product candidates from research stage through clinical trials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and personnel related expenses for executive, finance and administrative personnel, stock-based compensation expense, professional fees, allocated facilities and information technology expenses, patent prosecution expenses and other general corporate expenses. Although we expect general and administrative expenses to decrease in the near-term in connection with the April 2023 Restructuring, November 2023 Restructuring and France Restructuring, we expect the growth of our business to require increased general and administrative expenses as we continue to advance our product candidates into and through the clinic.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements and the related disclosures have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these Condensed Consolidated Financial Statements requires us to make estimates, assumptions and judgments that affect the reported amounts in our Condensed Consolidated Financial Statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe the following policies to be the most critical to an understanding of our financial condition and results of operations because they require us to make estimates, assumptions and judgments about matters that are inherently uncertain.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our critical accounting policies and estimates relating to valuation of long-lived assets are the most significant estimates and assumptions used in the preparation of our Condensed Consolidated Financial Statements. See Note 1 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organization, Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the accompanying notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in our critical accounting policies and estimates during the three and nine months ended September&#160;30, 2024, as compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in Part II, Item 7 of the 2023 Annual Report.</span></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_100"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Three and Nine Months Ended September&#160;30, 2024 and 2023</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.652%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentage values)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentage values)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,249&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,941)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71%)</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues during the three and nine months ended September&#160;30, 2024 primarily consisted of revenues from the collaboration agreement with Genentech and royalties from our license agreements with Sigma-Aldrich Corporation, or Sigma, and Open Monoclonal Technology, Inc. (now Ligand Pharmaceuticals Inc.), or Ligand. We anticipate revenues in the future will be derived primarily from our license agreements. The terminations of our collaboration agreements with Biogen and Novartis became effective in June 2023, following which we are not entitled to any further milestone payments or royalties from either Biogen or Novartis, nor does either Biogen or Novartis have any further obligations to develop or to reimburse us the costs of any of the programs previously subject to the Biogen and Novartis collaborations. Further, our collaboration agreement with Kite expired pursuant to its terms in April 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $40.0&#160;million in revenues for the three months ended September&#160;30, 2024, compared to the same period in 2023, was primarily attributed to $49.2&#160;million in revenue relating to our collaboration agreement with Genentech. This increase was offset by a decrease of $5.5&#160;million in revenue relating to our collaboration agreement with Kite which expired pursuant to its terms in April 2024, a decrease of $2.2 million in revenue relating to our research evaluation and option agreement with Prevail Therapeutics, and a decrease of $1.5 million in revenue relating to our other license agreements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of $123.9&#160;million in revenues for the nine months ended September&#160;30, 2024, compared to the same period in 2023, was primarily attributed to decreases of $134.8&#160;million and $12.2&#160;million in revenues relating to our collaboration agreements with Biogen and Novartis, respectively, due to the termination of collaboration agreements in June 2023, a decrease of $19.0&#160;million in revenue relating to our collaboration agreement with Kite which expired pursuant to its terms in April 2024, a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease of $4.3 million in revenue relating to our license agreements with Sigma and Ligand, and a decrease of $2.8 million in revenue relating to our other license agreements. These decreases were offset by $49.2&#160;million in revenue relating to our collaboration agreement with Genentech.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.652%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentage values)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentage values)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,918&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,869)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,068&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,207)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,799)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,711)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill and indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89,485)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,781&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,806&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,025)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,228&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386,136&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257,908)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67%)</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consisted primarily of compensation related expenses, including restructuring charges and stock-based compensation, laboratory supplies, preclinical and clinical studies, manufacturing clinical supply, contracted research and development, and allocated facilities and information technology expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of $29.4 million in research and development expenses for the three months ended September&#160;30, 2024, compared to the same period in 2023, was primarily attributable to lower preclinical, clinical and manufacturing expenses of $14.7 million primarily related to the deferral and reprioritization of certain programs, lower compensation and other personnel costs of $5.6 million due to lower headcount as a result of restructurings of operations and corresponding reductions in workforce announced during 2023, lower allocated overhead costs of $4.9 million due to changes in the pool of allocable costs as a result of restructuring of operations, and lower facilities and infrastructure related expenses of $4.7 million, including depreciation. Stock-based compensation expense included in research and development expenses was $1.5 million and $3.2 million for the three months ended September&#160;30, 2024 and 2023, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of $95.5 million in research and development expenses for the nine months ended September&#160;30, 2024, compared to the same period in 2023, was primarily attributable to lower preclinical, clinical and manufacturing expenses of $39.6 million primarily related to the termination of collaboration agreements with Biogen and Novartis and deferral and reprioritization of certain programs, lower compensation and other personnel costs of $33.7 million due to lower headcount as a result of restructurings of operations and corresponding reductions in workforce announced during 2023 and restructuring expenses, lower allocated overhead costs of $11.5 million due to changes in the pool of allocable costs as a result of restructuring of operations, and lower facilities and infrastructure related expenses of $10.4 million, including depreciation. Stock-based compensation expense included in research and development expenses was $4.2 million and $12.0 million for the nine months ended September&#160;30, 2024 and 2023, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to devote substantial resources to research and development in the future. While we anticipate that our research and development expenses will decrease in the near-term in connection with the April 2023 Restructuring, November 2023 Restructuring and France Restructuring and the related reprioritization of certain programs and deferral of certain new investments, we ultimately expect research and development expenses to increase in the next several years if we are successful in advancing our clinical programs and if we are able to progress our preclinical product candidates into clinical trials and/or if we are successful in securing new collaborations or other capital necessary to advance our clinical programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time required to complete our development programs and our development costs for those programs may be impacted by the results of preclinical testing, scope and timing of enrollment in clinical trials for our product candidates, our decisions to pursue development programs in other therapeutic areas, whether we pursue development of our product candidates with a partner or collaborator or independently and our ability to secure the necessary funding to progress the development of our programs. For example, our current focus is on our core neurology preclinical program, and we do not yet know whether and to what extent we will progress any resulting product candidates from our preclinical program into the clinic and in what therapeutic areas. We are actively seeking collaboration partners or a direct external investment, as applicable, to progress our Fabry disease program and STAC-BBB and modular integrase platforms. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued therapeutic area is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential therapeutic areas that we may elect to pursue, and even after having given such input, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of or complete costs associated with our development programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of any necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected. In addition, clinical trials of our product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. A discussion of the risks and uncertainties with respect to our research and development activities, including completing the development of our product candidates, and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of the 2023 Annual Report, as supplemented by the risks described under &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of compensation related expenses including restructuring charges and stock-based compensation for executive, legal, finance and administrative personnel, professional fees, allocated facilities and information technology expenses, and other general corporate expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of $2.9&#160;million in general and administrative expenses for the three months ended September&#160;30, 2024, compared to the same period in 2023, was primarily attributable to lower external professional services expenses of $2.4 million, lower facilities and infrastructure related costs of $2.4 million, an adjustment of $2.2 million to expense relating to settlement of obligations under a manufacturing agreement, and lower compensation and other personnel costs of $0.7 million due to lower headcount as a result of the April 2023 Restructuring and November 2023 Restructuring. These decreases were partially offset by higher allocated overhead costs of $4.9 million due to changes in the pool of allocable costs as a result of restructuring of operations. Stock-based compensation expense included in general and administrative expenses was $1.8 million and $3.0 million for the three months ended September&#160;30, 2024 and 2023, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of $13.2&#160;million in general and administrative expenses for the nine months ended September&#160;30, 2024, compared to the same period in 2023, was primarily attributable to lower compensation and other personnel costs of $9.8 million due to lower headcount as a result of restructurings of operations and corresponding reductions in workforce announced during 2023 and restructuring expenses, lower external professional services expenses of $6.3 million, lower facilities and infrastructure related costs of $5.6 million, and Biogen contract cost asset amortization of $2.6 million recorded in 2023 due to the termination of the collaboration agreement. These decreases were partially offset by higher allocated overhead costs of $11.5 million due to changes in the pool of allocable costs as a result of restructuring of operations. Stock-based compensation expense included in general and administrative expenses was $4.9 million and $9.3 million for the nine months ended September&#160;30, 2024 and 2023, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we anticipate that our general and administrative expenses will decrease modestly in the near-term in connection with the April 2023 Restructuring, November 2023 Restructuring and France Restructuring, we expect higher general and administrative expenses in the next several years if we are successful in advancing our clinical programs and if we are able to progress our preclinical product candidates into clinical trials and/or if we are successful in securing new collaborations or other capital.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Charges</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we executed a series of restructurings of operations and corresponding reductions in workforce announced in April 2023 and November 2023. In 2024, we are executing a wind-down of our French operations and a corresponding workforce reduction announced in March 2024. These restructurings were designed to reduce overall costs and advance our strategic transformation into a neurology focused genomic medicine company focused on epigenetic regulation programs addressing serious neurological diseases and novel AAV capsid delivery technology. Restructuring charges associated with the April 2023 Restructuring are complete as of September 30, 2024. In connection with the November 2023 Restructuring and France Restructuring, the expenses incurred and adjustments recorded during the three and nine months ended September&#160;30, 2024 related to employee severance and notice period payments, benefits, and other employee-related costs were not material.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information see&#160;Note&#160;10&#160;&#8211;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Charges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the accompanying notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form&#160;10-Q.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2024, there were no indicators of impairment for any of the Company&#8217;s asset groups and no additional impairment was recorded. During the nine months ended September&#160;30, 2024, we recognized impairment charges of $5.5 million. During the nine months ended September&#160;30, 2024, our Board of Directors approved the France Restructuring, we initiated several actions aimed at reducing costs, including activities related to the closure of our facility in Brisbane, California, and we faced a sustained decline in our stock price and related market capitalization. There was also a decline in the market rates for facility subleases, indicating the carrying values of right of use and leasehold improvement assets could be impaired. As a result of these factors, we concluded certain long-lived assets, primarily comprising right-of-use assets, related leasehold improvements, and certain manufacturing and laboratory equipment, were impaired.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2023, we recognized impairment charges of $44.8 million and $154.7 million, respectively. During the nine months ended September 30, 2023, we experienced a sustained decline in our stock price and related market capitalization, deferral and reprioritization of certain research and development programs, and our collaboration agreements with Biogen and Novartis were terminated. As a result of these factors, we concluded our goodwill, indefinite-lived intangible asset, and long-lived assets, primarily comprising right-of-use assets, related leasehold improvements and construction-in-progress, and manufacturing and laboratory equipment, were impaired.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information see&#160;Note&#160;6&#160;&#8211;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment and Write-Down of Assets Held For Sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the accompanying notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and other income, net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income, net was $0.1 million and $3.5 million for the three months ended September&#160;30, 2024 and 2023, respectively. The decrease of $3.4&#160;million was primarily driven by a decrease of $1.0&#160;million in interest income due to a decrease in marketable securities, a decrease of $1.8 million in research tax credits, and a decrease of $0.8 million related to fluctuations in foreign currency exchange rates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income, net was $3.7 million and $9.6 million for the nine months ended September&#160;30, 2024 and 2023, respectively. The decrease of $5.9&#160;million was primarily driven by a decrease of $4.6&#160;million in interest income due to a decrease in marketable securities, and a decrease of $2.3 million in research tax credits, partially offset by $0.6 million from gain on sale of investments, and $0.3 million related to fluctuations in foreign currency exchange rates.</span></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_103"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant net losses, and we have funded our operations primarily through the issuance of equity securities, payments from corporate collaborators and strategic partners and research grants.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, we had cash and cash equivalents totaling $39.2&#160;million, compared to cash, cash equivalents, and marketable securities of $81.0&#160;million as of December&#160;31, 2023. Our most significant use of capital during the year was for employee compensation and external research and development expenses, such as manufacturing, clinical trials and preclinical activity related to our therapeutic programs. Cash in excess of immediate requirements is invested in accordance with our investment policy with a view toward capital preservation and liquidity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we entered into an Open Market Sale Agreement&#8480;, or the sales agreement, with Jefferies LLC, providing for the sale of up to $150.0&#160;million of our common stock from time to time in &#8220;at-the-market&#8221; offerings under an existing shelf registration statement. In December 2022, we entered into an amendment to the Open Market Sale Agreement&#8480;, which increased the aggregate offering price under the sales agreement by an additional $175.0 million. No shares were sold during the three and nine months ended September&#160;30, 2024. Approximately $194.5&#160;million remained available under the sales agreement as of September&#160;30, 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Accounting Standard Codification Topic 205-40, Presentation of Financial Statements&#8212;Going Concern, or ASC Topic 205-40, we have the responsibility to evaluate whether conditions and/or events raise substantial doubt about our ability to meet our future financial obligations as they become due within one year after the date that the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q are issued. As required under ASC Topic 205-40, management&#8217;s evaluation should initially not take into consideration the potential mitigating effects of management&#8217;s plans that have not been fully implemented as of the date the Condensed Consolidated Financial Statements are issued. When substantial doubt exists, management evaluates whether the mitigating effects of its plans sufficiently alleviate the substantial doubt about the company&#8217;s ability to continue as a going concern. The mitigating effects of management&#8217;s plans, however, are only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans must have been approved by the company&#8217;s board of directors before the date that the financial statements are issued.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, our cash and cash equivalents as of September&#160;30, 2024, together with the $10.0&#160;million milestone payment that we received from Genentech in October&#160;2024, are expected to allow us to meet our liquidity requirements only into the first quarter of 2025. Our history of significant losses, negative cash flows from operations, limited liquidity resources currently on hand and dependence on our ability to obtain additional financing to fund our operations have resulted in management&#8217;s assessment that there is substantial doubt about our ability to continue as a going concern for at least the next 12 months from the date the financial statements included in this Quarterly Report are issued. Our ability to continue to operate as a going concern is dependent upon our ability to raise substantial additional capital to fund our operations and support our research and development endeavors, including to progress our preclinical and clinical programs as described in our 2023 Annual Report and in this Quarterly Report. Although we received the Genentech Payments, and raised capital via a registered direct offering to institutional investors of common stock and accompanying warrants in March 2024, we will still need substantial additional capital in order to continue to operate as a going concern and fund our operations. We have been actively seeking, and continue to actively seek, substantial additional capital, including through public or private equity or debt financing, royalty financing or other sources, such as strategic collaborations and other direct investments in our programs. We may be unable to attract new investments as a result of the speculative nature of our newly reprioritized core neurology preclinical programs. Additional capital may not be available on acceptable terms or at all. If adequate funds are not available to us on a timely basis, or at all, we will be required to take additional actions to address our liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering our research and development activities, which would have a material adverse effect on our business and prospects, or we may be required to cease operations entirely, liquidate all or a portion of our assets, and/or seek protection under the U.S. Bankruptcy Code, and you may lose all or part of your investment. We have explored, and will continue to explore, whether filing for bankruptcy protection is in the best interest of our Company and our stakeholders.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the April 2023 Restructuring was completed in the third quarter of 2024, and we expect the France Restructuring and November 2023 Restructuring to be complete by the fourth quarter of 2024 and second quarter of 2025, respectively, we may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, each of the restructurings. In addition, we may not achieve the expected benefits of these cost reduction measures and other cost reduction plans on the anticipated timeline, or at all, or we may use our available capital more quickly than we expect, which could otherwise accelerate our liquidity needs and could force us to further curtail or suspend, or entirely cease, our operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we rely in part on our collaboration partners to provide funding for and otherwise advance our preclinical and clinical programs. While we continue to advance ongoing business development discussions with potential collaboration partners regarding our Fabry disease program and our novel STAC-BBB capsid and our modular integrase platforms, we may not be successful in doing so in a timely manner, on acceptable terms or at all, and we may otherwise fail to raise sufficient additional capital to advance our programs, in which case, we may not receive the expected return on our investments in these programs, platforms and technologies. In any event, we need substantial additional funding in order to execute on our current operating plan. If we raise additional capital through public or private equity offerings, including sales pursuant to our at-the-market offering program with Jefferies LLC, the ownership interest of our existing stockholders will be diluted, and such dilution may be substantial given our current stock price decline, and the terms of any new equity securities may have a preference over, and include rights superior to, our common stock. If we raise additional capital through royalty financings or other collaborations, strategic alliances or licensing arrangements with third parties, we may need to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable. If we raise additional capital through debt financing, we may be subject to specified financial covenants or covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or pursuing certain transactions, any of which could restrict our ability to commercialize our product candidates or operate as a business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as we focus our efforts on proprietary human therapeutics, we will need to seek regulatory approvals of our product candidates from the FDA or other comparable foreign regulatory authorities, a process that could cost in excess of hundreds of millions of dollars per product. We may experience difficulties in accessing the capital markets due to external factors beyond our control, such as volatility in the equity markets for emerging biotechnology companies and general economic and market conditions both in the United States and abroad. In particular, our ability to raise the substantial additional capital we need in order to fund our business may be adversely impacted by global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide, such as has been experienced recently due in part to, among other things, the ongoing conflict between Russia and Ukraine and conflicts in the Middle East. We cannot be certain that we will be able to obtain financing on terms acceptable to us, or at all.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $63.8&#160;million for the nine months ended September&#160;30, 2024, primarily due to:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a net loss of $74.5&#160;million, adjusted for non-cash long-lived asset impairment charges of $5.5&#160;million, other non-cash expenses related to stock-based compensation of $9.1&#160;million, depreciation and amortization of $3.9&#160;million, and amortization of operating lease right-of-use assets of $3.4&#160;million, offset partially by accretion of discounts and impairment of marketable securities of $0.3&#160;million; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in accounts receivable by $9.6&#160;million, a decrease in accounts payable and other accrued liabilities by $6.9&#160;million, and a decrease in lease liabilities by $4.1&#160;million. These were partially offset by a decrease in prepaid expenses and other assets by $6.4&#160;million, an increase in accrued compensation and employee benefits by $2.1&#160;million, an increase in deferred revenue by $0.8&#160;million, and a decrease in interest receivable by $0.4&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $174.3 million for the nine months ended September 30, 2023, primarily due to:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a net loss of $197.5 million, adjusted for non-cash goodwill, indefinite-lived intangible assets, and long-lived asset impairment charges of $154.7 million, other non-cash expenses related to stock-based compensation of $21.3 million, depreciation and amortization of $13.2 million, and amortization of operating lease right-of-use assets of $5.9 million, offset by income tax benefit of $6.2 million related to reversal of the deferred tax liability as a result of impairment on the associated indefinite-lived intangible assets, accretion of discounts and impairment of marketable securities of $2.0 million, and other non-cash adjustments of $1.1 million; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in deferred revenues of $159.7 million, mainly attributed to the impact of the termination and related contract modification of our collaboration agreement with Biogen and a change in estimate for our collaboration agreement with Kite, a decrease in accounts payable and other accrued liabilities by $5.2 million, a decrease in accrued compensation and employee benefits by $4.2 million, and a decrease in lease liabilities by $3.7 million. These were partially offset by decrease in prepaid expenses and other assets by $5.2 million, and a decrease in accounts receivable by $2.5 million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $36.2&#160;million for the nine months ended September&#160;30, 2024, related to sales of marketable securities of $34.7&#160;million, maturities of marketable securities of $1.1&#160;million, and sales of assets classified as held for sale of $0.5&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $115.8 million for the nine months ended September 30, 2023, related to maturities of marketable securities of $193.9 million, partially offset by purchases of marketable securities of $59.6 million, and purchases of property and equipment of $18.5 million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $21.4&#160;million for the nine months ended September&#160;30, 2024, related to $21.9&#160;million of proceeds from issuance of common stock, net of offering expenses of $2.1&#160;million, and proceeds from issuance of common stock under employee stock purchase plan of $0.1&#160;million, partially offset by taxes paid related to net share settlement of equity awards of $0.7&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $14.4 million for the nine months ended September 30, 2023, related to $15.1 million of proceeds from the at-the-market offering, net of offering expenses of $0.4 million, and proceeds from purchases of common stock under the employee stock purchase plan of $0.7 million, partially offset by taxes paid related to net share settlement of equity awards of $1.4 million.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Capital and Capital Expenditure Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate continuing to incur operating losses for at least the next several years and need to raise substantial additional capital. The effects of the current macroeconomic environment, including the effects of war in Ukraine and conflicts in the Middle East, inflation, climate change, rising interest rates and other economic uncertainty and volatility, has resulted and may continue to result in significant disruption of global financial markets, which could impair our ability to access capital on terms that are acceptable or at all, and in turn could negatively affect our liquidity and our ability to continue to operate as a going concern. Future capital requirements beyond the first quarter of 2025, the period into which we expect our existing cash and cash equivalents, including the Genentech Payments, will be sufficient to fund our planned operations, will be substantial, and we need to raise substantial additional capital to continue to operate as a going concern and to fund the development, manufacturing and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential commercialization of our product candidates (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;Financial Position&#8211;Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;Liquidity and Capital Resources&#8211;Liquidity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; above). </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we focus our efforts on proprietary human therapeutics, we will need to seek FDA approvals of our product candidates, a process that could cost in excess of hundreds of millions of dollars per product. Our future capital requirements will depend on many forward-looking factors, including the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of preclinical testing of our early-stage core neurology program product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing and completion of clinical trials for our product candidates and potential product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays that may be caused by changing regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of product candidates that we pursue;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and terms of future in-licensing and out-licensing transactions;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of establishing sales, marketing, manufacturing and distribution capabilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of procuring clinical and commercial supplies of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products or technologies, including the costs associated with such acquisitions and investments; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of potential disputes and litigation.</span></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_109"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future minimum contractual obligations as of December&#160;31, 2023 were reported in the 2023 Annual Report. During the nine months ended September&#160;30, 2024, there have been no material changes outside the ordinary course of our business from the contractual obligations previously disclosed in our 2023 Annual Report.</span></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_115"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_118"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision of our principal executive officer and principal financial officer, we evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of September&#160;30, 2024. Based on that evaluation, as of September&#160;30, 2024, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including the principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures and our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well designed and operated, can only provide reasonable assurances that the objectives of the control system are met. The design of a control system reflects resource constraints; the benefits of controls must be considered relative to their costs. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, for our company have been or will be detected. As these inherent limitations are known features of the disclosure and financial reporting processes, it is possible to design into the processes safeguards to reduce, though not eliminate, these risks. These inherent limitations include the realities that judgments in decision-making can be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">faulty and that breakdowns occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events. While our disclosure controls and procedures and our internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives, there can be no assurance that any design will succeed in achieving its stated goals under all future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with the policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting that occurred during the quarter ended September&#160;30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_124"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not party to any material pending legal proceedings. From time to time, we may be involved in legal proceedings arising in the ordinary course of business.</span></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_127"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below we are providing, in supplemental form, changes to our risk factors from those previously disclosed in Part I, Item 1A of the 2023 Annual Report. Our risk factors disclosed in Part I, Item 1A of the 2023 Annual Report provide additional discussion about these supplemental risks and we encourage you to read and carefully consider the risk factors disclosed in Part I, Item 1A of the 2023 Annual Report for a more complete understanding of the risks and uncertainties material to our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have historically incurred significant operating losses since inception and anticipate that we will incur continued losses for the foreseeable future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a history of recurring net losses, including $74.5&#160;million for the nine months ended September 30, 2024 and $257.8 million and $192.3 million for the years ended December 31, 2023 and 2022, respectively, and we have otherwise generated operating losses since we began operations in 1995. The extent of our future losses and the timing of profitability are uncertain, and we expect to incur losses for the foreseeable future. We have been engaged in developing our zinc finger, or ZF, technology since inception, which has and will continue to require significant research and development expenditures. To date, we have generated our funding from issuance of equity securities, revenues derived from collaboration agreements, other strategic partnerships in non-therapeutic applications of our technology, federal government research grants and grants awarded by research foundations. We expect to continue to incur additional operating losses for the next several years as we continue to develop our preclinical core neurology therapeutic programs and capsid engineering platform. If the time required to generate significant product revenues and achieve profitability is longer than we currently anticipate or if we are unable to generate liquidity through equity financing or other sources of funding, we may be forced to further curtail or suspend, or entirely cease, our operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There is substantial doubt about our ability to continue to operate as a going concern. We need substantial additional funding to execute our operating plan and to continue to operate as a going concern. If adequate funds are not available to us on a timely basis, or at all, we will be required to take additional actions to address our liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering our research and development activities, which would have a material adverse effect on our business and prospects, or we may be required to cease operations entirely, liquidate all or a portion of our assets, and/or seek protection under the U.S. Bankruptcy Code, and you may lose all or part of your investment. Future sales and issuances of equity securities would also result in substantial dilution to our stockholders.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant operating losses and negative operating cash flows since inception and have not achieved profitability. Based on our current operating plan, our cash and cash equivalents as of September 30, 2024, including the $40.0&#160;million in upfront license fee, together with the $10.0&#160;million milestone payment that we received from Genentech in October&#160;2024, or the Genentech Payments, will be sufficient to fund our planned operations only into the first quarter of 2025. Our financial position raises substantial doubt about our ability to continue to operate as a going concern. Our ability to continue to operate as a going concern is dependent upon our ability to raise substantial additional capital to fund our operations and support our research and development endeavors, including to progress our preclinical and clinical programs as described in our 2023 Annual Report and in this Quarterly Report. In this regard, we have been seeking, and continue to actively seek substantial additional capital, including through public or private equity or debt financing, royalty financing or other sources, such as strategic collaborations and other direct investments in our programs. Although we received the Genentech Payments, and raised capital via a registered direct offering to institutional investors of common stock and accompanying warrants in March 2024, or the 2024 Registered Direct Offering, for net proceeds of approximately $21.8 million after deducting placement agents&#8217; fees and estimated offering expenses payable by us, we will still need substantial additional capital in order to continue to operate as a going concern and fund our operations. Additional capital may not be available on acceptable terms or at all. In particular, the perception of our ability to continue to operate as a going concern may make it more difficult to obtain financing for the continuation of our operations, particularly in light of currently challenging macroeconomic and market conditions. Further, we may be unable to attract new investments as a result of the speculative nature of our newly reprioritized core neurology preclinical programs. If adequate funds are not available to us on a timely basis, or at all, we will be required to take additional actions to address our liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering our research and development activities, which would have a material adverse effect on our business and prospects, or we may be required to cease operations entirely, liquidate all or a portion of our assets, and/or seek protection under the U.S. Bankruptcy Code, and you may lose all or part of your investment. We have </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">explored, and will continue to explore, whether filing for bankruptcy protection is in the best interest of our Company and our stakeholders.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we announced a restructuring of operations and a reduction in force and a significant reduction in our internal manufacturing and allogeneic research footprints in California, or the April 2023 Restructuring, and in November 2023, we announced a further restructuring of operations and reduction in force, or the November 2023 Restructuring, including a strategic transformation to focus resources on our proprietary neurology-focused epigenetic regulation programs and AAV capsid delivery technology and move all U.S. operations, including our headquarters, to our Richmond, California facility. On March 1, 2024, our board of directors approved the wind-down of our operations in France and closure of our facility in Valbonne, France by the end of 2024, or the France Restructuring. While the April 2023 Restructuring was completed in the third quarter of 2024, and we expect the France Restructuring and November 2023 Restructuring to be complete by the fourth quarter of 2024 and second quarter of 2025, respectively, we may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, each of the restructurings. In addition, we may not achieve the expected benefits of these cost reduction measures and other cost reduction plans on the anticipated timeline, or at all, or we may use our available capital more quickly than we expect, which could otherwise accelerate our liquidity needs and could force us to further curtail or suspend, or entirely cease, our operations. Moreover, we have historically relied in part on collaboration partners to provide funding for and otherwise advance our preclinical and clinical programs. However, in June 2023, our collaboration agreements with Biogen and Novartis terminated, and our collaboration agreement with Kite expired pursuant to its terms in April 2024. Further, while we may identify new collaboration partners who can progress some of the programs that were the subject of these collaborations as well as our Fabry disease program and STAC-BBB and modular integrase platforms, we have not yet been, and may never be, successful in doing so in a timely manner, on acceptable terms or at all, and we may otherwise fail to raise sufficient additional capital in order to progress these and our other programs ourselves, in which case, we will not receive any return on our investments in these programs. Although we have entered into the Genentech Agreement pursuant to which we are eligible to earn future development and commercial milestone payments, and have received the Genentech Payments, we may never receive any further payments thereunder. In any event, we need substantial additional funding in order to advance our core neurology programs as well as our Fabry disease program, capsid engineering efforts and modular integrase platform, and to otherwise execute on our current operating plan.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional capital through public or private equity offerings, including sales pursuant to our at-the-market offering program with Jefferies LLC, the ownership interest of our existing stockholders will be diluted, and such dilution may be substantial given our current stock price decline. For example, in the 2024 Registered Direct Offering, we issued 24,761,905 shares of common stock, pre-funded warrants to purchase 3,809,523 shares of common stock and accompanying warrants to purchase an aggregate of 28,571,428 shares of common stock at a price per share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrant of $0.84 per share. In addition, the terms of any new equity securities we may issue may have a preference over, and include rights superior to, our common stock. If we raise additional capital through royalty financings or other collaborations, strategic alliances or licensing arrangements with third parties, we may need to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable. If we raise additional capital through debt financing, we may be subject to specified financial covenants or covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or pursuing certain transactions, any of which could restrict our ability to commercialize our product candidates or operate as a business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as we focus our efforts on proprietary human therapeutics, we will need to seek regulatory approvals of our product candidates from the FDA or other comparable foreign regulatory authorities, a process that could cost in excess of hundreds of millions of dollars per product. We may experience difficulties in accessing the capital markets due to external factors beyond our control, such as volatility in the equity markets for emerging biotechnology companies and general economic and market conditions both in the United States and abroad. In particular, our ability to raise the substantial additional capital we need in order to fund our business may be adversely impacted by global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide, such as has been experienced recently. We cannot be certain that we will be able to obtain financing on terms acceptable to us, or at all. Our failure to obtain adequate and timely funding will adversely affect our ability to continue to operate as a going concern and our ability to develop our technology and products candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we seek to reorganize under the U.S. Bankruptcy Code, our future operations are uncertain, and such reorganization could be unsuccessful and/or result in no recovery for holders of our common stock. If we are unable to successfully reorganize, we may be forced to pursue a liquidation of some or all of our assets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, our cash and cash equivalents as of September 30, 2024, together with the $10.0&#160;million milestone payment that we received from Genentech in October&#160;2024, are expected to allow us to meet our liquidity requirements only into the first quarter of 2025. We continue to actively seek substantial additional capital, including through public or private equity or debt financing, royalty financing or other sources, such as strategic collaborations and other direct </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investments in our programs. We have explored, and will continue to explore, whether filing for bankruptcy protection is in the best interest of our Company and our stakeholders. In the event we file for relief under the U.S. Bankruptcy Code, our operations, our ability to develop our product candidates and execute on our operating plan, and our ability to continue as a going concern will be subject to the risks and uncertainties associated with bankruptcy proceedings, including, among others: our ability to execute, confirm and consummate a plan of reorganization; the additional, significant costs of bankruptcy proceedings and related fees; our ability to obtain sufficient financing to allow us to emerge from bankruptcy and execute our business plan thereafter, and our ability to comply with terms and conditions of any such financing; our ability to continue our operations in the ordinary course; our ability to maintain our relationships with our collaborators, counterparties, employees and other third parties; our ability to obtain, maintain or renew contracts that are critical to our operations on reasonably acceptable terms and conditions or at all; our ability to attract, motivate and retain key employees; the ability of third parties to use certain provisions of the U.S. Bankruptcy Code to terminate contracts without first seeking Bankruptcy Court approval; the ability of third parties to seek and obtain court approval to terminate or shorten the exclusivity period for us to propose and confirm a plan of reorganization, to appoint a trustee, or to convert a proceeding under Chapter 11 of the U.S. Bankruptcy Code to a proceeding under Chapter 7 of the U.S. Bankruptcy Code; and the actions and decisions of our stakeholders and other third parties who have interests in our bankruptcy proceedings that may be inconsistent with our operational and strategic plans. Any delays in our bankruptcy proceedings would increase the risks that we may not be able to reorganize our business and emerge from bankruptcy proceedings and may increase our costs associated with the bankruptcy process or result in prolonged operational disruption. In addition, we would need the prior approval of the Bankruptcy Court for transactions outside the ordinary course of business during the course of any bankruptcy proceedings, which may limit our ability to respond timely to certain events or take advantage of certain opportunities. Because of the risks and uncertainties associated with any bankruptcy proceedings, we cannot accurately predict or quantify the ultimate impact of events that could occur during any such proceedings. There can be no guarantees that if we seek protection under the U.S. Bankruptcy Code, we will emerge from any such proceedings as a going concern or that holders of our common stock will receive any recovery from any bankruptcy proceedings.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we are unable to pursue protection under Chapter 11 of the U.S. Bankruptcy Code, or, if pursued, successfully emerge from such proceedings, it may be necessary for us to pursue protection under Chapter 7 of the U.S. Bankruptcy Code for all or a part of our businesses. In such event, a Chapter 7 trustee would be appointed or elected to liquidate our assets for distribution in accordance with the priorities established by the U.S. Bankruptcy Code. We believe that liquidation under Chapter 7 would result in significantly smaller distributions being made to our stakeholders than those we might obtain under Chapter 11, or no distribution at all, primarily because of the likelihood that the assets would have to be sold or otherwise disposed of in a distressed fashion over a short period of time rather than in a controlled manner and as a going concern. In such event, you may lose part or all of your investment.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercialization of our technologies will depend, in part, on collaborations with other companies. If we are not able to find collaborators in the future or if our collaborators do not diligently pursue product development efforts, we may not be able to develop our technologies or product candidates, which could slow our growth and decrease the market value of our common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have financial resources ourselves to fully develop, obtain regulatory approval for and commercialize our product candidates. We have relied, and expect to continue to rely, on collaborations with other biopharmaceutical companies to provide funding for our research and development efforts, including preclinical studies and clinical tests, and expect to rely significantly on such collaborations to provide funding for the lengthy regulatory approval processes required to commercialize our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, on August 2, 2024, we entered into the Genentech Agreement with Genentech to develop intravenously administered genomic medicines to treat certain neurodegenerative diseases. Under the terms of Genentech Agreement, we were responsible for completing a technology transfer and certain preclinical activities, and Genentech is solely responsible for all clinical development, regulatory interactions, manufacturing and global commercialization of resulting products. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were party to collaboration agreements with Novartis and Biogen to develop product candidates to treat certain neurological diseases. In June 2023, our collaboration agreements with Novartis and Biogen terminated. We were also party to a collaboration agreement with Kite to develop engineered cell therapies for cancer, which expired by its terms in April 2024. As a result of these terminations and expirations, we are no longer entitled to any milestone payments or royalties from Novartis, Biogen or Kite, and such counterparties have no further obligations to develop or to reimburse the costs of any of the programs under the applicable agreement. We cannot guarantee that we will be able to successfully secure new collaborations in the future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to secure additional collaborations or if our collaborators are unable or unwilling to diligently advance the development, regulatory approval and commercialization of our product candidates, our growth may slow and adversely affect our ability to generate funding for development of our technologies and product candidates as well as our ability to continue to operate as a going concern, and we may be required to cease operations. For example, although we have decided to begin executing Biologics License Application, or BLA, readiness activities for our Fabry disease program, we continue to advance </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ongoing business development discussions with potential collaboration partners. There can be no assurance our efforts to secure a collaboration will be successful in a timely manner, or at all, in which case, we may not receive any return on our investments in these programs and our ability to continue to operate as a going concern may be materially and adversely affected. In addition, our ongoing collaborators may sublicense or abandon development programs with little advance notice, or we may have disagreements or disputes with our collaborators, which would cause associated product development to slow or cease. In addition, the business or operations of our collaborators may change significantly through restructurings, acquisitions, other strategic transactions that may negatively impact their ability to advance our programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under typical collaborations, we expect to receive revenue for the research and development of our product candidates based on achievement of specific milestones, as well as royalties based on a percentage of sales of any commercialized products. Achieving these milestones will depend, in part, on the efforts of our collaborators, which we have no control over, as well as our own efforts. In addition, business combinations, changes in a collaborator&#8217;s business strategy and financial difficulties or other factors could result in that collaborator abandoning or delaying development of any product candidates covered by our collaboration agreement with that collaborator. For example, Novartis&#8217;s and Biogen&#8217;s decisions to terminate their respective collaboration agreements with us each related to a recent strategic review. Further, if we fail or any collaboration partner fails to meet specific milestones, then the collaboration agreement may be terminated, which would preclude our ability to earn any additional milestone payments under that collaboration agreement and would reduce our revenues. In addition, even if a collaboration product candidate is successfully developed and approved for marketing by relevant regulatory authorities, if sales of the commercialized product fail to meet expectations, we could receive lower royalties than expected. In any event, the milestone and royalty payment opportunities associated with our collaborations involve a substantial degree of risk to achieve and may never be received. Accordingly, investors should not assume that we will receive all of the potential milestone payments provided for under our ongoing collaborations, and it is possible that we may never receive any further significant milestone payments or any royalty payments under our collaborations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have fully impaired our goodwill and indefinite-lived intangible assets, have recorded significant impairment of our long-lived assets, and may be required to record significant additional charges if our long-lived assets become further impaired in the future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate the carrying value of long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable. Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, general macroeconomic conditions, conditions specific to the industry and market, an adverse change in legal factors, business climate or operational performance of the business, and sustained decline in the stock price and market capitalization compared to the net book value. During the year ended December 31, 2023 and the nine months ended September 30, 2024, we recognized impairment charges of $155.0 million and $5.5&#160;million, respectively. We have fully impaired our goodwill and indefinite-lived intangible assets in 2023 and have significantly impaired our long-lived assets in both 2023 and 2024. We will continue to assess whether our long-lived assets are impaired in future periods. We are finalizing the wind-down of our France operations and corresponding reduction in force of all France employees, as well as the closure of our Brisbane facility, and we have recognized related impairments in the past twelve months. It is reasonably possible that additional impairment charges will be recognized, for example, if sublease rates of leased facilities or selling prices of the assets held for sale are less than those estimated. For additional information regarding these impairment charges, see Note 6 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment and Write-Down of Assets Held For Sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the accompanying notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that changes in circumstances, many of which are outside of our control, or in the numerous variables associated with the assumptions and estimates used in assessing the appropriate valuation of our long-lived assets, could in the future result in significant additional impairment charges to our long-lived assets, which could adversely affect our results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to meet the listing standards of the Nasdaq Stock Market LLC, or Nasdaq, could result in the delisting of our common stock. Delisting could adversely affect the liquidity of our common stock and the market price of our common stock could decrease, and our ability to obtain sufficient additional capital to fund our operations and to continue to operate as a going concern would be substantially impaired.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 24, 2024, we received a deficiency notice, or the Notice, from the Listing Qualifications Staff, or the Staff of Nasdaq, notifying us that, for the prior 30 consecutive business days, the bid price of our common stock had closed below $1.00 per share, thereby failing to satisfy the minimum closing bid price requirement set forth in the continued listing requirements of Nasdaq Listing Rule 5450(a)(1), or the Bid Price Requirement. The Notice had no immediate effect on the listing of our common stock on the Nasdaq Global Select Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we had 180 calendar days, or until October 21, 2024, or the Compliance Date, to regain compliance with the Bid Price Requirement by having shares of our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common stock maintain a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading days before the Compliance Date. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we had not regained compliance with the Bid Price Requirement by the Compliance Date, we filed an application to transfer the listing of our Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market. On October 24, 2024, we received approval from the Staff of Nasdaq to transfer the listing of our common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market, or the Approval. Our common stock was transferred to the Nasdaq Capital Market effective as of the opening of business on October 26, 2024 and has continued to trade under the symbol &#8220;SGMO.&#8221;  The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Select Market, and listed companies must meet certain financial requirements and comply with Nasdaq&#8217;s corporate governance requirements. As a result of the Approval, we were granted an additional 180-day grace period, or until April 21, 2025, or the Second Compliance Date, to regain compliance with the Bid Price Requirement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 5, 2024, we received a letter from the Staff of Nasdaq confirming that our common stock had regained compliance with the Bid Price Requirement, and as a result, our common stock will continue to be listed on the Nasdaq Capital Market.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will continue to meet the Bid Price Requirement, or any other Nasdaq continued listing requirements, in the future. If we fail to meet any of these requirements, including the Bid Price Requirement, Nasdaq may again notify us that we have failed to meet the minimum listing requirements and initiate the delisting process. If our common stock were delisted from Nasdaq, trading of our common stock could be conducted in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board, but there can be no assurance that our common stock will be eligible for trading on such alternative exchange or market. Additionally, if our common stock were delisted from Nasdaq, the liquidity of our common stock would be adversely affected, the market price of our common stock could decrease, our ability to obtain sufficient additional capital to fund our operations and to continue to operate as a going concern would be substantially impaired and transactions in our common stock could lose federal preemption of state securities laws. Furthermore, there could also be a further reduction in our coverage by securities analysts and the news media and broker-dealers may be deterred from making a market in or otherwise seeking or generating interest in our common stock, which could cause the price of our common stock to decline further. Moreover, delisting may also negatively affect our collaborators&#8217;, vendors&#8217;, suppliers&#8217; and employees&#8217; confidence in us and employee morale.</span></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_130"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_133"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_136"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_139"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_142"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.801%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828023020692/sgmo-20230602xex33.htm">Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Company&#8217;s Current Report on Form 8-K filed June 2, 2023).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828024026903/sgmo-20240605xex31.htm">Certificate of Amendment of the Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed June 5, 2024).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828022032209/sgmo-20221219xxex31fifth.htm">Fifth Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed December 19, 2022).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8273;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20240930xex101.htm">License Agreement between the Company and Genentech, Inc., dated August 2, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20240930xex101.htm">4.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="thirdamendmenttoleaseagr.htm">Third Amendment to Lease Agreement between the Company and PPF OFF 7000 Marina Boulevard LP dated July 3, 2024.</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20240930xex311.htm">Rule 13a &#8212; 14(a) Certification of Principal Executive Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20240930xex312.htm">Rule 13a &#8212; 14(a) Certification of Principal Financial Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20240930xex321.htm">Certifications Pursuant to 18 U.S.C. Section 1350.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from Sangamo&#8217;s Quarterly Report on Form 10-Q for the three months ended September&#160;30, 2024 is formatted in Inline XBRL Taxonomy Extension and it is contained in Exhibit 101.</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;The certifications attached as Exhibit&#160;32.1 accompany this Quarterly Report on Form&#160;10-Q pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the Registrant for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended.</span></div><div style="padding-left:54pt;text-indent:-54pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">**&#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability.</span></div><div style="padding-left:54pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8273;&#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain portions of this exhibit (indicated by &#8220;[*]&#8221;) have been omitted in accordance with 17 CFR &#167; 229.601(b).</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">+&#160;&#160;&#160;&#160;Filed herewith.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i2ce39f749ac4424b8fd01e23f7902cf4_145"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i2ce39f749ac4424b8fd01e23f7902cf4_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: November&#160;12, 2024 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SANGAMO THERAPEUTICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ ALEXANDER D. MACRAE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Alexander D. Macrae</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ PRATHYUSHA DURAIBABU</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prathyusha Duraibabu</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Senior Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>sgmo-20240930xex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i33b7a1bc6d5c48499ba12a5e5ef8e34e_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 10.1</font></div><div style="margin-bottom:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div style="margin-bottom:8pt;padding-left:360pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">LICENSE AGREEMENT</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">BETWEEN</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">SANGAMO THERAPEUTICS, INC.</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">AND</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">GENENTECH, INC.</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">AS OF AUGUST 2, 2024</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">TABLE OF CONTENTS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 1&#160;&#160;&#160;&#160;Definitions <a href="#i33b7a1bc6d5c48499ba12a5e5ef8e34e_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">1</a></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 2&#160;&#160;&#160;&#160;Technology Transfer <a href="#i33b7a1bc6d5c48499ba12a5e5ef8e34e_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">16</a></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 3&#160;&#160;&#160;&#160;&#91;*&#93; 18</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 4&#160;&#160;&#160;&#160;Diligence and Reporting <a href="#i33b7a1bc6d5c48499ba12a5e5ef8e34e_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">21</a></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 5&#160;&#160;&#160;&#160;Licenses <a href="#i33b7a1bc6d5c48499ba12a5e5ef8e34e_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">22</a></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 6&#160;&#160;&#160;&#160;Exclusivity <a href="#i33b7a1bc6d5c48499ba12a5e5ef8e34e_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">23</a></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 7&#160;&#160;&#160;&#160;Financial Terms <a href="#i33b7a1bc6d5c48499ba12a5e5ef8e34e_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">25</a> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 8&#160;&#160;&#160;&#160;Payment Terms, Reports, Audits <a href="#i33b7a1bc6d5c48499ba12a5e5ef8e34e_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">34</a></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 9&#160;&#160;&#160;&#160;Intellectual Property <a href="#i33b7a1bc6d5c48499ba12a5e5ef8e34e_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">37</a></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 10&#160;&#160;&#160;&#160;Confidentiality <a href="#i33b7a1bc6d5c48499ba12a5e5ef8e34e_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">46</a></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 11&#160;&#160;&#160;&#160;Press Releases and Publications <a href="#i33b7a1bc6d5c48499ba12a5e5ef8e34e_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">50</a></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 12&#160;&#160;&#160;&#160;Representations, Warranties and Covenants <a href="#i33b7a1bc6d5c48499ba12a5e5ef8e34e_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">52</a></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 13&#160;&#160;&#160;&#160;Indemnification, Limitation of Liability, Insurance <a href="#i33b7a1bc6d5c48499ba12a5e5ef8e34e_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">56</a></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 14&#160;&#160;&#160;&#160;Term, Termination <a href="#i33b7a1bc6d5c48499ba12a5e5ef8e34e_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">57</a></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 15&#160;&#160;&#160;&#160;Dispute Resolution <a href="#i33b7a1bc6d5c48499ba12a5e5ef8e34e_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">64</a></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 16&#160;&#160;&#160;&#160;Miscellaneous <a href="#i33b7a1bc6d5c48499ba12a5e5ef8e34e_4" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">66</a></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">EXHIBITS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;1.13&#160;&#160;&#160;&#160;Authorized Subcontractors</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;1.64&#160;&#160;&#160;&#160;Licensed Patents</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;1.71&#160;&#160;&#160;&#160;Licensed Tau Payload from ST-501</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;1.105&#160;&#160;&#160;&#160;Sangamo Proprietary AA Sequence</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;1.109&#160;&#160;&#160;&#160;STAC-BBB Sequence</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;2.1&#160;&#160;&#160;&#160;Technology Transfer Plan</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;3.1.1&#160;&#160;&#160;&#160;&#91;*&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;3.2&#160;&#160;&#160;&#160;Required Provisions for Agreements with Authorized Subcontractors</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit&#160;11.1&#160;&#160;&#160;&#160;Initial Press Release</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><div id="i33b7a1bc6d5c48499ba12a5e5ef8e34e_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">LICENSE AGREEMENT</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THIS LICENSE AGREEMENT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made and entered into as of August 2, 2024 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and between Sangamo Therapeutics, Inc. having its principal place of business at 501 Canal Blvd., Richmond, CA 94804 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sangamo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Genentech, Inc., a Delaware corporation, having its principal place of business at 1 DNA Way, South San Francisco, California 94080 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Genentech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Sangamo and Genentech are sometimes referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221; </font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BACKGROUND</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sangamo is developing STAC-BBB and certain zinc finger technologies directed to tau and &#91;*&#93;.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Genentech is a biopharmaceutical company that is engaged in the discovery, research, development, manufacture and sale of pharmaceutical products. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">subject to the terms of this Agreement, Sangamo wishes to grant to Genentech, and Genentech wishes to receive from Sangamo, an exclusive license under Sangamo&#8217;s intellectual property rights to research, develop, manufacture, commercialize and otherwise exploit STAC-BBB, certain variants of STAC-BBB, and zinc finger technologies directed to tau and &#91;*&#93;.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Genentech and Sangamo agree as follows&#58; </font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.66pt">Definitions </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the &#91;*&#93;, including any &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the period commencing on the Effective Date and ending on the earlier of&#58; (a) &#91;*&#93; and (b) &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Abandonment Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 9.6.1(b).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accounting Standard</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to an entity, either&#58; (a) International Financial Reporting Standards (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IFRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; or (b) United States generally accepted accounting principles (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in either case, which standards or principles (as applicable) are then-currently used at the applicable time, and as consistently applied, by such entity.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acquirer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) any &#8220;person&#8221; or &#8220;group&#8221; described in Section 1.21(a) for so long as such &#8220;person&#8221; or &#8220;group&#8221; retains beneficial ownership of more than fifty percent (&#62;50%) of the Voting Stock of Sangamo or otherwise has the power, directly or indirectly, to elect a majority of the members of the Board of Directors of Sangamo or (b) any Third Party described in Section 1.21(b) or (c) for so long as such Third Party remains an Affiliate of Sangamo. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acquisition Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 6.3.</font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any entity that, directly or indirectly (through one or more intermediaries) controls, is controlled by, or is under common control with a Party, at any point in time and for so long as such control exists. For purposes of this Section 1.5, &#8220;controls&#8221;, &#8220;controlled&#8221;, and &#8220;control&#8221; means (a) the direct or indirect ownership of more than fifty percent (&#62;50%) of the voting stock or other voting interests or interest in the profits of the applicable Party or entity or (b) the ability to otherwise control or direct the decisions of the board of directors or equivalent governing body thereof.  Notwithstanding the foregoing, for purposes of this Agreement, none of Chugai Pharmaceutical Co., Ltd (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Chugai</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) or any business entity controlled by Chugai, will be considered an Affiliate of Genentech, unless and until Genentech elects to include one or more of Chugai or any such business entity as an Affiliate of Genentech, by providing notice to Sangamo of such election.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 4.3.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annual Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Product, all Net Sales of such Product during a calendar year.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all laws, statutes, codes, ordinances, orders, rules, rulings, directives and regulations of any kind whatsoever of any governmental authority within the relevant jurisdiction applicable to the relevant activity.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 3.1.2.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Authorized Purposes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 3.1.2.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Authorized Subcontractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to any &#91;*&#93;, a subcontractor of Sangamo approved by Genentech in writing to perform such activity (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Subcontracted Activity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The pre-approved Authorized Subcontractors as of the Effective Date are listed in Exhibit 1.13.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any day, other than a Saturday, Sunday or day on which commercial banks located in the United States or Switzerland are authorized or required by Applicable Law to be closed.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Capsid</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any functional assembly of proteins (including fragments and derivatives thereof) which serves to package, coat or encapsulate a Payload for delivery to cells.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 3.1.1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 3.1.4.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 3.1.3.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 9.7.1.</font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to Sangamo, if any of the following occurs after the Effective Date&#58;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">any &#8220;person&#8221; or &#8220;group&#8221; (as such terms are defined below) (i)&#160;becomes the &#8220;beneficial owner&#8221; (as defined below), directly or indirectly, of shares of capital stock or other interests (including partnership interests) of Sangamo then outstanding and normally entitled (without regard to the occurrence of any contingency) to vote in the election of the directors, managers or similar supervisory positions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Voting Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of Sangamo representing more than fifty percent (&#62;50%) of the total voting power of all outstanding classes of Voting Stock of Sangamo or (ii)&#160;acquires the power, directly or indirectly, to elect a majority of the members of the board of directors or similar governing body (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of Sangamo&#59; or</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Sangamo enters into a merger, consolidation or similar transaction with a Third Party (whether or not Sangamo is the surviving entity) and as a result of such merger, consolidation or similar transaction (i)&#160;the members of the Board of Directors of Sangamo immediately prior to such transaction constitute less than a majority of the members of the Board of Directors of Sangamo or of such surviving entity immediately following such transaction or (ii)&#160;the individuals or entities that beneficially owned, directly or indirectly, the shares of Voting Stock of Sangamo immediately prior to such transaction cease to beneficially own, directly or indirectly, shares of Voting Stock of Sangamo representing at least a majority of the total voting power of all outstanding classes of Voting Stock of the surviving entity in substantially the same proportions as their ownership of Voting Stock of Sangamo immediately prior to such transaction&#59; or</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Sangamo sells or transfers to any Third Party, in one or more related transactions, properties or assets representing all or substantially all of Sangamo&#8217;s assets to which this Agreement relates.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this Section 1.21, (x)&#160;&#8220;person&#8221; and &#8220;group&#8221; have the meanings given such terms under Section 13(d) and 14(d) of the United States Securities Exchange Act of 1934 and the term &#8220;group&#8221; includes any group acting for the purpose of acquiring, holding or disposing of securities within the meaning of Rule 13d-5(b)(1) under the said Act&#59; (y)&#160;a &#8220;beneficial owner&#8221; will be determined in accordance with Rule 13d-3 under the aforesaid Act&#59; and (z)&#160;the terms &#8220;beneficially owned&#8221; and &#8220;beneficially own&#8221; will have meanings correlative to that of &#8220;beneficial owner.&#8221;  Notwithstanding the foregoing, (A) a transaction solely to change the domicile of Sangamo&#59; (B) Sangamo&#8217;s public offering of equity shares pursuant to a registration statement filed under the United States Securities and Exchange Act of 1933, or (C)&#160;any merger or consolidation between a Sangamo and one or more Affiliates will not constitute a Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) a single pharmaceutical formulation containing as its active ingredients both a Licensed Payload and one or more other Payloads, (b) a combination therapy comprised of (i) a Product and (ii) one or more other therapeutically or prophylactically active ingredients, which are either priced and sold in a single package containing such multiple </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">products or packaged separately but sold together for a single price, or (c) a combination therapy comprised of (i) a Product and (ii) a companion diagnostic, priced and sold in a single package containing such multiple products or packaged separately but sold together for a single price, in each case ((a) (b), and (c)), including all dosage forms, formulations, presentations, line extensions, and package configurations. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Party, the level of efforts consistent with the efforts such Party devotes to a pharmaceutical product that it has under a similar stage of research, development or commercialization, as applicable, in a similar area with similar market potential and similar strategic value in its portfolio, taking into account its safety and efficacy, its cost to develop and commercialize, its proprietary position, the likelihood of obtaining Marketing Authorization(s) and product reimbursement, anticipated profitability, return on investment, and other regulatory, technical, legal, scientific, medical or commercial factors, all in the context of other internal and external competitive products in development or on the market (including other products such Party may have in its portfolio), provided that with respect to Sangamo, such efforts will be at least consistent with those a similarly situated biotechnology company (on its own or acting through any of its affiliates, sublicensees or subcontractors) would use to accomplish a similar task or obligation under similar circumstances.  It is understood that the level of Commercially Reasonable Efforts may change from time to time based upon regulatory, technical, legal, scientific, medical or commercial factors as stated above. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Competing Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 6.3.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Competitive Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) with respect to a Product in a particular regulatory jurisdiction, any pharmaceutical product (i) (x) approved by the applicable Regulatory Authority as generic, biosimilar to or interchangeable with such Product pursuant to Section 351(k) of the Public Health Service Act, Article 10(4) of Directive 2001&#47;83&#47;EC and Section 4, Part II, Annex I of the European legislation, or any equivalent legislation in other countries, or any successor provision of any of the foregoing, or any implementing legislation, directive or regulation of any of the foregoing, or (y) for which the applicable Regulatory Authority has authorized one or more Clinical Trials to be foregone, in each case (x) or (y), wherein the Product was the reference product relied upon in making such determination, and (ii) that is approved for commercial sale in such country and sold by a (1) Third Party that is not Genentech, its Affiliate or Sublicensee and that has not otherwise been authorized, directly or indirectly, by Genentech to market and sell such product or (2) Compulsory Sublicensee, (b) with respect to &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Compulsory Sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a license or sublicense granted to a Third Party, through the order, decree or grant of a governmental authority having competent jurisdiction, authorizing such Third Party to make, use, sell, offer for sale, import or export a Product in any country.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Compulsory Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Third Party that was granted a Compulsory Sublicense.</font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 10.1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Continuation Election Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 14.6.5.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Continuation Election Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 14.6.5.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; (including variations such as &#8220;Controlled&#8221; and the like) means, (a) with respect to any Patent, Know-How or any other intellectual property right, the rightful possession by a Party of the ability to grant a license, sublicense or other right to exploit (other than by operation of any license granted herein) such Patent, Know-How or other intellectual property right, or (b) with respect to proprietary materials, the rightful possession by a Party of the ability to supply such proprietary materials to the other Party, in each case (a) and (b), in accordance with the terms and conditions set forth herein and without violating the terms of any agreement with any Third Party.  Notwithstanding anything to the contrary in this Agreement, in the event of a Change in Control, the following will not be deemed to be Controlled by Sangamo&#58; (i) any intellectual property (including Patents and Know-How) owned or licensed by the Acquirer immediately prior to the closing of such Change in Control&#59; and (ii) any intellectual property (including Patents and Know-How) that any Acquirer subsequently acquires or develops &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; (including variations such as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Covered</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Covering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and the like) means, with respect to a Valid Claim and in reference to a particular Product (in each case, whether alone or in combination with one or more ingredients) that the use, sale, offer for sale or import of such Product in a country would, but for ownership thereof or a license granted in this Agreement thereunder, infringe such Valid Claim in the applicable country on the date of sale.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CPA Firm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 8.9.2.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CRL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2.4.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 14.2.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DevGo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; &#91;*&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Directed To</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;*&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 10.1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disposition Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 7.9.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Divestiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section&#160;6.3.2.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Escalation Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 15.1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EU5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the United Kingdom, Germany, France, Spain and Italy.</font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Expert</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a person who has no less than ten (10) years of relevant experience in the pharmaceutical industry and has occupied at least one (1) senior position within a large pharmaceutical company and who is fluent in the English language, excluding any current or former employee or consultant of either Party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exploit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means research, develop, make, have made, use, sell, offer for sale, import, export and otherwise exploit.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the United States Food and Drug Administration, or any successor entity thereto performing similar functions.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a particular Product in a given country, the first bona fide commercial sale to a Third Party of such Product following Marketing Authorization in such country by or under authority of Genentech (or its Affiliates or Sublicensee(s) hereunder &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GNE Manufacturing Improvement IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Manufacturing Improvement(s) first conceived, reduced to practice or otherwise invented by or on behalf of Genentech (solely or jointly with Sangamo) &#91;*&#93;, and the intellectual property rights therein.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GNE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">STAC-BBB Improvement IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 13.3.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 13.3.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.51</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a recognized type of human medical disease or condition, provided that &#91;*&#93;. For purposes of the foregoing &#91;*&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indirect Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 8.8.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Information Security Incident</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 10.8.1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 9.7.1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inventor Remuneration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 9.6.7.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inventory List</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2.4.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IP Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 9.2.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.58</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all inventions, discoveries, creations and works, including Know-How, compositions of matter, articles of manufacture or other subject matter, whether patentable or copyrightable or not, that are first jointly conceived, reduced to practice or otherwise invented in the performance of this Agreement by or on behalf of both Parties, as determined in accordance </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with United States patent and copyright laws and other Applicable Laws in the United States, and the intellectual property rights therein.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any non-public information, including data, know-how, inventions, discoveries, creations, works, trade secrets, specifications, instructions, processes, formulae, methods, protocols, techniques, designs, results, test data, pharmacological, toxicological, pharmacokinetic, pre-clinical and clinical information, reports, structure-activity relationship data, statistical analysis, models and information regarding discovery, development, marketing, pricing, distribution, cost, sales and manufacturing.  For clarity, Know-How excludes Patents and tangible materials.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Launch Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 7.8.3.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed &#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed Capsid</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means STAC-BBB or a Licensed STAC-BBB &#91;*&#93;, in each case, with or without any Licensed STAC-BBB Improvement(s).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed Capsid Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Patent within the Licensed IP that claims &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Trademarks related to any Licensed Capsid and all intellectual property rights Controlled by Sangamo or any of its Affiliates as of the Effective Date or at any time during the Term that are necessary or reasonably useful to Exploit Products, including those Patents listed in Exhibit 1.64.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed Payload</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Licensed Tau Payload or a &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed Payload Improvement IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.67</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed Payload Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Patent within the Licensed IP that claims a &#91;*&#93; without reference to any specific Capsid or other delivery vehicle or method, including those Patents listed in Section A of Exhibit 1.64 &#91;*&#93; and Section B of Exhibit 1.64 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Existing Licensed Tau Payload Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed Product Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91; *&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed STAC-BBB Improvement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;*&#93; on or prior to the first anniversary of the Effective Date. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;&#8221; means a &#91;*&#93; in accordance with Section 3.1.3. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.71</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed Tau Payload</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any portion of a Payload that encodes a zinc finger protein Directed To Tau, intellectual property rights in which are Controlled by Sangamo prior to the Effective Date or at any time during the Term prior to expiration of the Tau Exclusivity Period, including those sequences listed in the Existing Licensed Tau Payload Patents, including </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the &#91;*&#93; as listed in Exhibit 1.71. For clarity, for any such Payload that &#91;*&#93; refers only to the portion of such Payload that &#91;*&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.72</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.73</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 13.1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.74</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing Improvement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any improvement, modification or enhancement to a manufacturing process, provided such manufacturing process is (a) &#91;*&#93; and (b) disclosed by Sangamo to Genentech in accordance with this Agreement. For clarity, any manufacturing process first conceived, reduced to practice or otherwise invented by or on behalf of Genentech, its Affiliate or a Third Party without the use of or reference to Confidential Information or materials of Sangamo or Product Information, in each case, provided by Sangamo to Genentech hereunder will not be deemed a Manufacturing Improvement hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Marketing Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Product and an Indication, final Regulatory Approval (including pricing approval, where required) required to sell such Product for such Indication in accordance with the Applicable Law of a given country or jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.76</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 7.9.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.77</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, for a Product in a particular period, the amount calculated by subtracting from the Sales of such Product for such period&#58; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.77.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#91;*&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.77.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#91;*&#93; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.77.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#91;*&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For clarity, &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.78</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Non-Disclosure Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Amended and Restated Mutual Confidentiality Agreement between the Parties effective December 15, 2023.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.79</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Sangamo Capsid</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Capsid, intellectual property rights in which are controlled by Sangamo or a Third Party prior to the Effective Date or at any time during the Term, other than a Licensed Capsid.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.80</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Sangamo Payload</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any portion of a Payload that encodes a zinc finger protein, intellectual property rights in which are controlled by Sangamo prior to the Effective Date or at any time during the Term, other than a Licensed Payload. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.81</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patent(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all patents and patent applications and any patents issuing therefrom or claiming priority thereto, worldwide, together with any extensions (including patent term extensions and supplementary protection certificates) and renewals thereof, reissues, re-</font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">examinations, substitutions, confirmation patents, registration patents, invention certificates, patents of addition, renewals, divisionals, continuations, and continuations-in-part of any of the foregoing. For clarity, Patents exclude Know-How and tangible materials.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.82</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Payload</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an active pharmaceutical ingredient, including but not limited to nucleic acid molecules.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.83</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Payable Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section&#160;7.5.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.84</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Payment Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 7.9.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.85</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Permitted Use</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section&#160;10.3.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.86</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Phase 1 Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a human clinical trial, the principal purpose of which is preliminary determination of safety and pharmacokinetics of a pharmaceutical product in healthy individuals or patients as further described in 21 C.F.R. &#167; 312.21, or similar clinical study in a country other than the United States, and which is prospectively designed to generate sufficient clinical data, including data sufficient to determine dosing, to proceed directly to a Phase 2 Trial of such product, or similar clinical study in a country other than the United States.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.87</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">&#8220;Phase 2 Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a human clinical trial, for which the primary endpoints include a determination of dose ranges or a preliminary determination of efficacy of a pharmaceutical product in patients being studied as further described in 21 C.F.R. &#167; 312.21, or similar clinical study in a country other than the United States. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.88</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Phase 3 Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a human clinical trial, the principal purpose of which is to demonstrate clinically and statistically the efficacy and safety of a pharmaceutical product for one or more Indications in order to obtain Marketing Authorization of such product for such Indication(s), as further defined in 21 C.F.R. &#167; 312.21 or a similar clinical study in a country other than the United States.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.89</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;&#91;*&#93; has the meaning set forth in Section 3.1.2.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any pharmaceutical product, including any Combination Product, containing&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.90.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">a Licensed Capsid &#91;*&#93; and a Licensed Payload(s) (each Product described in this Section 1.90.1, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Two-Component Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.90.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">a Licensed Capsid &#91;*&#93; and no Licensed Payload&#59; or</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.90.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">a Licensed Payload(s) and no Licensed Capsid (each Product described in Sections 1.90.2 and 1.90.3, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">One-Component Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For clarity, the Product &#91;*&#93;. </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.91</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 10.1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.92</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 9.6.9.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.93</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prosecution and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prosecute and Maintain</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prosecute or Maintain</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a given Patent, all activities associated with the preparation, filing, prosecution, and maintenance of such Patent as well as supplemental examinations, re-examinations, reissues, applications for patent term extensions, calculation and applications for patent term adjustments, supplementary protection certificates, and the like (as applicable) with respect to such Patent.  For clarity, Prosecute and Maintain will not include any such actions with respect to a Patent brought by a Third Party, including any reexaminations, inter partes reviews, and post grant reviews, as well as interferences and derivation proceedings, oppositions and other similar proceedings brought by a Third Party with respect to such Patent.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.94</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 11.6.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.95</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 10.1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.96</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Region</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means each of (a) &#91;*&#93;, (b) &#91;*&#93;, (c) &#91;*&#93; and (d) all countries in the world other than countries included in (a) through (c).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.97</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a pharmaceutical product in a country or jurisdiction, any and all approvals (including investigational new drug applications, new drug applications or biologics license applications, and any supplements thereto), licenses, registrations, or authorizations of any Regulatory Authority necessary to manufacture, use, store, import, transport, commercially distribute, sell, or market such pharmaceutical product in such country, including, where applicable, (a) pricing or reimbursement approval in such country, (b) post-approval marketing authorizations (including any prerequisite manufacturing approval or authorization related thereto), and (c) labeling approval.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.98</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any federal, national, multinational, state, provincial or local regulatory agency, department, bureau or other governmental entity with authority over the development, manufacturing, commercialization or other use or exploitation (including the granting of Regulatory Approvals or Marketing Authorizations) of pharmaceutical products in any jurisdiction, including the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.99</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 11.2.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.100</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Residuals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 10.6.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.101</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reversion IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 14.6.6(h).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.102</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reversion License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 14.6.6(h).</font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.103</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, on a country-by-country and Product-by-Product basis, the period commencing upon the date of the First Commercial Sale of such Product in such country and ending on &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.104</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8221; means, for a Product in a particular period, the sum of 1.104.1, 1.104.2, and 1.104.3.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.104.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By way of example, &#91;*&#93; include the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#91;*&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#91;*&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;&#91;*&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;&#91;*&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;&#91;*&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.104.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#91;*&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.104.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#91;*&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.104.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.105</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sangamo &#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.106</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sangamo &#91;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; has the meaning set forth in Section 10.3.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.107</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 3.1.2.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.108</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Skipped Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section&#160;7.5.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.109</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">STAC-BBB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Sangamo&#8217;s proprietary blood-brain barrier penetrant Capsid referred to as STAC-BBB. The sequence of STAC-BBB is set forth in Exhibit 1.109.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.110</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">STAC-BBB Improvement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.111</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">STAC-BBB </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;&#8221; means &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.112</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;&#91;*&#93;&#8221; has the meaning set forth in Section 3.1.1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.113</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">STAC-BBB </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;&#8221; means &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.114</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 3.1.2.</font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.115</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;&#91;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 3.1.4.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.116</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Third Party, other than a Compulsory Sublicensee, to which Genentech or any of its Affiliates grants a sublicense (through one or multiple tiers) under the license granted pursuant to Section 5.2 to commercialize a Product.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.117</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;*&#93; or Tau.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.118</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tau</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.119</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tau Exclusivity Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.120</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tech Transfer Completion Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2.3.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.121</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2.1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.122</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Technology Transfer Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2.2.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.123</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Technology Transfer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2.1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.124</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 14.1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.125</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Terminated Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.126</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any entity other than a Party or any of its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.127</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 13.1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.128</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Title 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 14.3.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.129</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any word, name, symbol, color, designation or device or any combination thereof that functions as a source identifier, including any trademark, trade dress, brand mark, service mark, trade name, brand name, logo or business symbol, whether or not registered.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.130</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transfer Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 14.6.6(i).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.131</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transfer Agreement Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 14.6.6(i).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.132</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transferred Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 2.1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.133</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Phase 1 Trial, Phase 2 Trial or Phase 3 Trial.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.134</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.66pt">Technology Transfer </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Sangamo will (a) transfer to Genentech all Know-How within the Licensed IP that is (i) listed in the technology transfer plan set forth in Exhibit 2.1 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Technology Transfer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) including those sequences, materials, inventory, documents, records, methods, reagents, and assays described in the Technology Transfer Plan, (ii) existing as of the Effective Date and necessary to exploit the Products or (iii) existing as of the Effective Date, reasonably useful to exploit the Products and requested by Genentech (such Know-How in clauses (i) through (iii), collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transferred Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (b) otherwise carry out the activities described in the Technology Transfer Plan, and use diligent efforts to do so in accordance with the timelines set forth in the Technology Transfer Plan (collectively, such transfer and the activities set forth in the Technology Transfer Plan, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). For clarity, the Transferred Know-How,  the Inventory List and the samples provided pursuant to Section 2.4 shall exclude all Know-How and materials related to (i) any &#91;*&#93; or &#91;*&#93;, (ii) Sangamo&#8217;s program Directed To &#91;*&#93;&#59; and (iii) Sangamo&#8217;s proprietary platform technologies &#91;*&#93;.  Each Party will bear its own costs incurred in the performance of the Technology Transfer. Except as otherwise specified in the Technology Transfer Plan, any materials and inventory shipped by Sangamo to Genentech will be shipped from Sangamo to Genentech DAP (location to be provided by Genentech) Incoterms 2020. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Technology Transfer Committee. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As of the Effective Date, the Parties will establish a technology transfer committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Technology Transfer Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) comprised of the Alliance Managers from each Party and at least one (1) scientific leader from each Party with the appropriate level of seniority, availability, function in their respective organization, training, experience and decision-making authority to carry out the activities of the Technology Transfer Committee. The Technology Transfer Committee will (a) meet on a weekly basis (unless the Parties agree on alternate timing) until the Tech Transfer Completion Date to oversee and coordinate the Technology Transfer, and (b) review progress towards completion of the Technology Transfer. Either Party may invite a reasonable number of other employees, consultants, contractors or scientific advisors to attend a Technology Transfer Committee meeting with prior written notice to the other Party&#8217;s Alliance Manager, provided that such invitees are bound by appropriate confidentiality and invention assignment obligations consistent with the terms of this Agreement. If the Technology Transfer Committee disagrees regarding the scope of the Technology Transfer or whether a particular item in the Technology Transfer Plan has been completed, either Party may submit the matter to the Alliance Managers to facilitate further discussion among the members of the Technology Transfer Committee (and if mutually agreed, their respective supervisors). If after such assistance, the Technology Transfer Committee still cannot resolve such matter in a timely fashion, either Party may refer the matter to the CEO of Sangamo or equivalent position or their nominee and Head of Corporate Business Development of Genentech or equivalent position or their nominee for resolution, who together will use good faith efforts to reach a decision by consensus within &#91;*&#93; after the date such matter is referred to them. If the CEO of Sangamo or equivalent position or their nominee and the Head of Corporate Business Development of Genentech or equivalent position or their nominee cannot reach such consensus decision, then either Party may refer the matter for resolution in </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">accordance with ARTICLE 15.  For clarity, the Technology Transfer Committee will serve only to facilitate the Technology Transfer and will not have any independent decision-making authority or power to amend, modify or waive compliance with this Agreement (including the Technology Transfer Plan), which may only be amended, modified or compliance with which may only be waived, as provided in Section 16.8.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Completion of Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Promptly following completion of the Technology Transfer, including completion of all activities set forth in the Technology Transfer Plan, Sangamo will provide notice to the Technology Transfer Committee thereof. Promptly (but in any event within &#91;*&#93; following receipt of such notice, the Technology Transfer Committee will meet to review the status of the Technology Transfer. Promptly (but in any event within &#91;*&#93; following such meeting, Genentech will provide notice to Sangamo either confirming completion of the Technology Transfer (the date of such confirmation, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tech Transfer Completion Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) or specifying any aspects of the Technology Transfer that remain incomplete. If Genentech provides the latter notice, promptly after receipt of such notice, Sangamo will complete the aspects of the Technology Transfer identified by Genentech as incomplete and thereafter, submit notice to Genentech in accordance with the first sentence of this Section 2.3.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Transfer of Samples and DNA&#59; Completion of Final Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In addition to and separately from the Technology Transfer, promptly after the Tech Transfer Completion Date, Sangamo will, as quickly as reasonably possible, generate and provide to Genentech a list of inventory of samples from specimens that contain a Licensed &#91;*&#93; or Licensed Tau Payload in Sangamo&#8217;s possession from the Tau-related and &#91;*&#93; pre-clinical studies it conducted (or had conducted on its behalf) prior to the Effective Date (including tissue samples and DNA), other than&#58; (a) &#91;*&#93;&#59; and (b) &#91;*&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inventory List</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Following receipt of such Inventory List, Genentech will select from such Inventory List the samples that Genentech wishes to receive, and Sangamo will promptly transfer to Genentech such selected samples to the extent such samples are Controlled by Sangamo, provided that if any such samples are not Controlled by Sangamo, Sangamo will respond to Genentech&#8217;s Alliance Manager&#8217;s reasonable inquiries regarding ownership and control of such samples without disclosing the confidential information of any Third Party to Genentech.  Genentech will reimburse Sangamo for all reasonable out-of-pocket costs and expenses incurred by Sangamo in connection with the shipment of such selected samples. To the extent requested by Genentech, and in accordance with the timing requested by Genentech, &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Ongoing Support</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  After the Tech Transfer Completion Date, if either Party becomes aware that Sangamo failed to transfer any item required to be transferred to Genentech pursuant to the Technology Transfer, such Party will promptly provide written notice to the other Party thereof, which notice will identify such item, and Sangamo will promptly transfer such item to Genentech. During the Term, Sangamo will provide assistance to Genentech, as reasonably requested by Genentech, to enable Genentech to exercise the licenses set forth herein, provided that Sangamo will not be required to disclose (a) any of the excluded Know-How listed in the second sentence of Section 2.1 or (b) any STAC-BBB Improvements or Manufacturing Improvements to Genentech except as set forth in the Technology Transfer Plan. </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.66pt">&#91;*&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">&#91;*&#93; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Sangamo Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to Section 3.1.4, Sangamo will conduct the activities described in &#91;*&#93; set forth in Exhibit 3.1.1 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and will use diligent efforts to conduct such activities in accordance with the timelines set forth therein. Promptly following completion of the activities described in the &#91;*&#93;, Sangamo will provide to Genentech the results, sequences, data and materials listed in the section of the &#91;*&#93;. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">&#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Genentech may &#91;*&#93;by providing notice to Sangamo thereof. Until Genentech &#91;*&#93;, Sangamo will respond to all reasonable requests from Genentech for additional information regarding &#91;*&#93; and will meet with Genentech, upon Genentech&#8217;s reasonable request. Genentech will &#91;*&#93;.  No later than &#91;*&#93; after the &#91;*&#93;, Sangamo will &#91;*&#93;  Notwithstanding any provision to the contrary in ARTICLE 10 and except as set forth in this Section 3.1.2, the &#91;*&#93; and shall &#91;*&#93;. &#91;*&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Genentech Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Following completion of the &#91;*&#93;in accordance with Section 3.1.1 or 3.1.4 (as applicable), Genentech will perform the &#91;*&#93; and such other activities (including additional non-human primate studies) necessary or reasonably useful to &#91;* &#93; as described in this Section 3.1.3 &#91;*&#93;. The &#91;*&#93; will not include (a) any activity &#91;*&#93; or (b) &#91;*&#93;.  Genentech may, &#91;*&#93;. For clarity, any &#91;*&#93; in accordance with this Section 3.1.3 &#91;*&#93; Genentech will provide notice to Sangamo upon completion of the &#91;*&#93;, provided that, notwithstanding &#91;*&#93; will be deemed complete upon &#91;*&#93; in accordance with this Section 3.1.3.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">&#91;*&#93;. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sangamo will promptly provide written notice to Genentech upon completion of each event described in the table &#91;*&#93;&#8221; in the &#91;*&#93; If Sangamo &#91;*&#93; and Sangamo does &#91;*&#93;, Genentech may &#91;*&#93;.  For clarity, Genentech&#8217;s &#91;*&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Authorized Subcontractors. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sangamo will not subcontract, without Genentech&#8217;s consent, any material activities under the &#91;*&#93; to any Third Party, other than to the applicable Authorized Subcontractor.  The activities performed by an Authorized Subcontractor on behalf of Sangamo will be made pursuant to a written subcontract specifying the work to be subcontracted and containing provisions consistent with the terms and conditions of this Agreement, including with respect to confidentiality and intellectual property. Sangamo will provide Genentech the opportunity to (a) participate in meetings with, audits or inspections of, or other assessments of any Authorized Subcontractor, and (b) review any draft and final reports prepared by an Authorized Subcontractor.  Sangamo will use its diligent efforts to include the provisions set forth in Exhibit 3.2 in each subcontract with an Authorized Subcontractor under which a Subcontracted Activity will be performed, provided that if such Authorized Subcontractor does not agree to include one or more of the provisions set forth in Exhibit 3.2 despite the use of Sangamo&#8217;s diligent efforts, Genentech will promptly propose alternative, commercially reasonable language for Sangamo to propose to such Authorized Subcontractor. </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Sangamo will keep Genentech informed of its activities under the &#91;*&#93;, including by &#91;*&#93; in accordance with &#91;*&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party will conduct its activities &#91;*&#93; at its own expense and in accordance with the terms and conditions of this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Research Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party will, and will ensure that any of its Third Party subcontractors, maintain records in sufficient detail and in good scientific manner appropriate for Prosecution and Maintenance and regulatory purposes, and in compliance with Applicable Law. Such records will be complete and accurate and will properly reflect all work done and results achieved in performance of the &#91;*&#93;. Such records will record only activities conducted for the &#91;*&#93;and will not include or be commingled with records of activities other than those conducted pursuant thereto. Such records will be maintained by the applicable Party through the completion of the &#91;*&#93; and for &#91;*&#93; thereafter, or for such longer period as may be required by Applicable Law.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.66pt">Diligence and Reporting</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Diligence Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as set forth in ARTICLE 2 and ARTICLE 3, as between Genentech and Sangamo, Genentech will have the sole right to perform research, development, manufacturing and commercialization activities related to the Licensed Payloads and Products.  Following the Tech Transfer Completion Date, Genentech will use Commercially Reasonable Efforts to develop and seek Marketing Authorization for one (1) Product Directed To Tau and one (1) Product Directed To &#91;*&#93;, in each case, in &#91;*&#93;.  Following receipt of Marketing Authorization in the applicable country, Genentech will use Commercially Reasonable Efforts to commercialize one (1) Product Directed To Tau and one (1) Product Directed To &#91;*&#93;, in each case, in &#91;*&#93;, one (1) &#91;*&#93;. Notwithstanding the foregoing, the Parties acknowledge and agree that subject to the terms and conditions of &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within &#91;*&#93; days after the beginning of each calendar year during the Term, Genentech will provide to Sangamo a written report summarizing Genentech&#8217;s progress in the development of Products, including any material developments related to such Products achieved since the last such report. Genentech&#8217;s obligations under this Section 4.2 will end (a) with respect to Products Directed To Tau, upon the First Commercial Sale of a Product Directed To Tau, and (b) with respect to Products Directed To &#91;*&#93;, upon the First Commercial Sale of a Product Directed To &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  On the Effective Date, each Party will designate an individual to act as the primary business contact for such Party for matters related to this Agreement (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), unless another contact is expressly specified in the Agreement or designated by the Parties for a particular purpose.  The Alliance Manager will promote communication and collaboration between the Parties and assist in the resolution of potential and pending issues and potential disputes in a timely manner.  Either Party may replace its Alliance Manager at any time by notifying the other Party&#8217;s Alliance Manager in writing (which may be by e-mail).</font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Pharmacovigilance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party will inform the other about any adverse events that are causally related to use of any Licensed Capsid of which such Party becomes aware. Sangamo will ensure that any Third Party to which Sangamo grants any right or license to Exploit the Licensed Capsids is required to inform Sangamo about any adverse events that are causally related to use of any Licensed Capsid of which such Third Party becomes aware. The Parties will handle data and information about such adverse events according to the regulatory guidelines of the applicable Regulatory Authority. If Genentech determines it to be appropriate, the Parties will enter into a pharmacovigilance or safety data exchange agreement concerning the procedures and timeframes for reporting safety information related to the Licensed Capsid or Product.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.66pt">Licenses</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Co-Exclusive Research License to Genentech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Sangamo hereby grants to Genentech a worldwide, co-exclusive (with Sangamo) right and license under the &#91;*&#93; solely to perform the &#91;*&#93;. The foregoing license will expire upon the earlier of&#58; (a) &#91;*&#93; in accordance with Section 3.1.3 and (b) the expiration of the first-to-expire of the&#58; (i) &#91;*&#93; and (ii) &#91;*&#93;.  For clarity, except as set forth in this Section 5.1, Section 5.2 and ARTICLE 6, nothing in this Agreement prohibits Sangamo from Exploiting any STAC-BBB &#91;*&#93; created under the &#91;*&#93; and controlled by Sangamo during the foregoing period or at any time during the Term.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Exclusive License to Genentech.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sangamo hereby grants to Genentech a worldwide, exclusive (even as to Sangamo) right and license, including the right to sublicense through multiple tiers (as set forth in Section 5.3), under the Licensed IP to Exploit Products Directed To Tau or &#91;*&#93;, provided however, that the foregoing license will not include rights to (a) any Other Sangamo Capsid or Other Sangamo Payload&#59; (b) any other active pharmaceutical agent or compound proprietary to Sangamo, &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Sublicenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Genentech will have the right to grant sublicenses through multiple tiers under the license set forth in Section 5.2 to its Affiliates and to Third Parties, provided that such sublicenses are (a) subject to and consistent with the terms of this Agreement, including ARTICLE 5 and ARTICLE 9, and (b) Genentech (or its Affiliate) will remain responsible for the Sublicensee&#8217;s compliance with the applicable provisions of this Agreement in connection with such performance.  Genentech will provide Sangamo with written notice of any executed sublicense agreement with any such Sublicensee no later than &#91;*&#93; days after the execution thereof.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Non-Exclusive License to Sangamo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to the licenses set forth in Sections 5.1 and 5.2 and the obligations set forth in ARTICLE 6, Genentech hereby grants to Sangamo a worldwide, non-exclusive, perpetual, royalty-free license (a) under the &#91;*&#93; solely to Exploit products comprising &#91;*&#93; and (b) under the &#91;*&#93; solely to Exploit products comprising &#91;*&#93;.  For clarity, Genentech will not &#91;*&#93;.</font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">No Additional Licenses.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Except as expressly provided in this Agreement, nothing in this Agreement will grant either Party any right, title or interest in and to the Know-How, Patents or other intellectual property rights of the other Party (either expressly or by implication or estoppel).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.66pt">Exclusivity</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">&#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. During the &#91;*&#93;, to the extent permitted by Applicable Law, Sangamo will not, itself or through or with any of its Affiliates, directly or indirectly, (a) research, develop or commercialize any Capsid for use with any Payload Directed To &#91;*&#93;, (b) research, develop or commercialize any zinc finger domain or other Payload Directed To &#91;*&#93;, or (c) license, authorize, appoint or otherwise enable, any Third Party to conduct any of the activities described in the foregoing (a) or (b). For clarity, Sangamo will not be in breach of the foregoing obligations set forth in this Section 6.1 as a result of its conduct (itself or with or for a Third Party) of general research (i) with respect to any Payload that, at the time of such research, is not known to be Directed To &#91;*&#93;, provided that such research is not designed to generate Payloads that are Directed To &#91;*&#93; or (ii) that is not designed to optimize a &#91;*&#93; specifically for use with any Payload Directed To &#91;*&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Tau</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. During the Tau Exclusivity Period, to the extent permitted by Applicable Law, Sangamo will not, itself or through or with any of its Affiliates, directly or indirectly, (a) research, develop or commercialize any Capsid for use with any Payload Directed To Tau, (b) research, develop or commercialize any zinc finger domain or other Payload Directed To Tau, or (c) license, authorize, appoint or otherwise enable, any Third Party to conduct any of the activities described in the foregoing (a) or (b). For clarity, Sangamo will not be in breach of the foregoing obligations set forth in this Section 6.2 as a result of its conduct (itself or with or for a Third Party) of general research (i) with respect to any Payload that, at the time of such research, is not known to be Directed To Tau, provided that such research is not designed to generate Payloads that are Directed To Tau or (ii) that is not designed to optimize a &#91;*&#93; specifically for use with any Payload Directed to Tau.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If a Third Party becomes an Affiliate of Sangamo after the Effective Date (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acquisition Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and as of the closing date of the transaction in which such Acquisition Affiliate becomes an Affiliate of Sangamo, such Acquisition Affiliate is engaged in activities that, if conducted by Sangamo would cause Sangamo to be in breach of the obligations set forth in Sections 6.1 or 6.2 (such activities of the Acquisition Affiliate, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Competing Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">if such transaction (a) constitutes a Change in Control of Sangamo or (b) constitutes the acquisition of a Third Party by an Acquirer after a Change in Control of Sangamo, then such Acquisition Affiliate may continue such Competing Program after such Change in Control and such continuation will not constitute a breach of Sangamo&#8217;s exclusivity obligations set forth in Sections 6.1 or 6.2, provided that such Acquisition Affiliate conducts such Competing Program independently of the activities of this Agreement (including ensuring that no personnel involved in the Competing Program have </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">access to (i) non-public plans or information relating to the development or commercialization of Products or (ii) Confidential Information of Genentech, in each case of (i) and (ii), except for senior management personnel reviewing and evaluating such plans and information in connection with portfolio decision-making, provided that such senior management personnel are not involved in day-to-day activities for such Competing Program and do not conduct any drug discovery or optimization work for such Competing Program, and segregating all personnel (other than such senior management personnel) conducting activities related to this Agreement from all personnel conducting the Competing Program) and does not use any of the Licensed IP or Sangamo&#8217;s proprietary technology *&#93; and </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">if such transaction does not result in a Change in Control of Sangamo, then Sangamo and such Acquisition Affiliate will have &#91;*&#93; from the closing date of such transaction to wind down or complete the Divestiture of such Competing Program and will cease all activities with respect to such Competing Program if it has not completed such Divestiture within such period (it being understood that Sangamo and such Acquisition Affiliate may thereafter continue its efforts to complete Divestiture), and such Acquisition Affiliate&#8217;s conduct of such Competing Program during such &#91;*&#93;period will not be deemed a breach of the exclusivity obligations set forth in Sections 6.1 or 6.2&#59; provided that such Acquisition Affiliate conducts such Competing Program during such &#91;*&#93; period independently of the activities of this Agreement (including ensuring that no personnel involved in the Competing Program have access to (i) non-public plans or information relating to the development or commercialization of Products or (ii) Confidential Information of Genentech, in each case of (i) and (ii), except for Sangamo&#8217;s senior management personnel reviewing and evaluating such plans and information in connection with portfolio decision-making, provided that such senior management personnel are not involved in day-to-day activities for such Competing Program and do not conduct any drug discovery or optimization work for such Competing Program and segregating all personnel (other than such senior management personnel) conducting activities related to this Agreement from all personnel conducting the Competing Program) and does not use any of the Licensed IP or Sangamo&#8217;s proprietary technology or Genentech&#8217;s Confidential Information in the conduct of such Competing Program.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Divestiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, as used in this Section 6.3, means the sale or transfer of all rights to the Competing Program, as applicable, to a Third Party.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">For clarity, Section 6.3.1 (and not Section 6.3.2) will apply to any Third Party that becomes an Affiliate of an Acquirer after a Change in Control of Sangamo.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.66pt">Financial Terms</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In consideration of the rights and licenses set forth herein, Genentech will pay to Sangamo a one-time upfront payment of forty million dollars ($40,000,000) no later than &#91;*&#93; after the Effective Date and Genentech&#8217;s receipt of an invoice therefor.</font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Technology Transfer Completion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Genentech will pay to Sangamo ten million dollars ($10,000,000) no later than &#91;*&#93; after the Tech Transfer Completion Date and Genentech&#8217;s receipt of an invoice therefor.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Development Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Genentech will pay Sangamo the milestone payment amounts set forth in the following table in accordance with Section 8.1 following the first achievement of the corresponding milestone event by or on behalf of Genentech, its Affiliate or its Sublicensee&#58; </font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">#</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Milestone Event</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Milestone Payment Amount</font></td></tr><tr><td colspan="9" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">1</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93; </font></td></tr><tr><td colspan="9" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93; </font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">4</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93; </font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="9" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">6</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">7</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="9" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">8</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">9</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="9" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">10</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">11</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">12</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="9" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">13</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">14</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">15</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each milestone payment specified in this Section 7.3 is payable &#91;*&#93;.  For the avoidance of doubt, (a) &#91;*&#93;, Genentech&#8217;s cumulative obligation under this Section 7.3 will in no event exceed &#91;*&#93;, (b) &#91;*&#93;, (c) &#91;*&#93;, and (d) &#91;*&#93;.  &#91;*&#93;.</font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">First Commercial Sale and Marketing Authorization Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Genentech will pay Sangamo the milestone payment amounts set forth in the following table in accordance with Section 8.1 following the first achievement of the corresponding milestone event by or on behalf of Genentech, its Affiliate or its Sublicensee&#58;</font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">#</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Milestone Event</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Milestone Payment Amount</font></td></tr><tr><td colspan="9" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">16</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">17</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">18</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">19</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">20</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">21</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="9" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">22</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">23</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">24</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">25</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">26</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">27</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="9" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">28</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">29</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">30</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">31</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">32</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">33</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="9" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">34</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">35</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">36</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">37</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">38</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">39</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each milestone payment specified in this Section 7.4 is payable &#91;*&#93;.  For the avoidance of doubt, (a) &#91;*&#93;, (b) &#91;*&#93;, (c) &#91;*&#93;, and (d) &#91;*&#93;. &#91;*&#93;.</font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Skipped Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If a milestone payment listed in Column A of the following table (for purposes of this provision, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Payable Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) becomes payable before the milestone payment listed in Column B of the same row of the following table (for purposes of this provision, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Skipped Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and such Skipped Milestone has not previously been paid, then such Skipped Milestone will become payable at the same time as such Payable Milestone.  For clarity, the numbers listed in Column A and Column B of the following table correspond to the numbers listed in the left-most column of the tables in Sections 7.3 and 7.4.</font></div><div style="margin-bottom:8pt;padding-left:126.45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.153%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Column A</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Column B</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Annual Net Sales Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Genentech will pay Sangamo the milestone payments set forth in the following table in accordance with Section 8.1 following the first achievement of the corresponding milestone event by or on behalf of Genentech, its Affiliate or its Sublicensee&#58; </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.554%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Milestone Event</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Milestone Payment Amount</font></td></tr><tr><td colspan="6" style="background-color:#d9d9d9;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="6" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="6" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="6" style="background-color:#808080;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="6" style="background-color:#d9d9d9;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="6" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="6" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each milestone payment specified in this Section 7.6 is payable &#91;*&#93;.  For the avoidance of doubt, Genentech&#8217;s cumulative obligation under this Section 7.6 for (a) &#91;*&#93;, (b) &#91;*&#93;, (c) &#91;*&#93; and (d) &#91;*&#93;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Royalty Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to Section 7.8, during the applicable Royalty Term, Genentech will pay Sangamo, on a Product-by-Product and country-by-country basis, a royalty on Annual Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of such Product in accordance with Section 8.2, at the following rates&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:8pt;padding-left:74.38pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.269%"><tr><td style="width:1.0%"></td><td style="width:72.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.661%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Annual Net Sales</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Royalty Rate</font></td></tr><tr><td colspan="6" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="6" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;*&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Upon expiration of the Royalty Term with respect to a Product in a country, the licenses in Section 5.2 will be fully paid-up, perpetual and irrevocable in respect of that Product in that country. No more than &#91;*&#93; under this Section 7.7 with respect to sales of any one particular Product.  For the avoidance of doubt, &#91;*&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Payment Offsets and Reductions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Third Party IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Sangamo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">Sangamo will make all payments owed under any agreements entered into by Sangamo with Third Parties (A) prior to the Effective Date that relate to any Product or (B) if failure to enter into such agreement would result in Sangamo&#8217;s breach of any representation, warranty or covenant set forth in Section 12.2.1.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">With respect to any intellectual property controlled by Sangamo or its Affiliates pursuant to an agreement other than an agreement with a Third Party referred to in Section 7.8.1(a)(i), notwithstanding anything to the contrary in this Agreement but subject to the remainder of this Section 7.8.1(a)(ii), Sangamo or its Affiliates will not be deemed to Control such intellectual property for the purpose of this Agreement (and Genentech will not receive rights thereunder) unless Genentech agrees in writing to (A) comply with the applicable terms and conditions of such Third Party agreement, and (B) bear all payment obligations thereunder to the extent attributable to the grant of the sublicense to Genentech or the practice of such sublicense by Genentech, its Affiliates or its or their Sublicensees. With respect to the intellectual property described in the foregoing sentence, promptly after Sangamo first obtains access to such intellectual property, Sangamo will provide a description to Genentech thereof, including any payment obligations associated with Genentech obtaining a sublicense thereunder and any other obligations associated with receiving a sublicense under such intellectual property. If Genentech provides Sangamo with written notice that it agrees to comply with the applicable </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">terms and conditions of such Third Party agreement and bear all payment obligations thereunder to the extent attributable to the grant of the sublicense to Genentech or the practice of such sublicense by Genentech, its Affiliates or its or their Sublicensees, then Sangamo or its Affiliate (as applicable) will be deemed to Control such intellectual property for the purpose of this Agreement (and Genentech will receive rights thereunder) and such intellectual property will automatically be included in the Licensed IP upon receipt of such notice.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Genentech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that Genentech (or its Affiliate or Sublicensee hereunder) acquires rights under any intellectual property from a Third Party that are necessary or reasonably useful for the manufacture, use, importation, offer for sale or sale of a Product (including any Third Party intellectual property controlled by Sangamo after the Effective Date and sublicensed to Genentech pursuant to Section 7.8.1(a)(ii)), Genentech may offset any royalty payments due and payable by Genentech to Sangamo pursuant to Section 7.7 in any calendar quarter for such Product by &#91;*&#93; of the amount of the payments paid by Genentech (or its Affiliates or Sublicensees) to such Third Party (or to Sangamo, as applicable) for such rights and to the extent attributable to such Product. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">No Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. On a Product-by-Product and country-by-country basis, if during any portion of the Royalty Term for such Product in the country of sale of such Product, no Valid Claim Covers such Product in such country, then the royalty payments that would otherwise be owed and payable pursuant to Section 7.7 with respect to Annual Net Sales of such Product in such country will be reduced by &#91;*&#93;. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Competitive Products.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In any calendar quarter after the Launch Quarter in the applicable country, if the quarterly Net Sales of the applicable Product in such country is less than &#91;*&#93; of the average quarterly Net Sales such Product achieved in such country in the &#91;*&#93;. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Launch Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) &#91;*&#93; or (b) &#91;*&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Cumulative Reduction Floor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The royalty reductions in Sections 7.8.1(b), 7.8.2, and 7.8.3 are cumulative, but in no event will the aggregate amount of royalties due to Sangamo for a Product during a calendar quarter be reduced, by reason of Sections 7.8.1(b), 7.8.2, and 7.8.3 to &#91;*&#93;. Genentech &#91;*&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">&#91;*&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">&#91;*&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.66pt">Payment Terms, Reports, Audits</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Notice of Milestone Achievement&#59; Timing of Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">With respect to each of the milestone events set forth in Sections 7.3 and 7.4, Genentech will inform Sangamo within &#91;*&#93;following the achievement of such event. With respect to each of the milestone events set forth in Section 7.6, Genentech will inform Sangamo within &#91;*&#93; following the end of the calendar quarter during which such achievement of such event occurred. Following such notice, </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Genentech will pay Sangamo the respective payable milestone payment within &#91;*&#93; of receipt of an invoice from Sangamo with respect thereto.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Timing of Royalty Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All royalty payments for a calendar quarter will be due &#91;*&#93; after the end of such calendar quarter.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Royalty Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For each calendar quarter for which Genentech has an obligation to make royalty payments pursuant to Section 7.7, such payments will be accompanied by a report that specifies for such calendar quarter the following information on a Product-by-Product basis&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">the Sales and Net Sales in those countries where the Royalty Term is then in effect, provided that Net Sales will be specified on an aggregate and a country-by-country basis&#59; &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">the applicable royalty rate(s) applied&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">the total royalties due to Sangamo on such Net Sales&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">any applicable royalty adjustments, reductions or offsets set forth herein&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">the total royalties due to Sangamo on such Net Sales after applying applicable, if any, adjustments, reductions and offsets as set forth herein, including a summary of the current exchange rate methodology used (if applicable). </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Invoicing. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sangamo will send invoices under this Agreement to Genentech via e-mail to Genentech&#8217;s Alliance Manager and at&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Alliance Manager, Pharma Partnering</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Genentech, Inc.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">One DNA Way, Mail Stop 53</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">South San Francisco, CA 94080</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or to such other address as Genentech may designate from time to time.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Mode of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All payments hereunder will (unless otherwise specifically set forth in this Agreement) be non-creditable and non-refundable.  All payments to Sangamo hereunder will be made in immediately available funds to the account listed below (or such other account as Sangamo will designate before such payment is due)&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Account Name&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Sangamo Therapeutics Inc</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">501 Canal Blvd Ste A100</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Richmond CA 94804</font></div><div style="text-align:justify"><font><br></font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Bank Details&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Currency of Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All amounts set forth herein (including all payments) will be in United States dollars, unless otherwise expressly provided in this Agreement.  Net Sales outside of the United States will be first determined in the currency in which they are earned and will then be converted into an amount in United States dollars as follows&#58; (a) with respect to Sales by or on behalf of Genentech or an Affiliate, using Genentech&#8217;s or such Affiliate&#8217;s customary and usual conversion procedures, consistently applied and (b) with respect to Sales by or on behalf of a given Sublicensee, using the conversion procedures applicable to payments by such Sublicensee to Genentech for such sales.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Blocked Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If, at any time, Applicable Law prevents Genentech (or an Affiliate or Sublicensee) from remitting part or all of any payments when due with respect to any country where a Product is sold, Genentech will continue to provide the reports set forth in Section 8.3 for such payments, and such payments will be deposited in local currency in the relevant country to the credit of Sangamo in a recognized banking institution designated by Sangamo and identified in a written notice given to Genentech.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Sangamo will pay all income and revenue taxes levied on account of any payments accruing or made to Sangamo under this Agreement.  Except as otherwise provided in this Section 8.8, any payments made under this Agreement are exclusive of any transfer taxes such as sales, use, transfer, documentary, stamp, registration, VAT, goods or service (GST), or similar tax (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indirect Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which shall be added thereon as applicable.  If any Indirect Tax is required with respect to the transactions, payments or the related transfer of rights or other property pursuant to the terms of this Agreement pursuant to Applicable Law, Genentech shall pay such Indirect Tax (and shall indemnify Sangamo for such Indirect Taxes) at the applicable rate with respect to any such payments following the receipt of a valid invoice. If provision is made in Applicable Law of any country for withholding of taxes of any type, levies or other charges with respect to any royalty or other amounts payable under this Agreement to Sangamo, then Genentech will promptly pay such tax, levy or charge for and on behalf of Sangamo to the proper governmental authority and will promptly furnish Sangamo with receipt of payment.  Each Party agrees to reasonably assist the other Party in claiming exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to time in force and in minimizing the amount required to be so withheld or deducted. Notwithstanding the foregoing, if an action taken by Genentech after the Effective Date (including any assignment of this Agreement, any sublicense of its rights or obligations under this Agreement, any transfer of payment obligations hereunder, or a change in tax residency of Genentech) leads to the imposition of withholding tax liability on payment to Sangamo that would not have been imposed in the absence of such action or an increase in such liability above the liability that would have been imposed in the absence of such action, then the sum payable by Genentech (with respect to which such deduction or withholding is required to be made) shall be increased to the extent necessary to ensure that Sangamo receives a sum equal to the sum it would have received had no such action occurred.  Any payments due to Sangamo pursuant to </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">this Section 8.8 shall promptly be paid by Genentech within &#91;*&#93; of receipt of an invoice from Sangamo with respect thereto.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Records&#59; Inspection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Genentech agrees to keep, for &#91;*&#93; from the end of the year of creation, records of all sales of Products for each reporting period in which royalty payments are due, showing sales of Products for Genentech and applicable deductions in sufficient detail to enable the reports provided under Section 8.3 to be verified.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Sangamo will have the right to request that royalty reports provided under Section 8.3 be verified by an independent, certified and internationally recognized public accounting firm selected by Sangamo and reasonably acceptable to Genentech (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CPA Firm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Such right to request a verified report will (a) be limited to the &#91;*&#93; period during which Genentech is required to maintain the same pursuant to Section 8.9.1, (b) not be exercised more than once in any calendar year, and (c) not be exercised more than once with respect to records covering any specific period of time.  Subject to Section 8.9.3, Genentech will, upon reasonable advance notice and at a mutually agreeable time during its regular business hours, make its records available for inspection by such CPA Firm at such place or places where such records are customarily kept, solely to verify the accuracy of such applicable royalty report(s) and related payments due under this Agreement.  The CPA Firm will only state factual findings in the audit reports.  The CPA Firm will share all draft audit reports with Genentech before any such draft audit report is shared with Sangamo and before the final document is issued.  All final audit reports will be shared with Genentech at the same time that the applicable report is shared with Sangamo.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Prior to any audit under Section 8.9.2, the CPA Firm will enter into a written confidentiality agreement with Genentech that (a) limits the CPA Firm&#8217;s use of the Genentech&#8217;s records to the verification purpose described in Section 8.9.2&#59; (b) limits the information that the CPA Firm may disclose to Sangamo to the numerical summary of payments due and paid&#59; and (c) prohibits the disclosure of any information contained in such records to any Third Party for any purpose.  The Parties agree that all information subject to review under Section 8.9.2 or provided by the CPA Firm to Sangamo is Genentech&#8217;s Confidential Information, and Sangamo will not use any such information for any purpose that is not germane to Section 8.9.2.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Underpayment&#59; Overpayment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. After reviewing the CPA Firm&#8217;s final audit report, Genentech will promptly pay any uncontested, understated amounts due to Sangamo.  Any overpayment made by Genentech will be promptly refunded or fully creditable against amounts payable in subsequent payment periods, at Genentech&#8217;s election.  Any audit under Section 8.9.2 will be at Sangamo&#8217;s expense&#59; provided, however, Genentech will reimburse reasonable audit fees for a given audit if the results of such audit </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">reveal that Genentech underpaid Sangamo with respect to royalty payments by &#91;*&#93; or more for the audited period.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Late Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If any payment due to either Party under this Agreement is not paid when due, then such paying Party will pay interest thereon (before and after any judgment) at an annual rate (but with interest accruing on a daily basis) of &#91;*&#93; (or such other interbank rate acceptable to both Parties), such interest to run from the date on which payment of such sum became due until payment thereof in full together with such interest.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.66pt">Intellectual Property</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Disclosures of IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term, Genentech will promptly disclose to Sangamo any &#91;*&#93; of which Genentech becomes aware.  Until completion of the &#91;*&#93;, Sangamo will promptly disclose to Genentech any &#91;*&#93;, or &#91;*&#93;, of which it becomes aware. During the Term, each Party will promptly disclose to the other Party any Joint IP of which it becomes aware.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">IP Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Within thirty (30) days following the Effective Date, the Parties will establish a joint intellectual property committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IP Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) comprised of at least one patent attorney from each Party (which may include outside counsel). The IP Committee will (a) meet on a quarterly basis (unless the Parties agree on alternate timing) during the Term to coordinate strategic matters related to &#91;*&#93;, (b) &#91;*&#93;, and (c) &#91;*&#93;. If the IP Committee &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The determination of whether inventions, discoveries, creations, or works are conceived, reduced to practice or otherwise invented by or on behalf of a Party for purposes of allocating intellectual property rights therein will, for purposes of this Agreement, be made in accordance with the United States patent and copyright laws and other Applicable Laws in the United States.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Pre-Existing IP and IP Developed Outside Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party will continue to own any Patents and Know-How that it owned prior to the Effective Date or that it creates or obtains independently of this Agreement.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">IP Developed under Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to ARTICLE 5, (a) Sangamo will own (i) &#91;*&#93; and (ii) &#91;*&#93;, and (b) as between the Parties, ownership of all other inventions, discoveries, creations and works, including Know-How, compositions of matter, articles of manufacture or other subject matter, whether patentable or copyrightable or not, that are first conceived, reduced to practice or otherwise invented in the performance of this Agreement by or on behalf of one or both Parties (and the intellectual property rights therein) will be determined based on inventorship. Notwithstanding Section 10.2.1, &#91;*&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Assignment and Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The assignments necessary to accomplish the ownership provisions set forth in Section 9.3 are hereby made, and each Party will execute such further documentation as may be necessary or appropriate and provide reasonable assistance and cooperation to implement the provisions of Section 9.3.  Without limiting the foregoing, each </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Party agrees to execute such documents, render such assistance, and take such other action as the other Party may reasonably request, to apply for, register, perfect, confirm, and protect the other Party&#8217;s rights in such intellectual property rights (including Patents and Know-How) therein to effect the intent of Section 9.3.  Each Party will require, to the extent legally possible under relevant national or local laws, all of its employees, Affiliates and subcontractors to assign to such Party its right, title and interests in any Patents and Know-How conceived, reduced to practice or otherwise invented by such employee, Affiliate or subcontractor (or if assignment is not possible, to otherwise convey rights) and to cooperate with such Party in connection with obtaining Patent protection therefor.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Joint IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to ARTICLE 5, ARTICLE 6, and ARTICLE 10, each Party has the right to practice, license, sublicense, assign, transfer and otherwise exploit such Party&#8217;s interest in the Joint IP (including Patents therein) for any and all purposes on a worldwide basis, without restriction, and without the consent of, and without a duty of accounting to, the other Party. Each Party will grant and hereby does grant all permissions, consents and waivers with respect to, and all licenses under, such Party&#8217;s interest in the Joint IP, throughout the world, necessary to provide the other Party with the foregoing rights.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Prosecution and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Licensed Payload Patents and Licensed Product Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As between the Parties, &#91;*&#93;.  &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Licensed Capsid Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Sangamo will, at its expense, Prosecute and Maintain the Licensed Capsid Patents &#91;*&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Patents within Joint IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as set forth in Sections 9.6.1(a) and 9.6.1(b), each Party will, at its expense, have the right to control Prosecution and Maintenance of Patents within the Joint IP by providing notice thereof to the other Party, provided that if both Parties desire to control Prosecution and Maintenance for any Patent(s) within the Joint IP, Genentech, at its expense, will have the first right to Prosecute and Maintain such Patent(s).  If a Party decides not to Prosecute and Maintain any Patent within the Joint IP that it has the right to Prosecute and Maintain pursuant to this Section 9.6.1(c), such Party will notify the other Party at least forty-five (45) days prior to any relevant deadline or filing or response date, and the other Party will thereupon have the right, but not the obligation, to assume the Prosecution and Maintenance of such Patent at its expense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Other Patents within Licensed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As between the Parties, except as set forth in Sections 9.6.1(a), 9.6.1(b) and 9.6.1(c), Sangamo will, at its expense, have the right to control and make decisions with respect to Prosecution and Maintenance of Patents within the Licensed IP.</font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Further Acts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. At the requesting Party&#8217;s expense, each Party will reasonably cooperate with and assist the other in the Prosecution and Maintenance of Patents within the Licensed IP and Joint IP, including making scientists and scientific records reasonably available and using its reasonable efforts to have documents signed as necessary in connection with such Prosecution and Maintenance.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Patent Term Restoration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As between the Parties, with respect to each Product, &#91;*&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">German Statute on Employee Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  With respect to any inventions arising under this Agreement that are within the scope of the German Statute on Employee&#8217;s Inventions, each Party will claim the unlimited use of any such inventions.  Each Party will be responsible for its own compliance with the German Statute on Employee&#8217;s Inventions.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Genentech will have the sole right to determine and own all Trademarks used on or in connection with a Product (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and will, at its sole expense and discretion, procure, maintain, enforce, and defend any such Product Trademarks. &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Enforcement&#59; Challenges&#59; Defense of Third Party Infringement Claims.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Notice.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Each Party will promptly notify the other Party upon learning of any (a) actual or suspected infringement or misappropriation by a Third Party of any Patent within the Licensed IP or Joint IP arising from the exploitation of a product that is Directed To the same Target as a Product and competitive with such Product (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) or (b) claim by a Third Party that is developing or commercializing any therapeutic product Directed To the same Target as a Product alleging invalidity, unpatentability (including any Third Party-filed observations, reexaminations, inter partes reviews, and post grant reviews, as well as interferences and derivation proceedings, oppositions and other similar proceedings brought by a Third Party), unenforceability or non-infringement (or non-misappropriation) of any Patent within the Licensed IP or Joint IP that claims a Product (or a component thereof) or the composition of matter, method of use, or method of making the Product (or a component thereof) (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Any certification, notice of allegation, declaration, or similar notice pursuant to a patent listing or patent linkage regulation under Applicable Law or any notice of filing of an abbreviated new drug application or biosimilar application, notice of commercial marketing, or similar notice pursuant to regulations under Applicable Law, in either case, received by either Party from a Third Party for a Product will be deemed an Infringement of the applicable Patent(s). </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.69pt">Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As between the Parties, (A) &#91;*&#93;, and (B) &#91;*&#93;, at its sole expense, and to enter into, or permit, the settlement of any such litigation or other enforcement or defense action with respect to any such Infringement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.36pt">Licensed Capsid Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Promptly following receipt of any notice regarding Infringement of a Licensed Capsid Patent, the Parties will meet to discuss the appropriate course of action to enforce, defend or otherwise abate such Infringement &#91;*&#93;. Sangamo will have the sole right, but not the obligation, to determine the appropriate course of action, and to take (or otherwise refrain from taking) action to enforce, defend, or control such litigation or other enforcement or defense action with respect to such Infringement, will keep Genentech fully informed of any actions it is taking (or refraining from taking) &#91;*&#93;.  If Sangamo elects to not take any steps to abate an Infringement of a Licensed Capsid Patent, Sangamo agrees to notify Genentech. &#91;*&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In any action under Section 9.7.2, the non-controlling Party will cooperate with the Party controlling any such action (as may be reasonably requested by the controlling Party) at the controlling Party&#8217;s expense, including, if necessary, by being joined as a party and the Party controlling any such action will keep the other Party regularly updated and informed with respect to any such action, including providing copies of material documents received or filed in connection with any such action.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary in Section 9.7.2(a), the Party controlling any action described in Section 9.7.2 will not settle or consent to an adverse judgment without the express consent of the non-controlling Party (such consent not to be unreasonably withheld or delayed), &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Damages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. &#91;*&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Challenges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.69pt">Generally. &#91;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.36pt">Licensed Capsid Patents. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Counterclaims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding the foregoing in Section 9.7.3, Section 9.7.3(a) will govern the rights and obligations of the Parties with respect to any counterclaim brought in response to an action to abate an Infringement.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Defense of Third Party Infringement Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event that a claim is brought against either Party alleging the infringement, violation or misappropriation of any Third Party&#8217;s intellectual property right based on the Exploitation of any Product(s), the </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Parties will promptly meet to discuss the defense of such claim, and the Parties will, as appropriate, enter into a joint defense agreement with respect to the common interest privilege protecting communications regarding such claim in a form reasonably acceptable to the Parties.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Common Interest Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  With regard to any information or opinions disclosed pursuant to this Agreement by one Party to the other Party regarding intellectual property or technology owned by Third Parties, the Parties agree that they have a common legal interest in determining whether, and to what extent, Third Party intellectual property rights may affect the Products, and have a further common legal interest in defending against any actual or prospective Third Party claims based on allegations of misuse or infringement of intellectual property rights relating to the Products.  &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.16pt">Confidentiality</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Definition of Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of a Party means the confidential or proprietary information (of whatever kind and in whatever form or medium, including copies thereof) disclosed in any form (whether written, oral, electronic, photographic or otherwise) by or on behalf of such Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to, or otherwise accessed by, the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in connection with this Agreement, whether prior to or during the Term, including Know-How or other information (whether or not patentable) regarding such Party&#8217;s research, development plans, designs of Trials, preclinical and clinical data, technology, products, business information or objectives, reports, and audits and other information of the type that is customarily considered to be confidential or proprietary information by entities engaged in activities that are substantially similar to the activities being engaged in by the Parties pursuant to this Agreement, including all proprietary materials as well as data and information associated therewith.  Notwithstanding the foregoing and Sections 10.2.1 and 10.2.5, but subject to the exclusions set forth in Sections 10.2.2 through 10.2.4 and 10.2.6, (a)&#160;the terms of this Agreement (including the Targets hereunder) will be the Confidential Information of both Parties, (b) during the Term, &#91;*&#93;, and (c) &#91;*&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Exclusions Regarding Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary in Section 10.1, Confidential Information of the Disclosing Party will not include information that the Receiving Party can demonstrate with competent written records&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">was already known to the Receiving Party, other than under an obligation of confidentiality, at the time of receipt by the Receiving Party&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">was generally available to the public or otherwise part of the public domain at the time of its receipt by the Receiving Party&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">became generally available to the public or otherwise part of the public domain after its receipt by the Receiving Party other than through any act or omission of such Receiving Party in breach of this Agreement&#59;</font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">was received by the Receiving Party without an obligation of confidentiality and non-use from a Third Party, who had no obligation of confidentiality and non-use regarding such information&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">was independently developed by or for the Receiving Party without use of or reference to the Confidential Information of the Disclosing Party&#59; or</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">was released from the restrictions set forth in this ARTICLE 10 by express prior written consent of the Disclosing Party.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">Specific aspects or details of Confidential Information will not be deemed to be within the public domain or in the possession of the Receiving Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the Receiving Party.  Further, any combination of Confidential Information will not be considered in the public domain or in the possession of the Receiving Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the Receiving Party unless the combination and its principles are in the public domain or in the possession of the Receiving Party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Non-Use and Non-Disclosure of Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term, and for a period of &#91;*&#93; thereafter, a Party will (a) except to the extent expressly permitted by this Agreement or otherwise agreed to in writing, keep confidential and not disclose to any Third Party or use for any other purpose any Confidential Information of the other Party&#59; and (b) take reasonable precautions to protect the Confidential Information of the other Party from unauthorized use or disclosure (including all precautions a Party employs with respect to its own confidential information of a similar nature and taking reasonable precautions designed to assure that no unauthorized use or disclosure is made by others to whom access to the Confidential Information of the Party is granted).  &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Authorized Disclosures of Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A Receiving Party may use and disclose the Confidential Information of the Disclosing Party as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">to the extent required by Applicable Law provided that the Receiving Party (a) if permitted by Applicable Law, uses all reasonable efforts to inform the Disclosing Party prior to making any such disclosures and reasonably cooperates with the Disclosing Party in seeking a protective order or other appropriate remedy (including redaction) and (b) whenever possible, requests confidential treatment of such Confidential Information&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">as necessary or reasonably useful to exercise its rights or fulfill its obligations under this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">to the extent such use and disclosure is reasonably required in the Prosecution and Maintenance of a Patent claiming or describing any Know-How within the Licensed IP in accordance with this Agreement&#59;</font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">as reasonably necessary to obtain or maintain any Regulatory Approval, including to conduct preclinical studies and Trials, consult with Regulatory Authorities for guidance and feedback, and for pricing approvals, for any Product, provided, that, the Receiving Party will take all reasonable steps to limit disclosure of the Confidential Information outside such Regulatory Authority and to otherwise maintain the confidentiality of the Confidential Information&#59; or</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">to the extent necessary, to its board members, Sublicensees, collaborators, vendors, consultants, agents, attorneys, accountants, contractors and clinicians under written agreements of confidentiality at least as restrictive as those set forth in this Agreement and who have a need to know such information in connection with the Receiving Party performing its obligations, exercising its licenses or other rights under this Agreement or as required under Applicable Law.  Further, the Receiving Party may disclose Confidential Information to existing or bona fide potential acquirers, merger partners, permitted collaborators, sublicensees and sources of financing or to professional advisors (e.g. attorneys, accountants and prospective investment bankers) for the limited purpose of evaluating a transaction, collaboration or sublicense with the Receiving Party, provided that such disclosures are limited to only such information that is strictly necessary for such purpose and are made under a written agreement by those permitted individuals to maintain such Confidential Information in strict confidence. Each Receiving Party will remain liable for the breach of this Agreement by the permitted recipients in this Section 10.4.5 as if such breach were by the Receiving Party itself.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, Sections 10.4.2 through 10.4.5 &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Termination of Prior Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As of the Effective Date, as between the Parties, this Agreement supersedes the Non-Disclosure Agreement.  Disclosures of Confidential Information (as defined in the Non-Disclosure Agreement) made prior to the Effective Date pursuant to the Non-Disclosure Agreement will be subject to the provisions of this ARTICLE 10 and such Confidential Information will be treated as the Confidential Information of the Party that disclosed such information pursuant to such prior Non-Disclosure Agreement. Each Party will remain liable for its breach, if any, of the Non-Disclosure Agreement that occurred prior to the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Residuals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary herein, except for &#91;*&#93; and is not subject to the exclusions set forth in Sections 10.2.2 through 10.2.6, and subject to ARTICLE 6, each Party and its Affiliates may use Residuals for any and all research purposes.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Residuals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Know-How or other Confidential Information of a Disclosing Party that is retained in the unaided memory of a Receiving Party&#8217;s (or any of its Affiliate&#8217;s) employees, consultants, or agents.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">No License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As between the Parties, Confidential Information disclosed hereunder will remain the property of the Disclosing Party, except as expressly set forth in this Agreement.  Disclosure of Confidential Information to the other Party will not constitute any grant, option or </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">license to the other Party, beyond those licenses expressly granted under Sections 5.1, 5.2, and 5.4 under any Patent, Know-How, or other rights now or hereinafter held by the Disclosing Party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Information Security Incident</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A Party will provide to the other Party written notice within &#91;*&#93; of such Party&#8217;s confirmation of any unauthorized use, unauthorized disclosure, corruption (including ransomware attack), or loss or other misuse of, or unauthorized access to, with respect to the other Party&#8217;s Confidential Information (each such incident, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Information Security Incident</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Information Security Incidents will not include unsuccessful attempts or activities that do not compromise the security of the applicable Confidential Information, including unsuccessful log-in attempts, pings, port scans, denial of service attacks, or other network attacks on firewalls or networked systems.  Such notice will describe in reasonable detail the Information Security Incident, including the other Party&#8217;s Confidential Information impacted, the extent of such impact and any corrective action taken or to be taken by such Party.  In addition, if a Party reasonably suspects (even if it has not confirmed) that an actual or attempted Information Security Incident has occurred with respect to the other Party&#8217;s Confidential Information, then such Party will promptly notify the other Party of such suspected actual or attempted Information Security Incident.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Non-Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except to the extent required by Applicable Law, neither Party will disclose any information related to an actual or suspected Information Security Incident of the other Party&#8217;s Confidential Information to any Third Party without the other Party&#8217;s prior written consent.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.16pt">Press Releases and Publications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Initial Press Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Following the Effective Date, Sangamo may issue a press release concerning the execution of this Agreement in the form attached hereto as Exhibit 11.1.  Any response to media inquiries or inquiries by Third Parties after issuance of the initial press release will consist solely of the content of the initial press release or conform with response guidelines mutually agreed to by the Parties prior to any such response.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Subsequent Releases</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Following the initial press release by Sangamo announcing the Agreement described in Section 11.1, (a) Genentech may issue press releases, presentations, interviews, campaigns, or other public announcements concerning this Agreement, the subject matter hereof, or the research, development, manufacturing or commercial results of the Licensed Payloads or Products hereunder (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), without Sangamo&#8217;s prior written consent, unless such Release includes reference to Sangamo by name or discloses Sangamo&#8217;s Confidential Information, and (b) except as permitted under Section 11.3 or 11.4, Sangamo may not issue any Release, without Genentech&#8217;s prior written consent, provided that Sangamo may, without Genentech&#8217;s prior written consent, issue any Release that (i) relates to the Licensed </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Capsids or Sangamo&#8217;s proprietary platform technologies (including the AAV capsid discovery platform referred to as SIFTER, modular integrase technology referred to as MINT and zinc finger technologies generally that do not specifically relate to a Licensed Payload) and (ii) does not specifically relate to a Target, Licensed Payload or a Product.  For any Release that requires consent of the other Party, the issuing Party will provide a draft of such Release to the other Party for its review at least &#91;*&#93; prior to the intended date of issuance of such Release.  For any Release that does not require consent of the other Party (including any Release permitted under Section 11.3), the issuing Party will provide notice of such Release to the other Party reasonably prior to the intended date of issuance of such Release or, if prior notice is impracticable, soon after such issuance. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Approved Releases</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If a Release requires consent pursuant to Section 11.2, after consent has been given, either Party may make subsequent public disclosure of the contents of such Release (or the Release issued pursuant to Section 11.1) without the further approval of the other Party, provided that such information remains accurate as of such time and is not presented with any new data or information or conclusions or in a form or manner that materially alters the subject matter therein or would be misleading.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Releases Required by Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party may issue any Release it is required to issue by Applicable Law, provided that if Applicable Law requires the issuing Party to disclose any of the other Party&#8217;s Confidential Information in such Release, the Party issuing such Release will (a) to the extent permitted by Applicable Law, use reasonable efforts to inform the other Party no less than &#91;*&#93; prior to making any such Release to permit such other Party the opportunity to seek to obtain a protective order or other confidential treatment preventing or limiting the required disclosure, and (b) disclose only such Confidential Information of the other Party that it is advised by counsel is legally required to be disclosed in such Release.  To the extent such other Party seeks to obtain a protective order or other confidential treatment to prevent or limit the required disclosure, the issuing Party will reasonably assist such other Party (unless prohibited by Applicable Law), but will not be required to delay such Release beyond the requirements of Applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Filing of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A Party may disclose this Agreement in securities filings with the US Securities Exchange Commission or equivalent foreign agency to the extent required by Applicable Law (including relevant rules of a security exchange on which the securities of the filing Party or its Affiliate are listed).  In such event, the filing Party will, at the request of the other Party, seek confidential treatment of portions of this Agreement from the applicable governmental agency and will provide such other Party with the opportunity, for no less than &#91;*&#93; before the date of the proposed filing, to review and comment on any such proposed filing of this Agreement, and will thereafter provide reasonable advance notice and opportunity for comment on any subsequent changes to such filing.  &#91;*&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Publications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Genentech, its Affiliates, and its and their Sublicensees will have the right, without Sangamo&#8217;s review or consent, to publish or disclose papers, abstracts, or written or oral presentations regarding activities under this Agreement (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Notwithstanding </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the foregoing, with respect to any Publication by Genentech, its Affiliates, or its or their Sublicensees that includes Product Information that is then Confidential Information or Sangamo&#8217;s Confidential Information, Genentech will submit to Sangamo such proposed Publication at least &#91;*&#93;  (&#91;*&#93; for abstracts) prior to the date of submission for publication or the date of presentation, as applicable, and Sangamo may review such Product Information and Sangamo&#8217;s Confidential Information in such proposed Publication and respond to Genentech as soon as reasonably possible, but in any case, within &#91;*&#93; (&#91;*&#93; for abstracts) of receipt thereof.  If Sangamo fails to respond within the time limits specified in this Section 11.6, such proposed Publication will be deemed approved.  As requested by Sangamo within the time limits specified in this Section 11.6, Genentech will (a) delete from such proposed Publication any of Sangamo&#8217;s Confidential Information or (b) delay the date of such submission for publication or the date of such presentation, as applicable, for a period of time sufficiently long (but in no event longer than &#91;*&#93; to permit Sangamo to seek appropriate Patent protection of its rights in the Confidential Information to be disclosed therein.  After a Publication of Product Information or Sangamo Confidential Information has been approved by Sangamo or deemed approved, Genentech may make subsequent public disclosure of the contents of such Publication without the further review or approval of Sangamo.  Except as expressly permitted by this Agreement, Sangamo and its Affiliates will not make any Publication or other public disclosures regarding any Licensed Payload, Product controlled by Genentech, Product Information or any other Genentech Confidential Information without Genentech&#8217;s prior written consent.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Use of Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as expressly provided herein and to the extent that such use is not inconsistent with prior public disclosures or presentations, no right, express or implied, is granted by this Agreement to use in any manner the name of a Party or its Affiliates (i.e., &#8220;Sangamo&#8221; or &#8220;Genentech&#8221; or &#8220;Roche&#8221;, as applicable) or any Trademark of the other Party in connection with the performance of this Agreement, except to the extent required by Applicable Law.  Notwithstanding the foregoing, Sangamo will be permitted to include the name or Genentech-approved version of Genentech&#8217;s corporate logo in connection with the description of this Agreement on Sangamo&#8217;s corporate website and investor presentations, in each case, solely for the purpose of identifying Genentech as a licensee and subject to Genentech&#8217;s review and approval (not to be unreasonably withheld or delayed) that Sangamo&#8217;s proposed use complies with Genentech&#8217;s written branding guidelines with respect to the use of such name, trademark or logo and such use only contains accurate and non-misleading factual statements regarding the Parties&#8217; relationship.  Genentech may reasonably request from time to time samples of the documents or other materials, or screen shots of the websites, containing Sangamo&#8217;s use of Genentech&#8217;s name, trademarks or logo to ensure compliance with Genentech&#8217;s written branding guidelines and the terms of this Section 11.7, and Sangamo will promptly comply with such reasonable requests.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.16pt">Representations, Warranties and Covenants</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Mutual Representations, Warranties, and Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party represents, warrants, and covenants, as applicable, to the other Party the following&#58;</font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. It is duly organized, validly existing and in good standing under the laws of the jurisdiction of its formation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid, binding obligation, enforceable against it in accordance with its terms, except to the extent that enforcement of the rights and remedies created hereby is subject to (a) bankruptcy, insolvency, reorganization, moratorium and other similar laws of general application affecting the rights and remedies of creditors, or (b) laws governing specific performance, injunctive relief and other equitable remedies.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">No Conflict</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The execution, delivery and performance of this Agreement and all instruments and documents to be delivered by such Party hereunder (a) does not conflict with any agreement or any provision thereof, or any instrument or understanding, oral or written, to which it is a party or by which it is bound, nor violate any Applicable Law of any governmental authority having jurisdiction over such Party, (b) have been duly authorized by all necessary or proper corporate action, (c) are not in contravention of any provision of the organizational documents of such Party, and (d) to the knowledge of such Party, will not violate Applicable Law or any order or decree of any court of governmental instrumentality.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Protection of Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. It follows reasonable commercial practices common in the industry to protect its proprietary and confidential information, including requiring its officers, employees, contractors, consultants, and agents to be bound in writing by obligations of confidentiality and non-disclosure, and requiring its officers, employees, contractors, consultants, and agents to assign to it any and all inventions, discoveries, creations or works conceived, reduced to practice or otherwise invented by such officers, employees, contractors, consultants, or agents within the scope of and during their employment or in the course of providing services for such Party, as applicable, and only disclosing proprietary and confidential information to Third Parties pursuant to written confidential and non-disclosure agreements.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Compliance with Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In fulfilling its obligations under this Agreement, it will comply with all Applicable Law.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">No Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither such Party nor any of its Affiliates have used or will use in any capacity, in connection with the preclinical or clinical development activities performed or to be performed under this Agreement, any individual or entity that has been debarred pursuant to Section 306 of the US Federal Food, Drug, and Cosmetic Act, or who is the subject of a conviction described in such section.  Such Party agrees to inform the other Party in writing immediately if it becomes aware that it or any individual or entity that is performing any such activity by or on behalf of such Party hereunder is debarred or is the subject of a conviction described in Section 306, or if any action, suit, </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">claim, investigation, or legal or administrative proceeding is pending or is threatened in writing, relating to the debarment or conviction of such Party or any individual or entity that is performing any such activity by or on behalf of such Party hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Sangamo Representations, Warranties, and Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Sangamo, on behalf of itself and each of its Affiliates, hereby represents and warrants to Genentech, as of the Effective Date, and covenants, as applicable, the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Intellectual Property</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Complete Lists</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  &#91;*&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Right to Grant Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Sangamo has the lawful right and authority to grant the licenses set forth in Sections 5.1 and 5.2. Sangamo has not granted, and will not grant during the Term, any right, license or interest in or to the Licensed IP or &#91;*&#93; or any portion thereof that is inconsistent with the rights granted to Genentech herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">&#91;*&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">No Encumbrances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Licensed IP is, and will be for the duration of the Term, free and clear of all liens, claims, security interests, licenses, covenants not to sue, or other encumbrances of any kind that would interfere, or the exercise of which would interfere, with Genentech exercising any of the licenses or other rights granted to it hereunder. As of the date of transfer to Genentech, Sangamo Controls all Know-How and materials transferred by or on behalf of Sangamo to Genentech pursuant to the Technology Transfer, free and clear of all liens, claims, security interests, licenses, covenants not to sue, or other encumbrances of any kind that would interfere, or the exercise of which would interfere, with Genentech exercising any of the licenses or other rights granted to it hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">No Infringement or Misappropriation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As of the Effective Date, Sangamo and its Affiliates have not received any written notice, and have no actual knowledge, of any claim that any Patent or Know-How owned or controlled by a Third Party has been or would be infringed or misappropriated by the Exploitation of any Licensed Payload, Licensed Capsid or Product, or by the performance &#91;*&#93;.  To the best of Sangamo&#8217;s actual knowledge as of the Effective Date (without any obligation to perform any freedom-to-operate analyses), the &#91;*&#93;, Licensed Capsids or Products by Genentech as contemplated under this Agreement does not and will not infringe any issued Patent of any Third Party. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.03pt">No Knowledge of Invalidity or Unenforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither Sangamo nor any of its Affiliates (i) have any knowledge or information that could render invalid or unenforceable any claims that are in any Patents within the Licensed IP or (ii) has any knowledge of any inventorship disputes concerning any Patents within the Licensed IP.  All filing and renewal fees payable with respect to the Patents within the Licensed IP have been timely paid.</font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Inventor Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All current and former officers, employees, contractors, consultants, and agents of Sangamo of any of its Affiliates, in each case, who are inventors of, or have otherwise contributed in a material manner to the creation or development of, or will contribute to the creation or development of, any part of the Licensed Capsid, Licensed Payload, Product or any invention claimed in the Patents within the Licensed IP existing at the Effective Date, have executed and delivered to Sangamo an assignment or other agreement regarding the protection of proprietary information and the assignment of their entire rights, title, and interest in and to any such inventions to Sangamo.  With respect to each of the Patents within the Licensed IP (i) all inventors of such Patents are correctly identified, (ii) such Patents have been timely and duly filed in such a manner as to perfect title and preserve priority entitlement, including by virtue of assignment documents associated with each priority filing, and (iii) no current officer, employee, contractor, consultant, or agent of Sangamo or any of its Affiliates is in violation of any term of any assignment or other agreement regarding the protection of such Patents or any other intellectual property or proprietary information of Sangamo or the applicable Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">No Governmental Authority Funding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No portion of any Licensed IP or &#91;*&#93; existing as of the Effective Date was developed, and no portion of any Licensed IP or &#91;*&#93; not existing as of the Effective Date will be developed, in each case, using funding from any governmental authority, whether directly or indirectly.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.69pt">No Prior Consent Required</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Sangamo has the lawful right to grant Genentech the rights and licenses described in this Agreement without the prior consent or approval of any Third Party (including any governmental authority or Regulatory Authority), and none of the Licensed IP existing as of the Effective Date is subject to any right of any Regulatory Authority to grant a license to or assign all or any portion of such Licensed IP to any Third Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.69pt">Existing Third Party Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As of the Effective Date, there is no agreement with any Third Party pursuant to which Sangamo in-licensed any Patent within the Licensed IP or &#91;*&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Pre-Clinical Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As of the Effective Date, Sangamo has disclosed to Genentech, the results of all material pre-clinical testing of Licensed Payloads, Licensed Capsids and Products in its possession or control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Material Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As of the Effective Date, Sangamo has not withheld any material information in its possession from Genentech in response to Genentech&#8217;s reasonable inquiries in connection with its due diligence process relating to any Licensed Payload, Licensed Capsid or Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">No False Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither Sangamo nor any of its Affiliates, nor any of its or their respective officers, employees, or agents has (i) made an untrue statement of material fact or fraudulent statement to the FDA or any other Regulatory Authority with respect </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to any Licensed Payload, Licensed Capsid or Product, (ii) failed to disclose a material fact required to be disclosed to any such Regulatory Authority with respect to any Licensed Payload, Licensed Capsid or Product, or (iii) committed an act, made a statement, or failed to make a statement with respect to any Licensed Payload, Licensed Capsid or Product that could reasonably be expected to provide a basis for the FDA to invoke its policy respecting &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221;, set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto or any analogous laws or policies.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">No Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  &#91;*&#93;, judicial or legal, administrative or other proceedings or governmental investigations pending or threatened in writing against Sangamo or any of its Affiliates which would be reasonably expected to adversely affect or restrict the ability of Sangamo to consummate this Agreement or the activities contemplated herein. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">No Authorizations Required</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No government authorization, consent, approval, license, exemption of or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any Applicable Law currently in effect, is necessary for the consummation of the transactions contemplated by this Agreement or for the performance by it of its obligations under this Agreement (including, the grant of the rights to Genentech hereunder). </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">No Other Representations, Warranties, or Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND EACH PARTY HEREBY EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES NOT EXPRESSLY PROVIDED IN THIS AGREEMENT, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.16pt">Indemnification, Limitation of Liability, Insurance</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Indemnification by Sangamo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to Section 13.3, Sangamo will indemnify, defend and hold each of Genentech, its Affiliates and their respective directors, officers, and employees, and the successors and assigns of any of the foregoing, harmless from and against any and all liabilities, damages, settlements, penalties, fines, costs or expenses (including, without limitation, reasonable attorneys&#8217; fees and other expenses of litigation) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) as a result of any Third Party claims, suits, actions, demands or judgments (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) arising out of (a) breach by Sangamo of any provision under this Agreement, (b) the gross negligence or willful misconduct on the part of Sangamo or its Affiliates or their respective directors, officers, employees, and agents in connection with this Agreement, (c) the research or development of any Licensed Payload, Licensed Capsid or Product by or on behalf of Sangamo prior to the Effective Date, or (d) the Exploitation of Terminated Products by or on behalf of Sangamo, its Affiliates or sublicensees following termination of this Agreement, except, in each </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">case, for those Losses for which Genentech has an obligation to indemnify Sangamo pursuant to Section 13.2, as to which Losses each Party will indemnify the other to the extent of their respective liability for the Losses.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Indemnification by Genentech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to Section 13.3, Genentech will indemnify, defend and hold each of Sangamo, its Affiliates and their respective directors, officers, and employees, and the successors and assigns of any of the foregoing, harmless from and against any and all Losses as a result of any Third Party Claims arising out of (a) breach by Genentech of any provision under this Agreement, (b) the gross negligence or willful misconduct on the part of Genentech or its Affiliates or their respective directors, officers, employees, and agents in connection with this Agreement or (c) the Exploitation of any Licensed Capsid, Licensed Payload or Product by or on behalf of Genentech, its Affiliates or Sublicensees hereunder, except, in each case, for those Losses for which Sangamo has an obligation to indemnify Genentech pursuant to Section 13.1, as to which Losses each Party will indemnify the other to the extent of their respective liability for the Losses.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If a Party intends to claim indemnification under this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), it will promptly notify the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of such alleged Loss.  The failure to deliver notice to the Indemnitor within a reasonable time after the commencement of any such action, to the extent prejudicial to its ability to defend such action, will relieve the Indemnitor of any obligation to the Indemnitee under this ARTICLE 13 with regard to such action.  Only Genentech and Sangamo may claim indemnity under this Agreement (on its own behalf or on behalf of its Indemnitees), and other Indemnitees may not directly claim indemnity hereunder.  The Indemnitor will have the right to control the defense thereof with counsel of its choice and reasonably acceptable to Indemnitee.  Any Indemnitee will have the right to retain its own counsel at its own expense for any reason.  The Indemnitee, its employees, agents and other Indemnitees, will reasonably cooperate with the Indemnitor and its legal representatives in the investigation of any Third Party Claims covered by this Agreement.  The obligations of this ARTICLE 13 will not apply to amounts paid in settlement of any claim, demand, action or other proceeding if such settlement is effected without the consent of the Indemnitor, which consent will not be unreasonably withheld or delayed.  The Indemnitor will not, without the written consent of the Indemnitee, effect any settlement of any Third Party Claims, unless such settlement is solely for monetary damages and includes an unconditional release of the Indemnitee from all liability on claims that are the subject matter of such proceeding.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term and for three (3) years thereafter, each Party will maintain commercial general liability insurance (a) combined single limit for bodily injury and property damage liability, in the minimum amount per occurrence of &#91;*&#93; all commencing as of the Effective Date&#59; provided, however, Genentech has the right, in its sole discretion, to self-insure, in part or in whole, for any such coverage.  The insurance policies for such coverage will be an occurrence form, but if only a claims made form is available to a Party, such Party will maintain such coverage for at least three (3) years after the later of (i) termination or expiration of this Agreement or (ii) such Party having no further obligations under this Agreement.  Insurance coverage will be maintained with an insurance company or companies having an A.M. Best&#8217;s </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">rating (or its equivalent) of A-VII or better.  On written request, Sangamo will provide to Genentech certificates of insurance evidencing the insurance coverage required under this Section 13.4.  Each Party agrees to waive its right of subrogation with respect to workers&#8217; compensation claims.  The limits of a Party&#8217;s insurance or self-insurance coverage will not limit the Party&#8217;s liability, including under the indemnification provisions of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Limitation of Damages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  IN NO EVENT WILL EITHER PARTY OR ITS AFFILIATES BE LIABLE TO THE OTHER PARTY FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE, TREBLE OR CONSEQUENTIAL DAMAGES OR LOST PROFITS, WHETHER BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES, EXCEPT IN RESPECT OF (A) THE INDEMNIFICATION OBLIGATION OF SUCH PARTY IN RESPECT OF THIRD PARTY CLAIMS UNDER THE PROVISIONS OF THIS ARTICLE 13, (B) DAMAGES AVAILABLE FOR BREACH OF ARTICLE 10 OR ARTICLE 11, OR (C) LIABILITY IN THE CASE OF GROSS NEGLIGENCE, WILLFUL MISCONDUCT OR FRAUD BY A PARTY.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.16pt">Term, Termination</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement will commence on the Effective Date and, unless earlier terminated in accordance herewith, will continue in full force and effect, on a country-by-country and Product-by-Product basis, until the date when there is no remaining royalty payment obligation in such country with respect to such Product (such period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), at which time this Agreement will expire with respect to such Product in such country.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Termination by Either Party for Material Breach.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Either Party may terminate this Agreement in its entirety, or with respect to a particular Product or Target, by written notice to the other Party for any material breach of this Agreement by the other Party if such material breach is not cured within &#91;*&#93; after the breaching Party receives written notice of such material breach from the non-breaching Party (such period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), provided that if such material breach is not capable of being cured within the Cure Period, the Cure Period will be extended for such amount of time that the Parties may agree in writing is reasonably necessary to cure such material breach, so long as (a) the breaching Party is making diligent efforts to cure such breach, and (b) the Parties agree on an extension within such &#91;*&#93; period.  Notwithstanding anything to the contrary herein, if the allegedly breaching Party in good faith either disputes (i) whether a breach is material or has occurred or (ii) the alleged failure to cure such material breach, and provides written notice of that dispute to the other Party within the Cure Period, then the matter will be addressed under the dispute resolution provisions in ARTICLE 15, and the Party alleging material breach may not so terminate this Agreement (in whole or in part) until it has been determined under ARTICLE 15 that the allegedly materially breaching Party is in material breach of this Agreement, and such breaching Party further fails to cure such breach within &#91;*&#93; after the conclusion of such dispute resolution procedure.  For clarity, where an uncured material breach is related solely to a particular Product or Target, any termination </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">hereunder will be limited to terminating the Agreement solely with respect to that Product or Target and not to any other Product or Target or this Agreement in its entirety.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Termination by Either Party for Insolvency.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Either Party may terminate this Agreement effective on written notice to the other Party upon the liquidation, dissolution, winding-up, insolvency proceeding, bankruptcy, or filing of any petition therefor, appointment of a receiver, custodian, trustee, or any other similar proceeding by or of the other Party where such petition, appointment or similar proceeding is not dismissed or vacated within &#91;*&#93; following the filing thereof.  All rights and licenses granted pursuant to this Agreement are, for purposes of Section 365(n) of Title 11 of the US Code or any foreign equivalents thereof (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Title 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), licenses of rights to &#8220;intellectual property&#8221; as defined in Title 11.  Each Party in its capacity as a licensor hereunder, as applicable, agrees that, unless this Agreement is terminated, in the event of the commencement of bankruptcy proceedings by or against such bankrupt Party under Title 11, (a) the other Party, in its capacity as a licensee of rights under this Agreement, will retain and may fully exercise all of such licensed rights under this Agreement and all of its rights and elections under Title 11 and (b) the other Party will be entitled to a complete duplicate of all embodiments of the licensed intellectual property (including physical embodiments and embodiments comprising data, lab notebooks, methods, or protocols, and all data within the Licensed IP), and such embodiments, if not already in possession of the other Party, will be promptly delivered to the other Party (i) upon any such commencement of a bankruptcy proceeding, unless the bankrupt Party elects to continue to perform all of its obligations under this Agreement, or (ii) if not delivered under the immediately preceding clause (i), immediately upon the rejection of this Agreement by or on behalf of the bankrupt Party. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Elective Termination by Genentech.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Genentech will have the right to terminate this Agreement, in its entirety or on a Product-by-Product, Region-by-Region or Target-by-Target basis, in its sole discretion, at any time by providing written notice to Sangamo.  Such termination will be effective &#91;*&#93; after Sangamo&#8217;s receipt of such notice, except that with respect to any Two-Component Product (that is not a Combination Product) with which a patient has been dosed in a Phase 1 Trial prior to the date of such notice, such termination will be effective with respect to such Two-Component Product one &#91;*&#93; after Sangamo&#8217;s receipt of such notice. For clarity, Genentech may terminate this Agreement under this Section 14.4 with respect to a particular Product in a particular Region. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Accrued Rights and Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Expiration or termination of this Agreement for any reason will not release either Party from any liability which, as of the effective date of such expiration or termination, had already accrued to the other Party or which is attributable to a period prior to such expiration or termination, nor preclude either Party from pursuing any rights or remedies it may have hereunder or at law or in equity which accrued or are based upon any event occurring prior to the effective date of such expiration or termination. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Effects of Termination by Sangamo for Material Breach or Insolvency or Elective Termination by Genentech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon termination of this Agreement by Sangamo in its entirety or with respect to a particular Product or Target pursuant to Sections 14.2 or 14.3, as applicable, or </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Genentech&#8217;s termination of this Agreement in its entirety or with respect to a particular Product, Region or Target pursuant to Section 14.4, the following provisions will apply to any Product(s), Region(s) or Target(s) affected by such termination&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Termination of Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except for the activities expressly provided in Sections 14.6.2, 14.6.3, and 14.6.6, all licenses set forth in Section 5.1 and 5.2 will terminate solely with respect to such Product(s), Region(s), or Target(s), as applicable, on the effective date of termination.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Wind-Down&#59; Continued Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of termination of this Agreement, notwithstanding the provision of a Continuation Election Notice, as of the date of notice of termination, Genentech will (a) have the right, at its cost and discretion, to wind-down, cancel, or complete all ongoing obligations relating to or arising from the terminated aspects of this Agreement and terminate any related agreements with Third Parties and (b) not be obligated to initiate any new activities under the terminated aspects of this Agreement.  Notwithstanding anything to the contrary in this Agreement, Genentech will have the right to continue, complete, amend, or wind-down any ongoing Trials relating to any such Product(s) (including any Terminated Product(s)) for which Genentech remains the Trial sponsor or is otherwise the responsible party with respect to any Regulatory Authority, on a timeline and in a manner elected by Genentech in its reasonable direction, taking into account legal, regulatory, patient safety, and ethical considerations, and Genentech shall remain responsible for all obligations and liabilities arising out of the continuation, completion, amendment or wind-down of any such ongoing Trials.   </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Inventory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except to the extent requested in an applicable Continuation Election Notice provided in accordance with Section 14.6.5, upon termination of this Agreement, Genentech, its Affiliates and Sublicensees will have the right to sell or otherwise dispose of all inventory of all Product(s) affected by such termination (including, if this Agreement is terminated solely with respect to a Region(s), in such terminated Region(s)) then in stock for &#91;*&#93; (or such longer period as may be agreed to by the Parties), subject to the applicable royalty payments due under Section 7.7 (as may be adjusted in accordance with Section 7.8), and Sangamo covenants not to sue Genentech, its Affiliates or Sublicensees for infringement under any of the Patents that were licensed by Sangamo to Genentech under this Agreement or that are licensed by Genentech to Sangamo under Section 14.6.6(h), solely with respect to such activities conducted by Genentech, its Affiliates, or Sublicensees pursuant to this Section 14.6.3.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Continuation of Sublicenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of termination of this Agreement by Sangamo pursuant to Sections 14.2 or 14.3, any then-existing, sublicense granted by Genentech under this Agreement will continue in full force and effect, provided that if the applicable termination was pursuant to Section 14.2, (a) the Sublicensee did not cause the uncured material breach that gave rise to such termination and (b) the Sublicensee agrees to be bound by all terms and conditions of this Agreement that are applicable to such </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sublicensee including remitting directly to Sangamo all payments and other obligations due to Sangamo related to such sublicense.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Continuation Election.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Within &#91;*&#93; of the date of notice of termination, provided that such thirty (30) day period will be stayed pending resolution of any dispute related to whether the terminating Party has the right to terminate this Agreement, Genentech will provide Sangamo a summary report of the status of material, ongoing activities for the development, manufacture, and commercialization of any such Product(s) that are Terminated Product(s) conducted by or on behalf of Genentech, its Affiliates, and Sublicensees (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Continuation Election Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), provided that if Genentech terminates this Agreement solely with respect to a Product in a particular Region(s), the Continuation Election Report will provide a report of such activities only in the terminated Region(s).  If Sangamo wishes to assume and continue any such development, manufacture, and commercialization activities, then within &#91;*&#93;of receipt of the Continuation Election Report, Sangamo will provide Genentech written notice of its intention, including a detailed list of the activities that Sangamo wishes to assume and continue and the documents and materials that Sangamo wishes for Genentech to transfer consistent with Section 14.6.6 (such notice, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Continuation Election Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Upon Genentech&#8217;s timely receipt of the Continuation Election Notice, the Parties will conduct the activities described in Section 14.6.6.  &#91;*&#93;.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.6.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Transfer of Terminated Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If Genentech timely receives the Continuation Election Notice with respect to any Terminated Product(s), then&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Regulatory Documentation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Effective as of the effective date of termination of this Agreement or promptly thereafter, to the extent requested in the applicable Continuation Election Notice, Genentech will assign to Sangamo all Regulatory Approvals solely relating to the Terminated Product(s) (solely in the affected Region, if this Agreement is terminated solely with respect to a Region) to the extent permitted under Applicable Law.  &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Regulatory and Clinical Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. On or prior to the effective date of termination of this Agreement, to the extent requested in the applicable Continuation Election Notice, Genentech will electronically transfer a copy of all final Trial reports for the Terminated Product(s) and all material correspondence with Regulatory Authorities (solely with Regulatory Authorities in the affected Region, if this Agreement is terminated solely with respect to a Region) solely relating to the Terminated Product(s) to Sangamo.  For clarity, &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Drug Safety Databases</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Effective as of the effective date of termination of this Agreement, or if not practicable, within a reasonable period of time following the effective date of termination, to the extent requested in the applicable Continuation Election Notice, Genentech will assign and transfer to Sangamo all global drug safety databases for the Terminated Product(s), provided, however, that if this Agreement is terminated only with respect to certain Region(s), Genentech will retain the global safety database for the Terminated Product(s) and the Parties will enter into a pharmacovigilance or safety data exchange agreement </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">concerning the procedures and timeframes for reporting safety information related to any Product(s) affected by such termination if Genentech determines it to be appropriate. Notwithstanding the foregoing, &#91;*&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Third Party Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Effective as of the effective date of termination of this Agreement, with respect to any Terminated Product(s) for which termination of this Agreement is not limited to particular Region(s), for any clinical or manufacturing agreement between Genentech and a Third Party that Sangamo requests to assume in the Continuation Election Notice relating to such Terminated Product, Genentech will assign to Sangamo the applicable agreement(s), to the extent Genentech is permitted to do so under such agreement(s) without additional consideration or undue burden.  If Genentech is unable to assign any such agreement or if the termination of this Agreement with respect to such Terminated Product is limited to a particular Region(s), Genentech will use reasonable efforts to facilitate an introduction between Sangamo and the applicable Third Party for Sangamo to enter into its own agreement with such Third Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Product Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Effective as of the effective date of termination of this Agreement, to the extent requested in the applicable Continuation Election Notice, Genentech will assign to Sangamo all of Genentech&#8217;s and its Affiliates&#8217; rights, title, and interests in and to any Product Trademark(s) for the Terminated Product(s) in the terminated Region(s), provided that Genentech will in no event be obligated to assign any house marks of Genentech or its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.03pt">Inventory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. On or promptly following the effective date of termination of this Agreement, to the extent requested in the applicable Continuation Election Notice, Genentech will transfer to Sangamo all then-existing and available inventory of the Terminated Product (except if such termination is limited to a particular Region(s), in which case Genentech will provide a reasonable portion of such inventory that is usable in such Region(s)). &#91;*&#93;.  All inventory will be shipped from Genentech to Sangamo (or its designee) FCA (location to be provided by Sangamo) Incoterms 2020.  Any and all inventory that Genentech provides to Sangamo will be provided &#8220;as is&#8221; without any representation or express or implied warranty.  For clarity, nothing in this Section 14.6.6(f) will be construed as an obligation for Genentech to perform any additional activities regarding the inventory, including retesting or analyzing, prior to such transfer. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Genentech&#8217;s Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Reversion License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to timely provision of the Continuation Election Notice pursuant to Section 14.6.5 and this Section 14.6.6(h), effective upon the effective date of termination with respect to the applicable Terminated Product (and, for clarity, not dependent upon execution of the Transfer Agreement), Genentech hereby grants Sangamo an exclusive, worldwide (except if such termination is limited to a particular Region(s), in which case the license set forth in this Section 14.6.6(h) will be limited to such Region(s)), sublicensable right and license under all intellectual property Controlled by Genentech as of the </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">effective date of termination that is (i) &#91;*&#93; or (ii) &#91;*&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reversion IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) solely to Exploit such Terminated Product (such license, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reversion License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), provided that such Reversion License will not include (x) &#91;*&#93;, (y) &#91;*&#93;or (z) &#91;*&#93;.  The Reversion License will be subject to (1) &#91;*&#93; and (2) &#91;*&#93; in each case (1) and (2), to be negotiated in good faith between the Parties as part of the Transfer Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.69pt">Transfer Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For a period of &#91;*&#93; following Genentech&#8217;s receipt of a Continuation Election Notice or such longer period as agreed to by the Parties (in either case, such period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transfer Agreement Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Parties will negotiate and use good faith efforts to agree upon a transfer agreement whereby each Party will conduct its respective activities to facilitate the transfer of any activities and materials to the extent identified in such Continuation Election Notice and not transferred in accordance with Sections 14.6.6(a) through 14.6.6(f) (such agreement, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transfer Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Transfer Agreement will be consistent with the following terms and conditions, as applicable to the Terminated Product(s) and terminated Region(s)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.69pt">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If at the time of the notice of termination, (a) Genentech is conducting a Phase 3 Trial for the Terminated Product or is marketing the Terminated Product in any country (or if such termination is limited to a particular Region(s), in any country in such Region(s)), and (b) Genentech manufactures such Terminated Product itself, then, at Sangamo&#8217;s request and Sangamo&#8217;s cost and expense, Genentech will manufacture and supply reasonable amounts of such Terminated Product to Sangamo to be negotiated under the Transfer Agreement, provided that (i) the duration of Genentech&#8217;s obligation to supply such Terminated Product will not exceed &#91;*&#93; from the effective date of termination of this Agreement and (ii) the cost of such supply will not be less than Genentech&#8217;s fully burdened manufacturing costs to manufacture the Terminated Product plus a mark-up of &#91;*&#93; as calculated according to Genentech&#8217;s Accounting Standard.  Notwithstanding the foregoing, Sangamo will use Commercially Reasonable Efforts to take over manufacturing of the Terminated Product as soon as possible after the effective date of termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.36pt">Third Party IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. With respect to any intellectual property rights Controlled by Genentech for which the license grant in Section 14.6.6(h) would cause Genentech or its Affiliates or Sublicensees to incur a financial obligation to a Third Party, to the extent permitted under the applicable agreement with such Third Party, Genentech will either assign the agreement with such Third Party under which Genentech receives rights to such intellectual property to Sangamo or Genentech will include in the Reversion License a sublicense under such intellectual property rights, provided that Sangamo agrees to (a) comply with the terms and conditions of the applicable agreement with such Third Party, and (b) bear all payment obligations thereunder to the extent attributable to the grant of the sublicense to Sangamo or the practice of such sublicense by Sangamo, its Affiliates or its or their sublicensees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18.03pt">Genentech&#8217;s Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  &#91;*&#93;.</font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.6.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Prosecution and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Transfer Agreement Negotiation Period, the IP Committee will agree upon a fair and reasonable solution for the continued Prosecution and Maintenance of any Patents that claim the Terminated Product, including responsibility, assignments (if any), and costs in connection thereto, provided that if the applicable termination is limited to a particular Region(s), this Section 14.6.7 will apply only with respect to Patents in such Region(s). The Parties will include such solution in the Transfer Agreement.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.6.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Baseball-Style Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  &#91;*&#93;.  No other issues relating to the Transfer Agreement may be brought under ARTICLE 15.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Effects of Termination by Genentech for Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon termination of this Agreement by Genentech in its entirety or with respect to a particular Product or Target pursuant to Section 14.2, (a) all rights and licenses set forth in Section 5.1 and 5.2 will survive and become perpetual with respect to the Product(s) affected by such termination, (b) the milestone payment obligations due under Section 7.3, 7.4, and 7.6 and the royalty payment obligations under Section 7.7 (as may be adjusted in accordance with Section 7.8) will survive, provided that in addition to any other remedies Genentech may have in law or in equity, Genentech will have the right to setoff any amounts payable to Sangamo under Sections 7.3, 7.4, 7.6, or 7.7 against any amounts to which Genentech is entitled for Sangamo&#8217;s breach of this Agreement or are otherwise payable by Sangamo to Genentech or any Indemnitee of Genentech pursuant to Section 13.2, and (c) Genentech will have no further diligence or other obligation under ARTICLE 4.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In addition to any provisions specified in this Agreement as surviving under the applicable circumstances, the following provisions will survive in the event of expiration or any termination of this Agreement&#58; &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.16pt">Dispute Resolution</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise set forth in this Agreement, in the event of any dispute arising from this Agreement, such dispute will first be referred, by written notice, to the Alliance Managers for attempted resolution.  If the Alliance Managers are unable to resolve the dispute within &#91;*&#93; following the date of receipt of such written notice, either Party may refer, by written notice (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Escalation Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), such dispute to the respective officers of the Parties designated below or their designees, for good faith negotiations attempting to resolve the dispute within &#91;*&#93;.  The designated officers are as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For Sangamo&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CEO</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For Genentech&#58;&#160;&#160;&#160;&#160;Head of Genentech Corporate Business Development</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as provided under Section 14.6.8, if the Parties are unable to resolve any dispute under Section 15.1 within the time specified therein, either Party will have the right to submit the dispute for final and exclusive resolution under the International Chamber of Commerce (ICC) Rules of Arbitration, applying the substantive law specified in Sections 15.2.3 and 16.1.  The arbitration tribunal will consist of three (3) arbitrators appointed in accordance with such ICC Rules of Arbitration.  Any arbitration proceeding hereunder will be conducted in San Francisco, CA and will be conducted in the English language.  The arbitration tribunal may only award damages consistent with this Agreement, including Section 13.5.  In the event of any conflict between the ICC Rules of Arbitration and any provision of this Agreement, this Agreement will govern.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary in Section 15.2, either Party may apply to any court having competent jurisdiction to enforce the arbitration provisions of this Agreement or an arbitration award as determined pursuant to this Section 15.2.  Such court will have no jurisdiction or ability to resolve disputes beyond the specific foregoing issues.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Subject Matter Exclusion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary in Section 15.2, any dispute not resolved internally by the Parties pursuant to Section 15.1 that involves the validity or infringement of a Patent will be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions having issued the Patent in question. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Interim Equitable Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary in Sections 15.1 or 15.2, in the event that a Party reasonably requires relief on a more expedited basis than would be possible pursuant to the procedure set forth in this ARTICLE 15, such Party may seek a temporary injunction or other interim equitable relief in a court of competent jurisdiction pending the ability of the arbitrators to review the decision under Section 15.2.  Such court will have no jurisdiction or ability to resolve disputes under this Agreement beyond the specific issue of temporary injunction or other interim equitable relief.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Baseball-Style Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If the Parties are unable to agree to the financial terms of a Reversion License, scope of a diligence obligation (if any) to be included with a Reversion License, or the Prosecution and Maintenance of Patents that claim a Terminated Product, Sangamo may provide written notice to Genentech, no later than &#91;*&#93;after expiration of the applicable Transfer Agreement Negotiation Period, to initiate a baseball-style arbitration proceeding pursuant to Section 15.3.  Within &#91;*&#93; following Genentech&#8217;s receipt of such notice, the Parties will use commercially reasonable efforts to mutually appoint an Expert.  If the Parties cannot agree on such Expert within such time period, each Party will select one (1) Expert within such &#91;*&#93; period, and within &#91;*&#93; of their selection, the two (2) Experts so selected will appoint the Expert to conduct the arbitration in accordance with Section </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.3.  Within &#91;*&#93; after appointment of the Expert, such Expert will set a date for the arbitration, which date will be no more than &#91;*&#93; after the date the arbitration is demanded above.  The arbitration will be &#8220;baseball-style&#8221; arbitration&#59; accordingly, at least &#91;*&#93; prior to the arbitration, each Party will provide the Expert and the other Party with a form of the definitive written agreement containing the terms of its proposal with respect to the financial terms of a Reversion License, scope of a diligence obligation (if any) to be included with a Reversion License, or the Prosecution and Maintenance of Patents that claim the Terminated Product and not any other provisions outside the scope described in Section 14.6.8.  Such proposal may be no more than thirty (30) pages and must clearly provide and identify the Party&#8217;s position with respect to such matter.  &#91;*&#93; in advance of the arbitration, the Parties will submit to the Expert and exchange response briefs of no more than fifteen (15) pages.  In addition, at least &#91;*&#93; in advance of the arbitration, each Party may submit to the Expert and the other Party a revised version of its proposal (together with a redline showing the changes from the prior draft of the proposal).  Subject to the foregoing page limitations, the Parties&#8217; briefs may include or attach (a) relevant exhibits in the form of documentary evidence, (b) publicly available information, (c) demonstratives or (d) expert opinions.  Neither Party may have any other communications (either written or oral) with the Expert other than for the sole purpose of engaging the Expert or as expressly permitted in this Section 15.3.  The arbitration will consist of a &#91;*&#93; hearing of no longer than &#91;*&#93;, such time to be split equally between the Parties, in the form of presentations by counsel or employees and officers of the Parties.  No live witnesses will be permitted except expert witnesses whose opinions were provided with the respective Party&#8217;s briefs.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Decisions&#59; Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No later than &#91;*&#93; following the arbitration, the Expert will issue a written decision.  The Expert will select one Party&#8217;s proposal as his or her decision and will not have the authority to render any substantive decision other than to select the proposal submitted by either Genentech or Sangamo.  The Expert will have no discretion or authority with respect to modifying the positions of the Parties.  The Expert&#8217;s decision will be final and binding on the Parties and the written agreement selected by the Expert will constitute a binding agreement between the Parties on the applicable disputed matter that may be enforced in any court of competent jurisdiction.  Each Party will bear its own costs and expenses in connection with such arbitration and will share equally the Expert&#8217;s fees and expenses.  The violation of one of the time limits prescribed in this Section 15.3.2 by the Expert will not affect the Expert&#8217;s competence to decide on the subject matter and will not affect the final and binding decision rendered by the Expert, unless otherwise agreed by the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Continued Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Provided that this Agreement has not terminated, the Parties will continue performing their respective obligations under this Agreement pending the final resolution of any dispute under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The existence and status of activities conducted under this ARTICLE 15, including any arbitration proceeding or decisions hereunder will be deemed Confidential </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Information of each Party, and will be subject to ARTICLE 10.  Either Party may request that the arbitration tribunal issue appropriate protective orders to safeguard such Party&#8217;s Confidential Information.  Except as required by law, neither Party will make (or request the arbitration tribunal or Expert to make) any public announcement with respect to the proceedings or decision of the arbitration tribunal or Expert without prior written consent of the other Party.  The existence of any dispute submitted to arbitration and any decision or award will be kept in confidence by each Party and the arbitration tribunal or Expert, except as required in connection with the enforcement of such award or as otherwise required by Applicable Law.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.16pt">Miscellaneous</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Choice of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement (including the arbitration provisions of Sections 15.2 and 15.3) will be governed by and interpreted in accordance with the laws of the State of Delaware, without reference to the principles of conflicts of laws.  The United Nations Convention on Contracts for the International Sale of Goods will not apply to the transactions contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise expressly provided in the Agreement, any notice required under this Agreement will be in writing and will specifically refer to this Agreement.  Notices will be sent via one of the following means and will be effective (a) on the date of delivery, if delivered in person&#59; (b) &#91;*&#93; after the date mailed if mailed by first class certified mail return receipt requested, postage prepaid to a destination within the same country&#59; (c) &#91;*&#93; after the date mailed if mailed by registered or certified mail return receipt requested, postage prepaid to a destination outside the country of the Party sending the notice&#59; or (d) on the date of receipt, if sent by private express courier.  Notices will be sent to the other Party at the addresses set forth below.  Either Party may change its address for purposes of this Section 16.2 by sending notice to the other Party in accordance with this Section 16.2.  Notwithstanding the foregoing, notices required to be provided solely to a Party&#8217;s Alliance Manager may be provided solely by email to such Alliance Director&#8217;s email address.</font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">If to Genentech&#58;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Genentech, Inc.  </font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58; Corporate Secretary</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1 DNA Way</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">South San Francisco, CA 94080</font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">with required copies (which will not constitute notice) to&#58;</font></div></td></tr></table></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Genentech, Inc.</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58; Head of Global Asset &#38; Alliance Management</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1 DNA Way</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">South San Francisco, CA 94080</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email address&#58; to be provided by Alliance Manager</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">If to Sangamo&#58;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc.</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58; Chief Executive Officer</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">501 Canal Blvd.</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Richmond, CA 94804</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">with required copies (which will not constitute notice) to&#58;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc.</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58; General Counsel</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">501 Canal Blvd.</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Richmond, CA 94804</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cooley LLP</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58; Marya Postner, Ph.D.&#59; Jennifer Raab</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3175 Hanover Street</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Palo Alto, CA 94304</font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither Party may assign or otherwise transfer this Agreement, in whole or in part (including any rights or obligations hereunder), without the prior written consent of the non-assigning Party, such approval not to be unreasonably withheld or delayed.  Notwithstanding the foregoing, either Party may assign this Agreement to (a) an Affiliate or (b) any purchaser of all or substantially all of the assets of such Party to which this Agreement relates, or of all of its capital stock, or to any successor corporation or entity resulting from any merger or consolidation of such Party with or into such corporation or entity, provided that in each case ((a) and (b)) the party to which this Agreement is assigned expressly agrees to assume and be bound by all obligations of the assigning Party under this Agreement.  A copy of such written agreement by such assignee will be provided to the non-assigning Party within &#91;*&#93; of execution of such assignment.  Subject to the foregoing, this Agreement will benefit and bind the Parties&#8217; </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">successors and assigns.  Any attempted assignment not in accordance with this Section 16.3 will be null and void.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Independent Contractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties are independent contractors and nothing contained in this Agreement will be deemed or construed to create a partnership, joint venture, employment, franchise, agency or fiduciary relationship between the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Actions of Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A Party may exercise its rights or perform its obligations under this Agreement personally or through one or more Affiliates, provided that such Party will nonetheless be primarily liable for the performance of its Affiliates and for any failure by its Affiliates to comply with the restrictions, limitations and obligations set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither Party will be deemed to have breached this Agreement for failure to perform its obligations under this Agreement (other than such Party&#8217;s obligations to make any payment to the other Party under this Agreement) to the extent such failure results from causes beyond the reasonable control of the affected Party. Such causes include acts of God, earthquakes, fires, floods, embargoes, wars, acts of terrorism, insurrections, riots, civil commotions, epidemics, pandemics, omissions or delays in action by any governmental authority, acts of a government or agency thereof and judicial orders or decrees. Any deadline or time period affected by such a force majeure event or a Party&#8217;s failure to perform resulting therefrom will be extended automatically by the number of days equal to the number of days that such force majeure or failure persisted.  If such a force majeure event occurs, the Party unable to perform will promptly notify the other Party of the occurrence of such event, and the Parties will meet (in person, telephonically or by teleconference) promptly thereafter to discuss the circumstances relating thereto.  The Party unable to perform will (a) provide reasonable status updates to the other Party from time-to-time&#59; (b) use Commercially Reasonable Efforts to mitigate any adverse consequences arising out of its failure to perform&#59; and (c) resume performance as promptly as possible.  Further, in the event the end of any time period set forth herein falls (or any deadline herein otherwise expires) during the period beginning on December 25 of any calendar year in the Term and ending on January 1 of the following year, such time period (or deadline) will be extended by &#91;*&#93;, unless otherwise agreed by the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except to the extent expressly provided herein, this Agreement, including the Exhibits hereto, constitutes the entire agreement between the Parties relating to the subject matter of this Agreement and supersedes all previous oral and written communications between the Parties with respect to the subject matter of this Agreement, including the Non-Disclosure Agreement as set forth in Section 10.5.  In the event of any conflict or inconsistency between the body of this Agreement and an Exhibit, the terms and conditions of the body of this Agreement will prevail.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Amendment&#59; Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise expressly provided herein, no alteration of or modification to this Agreement will be effective unless made in writing and executed by an authorized representative of each Party.  No course of dealing or failing of either Party to strictly enforce any term, right or condition of this Agreement in any instance will be construed as a </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">general waiver or relinquishment of such term, right or condition.  The observance of any provision of this Agreement may be waived (either generally or any given instance and either retroactively or prospectively) only with the consent of the Party granting such waiver.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties do not intend to violate any public policy or statutory or common law.  However, if any sentence, paragraph, clause or combination or part thereof of this Agreement is in violation of any law or is found to be otherwise unenforceable, such sentence, paragraph, clause or combination or part of the same will be deleted and the remainder of this Agreement will remain binding, provided that such deletion does not alter the basic purpose and structure of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">No Third Party Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties do not intend that any term of this Agreement should be enforceable by any person who is not a Party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties mutually acknowledge that they and their attorneys have participated in the negotiation and preparation of this Agreement.  Ambiguities, if any, in this Agreement will not be construed against any Party, irrespective of which Party may be deemed to have drafted this Agreement (or any provision herein) or authorized the ambiguous provision.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The captions and headings to this Agreement are for convenience only and are to be of no force or effect in construing or interpreting any of the provisions of this Agreement.  Unless context otherwise clearly requires, whenever used in this Agreement&#58; (a) the words &#8220;include&#8221; or &#8220;including&#8221; will be construed as incorporating &#8220;but not limited to&#8221; or &#8220;without limitation&#8221;&#59; (b) the words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby&#8221;, &#8220;hereunder&#8221; and derivative or similar words refer to this Agreement, including the Exhibits&#59; (c) all references herein to Articles, Sections or Exhibits will be construed to refer to Articles, Sections or Exhibits of this Agreement&#59; (d) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein)&#59; (e) the word &#8220;notice&#8221; means notice in writing (whether or not specifically stated) and will include notices, consents, approvals and other written communications contemplated under this Agreement&#59; (f) provisions that require that a Party, the Parties or any committee hereunder &#8220;agree&#8221;, &#8220;consent&#8221; or &#8220;approve&#8221; or the like will require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding instant messaging)&#59; (g) references to any specific law, rule or regulation, section or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof&#59; (h) all references to the word &#8220;shall&#8221; are interchangeable with the word &#8220;will&#8221; and will be understood to be imperative or mandatory in nature&#59; (i) the singular will include the plural and vice versa&#59; (j) the word &#8220;or&#8221; has the inclusive meaning represented by the phrase &#8220;and&#47;or&#8221;&#59; (k) all references to days, months, quarters or years are references to calendar days, calendar months, calendar quarters, or calendar years, unless otherwise explicitly stated and (l) all references to &#8220;intellectual property rights&#8221; herein mean Patents, proprietary rights in Know-How, trade secrets, proprietary rights associated with works of authorship, including </font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">copyrights, moral rights, and all applications, registrations and renewals relating thereto, and other forms of proprietary and intellectual property rights, however denominated throughout the world, other than Trademarks.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Counterparts&#59; Electronic Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be executed in one or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.  For purposes hereof, a facsimile copy, or email with attached .pdf copy, of this Agreement, including the signature pages hereto, will be deemed to be an original.  Execution of this Agreement by e-Signatures or by exchanging executed signature pages in .pdf format will have the same legal force and effect as the exchange of original signatures.  As used in this Section 16.13, &#8220;e-Signature&#8221; will mean a signature that consists of one or more letters, characters, numbers or other symbols in digital form incorporated in, attached to or associated with the electronic document, that (a) is unique to the person executing the signature&#59; (b) the technology or process used to make the signature is under the sole control of the person making the signature&#59; (c) the technology or process can be used to identify the person using the technology or process&#59; and (d) the electronic signature can be linked with an electronic document in such a way that it can be used to determine whether the electronic document has been changed since the electronic signature was incorporated in, attached to or associated with the electronic document.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;Signature page follows &#8211; the rest of this page intentionally left blank.&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">57</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;*&#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) the type that the Registrant treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">58</font></div></div></div><div id="i33b7a1bc6d5c48499ba12a5e5ef8e34e_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div id="i33b7a1bc6d5c48499ba12a5e5ef8e34e_10"></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Sangamo and Genentech have executed this Agreement by their respective officers hereunto duly authorized, effective as of the Effective Date.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.147%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SANGAMO THERAPEUTICS, INC.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;padding-right:-2.13pt"><font><br></font></div><div style="padding-right:-2.13pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">  &#47;s&#47; Sandy Macrae&#160;&#160;&#160;&#160;</font></div><div style="padding-right:-2.13pt"><font><br></font></div><div style="margin-bottom:8pt;padding-left:28.47pt;padding-right:-2.13pt;text-align:justify;text-indent:-30.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Dr. Sandy Macrae</font></div><div style="margin-bottom:8pt;padding-left:28.47pt;padding-right:-2.13pt;text-align:justify;text-indent:-30.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58;  CEO</font></div></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.935%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">GENENTECH, INC. </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;padding-right:-2.13pt"><font><br></font></div><div style="padding-right:-2.13pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Jeff Hutchings&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-right:-2.13pt"><font><br></font></div><div style="padding-right:-2.13pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; </font></div><div style="padding-right:-2.13pt"><font><br></font></div><div style="padding-right:-2.13pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; VP, Controller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font></div></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 1.13</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(one page omitted)</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 1.64</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(4 pages omitted) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i33b7a1bc6d5c48499ba12a5e5ef8e34e_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.222%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 1.71</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(one page omitted) </font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i33b7a1bc6d5c48499ba12a5e5ef8e34e_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 1.105</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(1 page omitted)</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 1.109</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(2 pages omitted) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 2.1</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(18 pages omitted)</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 3.1.1</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(7 pages omitted) </font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 3.2</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(2 pages omitted) </font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Confidential</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Execution Version</font></td></tr></table></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 11.1</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(3 pages omitted) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>thirdamendmenttoleaseagr.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>thirdamendmenttoleaseagr</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- thirdamendmenttoleaseagr001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="thirdamendmenttoleaseagr001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">THIRD AMENDMENT TO LEASE AGREEMENT  THIS THIRD AMENDMENT TO LEASE AGREEMENT (this &#8220;Third  Amendment&#8221;) is entered into as of July 3, 2024, (the &#8220;Third Amendment Effective Date&#8221;),  by and between PPF OFF 7000 MARINA BOULEVARD LP, a Delaware limited partnership  (&#8220;Landlord&#8221;), and SANGAMO THERAPEUTICS, INC., a Delaware corporation  (&#8220;Tenant&#8221;), with reference to the following facts:  A. Landlord (as successor to Marina Boulevard Property, LLC) and Tenant are  parties to that certain Lease Agreement dated November 3, 2017 (the &#8220;Original Lease&#8221;), as  amended by that certain First Amendment to Lease Agreement dated as of January 1, 2019 (the  &#8220;First Amendment&#8221;) and that certain Second Amendment to Lease Agreement dated as of  February 5, 2024 (the &#8220;Second Amendment&#8221;) (the Original Lease, as so amended, being  referred to herein as the &#8220;Lease&#8221;), pursuant to which Landlord leases to Tenant the entire  rentable square feet of the building located at 7000 Marina Boulevard, Brisbane, California (the  &#8220;Building&#8221;), which contains approximately 87,695 rentable square feet in the aggregate (the  &#8220;Premises&#8221;). The Building is part of a multi-building complex known as Marina Landing.  B. Landlord and Tenant desire to modify the timing for Tenant's replacement of the  letter of credit or delivery of the cash security deposit as originally contemplated in Section  1(b) of the Second Amendment.  NOW, THEREFORE, in consideration of the above recitals which by this reference  are incorporated herein, the mutual covenants and conditions contained herein and other  valuable consideration, the receipt and sufficiency of which are hereby acknowledged,  Landlord and Tenant agree as follows:  1. Time for delivery of Cash Security Deposit or Letter of Credit. The  reference to &#8220;June 1, 2024&#8221; set forth in Section l (b) of the Second Amendment is hereby  deleted and replaced with &#8220;September 30, 2024.&#8221;  2. Miscellaneous.  (a) This Third Amendment sets forth the entire agreement between the  parties with respect to the matters set forth herein. There have been no additional oral or written  representations or agreements. Except as herein modified or amended, the provisions,  conditions and terms of the Lease shall remain unchanged and in full force and effect.  (b) In the case of any inconsistency between the provisions of the Lease and  this Third Amendment, the provisions of this Third Amendment shall govern and control.  (c) Submission of this Third Amendment by Landlord is not an offer to enter  into this Third Amendment. Landlord and Tenant shall not be bound by this Third Amendment  until Landlord and Tenant have mutually executed and delivered the same to Tenant.  (d) Capitalized terms used in this Third Amendment shall have the same  definitions as set forth in the Lease to the extent that such capitalized terms are defined therein  and not redefined in this Third Amendment.      </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- thirdamendmenttoleaseagr002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="thirdamendmenttoleaseagr002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">(e) Tenant hereby represents to Landlord that Tenant has dealt with no broker  in connection with this Third Amendment. Tenant agrees to defend, indemnify and hold  Landlord harmless from all claims of any brokers claiming to have represented Tenant in  connection with this Third Amendment. Landlord hereby represents to Tenant that Landlord  has dealt with no broker in connection with this Third Amendment. Landlord agrees to  indemnify and hold Tenant harmless from all claims of any brokers claiming to have  represented Landlord in connection with this Third Amendment.  (f) Each signatory of this Third Amendment represents hereby that such  signatory has the authority to execute and deliver the same on behalf of the party hereto for  which such signatory is acting.  (g) Tenant represents and warrants to Landlord that Tenant is currently in  compliance with and shall at all times (including any extension thereof) remain in compliance  with the regulations of the Office of Foreign Asset Control (&#8220;OFAC&#8221;) of the Department of  the Treasury and any statute, executive order (including the September 24, 2001, Executive  Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten  to Commit, or Support Terrorism), or other governmental action relating thereto.  (h) This Third Amendment may be executed in multiple counterparts each of  which is deemed an original but together constitute one and the same instrument. This Third  Amendment may be executed in so-called &#8220;pdf' format and each party has the right to rely  upon a pdf counterpart of this Third Amendment signed by the other party to the same extent  as if such party had received an original counterpart. Electronic signatures on this Third  Amendment shall be valid and effective to bind the party so signing electronically.  [SIGNATURES ARE ON FOLLOWING PAGE]                                                </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- thirdamendmenttoleaseagr003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="thirdamendmenttoleaseagr003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">      IN WITNESS WHEREOF, Landlord and Tenant have duly executed this Third  Amendment to Lease Agreement as of the Third Amendment Effective Date.  LANDLORD:      PPF PFF 7000 MARINA BOULEVARD LP,   a Delaware limited liability company     By:  /s/ Todd O&#8217;Sanders                                    Name: Todd O&#8217;Sanders          Title: Executive Director          TENANT:    SANGAMO THERAPEUTICS, INC.,  a Delaware corporation      By:  /s/ Prathyusha Duraibabu                               Print Name: Prathyusha Duraibabu          Its: CFO          </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>sgmo-20240930xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i769d40e26a8349c79cc8a11f55bf9ffd_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Alexander D. Macrae, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this quarterly report on Form 10-Q of Sangamo Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:144pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;12, 2024</font></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ALEXANDER D. MACRAE</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alexander D. Macrae</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>sgmo-20240930xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ia635077fdfb149c8b3494b764ff042f4_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Prathyusha Duraibabu, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this quarterly report on Form 10-Q of Sangamo Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:144pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;12, 2024</font></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PRATHYUSHA DURAIBABU</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>sgmo-20240930xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i130db5b9be924687b6758dc43788a0cd_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certifications Pursuant to 18 U.S.C. &#167;1350, as Adopted</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), each of the undersigned hereby certifies in his or her capacity as an officer of Sangamo Therapeutics, Inc. (the &#8220;Company&#8221;), that, to the best of his or her knowledge&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;the Company&#8217;s Quarterly Report on Form 10-Q for the period ended September&#160;30, 2024, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:79.134%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ALEXANDER D. MACRAE</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alexander D. Macrae</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;12, 2024</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PRATHYUSHA DURAIBABU</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;12, 2024</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Sangamo Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form&#160;10-Q), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section&#160;906 of the Sarbanes-Oxley Act of 2002 has been provided to Sangamo Therapeutics, Inc. and will be retained by Sangamo Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>sgmo-20240930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:71d79187-a2e4-4f72-bd61-283a5977d997,g:6e5f68a8-3875-4e0a-8723-d2906a1af0a5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgmo="http://www.sangamo.com/20240930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sangamo.com/20240930">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sangamo.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>9952156 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>9952157 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIES" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES">
        <link:definition>9952158 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASICANDDILUTEDNETINCOMELOSSPERSHARE" roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARE">
        <link:definition>9952159 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES">
        <link:definition>9952160 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALE" roleURI="http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALE">
        <link:definition>9952161 - Disclosure - IMPAIRMENT AND WRITE-DOWN OF ASSETS HELD FOR SALE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>9952162 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>9952163 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITY">
        <link:definition>9952164 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGCHARGES" roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGES">
        <link:definition>9952165 - Disclosure - RESTRUCTURING CHARGES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTS">
        <link:definition>9952166 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9954471 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9954472 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>9954473 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESTables" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables">
        <link:definition>9954474 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASICANDDILUTEDNETINCOMELOSSPERSHARETables" roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARETables">
        <link:definition>9954475 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables">
        <link:definition>9954476 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>9954477 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGCHARGESTables" roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGESTables">
        <link:definition>9954478 - Disclosure - RESTRUCTURING CHARGES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>9954479 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails">
        <link:definition>9954480 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration And Licensing Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails">
        <link:definition>9954481 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSDetails" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails">
        <link:definition>9954482 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails">
        <link:definition>9954483 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails">
        <link:definition>9954484 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Available-for-Sale Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails">
        <link:definition>9954485 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails" roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails">
        <link:definition>9954486 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails">
        <link:definition>9954487 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE - Components of Basic and Diluted Net Income (Loss) per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails">
        <link:definition>9954488 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Genentech, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails">
        <link:definition>9954489 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails">
        <link:definition>9954490 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails" roleURI="http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails">
        <link:definition>9954491 - Disclosure - IMPAIRMENT AND WRITE-DOWN OF ASSETS HELD FOR SALE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>9954492 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONDetails" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONDetails">
        <link:definition>9954493 - Disclosure - STOCK-BASED COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDetails" roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails">
        <link:definition>9954494 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGCHARGESNarrativeDetails" roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails">
        <link:definition>9954495 - Disclosure - RESTRUCTURING CHARGES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails" roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails">
        <link:definition>9954496 - Disclosure - RESTRUCTURING CHARGES - Accrued Restructuring Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets" abstract="false" name="IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_WarrantOrRightPolicyPolicyTextBlock" abstract="false" name="WarrantOrRightPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" abstract="false" name="ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sgmo_GenentechRocheGroupMember" abstract="true" name="GenentechRocheGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_KitePharmaIncMember" abstract="true" name="KitePharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_ChangeInAgreementEstimateMarch2023Member" abstract="true" name="ChangeInAgreementEstimateMarch2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_ChangeInAgreementEstimateSeptember2023Member" abstract="true" name="ChangeInAgreementEstimateSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" abstract="false" name="IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" abstract="false" name="IncreaseDecreaseInNetIncomeLossAttributableToParent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_IncreaseDecreaseInEarningsPerShareBasic" abstract="false" name="IncreaseDecreaseInEarningsPerShareBasic" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sgmo_IncreaseDecreaseInEarningsPerShareDiluted" abstract="false" name="IncreaseDecreaseInEarningsPerShareDiluted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_BiogenMAIncMember" abstract="true" name="BiogenMAIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_NovartisInstitutesForBioMedicalResearchIncMember" abstract="true" name="NovartisInstitutesForBioMedicalResearchIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_OtherLicensingAgreementsMember" abstract="true" name="OtherLicensingAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" abstract="true" name="RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_PreFundedCommonStockWarrantMember" abstract="true" name="PreFundedCommonStockWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" abstract="true" name="EarningsPerShareBasicAndDilutedEPSAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_LicenseTechnologyTransferMember" abstract="true" name="LicenseTechnologyTransferMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_RoyaltyObligationTerm" abstract="false" name="RoyaltyObligationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations" abstract="false" name="RevenueFromContractsWithCustomerNumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_PfizerMember" abstract="true" name="PfizerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_PfizerSB525Member" abstract="true" name="PfizerSB525Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember" abstract="true" name="AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_SBFiveTwoFiveAndOtherProductsMember" abstract="true" name="SBFiveTwoFiveAndOtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_SBFiveTwoFiveMember" abstract="true" name="SBFiveTwoFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CNineORFSevenTwoMember" abstract="true" name="CNineORFSevenTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" abstract="true" name="AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_AchievementOfCommercialMilestonesMember" abstract="true" name="AchievementOfCommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_AgreementTerminationTerm" abstract="false" name="AgreementTerminationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" abstract="false" name="CustomerContractLiabilityMilestonePaymentEligibleToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" abstract="false" name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" abstract="false" name="CollaborativeArrangementNumberOfMilestonesAchieved" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_MilestonePaymentsReceived" abstract="false" name="MilestonePaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_MilestoneRevenueReceivable" abstract="false" name="MilestoneRevenueReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" abstract="false" name="ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementTransactionPrice" abstract="false" name="CollaborativeArrangementTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" abstract="false" name="CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" abstract="false" name="NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_OtherCollaborationAndLicenseAgreementsMember" abstract="true" name="OtherCollaborationAndLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_EquipmentFurnitureAndFixturesMember" abstract="true" name="EquipmentFurnitureAndFixturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_LeaseholdImprovementsAndConstructionInProgressMember" abstract="true" name="LeaseholdImprovementsAndConstructionInProgressMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember" abstract="true" name="FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_RichmondCaliforniaMember" abstract="true" name="RichmondCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_OperatingLeaseRightOfUseAssetModificationReduction" abstract="false" name="OperatingLeaseRightOfUseAssetModificationReduction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination" abstract="false" name="LesseeOperatingLeaseRequiredNoticeOfTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_LesseeRequiredLetterOfCreditOutstandingAmount" abstract="false" name="LesseeRequiredLetterOfCreditOutstandingAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_JefferiesLLCMember" abstract="true" name="JefferiesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_AtTheMarketOfferingProgramMember" abstract="true" name="AtTheMarketOfferingProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sgmo_CommonWarrantMember" abstract="true" name="CommonWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_StockOfferingProgramMaximumValue" abstract="false" name="StockOfferingProgramMaximumValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" abstract="false" name="SaleOfStockIncreaseToAggregateOfferingPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SaleOfStockOutstandingAmountAvailable" abstract="false" name="SaleOfStockOutstandingAmountAvailable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit" abstract="false" name="SaleOfStockNumberOfSharesIssuedInTransactionPerUnit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance" abstract="false" name="WarrantOrRightOutstandingExercisablePeriodAfterIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds" abstract="false" name="SaleOfStockPlacementFeePercentageOfGrossProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sgmo_SaleOfStockAgentPlacementFees" abstract="false" name="SaleOfStockAgentPlacementFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SaleOfStockOtherOfferingCosts" abstract="false" name="SaleOfStockOtherOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_April2023RestructuringPlanMember" abstract="true" name="April2023RestructuringPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_November2023RestructuringPlanMember" abstract="true" name="November2023RestructuringPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_FranceRestructuringPlanMember" abstract="true" name="FranceRestructuringPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_FullTimeEmployeesMember" abstract="true" name="FullTimeEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_ContractedEmployeesMember" abstract="true" name="ContractedEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>sgmo-20240930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:71d79187-a2e4-4f72-bd61-283a5977d997,g:6e5f68a8-3875-4e0a-8723-d2906a1af0a5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sgmo-20240930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_274fd26b-2d16-42a8-b5b0-576149d12633" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_affb31b3-1293-4192-9b86-cf8c49747cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_274fd26b-2d16-42a8-b5b0-576149d12633" xlink:to="loc_us-gaap_Liabilities_affb31b3-1293-4192-9b86-cf8c49747cd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_913ce8a9-49fd-4bc3-baf7-759cdb48dbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_274fd26b-2d16-42a8-b5b0-576149d12633" xlink:to="loc_us-gaap_CommitmentsAndContingencies_913ce8a9-49fd-4bc3-baf7-759cdb48dbbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9f1555d7-91b1-4471-bd38-73451960d744" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_274fd26b-2d16-42a8-b5b0-576149d12633" xlink:to="loc_us-gaap_StockholdersEquity_9f1555d7-91b1-4471-bd38-73451960d744" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6a1d9949-c8ca-4bd0-a62c-0a0bae987b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9bb1a974-0f70-480a-91f1-942ba42eb45e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6a1d9949-c8ca-4bd0-a62c-0a0bae987b4e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9bb1a974-0f70-480a-91f1-942ba42eb45e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets_dd4c619b-a791-4790-9453-2245552f4f10" xlink:href="sgmo-20240930.xsd#sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6a1d9949-c8ca-4bd0-a62c-0a0bae987b4e" xlink:to="loc_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets_dd4c619b-a791-4790-9453-2245552f4f10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba7c84f4-cfc4-4a17-b31f-3b983ff656c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6a1d9949-c8ca-4bd0-a62c-0a0bae987b4e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba7c84f4-cfc4-4a17-b31f-3b983ff656c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_85af13de-1977-4892-9728-70d69d9e3d38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6a1d9949-c8ca-4bd0-a62c-0a0bae987b4e" xlink:to="loc_us-gaap_AssetsCurrent_85af13de-1977-4892-9728-70d69d9e3d38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_b6a16663-218c-4118-a440-1caad52d20c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6a1d9949-c8ca-4bd0-a62c-0a0bae987b4e" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_b6a16663-218c-4118-a440-1caad52d20c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_21f56f9a-6501-4f70-89c5-50be0538f7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_33413123-b6b3-4d46-82fd-786ad6efbc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_21f56f9a-6501-4f70-89c5-50be0538f7f7" xlink:to="loc_us-gaap_AccountsPayableCurrent_33413123-b6b3-4d46-82fd-786ad6efbc4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_94180a64-eb6c-44bf-b121-29747afdc5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_21f56f9a-6501-4f70-89c5-50be0538f7f7" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_94180a64-eb6c-44bf-b121-29747afdc5c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_02a9d0fe-80c6-46fe-abf1-7ce9ba0f81bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_21f56f9a-6501-4f70-89c5-50be0538f7f7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_02a9d0fe-80c6-46fe-abf1-7ce9ba0f81bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8fbb7015-8a43-44fc-87cc-65140aedaca9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_21f56f9a-6501-4f70-89c5-50be0538f7f7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8fbb7015-8a43-44fc-87cc-65140aedaca9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8c274214-2a49-4c93-9cb0-d8de971d5969" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4d0e983c-5a2f-48e9-bf15-61d245f34ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8c274214-2a49-4c93-9cb0-d8de971d5969" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4d0e983c-5a2f-48e9-bf15-61d245f34ef2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_cbdec260-56c8-4e63-9301-2a163a319d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8c274214-2a49-4c93-9cb0-d8de971d5969" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_cbdec260-56c8-4e63-9301-2a163a319d2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_fbef4789-6ad3-478a-a4a9-6c64c4542cef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8c274214-2a49-4c93-9cb0-d8de971d5969" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_fbef4789-6ad3-478a-a4a9-6c64c4542cef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_18ec7851-6317-4035-bb16-44722b660a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8c274214-2a49-4c93-9cb0-d8de971d5969" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_18ec7851-6317-4035-bb16-44722b660a0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_df6313c7-63a7-4b32-a33a-75e1de6c5770" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a5338681-1002-4579-94f6-a7411d708029" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_df6313c7-63a7-4b32-a33a-75e1de6c5770" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a5338681-1002-4579-94f6-a7411d708029" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_44455777-7b13-4dfa-9a78-b02f5ace2491" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_df6313c7-63a7-4b32-a33a-75e1de6c5770" xlink:to="loc_us-gaap_LiabilitiesCurrent_44455777-7b13-4dfa-9a78-b02f5ace2491" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_567c6508-8965-4925-ba64-71285a4fd261" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_df6313c7-63a7-4b32-a33a-75e1de6c5770" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_567c6508-8965-4925-ba64-71285a4fd261" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c94cfebf-c0b5-418b-8958-62fabdee86bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_0d0795f4-de43-4b31-b68e-677a55b217fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c94cfebf-c0b5-418b-8958-62fabdee86bb" xlink:to="loc_us-gaap_PreferredStockValue_0d0795f4-de43-4b31-b68e-677a55b217fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_72f555b7-ac4f-4876-bc49-6065b18811b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c94cfebf-c0b5-418b-8958-62fabdee86bb" xlink:to="loc_us-gaap_CommonStockValue_72f555b7-ac4f-4876-bc49-6065b18811b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_818915a5-53fa-4a7b-8b01-3109b6fe61b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c94cfebf-c0b5-418b-8958-62fabdee86bb" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_818915a5-53fa-4a7b-8b01-3109b6fe61b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_65a8830e-d450-47b3-90c2-e74e58819e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c94cfebf-c0b5-418b-8958-62fabdee86bb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_65a8830e-d450-47b3-90c2-e74e58819e8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_246c2f80-7f14-4b6f-9b4d-e4c9ee1ce141" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c94cfebf-c0b5-418b-8958-62fabdee86bb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_246c2f80-7f14-4b6f-9b4d-e4c9ee1ce141" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sgmo-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_58ce4e49-d25a-4082-aa81-eac279b726ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ae2fddcc-f1e1-4255-bc7a-5ff0ccbde134" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_58ce4e49-d25a-4082-aa81-eac279b726ca" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ae2fddcc-f1e1-4255-bc7a-5ff0ccbde134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a02d96ed-e55d-46a9-854b-e77d503f9518" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_58ce4e49-d25a-4082-aa81-eac279b726ca" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a02d96ed-e55d-46a9-854b-e77d503f9518" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a6c10852-731d-4cb0-8431-bb70f53a60ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_80160a1b-90ec-45fa-bcb4-cb95aa2d50c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a6c10852-731d-4cb0-8431-bb70f53a60ec" xlink:to="loc_us-gaap_OperatingIncomeLoss_80160a1b-90ec-45fa-bcb4-cb95aa2d50c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_d8bd9266-a553-415e-b1eb-0b728399e839" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a6c10852-731d-4cb0-8431-bb70f53a60ec" xlink:to="loc_us-gaap_InterestAndOtherIncome_d8bd9266-a553-415e-b1eb-0b728399e839" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_70819ef6-43db-4336-a6ea-7c32990e8331" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f7f8ce45-5b9c-4eda-9d11-b213c86075c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_70819ef6-43db-4336-a6ea-7c32990e8331" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f7f8ce45-5b9c-4eda-9d11-b213c86075c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b0a67dff-11eb-4002-abc6-f787fdac229e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_70819ef6-43db-4336-a6ea-7c32990e8331" xlink:to="loc_us-gaap_OperatingExpenses_b0a67dff-11eb-4002-abc6-f787fdac229e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_ac3fd084-9aa6-484f-aaab-e21699ae166c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b83a9e4a-c965-42d5-9bc9-d33b75d64bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_ac3fd084-9aa6-484f-aaab-e21699ae166c" xlink:to="loc_us-gaap_NetIncomeLoss_b83a9e4a-c965-42d5-9bc9-d33b75d64bd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_0615c4ca-94de-42d0-b282-231395f39526" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_ac3fd084-9aa6-484f-aaab-e21699ae166c" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_0615c4ca-94de-42d0-b282-231395f39526" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_4f0c68a4-9fb6-463a-8dc3-4380c1a78275" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d2f345f9-b19c-49b8-ab61-f79293514bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4f0c68a4-9fb6-463a-8dc3-4380c1a78275" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d2f345f9-b19c-49b8-ab61-f79293514bfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0facfcf7-6e8e-4345-a24b-cbda2d7b5dda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4f0c68a4-9fb6-463a-8dc3-4380c1a78275" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0facfcf7-6e8e-4345-a24b-cbda2d7b5dda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_ad41fd63-f7c0-471e-87d6-86966d3b3546" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4f0c68a4-9fb6-463a-8dc3-4380c1a78275" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_ad41fd63-f7c0-471e-87d6-86966d3b3546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_905982fc-31ba-4815-9719-aad45ad32043" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4f0c68a4-9fb6-463a-8dc3-4380c1a78275" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_905982fc-31ba-4815-9719-aad45ad32043" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="sgmo-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_de4f26a3-12c1-4df8-9d4f-de41fc2fa0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2eace75e-b884-4efc-8050-fcc218e50d73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_de4f26a3-12c1-4df8-9d4f-de41fc2fa0b0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2eace75e-b884-4efc-8050-fcc218e50d73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_64668f52-2628-41f4-bc27-ed25563b2d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_de4f26a3-12c1-4df8-9d4f-de41fc2fa0b0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_64668f52-2628-41f4-bc27-ed25563b2d3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_8f9b1328-8666-442b-bb85-defe2a7756d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_de4f26a3-12c1-4df8-9d4f-de41fc2fa0b0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_8f9b1328-8666-442b-bb85-defe2a7756d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_77f96cf5-f373-4b2e-a2b2-1378e6069da7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_de4f26a3-12c1-4df8-9d4f-de41fc2fa0b0" xlink:to="loc_us-gaap_NetIncomeLoss_77f96cf5-f373-4b2e-a2b2-1378e6069da7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgmo-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c553969-6ded-43ca-a7ce-1a90fb200138" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46fea66e-03c5-4206-bbe7-47991307e3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c553969-6ded-43ca-a7ce-1a90fb200138" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46fea66e-03c5-4206-bbe7-47991307e3dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d927b7f-a2f5-4028-8d0a-1672fd9281e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c553969-6ded-43ca-a7ce-1a90fb200138" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d927b7f-a2f5-4028-8d0a-1672fd9281e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1006fe7f-0682-4457-85aa-9bc7a7a2a914" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c553969-6ded-43ca-a7ce-1a90fb200138" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1006fe7f-0682-4457-85aa-9bc7a7a2a914" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e41c410f-2b80-4fb9-9a45-c6cb511425b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c553969-6ded-43ca-a7ce-1a90fb200138" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e41c410f-2b80-4fb9-9a45-c6cb511425b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74b8e643-8716-4d39-8244-dab9f23d6427" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_9e42525b-26cd-418a-8923-ff607a14ffcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74b8e643-8716-4d39-8244-dab9f23d6427" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_9e42525b-26cd-418a-8923-ff607a14ffcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_f8c14689-3fcf-49f1-a336-d463962c3ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74b8e643-8716-4d39-8244-dab9f23d6427" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_f8c14689-3fcf-49f1-a336-d463962c3ea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_9e81c61d-1507-45d8-9a1f-ed3d9e1f4589" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74b8e643-8716-4d39-8244-dab9f23d6427" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_9e81c61d-1507-45d8-9a1f-ed3d9e1f4589" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_96b83576-0087-4424-b063-1c01d6df1e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74b8e643-8716-4d39-8244-dab9f23d6427" xlink:to="loc_us-gaap_NetIncomeLoss_96b83576-0087-4424-b063-1c01d6df1e3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_847cbafb-db1b-4045-add8-6a9e74e50549" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74b8e643-8716-4d39-8244-dab9f23d6427" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_847cbafb-db1b-4045-add8-6a9e74e50549" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_819d83bf-3235-4850-9099-17241ad838dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74b8e643-8716-4d39-8244-dab9f23d6427" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_819d83bf-3235-4850-9099-17241ad838dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_3d891354-7597-46f3-b11c-7f38b02e17f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74b8e643-8716-4d39-8244-dab9f23d6427" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_3d891354-7597-46f3-b11c-7f38b02e17f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c53c5080-91c8-4fbd-b7ef-7d7f31367792" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74b8e643-8716-4d39-8244-dab9f23d6427" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c53c5080-91c8-4fbd-b7ef-7d7f31367792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_25975a79-8b71-495f-96d2-dc2cdfe261bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74b8e643-8716-4d39-8244-dab9f23d6427" xlink:to="loc_us-gaap_ShareBasedCompensation_25975a79-8b71-495f-96d2-dc2cdfe261bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_a2daddb0-fee3-40c8-825b-1cb45b2c7d33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74b8e643-8716-4d39-8244-dab9f23d6427" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_a2daddb0-fee3-40c8-825b-1cb45b2c7d33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c86904be-874f-4d25-8b59-80a26da001bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74b8e643-8716-4d39-8244-dab9f23d6427" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c86904be-874f-4d25-8b59-80a26da001bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_03ee3804-884e-4874-8713-12fd854cb346" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74b8e643-8716-4d39-8244-dab9f23d6427" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_03ee3804-884e-4874-8713-12fd854cb346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c48da746-9db9-401c-a56e-19f93d4cbe4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74b8e643-8716-4d39-8244-dab9f23d6427" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c48da746-9db9-401c-a56e-19f93d4cbe4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ff445d0f-570d-4694-9bcd-850e5c413fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74b8e643-8716-4d39-8244-dab9f23d6427" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ff445d0f-570d-4694-9bcd-850e5c413fd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c61da288-42b4-4551-8fa0-13285e2ad59f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74b8e643-8716-4d39-8244-dab9f23d6427" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c61da288-42b4-4551-8fa0-13285e2ad59f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_41726370-e17d-4ea5-b43f-012b6d057ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74b8e643-8716-4d39-8244-dab9f23d6427" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_41726370-e17d-4ea5-b43f-012b6d057ff5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_50375f71-a134-46ed-85d2-59fc62e7c62d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74b8e643-8716-4d39-8244-dab9f23d6427" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_50375f71-a134-46ed-85d2-59fc62e7c62d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_de3f5e5b-9357-4033-b4b7-22b18c7be54e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d0eef8fa-3768-4aa6-8fa2-5be6e2f46cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_de3f5e5b-9357-4033-b4b7-22b18c7be54e" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d0eef8fa-3768-4aa6-8fa2-5be6e2f46cd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2185b098-092e-49af-b22e-ae9eb35e0d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_de3f5e5b-9357-4033-b4b7-22b18c7be54e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2185b098-092e-49af-b22e-ae9eb35e0d6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_b7f659b0-e8e9-4f0c-b5a6-c075b19ba681" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_de3f5e5b-9357-4033-b4b7-22b18c7be54e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_b7f659b0-e8e9-4f0c-b5a6-c075b19ba681" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_d7a80d4a-799a-4a68-98b3-cc69f80cb278" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_de3f5e5b-9357-4033-b4b7-22b18c7be54e" xlink:to="loc_us-gaap_ProceedsFromStockPlans_d7a80d4a-799a-4a68-98b3-cc69f80cb278" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de965e16-4551-4775-9629-3ebc57861158" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_09a7d329-f194-49b2-8a12-020d03d234c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de965e16-4551-4775-9629-3ebc57861158" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_09a7d329-f194-49b2-8a12-020d03d234c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_5c308902-b387-43fa-b8fb-1e243e1f6e71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de965e16-4551-4775-9629-3ebc57861158" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_5c308902-b387-43fa-b8fb-1e243e1f6e71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2befebeb-c0be-417f-9355-34d6d53cf048" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de965e16-4551-4775-9629-3ebc57861158" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2befebeb-c0be-417f-9355-34d6d53cf048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_d7f9a3b2-1dfa-4d80-8651-69fa34299e12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de965e16-4551-4775-9629-3ebc57861158" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_d7f9a3b2-1dfa-4d80-8651-69fa34299e12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_384a5b4d-ac59-4ca4-8731-100bd9a5fb32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de965e16-4551-4775-9629-3ebc57861158" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_384a5b4d-ac59-4ca4-8731-100bd9a5fb32" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f8bda67c-706c-42b5-afb2-f269cc268fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_869c82ef-3d0e-42ae-b017-493cd085012a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f8bda67c-706c-42b5-afb2-f269cc268fb4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_869c82ef-3d0e-42ae-b017-493cd085012a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_b3041169-71c2-46b8-a4da-b38eee8a3100" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f8bda67c-706c-42b5-afb2-f269cc268fb4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_b3041169-71c2-46b8-a4da-b38eee8a3100" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_90fc5f76-f41c-4456-895f-15826eaaa958" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3b76eadf-3331-4cb7-b50f-d6b03fa2be63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_90fc5f76-f41c-4456-895f-15826eaaa958" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3b76eadf-3331-4cb7-b50f-d6b03fa2be63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_43f49d37-b338-4c1f-9fd5-87c3de6a500b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_90fc5f76-f41c-4456-895f-15826eaaa958" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_43f49d37-b338-4c1f-9fd5-87c3de6a500b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent_04e12540-eca2-4cc6-b9a2-da737cd57c00" xlink:href="sgmo-20240930.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_e1a901d8-e6e7-4194-a5b7-f938304495fb" xlink:href="sgmo-20240930.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent_04e12540-eca2-4cc6-b9a2-da737cd57c00" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_e1a901d8-e6e7-4194-a5b7-f938304495fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_32c505b8-e5e6-4b22-a82f-03b87544f032" xlink:href="sgmo-20240930.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent_04e12540-eca2-4cc6-b9a2-da737cd57c00" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_32c505b8-e5e6-4b22-a82f-03b87544f032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent_d750eb3b-63dc-422e-bcaa-eb37c113877c" xlink:href="sgmo-20240930.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent_04e12540-eca2-4cc6-b9a2-da737cd57c00" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent_d750eb3b-63dc-422e-bcaa-eb37c113877c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent_36312e3d-a4d7-4341-9819-d18141a96b47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_186b74aa-c10c-48b6-b290-ea600b00fa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent_36312e3d-a4d7-4341-9819-d18141a96b47" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_186b74aa-c10c-48b6-b290-ea600b00fa4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_97159b11-b14a-4e4a-b06a-60be9a70ad31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent_36312e3d-a4d7-4341-9819-d18141a96b47" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_97159b11-b14a-4e4a-b06a-60be9a70ad31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_2ac60014-a831-454c-9e89-2fde0e61b23f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent_36312e3d-a4d7-4341-9819-d18141a96b47" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_2ac60014-a831-454c-9e89-2fde0e61b23f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0bb97e3f-4114-40d2-9e9c-c350e6bc3e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_4a9f60be-513e-4853-9106-c2bd01b5bf83" xlink:href="sgmo-20240930.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0bb97e3f-4114-40d2-9e9c-c350e6bc3e2c" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_4a9f60be-513e-4853-9106-c2bd01b5bf83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_6e7410cf-2b5e-4e76-8e62-a3e0ebab894e" xlink:href="sgmo-20240930.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0bb97e3f-4114-40d2-9e9c-c350e6bc3e2c" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_6e7410cf-2b5e-4e76-8e62-a3e0ebab894e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f850efa0-49b7-44d4-a093-0eaea31c52a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0bb97e3f-4114-40d2-9e9c-c350e6bc3e2c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f850efa0-49b7-44d4-a093-0eaea31c52a9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_e1880ae6-4f86-4304-b30c-cc5dec421b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_26a2bd89-ee22-4795-9d39-dd34b4c5ccf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_e1880ae6-4f86-4304-b30c-cc5dec421b5c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_26a2bd89-ee22-4795-9d39-dd34b4c5ccf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_211b9dcd-cdc4-4b3e-8c3f-fb4c80fd39d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_e1880ae6-4f86-4304-b30c-cc5dec421b5c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_211b9dcd-cdc4-4b3e-8c3f-fb4c80fd39d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_770c4df4-b3e3-475b-9a0c-25232d7f9566" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6626996a-6d49-47c4-95a7-e5516f02f2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_770c4df4-b3e3-475b-9a0c-25232d7f9566" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6626996a-6d49-47c4-95a7-e5516f02f2ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_b561a6c0-8263-4c71-ba68-575815e85052" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_770c4df4-b3e3-475b-9a0c-25232d7f9566" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_b561a6c0-8263-4c71-ba68-575815e85052" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>sgmo-20240930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:71d79187-a2e4-4f72-bd61-283a5977d997,g:6e5f68a8-3875-4e0a-8723-d2906a1af0a5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_03dfc61f-4bc6-438c-af82-89694a8b0d81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8258735e-8cf8-405f-9cfb-5dba0c10da25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_03dfc61f-4bc6-438c-af82-89694a8b0d81" xlink:to="loc_us-gaap_StatementTable_8258735e-8cf8-405f-9cfb-5dba0c10da25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c5776b97-c53b-4077-8d5f-2ef95ea11cab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8258735e-8cf8-405f-9cfb-5dba0c10da25" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c5776b97-c53b-4077-8d5f-2ef95ea11cab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c5776b97-c53b-4077-8d5f-2ef95ea11cab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c5776b97-c53b-4077-8d5f-2ef95ea11cab" xlink:to="loc_us-gaap_EquityComponentDomain_c5776b97-c53b-4077-8d5f-2ef95ea11cab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f8d6254e-b3da-4708-a4e8-0d10f59fa625" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c5776b97-c53b-4077-8d5f-2ef95ea11cab" xlink:to="loc_us-gaap_EquityComponentDomain_f8d6254e-b3da-4708-a4e8-0d10f59fa625" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_361ccef7-9ed2-4739-9f0c-51e852c7bc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f8d6254e-b3da-4708-a4e8-0d10f59fa625" xlink:to="loc_us-gaap_CommonStockMember_361ccef7-9ed2-4739-9f0c-51e852c7bc0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d7e4634e-07e6-45ea-ac6d-7284c5102b79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f8d6254e-b3da-4708-a4e8-0d10f59fa625" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d7e4634e-07e6-45ea-ac6d-7284c5102b79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5853596c-e12a-468b-a80f-5287258e3629" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f8d6254e-b3da-4708-a4e8-0d10f59fa625" xlink:to="loc_us-gaap_RetainedEarningsMember_5853596c-e12a-468b-a80f-5287258e3629" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e5197797-1547-43b7-a3ea-b29ff0c72e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f8d6254e-b3da-4708-a4e8-0d10f59fa625" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e5197797-1547-43b7-a3ea-b29ff0c72e9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_03dfc61f-4bc6-438c-af82-89694a8b0d81" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c6e7160a-b8c4-41f7-b857-d03590e6199c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c6e7160a-b8c4-41f7-b857-d03590e6199c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cc8c4677-93de-4c32-b9c5-077222f9a98f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_StockholdersEquity_cc8c4677-93de-4c32-b9c5-077222f9a98f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_06acb5e0-aa22-4dfe-a0e9-3037c9036ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_06acb5e0-aa22-4dfe-a0e9-3037c9036ed6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_779a676d-a25f-4794-bd16-cbd26e8bd974" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_779a676d-a25f-4794-bd16-cbd26e8bd974" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ce855ed8-4273-4c94-9ee2-ef2c3e365d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ce855ed8-4273-4c94-9ee2-ef2c3e365d7f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_15520e40-60c8-4af9-9a22-d733dcbd09f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_15520e40-60c8-4af9-9a22-d733dcbd09f9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_cb80cafa-0819-42c3-abcb-6317aa7b0ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_cb80cafa-0819-42c3-abcb-6317aa7b0ffd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f92b1327-a9b2-4f85-beb2-30749cc9988b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f92b1327-a9b2-4f85-beb2-30749cc9988b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_cc439a27-d9fb-429c-a460-143391916884" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_cc439a27-d9fb-429c-a460-143391916884" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_05079d46-d381-4b67-840e-601fc5e3aad6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_05079d46-d381-4b67-840e-601fc5e3aad6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_15091c2c-0d58-4712-b5e7-0122de36f0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_15091c2c-0d58-4712-b5e7-0122de36f0ba" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_02832013-7286-4a99-9fbb-0f04b8829392" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_02832013-7286-4a99-9fbb-0f04b8829392" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_f510cd94-9d9e-44ea-949d-c41518378b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_f510cd94-9d9e-44ea-949d-c41518378b0f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_80edc9cb-ae1e-4144-84df-ac32cc7e8855" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_80edc9cb-ae1e-4144-84df-ac32cc7e8855" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6079c25f-c31b-4aab-9854-ca20bbf91a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_NetIncomeLoss_6079c25f-c31b-4aab-9854-ca20bbf91a0d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e59a7bf4-7ebc-430e-b697-f46b83cac825" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1a5ac14d-d17d-423b-84c7-4181924d8cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9c8b4434-768f-497f-a5e5-05f586225f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:to="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9c8b4434-768f-497f-a5e5-05f586225f8f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_dc18ec39-4b74-44f0-9124-3e1a236be205" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9c8b4434-768f-497f-a5e5-05f586225f8f" xlink:to="loc_srt_CounterpartyNameAxis_dc18ec39-4b74-44f0-9124-3e1a236be205" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc18ec39-4b74-44f0-9124-3e1a236be205_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_dc18ec39-4b74-44f0-9124-3e1a236be205" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc18ec39-4b74-44f0-9124-3e1a236be205_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f40b86c0-a3e0-492f-82cb-a1f7e3955e58" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_dc18ec39-4b74-44f0-9124-3e1a236be205" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f40b86c0-a3e0-492f-82cb-a1f7e3955e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GenentechRocheGroupMember_365717cd-0bd9-440f-8fed-52732df6d76f" xlink:href="sgmo-20240930.xsd#sgmo_GenentechRocheGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f40b86c0-a3e0-492f-82cb-a1f7e3955e58" xlink:to="loc_sgmo_GenentechRocheGroupMember_365717cd-0bd9-440f-8fed-52732df6d76f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_7e78f44c-a169-4627-9ab5-9e2d28fa741b" xlink:href="sgmo-20240930.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f40b86c0-a3e0-492f-82cb-a1f7e3955e58" xlink:to="loc_sgmo_KitePharmaIncMember_7e78f44c-a169-4627-9ab5-9e2d28fa741b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_08ff100c-fff7-4936-a2bb-7c2d8b6f17c3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9c8b4434-768f-497f-a5e5-05f586225f8f" xlink:to="loc_srt_ProductOrServiceAxis_08ff100c-fff7-4936-a2bb-7c2d8b6f17c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_08ff100c-fff7-4936-a2bb-7c2d8b6f17c3_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_08ff100c-fff7-4936-a2bb-7c2d8b6f17c3" xlink:to="loc_srt_ProductsAndServicesDomain_08ff100c-fff7-4936-a2bb-7c2d8b6f17c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1f0fdff7-11e4-4311-ba0c-2f762dd76936" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_08ff100c-fff7-4936-a2bb-7c2d8b6f17c3" xlink:to="loc_srt_ProductsAndServicesDomain_1f0fdff7-11e4-4311-ba0c-2f762dd76936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_6e09a89a-6cf9-437d-b50d-e3d1e794eb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1f0fdff7-11e4-4311-ba0c-2f762dd76936" xlink:to="loc_us-gaap_LicenseMember_6e09a89a-6cf9-437d-b50d-e3d1e794eb1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_8a192a7e-2a1e-49df-81cf-0f3105d4da1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9c8b4434-768f-497f-a5e5-05f586225f8f" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_8a192a7e-2a1e-49df-81cf-0f3105d4da1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_8a192a7e-2a1e-49df-81cf-0f3105d4da1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_8a192a7e-2a1e-49df-81cf-0f3105d4da1e" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_8a192a7e-2a1e-49df-81cf-0f3105d4da1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_6550417d-eea2-429e-87c4-f73c72e0c9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_8a192a7e-2a1e-49df-81cf-0f3105d4da1e" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_6550417d-eea2-429e-87c4-f73c72e0c9a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInAgreementEstimateMarch2023Member_5aff5ade-1e73-4dc0-96a2-10db0b85410a" xlink:href="sgmo-20240930.xsd#sgmo_ChangeInAgreementEstimateMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_6550417d-eea2-429e-87c4-f73c72e0c9a5" xlink:to="loc_sgmo_ChangeInAgreementEstimateMarch2023Member_5aff5ade-1e73-4dc0-96a2-10db0b85410a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInAgreementEstimateSeptember2023Member_4c670fff-6579-4247-b1f7-e704b8572a15" xlink:href="sgmo-20240930.xsd#sgmo_ChangeInAgreementEstimateSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_6550417d-eea2-429e-87c4-f73c72e0c9a5" xlink:to="loc_sgmo_ChangeInAgreementEstimateSeptember2023Member_4c670fff-6579-4247-b1f7-e704b8572a15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_dc79e816-3ff7-4808-a8b4-e8e0633d5f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9c8b4434-768f-497f-a5e5-05f586225f8f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_dc79e816-3ff7-4808-a8b4-e8e0633d5f2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_dc79e816-3ff7-4808-a8b4-e8e0633d5f2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_dc79e816-3ff7-4808-a8b4-e8e0633d5f2b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_dc79e816-3ff7-4808-a8b4-e8e0633d5f2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ea00faaf-c7c6-4c23-8189-7bc6c372e2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_dc79e816-3ff7-4808-a8b4-e8e0633d5f2b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ea00faaf-c7c6-4c23-8189-7bc6c372e2e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0b21b8ec-b236-4688-b7f8-abe137faf4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ea00faaf-c7c6-4c23-8189-7bc6c372e2e6" xlink:to="loc_us-gaap_SubsequentEventMember_0b21b8ec-b236-4688-b7f8-abe137faf4b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_cc8066f2-1f45-4b4e-898c-c12840b6b1c4" xlink:href="sgmo-20240930.xsd#sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:to="loc_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_cc8066f2-1f45-4b4e-898c-c12840b6b1c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_e64a6046-234b-4e5d-a3f4-0ffafeb62945" xlink:href="sgmo-20240930.xsd#sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:to="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_e64a6046-234b-4e5d-a3f4-0ffafeb62945" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic_67377fd1-1af5-4203-89f4-20b022ebde2d" xlink:href="sgmo-20240930.xsd#sgmo_IncreaseDecreaseInEarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:to="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic_67377fd1-1af5-4203-89f4-20b022ebde2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_e04cd75d-7fbd-4aad-b029-1bd5c3c7f933" xlink:href="sgmo-20240930.xsd#sgmo_IncreaseDecreaseInEarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:to="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_e04cd75d-7fbd-4aad-b029-1bd5c3c7f933" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_28503a3c-7a58-49b3-9e68-369e4859be0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_28503a3c-7a58-49b3-9e68-369e4859be0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1211f26d-8485-443d-ac51-c0aaa25258e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1211f26d-8485-443d-ac51-c0aaa25258e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d6aba844-10a7-41c0-9832-49ae8ef1bd80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d6aba844-10a7-41c0-9832-49ae8ef1bd80" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount_a1d7faa4-f8dc-46ee-9f2f-21062a5592be" xlink:href="sgmo-20240930.xsd#sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:to="loc_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount_a1d7faa4-f8dc-46ee-9f2f-21062a5592be" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a903913a-cd3a-4f25-b968-f0f595a83efc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a903913a-cd3a-4f25-b968-f0f595a83efc" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_1d5bc125-231e-478f-96f4-56c48584d23f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_83082d4e-19bd-47bd-a5a4-8593d9a6dbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1d5bc125-231e-478f-96f4-56c48584d23f" xlink:to="loc_us-gaap_ConcentrationRiskTable_83082d4e-19bd-47bd-a5a4-8593d9a6dbc8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4be9d0c4-f672-4042-b54c-40cfe0c34916" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_83082d4e-19bd-47bd-a5a4-8593d9a6dbc8" xlink:to="loc_srt_CounterpartyNameAxis_4be9d0c4-f672-4042-b54c-40cfe0c34916" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4be9d0c4-f672-4042-b54c-40cfe0c34916_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4be9d0c4-f672-4042-b54c-40cfe0c34916" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4be9d0c4-f672-4042-b54c-40cfe0c34916_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6c64c28-d78f-4c3f-97cc-576e2878eb34" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4be9d0c4-f672-4042-b54c-40cfe0c34916" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6c64c28-d78f-4c3f-97cc-576e2878eb34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GenentechRocheGroupMember_3e40e89b-0f84-4fce-9606-6bca8ccc1161" xlink:href="sgmo-20240930.xsd#sgmo_GenentechRocheGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6c64c28-d78f-4c3f-97cc-576e2878eb34" xlink:to="loc_sgmo_GenentechRocheGroupMember_3e40e89b-0f84-4fce-9606-6bca8ccc1161" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_a931d594-9f14-49d6-9552-f1db04471603" xlink:href="sgmo-20240930.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6c64c28-d78f-4c3f-97cc-576e2878eb34" xlink:to="loc_sgmo_KitePharmaIncMember_a931d594-9f14-49d6-9552-f1db04471603" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_78aea48c-ebec-4228-a714-fea8d39f38f1" xlink:href="sgmo-20240930.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6c64c28-d78f-4c3f-97cc-576e2878eb34" xlink:to="loc_sgmo_BiogenMAIncMember_78aea48c-ebec-4228-a714-fea8d39f38f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_a10639bb-dfe6-4f93-8a8d-368af34f39ba" xlink:href="sgmo-20240930.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6c64c28-d78f-4c3f-97cc-576e2878eb34" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_a10639bb-dfe6-4f93-8a8d-368af34f39ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherLicensingAgreementsMember_87241513-15a1-49aa-97a5-aa476bb4648b" xlink:href="sgmo-20240930.xsd#sgmo_OtherLicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6c64c28-d78f-4c3f-97cc-576e2878eb34" xlink:to="loc_sgmo_OtherLicensingAgreementsMember_87241513-15a1-49aa-97a5-aa476bb4648b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_712d701c-2c20-4c07-9d49-5108737ba882" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_83082d4e-19bd-47bd-a5a4-8593d9a6dbc8" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_712d701c-2c20-4c07-9d49-5108737ba882" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_712d701c-2c20-4c07-9d49-5108737ba882_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_712d701c-2c20-4c07-9d49-5108737ba882" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_712d701c-2c20-4c07-9d49-5108737ba882_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_940cdb8f-5980-4b47-b634-93fe04c9c5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_712d701c-2c20-4c07-9d49-5108737ba882" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_940cdb8f-5980-4b47-b634-93fe04c9c5a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_2eb4f2aa-117e-470c-8019-838e5dc1cfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_940cdb8f-5980-4b47-b634-93fe04c9c5a0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_2eb4f2aa-117e-470c-8019-838e5dc1cfe9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_637f5b86-da21-4500-aaf8-442a30c64f56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_83082d4e-19bd-47bd-a5a4-8593d9a6dbc8" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_637f5b86-da21-4500-aaf8-442a30c64f56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_637f5b86-da21-4500-aaf8-442a30c64f56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_637f5b86-da21-4500-aaf8-442a30c64f56" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_637f5b86-da21-4500-aaf8-442a30c64f56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9390d4e6-656a-4d34-9b3a-267a4bd08e53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_637f5b86-da21-4500-aaf8-442a30c64f56" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9390d4e6-656a-4d34-9b3a-267a4bd08e53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_2b4f40e7-72c4-4c48-8ac7-dacd441080dd" xlink:href="sgmo-20240930.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_9390d4e6-656a-4d34-9b3a-267a4bd08e53" xlink:to="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_2b4f40e7-72c4-4c48-8ac7-dacd441080dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f7929ac4-1fff-4f6d-8946-cefb3d20320c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1d5bc125-231e-478f-96f4-56c48584d23f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f7929ac4-1fff-4f6d-8946-cefb3d20320c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_362a6f3c-1508-4a07-9b55-43a458e49613" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e400344f-371b-4e7f-8203-9c4280abf6da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_362a6f3c-1508-4a07-9b55-43a458e49613" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e400344f-371b-4e7f-8203-9c4280abf6da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1773a115-af50-419f-81cd-d4c8d3c60185" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e400344f-371b-4e7f-8203-9c4280abf6da" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1773a115-af50-419f-81cd-d4c8d3c60185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1773a115-af50-419f-81cd-d4c8d3c60185_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1773a115-af50-419f-81cd-d4c8d3c60185" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1773a115-af50-419f-81cd-d4c8d3c60185_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c24fe382-b3a2-402d-9a82-a8ba3cb2cda3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1773a115-af50-419f-81cd-d4c8d3c60185" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c24fe382-b3a2-402d-9a82-a8ba3cb2cda3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_293446b0-862b-411c-98a7-e99b481a5536" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c24fe382-b3a2-402d-9a82-a8ba3cb2cda3" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_293446b0-862b-411c-98a7-e99b481a5536" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_824fe5e0-99e7-4c95-a1aa-95c45828aa9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e400344f-371b-4e7f-8203-9c4280abf6da" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_824fe5e0-99e7-4c95-a1aa-95c45828aa9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_824fe5e0-99e7-4c95-a1aa-95c45828aa9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_824fe5e0-99e7-4c95-a1aa-95c45828aa9d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_824fe5e0-99e7-4c95-a1aa-95c45828aa9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e9dd726f-9fda-4e03-9d93-47f80010a033" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_824fe5e0-99e7-4c95-a1aa-95c45828aa9d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e9dd726f-9fda-4e03-9d93-47f80010a033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9f65f0af-4a65-4b9d-90db-b7808a08c5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e9dd726f-9fda-4e03-9d93-47f80010a033" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9f65f0af-4a65-4b9d-90db-b7808a08c5aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_895ff637-3bd6-4004-8056-6c5b1c56dc75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e9dd726f-9fda-4e03-9d93-47f80010a033" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_895ff637-3bd6-4004-8056-6c5b1c56dc75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_07bf9f21-9953-4c08-8d43-ff65962eee9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e9dd726f-9fda-4e03-9d93-47f80010a033" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_07bf9f21-9953-4c08-8d43-ff65962eee9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_08ab171f-3bff-4444-addb-7c214e339f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e400344f-371b-4e7f-8203-9c4280abf6da" xlink:to="loc_us-gaap_FinancialInstrumentAxis_08ab171f-3bff-4444-addb-7c214e339f6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08ab171f-3bff-4444-addb-7c214e339f6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_08ab171f-3bff-4444-addb-7c214e339f6b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08ab171f-3bff-4444-addb-7c214e339f6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b34ce5b-2895-44b7-82e9-721a2e5723fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_08ab171f-3bff-4444-addb-7c214e339f6b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b34ce5b-2895-44b7-82e9-721a2e5723fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_b9bf19a7-08a9-4746-a882-03327977a4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b34ce5b-2895-44b7-82e9-721a2e5723fa" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_b9bf19a7-08a9-4746-a882-03327977a4d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_ba471811-c8e7-429e-9d00-0b712111821c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b34ce5b-2895-44b7-82e9-721a2e5723fa" xlink:to="loc_us-gaap_CommercialPaperMember_ba471811-c8e7-429e-9d00-0b712111821c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6153804b-a57b-4ea3-960f-91cb7552ce5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b34ce5b-2895-44b7-82e9-721a2e5723fa" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6153804b-a57b-4ea3-960f-91cb7552ce5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_a2299f70-3719-4690-a953-0c2530402ace" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b34ce5b-2895-44b7-82e9-721a2e5723fa" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_a2299f70-3719-4690-a953-0c2530402ace" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_ac1fd851-0686-4b44-8bff-fd3ba81bae07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b34ce5b-2895-44b7-82e9-721a2e5723fa" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_ac1fd851-0686-4b44-8bff-fd3ba81bae07" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_e57c7287-4545-49d1-9064-7edc624d8573" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b34ce5b-2895-44b7-82e9-721a2e5723fa" xlink:to="loc_us-gaap_CertificatesOfDepositMember_e57c7287-4545-49d1-9064-7edc624d8573" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_68664117-2aae-4f40-9d3f-d279f38cff64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e400344f-371b-4e7f-8203-9c4280abf6da" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_68664117-2aae-4f40-9d3f-d279f38cff64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_68664117-2aae-4f40-9d3f-d279f38cff64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_68664117-2aae-4f40-9d3f-d279f38cff64" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_68664117-2aae-4f40-9d3f-d279f38cff64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e605d106-7e55-40f6-949c-a20fb819a573" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_68664117-2aae-4f40-9d3f-d279f38cff64" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e605d106-7e55-40f6-949c-a20fb819a573" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_a09c099f-a53b-4be2-9658-3486e205bd58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e605d106-7e55-40f6-949c-a20fb819a573" xlink:to="loc_us-gaap_MoneyMarketFundsMember_a09c099f-a53b-4be2-9658-3486e205bd58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_18d040f3-209f-4be8-bd7a-64df8325300c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_362a6f3c-1508-4a07-9b55-43a458e49613" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_18d040f3-209f-4be8-bd7a-64df8325300c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_03feca04-5238-4616-8ade-ee15bb75e8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_362a6f3c-1508-4a07-9b55-43a458e49613" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_03feca04-5238-4616-8ade-ee15bb75e8d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e2a5005c-15b9-4df7-aaec-0d5f71ecf545" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_362a6f3c-1508-4a07-9b55-43a458e49613" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e2a5005c-15b9-4df7-aaec-0d5f71ecf545" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_790ff579-5944-4783-90c1-09d8f9e0c459" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_93313454-cc88-467a-86fa-e2ec497034bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_790ff579-5944-4783-90c1-09d8f9e0c459" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_93313454-cc88-467a-86fa-e2ec497034bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_bbb5f353-21fb-4bb5-9960-84ad6bbf64fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_93313454-cc88-467a-86fa-e2ec497034bb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_bbb5f353-21fb-4bb5-9960-84ad6bbf64fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bbb5f353-21fb-4bb5-9960-84ad6bbf64fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_bbb5f353-21fb-4bb5-9960-84ad6bbf64fd" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bbb5f353-21fb-4bb5-9960-84ad6bbf64fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c8df31b9-68fe-43cf-b1a7-c901c0338a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_bbb5f353-21fb-4bb5-9960-84ad6bbf64fd" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c8df31b9-68fe-43cf-b1a7-c901c0338a9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_87a61c31-8bc2-4fbb-bf46-6ba667dcad6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c8df31b9-68fe-43cf-b1a7-c901c0338a9b" xlink:to="loc_us-gaap_CashEquivalentsMember_87a61c31-8bc2-4fbb-bf46-6ba667dcad6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_bf31c864-fdf1-4044-a2e9-ed47cf86e65a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsMember_87a61c31-8bc2-4fbb-bf46-6ba667dcad6d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_bf31c864-fdf1-4044-a2e9-ed47cf86e65a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8174581d-9cb1-4cb2-83a8-34986230363a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_93313454-cc88-467a-86fa-e2ec497034bb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8174581d-9cb1-4cb2-83a8-34986230363a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8174581d-9cb1-4cb2-83a8-34986230363a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8174581d-9cb1-4cb2-83a8-34986230363a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8174581d-9cb1-4cb2-83a8-34986230363a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97ff892d-2243-4fa2-8bc3-1d7c1d1930ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8174581d-9cb1-4cb2-83a8-34986230363a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97ff892d-2243-4fa2-8bc3-1d7c1d1930ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_53d44467-39c0-4aae-8105-eb3a780e46ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97ff892d-2243-4fa2-8bc3-1d7c1d1930ba" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_53d44467-39c0-4aae-8105-eb3a780e46ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_0f6090d7-d71a-4116-b1a4-4f03927d8fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97ff892d-2243-4fa2-8bc3-1d7c1d1930ba" xlink:to="loc_us-gaap_CommercialPaperMember_0f6090d7-d71a-4116-b1a4-4f03927d8fcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_f66898bf-ca08-440e-ad85-286a4db622d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97ff892d-2243-4fa2-8bc3-1d7c1d1930ba" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_f66898bf-ca08-440e-ad85-286a4db622d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_12e773f5-7b38-415f-aa2b-f561282ce724" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97ff892d-2243-4fa2-8bc3-1d7c1d1930ba" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_12e773f5-7b38-415f-aa2b-f561282ce724" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_169bd8a3-65ab-4bd5-981f-06b24d2aedce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97ff892d-2243-4fa2-8bc3-1d7c1d1930ba" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_169bd8a3-65ab-4bd5-981f-06b24d2aedce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_93892dfd-c915-470f-9121-096924f87f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97ff892d-2243-4fa2-8bc3-1d7c1d1930ba" xlink:to="loc_us-gaap_CertificatesOfDepositMember_93892dfd-c915-470f-9121-096924f87f7f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_47c922b7-d51e-4e35-96de-893c4bd2ecf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_790ff579-5944-4783-90c1-09d8f9e0c459" xlink:to="loc_us-gaap_AssetsAbstract_47c922b7-d51e-4e35-96de-893c4bd2ecf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_dbccdddc-4b1a-4659-b33c-19617d1c1ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_47c922b7-d51e-4e35-96de-893c4bd2ecf3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_dbccdddc-4b1a-4659-b33c-19617d1c1ea9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_28ba5e47-c7aa-4c0d-9242-09f38efe2140" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_dbccdddc-4b1a-4659-b33c-19617d1c1ea9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_28ba5e47-c7aa-4c0d-9242-09f38efe2140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_a1eb66f4-f622-465c-89e5-7e6a22ace9bb" xlink:href="sgmo-20240930.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_dbccdddc-4b1a-4659-b33c-19617d1c1ea9" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_a1eb66f4-f622-465c-89e5-7e6a22ace9bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_2a904e8a-a558-4124-be5f-9ea4ab9d6d76" xlink:href="sgmo-20240930.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_dbccdddc-4b1a-4659-b33c-19617d1c1ea9" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_2a904e8a-a558-4124-be5f-9ea4ab9d6d76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c5d7da16-9e36-45b3-9648-9eb1fe5c93b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_dbccdddc-4b1a-4659-b33c-19617d1c1ea9" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c5d7da16-9e36-45b3-9648-9eb1fe5c93b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract_e2e5f5c4-8597-4cdb-91c4-e83f6c411996" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_47c922b7-d51e-4e35-96de-893c4bd2ecf3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract_e2e5f5c4-8597-4cdb-91c4-e83f6c411996" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent_9b393f84-6b87-49b9-9535-07f4bbf53877" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract_e2e5f5c4-8597-4cdb-91c4-e83f6c411996" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent_9b393f84-6b87-49b9-9535-07f4bbf53877" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_05e52843-5d5f-4b33-9b6b-8bcbb80ebd20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract_e2e5f5c4-8597-4cdb-91c4-e83f6c411996" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_05e52843-5d5f-4b33-9b6b-8bcbb80ebd20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0b5a7ca1-7c6e-43d4-a885-618cdd135844" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract_e2e5f5c4-8597-4cdb-91c4-e83f6c411996" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0b5a7ca1-7c6e-43d4-a885-618cdd135844" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_5a15c0c3-d155-4463-a4c1-6fd0929018b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract_e2e5f5c4-8597-4cdb-91c4-e83f6c411996" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_5a15c0c3-d155-4463-a4c1-6fd0929018b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent_172bbe15-872c-4b0a-afc8-02c41ac08b8b" xlink:href="sgmo-20240930.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_790ff579-5944-4783-90c1-09d8f9e0c459" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent_172bbe15-872c-4b0a-afc8-02c41ac08b8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_ebad8cf8-9f6c-4420-842b-c0df650532e8" xlink:href="sgmo-20240930.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_790ff579-5944-4783-90c1-09d8f9e0c459" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_ebad8cf8-9f6c-4420-842b-c0df650532e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_6ddb666e-130d-4b7c-a4ce-86a03476b38d" xlink:href="sgmo-20240930.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_790ff579-5944-4783-90c1-09d8f9e0c459" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_6ddb666e-130d-4b7c-a4ce-86a03476b38d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent_8fe9581b-c647-4565-873f-b553e24eaec6" xlink:href="sgmo-20240930.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_790ff579-5944-4783-90c1-09d8f9e0c459" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent_8fe9581b-c647-4565-873f-b553e24eaec6" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_84e98c3f-9538-4a5e-9587-381497a14ead" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_8101a3ff-6a44-40cd-8dee-05cb885ac012" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84e98c3f-9538-4a5e-9587-381497a14ead" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_8101a3ff-6a44-40cd-8dee-05cb885ac012" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_364ae941-fa9e-4521-a506-1359b3994839" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_8101a3ff-6a44-40cd-8dee-05cb885ac012" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_364ae941-fa9e-4521-a506-1359b3994839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_364ae941-fa9e-4521-a506-1359b3994839_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_364ae941-fa9e-4521-a506-1359b3994839" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_364ae941-fa9e-4521-a506-1359b3994839_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ae7c7de7-a410-4d3d-a5af-4f7142c6a1af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_364ae941-fa9e-4521-a506-1359b3994839" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ae7c7de7-a410-4d3d-a5af-4f7142c6a1af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreFundedCommonStockWarrantMember_ab2cb265-85e8-4c3c-83f0-7e243c5fde09" xlink:href="sgmo-20240930.xsd#sgmo_PreFundedCommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ae7c7de7-a410-4d3d-a5af-4f7142c6a1af" xlink:to="loc_sgmo_PreFundedCommonStockWarrantMember_ab2cb265-85e8-4c3c-83f0-7e243c5fde09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ffeac777-02d4-4667-8b07-b06b6db692ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84e98c3f-9538-4a5e-9587-381497a14ead" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ffeac777-02d4-4667-8b07-b06b6db692ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_66cf6e02-ed1b-4fac-bbde-e4ba6a94c92e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84e98c3f-9538-4a5e-9587-381497a14ead" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_66cf6e02-ed1b-4fac-bbde-e4ba6a94c92e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_100caf72-1491-488d-a90a-4d9f9c7f26e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84e98c3f-9538-4a5e-9587-381497a14ead" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_100caf72-1491-488d-a90a-4d9f9c7f26e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_732cf811-494a-4a98-9657-f4ffd39e05b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84e98c3f-9538-4a5e-9587-381497a14ead" xlink:to="loc_us-gaap_SharePrice_732cf811-494a-4a98-9657-f4ffd39e05b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_593bc287-5d59-403c-bcad-4787a0501acd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84e98c3f-9538-4a5e-9587-381497a14ead" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_593bc287-5d59-403c-bcad-4787a0501acd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_37f7106d-a415-427e-bbe3-6bf79f086073" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84e98c3f-9538-4a5e-9587-381497a14ead" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_37f7106d-a415-427e-bbe3-6bf79f086073" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_1e103764-a413-4e51-8738-95199e749997" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_be95354c-4c29-4ce7-97d4-2e9abeedb284" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_1e103764-a413-4e51-8738-95199e749997" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_be95354c-4c29-4ce7-97d4-2e9abeedb284" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b76d9b3d-13a3-4a77-ac27-33e38b38454e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_be95354c-4c29-4ce7-97d4-2e9abeedb284" xlink:to="loc_us-gaap_AwardTypeAxis_b76d9b3d-13a3-4a77-ac27-33e38b38454e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b76d9b3d-13a3-4a77-ac27-33e38b38454e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b76d9b3d-13a3-4a77-ac27-33e38b38454e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b76d9b3d-13a3-4a77-ac27-33e38b38454e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf3c707e-ebfc-4a76-827b-540646fc3eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b76d9b3d-13a3-4a77-ac27-33e38b38454e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf3c707e-ebfc-4a76-827b-540646fc3eb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_160c50fa-fd57-47a1-8be8-3f65df4d7928" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf3c707e-ebfc-4a76-827b-540646fc3eb7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_160c50fa-fd57-47a1-8be8-3f65df4d7928" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a3cab468-d617-4713-8e0a-4b8b103a6eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf3c707e-ebfc-4a76-827b-540646fc3eb7" xlink:to="loc_us-gaap_EmployeeStockMember_a3cab468-d617-4713-8e0a-4b8b103a6eeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_96c08787-e911-4954-baac-6575ad59004c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_1e103764-a413-4e51-8738-95199e749997" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_96c08787-e911-4954-baac-6575ad59004c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1a4962e2-c58b-4b89-acea-d5a67fd39619" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_96c08787-e911-4954-baac-6575ad59004c" xlink:to="loc_us-gaap_NetIncomeLoss_1a4962e2-c58b-4b89-acea-d5a67fd39619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_3375ff97-9ec1-4adf-8132-70509eb36584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_96c08787-e911-4954-baac-6575ad59004c" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_3375ff97-9ec1-4adf-8132-70509eb36584" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6111ce88-3c92-4a33-bfcc-1401bb2b2176" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_96c08787-e911-4954-baac-6575ad59004c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6111ce88-3c92-4a33-bfcc-1401bb2b2176" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5bcf8b8c-8dee-48f9-9efe-f9c9c82f6c57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_1e103764-a413-4e51-8738-95199e749997" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5bcf8b8c-8dee-48f9-9efe-f9c9c82f6c57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_84bcdd70-ba7d-44fb-b659-dc25cfd54e21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5bcf8b8c-8dee-48f9-9efe-f9c9c82f6c57" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_84bcdd70-ba7d-44fb-b659-dc25cfd54e21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f49c8f96-6296-450d-acf2-23caba2f408d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_84bcdd70-ba7d-44fb-b659-dc25cfd54e21" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f49c8f96-6296-450d-acf2-23caba2f408d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7f99f962-ab49-4130-88ad-a2d428b07a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5bcf8b8c-8dee-48f9-9efe-f9c9c82f6c57" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7f99f962-ab49-4130-88ad-a2d428b07a8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8378aab4-4bfc-46bf-b853-0e9a49fccd35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9e1c74bd-6625-421c-9470-f1e8d9f31200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7f99f962-ab49-4130-88ad-a2d428b07a8a" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9e1c74bd-6625-421c-9470-f1e8d9f31200" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_327edfb8-ee8a-472d-b9fd-a21bc5dcc11d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7f99f962-ab49-4130-88ad-a2d428b07a8a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_327edfb8-ee8a-472d-b9fd-a21bc5dcc11d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_26c16f89-95b6-4d7c-8728-d0ff03fa50c3" xlink:href="sgmo-20240930.xsd#sgmo_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5bcf8b8c-8dee-48f9-9efe-f9c9c82f6c57" xlink:to="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_26c16f89-95b6-4d7c-8728-d0ff03fa50c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_17622b11-62fa-439e-9d6a-e78af997b73a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_26c16f89-95b6-4d7c-8728-d0ff03fa50c3" xlink:to="loc_us-gaap_EarningsPerShareBasic_17622b11-62fa-439e-9d6a-e78af997b73a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a02ac702-ed2e-4742-aaf1-b504f9140b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_26c16f89-95b6-4d7c-8728-d0ff03fa50c3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a02ac702-ed2e-4742-aaf1-b504f9140b4f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aed626dc-2227-4c78-971a-87e3944084ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fb28cda9-0372-4cdf-8af6-d937efd4ae54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aed626dc-2227-4c78-971a-87e3944084ed" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fb28cda9-0372-4cdf-8af6-d937efd4ae54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b1ff38e2-618b-4cc5-95b8-f53cae3e431d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fb28cda9-0372-4cdf-8af6-d937efd4ae54" xlink:to="loc_srt_ProductOrServiceAxis_b1ff38e2-618b-4cc5-95b8-f53cae3e431d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b1ff38e2-618b-4cc5-95b8-f53cae3e431d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b1ff38e2-618b-4cc5-95b8-f53cae3e431d" xlink:to="loc_srt_ProductsAndServicesDomain_b1ff38e2-618b-4cc5-95b8-f53cae3e431d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9767f8d2-3bbc-4eb2-b8ae-169a83a64a9f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b1ff38e2-618b-4cc5-95b8-f53cae3e431d" xlink:to="loc_srt_ProductsAndServicesDomain_9767f8d2-3bbc-4eb2-b8ae-169a83a64a9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_7fb9cdd0-7c0c-40b8-8e5b-f206ec160b31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9767f8d2-3bbc-4eb2-b8ae-169a83a64a9f" xlink:to="loc_us-gaap_LicenseMember_7fb9cdd0-7c0c-40b8-8e5b-f206ec160b31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LicenseTechnologyTransferMember_c067efc4-aca4-4e73-b510-136d01c87d33" xlink:href="sgmo-20240930.xsd#sgmo_LicenseTechnologyTransferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LicenseMember_7fb9cdd0-7c0c-40b8-8e5b-f206ec160b31" xlink:to="loc_sgmo_LicenseTechnologyTransferMember_c067efc4-aca4-4e73-b510-136d01c87d33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_65dae070-8129-4b6a-923b-0b493906cebf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fb28cda9-0372-4cdf-8af6-d937efd4ae54" xlink:to="loc_srt_CounterpartyNameAxis_65dae070-8129-4b6a-923b-0b493906cebf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65dae070-8129-4b6a-923b-0b493906cebf_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_65dae070-8129-4b6a-923b-0b493906cebf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65dae070-8129-4b6a-923b-0b493906cebf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41ad56ad-7f66-41a6-905a-0cf99aa47029" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_65dae070-8129-4b6a-923b-0b493906cebf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41ad56ad-7f66-41a6-905a-0cf99aa47029" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GenentechRocheGroupMember_9b75ab16-e8a8-4104-8804-04b1ac4f6ef4" xlink:href="sgmo-20240930.xsd#sgmo_GenentechRocheGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41ad56ad-7f66-41a6-905a-0cf99aa47029" xlink:to="loc_sgmo_GenentechRocheGroupMember_9b75ab16-e8a8-4104-8804-04b1ac4f6ef4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7e2d3b4c-4405-4e91-9adf-ca4006ab5236" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fb28cda9-0372-4cdf-8af6-d937efd4ae54" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7e2d3b4c-4405-4e91-9adf-ca4006ab5236" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7e2d3b4c-4405-4e91-9adf-ca4006ab5236_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7e2d3b4c-4405-4e91-9adf-ca4006ab5236" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7e2d3b4c-4405-4e91-9adf-ca4006ab5236_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9fa6908e-0437-4a29-acc7-155cd4528ece" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7e2d3b4c-4405-4e91-9adf-ca4006ab5236" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9fa6908e-0437-4a29-acc7-155cd4528ece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9cc36aa3-5ecf-4123-af30-fb73b2748e75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9fa6908e-0437-4a29-acc7-155cd4528ece" xlink:to="loc_us-gaap_SubsequentEventMember_9cc36aa3-5ecf-4123-af30-fb73b2748e75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_eefee5e8-3fe2-4927-be5b-96c15b62387a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aed626dc-2227-4c78-971a-87e3944084ed" xlink:to="loc_us-gaap_ContractWithCustomerLiability_eefee5e8-3fe2-4927-be5b-96c15b62387a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount_cd70d031-4ee6-4fa9-a47e-fba27267be6e" xlink:href="sgmo-20240930.xsd#sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aed626dc-2227-4c78-971a-87e3944084ed" xlink:to="loc_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount_cd70d031-4ee6-4fa9-a47e-fba27267be6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RoyaltyObligationTerm_78965568-899b-476d-9372-141e81bca1fa" xlink:href="sgmo-20240930.xsd#sgmo_RoyaltyObligationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aed626dc-2227-4c78-971a-87e3944084ed" xlink:to="loc_sgmo_RoyaltyObligationTerm_78965568-899b-476d-9372-141e81bca1fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_870f726e-6a33-4407-a7f1-6bb369314356" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aed626dc-2227-4c78-971a-87e3944084ed" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_870f726e-6a33-4407-a7f1-6bb369314356" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations_c4cbba83-8581-4c0a-8abf-5ac2226cbb04" xlink:href="sgmo-20240930.xsd#sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aed626dc-2227-4c78-971a-87e3944084ed" xlink:to="loc_sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations_c4cbba83-8581-4c0a-8abf-5ac2226cbb04" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_cdcd6e07-1106-4647-ac1a-56f8b5300d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aed626dc-2227-4c78-971a-87e3944084ed" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_cdcd6e07-1106-4647-ac1a-56f8b5300d7c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b93ff8f3-3ca8-4a27-9c99-b44a26d5bbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aed626dc-2227-4c78-971a-87e3944084ed" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b93ff8f3-3ca8-4a27-9c99-b44a26d5bbdb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1d6f2fbc-edcb-4b4b-8899-868e26645349" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aed626dc-2227-4c78-971a-87e3944084ed" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1d6f2fbc-edcb-4b4b-8899-868e26645349" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3ec95d67-5c3c-4d4d-8e59-fc2d3b70201e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3ec95d67-5c3c-4d4d-8e59-fc2d3b70201e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_91a68763-dd28-4729-815a-93e3b5329a1a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3ec95d67-5c3c-4d4d-8e59-fc2d3b70201e" xlink:to="loc_srt_CounterpartyNameAxis_91a68763-dd28-4729-815a-93e3b5329a1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91a68763-dd28-4729-815a-93e3b5329a1a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_91a68763-dd28-4729-815a-93e3b5329a1a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91a68763-dd28-4729-815a-93e3b5329a1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3bd0d86f-167c-445f-abd1-3e82a9b0c86c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_91a68763-dd28-4729-815a-93e3b5329a1a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3bd0d86f-167c-445f-abd1-3e82a9b0c86c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_80088861-f726-4751-8163-47b6f6bccbdd" xlink:href="sgmo-20240930.xsd#sgmo_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3bd0d86f-167c-445f-abd1-3e82a9b0c86c" xlink:to="loc_sgmo_PfizerMember_80088861-f726-4751-8163-47b6f6bccbdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_94f47401-6ce7-4aff-82ab-2939c71af4d5" xlink:href="sgmo-20240930.xsd#sgmo_PfizerSB525Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3bd0d86f-167c-445f-abd1-3e82a9b0c86c" xlink:to="loc_sgmo_PfizerSB525Member_94f47401-6ce7-4aff-82ab-2939c71af4d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember_57ed0f5c-92be-4783-927f-bdba1e14909f" xlink:href="sgmo-20240930.xsd#sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3bd0d86f-167c-445f-abd1-3e82a9b0c86c" xlink:to="loc_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember_57ed0f5c-92be-4783-927f-bdba1e14909f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b310567b-4802-47ba-be5e-fca8a5a9c032" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3ec95d67-5c3c-4d4d-8e59-fc2d3b70201e" xlink:to="loc_srt_ProductOrServiceAxis_b310567b-4802-47ba-be5e-fca8a5a9c032" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b310567b-4802-47ba-be5e-fca8a5a9c032_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b310567b-4802-47ba-be5e-fca8a5a9c032" xlink:to="loc_srt_ProductsAndServicesDomain_b310567b-4802-47ba-be5e-fca8a5a9c032_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d4ddc9d8-a9d4-443e-82c0-ebdcaf2afcf6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b310567b-4802-47ba-be5e-fca8a5a9c032" xlink:to="loc_srt_ProductsAndServicesDomain_d4ddc9d8-a9d4-443e-82c0-ebdcaf2afcf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_dfd29300-43fe-411b-a7ae-992ee414cf3d" xlink:href="sgmo-20240930.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d4ddc9d8-a9d4-443e-82c0-ebdcaf2afcf6" xlink:to="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_dfd29300-43fe-411b-a7ae-992ee414cf3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveMember_10807510-7f44-4ce7-abce-4f5fecc1b75c" xlink:href="sgmo-20240930.xsd#sgmo_SBFiveTwoFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_dfd29300-43fe-411b-a7ae-992ee414cf3d" xlink:to="loc_sgmo_SBFiveTwoFiveMember_10807510-7f44-4ce7-abce-4f5fecc1b75c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_ec53bb98-c6b3-42d9-b806-8112aba59c49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d4ddc9d8-a9d4-443e-82c0-ebdcaf2afcf6" xlink:to="loc_us-gaap_LicenseMember_ec53bb98-c6b3-42d9-b806-8112aba59c49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember_16e14e8e-0455-4340-9fc5-405942082ed8" xlink:href="sgmo-20240930.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d4ddc9d8-a9d4-443e-82c0-ebdcaf2afcf6" xlink:to="loc_sgmo_CNineORFSevenTwoMember_16e14e8e-0455-4340-9fc5-405942082ed8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_951785a8-27a0-426f-b216-63cec28915d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3ec95d67-5c3c-4d4d-8e59-fc2d3b70201e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_951785a8-27a0-426f-b216-63cec28915d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_951785a8-27a0-426f-b216-63cec28915d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_951785a8-27a0-426f-b216-63cec28915d9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_951785a8-27a0-426f-b216-63cec28915d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_42763e42-2ea2-41f7-8a0c-0da04b2fc59b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_951785a8-27a0-426f-b216-63cec28915d9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_42763e42-2ea2-41f7-8a0c-0da04b2fc59b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_f6a98f91-9574-4025-8ecc-32cb5e0eb799" xlink:href="sgmo-20240930.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_42763e42-2ea2-41f7-8a0c-0da04b2fc59b" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_f6a98f91-9574-4025-8ecc-32cb5e0eb799" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_cc824341-14f3-44dc-b79f-e006fd13ac49" xlink:href="sgmo-20240930.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_42763e42-2ea2-41f7-8a0c-0da04b2fc59b" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_cc824341-14f3-44dc-b79f-e006fd13ac49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_a842ace3-bdcc-4ac9-b326-e48002e95d5e" xlink:href="sgmo-20240930.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_42763e42-2ea2-41f7-8a0c-0da04b2fc59b" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_a842ace3-bdcc-4ac9-b326-e48002e95d5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3dec3c9a-5cd2-4da1-bcbc-9d9e7a40f9c5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3ec95d67-5c3c-4d4d-8e59-fc2d3b70201e" xlink:to="loc_srt_RangeAxis_3dec3c9a-5cd2-4da1-bcbc-9d9e7a40f9c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3dec3c9a-5cd2-4da1-bcbc-9d9e7a40f9c5_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3dec3c9a-5cd2-4da1-bcbc-9d9e7a40f9c5" xlink:to="loc_srt_RangeMember_3dec3c9a-5cd2-4da1-bcbc-9d9e7a40f9c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_893bd6f5-e272-4bb2-81da-0c495bd418ec" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3dec3c9a-5cd2-4da1-bcbc-9d9e7a40f9c5" xlink:to="loc_srt_RangeMember_893bd6f5-e272-4bb2-81da-0c495bd418ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f5e26096-6c30-4d1d-9d55-93fc1dc31743" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_893bd6f5-e272-4bb2-81da-0c495bd418ec" xlink:to="loc_srt_MinimumMember_f5e26096-6c30-4d1d-9d55-93fc1dc31743" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c8a76cb3-25db-4283-a6d3-f2fcd65f6d2d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_893bd6f5-e272-4bb2-81da-0c495bd418ec" xlink:to="loc_srt_MaximumMember_c8a76cb3-25db-4283-a6d3-f2fcd65f6d2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm_5ef861ff-718c-4984-97af-0fa71a67545f" xlink:href="sgmo-20240930.xsd#sgmo_AgreementTerminationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_sgmo_AgreementTerminationTerm_5ef861ff-718c-4984-97af-0fa71a67545f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_fd5a75da-d698-4f48-b5ab-f0fc4cd6eca3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_fd5a75da-d698-4f48-b5ab-f0fc4cd6eca3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_c9ac431e-b2e5-45a6-ae9c-3a5f2c72b2aa" xlink:href="sgmo-20240930.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_c9ac431e-b2e5-45a6-ae9c-3a5f2c72b2aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_1109ea1b-a46d-4f36-a820-b8d332439bc7" xlink:href="sgmo-20240930.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_1109ea1b-a46d-4f36-a820-b8d332439bc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_75bdde88-efc1-46f4-b325-8e46d03837a6" xlink:href="sgmo-20240930.xsd#sgmo_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_75bdde88-efc1-46f4-b325-8e46d03837a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_6ca3877f-1331-4ea8-8000-b856370b5efa" xlink:href="sgmo-20240930.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_sgmo_MilestonePaymentsReceived_6ca3877f-1331-4ea8-8000-b856370b5efa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_8709ec15-79f5-4d14-8995-bbd195a9b1f6" xlink:href="sgmo-20240930.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_sgmo_MilestoneRevenueReceivable_8709ec15-79f5-4d14-8995-bbd195a9b1f6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_383fe03f-145d-47e9-be83-7b22bd1288e8" xlink:href="sgmo-20240930.xsd#sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_383fe03f-145d-47e9-be83-7b22bd1288e8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_74a73f94-cafa-40a9-82bc-c8d28669c046" xlink:href="sgmo-20240930.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_74a73f94-cafa-40a9-82bc-c8d28669c046" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_be95b4fd-c527-43ca-b7ed-0e8dda983b26" xlink:href="sgmo-20240930.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_be95b4fd-c527-43ca-b7ed-0e8dda983b26" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_b5365270-7542-4894-b384-acf79d74e692" xlink:href="sgmo-20240930.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_b5365270-7542-4894-b384-acf79d74e692" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97e8a9e1-5322-4373-823f-9f6181efb05b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97e8a9e1-5322-4373-823f-9f6181efb05b" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_755001ad-e86d-4c76-bb55-604e611eda12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d0c923f8-db04-4e69-8000-34eeca01b6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_755001ad-e86d-4c76-bb55-604e611eda12" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d0c923f8-db04-4e69-8000-34eeca01b6d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_36961989-8fd2-4a5e-8c97-1eecc5da190f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d0c923f8-db04-4e69-8000-34eeca01b6d4" xlink:to="loc_srt_CounterpartyNameAxis_36961989-8fd2-4a5e-8c97-1eecc5da190f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36961989-8fd2-4a5e-8c97-1eecc5da190f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_36961989-8fd2-4a5e-8c97-1eecc5da190f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36961989-8fd2-4a5e-8c97-1eecc5da190f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b376f9b0-f073-4b7c-8820-003c5b2ecf39" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_36961989-8fd2-4a5e-8c97-1eecc5da190f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b376f9b0-f073-4b7c-8820-003c5b2ecf39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GenentechRocheGroupMember_d15c858d-94b8-4061-b934-36404734d42a" xlink:href="sgmo-20240930.xsd#sgmo_GenentechRocheGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b376f9b0-f073-4b7c-8820-003c5b2ecf39" xlink:to="loc_sgmo_GenentechRocheGroupMember_d15c858d-94b8-4061-b934-36404734d42a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherCollaborationAndLicenseAgreementsMember_e5d9a6db-3c07-4c7d-bbad-badff61ae723" xlink:href="sgmo-20240930.xsd#sgmo_OtherCollaborationAndLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b376f9b0-f073-4b7c-8820-003c5b2ecf39" xlink:to="loc_sgmo_OtherCollaborationAndLicenseAgreementsMember_e5d9a6db-3c07-4c7d-bbad-badff61ae723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_82a69e9e-f205-4971-9f42-fd46fe0c515d" xlink:href="sgmo-20240930.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OtherCollaborationAndLicenseAgreementsMember_e5d9a6db-3c07-4c7d-bbad-badff61ae723" xlink:to="loc_sgmo_KitePharmaIncMember_82a69e9e-f205-4971-9f42-fd46fe0c515d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_c7213637-86b4-414d-a563-7ca368775421" xlink:href="sgmo-20240930.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OtherCollaborationAndLicenseAgreementsMember_e5d9a6db-3c07-4c7d-bbad-badff61ae723" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_c7213637-86b4-414d-a563-7ca368775421" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_3e8d2de2-a471-4764-b75a-1bc5192c303a" xlink:href="sgmo-20240930.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OtherCollaborationAndLicenseAgreementsMember_e5d9a6db-3c07-4c7d-bbad-badff61ae723" xlink:to="loc_sgmo_BiogenMAIncMember_3e8d2de2-a471-4764-b75a-1bc5192c303a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherLicensingAgreementsMember_6a817311-ee92-44be-aa7d-9b105da5ebd0" xlink:href="sgmo-20240930.xsd#sgmo_OtherLicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OtherCollaborationAndLicenseAgreementsMember_e5d9a6db-3c07-4c7d-bbad-badff61ae723" xlink:to="loc_sgmo_OtherLicensingAgreementsMember_6a817311-ee92-44be-aa7d-9b105da5ebd0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4772ad3e-fd19-437f-b060-311cf07a28d9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d0c923f8-db04-4e69-8000-34eeca01b6d4" xlink:to="loc_srt_ProductOrServiceAxis_4772ad3e-fd19-437f-b060-311cf07a28d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4772ad3e-fd19-437f-b060-311cf07a28d9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4772ad3e-fd19-437f-b060-311cf07a28d9" xlink:to="loc_srt_ProductsAndServicesDomain_4772ad3e-fd19-437f-b060-311cf07a28d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_02ad990e-9a4a-429a-a766-e88bfe41a090" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4772ad3e-fd19-437f-b060-311cf07a28d9" xlink:to="loc_srt_ProductsAndServicesDomain_02ad990e-9a4a-429a-a766-e88bfe41a090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_d9564a4d-1acd-439c-9694-89e53ad7d5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_02ad990e-9a4a-429a-a766-e88bfe41a090" xlink:to="loc_us-gaap_LicenseMember_d9564a4d-1acd-439c-9694-89e53ad7d5dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_3f937142-aac0-4e24-86cc-63f39678a151" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_02ad990e-9a4a-429a-a766-e88bfe41a090" xlink:to="loc_us-gaap_ServiceMember_3f937142-aac0-4e24-86cc-63f39678a151" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_db022127-fbe1-4d94-a7e4-72d4037647ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_755001ad-e86d-4c76-bb55-604e611eda12" xlink:to="loc_us-gaap_RevenuesAbstract_db022127-fbe1-4d94-a7e4-72d4037647ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8337433f-2a1e-48f2-aa3b-a3beb5086361" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_db022127-fbe1-4d94-a7e4-72d4037647ee" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8337433f-2a1e-48f2-aa3b-a3beb5086361" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a7c1785f-c3f8-402d-bfc4-16dbb5bbdbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_61d7c739-40b4-4d61-aa4f-73671da3e227" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a7c1785f-c3f8-402d-bfc4-16dbb5bbdbbb" xlink:to="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_61d7c739-40b4-4d61-aa4f-73671da3e227" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5fd8f69-c655-450b-842f-443240b2d12f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_61d7c739-40b4-4d61-aa4f-73671da3e227" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5fd8f69-c655-450b-842f-443240b2d12f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a5fd8f69-c655-450b-842f-443240b2d12f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5fd8f69-c655-450b-842f-443240b2d12f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a5fd8f69-c655-450b-842f-443240b2d12f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be2292d6-9de2-4c9c-bc3e-109ee1ca89cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5fd8f69-c655-450b-842f-443240b2d12f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be2292d6-9de2-4c9c-bc3e-109ee1ca89cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EquipmentFurnitureAndFixturesMember_418b6e3a-a9d9-4305-a0b9-4773b626fe6f" xlink:href="sgmo-20240930.xsd#sgmo_EquipmentFurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be2292d6-9de2-4c9c-bc3e-109ee1ca89cd" xlink:to="loc_sgmo_EquipmentFurnitureAndFixturesMember_418b6e3a-a9d9-4305-a0b9-4773b626fe6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_e69cf7de-3ddd-4ce1-a63f-8add755f0c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be2292d6-9de2-4c9c-bc3e-109ee1ca89cd" xlink:to="loc_us-gaap_ConstructionInProgressMember_e69cf7de-3ddd-4ce1-a63f-8add755f0c3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LeaseholdImprovementsAndConstructionInProgressMember_1e10ee9e-48a0-457a-8d00-68d4e4e08073" xlink:href="sgmo-20240930.xsd#sgmo_LeaseholdImprovementsAndConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be2292d6-9de2-4c9c-bc3e-109ee1ca89cd" xlink:to="loc_sgmo_LeaseholdImprovementsAndConstructionInProgressMember_1e10ee9e-48a0-457a-8d00-68d4e4e08073" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember_8dafe8ad-7bf4-450e-9c4f-cc404eeebea2" xlink:href="sgmo-20240930.xsd#sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be2292d6-9de2-4c9c-bc3e-109ee1ca89cd" xlink:to="loc_sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember_8dafe8ad-7bf4-450e-9c4f-cc404eeebea2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2b95b2db-8397-4dc3-bba7-577bc44ecc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a7c1785f-c3f8-402d-bfc4-16dbb5bbdbbb" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2b95b2db-8397-4dc3-bba7-577bc44ecc9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_cbe3459d-9520-4b59-8652-3d9995b00807" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a7c1785f-c3f8-402d-bfc4-16dbb5bbdbbb" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_cbe3459d-9520-4b59-8652-3d9995b00807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount_9aa83fbe-3447-4110-8b71-6dcab1580b47" xlink:href="sgmo-20240930.xsd#sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a7c1785f-c3f8-402d-bfc4-16dbb5bbdbbb" xlink:to="loc_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount_9aa83fbe-3447-4110-8b71-6dcab1580b47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_7d846bdc-3007-4c29-b0b0-808507cccec8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a7c1785f-c3f8-402d-bfc4-16dbb5bbdbbb" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_7d846bdc-3007-4c29-b0b0-808507cccec8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_2e015355-a6eb-43c9-8868-bded2c371bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a7c1785f-c3f8-402d-bfc4-16dbb5bbdbbb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_2e015355-a6eb-43c9-8868-bded2c371bd2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_6c851b99-0ad9-4787-b57a-dae08a73f0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a7c1785f-c3f8-402d-bfc4-16dbb5bbdbbb" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_6c851b99-0ad9-4787-b57a-dae08a73f0b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLeasehold_090d5578-1512-40a1-8929-def58f2a434f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLeasehold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a7c1785f-c3f8-402d-bfc4-16dbb5bbdbbb" xlink:to="loc_us-gaap_ImpairmentOfLeasehold_090d5578-1512-40a1-8929-def58f2a434f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_8dad6019-1198-4e24-878b-351bd4b3dbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a7c1785f-c3f8-402d-bfc4-16dbb5bbdbbb" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_8dad6019-1198-4e24-878b-351bd4b3dbe1" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_1573ec5a-82f7-4701-b2c7-f0bedd3eabcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_05442794-e0dc-455b-becb-baf68d06b8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1573ec5a-82f7-4701-b2c7-f0bedd3eabcd" xlink:to="loc_us-gaap_OtherCommitmentsTable_05442794-e0dc-455b-becb-baf68d06b8fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4abd4c2d-7ca2-4e5b-b805-0a2c8ffd7262" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_05442794-e0dc-455b-becb-baf68d06b8fe" xlink:to="loc_srt_StatementGeographicalAxis_4abd4c2d-7ca2-4e5b-b805-0a2c8ffd7262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4abd4c2d-7ca2-4e5b-b805-0a2c8ffd7262_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4abd4c2d-7ca2-4e5b-b805-0a2c8ffd7262" xlink:to="loc_srt_SegmentGeographicalDomain_4abd4c2d-7ca2-4e5b-b805-0a2c8ffd7262_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_51edebf7-1ebf-4324-a052-15afd0dc4374" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4abd4c2d-7ca2-4e5b-b805-0a2c8ffd7262" xlink:to="loc_srt_SegmentGeographicalDomain_51edebf7-1ebf-4324-a052-15afd0dc4374" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember_b3615a19-c817-46ab-834e-1a450339adb5" xlink:href="sgmo-20240930.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_51edebf7-1ebf-4324-a052-15afd0dc4374" xlink:to="loc_sgmo_RichmondCaliforniaMember_b3615a19-c817-46ab-834e-1a450339adb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OperatingLeaseRightOfUseAssetModificationReduction_1d57e408-b97a-4a6c-9cbd-277f16f2c1a3" xlink:href="sgmo-20240930.xsd#sgmo_OperatingLeaseRightOfUseAssetModificationReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1573ec5a-82f7-4701-b2c7-f0bedd3eabcd" xlink:to="loc_sgmo_OperatingLeaseRightOfUseAssetModificationReduction_1d57e408-b97a-4a6c-9cbd-277f16f2c1a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_53368e10-4076-4dc0-8411-8e3e004aa2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1573ec5a-82f7-4701-b2c7-f0bedd3eabcd" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_53368e10-4076-4dc0-8411-8e3e004aa2d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_3af4d6e0-59ca-4a01-b2a6-ed1b6ce2c37f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1573ec5a-82f7-4701-b2c7-f0bedd3eabcd" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_3af4d6e0-59ca-4a01-b2a6-ed1b6ce2c37f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination_b3700ab2-c762-4882-ae16-4215813cac6a" xlink:href="sgmo-20240930.xsd#sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1573ec5a-82f7-4701-b2c7-f0bedd3eabcd" xlink:to="loc_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination_b3700ab2-c762-4882-ae16-4215813cac6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount_80e984af-bf1e-42b7-b086-c81ba6327258" xlink:href="sgmo-20240930.xsd#sgmo_LesseeRequiredLetterOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1573ec5a-82f7-4701-b2c7-f0bedd3eabcd" xlink:to="loc_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount_80e984af-bf1e-42b7-b086-c81ba6327258" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#STOCKBASEDCOMPENSATIONDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_869c7643-1fe4-4df2-9108-ad1a2d3dbe61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_74369eb4-3236-4b55-89fe-57b5b93711a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_869c7643-1fe4-4df2-9108-ad1a2d3dbe61" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_74369eb4-3236-4b55-89fe-57b5b93711a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d4cefd38-05bb-42f5-8076-e306e5e3f46a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_74369eb4-3236-4b55-89fe-57b5b93711a8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d4cefd38-05bb-42f5-8076-e306e5e3f46a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d4cefd38-05bb-42f5-8076-e306e5e3f46a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d4cefd38-05bb-42f5-8076-e306e5e3f46a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d4cefd38-05bb-42f5-8076-e306e5e3f46a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4654b915-ecf1-47fc-b3e4-52fc5f78e1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d4cefd38-05bb-42f5-8076-e306e5e3f46a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4654b915-ecf1-47fc-b3e4-52fc5f78e1c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_308a6d9f-0fdd-4886-bf11-5bcd5fccaae4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4654b915-ecf1-47fc-b3e4-52fc5f78e1c4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_308a6d9f-0fdd-4886-bf11-5bcd5fccaae4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_89ebe3f8-b049-4778-bd0d-2493c9c281ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4654b915-ecf1-47fc-b3e4-52fc5f78e1c4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_89ebe3f8-b049-4778-bd0d-2493c9c281ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_46357525-a70b-4cf3-9823-647f88fac2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_74369eb4-3236-4b55-89fe-57b5b93711a8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_46357525-a70b-4cf3-9823-647f88fac2f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_46357525-a70b-4cf3-9823-647f88fac2f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_46357525-a70b-4cf3-9823-647f88fac2f8" xlink:to="loc_us-gaap_ClassOfStockDomain_46357525-a70b-4cf3-9823-647f88fac2f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d75c94d7-9394-42d6-9dec-4dfd22190ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_46357525-a70b-4cf3-9823-647f88fac2f8" xlink:to="loc_us-gaap_ClassOfStockDomain_d75c94d7-9394-42d6-9dec-4dfd22190ad3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreFundedCommonStockWarrantMember_215d9811-567d-47c6-91dd-2c2f5d607759" xlink:href="sgmo-20240930.xsd#sgmo_PreFundedCommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d75c94d7-9394-42d6-9dec-4dfd22190ad3" xlink:to="loc_sgmo_PreFundedCommonStockWarrantMember_215d9811-567d-47c6-91dd-2c2f5d607759" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f56ed8a4-e53d-4d5c-9d65-8e985e9cc4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_869c7643-1fe4-4df2-9108-ad1a2d3dbe61" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f56ed8a4-e53d-4d5c-9d65-8e985e9cc4fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ddfba15f-ee34-4a51-8b37-e7d78475ec70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_869c7643-1fe4-4df2-9108-ad1a2d3dbe61" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ddfba15f-ee34-4a51-8b37-e7d78475ec70" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#STOCKHOLDERSEQUITYDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd32be57-4962-4f33-b39f-ac0fdbc1c78a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd32be57-4962-4f33-b39f-ac0fdbc1c78a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_db1223dc-91ea-4ba6-8493-15019da60b52" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd32be57-4962-4f33-b39f-ac0fdbc1c78a" xlink:to="loc_srt_CounterpartyNameAxis_db1223dc-91ea-4ba6-8493-15019da60b52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db1223dc-91ea-4ba6-8493-15019da60b52_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_db1223dc-91ea-4ba6-8493-15019da60b52" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db1223dc-91ea-4ba6-8493-15019da60b52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d21cbd9c-6dcf-4442-8dbe-4f414545d5a8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_db1223dc-91ea-4ba6-8493-15019da60b52" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d21cbd9c-6dcf-4442-8dbe-4f414545d5a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember_fa702eb9-4ac5-486d-a27f-fc06a56708a7" xlink:href="sgmo-20240930.xsd#sgmo_JefferiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d21cbd9c-6dcf-4442-8dbe-4f414545d5a8" xlink:to="loc_sgmo_JefferiesLLCMember_fa702eb9-4ac5-486d-a27f-fc06a56708a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_70cee94a-f617-4672-b7f3-8f1ba9f763b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd32be57-4962-4f33-b39f-ac0fdbc1c78a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_70cee94a-f617-4672-b7f3-8f1ba9f763b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70cee94a-f617-4672-b7f3-8f1ba9f763b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_70cee94a-f617-4672-b7f3-8f1ba9f763b1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70cee94a-f617-4672-b7f3-8f1ba9f763b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbebf454-d69a-44fa-8f88-4c3f42bf02c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_70cee94a-f617-4672-b7f3-8f1ba9f763b1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbebf454-d69a-44fa-8f88-4c3f42bf02c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingProgramMember_c3702a0d-da96-4437-873b-af50468feddb" xlink:href="sgmo-20240930.xsd#sgmo_AtTheMarketOfferingProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbebf454-d69a-44fa-8f88-4c3f42bf02c0" xlink:to="loc_sgmo_AtTheMarketOfferingProgramMember_c3702a0d-da96-4437-873b-af50468feddb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_3feadd08-a6e5-4b0d-baf8-d2219ceb0f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbebf454-d69a-44fa-8f88-4c3f42bf02c0" xlink:to="loc_us-gaap_PrivatePlacementMember_3feadd08-a6e5-4b0d-baf8-d2219ceb0f3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3614340b-7a1c-4427-8098-9f9fe7a8b48d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd32be57-4962-4f33-b39f-ac0fdbc1c78a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3614340b-7a1c-4427-8098-9f9fe7a8b48d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3614340b-7a1c-4427-8098-9f9fe7a8b48d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3614340b-7a1c-4427-8098-9f9fe7a8b48d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3614340b-7a1c-4427-8098-9f9fe7a8b48d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8cce2858-3e1f-464d-9fd8-a30f0e228899" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3614340b-7a1c-4427-8098-9f9fe7a8b48d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8cce2858-3e1f-464d-9fd8-a30f0e228899" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommonWarrantMember_f181a1ba-a66e-4c6d-bd50-57e2f0ebb93f" xlink:href="sgmo-20240930.xsd#sgmo_CommonWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8cce2858-3e1f-464d-9fd8-a30f0e228899" xlink:to="loc_sgmo_CommonWarrantMember_f181a1ba-a66e-4c6d-bd50-57e2f0ebb93f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreFundedCommonStockWarrantMember_e1bf7db9-4273-4b1d-a44d-008153b89fc3" xlink:href="sgmo-20240930.xsd#sgmo_PreFundedCommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8cce2858-3e1f-464d-9fd8-a30f0e228899" xlink:to="loc_sgmo_PreFundedCommonStockWarrantMember_e1bf7db9-4273-4b1d-a44d-008153b89fc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bf5a03fd-9c9a-4f9c-a547-c96ea1d07e20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd32be57-4962-4f33-b39f-ac0fdbc1c78a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bf5a03fd-9c9a-4f9c-a547-c96ea1d07e20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bf5a03fd-9c9a-4f9c-a547-c96ea1d07e20_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bf5a03fd-9c9a-4f9c-a547-c96ea1d07e20" xlink:to="loc_us-gaap_ClassOfStockDomain_bf5a03fd-9c9a-4f9c-a547-c96ea1d07e20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ec7fa202-b831-4cbd-895a-e622c9eb37c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bf5a03fd-9c9a-4f9c-a547-c96ea1d07e20" xlink:to="loc_us-gaap_ClassOfStockDomain_ec7fa202-b831-4cbd-895a-e622c9eb37c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreFundedCommonStockWarrantMember_18f1052b-96de-42dd-b493-3fb498985610" xlink:href="sgmo-20240930.xsd#sgmo_PreFundedCommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ec7fa202-b831-4cbd-895a-e622c9eb37c9" xlink:to="loc_sgmo_PreFundedCommonStockWarrantMember_18f1052b-96de-42dd-b493-3fb498985610" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_719d9a1c-6227-46c7-ac3f-f74f9df28529" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd32be57-4962-4f33-b39f-ac0fdbc1c78a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_719d9a1c-6227-46c7-ac3f-f74f9df28529" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_719d9a1c-6227-46c7-ac3f-f74f9df28529_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_719d9a1c-6227-46c7-ac3f-f74f9df28529" xlink:to="loc_us-gaap_EquityComponentDomain_719d9a1c-6227-46c7-ac3f-f74f9df28529_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_97ccdc05-e287-42c2-8a4d-8bb11d242c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_719d9a1c-6227-46c7-ac3f-f74f9df28529" xlink:to="loc_us-gaap_EquityComponentDomain_97ccdc05-e287-42c2-8a4d-8bb11d242c5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_23c56409-20f5-4d5d-9678-50e7faaebf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_97ccdc05-e287-42c2-8a4d-8bb11d242c5b" xlink:to="loc_us-gaap_CommonStockMember_23c56409-20f5-4d5d-9678-50e7faaebf1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2011e3e3-2af9-4a6e-a3f8-0e27e9d84294" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2011e3e3-2af9-4a6e-a3f8-0e27e9d84294" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue_af0dac09-20f4-4fbf-b990-84b12ca0403d" xlink:href="sgmo-20240930.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_sgmo_StockOfferingProgramMaximumValue_af0dac09-20f4-4fbf-b990-84b12ca0403d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_f233ef83-3ed6-4582-b93e-510792da7e16" xlink:href="sgmo-20240930.xsd#sgmo_SaleOfStockIncreaseToAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_f233ef83-3ed6-4582-b93e-510792da7e16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockOutstandingAmountAvailable_40dbd3a0-69b2-44fc-b60f-b89854a083c2" xlink:href="sgmo-20240930.xsd#sgmo_SaleOfStockOutstandingAmountAvailable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_sgmo_SaleOfStockOutstandingAmountAvailable_40dbd3a0-69b2-44fc-b60f-b89854a083c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1b6d5262-b253-4b91-b41a-87a896592cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1b6d5262-b253-4b91-b41a-87a896592cf3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e9ecc827-6506-4182-9623-cda7f5a4af72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e9ecc827-6506-4182-9623-cda7f5a4af72" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_04538e73-a80e-439c-9356-8e2710712508" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_04538e73-a80e-439c-9356-8e2710712508" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_04f63701-3ba9-4ed5-9597-c2732d8f0dad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_04f63701-3ba9-4ed5-9597-c2732d8f0dad" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_48573e20-2577-44c0-ba91-d1da06f0350d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_48573e20-2577-44c0-ba91-d1da06f0350d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_66803fb0-1629-4f09-96f7-53c352548fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_66803fb0-1629-4f09-96f7-53c352548fc7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit_27157c78-7f4e-4662-be1b-c6be6ef4a750" xlink:href="sgmo-20240930.xsd#sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit_27157c78-7f4e-4662-be1b-c6be6ef4a750" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_caef4bb7-a379-4fca-8d40-14e11ea7cb79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_caef4bb7-a379-4fca-8d40-14e11ea7cb79" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_60b258e6-94b5-4be6-b3f8-125079d5da89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_SharePrice_60b258e6-94b5-4be6-b3f8-125079d5da89" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance_38dc14bf-6ae3-4544-8fd1-3755d0af61d5" xlink:href="sgmo-20240930.xsd#sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance_38dc14bf-6ae3-4544-8fd1-3755d0af61d5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_7bade6ff-b658-4267-a178-54a03cecacd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_7bade6ff-b658-4267-a178-54a03cecacd0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3813e723-e030-4b34-9ebb-b93b7589fa92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3813e723-e030-4b34-9ebb-b93b7589fa92" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds_e5d8fcc9-4323-444b-a8fa-776b67fbd5ef" xlink:href="sgmo-20240930.xsd#sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds_e5d8fcc9-4323-444b-a8fa-776b67fbd5ef" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockAgentPlacementFees_1cd4313d-764d-4c60-853e-3dcfa6275ea7" xlink:href="sgmo-20240930.xsd#sgmo_SaleOfStockAgentPlacementFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_sgmo_SaleOfStockAgentPlacementFees_1cd4313d-764d-4c60-853e-3dcfa6275ea7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockOtherOfferingCosts_6f90333c-4a31-4c40-a547-ddbac304aea1" xlink:href="sgmo-20240930.xsd#sgmo_SaleOfStockOtherOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_sgmo_SaleOfStockOtherOfferingCosts_6f90333c-4a31-4c40-a547-ddbac304aea1" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e80f5d86-ece1-47ef-b4fe-9874181034f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e80f5d86-ece1-47ef-b4fe-9874181034f4" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#RESTRUCTURINGCHARGESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_0e0c8591-1306-40cd-b09a-71da15784345" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03f53d7b-f553-4061-aa7b-c93a949eded6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0e0c8591-1306-40cd-b09a-71da15784345" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03f53d7b-f553-4061-aa7b-c93a949eded6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_df468b48-8773-48b6-a2a0-6b6534eac242" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03f53d7b-f553-4061-aa7b-c93a949eded6" xlink:to="loc_us-gaap_RestructuringPlanAxis_df468b48-8773-48b6-a2a0-6b6534eac242" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_df468b48-8773-48b6-a2a0-6b6534eac242_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_df468b48-8773-48b6-a2a0-6b6534eac242" xlink:to="loc_us-gaap_RestructuringPlanDomain_df468b48-8773-48b6-a2a0-6b6534eac242_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_0a7be46f-cfce-4b0c-9594-a3d316ca24a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_df468b48-8773-48b6-a2a0-6b6534eac242" xlink:to="loc_us-gaap_RestructuringPlanDomain_0a7be46f-cfce-4b0c-9594-a3d316ca24a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_April2023RestructuringPlanMember_e6a00c6b-b0bf-4cae-8e1e-dd17c556e9fd" xlink:href="sgmo-20240930.xsd#sgmo_April2023RestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_0a7be46f-cfce-4b0c-9594-a3d316ca24a9" xlink:to="loc_sgmo_April2023RestructuringPlanMember_e6a00c6b-b0bf-4cae-8e1e-dd17c556e9fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_November2023RestructuringPlanMember_2492b6fe-a264-42f9-a639-39e2ffd3e31d" xlink:href="sgmo-20240930.xsd#sgmo_November2023RestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_0a7be46f-cfce-4b0c-9594-a3d316ca24a9" xlink:to="loc_sgmo_November2023RestructuringPlanMember_2492b6fe-a264-42f9-a639-39e2ffd3e31d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FranceRestructuringPlanMember_a26d5475-9ff4-4de1-bb0d-f4488d50d7e0" xlink:href="sgmo-20240930.xsd#sgmo_FranceRestructuringPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_0a7be46f-cfce-4b0c-9594-a3d316ca24a9" xlink:to="loc_sgmo_FranceRestructuringPlanMember_a26d5475-9ff4-4de1-bb0d-f4488d50d7e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_c0e96729-d4ee-45f8-bad8-766886122738" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03f53d7b-f553-4061-aa7b-c93a949eded6" xlink:to="loc_srt_TitleOfIndividualAxis_c0e96729-d4ee-45f8-bad8-766886122738" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c0e96729-d4ee-45f8-bad8-766886122738_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_c0e96729-d4ee-45f8-bad8-766886122738" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c0e96729-d4ee-45f8-bad8-766886122738_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_035b197e-e24c-46c2-b337-2dd6def76957" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_c0e96729-d4ee-45f8-bad8-766886122738" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_035b197e-e24c-46c2-b337-2dd6def76957" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FullTimeEmployeesMember_bd61057c-81ac-4ec4-8255-efc9480f1acc" xlink:href="sgmo-20240930.xsd#sgmo_FullTimeEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_035b197e-e24c-46c2-b337-2dd6def76957" xlink:to="loc_sgmo_FullTimeEmployeesMember_bd61057c-81ac-4ec4-8255-efc9480f1acc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractedEmployeesMember_7d5b4ad0-f1fb-4c7e-b4a9-fe8fac79398e" xlink:href="sgmo-20240930.xsd#sgmo_ContractedEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_035b197e-e24c-46c2-b337-2dd6def76957" xlink:to="loc_sgmo_ContractedEmployeesMember_7d5b4ad0-f1fb-4c7e-b4a9-fe8fac79398e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0fd5a1c9-39cc-4d55-a621-d9a586c86f76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03f53d7b-f553-4061-aa7b-c93a949eded6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0fd5a1c9-39cc-4d55-a621-d9a586c86f76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0fd5a1c9-39cc-4d55-a621-d9a586c86f76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0fd5a1c9-39cc-4d55-a621-d9a586c86f76" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0fd5a1c9-39cc-4d55-a621-d9a586c86f76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c6309507-6b02-4db0-9fdb-6392ba6f5fde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0fd5a1c9-39cc-4d55-a621-d9a586c86f76" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c6309507-6b02-4db0-9fdb-6392ba6f5fde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_70f1bf77-2b91-470a-9ed6-963601527732" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c6309507-6b02-4db0-9fdb-6392ba6f5fde" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_70f1bf77-2b91-470a-9ed6-963601527732" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ab86fea0-1363-4479-a27f-cd831b91c27d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c6309507-6b02-4db0-9fdb-6392ba6f5fde" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ab86fea0-1363-4479-a27f-cd831b91c27d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0f89c2e3-e4e3-4fce-a63a-9d42215b4656" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03f53d7b-f553-4061-aa7b-c93a949eded6" xlink:to="loc_srt_RangeAxis_0f89c2e3-e4e3-4fce-a63a-9d42215b4656" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0f89c2e3-e4e3-4fce-a63a-9d42215b4656_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0f89c2e3-e4e3-4fce-a63a-9d42215b4656" xlink:to="loc_srt_RangeMember_0f89c2e3-e4e3-4fce-a63a-9d42215b4656_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c688261b-a9eb-433c-91c8-59955aeb20c7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0f89c2e3-e4e3-4fce-a63a-9d42215b4656" xlink:to="loc_srt_RangeMember_c688261b-a9eb-433c-91c8-59955aeb20c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2b729adf-4eac-42e2-9a53-547cf4b9336f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c688261b-a9eb-433c-91c8-59955aeb20c7" xlink:to="loc_srt_MinimumMember_2b729adf-4eac-42e2-9a53-547cf4b9336f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ca5bb2cc-7981-4438-95cb-0f25af4305fa" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c688261b-a9eb-433c-91c8-59955aeb20c7" xlink:to="loc_srt_MaximumMember_ca5bb2cc-7981-4438-95cb-0f25af4305fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_fdf9588e-dd18-4b14-bdc4-8e46d5c555e2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03f53d7b-f553-4061-aa7b-c93a949eded6" xlink:to="loc_srt_StatementScenarioAxis_fdf9588e-dd18-4b14-bdc4-8e46d5c555e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fdf9588e-dd18-4b14-bdc4-8e46d5c555e2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_fdf9588e-dd18-4b14-bdc4-8e46d5c555e2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fdf9588e-dd18-4b14-bdc4-8e46d5c555e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_84253d1f-833a-41fe-be85-ea6a77f0e8ed" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_fdf9588e-dd18-4b14-bdc4-8e46d5c555e2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_84253d1f-833a-41fe-be85-ea6a77f0e8ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c404435b-1cca-42c4-a55f-07108ccb7678" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_84253d1f-833a-41fe-be85-ea6a77f0e8ed" xlink:to="loc_srt_ScenarioForecastMember_c404435b-1cca-42c4-a55f-07108ccb7678" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_61e4e272-9d5f-4380-89b2-a638b88d0589" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0e0c8591-1306-40cd-b09a-71da15784345" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_61e4e272-9d5f-4380-89b2-a638b88d0589" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_19765bac-bb0a-4f95-89e3-ce0639ede054" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0e0c8591-1306-40cd-b09a-71da15784345" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_19765bac-bb0a-4f95-89e3-ce0639ede054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e3cb2742-1fbd-4342-a8c4-ea858522a05f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0e0c8591-1306-40cd-b09a-71da15784345" xlink:to="loc_us-gaap_RestructuringCharges_e3cb2742-1fbd-4342-a8c4-ea858522a05f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_f591eb07-2ebb-4ffc-a094-4328e9a6c640" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0e0c8591-1306-40cd-b09a-71da15784345" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_f591eb07-2ebb-4ffc-a094-4328e9a6c640" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_08e75284-24bc-489e-9366-a7dd3af509c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0e0c8591-1306-40cd-b09a-71da15784345" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_08e75284-24bc-489e-9366-a7dd3af509c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_4b9422dc-fa1a-4033-85e4-600c65f56f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0e0c8591-1306-40cd-b09a-71da15784345" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_4b9422dc-fa1a-4033-85e4-600c65f56f8b" xlink:type="arc" order="5"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>sgmo-20240930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:71d79187-a2e4-4f72-bd61-283a5977d997,g:6e5f68a8-3875-4e0a-8723-d2906a1af0a5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_sgmo_EquipmentFurnitureAndFixturesMember_10c80cbb-e96b-4859-8036-f87a93b4a9bd_terseLabel_en-US" xlink:label="lab_sgmo_EquipmentFurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment, Furniture, And Fixtures</link:label>
    <link:label id="lab_sgmo_EquipmentFurnitureAndFixturesMember_label_en-US" xlink:label="lab_sgmo_EquipmentFurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment, Furniture, And Fixtures [Member]</link:label>
    <link:label id="lab_sgmo_EquipmentFurnitureAndFixturesMember_documentation_en-US" xlink:label="lab_sgmo_EquipmentFurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equipment, Furniture, And Fixtures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EquipmentFurnitureAndFixturesMember" xlink:href="sgmo-20240930.xsd#sgmo_EquipmentFurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_EquipmentFurnitureAndFixturesMember" xlink:to="lab_sgmo_EquipmentFurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance_77e1e953-f903-4992-91f9-6532690d5c8e_terseLabel_en-US" xlink:label="lab_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercisable, period after issuance</link:label>
    <link:label id="lab_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance_label_en-US" xlink:label="lab_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Or Right Outstanding, Exercisable, Period After Issuance</link:label>
    <link:label id="lab_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance_documentation_en-US" xlink:label="lab_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Or Right Outstanding, Exercisable, Period After Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance" xlink:href="sgmo-20240930.xsd#sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance" xlink:to="lab_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ee796adc-c11b-42c6-bbdc-2e3c694d6e8d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_57796cbc-fd79-468a-94cc-54641c919a53_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2310e54d-1ffc-4c74-9cc8-ce217bcee269_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9bd6c4ee-9624-4a1a-bb1f-87811358d3b1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_993b1ad0-01bc-4298-b846-44101f9c2631_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_3c3f2cf4-4959-4361-a4fb-247033ee8228_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_85551940-af9b-4b08-ab6c-7ad0d262444d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_b9e4fb38-29c6-4beb-8bf7-11f6782ed4b3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for credit loss related to marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_7b4fc5c3-b015-4f00-8f22-26dd85c13df8_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_JefferiesLLCMember_06fe6db3-d608-4510-ab02-59d25638d5fa_terseLabel_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Jefferies LLC</link:label>
    <link:label id="lab_sgmo_JefferiesLLCMember_label_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jefferies LLC [Member]</link:label>
    <link:label id="lab_sgmo_JefferiesLLCMember_documentation_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Jefferies LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember" xlink:href="sgmo-20240930.xsd#sgmo_JefferiesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_JefferiesLLCMember" xlink:to="lab_sgmo_JefferiesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded_4dbd2e94-cc9b-4bbd-be8c-8744b3d37e1a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for credit loss related to marketable securities, not previously recorded</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Allowance for Credit Loss, Not Previously Recorded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b7fbf326-a817-441f-8a76-7d99c52e9a7d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Basic and Diluted Net Income (Loss) per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockOtherOfferingCosts_c6298359-7cc4-4a01-8fb1-d227c4e41f15_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockOtherOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from other offering expenses</link:label>
    <link:label id="lab_sgmo_SaleOfStockOtherOfferingCosts_label_en-US" xlink:label="lab_sgmo_SaleOfStockOtherOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Other Offering Costs</link:label>
    <link:label id="lab_sgmo_SaleOfStockOtherOfferingCosts_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockOtherOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Other Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockOtherOfferingCosts" xlink:href="sgmo-20240930.xsd#sgmo_SaleOfStockOtherOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockOtherOfferingCosts" xlink:to="lab_sgmo_SaleOfStockOtherOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_51b6bba3-65b0-47d5-a6f1-5d311826bcbd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations_d6347f62-8591-4113-aef7-e3d1c25c3914_terseLabel_en-US" xlink:label="lab_sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations_label_en-US" xlink:label="lab_sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contracts With Customer, Number Of Performance Obligations</link:label>
    <link:label id="lab_sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations_documentation_en-US" xlink:label="lab_sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Contracts With Customer, Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations" xlink:href="sgmo-20240930.xsd#sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations" xlink:to="lab_sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_79f838f2-63a1-49f7-8916-9a5beb465694_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of pre-funded warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember_0f898346-e6aa-44da-bd77-3cc1e398e9c8_terseLabel_en-US" xlink:label="lab_sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture, Fixtures And Laboratory And Manufacturing Equipment</link:label>
    <link:label id="lab_sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember_label_en-US" xlink:label="lab_sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture, Fixtures And Laboratory And Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Furniture, Fixtures And Laboratory And Manufacturing Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember" xlink:href="sgmo-20240930.xsd#sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember" xlink:to="lab_sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_0120e0b1-1cc3-459a-9590-9d3ab2fc0fde_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_f4ef5b26-db85-4b27-8f04-9a724e6299af_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_843dcb82-43eb-4a62-91a5-998d48cb3beb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_a01e32a0-8fc1-4345-b79c-9f0f5e33590f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_866916df-9a38-47ce-83d4-25f085ef2afb_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_e6f59508-9e20-437c-8794-8602191cfc47_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2a371f08-e166-4ef9-90e2-207dff0a4f57_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_aa62f405-98eb-4145-933f-b153a3255b51_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized (loss) gain on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PreFundedCommonStockWarrantMember_de548d22-7385-42c5-884b-312727aac653_terseLabel_en-US" xlink:label="lab_sgmo_PreFundedCommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-funded warrants</link:label>
    <link:label id="lab_sgmo_PreFundedCommonStockWarrantMember_label_en-US" xlink:label="lab_sgmo_PreFundedCommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre Funded Common Stock Warrant [Member]</link:label>
    <link:label id="lab_sgmo_PreFundedCommonStockWarrantMember_documentation_en-US" xlink:label="lab_sgmo_PreFundedCommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre Funded Common Stock Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreFundedCommonStockWarrantMember" xlink:href="sgmo-20240930.xsd#sgmo_PreFundedCommonStockWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PreFundedCommonStockWarrantMember" xlink:to="lab_sgmo_PreFundedCommonStockWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9e906d5f-7fff-44a5-a6c4-e8d36000e86e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b5590305-f68d-40d9-b160-e03442ed82d4_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_bcebe049-edcc-45e9-884f-770c2dadc511_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_156646dd-094e-4588-8b1d-9ba33809293c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of employees eliminated in restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_e9717a26-e145-4ca3-a3ec-b7c4b92a8af9_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_06c9e9de-382c-48f9-b35e-5c9f8db77717_terseLabel_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Richmond, California</link:label>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_label_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Richmond, California [Member]</link:label>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_documentation_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Richmond, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember" xlink:href="sgmo-20240930.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RichmondCaliforniaMember" xlink:to="lab_sgmo_RichmondCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_ecae1af4-eadd-4aa0-9230-432223f6924f_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_0e3f246d-0a8c-48c8-bbe1-81fb64c7f37a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_76f46e79-4342-4d01-aeac-7e17e64917b8_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ec88177b-ae51-4c1e-9265-9021a7daf527_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_e6e3acae-fefb-4d53-806b-14412773365e_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement transaction price</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Transaction Price</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative arrangement transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice" xlink:href="sgmo-20240930.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementTransactionPrice" xlink:to="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_9b5d7e92-cb7d-4769-9e57-021c757fcf40_terseLabel_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential amount to be funded for achievement of specified commercialized and sales milestones</link:label>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_label_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive</link:label>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_documentation_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate additional revenue recognition milestone method revenue eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:href="sgmo-20240930.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:to="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_45b922ee-5645-410b-b654-bf8df2735385_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_883bc6be-c65e-4310-9ad4-b6c4b1663100_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit_ef9f373b-624f-4764-85ad-2f9d9c03262e_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, number of shares issued in transaction, per unit (in shares)</link:label>
    <link:label id="lab_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit_label_en-US" xlink:label="lab_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction, Per Unit</link:label>
    <link:label id="lab_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction, Per Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit" xlink:href="sgmo-20240930.xsd#sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit" xlink:to="lab_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_20b81732-024d-4a40-807a-009cd86d0d7a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_23b18538-5da4-4d1a-9fd0-edc2d7337e4b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_81d33bb4-9467-4285-a2f8-583b06fc9b3f_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury bills</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent_cb13fe8c-a105-4d5f-af73-e15401ad7226_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_70a72d9a-e204-4a15-a648-45e37e57c39f_negatedTerseLabel_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents accumulated gross unrealized loss before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="sgmo-20240930.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_edd3ad68-e5fc-4035-a296-41a6e39bbfbe_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Achievement of specified preclinical development clinical development and first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20240930.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3d3e83d4-3b00-454c-bd18-a239aa72fccd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6de51003-5465-4e6d-a11b-4aabe5c8f512_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_296b44bc-2195-4d70-8cb6-f4fc28caf986_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of milestones included in transaction price</link:label>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_label_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Clinical Or Regulatory Milestones Included In Transaction Price</link:label>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_documentation_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of clinical or regulatory milestones included in transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:href="sgmo-20240930.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:to="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_April2023RestructuringPlanMember_ca7a6301-b39c-465e-9995-2d0b2ac20f64_terseLabel_en-US" xlink:label="lab_sgmo_April2023RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">April 2023 Restructuring Plan</link:label>
    <link:label id="lab_sgmo_April2023RestructuringPlanMember_label_en-US" xlink:label="lab_sgmo_April2023RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">April 2023 Restructuring Plan [Member]</link:label>
    <link:label id="lab_sgmo_April2023RestructuringPlanMember_documentation_en-US" xlink:label="lab_sgmo_April2023RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">April 2023 Restructuring Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_April2023RestructuringPlanMember" xlink:href="sgmo-20240930.xsd#sgmo_April2023RestructuringPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_April2023RestructuringPlanMember" xlink:to="lab_sgmo_April2023RestructuringPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_f6adfc9a-0eb1-4146-971e-0c19ea0029e0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3693150b-c9a3-4111-b8e6-c8775df45f52_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_37e1f0cd-4818-4d9e-b3be-39aee55c55bb_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_b7273ad3-db91-4c1d-aa21-0823aa6af639_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_53c99953-d66c-4a8e-93f1-f1fd2b81a01f_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_f1d35570-44a5-4b1c-8501-126bcb44e2ec_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OtherCollaborationAndLicenseAgreementsMember_6782f1da-464e-483f-85f2-b485fe38d327_terseLabel_en-US" xlink:label="lab_sgmo_OtherCollaborationAndLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Collaboration And License Agreements</link:label>
    <link:label id="lab_sgmo_OtherCollaborationAndLicenseAgreementsMember_label_en-US" xlink:label="lab_sgmo_OtherCollaborationAndLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Collaboration And License Agreements [Member]</link:label>
    <link:label id="lab_sgmo_OtherCollaborationAndLicenseAgreementsMember_documentation_en-US" xlink:label="lab_sgmo_OtherCollaborationAndLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Collaboration And License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherCollaborationAndLicenseAgreementsMember" xlink:href="sgmo-20240930.xsd#sgmo_OtherCollaborationAndLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OtherCollaborationAndLicenseAgreementsMember" xlink:to="lab_sgmo_OtherCollaborationAndLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_044a6eaa-1d96-4a29-9b2f-5ef3aaf5c4e8_negatedLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents and marketable securities, gross unrealized losses</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash equivalents and available for sale securities, gross unrealized loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:href="sgmo-20240930.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_775ba507-593e-4e4e-8786-2146039ee7d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Restructuring Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_03a52653-4226-4b2a-b165-0d5253645748_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2df8fa68-81d2-4bec-87ca-32e9934790f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ca25656c-3a11-4361-aa81-d4096ccc80ca_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of new stock issued during the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_47186496-fd09-484b-89db-b365dae72dda_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_291bf206-f355-49f6-8fc7-95b9358ec4f9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3c1a6121-c446-47a3-93df-72376b4aba4b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7f0d782f-c69d-4b63-8eea-2db3bef00089_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets_217bac0f-3bce-4172-9e69-bdc50554b2a7_terseLabel_en-US" xlink:label="lab_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Refundable research income tax credits and other non-current assets</link:label>
    <link:label id="lab_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets_label_en-US" xlink:label="lab_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Refundable Research Credits And Other Non-current Assets</link:label>
    <link:label id="lab_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets_documentation_en-US" xlink:label="lab_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax, Refundable Research Credits And Other Non-current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets" xlink:href="sgmo-20240930.xsd#sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets" xlink:to="lab_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_c7efa5d6-116e-48ef-8e72-c189f9526890_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of assets to be disposed of</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_44d21536-2afe-4b44-957b-e57fa8574033_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9d4d91ae-0a5c-4574-b39f-dd85b4946b10_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bc1217ef-525e-4984-a852-648955b47999_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_208d9509-7574-46b1-887d-a795a8a58b65_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_386462a3-4a0a-4843-9307-2592ad969aa1_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1a9319b4-d4ae-4388-b62c-9f90dfb3d39f_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accretion of discount and impairment on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_bc05404c-2761-4dc7-9df8-30d3e92d3e2c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6040b2d4-9ece-43a9-8382-3b75c591fc8f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_c4c423fa-44a0-496f-9b9a-f379bd335b8a_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, number of milestones achieved</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Number Of Milestones Achieved</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Number Of Milestones Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:href="sgmo-20240930.xsd#sgmo_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:to="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerSB525Member_249db6b2-d5ef-485a-bf84-b38f5d468b8f_terseLabel_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer SB-525</link:label>
    <link:label id="lab_sgmo_PfizerSB525Member_label_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer SB-525 [Member]</link:label>
    <link:label id="lab_sgmo_PfizerSB525Member_documentation_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer SB-525 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member" xlink:href="sgmo-20240930.xsd#sgmo_PfizerSB525Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerSB525Member" xlink:to="lab_sgmo_PfizerSB525Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_8ef2021b-d1f6-4b52-a36a-ba1aeef459cd_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_7b1e99fa-a17d-4e99-ade6-c257f954720d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_e2a57a8f-1756-43f5-86ac-c46c97c10ab2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_9d9e84c0-97a5-4142-97ad-267b7e30f440_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_ddcc4cc6-b0d7-49db-a4bc-e98d8b31a957_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_d88ae107-6cec-4c18-badf-442c6e876ab7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_cf3ae7be-a625-4fcf-a2d0-bda0d8f03481_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Marketable Securities by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_425bbc6a-0147-43ad-8dfc-6787dfb42986_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_df828e30-30fa-4900-b465-f0c6cefd1814_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_c0bdb0e9-1943-45da-8429-f8b64b40c9f3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5e6981cd-fbda-41eb-8d3f-b68b2c4bff73_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentChargesTextBlock_871ccf9e-a46a-4896-96ed-56605d596c6c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentChargesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IMPAIRMENT AND WRITE-DOWN OF ASSETS HELD FOR SALE</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentChargesTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentChargesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentChargesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentChargesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentChargesTextBlock" xlink:to="lab_us-gaap_AssetImpairmentChargesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c8e99df0-2dee-43a8-8a25-582f51b40905_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_05f5bdb7-abbe-4537-ae30-bada3af30655_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d19154bc-6beb-4c30-ac95-fc00f3043730_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a93f5c02-1700-4655-b41a-b6d05152e8a2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_48981add-292a-4c07-b3c8-d15b35ab884d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_01d55a6f-ed41-4526-bc1a-03aa6a12f19d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_15dff086-b746-487c-925b-f1fd4fa54fd7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of common stock for each Common warrant (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_41c171f1-0357-4117-a072-580eab1b6343_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_fe49abe7-f76f-486e-8ac0-025854382711_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CommonWarrantMember_deef8f0c-5a8d-48d8-b375-e0b6647b9167_terseLabel_en-US" xlink:label="lab_sgmo_CommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common warrants</link:label>
    <link:label id="lab_sgmo_CommonWarrantMember_label_en-US" xlink:label="lab_sgmo_CommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Warrant [Member]</link:label>
    <link:label id="lab_sgmo_CommonWarrantMember_documentation_en-US" xlink:label="lab_sgmo_CommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommonWarrantMember" xlink:href="sgmo-20240930.xsd#sgmo_CommonWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CommonWarrantMember" xlink:to="lab_sgmo_CommonWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_e7bba544-31b7-407f-b08a-e94e5d3af752_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_50c3e656-e007-4eaf-8deb-69d10c63ce2a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_a4d1006d-09ac-441a-93d1-ad37864021c6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill and indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent_aa889c50-2314-4584-8ffb-d12797f0fd91_totalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents and marketable securities, amortized cost</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Amortized Cost, Current</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash equivalents and available for Sale Securities Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent" xlink:href="sgmo-20240930.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_267d9495-b4c7-484b-bb62-6c120c39b628_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_194316ed-9b01-491a-9f82-f56b1b407c0b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6304ea3a-e159-4d31-a9d5-1653a834c6f7_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_6fb7e172-a84b-44a8-a4f1-76307c0b8966_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring expected cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract_89fedb5d-8bff-4612-9ea1-f84b9a85ec59_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities:</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_d38b5370-70cc-4636-ba70-d714e97284f5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_079dcb39-c7ff-4dc2-ab87-1e5dae4856ca_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6ba9817f-438f-4514-b19b-13bf1c3abb27_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_cfc32087-e1b1-4597-93de-384d5179db74_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LeaseholdImprovementsAndConstructionInProgressMember_e6b13f6d-fdbd-4870-9340-f7dd8b53c6fc_terseLabel_en-US" xlink:label="lab_sgmo_LeaseholdImprovementsAndConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold Improvements and Construction in Progress</link:label>
    <link:label id="lab_sgmo_LeaseholdImprovementsAndConstructionInProgressMember_label_en-US" xlink:label="lab_sgmo_LeaseholdImprovementsAndConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements and Construction in Progress [Member]</link:label>
    <link:label id="lab_sgmo_LeaseholdImprovementsAndConstructionInProgressMember_documentation_en-US" xlink:label="lab_sgmo_LeaseholdImprovementsAndConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leasehold Improvements and Construction in Progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LeaseholdImprovementsAndConstructionInProgressMember" xlink:href="sgmo-20240930.xsd#sgmo_LeaseholdImprovementsAndConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LeaseholdImprovementsAndConstructionInProgressMember" xlink:to="lab_sgmo_LeaseholdImprovementsAndConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_f61f350f-785a-4fbc-a562-bcb8b61c3ccc_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7e118235-91c9-4f4f-ab55-aa61e977dfe1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_127f5238-ae91-49c0-866a-a41837a64df7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_23a19146-6a88-49f4-9ab9-293ee9ec1bef_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_0417776a-3792-442c-9fdf-3364d94a83ad_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letter of credit established as a deposit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_b27acc3d-cef8-4522-b886-c32e31d32882_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_3272e3ac-1fe1-404c-b731-99c324e09880_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_e6e1f2e3-9b5d-4016-ae80-6cea89c6cb93_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_ca911e83-a257-4a80-8c11-892601158650_terseLabel_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis Institutes For BioMedical Research Inc.</link:label>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_label_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Institutes For BioMedical Research Inc. [Member]</link:label>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_documentation_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Novartis Institutes For BioMedical Research Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:href="sgmo-20240930.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:to="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_ff4cbbcf-eca7-4888-b8a3-f836b140631a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Fair Value Measurements of Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_843c52f6-d96f-4e5e-86b9-99871a021c27_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_98c4e783-77af-4b5a-a06f-5a1b11a5ac8e_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive effect of share-based payment arrangements (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_GenentechRocheGroupMember_a928b387-f8e1-499a-8427-6abdefa5978a_terseLabel_en-US" xlink:label="lab_sgmo_GenentechRocheGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genentech, Inc.</link:label>
    <link:label id="lab_sgmo_GenentechRocheGroupMember_label_en-US" xlink:label="lab_sgmo_GenentechRocheGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genentech, Roche Group [Member]</link:label>
    <link:label id="lab_sgmo_GenentechRocheGroupMember_documentation_en-US" xlink:label="lab_sgmo_GenentechRocheGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Genentech, Roche Group</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GenentechRocheGroupMember" xlink:href="sgmo-20240930.xsd#sgmo_GenentechRocheGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_GenentechRocheGroupMember" xlink:to="lab_sgmo_GenentechRocheGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_815384b3-5100-484c-8dc4-1b11bedd1c8b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_372659c7-d694-4e4d-8ba9-7efd2b8af292_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_55f2d5a0-9c37-4c71-a505-6373bc290543_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_8a588404-7a9c-416c-a931-00e85a8b90c8_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper securities</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember_c97fbbba-5482-4fdc-baf2-1ec007b75b8d_terseLabel_en-US" xlink:label="lab_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease</link:label>
    <link:label id="lab_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember_label_en-US" xlink:label="lab_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease [Member]</link:label>
    <link:label id="lab_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember_documentation_en-US" xlink:label="lab_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember" xlink:href="sgmo-20240930.xsd#sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember" xlink:to="lab_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_eb95da0a-c963-4bda-829b-ec751ef94cba_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8c3bf9dd-07b5-4d69-84ac-695c7830cd56_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_22b174a1-2f1c-40c7-8617-e86865a90c8e_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_48c9fdc5-aa0c-4922-b3ae-82e0a951bbce_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_WarrantOrRightPolicyPolicyTextBlock_a48d7cb8-f3ea-4715-93cd-d3893c9a4ed5_terseLabel_en-US" xlink:label="lab_sgmo_WarrantOrRightPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to Purchase Shares of Company Stock</link:label>
    <link:label id="lab_sgmo_WarrantOrRightPolicyPolicyTextBlock_label_en-US" xlink:label="lab_sgmo_WarrantOrRightPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Or Right, Policy [Policy Text Block]</link:label>
    <link:label id="lab_sgmo_WarrantOrRightPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_sgmo_WarrantOrRightPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Or Right, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_WarrantOrRightPolicyPolicyTextBlock" xlink:href="sgmo-20240930.xsd#sgmo_WarrantOrRightPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_WarrantOrRightPolicyPolicyTextBlock" xlink:to="lab_sgmo_WarrantOrRightPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_f01f956e-01c1-402c-ad24-af1329480eef_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_FullTimeEmployeesMember_dac43214-3eda-48bb-83ad-b4125efcef63_terseLabel_en-US" xlink:label="lab_sgmo_FullTimeEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Full-Time Employees</link:label>
    <link:label id="lab_sgmo_FullTimeEmployeesMember_label_en-US" xlink:label="lab_sgmo_FullTimeEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Full-Time Employees [Member]</link:label>
    <link:label id="lab_sgmo_FullTimeEmployeesMember_documentation_en-US" xlink:label="lab_sgmo_FullTimeEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Full-Time Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FullTimeEmployeesMember" xlink:href="sgmo-20240930.xsd#sgmo_FullTimeEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_FullTimeEmployeesMember" xlink:to="lab_sgmo_FullTimeEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_aec45e33-a79f-4110-8684-b7aeb7a2226e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_d90489af-e32c-47b0-b193-b00c4c03e30c_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue related to agreements</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_cfb7b6c4-27f3-4dfe-8166-3952d9c41579_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone revenue receivable</link:label>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_label_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Revenue Receivable</link:label>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_documentation_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone&#8203; revenue receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable" xlink:href="sgmo-20240930.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneRevenueReceivable" xlink:to="lab_sgmo_MilestoneRevenueReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_25e7ccd9-22e4-419f-9f06-bcf33fae7481_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_bcf840a9-9ac5-402c-a2c2-27a6f761adc1_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_9ea58b67-e12f-4139-a101-99f1912a43cc_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OperatingLeaseRightOfUseAssetModificationReduction_b7367ae6-c5a8-4b34-85e4-811294aad33e_terseLabel_en-US" xlink:label="lab_sgmo_OperatingLeaseRightOfUseAssetModificationReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction to right of use asset from lease modification</link:label>
    <link:label id="lab_sgmo_OperatingLeaseRightOfUseAssetModificationReduction_label_en-US" xlink:label="lab_sgmo_OperatingLeaseRightOfUseAssetModificationReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Modification Reduction</link:label>
    <link:label id="lab_sgmo_OperatingLeaseRightOfUseAssetModificationReduction_documentation_en-US" xlink:label="lab_sgmo_OperatingLeaseRightOfUseAssetModificationReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Modification Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OperatingLeaseRightOfUseAssetModificationReduction" xlink:href="sgmo-20240930.xsd#sgmo_OperatingLeaseRightOfUseAssetModificationReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OperatingLeaseRightOfUseAssetModificationReduction" xlink:to="lab_sgmo_OperatingLeaseRightOfUseAssetModificationReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2c3e548d-a47e-4b5c-9e82-a3249412355c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_4ee56933-76c5-45f8-b50e-2ef8448b6055_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impaired Long-Lived Assets Held and Used [Line Items]</link:label>
    <link:label id="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_label_en-US" xlink:label="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impaired Long-Lived Assets Held and Used [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:to="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b3d6fb9-8047-4765-abcc-0349a1fc1fab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_477a21dd-b7e5-48a0-b715-e21be9be499b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_44ad0dca-ea5e-45af-9eec-0de5f31578fd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_a018aac9-4efd-4b42-9923-45e7ade5f778_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockAgentPlacementFees_d3425fd2-5adb-4709-8752-8cff6f72852b_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockAgentPlacementFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net of placement fees</link:label>
    <link:label id="lab_sgmo_SaleOfStockAgentPlacementFees_label_en-US" xlink:label="lab_sgmo_SaleOfStockAgentPlacementFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Agent Placement Fees</link:label>
    <link:label id="lab_sgmo_SaleOfStockAgentPlacementFees_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockAgentPlacementFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Agent Placement Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockAgentPlacementFees" xlink:href="sgmo-20240930.xsd#sgmo_SaleOfStockAgentPlacementFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockAgentPlacementFees" xlink:to="lab_sgmo_SaleOfStockAgentPlacementFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_5dfbccc4-d4e9-486f-94b3-12653b74d7dd_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic_0dde2642-dafb-48bf-baf8-4c8cdea2c150_negatedLabel_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Increased earnings per share, basic (in dollars per share)</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic_label_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Earnings Per Share, Basic</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic_documentation_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic" xlink:href="sgmo-20240930.xsd#sgmo_IncreaseDecreaseInEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic" xlink:to="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_2a5618a8-8bce-459b-bf5e-9ad087fbe60a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_a9759055-e161-4e8a-8306-1f8ac2889640_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockOutstandingAmountAvailable_8bb1ea3c-116e-46d0-927e-bac0b28ed0e1_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockOutstandingAmountAvailable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock agreement</link:label>
    <link:label id="lab_sgmo_SaleOfStockOutstandingAmountAvailable_label_en-US" xlink:label="lab_sgmo_SaleOfStockOutstandingAmountAvailable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Outstanding Amount Available</link:label>
    <link:label id="lab_sgmo_SaleOfStockOutstandingAmountAvailable_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockOutstandingAmountAvailable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Outstanding Amount Available</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockOutstandingAmountAvailable" xlink:href="sgmo-20240930.xsd#sgmo_SaleOfStockOutstandingAmountAvailable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockOutstandingAmountAvailable" xlink:to="lab_sgmo_SaleOfStockOutstandingAmountAvailable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e4db3d8b-b3c4-4542-aa53-84c8374a0c0e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_81f78814-7a16-46d6-84cb-6fa81f5e43bd_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_ba3f2482-efc7-4448-996d-df68833ae04c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_15bee091-2a4c-45f1-adbd-c80c3e07b993_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_d5e91104-76e5-4d77-afdc-d48061ce5bc9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_d36b4711-66c8-423b-8b08-8704c13b3d00_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_ecf6b9cb-cd2f-4f7e-8544-8e5a14d27d9e_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_904bdeb6-bc32-4b1e-b7f6-e68612312df2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_70eb1f42-df27-4922-a999-70592776eef0_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization in operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_a873ac44-32de-4668-b5b8-03a8e32240a2_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8341b0cc-e25d-412a-a8cf-ca92a0c16449_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_a54ede3d-e206-434d-877b-7619b8a13e82_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_663f29ba-6b24-48b9-9472-630ac0681a5a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_ac9e6c81-fc15-4397-afc8-53d9b7c865ef_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of positions eliminated in restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_4063fe3d-fdd9-46f0-aee3-cd89a26eccac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_c0ec57df-9e64-4191-9e4b-c36bfa2b6767_terseLabel_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock offering program, maximum value</link:label>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_label_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Offering Program, Maximum Value</link:label>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_documentation_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Offering Program, Maximum Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue" xlink:href="sgmo-20240930.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_StockOfferingProgramMaximumValue" xlink:to="lab_sgmo_StockOfferingProgramMaximumValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_7fe841a4-4ac6-4698-93e7-4a582a7673a7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_1c213e62-730d-4f46-a16f-fabfb2dc6140_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RESTRUCTURING CHARGES</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_068ce479-4ddb-4f85-8dbf-b303b665f4eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_befea986-11c4-459b-8b5b-873d583f18cb_terseLabel_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and sales-based milestone payments to be received</link:label>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_label_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Contract Liability Milestone Payment Eligible To Receive</link:label>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_documentation_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer contract liability milestone payment eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:href="sgmo-20240930.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:to="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d9ab197a-8b73-432e-a655-1c2db87e94b3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8bc62ac6-eedc-45ac-a8a4-fbacdf97c578_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_d1a69af7-8b27-413f-921c-f4b10d5d0a5a_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_19d3461b-d6ec-47fc-b1e4-93340f3de4bd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c205362a-f894-4ef4-baa7-ca088baf59e7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_dd554681-915c-4b5f-b48c-8b5b7c27c8c6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8f6cbbf-9baf-4fea-a79e-d81740379ddf_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f149ba27-5a38-4ead-9fca-dd053ac7193a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_e5c2e5d7-0527-48bf-86a4-6a0a6134a899_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net of offering expenses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_fedabc7d-be7e-48e4-b3b7-41b1ced216f5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_39d30b5f-8214-49fc-a4d4-a8d6d8500dce_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_e2305ea5-4893-4100-9474-56139d71aa10_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3aafe464-6bca-45cb-9e14-040ee5ac4a00_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_206eb525-d6df-4d8b-a995-e657fa7cb837_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment on right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_833e5a87-a257-44de-b329-4c1aeed08a7d_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_ced9d590-9a65-48a4-b680-7cfff37d0756_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BiogenMAIncMember_6402e6b5-ae9a-4b53-adbc-b96b69aaf32d_terseLabel_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen MA, Inc.</link:label>
    <link:label id="lab_sgmo_BiogenMAIncMember_label_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen MA, Inc. [Member]</link:label>
    <link:label id="lab_sgmo_BiogenMAIncMember_documentation_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen MA, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember" xlink:href="sgmo-20240930.xsd#sgmo_BiogenMAIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BiogenMAIncMember" xlink:to="lab_sgmo_BiogenMAIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bbd5ac9c-4767-4252-9156-1ade950063ba_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_a05e332b-1a51-4ce6-807a-58aa4b9b84ea_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_9397e75f-47ea-4edf-950e-8aee0fc61004_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues under agreement</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ca9395d6-ae2d-43e2-9f81-950813d7ecd6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_f5e6559c-4191-4118-b911-b89ec62af873_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_9356cedf-3146-446d-9dd1-1f54c16919fd_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_be06dd3f-8939-4510-85ae-699e3ed7dd1d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_4e79d91a-c787-4bb3-98b2-783219c53e0c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount_a42d2172-f182-4865-baac-08004b8c0d5b_terseLabel_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable consideration amount</link:label>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="sgmo-20240930.xsd#sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_3d941c02-062e-4c59-b2e1-cf6d7d9c6df2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6c6d3724-7e1d-43cb-b00d-9ede933f3b73_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ed8bc771-48d9-43c2-b250-33a6fac85e34_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds_a6251689-e677-4847-8088-b50a435017b4_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash placement fees</link:label>
    <link:label id="lab_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds_label_en-US" xlink:label="lab_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Placement Fee, Percentage Of Gross Proceeds</link:label>
    <link:label id="lab_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Placement Fee, Percentage Of Gross Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds" xlink:href="sgmo-20240930.xsd#sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds" xlink:to="lab_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_18b10dd1-1116-4972-a42a-2aecf4cdd8ed_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring costs incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_3d665067-91d5-410b-b7d7-73b8268fc581_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_31110f97-3883-4db7-9e21-038d5e1a152d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_1feec2b2-716a-4012-ac2f-f44508771d14_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_3b6fcc73-36df-478a-aada-24eb7bd714a9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_e7ad232a-d816-45f2-bda3-505ccdc18328_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Impaired Long-Lived Assets Held and Used [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impaired Long-Lived Asset, Held and Used [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:to="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_516c13e0-602c-47a1-8782-9679bbab4d60_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_5f979645-db95-4ed5-9cef-727f6ec7694d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BASIC AND DILUTED NET INCOME (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_dc8ec47d-b690-4e69-bef0-6b9ba0004887_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_113bdb7d-4575-4f7c-8571-7608e076b0ac_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_4f9c001b-4adc-4137-9d8c-62f6dd26094c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_f42b2758-2470-42a8-80fa-fd5f1c8838d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_0700f20a-7dae-4b74-a5be-6024c2561411_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_6651c741-7392-4393-9c20-919ee60036f9_terseLabel_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_label_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk [Member]</link:label>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_documentation_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:href="sgmo-20240930.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:to="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_6491b564-cf52-4086-896f-c5c99033a35f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome" xlink:to="lab_us-gaap_InterestAndOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_82b615e4-f3e9-42cc-a13f-a9c08ddfd575_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, discount rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_fedc6a07-e336-4b2b-9377-20b3907b7ab7_terseLabel_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">S B Five Two Five And Other Products</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_label_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">S B Five Two Five And Other Products [Member]</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_documentation_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">S B Five Two Five And Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:href="sgmo-20240930.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:to="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_dc985168-54d6-4e0b-b23e-3eb64c82ef41_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0c6427a7-6d58-4ad3-9961-cc71c6a6f3dd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_59ee3491-dab9-415f-9f2b-ba92741200d7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_KitePharmaIncMember_2eec57b7-696b-400c-b3be-a10de3d658ae_terseLabel_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kite Pharma Inc</link:label>
    <link:label id="lab_sgmo_KitePharmaIncMember_label_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kite Pharma Inc [Member]</link:label>
    <link:label id="lab_sgmo_KitePharmaIncMember_documentation_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kite Pharma Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember" xlink:href="sgmo-20240930.xsd#sgmo_KitePharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_KitePharmaIncMember" xlink:to="lab_sgmo_KitePharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination_357bb75e-5b39-4f85-811d-ff7be7a5acf3_terseLabel_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, required notice of termination</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination_label_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Required Notice Of Termination</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination_documentation_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Required Notice Of Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination" xlink:href="sgmo-20240930.xsd#sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination" xlink:to="lab_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c72d9ec2-13c5-4ada-82ca-6270429414f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_FranceRestructuringPlanMember_86972523-caf1-494d-a2a8-4d0733ee7039_terseLabel_en-US" xlink:label="lab_sgmo_FranceRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">France Restructuring Plan</link:label>
    <link:label id="lab_sgmo_FranceRestructuringPlanMember_label_en-US" xlink:label="lab_sgmo_FranceRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">France Restructuring Plan [Member]</link:label>
    <link:label id="lab_sgmo_FranceRestructuringPlanMember_documentation_en-US" xlink:label="lab_sgmo_FranceRestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">France Restructuring Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FranceRestructuringPlanMember" xlink:href="sgmo-20240930.xsd#sgmo_FranceRestructuringPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_FranceRestructuringPlanMember" xlink:to="lab_sgmo_FranceRestructuringPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_0d9aad50-9fd5-4d6c-b350-4b3962d6addc_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock offering program, increase to aggregate offering price</link:label>
    <link:label id="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_label_en-US" xlink:label="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Increase To Aggregate Offering Price</link:label>
    <link:label id="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Increase To Aggregate Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" xlink:href="sgmo-20240930.xsd#sgmo_SaleOfStockIncreaseToAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" xlink:to="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8c213461-279b-4ba0-b362-617ab18e9b83_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6470d1d8-a7d7-4fca-a054-4369b6505c76_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_2306c223-8fea-4088-9d49-2dcb3b901cac_terseLabel_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in revenue</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Revenue From Contract With Customer, Excluding Assessed Tax</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_documentation_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Revenue From Contract With Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="sgmo-20240930.xsd#sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_d1866858-597e-4c39-90d2-f12cd4a6e243_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_November2023RestructuringPlanMember_8c161dd0-da8b-4895-ae1c-1954d12fc1b4_terseLabel_en-US" xlink:label="lab_sgmo_November2023RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">November 2023 Restructuring Plan</link:label>
    <link:label id="lab_sgmo_November2023RestructuringPlanMember_label_en-US" xlink:label="lab_sgmo_November2023RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">November 2023 Restructuring Plan [Member]</link:label>
    <link:label id="lab_sgmo_November2023RestructuringPlanMember_documentation_en-US" xlink:label="lab_sgmo_November2023RestructuringPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">November 2023 Restructuring Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_November2023RestructuringPlanMember" xlink:href="sgmo-20240930.xsd#sgmo_November2023RestructuringPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_November2023RestructuringPlanMember" xlink:to="lab_sgmo_November2023RestructuringPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_787184bf-61af-4bd5-8270-2af733099faa_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value of equipment, furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_53d46fb0-497e-4cfc-8a1b-50f7656cb6fe_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LicenseTechnologyTransferMember_8df126e5-5c7c-4451-80cb-837f2f32e325_terseLabel_en-US" xlink:label="lab_sgmo_LicenseTechnologyTransferMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License, Technology Transfer</link:label>
    <link:label id="lab_sgmo_LicenseTechnologyTransferMember_label_en-US" xlink:label="lab_sgmo_LicenseTechnologyTransferMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Technology Transfer [Member]</link:label>
    <link:label id="lab_sgmo_LicenseTechnologyTransferMember_documentation_en-US" xlink:label="lab_sgmo_LicenseTechnologyTransferMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Technology Transfer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LicenseTechnologyTransferMember" xlink:href="sgmo-20240930.xsd#sgmo_LicenseTechnologyTransferMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LicenseTechnologyTransferMember" xlink:to="lab_sgmo_LicenseTechnologyTransferMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_72973eb4-3a70-4431-9e44-5bb1fdc4bb8a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_ade62b8e-d758-4ed2-ab0f-346b304d3226_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_0a014aa5-396c-422e-aa8d-bc7da6f6fc3a_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gain and losses on the sales of investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_716fd06a-dff6-42b0-ae32-39ac0277d521_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ce84510-1c08-4387-a0e1-9c673ed3afce_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_aecf51a3-4d27-4fff-9835-f9bf11f6040c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ed72800a-d16f-4394-bf07-d2d59f20df32_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4c817c91-ecb9-4e4b-9f59-1d2103d81d74_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_55b582c6-c7b0-4cce-a19e-434c3cbc29ba_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government-sponsored entity debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c27490d1-8ccb-4562-a64f-f3392755cd80_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_74bb3f83-a9b3-4515-be1f-393884746975_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e459d4c7-b9c4-4452-aecb-967a2a2101f9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_81cca235-51fe-4e40-9b88-7c5df312ec82_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock price (USD) (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_561d7502-c30f-46b2-b64a-8880080a7d73_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of offering expenses (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_45f3503a-0179-464d-9dac-35816030bba2_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1a0e0e45-3368-4fef-8e8e-a2d0207d9c3d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_0ebefd2d-2200-4343-a017-5e9bb7320613_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_398482a8-0fdd-4118-a36d-4a42d35b93a7_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_57e0f9c2-6489-441d-84eb-1119471c2f65_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ChangeInAgreementEstimateMarch2023Member_5c2086ce-e7a5-4864-9d13-be610623bab2_terseLabel_en-US" xlink:label="lab_sgmo_ChangeInAgreementEstimateMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change In Agreement Estimate, March 2023</link:label>
    <link:label id="lab_sgmo_ChangeInAgreementEstimateMarch2023Member_label_en-US" xlink:label="lab_sgmo_ChangeInAgreementEstimateMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Agreement Estimate, March 2023 [Member]</link:label>
    <link:label id="lab_sgmo_ChangeInAgreementEstimateMarch2023Member_documentation_en-US" xlink:label="lab_sgmo_ChangeInAgreementEstimateMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Agreement Estimate, March 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInAgreementEstimateMarch2023Member" xlink:href="sgmo-20240930.xsd#sgmo_ChangeInAgreementEstimateMarch2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ChangeInAgreementEstimateMarch2023Member" xlink:to="lab_sgmo_ChangeInAgreementEstimateMarch2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d1646c27-7bac-4829-bfa6-d8f16e511fe3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateLineItems_f870ccab-cfd6-4a32-9ec2-c10305522aff_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateLineItems_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_988a4b0d-7838-4bad-a1d5-d003e6f3e4de_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ab9947fd-578b-4588-8c8a-c45181ca3ffc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1826fee7-7b34-4020-b4f0-c03f77a27302_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_04937015-07bf-4a60-82db-2fcf589ac926_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_64e01822-872f-48bf-a0f8-93d184a2603e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_eea42be8-61ca-474a-b0c2-aafa1f1d26de_verboseLabel_en-US" xlink:label="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share:</link:label>
    <link:label id="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_label_en-US" xlink:label="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic And Diluted EPS [Abstract]</link:label>
    <link:label id="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_documentation_en-US" xlink:label="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic And Diluted EPS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:href="sgmo-20240930.xsd#sgmo_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:to="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_1a665fea-d1cd-42e0-851d-f1d63a00a84a_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_3d20afca-4e42-4de0-954b-63a19961e3a7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ChangeInAgreementEstimateSeptember2023Member_bf92395b-4c5a-4d0b-8454-62971390d71b_terseLabel_en-US" xlink:label="lab_sgmo_ChangeInAgreementEstimateSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change In Agreement Estimate, September 2023</link:label>
    <link:label id="lab_sgmo_ChangeInAgreementEstimateSeptember2023Member_label_en-US" xlink:label="lab_sgmo_ChangeInAgreementEstimateSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Agreement Estimate, September 2023 [Member]</link:label>
    <link:label id="lab_sgmo_ChangeInAgreementEstimateSeptember2023Member_documentation_en-US" xlink:label="lab_sgmo_ChangeInAgreementEstimateSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Agreement Estimate, September 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInAgreementEstimateSeptember2023Member" xlink:href="sgmo-20240930.xsd#sgmo_ChangeInAgreementEstimateSeptember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ChangeInAgreementEstimateSeptember2023Member" xlink:to="lab_sgmo_ChangeInAgreementEstimateSeptember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable_6143b07f-5c48-4def-b333-542143aefff3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Change in Accounting Estimate [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_c27e3765-66c6-461e-98d9-48d7a971428c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Held-to-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_af3956a0-5db9-47de-be11-ae06fcb15a1e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_e992a7c3-af80-493d-88c0-912da29f8c8e_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement Of Commercial Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement Of Commercial Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Achievement of Commercial Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember" xlink:href="sgmo-20240930.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfCommercialMilestonesMember" xlink:to="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_102405e1-6424-4666-9bdb-3b74a7e62354_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_16d248d1-a590-497a-bf5c-c7263b691c07_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_69e60231-0ad4-4379-a34b-477ec896cf84_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_2e0f0595-8fc5-4702-9cf1-47c53d627061_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_ce261caf-46e6-47de-8c01-05ba55fba575_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected cost remaining</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ContractedEmployeesMember_e2fa9955-6d60-441c-acbe-9c5b40b440f4_terseLabel_en-US" xlink:label="lab_sgmo_ContractedEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contracted Employees</link:label>
    <link:label id="lab_sgmo_ContractedEmployeesMember_label_en-US" xlink:label="lab_sgmo_ContractedEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contracted Employees [Member]</link:label>
    <link:label id="lab_sgmo_ContractedEmployeesMember_documentation_en-US" xlink:label="lab_sgmo_ContractedEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contracted Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractedEmployeesMember" xlink:href="sgmo-20240930.xsd#sgmo_ContractedEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ContractedEmployeesMember" xlink:to="lab_sgmo_ContractedEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerMember_6657e981-e98e-4e66-9f10-9a0bd1b82f8b_terseLabel_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer Inc.</link:label>
    <link:label id="lab_sgmo_PfizerMember_label_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_sgmo_PfizerMember_documentation_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember" xlink:href="sgmo-20240930.xsd#sgmo_PfizerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerMember" xlink:to="lab_sgmo_PfizerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_1aac1278-7d41-436b-829b-7ea72e506d52_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_8dd3a983-f90b-4e65-89bc-5a42d6a74656_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OtherLicensingAgreementsMember_4f3e1f4b-c0b8-47d6-8ccd-aaa033362188_terseLabel_en-US" xlink:label="lab_sgmo_OtherLicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other license agreements</link:label>
    <link:label id="lab_sgmo_OtherLicensingAgreementsMember_label_en-US" xlink:label="lab_sgmo_OtherLicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Licensing Agreements [Member]</link:label>
    <link:label id="lab_sgmo_OtherLicensingAgreementsMember_documentation_en-US" xlink:label="lab_sgmo_OtherLicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Licensing Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherLicensingAgreementsMember" xlink:href="sgmo-20240930.xsd#sgmo_OtherLicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OtherLicensingAgreementsMember" xlink:to="lab_sgmo_OtherLicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_0dff3a5f-8370-4a82-af89-6f600903ecd8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_7c2c2dd0-778b-4f19-acf1-4267aa20dbea_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c55f35a1-582f-46ba-b858-fbedde837fc6_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_e6ddccea-8218-419b-8509-0798a3803cde_negatedTerseLabel_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase in net income</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_label_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Net Income (Loss) Attributable To Parent</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_documentation_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Net Income (Loss) Attributable To Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" xlink:href="sgmo-20240930.xsd#sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" xlink:to="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_676d0cd8-5e0c-452a-86fe-723290640ea6_terseLabel_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">C9ORF72</link:label>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_label_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">C Nine O R F Seven Two [Member]</link:label>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_documentation_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">C nine ORF seven two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember" xlink:href="sgmo-20240930.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CNineORFSevenTwoMember" xlink:to="lab_sgmo_CNineORFSevenTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_6df5ffa0-924a-4d6a-afbc-f40543bc7046_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_87f221b3-6f4c-41a6-afa2-2ad521ddef1a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_2443b6bf-3768-4d3c-8322-f9d92243ca9d_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_53fa2066-3926-48c0-b2fe-6d42a908ab75_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_acec4117-70ba-4476-bd9b-78a9341cf0d3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_b9399396-7a32-4519-b3a7-a11ad91f7f09_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4b043e87-addc-430d-b571-3587c4984fbc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_cb056d69-bd46-465f-b432-6805d9f83b76_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fd7ed41d-13b7-4b35-8530-379b9d4a7ee7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_13053b8d-46eb-4cb3-97c8-68b820ecf06f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from contract with customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_13a57663-2e7c-4666-ae0d-94f5627e5e03_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of products approved</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_label_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration And License Agreements Number Of Products Approved Under Agreement</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_documentation_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration and license agreements number of products approved under agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:href="sgmo-20240930.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:to="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_7a19fe1e-40a0-4066-9a3c-3e52850edf63_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5a254fac-c309-4d8a-bf75-4c7e11cab19e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_b0a9b3cb-7ee5-47ef-87ee-259c13086707_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_50a47def-63e1-4810-b159-e7e00abd0ca3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH EQUIVALENTS AND MARKETABLE SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_aff3d6ae-f396-4b4e-bbd7-3a1542d4f588_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement of specified clinical development intellectual property and regulatory milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement Of Specified Clinical Development Intellectual Property And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Achievement of specified clinical development intellectual property and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:href="sgmo-20240930.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_538d8534-9c9d-4082-90b6-b02898c205d9_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_73968928-46ea-478c-a37f-3039a7da6426_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_a33caa05-9252-4dc9-bdbb-c991358bf86a_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RoyaltyObligationTerm_20ae8656-9572-4259-a0a9-07e4ffd9eac1_terseLabel_en-US" xlink:label="lab_sgmo_RoyaltyObligationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty obligation, term</link:label>
    <link:label id="lab_sgmo_RoyaltyObligationTerm_label_en-US" xlink:label="lab_sgmo_RoyaltyObligationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Obligation, Term</link:label>
    <link:label id="lab_sgmo_RoyaltyObligationTerm_documentation_en-US" xlink:label="lab_sgmo_RoyaltyObligationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Obligation, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RoyaltyObligationTerm" xlink:href="sgmo-20240930.xsd#sgmo_RoyaltyObligationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RoyaltyObligationTerm" xlink:to="lab_sgmo_RoyaltyObligationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_6821ccda-1201-454f-a09c-67df8b2f449c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3d337e6e-473b-4d53-8027-49bfb19c9ce9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_a5973bab-2fa4-48a6-99e7-00429c7475a4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_747e5609-2300-4dc6-9fd5-a9d99857b450_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_d79c7eed-2e2f-449a-98c8-93a02d29b0e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f460798-48fa-4762-9de3-d641f64ba9fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a9a3d40e-678e-4e8b-ad38-763671ac9d07_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_7c040f8e-bb6f-4fae-b5aa-db0cd1a10112_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_bece2217-38f7-442e-b8fe-8e04212f9c26_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_bae0da4f-8ac4-477b-a104-d60ea1b284e4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of offering expenses</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_b75b8ac1-96ea-40d5-a85e-4357f700d2d0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_4add3407-76b5-41be-adcc-b227269d036d_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_2ce35aeb-eeaf-498e-90d5-4a762418c67f_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3f4cad69-e6c8-4763-9bce-ffabcd8a96e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5bc8beaa-7545-4e25-b672-d46226c8db85_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_bf685f65-6a37-47fa-8107-984b58375c84_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_877d8413-8e0f-4f0e-b5ed-9157bee52f30_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ec76d195-5a59-4d69-881e-f5b6f9ac6005_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_68d6ced3-9e82-44a8-888d-d0f3749ff996_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5af70d84-c357-4e44-aa9f-3d564425cd41_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5df387d3-2f6b-4959-b6ed-e55aa71ddb4e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7dc42fdb-462b-44f7-9218-b5583737862b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4abae196-9fee-4a6f-b554-35ab28c302a4_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount_21a70987-7190-4410-a4e0-172971295c12_terseLabel_en-US" xlink:label="lab_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, required letter of credit outstanding, amount</link:label>
    <link:label id="lab_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount_label_en-US" xlink:label="lab_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Required Letter Of Credit Outstanding, Amount</link:label>
    <link:label id="lab_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount_documentation_en-US" xlink:label="lab_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Required Letter Of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount" xlink:href="sgmo-20240930.xsd#sgmo_LesseeRequiredLetterOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount" xlink:to="lab_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_36ef9df7-d3ff-44ae-8979-225a4918ccd1_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets, indefinite-lived</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_e5e4907b-330b-4a5a-aa01-d040c9153f60_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d32358a9-fb79-4b83-abda-d7b248859b56_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_4bd96b35-c7d6-43c9-8855-276995c01b2a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_9d4e8e21-f31c-4aa4-a64a-23accc8c09f1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3f9c15b7-a4d9-4900-9093-fe157f86538f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_9be0a7dc-2123-4b05-a070-e5248abee66b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_7f5c7117-5f6e-443c-a895-bd0a595dcb9d_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_709e9322-bac5-475c-94e2-acdd22593e7a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_0e58409e-21c9-440c-8757-ba8c085b0ff4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_14583de4-3823-4197-ae9d-4887b88ca9a1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from at-the-market offering, net of offering expenses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AgreementTerminationTerm_d95a6fc9-87cb-4bb5-960d-5e996057485d_terseLabel_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement termination, term</link:label>
    <link:label id="lab_sgmo_AgreementTerminationTerm_label_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement Termination, Term</link:label>
    <link:label id="lab_sgmo_AgreementTerminationTerm_documentation_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement Termination, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm" xlink:href="sgmo-20240930.xsd#sgmo_AgreementTerminationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AgreementTerminationTerm" xlink:to="lab_sgmo_AgreementTerminationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_846e494f-fc1f-43aa-bc70-ce7308a37d8a_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment included in unpaid liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2e990117-c97e-4c06-934c-2995d7f72478_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) available to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_679defd0-9d80-4125-b75b-e9dbc90836b6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5e63c357-405b-49b9-97eb-584a4447984d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0f806e2d-26d3-4e9c-860f-a6e44c86d7aa_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount_47e3402c-6289-4485-9412-92dfd2b39140_terseLabel_en-US" xlink:label="lab_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in deferred tax liabilities</link:label>
    <link:label id="lab_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount_label_en-US" xlink:label="lab_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Reduction In Deferred Tax Liabilities, Amount</link:label>
    <link:label id="lab_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount_documentation_en-US" xlink:label="lab_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Reduction In Deferred Tax Liabilities, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" xlink:href="sgmo-20240930.xsd#sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" xlink:to="lab_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_0ca26dc9-c16d-4d26-aef5-cc62e4cd9616_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2fb3cea6-b7a2-464c-8901-10778e105769_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent_7bcdf3c9-9b49-4d4f-a15e-fcd23ce4e1b0_terseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents and marketable securities, estimated fair value</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Available For Sale Securities, Current</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash equivalents and available for sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent" xlink:href="sgmo-20240930.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a76bde5b-e902-4a51-b8ca-a4fe29e4233d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c276b271-4637-4710-baac-b2f1f7f7c92d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_48b3fb76-13ca-48df-b0d2-e3c4dbe7b0b0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4e98161f-cf24-4971-8ae9-48cf1654bd1d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering price of each common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_48705a8b-ddc3-4704-b87c-16d1fd8d02db_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0c206d0d-08df-48eb-9dfe-0e414bbc00ac_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e421ffad-1896-4d70-8121-2ddc59b695c2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_ebfc4961-501b-4dad-a4b9-6a79573c27e3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_ce5391cf-96ca-4eee-ad5e-7463b90ee92a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b0cc4fd1-1154-408c-afa6-c2e1ea3268f5_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_9b260694-0a74-4691-a423-f392bf599452_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_06963496-8808-404d-90e7-f944f2835e58_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b685c0c8-6682-4d8c-95da-1e2722ad90a6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_72239d49-48c8-429c-8ef3-2451f0932da4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of pre-funded warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_ba9a5299-8a7f-496f-8b25-f6e300d22b6d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_0754c698-0c96-428d-9fb5-38992b96a37b_terseLabel_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments received</link:label>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_label_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments Received</link:label>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_documentation_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payments received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived" xlink:href="sgmo-20240930.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestonePaymentsReceived" xlink:to="lab_sgmo_MilestonePaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ad4b51ca-c1f3-4e06-ba55-ddf0a237c9c9_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_008c9d5b-9c5c-494e-bfdf-d578256d1417_terseLabel_en-US" xlink:label="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of net sales per developed licensed product which will trigger royalties by counterparty</link:label>
    <link:label id="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_label_en-US" xlink:label="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Eligible Royalties, Triggered By Percentage Of Net Sales Per Developed Licensed Product By Counterparty</link:label>
    <link:label id="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_documentation_en-US" xlink:label="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Eligible Royalties, Triggered By Percentage Of Net Sales Per Developed Licensed Product By Counterparty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" xlink:href="sgmo-20240930.xsd#sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" xlink:to="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_a4344a6f-2f1e-4e4f-919e-e2036704b321_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_d8578379-f355-4e76-b9f7-7ef6ff8236d4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_748ae8e1-9b4b-4c16-87fa-6f9fa3213219_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6286872f-388d-42d9-8a53-fc8f70dccf89_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_949495c1-93ab-4bcf-965a-1984e4a8f2c0_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_318a7128-c082-4f82-9b4f-dd035366c9f2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AtTheMarketOfferingProgramMember_285d0864-e76f-4918-9ec5-1e5b14cf4f8b_terseLabel_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-The-Market Offering Program</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingProgramMember_label_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering Program [Member]</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingProgramMember_documentation_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At the market offering agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingProgramMember" xlink:href="sgmo-20240930.xsd#sgmo_AtTheMarketOfferingProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AtTheMarketOfferingProgramMember" xlink:to="lab_sgmo_AtTheMarketOfferingProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d83829c6-3f0d-429c-906c-4c2818984bc5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_d6c46f40-b6c2-4c9c-bba0-5ff05ca6daa9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_d0adbe8f-2c06-4a6d-8982-1b3557abf7ef_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_18fdc352-edc2-407c-b1ad-2b7ad39bf4fa_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents and marketable securities</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_393c092c-84b8-4387-bcf7-3694ec949277_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_c2f25fc1-c86e-4307-990c-ce08fa264e72_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_15c39e95-13d0-4056-9017-20c1032af28e_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other non-cash adjustments</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_b6d23074-166d-426c-a9f1-bbfce0d487b9_terseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents and marketable securities, gross unrealized gains</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash equivalents and available for sale securities, gross unrealized gain, before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:href="sgmo-20240930.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_511cb436-f0d9-4a9e-942c-1716b1705878_negatedLabel_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Increased earnings per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_label_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Earnings Per Share, Diluted</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_documentation_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted" xlink:href="sgmo-20240930.xsd#sgmo_IncreaseDecreaseInEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted" xlink:to="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_52a982e1-c196-43b1-8db1-b3bc100f71f8_terseLabel_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">S B Five Two Five</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_label_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">S B Five Two Five [Member]</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_documentation_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">S B Five Two Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveMember" xlink:href="sgmo-20240930.xsd#sgmo_SBFiveTwoFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SBFiveTwoFiveMember" xlink:to="lab_sgmo_SBFiveTwoFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_55b2f2cf-424c-430e-9b8d-3cb84955ca29_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fece13bb-f7d8-448c-9c70-417f598305fd_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_2c20d6cf-a7c6-45e0-891e-bc800eb3b401_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b295b806-7018-4af9-9cc7-cd18ce1d6203_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_8110d8d1-7276-4341-92dc-1bb30c1b3e9c_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_4f4132c4-bf60-4450-b8ce-79df12e34d25_terseLabel_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues</link:label>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_label_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues [Table Text Block]</link:label>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_documentation_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:href="sgmo-20240930.xsd#sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:to="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_01cf303f-2781-40a1-8fb4-549cd2fa8b47_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net pension (loss) gain</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d405a227-a386-4ff6-84e3-11c694cfab28_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_beecf51f-fa57-4bc4-a9b7-561d177ee71e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_bcdf68fb-cb7f-46b2-929f-df8933722d38_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_d00ad41b-4161-4b8c-83e0-bb67719dc4aa_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLeasehold_b403eec6-d787-4b68-9731-0b64f2834a58_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLeasehold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of leasehold improvements</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLeasehold_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLeasehold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Leasehold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLeasehold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLeasehold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLeasehold" xlink:to="lab_us-gaap_ImpairmentOfLeasehold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2ca2efcd-551e-40a0-9e02-b3cdc6289bb1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ebde7530-59ba-41e3-a7c6-3c97255af0ab_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_24a58cfd-ecd1-4fd3-8919-7a3e5fd148bc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of assets classified as held for sale</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_8dea8815-9799-433d-b42d-9b16bef91b92_terseLabel_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents accumulated gross unrealized gain before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="sgmo-20240930.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_47c4231d-2aa2-4d85-9a70-c7bbeb2f64c2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_96704ee9-1abc-4340-ad25-b59e7b92daec_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_7d703967-69e4-4ced-b8ed-0be4c0ee4b2c_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in Progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_fd045ff6-d529-402d-9bb1-be06c49cd82b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_83ecacc1-8cfa-49a8-8de5-eea267a1abde_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at December 31, 2023</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_f8cdb08b-6066-4a04-b4bc-801cac6e0f7a_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at September 30, 2024</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_757d1ae3-c034-4f2f-b09e-9bd5ce6ae65a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining performance obligation amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_10b16366-07ff-459f-bf29-3d4f220ccf8a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_b63e13e9-2089-413e-9ab0-3c2c3d03e241_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Direct offering</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>sgmo-20240930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:71d79187-a2e4-4f72-bd61-283a5977d997,g:6e5f68a8-3875-4e0a-8723-d2906a1af0a5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/Cover" xlink:type="simple" xlink:href="sgmo-20240930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5b85630b-9d76-41b0-ba88-b04a67a59012" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_DocumentType_5b85630b-9d76-41b0-ba88-b04a67a59012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_f000c1ff-7ef2-457f-88e1-917d20cdf77a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_DocumentQuarterlyReport_f000c1ff-7ef2-457f-88e1-917d20cdf77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_fdc49632-21aa-4b9c-8282-01ada9706fb8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_DocumentPeriodEndDate_fdc49632-21aa-4b9c-8282-01ada9706fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f12c1374-be46-4de6-a2fb-e9b772b47326" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_DocumentTransitionReport_f12c1374-be46-4de6-a2fb-e9b772b47326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7ae035f5-c582-4095-a39a-935937e7535a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_EntityFileNumber_7ae035f5-c582-4095-a39a-935937e7535a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a0336b6b-fb78-4a9a-aab7-85c771727296" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_EntityRegistrantName_a0336b6b-fb78-4a9a-aab7-85c771727296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4847d4bb-db3c-427a-978b-1410b3576270" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4847d4bb-db3c-427a-978b-1410b3576270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a3ed3878-51eb-48e9-a02a-2e2e3bd019ca" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_EntityTaxIdentificationNumber_a3ed3878-51eb-48e9-a02a-2e2e3bd019ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_334dafa5-d638-4680-9b0a-35f2a05e1def" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_EntityAddressAddressLine1_334dafa5-d638-4680-9b0a-35f2a05e1def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b73f9e41-dc48-4fa1-a5cc-a6808895d373" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_EntityAddressCityOrTown_b73f9e41-dc48-4fa1-a5cc-a6808895d373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_df445203-61b5-4833-8d84-32ed3245df9e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_EntityAddressStateOrProvince_df445203-61b5-4833-8d84-32ed3245df9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c3258001-a19b-483a-bab0-efb7a933d3c8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_EntityAddressPostalZipCode_c3258001-a19b-483a-bab0-efb7a933d3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_07d6c1b0-3fdd-4df7-b684-3347fa38a1b0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_CityAreaCode_07d6c1b0-3fdd-4df7-b684-3347fa38a1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6d65d4d1-c372-46fe-903c-b53a19f4ae81" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_LocalPhoneNumber_6d65d4d1-c372-46fe-903c-b53a19f4ae81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5e6ac50f-ed0f-47ea-901f-119b86f17ec4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_Security12bTitle_5e6ac50f-ed0f-47ea-901f-119b86f17ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9b82dbea-c301-4b52-8977-fff83466cfb7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_TradingSymbol_9b82dbea-c301-4b52-8977-fff83466cfb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f347b476-4678-4097-84e9-8e78b4ee707f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_SecurityExchangeName_f347b476-4678-4097-84e9-8e78b4ee707f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_70b0f75b-f4b7-4dbb-8886-948fcd7eacac" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_EntityCurrentReportingStatus_70b0f75b-f4b7-4dbb-8886-948fcd7eacac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_12ad53bf-15f3-4b8b-9c07-3e5c6ce5ffe8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_EntityInteractiveDataCurrent_12ad53bf-15f3-4b8b-9c07-3e5c6ce5ffe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1081329c-1127-4c45-a454-dfb827d269a1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_EntityFilerCategory_1081329c-1127-4c45-a454-dfb827d269a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_25911ed3-9f64-4148-a953-c6881b5588e2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_EntitySmallBusiness_25911ed3-9f64-4148-a953-c6881b5588e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3b314dab-8586-4705-98c6-373d3f232085" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_EntityEmergingGrowthCompany_3b314dab-8586-4705-98c6-373d3f232085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ab03cd81-b997-4484-a45d-4140667b3b56" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_EntityShellCompany_ab03cd81-b997-4484-a45d-4140667b3b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fa8654ba-2609-4060-8f0d-a9a570b91a5d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fa8654ba-2609-4060-8f0d-a9a570b91a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_262ffc80-3479-4d37-aa70-1207d5a35607" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_AmendmentFlag_262ffc80-3479-4d37-aa70-1207d5a35607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_daa9525c-db97-4e3e-a2bd-dad885a809f1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_DocumentFiscalYearFocus_daa9525c-db97-4e3e-a2bd-dad885a809f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1eb9d0d5-527b-4c5c-a309-6ada6c19b0f5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1eb9d0d5-527b-4c5c-a309-6ada6c19b0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c8f1ad5d-63cf-4bef-be6b-bdeb4c5ca2d0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_EntityCentralIndexKey_c8f1ad5d-63cf-4bef-be6b-bdeb4c5ca2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f2779d9e-2647-4bcc-b0a6-3c8a9ced4ff7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_55113f38-9718-49e3-92e1-082f6b1f3abb" xlink:to="loc_dei_CurrentFiscalYearEndDate_f2779d9e-2647-4bcc-b0a6-3c8a9ced4ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sgmo-20240930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b48da39e-b8ea-4310-b5ed-4ae67248812e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_51194a3c-b176-4ab2-b64b-b26ba621ec2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b48da39e-b8ea-4310-b5ed-4ae67248812e" xlink:to="loc_us-gaap_AssetsAbstract_51194a3c-b176-4ab2-b64b-b26ba621ec2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7f317df3-d337-4f11-873a-cad8a957d1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_51194a3c-b176-4ab2-b64b-b26ba621ec2d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7f317df3-d337-4f11-873a-cad8a957d1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1eac92cc-d1ba-4084-973d-7e4be40fb812" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f317df3-d337-4f11-873a-cad8a957d1d3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1eac92cc-d1ba-4084-973d-7e4be40fb812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_8f6bc5ce-78a3-4835-8bce-6794a4a0aa95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f317df3-d337-4f11-873a-cad8a957d1d3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_8f6bc5ce-78a3-4835-8bce-6794a4a0aa95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_73ef72f3-2bae-441e-94ae-9c41f4ad02de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f317df3-d337-4f11-873a-cad8a957d1d3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_73ef72f3-2bae-441e-94ae-9c41f4ad02de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_90bd1d0e-5c1f-4031-a37d-c976e79ad38f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f317df3-d337-4f11-873a-cad8a957d1d3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_90bd1d0e-5c1f-4031-a37d-c976e79ad38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_dda77bb2-780c-4ad2-99b1-594b9b18e627" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f317df3-d337-4f11-873a-cad8a957d1d3" xlink:to="loc_us-gaap_AssetsCurrent_dda77bb2-780c-4ad2-99b1-594b9b18e627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5652fff0-6b9e-4624-a34c-e3ae17b43c94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_51194a3c-b176-4ab2-b64b-b26ba621ec2d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5652fff0-6b9e-4624-a34c-e3ae17b43c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_da5130a1-2edf-4d6a-a3f7-bf95c4e99101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_51194a3c-b176-4ab2-b64b-b26ba621ec2d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_da5130a1-2edf-4d6a-a3f7-bf95c4e99101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets_b4ea6b28-b494-4c60-bf9e-90a199a9cc76" xlink:href="sgmo-20240930.xsd#sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_51194a3c-b176-4ab2-b64b-b26ba621ec2d" xlink:to="loc_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets_b4ea6b28-b494-4c60-bf9e-90a199a9cc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_1029bd68-ea70-40f4-bdef-447944d5bae8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_51194a3c-b176-4ab2-b64b-b26ba621ec2d" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_1029bd68-ea70-40f4-bdef-447944d5bae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b6304b78-79c2-4406-83ec-e914955e7be7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_51194a3c-b176-4ab2-b64b-b26ba621ec2d" xlink:to="loc_us-gaap_Assets_b6304b78-79c2-4406-83ec-e914955e7be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4b33a74e-df4d-4b1e-b585-f8ac8a15174f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b48da39e-b8ea-4310-b5ed-4ae67248812e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4b33a74e-df4d-4b1e-b585-f8ac8a15174f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_39bc4bf6-8960-47e6-a2fa-6436710dde7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4b33a74e-df4d-4b1e-b585-f8ac8a15174f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_39bc4bf6-8960-47e6-a2fa-6436710dde7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_95da5c22-91c0-47df-a8ce-0af00e138fae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39bc4bf6-8960-47e6-a2fa-6436710dde7b" xlink:to="loc_us-gaap_AccountsPayableCurrent_95da5c22-91c0-47df-a8ce-0af00e138fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_cecaf562-37b0-491b-b03f-e4ed02f639e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39bc4bf6-8960-47e6-a2fa-6436710dde7b" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_cecaf562-37b0-491b-b03f-e4ed02f639e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_07e90f4e-b861-4ea6-8b77-b3b98f244aba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39bc4bf6-8960-47e6-a2fa-6436710dde7b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_07e90f4e-b861-4ea6-8b77-b3b98f244aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_80202122-8b6d-4b78-ac7a-e1d56d24a5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39bc4bf6-8960-47e6-a2fa-6436710dde7b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_80202122-8b6d-4b78-ac7a-e1d56d24a5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1d22a2fe-11df-4333-be91-a0e9d660347e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39bc4bf6-8960-47e6-a2fa-6436710dde7b" xlink:to="loc_us-gaap_LiabilitiesCurrent_1d22a2fe-11df-4333-be91-a0e9d660347e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2ebf90bb-d24a-42d2-9c30-5d5b737dabec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4b33a74e-df4d-4b1e-b585-f8ac8a15174f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2ebf90bb-d24a-42d2-9c30-5d5b737dabec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bc174d3a-4035-45d6-a720-fe55e6d529ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4b33a74e-df4d-4b1e-b585-f8ac8a15174f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bc174d3a-4035-45d6-a720-fe55e6d529ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a1bb68ce-80d6-4645-a0ac-184a106c8558" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4b33a74e-df4d-4b1e-b585-f8ac8a15174f" xlink:to="loc_us-gaap_Liabilities_a1bb68ce-80d6-4645-a0ac-184a106c8558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3275a0f2-af2c-4b3b-8d2f-f945ad45d796" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4b33a74e-df4d-4b1e-b585-f8ac8a15174f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3275a0f2-af2c-4b3b-8d2f-f945ad45d796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_86ad3a2c-3914-4ebc-a00d-882b48c10408" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4b33a74e-df4d-4b1e-b585-f8ac8a15174f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_86ad3a2c-3914-4ebc-a00d-882b48c10408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_cf0400f2-4904-4c58-8006-63c13101d9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_86ad3a2c-3914-4ebc-a00d-882b48c10408" xlink:to="loc_us-gaap_PreferredStockValue_cf0400f2-4904-4c58-8006-63c13101d9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_10e937be-95dc-4c03-8377-9e54af0262f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_86ad3a2c-3914-4ebc-a00d-882b48c10408" xlink:to="loc_us-gaap_CommonStockValue_10e937be-95dc-4c03-8377-9e54af0262f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_008dbe8e-5785-4084-b73a-1ad1d46bba9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_86ad3a2c-3914-4ebc-a00d-882b48c10408" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_008dbe8e-5785-4084-b73a-1ad1d46bba9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ab5e3961-513f-44f6-84f7-0f3cb9017320" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_86ad3a2c-3914-4ebc-a00d-882b48c10408" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ab5e3961-513f-44f6-84f7-0f3cb9017320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_db199797-bd1d-43b5-b395-f0efee957a57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_86ad3a2c-3914-4ebc-a00d-882b48c10408" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_db199797-bd1d-43b5-b395-f0efee957a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c55774f8-b191-4df5-9e93-f0ff6fd10fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_86ad3a2c-3914-4ebc-a00d-882b48c10408" xlink:to="loc_us-gaap_StockholdersEquity_c55774f8-b191-4df5-9e93-f0ff6fd10fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_24a711a3-1260-469d-9b7b-c024a42c6661" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4b33a74e-df4d-4b1e-b585-f8ac8a15174f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_24a711a3-1260-469d-9b7b-c024a42c6661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sgmo-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a8202b8e-4f8e-4669-bab7-7a22907f1ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_b4c4ab92-7fa3-4743-8458-783f0b5b8317" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a8202b8e-4f8e-4669-bab7-7a22907f1ca0" xlink:to="loc_us-gaap_RevenuesAbstract_b4c4ab92-7fa3-4743-8458-783f0b5b8317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_047f31a5-341a-4104-8fb3-136da966e3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_b4c4ab92-7fa3-4743-8458-783f0b5b8317" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_047f31a5-341a-4104-8fb3-136da966e3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_97f9ba86-9a55-418e-8e3d-6e98bc1c31f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a8202b8e-4f8e-4669-bab7-7a22907f1ca0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_97f9ba86-9a55-418e-8e3d-6e98bc1c31f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9a5bb2d2-64fd-4ddb-8899-42df4f7ef12d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97f9ba86-9a55-418e-8e3d-6e98bc1c31f2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9a5bb2d2-64fd-4ddb-8899-42df4f7ef12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_02ce402a-d06a-4e81-8403-336968589532" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97f9ba86-9a55-418e-8e3d-6e98bc1c31f2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_02ce402a-d06a-4e81-8403-336968589532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_dc1800f8-1c86-42db-a3a1-4706ca3b43ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97f9ba86-9a55-418e-8e3d-6e98bc1c31f2" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_dc1800f8-1c86-42db-a3a1-4706ca3b43ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_582a367e-bc18-4a13-a1bd-cf4e3f387754" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97f9ba86-9a55-418e-8e3d-6e98bc1c31f2" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_582a367e-bc18-4a13-a1bd-cf4e3f387754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_efbc0dce-d050-431e-bc6f-f30765e74aae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97f9ba86-9a55-418e-8e3d-6e98bc1c31f2" xlink:to="loc_us-gaap_OperatingExpenses_efbc0dce-d050-431e-bc6f-f30765e74aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f854369b-a088-41bb-aa35-581b60612638" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a8202b8e-4f8e-4669-bab7-7a22907f1ca0" xlink:to="loc_us-gaap_OperatingIncomeLoss_f854369b-a088-41bb-aa35-581b60612638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_14bf591d-fc81-4c0d-b6df-8958e2681b11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a8202b8e-4f8e-4669-bab7-7a22907f1ca0" xlink:to="loc_us-gaap_InterestAndOtherIncome_14bf591d-fc81-4c0d-b6df-8958e2681b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fa5df650-2cdd-4d57-9667-64bd312b0ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a8202b8e-4f8e-4669-bab7-7a22907f1ca0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fa5df650-2cdd-4d57-9667-64bd312b0ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7baed167-2007-4b0e-99b6-63bc2e8f089f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a8202b8e-4f8e-4669-bab7-7a22907f1ca0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7baed167-2007-4b0e-99b6-63bc2e8f089f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ebdce5a8-86eb-496c-8d2d-b82a7a3a878a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a8202b8e-4f8e-4669-bab7-7a22907f1ca0" xlink:to="loc_us-gaap_NetIncomeLoss_ebdce5a8-86eb-496c-8d2d-b82a7a3a878a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_0e5e0bad-62ef-4748-8d92-2147f4b955e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a8202b8e-4f8e-4669-bab7-7a22907f1ca0" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_0e5e0bad-62ef-4748-8d92-2147f4b955e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f7f31fb3-33ad-4e4f-b0e9-20a602030835" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a8202b8e-4f8e-4669-bab7-7a22907f1ca0" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f7f31fb3-33ad-4e4f-b0e9-20a602030835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2f9c6b8d-e18a-4166-8529-9213f506351d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a8202b8e-4f8e-4669-bab7-7a22907f1ca0" xlink:to="loc_us-gaap_EarningsPerShareAbstract_2f9c6b8d-e18a-4166-8529-9213f506351d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_28cc3c1d-3b66-4036-80a2-df877265622a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2f9c6b8d-e18a-4166-8529-9213f506351d" xlink:to="loc_us-gaap_EarningsPerShareBasic_28cc3c1d-3b66-4036-80a2-df877265622a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_23c72dd2-23ac-458a-adb4-d6983d39ef64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2f9c6b8d-e18a-4166-8529-9213f506351d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_23c72dd2-23ac-458a-adb4-d6983d39ef64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_10bf5ccd-b495-4e52-be6e-72e7f45fb797" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a8202b8e-4f8e-4669-bab7-7a22907f1ca0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_10bf5ccd-b495-4e52-be6e-72e7f45fb797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b5649665-20bf-44ca-a5cb-9bc7b28e35a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_10bf5ccd-b495-4e52-be6e-72e7f45fb797" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b5649665-20bf-44ca-a5cb-9bc7b28e35a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bb729064-cf54-4cc7-b66f-b274e31271c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_10bf5ccd-b495-4e52-be6e-72e7f45fb797" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bb729064-cf54-4cc7-b66f-b274e31271c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="sgmo-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4f73ff58-1910-4852-a34b-f5e881480a26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0feea1af-1645-4ae6-8cd5-9221f5a64e69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4f73ff58-1910-4852-a34b-f5e881480a26" xlink:to="loc_us-gaap_NetIncomeLoss_0feea1af-1645-4ae6-8cd5-9221f5a64e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d01d6803-ad39-4af0-b7fe-74f68ed7cbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4f73ff58-1910-4852-a34b-f5e881480a26" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d01d6803-ad39-4af0-b7fe-74f68ed7cbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_a7152be1-b79a-4a6d-80ec-92a51208e89f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4f73ff58-1910-4852-a34b-f5e881480a26" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_a7152be1-b79a-4a6d-80ec-92a51208e89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_eb38f1fc-997c-4f69-ad0d-994ad93d4f13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4f73ff58-1910-4852-a34b-f5e881480a26" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_eb38f1fc-997c-4f69-ad0d-994ad93d4f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_438316cd-4949-47ac-b5b7-12df80bcf77e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4f73ff58-1910-4852-a34b-f5e881480a26" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_438316cd-4949-47ac-b5b7-12df80bcf77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_b65bfc97-fd60-4e59-89eb-71232391fdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8258735e-8cf8-405f-9cfb-5dba0c10da25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_b65bfc97-fd60-4e59-89eb-71232391fdcd" xlink:to="loc_us-gaap_StatementTable_8258735e-8cf8-405f-9cfb-5dba0c10da25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c5776b97-c53b-4077-8d5f-2ef95ea11cab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8258735e-8cf8-405f-9cfb-5dba0c10da25" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c5776b97-c53b-4077-8d5f-2ef95ea11cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f8d6254e-b3da-4708-a4e8-0d10f59fa625" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c5776b97-c53b-4077-8d5f-2ef95ea11cab" xlink:to="loc_us-gaap_EquityComponentDomain_f8d6254e-b3da-4708-a4e8-0d10f59fa625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_361ccef7-9ed2-4739-9f0c-51e852c7bc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f8d6254e-b3da-4708-a4e8-0d10f59fa625" xlink:to="loc_us-gaap_CommonStockMember_361ccef7-9ed2-4739-9f0c-51e852c7bc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d7e4634e-07e6-45ea-ac6d-7284c5102b79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f8d6254e-b3da-4708-a4e8-0d10f59fa625" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d7e4634e-07e6-45ea-ac6d-7284c5102b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5853596c-e12a-468b-a80f-5287258e3629" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f8d6254e-b3da-4708-a4e8-0d10f59fa625" xlink:to="loc_us-gaap_RetainedEarningsMember_5853596c-e12a-468b-a80f-5287258e3629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e5197797-1547-43b7-a3ea-b29ff0c72e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f8d6254e-b3da-4708-a4e8-0d10f59fa625" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e5197797-1547-43b7-a3ea-b29ff0c72e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_03dfc61f-4bc6-438c-af82-89694a8b0d81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8258735e-8cf8-405f-9cfb-5dba0c10da25" xlink:to="loc_us-gaap_StatementLineItems_03dfc61f-4bc6-438c-af82-89694a8b0d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_03dfc61f-4bc6-438c-af82-89694a8b0d81" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c6e7160a-b8c4-41f7-b857-d03590e6199c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c6e7160a-b8c4-41f7-b857-d03590e6199c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cc8c4677-93de-4c32-b9c5-077222f9a98f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_StockholdersEquity_cc8c4677-93de-4c32-b9c5-077222f9a98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_06acb5e0-aa22-4dfe-a0e9-3037c9036ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_06acb5e0-aa22-4dfe-a0e9-3037c9036ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_779a676d-a25f-4794-bd16-cbd26e8bd974" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_779a676d-a25f-4794-bd16-cbd26e8bd974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ce855ed8-4273-4c94-9ee2-ef2c3e365d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ce855ed8-4273-4c94-9ee2-ef2c3e365d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_15520e40-60c8-4af9-9a22-d733dcbd09f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_15520e40-60c8-4af9-9a22-d733dcbd09f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_cb80cafa-0819-42c3-abcb-6317aa7b0ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_cb80cafa-0819-42c3-abcb-6317aa7b0ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f92b1327-a9b2-4f85-beb2-30749cc9988b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f92b1327-a9b2-4f85-beb2-30749cc9988b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_cc439a27-d9fb-429c-a460-143391916884" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_cc439a27-d9fb-429c-a460-143391916884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_05079d46-d381-4b67-840e-601fc5e3aad6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_05079d46-d381-4b67-840e-601fc5e3aad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_15091c2c-0d58-4712-b5e7-0122de36f0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_15091c2c-0d58-4712-b5e7-0122de36f0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_02832013-7286-4a99-9fbb-0f04b8829392" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_02832013-7286-4a99-9fbb-0f04b8829392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_f510cd94-9d9e-44ea-949d-c41518378b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_f510cd94-9d9e-44ea-949d-c41518378b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_80edc9cb-ae1e-4144-84df-ac32cc7e8855" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_80edc9cb-ae1e-4144-84df-ac32cc7e8855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6079c25f-c31b-4aab-9854-ca20bbf91a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_NetIncomeLoss_6079c25f-c31b-4aab-9854-ca20bbf91a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e59a7bf4-7ebc-430e-b697-f46b83cac825" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e59a7bf4-7ebc-430e-b697-f46b83cac825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1a5ac14d-d17d-423b-84c7-4181924d8cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_01bc0357-4b1f-4ff5-bd42-dbc30dad1fef" xlink:to="loc_us-gaap_StockholdersEquity_1a5ac14d-d17d-423b-84c7-4181924d8cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgmo-20240930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0da5518b-ff13-4b1e-8bf9-8cef566b8780" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e5c8017a-6e9f-4693-b348-cd19f4e1e8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0da5518b-ff13-4b1e-8bf9-8cef566b8780" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e5c8017a-6e9f-4693-b348-cd19f4e1e8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_59685235-98aa-46f4-9f88-e12f90dd6954" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e5c8017a-6e9f-4693-b348-cd19f4e1e8c1" xlink:to="loc_us-gaap_NetIncomeLoss_59685235-98aa-46f4-9f88-e12f90dd6954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_161ec248-c190-4a65-953b-0e02aa2de68a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e5c8017a-6e9f-4693-b348-cd19f4e1e8c1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_161ec248-c190-4a65-953b-0e02aa2de68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_67014e66-cdb8-4a5a-aaf8-4ad5f0a27ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_161ec248-c190-4a65-953b-0e02aa2de68a" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_67014e66-cdb8-4a5a-aaf8-4ad5f0a27ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_bcde6cde-4935-4419-8396-a81c57248728" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_161ec248-c190-4a65-953b-0e02aa2de68a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_bcde6cde-4935-4419-8396-a81c57248728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c50b266f-3032-43a0-860e-929cf52a26e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_161ec248-c190-4a65-953b-0e02aa2de68a" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c50b266f-3032-43a0-860e-929cf52a26e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0f120b5c-a5b3-4329-a9db-d6c0eda3319f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_161ec248-c190-4a65-953b-0e02aa2de68a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0f120b5c-a5b3-4329-a9db-d6c0eda3319f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_541cd5a7-8598-450e-93fa-811756956cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_161ec248-c190-4a65-953b-0e02aa2de68a" xlink:to="loc_us-gaap_ShareBasedCompensation_541cd5a7-8598-450e-93fa-811756956cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_f6f9dcfd-0412-41bf-94d4-e69dbc0ddc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_161ec248-c190-4a65-953b-0e02aa2de68a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_f6f9dcfd-0412-41bf-94d4-e69dbc0ddc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_f09f08ac-2c2a-4482-b66b-a682ddf82a59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_161ec248-c190-4a65-953b-0e02aa2de68a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_f09f08ac-2c2a-4482-b66b-a682ddf82a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_481c728a-856a-4118-8ecc-85d56088b811" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_161ec248-c190-4a65-953b-0e02aa2de68a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_481c728a-856a-4118-8ecc-85d56088b811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_23e9aa08-fb53-4f2d-b3a7-9ef7580b75a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e5c8017a-6e9f-4693-b348-cd19f4e1e8c1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_23e9aa08-fb53-4f2d-b3a7-9ef7580b75a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_21b8c840-2310-4fc3-899d-89ce1c7026fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_23e9aa08-fb53-4f2d-b3a7-9ef7580b75a5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_21b8c840-2310-4fc3-899d-89ce1c7026fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b46659b7-ca79-433c-a8aa-3c30bfe7b379" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_23e9aa08-fb53-4f2d-b3a7-9ef7580b75a5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b46659b7-ca79-433c-a8aa-3c30bfe7b379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8a0ac4fe-baf6-44c8-b4a1-0760af5b8f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_23e9aa08-fb53-4f2d-b3a7-9ef7580b75a5" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8a0ac4fe-baf6-44c8-b4a1-0760af5b8f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_dea54a4d-2b6d-465f-a874-6c59c211ecd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_23e9aa08-fb53-4f2d-b3a7-9ef7580b75a5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_dea54a4d-2b6d-465f-a874-6c59c211ecd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_9238dda5-eac7-436b-800c-cd355870bf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_23e9aa08-fb53-4f2d-b3a7-9ef7580b75a5" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_9238dda5-eac7-436b-800c-cd355870bf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_d79d736f-92b8-4ab1-bf0a-7ba46547c0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_23e9aa08-fb53-4f2d-b3a7-9ef7580b75a5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_d79d736f-92b8-4ab1-bf0a-7ba46547c0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_e9adaadf-7ac5-44c5-b017-5ad7c58a0c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_23e9aa08-fb53-4f2d-b3a7-9ef7580b75a5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_e9adaadf-7ac5-44c5-b017-5ad7c58a0c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a8c59e8c-2881-467c-8a15-deb7b507f9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_23e9aa08-fb53-4f2d-b3a7-9ef7580b75a5" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a8c59e8c-2881-467c-8a15-deb7b507f9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_50d3fc66-a881-4e48-bbf6-67610121b5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e5c8017a-6e9f-4693-b348-cd19f4e1e8c1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_50d3fc66-a881-4e48-bbf6-67610121b5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_78ea793e-0859-4b33-a7f3-cfc3a481af42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0da5518b-ff13-4b1e-8bf9-8cef566b8780" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_78ea793e-0859-4b33-a7f3-cfc3a481af42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d1d4df21-953c-4f07-9045-705861c7df73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_78ea793e-0859-4b33-a7f3-cfc3a481af42" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d1d4df21-953c-4f07-9045-705861c7df73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_4eea9241-e4c3-423a-ba7d-866cfdc5e3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_78ea793e-0859-4b33-a7f3-cfc3a481af42" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_4eea9241-e4c3-423a-ba7d-866cfdc5e3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6026de6c-5b87-4124-891e-d54d5aa5c0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_78ea793e-0859-4b33-a7f3-cfc3a481af42" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6026de6c-5b87-4124-891e-d54d5aa5c0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_0aa5e60b-d141-4045-9071-ef61c1bdb348" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_78ea793e-0859-4b33-a7f3-cfc3a481af42" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_0aa5e60b-d141-4045-9071-ef61c1bdb348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ee1d9727-f9c6-477c-b0c2-92fb24b1bc37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_78ea793e-0859-4b33-a7f3-cfc3a481af42" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ee1d9727-f9c6-477c-b0c2-92fb24b1bc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_aa851565-cfc9-4a53-837b-ff2a7073119b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_78ea793e-0859-4b33-a7f3-cfc3a481af42" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_aa851565-cfc9-4a53-837b-ff2a7073119b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7c29891e-34da-443f-b66f-260158be7835" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0da5518b-ff13-4b1e-8bf9-8cef566b8780" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7c29891e-34da-443f-b66f-260158be7835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_950e3d85-8733-40c2-841d-cc8255a28d75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7c29891e-34da-443f-b66f-260158be7835" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_950e3d85-8733-40c2-841d-cc8255a28d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_da298a76-731a-4c81-84a1-944336541e87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7c29891e-34da-443f-b66f-260158be7835" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_da298a76-731a-4c81-84a1-944336541e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ae0b243d-2eab-4650-bab2-ffaab9a2d89b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7c29891e-34da-443f-b66f-260158be7835" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ae0b243d-2eab-4650-bab2-ffaab9a2d89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_e773f9eb-4e10-42f2-96db-50d10b6d494b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7c29891e-34da-443f-b66f-260158be7835" xlink:to="loc_us-gaap_ProceedsFromStockPlans_e773f9eb-4e10-42f2-96db-50d10b6d494b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_803dd070-7a54-4a10-a96e-f76a1eee4223" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7c29891e-34da-443f-b66f-260158be7835" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_803dd070-7a54-4a10-a96e-f76a1eee4223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_95e9817c-881d-4084-a055-7d9d8ed35e70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0da5518b-ff13-4b1e-8bf9-8cef566b8780" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_95e9817c-881d-4084-a055-7d9d8ed35e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b3c65f53-9cb0-4a94-8437-151de0cf9dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0da5518b-ff13-4b1e-8bf9-8cef566b8780" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b3c65f53-9cb0-4a94-8437-151de0cf9dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4d82bc7f-f8a0-43b9-af41-d77b2098f969" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0da5518b-ff13-4b1e-8bf9-8cef566b8780" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4d82bc7f-f8a0-43b9-af41-d77b2098f969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8331e694-9ba1-473a-bfce-1bece6eb6e71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0da5518b-ff13-4b1e-8bf9-8cef566b8780" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8331e694-9ba1-473a-bfce-1bece6eb6e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2a164c1d-1249-490a-b0cc-997a33cca684" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0da5518b-ff13-4b1e-8bf9-8cef566b8780" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2a164c1d-1249-490a-b0cc-997a33cca684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_7b00bb02-7852-43e1-8394-9e498e7d1fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2a164c1d-1249-490a-b0cc-997a33cca684" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_7b00bb02-7852-43e1-8394-9e498e7d1fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="sgmo-20240930.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8a2ea83-fa66-4c3b-ac34-22929cc1459e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_0c9fd9c2-5ff8-4de8-8d32-cd7f578a7901" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8a2ea83-fa66-4c3b-ac34-22929cc1459e" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_0c9fd9c2-5ff8-4de8-8d32-cd7f578a7901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="sgmo-20240930.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c43b3bf6-0792-467d-ab60-fab9a2829c24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2ca4ab2d-bc8d-4f09-8511-242bcb171131" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c43b3bf6-0792-467d-ab60-fab9a2829c24" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_2ca4ab2d-bc8d-4f09-8511-242bcb171131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="simple" xlink:href="sgmo-20240930.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_05ebeefd-7f86-4652-8e86-66075eea0cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_ad3ab442-a1c9-415f-9023-9f7ed6df0d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_05ebeefd-7f86-4652-8e86-66075eea0cc1" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_ad3ab442-a1c9-415f-9023-9f7ed6df0d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARE" xlink:type="simple" xlink:href="sgmo-20240930.xsd#BASICANDDILUTEDNETINCOMELOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cb4c461d-c772-44bd-9568-79abb0fea91e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_ab5fa1ae-7130-4bda-898a-5cc1a157e627" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cb4c461d-c772-44bd-9568-79abb0fea91e" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_ab5fa1ae-7130-4bda-898a-5cc1a157e627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="simple" xlink:href="sgmo-20240930.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7bd38025-445b-478b-abff-adfc614bd3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6f2df555-e6f3-40e1-b82a-3b2f5d4e09f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7bd38025-445b-478b-abff-adfc614bd3f8" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6f2df555-e6f3-40e1-b82a-3b2f5d4e09f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALE" xlink:type="simple" xlink:href="sgmo-20240930.xsd#IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALE"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5b8e4593-cf13-4594-a42d-9d4ca4fbbd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentChargesTextBlock_1c6cc899-70a9-4ddd-bcb6-7595601df556" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentChargesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5b8e4593-cf13-4594-a42d-9d4ca4fbbd9e" xlink:to="loc_us-gaap_AssetImpairmentChargesTextBlock_1c6cc899-70a9-4ddd-bcb6-7595601df556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="sgmo-20240930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8ddc4704-4eff-415b-80ba-470421ba40d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_082de84e-3e9f-4bfd-84cd-05e61b08388c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8ddc4704-4eff-415b-80ba-470421ba40d1" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_082de84e-3e9f-4bfd-84cd-05e61b08388c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="sgmo-20240930.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f57fee58-cb8f-4bbc-acce-ec01638fa893" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a219f9b4-5f19-4dc1-9cc1-047af828f4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f57fee58-cb8f-4bbc-acce-ec01638fa893" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a219f9b4-5f19-4dc1-9cc1-047af828f4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20240930.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_61d39fc5-d4a8-4812-bf27-31264a8e6a07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_731f5d71-7d71-4570-8fd3-e23b12e4d3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_61d39fc5-d4a8-4812-bf27-31264a8e6a07" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_731f5d71-7d71-4570-8fd3-e23b12e4d3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGES" xlink:type="simple" xlink:href="sgmo-20240930.xsd#RESTRUCTURINGCHARGES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/RESTRUCTURINGCHARGES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_310be210-3c66-42e7-9ae6-1fe4e7d2ee2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_c04c6dca-0e2b-49f0-8e1c-866ced1aff92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_310be210-3c66-42e7-9ae6-1fe4e7d2ee2d" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_c04c6dca-0e2b-49f0-8e1c-866ced1aff92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="sgmo-20240930.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9797c55a-4c1a-412f-827b-c23678b02762" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_ae0efb54-9d2a-4921-b651-9814be309c26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9797c55a-4c1a-412f-827b-c23678b02762" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_ae0efb54-9d2a-4921-b651-9814be309c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="sgmo-20240930.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_13565f01-23a9-430d-8628-8f30dbfbd9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c8922a95-913f-4dd6-8ce8-dde86496aef3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_13565f01-23a9-430d-8628-8f30dbfbd9ce" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c8922a95-913f-4dd6-8ce8-dde86496aef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_68a392ef-4095-439c-a9d4-ca3dc3338477" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_13565f01-23a9-430d-8628-8f30dbfbd9ce" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_68a392ef-4095-439c-a9d4-ca3dc3338477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_bee2da26-3738-4ac2-926e-b69fd10aba65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_13565f01-23a9-430d-8628-8f30dbfbd9ce" xlink:to="loc_us-gaap_UseOfEstimates_bee2da26-3738-4ac2-926e-b69fd10aba65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_b77490f1-1ab1-491c-867f-2f3657b8b718" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_13565f01-23a9-430d-8628-8f30dbfbd9ce" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_b77490f1-1ab1-491c-867f-2f3657b8b718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1caefd90-7d7c-4cf0-a2d2-c21a6af98725" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_13565f01-23a9-430d-8628-8f30dbfbd9ce" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1caefd90-7d7c-4cf0-a2d2-c21a6af98725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6ae12fe4-9d06-45fb-ac25-7acf986c209f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_13565f01-23a9-430d-8628-8f30dbfbd9ce" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6ae12fe4-9d06-45fb-ac25-7acf986c209f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_1e5d5164-35bc-4e2a-b6fa-eb3d60e8043a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_13565f01-23a9-430d-8628-8f30dbfbd9ce" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_1e5d5164-35bc-4e2a-b6fa-eb3d60e8043a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_WarrantOrRightPolicyPolicyTextBlock_38e04621-6081-4d5d-93b0-04f8d93db343" xlink:href="sgmo-20240930.xsd#sgmo_WarrantOrRightPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_13565f01-23a9-430d-8628-8f30dbfbd9ce" xlink:to="loc_sgmo_WarrantOrRightPolicyPolicyTextBlock_38e04621-6081-4d5d-93b0-04f8d93db343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_d3c2c675-4632-4a42-a004-b699f38aeaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_13565f01-23a9-430d-8628-8f30dbfbd9ce" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_d3c2c675-4632-4a42-a004-b699f38aeaf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_05c4a7d7-3075-4b90-bb04-ccfa580aa6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_13565f01-23a9-430d-8628-8f30dbfbd9ce" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_05c4a7d7-3075-4b90-bb04-ccfa580aa6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6887ff78-ca35-412c-8ae9-bf0f26ee698d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_13565f01-23a9-430d-8628-8f30dbfbd9ce" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6887ff78-ca35-412c-8ae9-bf0f26ee698d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="sgmo-20240930.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b7599fe5-5d6f-46c0-a76f-ba3d9ea8ed9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_b183b10e-2f8d-424f-9c6a-283ff6114dba" xlink:href="sgmo-20240930.xsd#sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b7599fe5-5d6f-46c0-a76f-ba3d9ea8ed9c" xlink:to="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_b183b10e-2f8d-424f-9c6a-283ff6114dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_417a1369-4d27-4647-b8e9-9d8b52f11a28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b7599fe5-5d6f-46c0-a76f-ba3d9ea8ed9c" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_417a1369-4d27-4647-b8e9-9d8b52f11a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_ddab71a2-c39e-4e9a-831a-703949a16140" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b7599fe5-5d6f-46c0-a76f-ba3d9ea8ed9c" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_ddab71a2-c39e-4e9a-831a-703949a16140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="sgmo-20240930.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f1172add-f413-4366-8855-c68a7b6d9018" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_b18f4fd1-f3e7-46f7-ad42-2306c28404ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f1172add-f413-4366-8855-c68a7b6d9018" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_b18f4fd1-f3e7-46f7-ad42-2306c28404ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="simple" xlink:href="sgmo-20240930.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6fb68dc9-feaa-4763-b2fd-1f69e39478d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_3ab69673-6b62-46c6-9aa8-2870626f1185" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6fb68dc9-feaa-4763-b2fd-1f69e39478d6" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_3ab69673-6b62-46c6-9aa8-2870626f1185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_dc9bf4a2-c399-4d8c-a83c-1cce41da8623" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6fb68dc9-feaa-4763-b2fd-1f69e39478d6" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_dc9bf4a2-c399-4d8c-a83c-1cce41da8623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARETables" xlink:type="simple" xlink:href="sgmo-20240930.xsd#BASICANDDILUTEDNETINCOMELOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2918cc7b-43aa-423b-932b-fcbf912ef65b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f1ba79a7-6bef-4eb8-9ea0-1c6e5981ce6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2918cc7b-43aa-423b-932b-fcbf912ef65b" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f1ba79a7-6bef-4eb8-9ea0-1c6e5981ce6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="simple" xlink:href="sgmo-20240930.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b404635e-741f-4c0a-854e-828cdf4a3964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_76e71b6e-d76e-4b5a-8121-3671a0444684" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b404635e-741f-4c0a-854e-828cdf4a3964" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_76e71b6e-d76e-4b5a-8121-3671a0444684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="sgmo-20240930.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_78bc7c0d-f420-418a-b364-5e24b0215a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_adccfb0e-d0ec-4999-a17b-6b10610423c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_78bc7c0d-f420-418a-b364-5e24b0215a2b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_adccfb0e-d0ec-4999-a17b-6b10610423c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGESTables" xlink:type="simple" xlink:href="sgmo-20240930.xsd#RESTRUCTURINGCHARGESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/RESTRUCTURINGCHARGESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_149dee1d-a614-4f22-9f86-1dbd6bb604e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_87be4f99-348c-4f11-8a82-6a66a0e04942" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_149dee1d-a614-4f22-9f86-1dbd6bb604e8" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_87be4f99-348c-4f11-8a82-6a66a0e04942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_af1227ed-d6b8-4cfc-ba60-c73da67a39cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9c8b4434-768f-497f-a5e5-05f586225f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_af1227ed-d6b8-4cfc-ba60-c73da67a39cc" xlink:to="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9c8b4434-768f-497f-a5e5-05f586225f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_dc18ec39-4b74-44f0-9124-3e1a236be205" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9c8b4434-768f-497f-a5e5-05f586225f8f" xlink:to="loc_srt_CounterpartyNameAxis_dc18ec39-4b74-44f0-9124-3e1a236be205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f40b86c0-a3e0-492f-82cb-a1f7e3955e58" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_dc18ec39-4b74-44f0-9124-3e1a236be205" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f40b86c0-a3e0-492f-82cb-a1f7e3955e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GenentechRocheGroupMember_365717cd-0bd9-440f-8fed-52732df6d76f" xlink:href="sgmo-20240930.xsd#sgmo_GenentechRocheGroupMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f40b86c0-a3e0-492f-82cb-a1f7e3955e58" xlink:to="loc_sgmo_GenentechRocheGroupMember_365717cd-0bd9-440f-8fed-52732df6d76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_7e78f44c-a169-4627-9ab5-9e2d28fa741b" xlink:href="sgmo-20240930.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f40b86c0-a3e0-492f-82cb-a1f7e3955e58" xlink:to="loc_sgmo_KitePharmaIncMember_7e78f44c-a169-4627-9ab5-9e2d28fa741b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_08ff100c-fff7-4936-a2bb-7c2d8b6f17c3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9c8b4434-768f-497f-a5e5-05f586225f8f" xlink:to="loc_srt_ProductOrServiceAxis_08ff100c-fff7-4936-a2bb-7c2d8b6f17c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1f0fdff7-11e4-4311-ba0c-2f762dd76936" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_08ff100c-fff7-4936-a2bb-7c2d8b6f17c3" xlink:to="loc_srt_ProductsAndServicesDomain_1f0fdff7-11e4-4311-ba0c-2f762dd76936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_6e09a89a-6cf9-437d-b50d-e3d1e794eb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1f0fdff7-11e4-4311-ba0c-2f762dd76936" xlink:to="loc_us-gaap_LicenseMember_6e09a89a-6cf9-437d-b50d-e3d1e794eb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_8a192a7e-2a1e-49df-81cf-0f3105d4da1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9c8b4434-768f-497f-a5e5-05f586225f8f" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_8a192a7e-2a1e-49df-81cf-0f3105d4da1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_6550417d-eea2-429e-87c4-f73c72e0c9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_8a192a7e-2a1e-49df-81cf-0f3105d4da1e" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_6550417d-eea2-429e-87c4-f73c72e0c9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInAgreementEstimateMarch2023Member_5aff5ade-1e73-4dc0-96a2-10db0b85410a" xlink:href="sgmo-20240930.xsd#sgmo_ChangeInAgreementEstimateMarch2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_6550417d-eea2-429e-87c4-f73c72e0c9a5" xlink:to="loc_sgmo_ChangeInAgreementEstimateMarch2023Member_5aff5ade-1e73-4dc0-96a2-10db0b85410a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInAgreementEstimateSeptember2023Member_4c670fff-6579-4247-b1f7-e704b8572a15" xlink:href="sgmo-20240930.xsd#sgmo_ChangeInAgreementEstimateSeptember2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_6550417d-eea2-429e-87c4-f73c72e0c9a5" xlink:to="loc_sgmo_ChangeInAgreementEstimateSeptember2023Member_4c670fff-6579-4247-b1f7-e704b8572a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_dc79e816-3ff7-4808-a8b4-e8e0633d5f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9c8b4434-768f-497f-a5e5-05f586225f8f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_dc79e816-3ff7-4808-a8b4-e8e0633d5f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ea00faaf-c7c6-4c23-8189-7bc6c372e2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_dc79e816-3ff7-4808-a8b4-e8e0633d5f2b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ea00faaf-c7c6-4c23-8189-7bc6c372e2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0b21b8ec-b236-4688-b7f8-abe137faf4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ea00faaf-c7c6-4c23-8189-7bc6c372e2e6" xlink:to="loc_us-gaap_SubsequentEventMember_0b21b8ec-b236-4688-b7f8-abe137faf4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_9c8b4434-768f-497f-a5e5-05f586225f8f" xlink:to="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_cc8066f2-1f45-4b4e-898c-c12840b6b1c4" xlink:href="sgmo-20240930.xsd#sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:to="loc_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax_cc8066f2-1f45-4b4e-898c-c12840b6b1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_e64a6046-234b-4e5d-a3f4-0ffafeb62945" xlink:href="sgmo-20240930.xsd#sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:to="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_e64a6046-234b-4e5d-a3f4-0ffafeb62945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic_67377fd1-1af5-4203-89f4-20b022ebde2d" xlink:href="sgmo-20240930.xsd#sgmo_IncreaseDecreaseInEarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:to="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic_67377fd1-1af5-4203-89f4-20b022ebde2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_e04cd75d-7fbd-4aad-b029-1bd5c3c7f933" xlink:href="sgmo-20240930.xsd#sgmo_IncreaseDecreaseInEarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:to="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_e04cd75d-7fbd-4aad-b029-1bd5c3c7f933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_28503a3c-7a58-49b3-9e68-369e4859be0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_28503a3c-7a58-49b3-9e68-369e4859be0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1211f26d-8485-443d-ac51-c0aaa25258e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1211f26d-8485-443d-ac51-c0aaa25258e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d6aba844-10a7-41c0-9832-49ae8ef1bd80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d6aba844-10a7-41c0-9832-49ae8ef1bd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount_a1d7faa4-f8dc-46ee-9f2f-21062a5592be" xlink:href="sgmo-20240930.xsd#sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:to="loc_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount_a1d7faa4-f8dc-46ee-9f2f-21062a5592be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a903913a-cd3a-4f25-b968-f0f595a83efc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_e98320a8-23d6-4752-97b5-0e230b578629" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a903913a-cd3a-4f25-b968-f0f595a83efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c57c6bf3-3aa4-4620-b1a8-e99c3c3b0e11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_83082d4e-19bd-47bd-a5a4-8593d9a6dbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c57c6bf3-3aa4-4620-b1a8-e99c3c3b0e11" xlink:to="loc_us-gaap_ConcentrationRiskTable_83082d4e-19bd-47bd-a5a4-8593d9a6dbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4be9d0c4-f672-4042-b54c-40cfe0c34916" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_83082d4e-19bd-47bd-a5a4-8593d9a6dbc8" xlink:to="loc_srt_CounterpartyNameAxis_4be9d0c4-f672-4042-b54c-40cfe0c34916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6c64c28-d78f-4c3f-97cc-576e2878eb34" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4be9d0c4-f672-4042-b54c-40cfe0c34916" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6c64c28-d78f-4c3f-97cc-576e2878eb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GenentechRocheGroupMember_3e40e89b-0f84-4fce-9606-6bca8ccc1161" xlink:href="sgmo-20240930.xsd#sgmo_GenentechRocheGroupMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6c64c28-d78f-4c3f-97cc-576e2878eb34" xlink:to="loc_sgmo_GenentechRocheGroupMember_3e40e89b-0f84-4fce-9606-6bca8ccc1161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_a931d594-9f14-49d6-9552-f1db04471603" xlink:href="sgmo-20240930.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6c64c28-d78f-4c3f-97cc-576e2878eb34" xlink:to="loc_sgmo_KitePharmaIncMember_a931d594-9f14-49d6-9552-f1db04471603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_78aea48c-ebec-4228-a714-fea8d39f38f1" xlink:href="sgmo-20240930.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6c64c28-d78f-4c3f-97cc-576e2878eb34" xlink:to="loc_sgmo_BiogenMAIncMember_78aea48c-ebec-4228-a714-fea8d39f38f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_a10639bb-dfe6-4f93-8a8d-368af34f39ba" xlink:href="sgmo-20240930.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6c64c28-d78f-4c3f-97cc-576e2878eb34" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_a10639bb-dfe6-4f93-8a8d-368af34f39ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherLicensingAgreementsMember_87241513-15a1-49aa-97a5-aa476bb4648b" xlink:href="sgmo-20240930.xsd#sgmo_OtherLicensingAgreementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6c64c28-d78f-4c3f-97cc-576e2878eb34" xlink:to="loc_sgmo_OtherLicensingAgreementsMember_87241513-15a1-49aa-97a5-aa476bb4648b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_712d701c-2c20-4c07-9d49-5108737ba882" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_83082d4e-19bd-47bd-a5a4-8593d9a6dbc8" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_712d701c-2c20-4c07-9d49-5108737ba882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_940cdb8f-5980-4b47-b634-93fe04c9c5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_712d701c-2c20-4c07-9d49-5108737ba882" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_940cdb8f-5980-4b47-b634-93fe04c9c5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_2eb4f2aa-117e-470c-8019-838e5dc1cfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_940cdb8f-5980-4b47-b634-93fe04c9c5a0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_2eb4f2aa-117e-470c-8019-838e5dc1cfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_637f5b86-da21-4500-aaf8-442a30c64f56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_83082d4e-19bd-47bd-a5a4-8593d9a6dbc8" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_637f5b86-da21-4500-aaf8-442a30c64f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9390d4e6-656a-4d34-9b3a-267a4bd08e53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_637f5b86-da21-4500-aaf8-442a30c64f56" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9390d4e6-656a-4d34-9b3a-267a4bd08e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_2b4f40e7-72c4-4c48-8ac7-dacd441080dd" xlink:href="sgmo-20240930.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_9390d4e6-656a-4d34-9b3a-267a4bd08e53" xlink:to="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_2b4f40e7-72c4-4c48-8ac7-dacd441080dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_1d5bc125-231e-478f-96f4-56c48584d23f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_83082d4e-19bd-47bd-a5a4-8593d9a6dbc8" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_1d5bc125-231e-478f-96f4-56c48584d23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f7929ac4-1fff-4f6d-8946-cefb3d20320c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1d5bc125-231e-478f-96f4-56c48584d23f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f7929ac4-1fff-4f6d-8946-cefb3d20320c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67513981-9641-46d5-a2c7-5d81709b74c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5552c8d0-4783-408e-b145-2de61eafdbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67513981-9641-46d5-a2c7-5d81709b74c0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5552c8d0-4783-408e-b145-2de61eafdbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c4cc3b29-54db-45b3-960c-30368f12ceef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67513981-9641-46d5-a2c7-5d81709b74c0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c4cc3b29-54db-45b3-960c-30368f12ceef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_31dbe646-d305-4f83-bc76-c56c16706c94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67513981-9641-46d5-a2c7-5d81709b74c0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_31dbe646-d305-4f83-bc76-c56c16706c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_71aaf548-2bd8-4bf0-9374-0eee7f0150fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e400344f-371b-4e7f-8203-9c4280abf6da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_71aaf548-2bd8-4bf0-9374-0eee7f0150fa" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e400344f-371b-4e7f-8203-9c4280abf6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1773a115-af50-419f-81cd-d4c8d3c60185" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e400344f-371b-4e7f-8203-9c4280abf6da" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1773a115-af50-419f-81cd-d4c8d3c60185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c24fe382-b3a2-402d-9a82-a8ba3cb2cda3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1773a115-af50-419f-81cd-d4c8d3c60185" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c24fe382-b3a2-402d-9a82-a8ba3cb2cda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_293446b0-862b-411c-98a7-e99b481a5536" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c24fe382-b3a2-402d-9a82-a8ba3cb2cda3" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_293446b0-862b-411c-98a7-e99b481a5536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_824fe5e0-99e7-4c95-a1aa-95c45828aa9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e400344f-371b-4e7f-8203-9c4280abf6da" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_824fe5e0-99e7-4c95-a1aa-95c45828aa9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e9dd726f-9fda-4e03-9d93-47f80010a033" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_824fe5e0-99e7-4c95-a1aa-95c45828aa9d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e9dd726f-9fda-4e03-9d93-47f80010a033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9f65f0af-4a65-4b9d-90db-b7808a08c5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e9dd726f-9fda-4e03-9d93-47f80010a033" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9f65f0af-4a65-4b9d-90db-b7808a08c5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_895ff637-3bd6-4004-8056-6c5b1c56dc75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e9dd726f-9fda-4e03-9d93-47f80010a033" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_895ff637-3bd6-4004-8056-6c5b1c56dc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_07bf9f21-9953-4c08-8d43-ff65962eee9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e9dd726f-9fda-4e03-9d93-47f80010a033" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_07bf9f21-9953-4c08-8d43-ff65962eee9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_08ab171f-3bff-4444-addb-7c214e339f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e400344f-371b-4e7f-8203-9c4280abf6da" xlink:to="loc_us-gaap_FinancialInstrumentAxis_08ab171f-3bff-4444-addb-7c214e339f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b34ce5b-2895-44b7-82e9-721a2e5723fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_08ab171f-3bff-4444-addb-7c214e339f6b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b34ce5b-2895-44b7-82e9-721a2e5723fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_b9bf19a7-08a9-4746-a882-03327977a4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b34ce5b-2895-44b7-82e9-721a2e5723fa" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_b9bf19a7-08a9-4746-a882-03327977a4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_ba471811-c8e7-429e-9d00-0b712111821c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b34ce5b-2895-44b7-82e9-721a2e5723fa" xlink:to="loc_us-gaap_CommercialPaperMember_ba471811-c8e7-429e-9d00-0b712111821c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6153804b-a57b-4ea3-960f-91cb7552ce5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b34ce5b-2895-44b7-82e9-721a2e5723fa" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6153804b-a57b-4ea3-960f-91cb7552ce5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_a2299f70-3719-4690-a953-0c2530402ace" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b34ce5b-2895-44b7-82e9-721a2e5723fa" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_a2299f70-3719-4690-a953-0c2530402ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_ac1fd851-0686-4b44-8bff-fd3ba81bae07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b34ce5b-2895-44b7-82e9-721a2e5723fa" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_ac1fd851-0686-4b44-8bff-fd3ba81bae07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_e57c7287-4545-49d1-9064-7edc624d8573" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b34ce5b-2895-44b7-82e9-721a2e5723fa" xlink:to="loc_us-gaap_CertificatesOfDepositMember_e57c7287-4545-49d1-9064-7edc624d8573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_68664117-2aae-4f40-9d3f-d279f38cff64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e400344f-371b-4e7f-8203-9c4280abf6da" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_68664117-2aae-4f40-9d3f-d279f38cff64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e605d106-7e55-40f6-949c-a20fb819a573" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_68664117-2aae-4f40-9d3f-d279f38cff64" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e605d106-7e55-40f6-949c-a20fb819a573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_a09c099f-a53b-4be2-9658-3486e205bd58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e605d106-7e55-40f6-949c-a20fb819a573" xlink:to="loc_us-gaap_MoneyMarketFundsMember_a09c099f-a53b-4be2-9658-3486e205bd58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_362a6f3c-1508-4a07-9b55-43a458e49613" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e400344f-371b-4e7f-8203-9c4280abf6da" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_362a6f3c-1508-4a07-9b55-43a458e49613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_18d040f3-209f-4be8-bd7a-64df8325300c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_362a6f3c-1508-4a07-9b55-43a458e49613" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_18d040f3-209f-4be8-bd7a-64df8325300c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_03feca04-5238-4616-8ade-ee15bb75e8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_362a6f3c-1508-4a07-9b55-43a458e49613" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_03feca04-5238-4616-8ade-ee15bb75e8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e2a5005c-15b9-4df7-aaec-0d5f71ecf545" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_362a6f3c-1508-4a07-9b55-43a458e49613" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e2a5005c-15b9-4df7-aaec-0d5f71ecf545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ccd30073-262a-4db9-bad1-85c29d6a340a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_93313454-cc88-467a-86fa-e2ec497034bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ccd30073-262a-4db9-bad1-85c29d6a340a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_93313454-cc88-467a-86fa-e2ec497034bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_bbb5f353-21fb-4bb5-9960-84ad6bbf64fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_93313454-cc88-467a-86fa-e2ec497034bb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_bbb5f353-21fb-4bb5-9960-84ad6bbf64fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c8df31b9-68fe-43cf-b1a7-c901c0338a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_bbb5f353-21fb-4bb5-9960-84ad6bbf64fd" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c8df31b9-68fe-43cf-b1a7-c901c0338a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_87a61c31-8bc2-4fbb-bf46-6ba667dcad6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c8df31b9-68fe-43cf-b1a7-c901c0338a9b" xlink:to="loc_us-gaap_CashEquivalentsMember_87a61c31-8bc2-4fbb-bf46-6ba667dcad6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_bf31c864-fdf1-4044-a2e9-ed47cf86e65a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsMember_87a61c31-8bc2-4fbb-bf46-6ba667dcad6d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_bf31c864-fdf1-4044-a2e9-ed47cf86e65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8174581d-9cb1-4cb2-83a8-34986230363a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_93313454-cc88-467a-86fa-e2ec497034bb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8174581d-9cb1-4cb2-83a8-34986230363a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97ff892d-2243-4fa2-8bc3-1d7c1d1930ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8174581d-9cb1-4cb2-83a8-34986230363a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97ff892d-2243-4fa2-8bc3-1d7c1d1930ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_53d44467-39c0-4aae-8105-eb3a780e46ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97ff892d-2243-4fa2-8bc3-1d7c1d1930ba" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_53d44467-39c0-4aae-8105-eb3a780e46ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_0f6090d7-d71a-4116-b1a4-4f03927d8fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97ff892d-2243-4fa2-8bc3-1d7c1d1930ba" xlink:to="loc_us-gaap_CommercialPaperMember_0f6090d7-d71a-4116-b1a4-4f03927d8fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_f66898bf-ca08-440e-ad85-286a4db622d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97ff892d-2243-4fa2-8bc3-1d7c1d1930ba" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_f66898bf-ca08-440e-ad85-286a4db622d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_12e773f5-7b38-415f-aa2b-f561282ce724" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97ff892d-2243-4fa2-8bc3-1d7c1d1930ba" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_12e773f5-7b38-415f-aa2b-f561282ce724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_169bd8a3-65ab-4bd5-981f-06b24d2aedce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97ff892d-2243-4fa2-8bc3-1d7c1d1930ba" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_169bd8a3-65ab-4bd5-981f-06b24d2aedce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_93892dfd-c915-470f-9121-096924f87f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97ff892d-2243-4fa2-8bc3-1d7c1d1930ba" xlink:to="loc_us-gaap_CertificatesOfDepositMember_93892dfd-c915-470f-9121-096924f87f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_790ff579-5944-4783-90c1-09d8f9e0c459" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_93313454-cc88-467a-86fa-e2ec497034bb" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_790ff579-5944-4783-90c1-09d8f9e0c459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_47c922b7-d51e-4e35-96de-893c4bd2ecf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_790ff579-5944-4783-90c1-09d8f9e0c459" xlink:to="loc_us-gaap_AssetsAbstract_47c922b7-d51e-4e35-96de-893c4bd2ecf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_dbccdddc-4b1a-4659-b33c-19617d1c1ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47c922b7-d51e-4e35-96de-893c4bd2ecf3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_dbccdddc-4b1a-4659-b33c-19617d1c1ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_28ba5e47-c7aa-4c0d-9242-09f38efe2140" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_dbccdddc-4b1a-4659-b33c-19617d1c1ea9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_28ba5e47-c7aa-4c0d-9242-09f38efe2140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_a1eb66f4-f622-465c-89e5-7e6a22ace9bb" xlink:href="sgmo-20240930.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_dbccdddc-4b1a-4659-b33c-19617d1c1ea9" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_a1eb66f4-f622-465c-89e5-7e6a22ace9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_2a904e8a-a558-4124-be5f-9ea4ab9d6d76" xlink:href="sgmo-20240930.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_dbccdddc-4b1a-4659-b33c-19617d1c1ea9" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_2a904e8a-a558-4124-be5f-9ea4ab9d6d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c5d7da16-9e36-45b3-9648-9eb1fe5c93b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_dbccdddc-4b1a-4659-b33c-19617d1c1ea9" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c5d7da16-9e36-45b3-9648-9eb1fe5c93b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract_e2e5f5c4-8597-4cdb-91c4-e83f6c411996" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_47c922b7-d51e-4e35-96de-893c4bd2ecf3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract_e2e5f5c4-8597-4cdb-91c4-e83f6c411996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent_9b393f84-6b87-49b9-9535-07f4bbf53877" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract_e2e5f5c4-8597-4cdb-91c4-e83f6c411996" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent_9b393f84-6b87-49b9-9535-07f4bbf53877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_05e52843-5d5f-4b33-9b6b-8bcbb80ebd20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract_e2e5f5c4-8597-4cdb-91c4-e83f6c411996" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_05e52843-5d5f-4b33-9b6b-8bcbb80ebd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0b5a7ca1-7c6e-43d4-a885-618cdd135844" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract_e2e5f5c4-8597-4cdb-91c4-e83f6c411996" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0b5a7ca1-7c6e-43d4-a885-618cdd135844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_5a15c0c3-d155-4463-a4c1-6fd0929018b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract_e2e5f5c4-8597-4cdb-91c4-e83f6c411996" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_5a15c0c3-d155-4463-a4c1-6fd0929018b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent_172bbe15-872c-4b0a-afc8-02c41ac08b8b" xlink:href="sgmo-20240930.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_790ff579-5944-4783-90c1-09d8f9e0c459" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent_172bbe15-872c-4b0a-afc8-02c41ac08b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_ebad8cf8-9f6c-4420-842b-c0df650532e8" xlink:href="sgmo-20240930.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_790ff579-5944-4783-90c1-09d8f9e0c459" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_ebad8cf8-9f6c-4420-842b-c0df650532e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_6ddb666e-130d-4b7c-a4ce-86a03476b38d" xlink:href="sgmo-20240930.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_790ff579-5944-4783-90c1-09d8f9e0c459" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_6ddb666e-130d-4b7c-a4ce-86a03476b38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent_8fe9581b-c647-4565-873f-b553e24eaec6" xlink:href="sgmo-20240930.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_790ff579-5944-4783-90c1-09d8f9e0c459" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent_8fe9581b-c647-4565-873f-b553e24eaec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_39f5249e-ed58-42e3-9480-0e0a317c1c72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_3d39fa56-5193-44b5-b616-3bc721cf62fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_39f5249e-ed58-42e3-9480-0e0a317c1c72" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_3d39fa56-5193-44b5-b616-3bc721cf62fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_d9a2861d-a5b6-49af-86d7-d2c7955f7277" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_39f5249e-ed58-42e3-9480-0e0a317c1c72" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_d9a2861d-a5b6-49af-86d7-d2c7955f7277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_0c7cd362-6bf8-4bc7-99e3-313cd4f10ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_39f5249e-ed58-42e3-9480-0e0a317c1c72" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_0c7cd362-6bf8-4bc7-99e3-313cd4f10ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8f1f3bc2-e229-4158-873f-302dcbc0edc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_36645633-ebea-4453-96e2-36fdd6ae375e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8f1f3bc2-e229-4158-873f-302dcbc0edc4" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_36645633-ebea-4453-96e2-36fdd6ae375e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded_197af9ae-a674-4160-9e80-97780d36b6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8f1f3bc2-e229-4158-873f-302dcbc0edc4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded_197af9ae-a674-4160-9e80-97780d36b6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_265f971b-03db-405c-a654-c70041aa4021" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8f1f3bc2-e229-4158-873f-302dcbc0edc4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_265f971b-03db-405c-a654-c70041aa4021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_151dca87-da2c-4599-95e7-4986d01a5b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8f1f3bc2-e229-4158-873f-302dcbc0edc4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_151dca87-da2c-4599-95e7-4986d01a5b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c9560cdd-e292-4e06-9483-f36c466b1c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_8101a3ff-6a44-40cd-8dee-05cb885ac012" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c9560cdd-e292-4e06-9483-f36c466b1c3b" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_8101a3ff-6a44-40cd-8dee-05cb885ac012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_364ae941-fa9e-4521-a506-1359b3994839" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_8101a3ff-6a44-40cd-8dee-05cb885ac012" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_364ae941-fa9e-4521-a506-1359b3994839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ae7c7de7-a410-4d3d-a5af-4f7142c6a1af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_364ae941-fa9e-4521-a506-1359b3994839" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ae7c7de7-a410-4d3d-a5af-4f7142c6a1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreFundedCommonStockWarrantMember_ab2cb265-85e8-4c3c-83f0-7e243c5fde09" xlink:href="sgmo-20240930.xsd#sgmo_PreFundedCommonStockWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ae7c7de7-a410-4d3d-a5af-4f7142c6a1af" xlink:to="loc_sgmo_PreFundedCommonStockWarrantMember_ab2cb265-85e8-4c3c-83f0-7e243c5fde09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_84e98c3f-9538-4a5e-9587-381497a14ead" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_8101a3ff-6a44-40cd-8dee-05cb885ac012" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_84e98c3f-9538-4a5e-9587-381497a14ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ffeac777-02d4-4667-8b07-b06b6db692ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84e98c3f-9538-4a5e-9587-381497a14ead" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ffeac777-02d4-4667-8b07-b06b6db692ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_66cf6e02-ed1b-4fac-bbde-e4ba6a94c92e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84e98c3f-9538-4a5e-9587-381497a14ead" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_66cf6e02-ed1b-4fac-bbde-e4ba6a94c92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_100caf72-1491-488d-a90a-4d9f9c7f26e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84e98c3f-9538-4a5e-9587-381497a14ead" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_100caf72-1491-488d-a90a-4d9f9c7f26e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_732cf811-494a-4a98-9657-f4ffd39e05b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84e98c3f-9538-4a5e-9587-381497a14ead" xlink:to="loc_us-gaap_SharePrice_732cf811-494a-4a98-9657-f4ffd39e05b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_593bc287-5d59-403c-bcad-4787a0501acd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84e98c3f-9538-4a5e-9587-381497a14ead" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_593bc287-5d59-403c-bcad-4787a0501acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_37f7106d-a415-427e-bbe3-6bf79f086073" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84e98c3f-9538-4a5e-9587-381497a14ead" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_37f7106d-a415-427e-bbe3-6bf79f086073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2a7bfcf7-324d-4b97-ab56-ec2a8238340f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_be95354c-4c29-4ce7-97d4-2e9abeedb284" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2a7bfcf7-324d-4b97-ab56-ec2a8238340f" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_be95354c-4c29-4ce7-97d4-2e9abeedb284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b76d9b3d-13a3-4a77-ac27-33e38b38454e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_be95354c-4c29-4ce7-97d4-2e9abeedb284" xlink:to="loc_us-gaap_AwardTypeAxis_b76d9b3d-13a3-4a77-ac27-33e38b38454e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf3c707e-ebfc-4a76-827b-540646fc3eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b76d9b3d-13a3-4a77-ac27-33e38b38454e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf3c707e-ebfc-4a76-827b-540646fc3eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_160c50fa-fd57-47a1-8be8-3f65df4d7928" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf3c707e-ebfc-4a76-827b-540646fc3eb7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_160c50fa-fd57-47a1-8be8-3f65df4d7928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_a3cab468-d617-4713-8e0a-4b8b103a6eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf3c707e-ebfc-4a76-827b-540646fc3eb7" xlink:to="loc_us-gaap_EmployeeStockMember_a3cab468-d617-4713-8e0a-4b8b103a6eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_1e103764-a413-4e51-8738-95199e749997" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_be95354c-4c29-4ce7-97d4-2e9abeedb284" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_1e103764-a413-4e51-8738-95199e749997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_96c08787-e911-4954-baac-6575ad59004c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_1e103764-a413-4e51-8738-95199e749997" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_96c08787-e911-4954-baac-6575ad59004c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1a4962e2-c58b-4b89-acea-d5a67fd39619" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_96c08787-e911-4954-baac-6575ad59004c" xlink:to="loc_us-gaap_NetIncomeLoss_1a4962e2-c58b-4b89-acea-d5a67fd39619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_3375ff97-9ec1-4adf-8132-70509eb36584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_96c08787-e911-4954-baac-6575ad59004c" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_3375ff97-9ec1-4adf-8132-70509eb36584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6111ce88-3c92-4a33-bfcc-1401bb2b2176" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_96c08787-e911-4954-baac-6575ad59004c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6111ce88-3c92-4a33-bfcc-1401bb2b2176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5bcf8b8c-8dee-48f9-9efe-f9c9c82f6c57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_1e103764-a413-4e51-8738-95199e749997" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5bcf8b8c-8dee-48f9-9efe-f9c9c82f6c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_84bcdd70-ba7d-44fb-b659-dc25cfd54e21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5bcf8b8c-8dee-48f9-9efe-f9c9c82f6c57" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_84bcdd70-ba7d-44fb-b659-dc25cfd54e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f49c8f96-6296-450d-acf2-23caba2f408d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_84bcdd70-ba7d-44fb-b659-dc25cfd54e21" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f49c8f96-6296-450d-acf2-23caba2f408d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7f99f962-ab49-4130-88ad-a2d428b07a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5bcf8b8c-8dee-48f9-9efe-f9c9c82f6c57" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7f99f962-ab49-4130-88ad-a2d428b07a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8378aab4-4bfc-46bf-b853-0e9a49fccd35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7f99f962-ab49-4130-88ad-a2d428b07a8a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8378aab4-4bfc-46bf-b853-0e9a49fccd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9e1c74bd-6625-421c-9470-f1e8d9f31200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7f99f962-ab49-4130-88ad-a2d428b07a8a" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9e1c74bd-6625-421c-9470-f1e8d9f31200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_327edfb8-ee8a-472d-b9fd-a21bc5dcc11d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7f99f962-ab49-4130-88ad-a2d428b07a8a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_327edfb8-ee8a-472d-b9fd-a21bc5dcc11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_26c16f89-95b6-4d7c-8728-d0ff03fa50c3" xlink:href="sgmo-20240930.xsd#sgmo_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5bcf8b8c-8dee-48f9-9efe-f9c9c82f6c57" xlink:to="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_26c16f89-95b6-4d7c-8728-d0ff03fa50c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_17622b11-62fa-439e-9d6a-e78af997b73a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_26c16f89-95b6-4d7c-8728-d0ff03fa50c3" xlink:to="loc_us-gaap_EarningsPerShareBasic_17622b11-62fa-439e-9d6a-e78af997b73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a02ac702-ed2e-4742-aaf1-b504f9140b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_26c16f89-95b6-4d7c-8728-d0ff03fa50c3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a02ac702-ed2e-4742-aaf1-b504f9140b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86ed75f5-f5c1-41ed-a6fd-a1c2df44cadd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fb28cda9-0372-4cdf-8af6-d937efd4ae54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86ed75f5-f5c1-41ed-a6fd-a1c2df44cadd" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fb28cda9-0372-4cdf-8af6-d937efd4ae54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b1ff38e2-618b-4cc5-95b8-f53cae3e431d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fb28cda9-0372-4cdf-8af6-d937efd4ae54" xlink:to="loc_srt_ProductOrServiceAxis_b1ff38e2-618b-4cc5-95b8-f53cae3e431d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9767f8d2-3bbc-4eb2-b8ae-169a83a64a9f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b1ff38e2-618b-4cc5-95b8-f53cae3e431d" xlink:to="loc_srt_ProductsAndServicesDomain_9767f8d2-3bbc-4eb2-b8ae-169a83a64a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_7fb9cdd0-7c0c-40b8-8e5b-f206ec160b31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9767f8d2-3bbc-4eb2-b8ae-169a83a64a9f" xlink:to="loc_us-gaap_LicenseMember_7fb9cdd0-7c0c-40b8-8e5b-f206ec160b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LicenseTechnologyTransferMember_c067efc4-aca4-4e73-b510-136d01c87d33" xlink:href="sgmo-20240930.xsd#sgmo_LicenseTechnologyTransferMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LicenseMember_7fb9cdd0-7c0c-40b8-8e5b-f206ec160b31" xlink:to="loc_sgmo_LicenseTechnologyTransferMember_c067efc4-aca4-4e73-b510-136d01c87d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_65dae070-8129-4b6a-923b-0b493906cebf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fb28cda9-0372-4cdf-8af6-d937efd4ae54" xlink:to="loc_srt_CounterpartyNameAxis_65dae070-8129-4b6a-923b-0b493906cebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41ad56ad-7f66-41a6-905a-0cf99aa47029" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_65dae070-8129-4b6a-923b-0b493906cebf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41ad56ad-7f66-41a6-905a-0cf99aa47029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GenentechRocheGroupMember_9b75ab16-e8a8-4104-8804-04b1ac4f6ef4" xlink:href="sgmo-20240930.xsd#sgmo_GenentechRocheGroupMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41ad56ad-7f66-41a6-905a-0cf99aa47029" xlink:to="loc_sgmo_GenentechRocheGroupMember_9b75ab16-e8a8-4104-8804-04b1ac4f6ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7e2d3b4c-4405-4e91-9adf-ca4006ab5236" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fb28cda9-0372-4cdf-8af6-d937efd4ae54" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7e2d3b4c-4405-4e91-9adf-ca4006ab5236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9fa6908e-0437-4a29-acc7-155cd4528ece" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7e2d3b4c-4405-4e91-9adf-ca4006ab5236" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9fa6908e-0437-4a29-acc7-155cd4528ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9cc36aa3-5ecf-4123-af30-fb73b2748e75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9fa6908e-0437-4a29-acc7-155cd4528ece" xlink:to="loc_us-gaap_SubsequentEventMember_9cc36aa3-5ecf-4123-af30-fb73b2748e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aed626dc-2227-4c78-971a-87e3944084ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fb28cda9-0372-4cdf-8af6-d937efd4ae54" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aed626dc-2227-4c78-971a-87e3944084ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_eefee5e8-3fe2-4927-be5b-96c15b62387a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aed626dc-2227-4c78-971a-87e3944084ed" xlink:to="loc_us-gaap_ContractWithCustomerLiability_eefee5e8-3fe2-4927-be5b-96c15b62387a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount_cd70d031-4ee6-4fa9-a47e-fba27267be6e" xlink:href="sgmo-20240930.xsd#sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aed626dc-2227-4c78-971a-87e3944084ed" xlink:to="loc_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount_cd70d031-4ee6-4fa9-a47e-fba27267be6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RoyaltyObligationTerm_78965568-899b-476d-9372-141e81bca1fa" xlink:href="sgmo-20240930.xsd#sgmo_RoyaltyObligationTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aed626dc-2227-4c78-971a-87e3944084ed" xlink:to="loc_sgmo_RoyaltyObligationTerm_78965568-899b-476d-9372-141e81bca1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_870f726e-6a33-4407-a7f1-6bb369314356" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aed626dc-2227-4c78-971a-87e3944084ed" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_870f726e-6a33-4407-a7f1-6bb369314356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations_c4cbba83-8581-4c0a-8abf-5ac2226cbb04" xlink:href="sgmo-20240930.xsd#sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aed626dc-2227-4c78-971a-87e3944084ed" xlink:to="loc_sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations_c4cbba83-8581-4c0a-8abf-5ac2226cbb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_cdcd6e07-1106-4647-ac1a-56f8b5300d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aed626dc-2227-4c78-971a-87e3944084ed" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_cdcd6e07-1106-4647-ac1a-56f8b5300d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b93ff8f3-3ca8-4a27-9c99-b44a26d5bbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aed626dc-2227-4c78-971a-87e3944084ed" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b93ff8f3-3ca8-4a27-9c99-b44a26d5bbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1d6f2fbc-edcb-4b4b-8899-868e26645349" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aed626dc-2227-4c78-971a-87e3944084ed" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1d6f2fbc-edcb-4b4b-8899-868e26645349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fb2e934-ac87-4045-af8c-128089fae8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3ec95d67-5c3c-4d4d-8e59-fc2d3b70201e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fb2e934-ac87-4045-af8c-128089fae8e1" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3ec95d67-5c3c-4d4d-8e59-fc2d3b70201e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_91a68763-dd28-4729-815a-93e3b5329a1a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3ec95d67-5c3c-4d4d-8e59-fc2d3b70201e" xlink:to="loc_srt_CounterpartyNameAxis_91a68763-dd28-4729-815a-93e3b5329a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3bd0d86f-167c-445f-abd1-3e82a9b0c86c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_91a68763-dd28-4729-815a-93e3b5329a1a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3bd0d86f-167c-445f-abd1-3e82a9b0c86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_80088861-f726-4751-8163-47b6f6bccbdd" xlink:href="sgmo-20240930.xsd#sgmo_PfizerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3bd0d86f-167c-445f-abd1-3e82a9b0c86c" xlink:to="loc_sgmo_PfizerMember_80088861-f726-4751-8163-47b6f6bccbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_94f47401-6ce7-4aff-82ab-2939c71af4d5" xlink:href="sgmo-20240930.xsd#sgmo_PfizerSB525Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3bd0d86f-167c-445f-abd1-3e82a9b0c86c" xlink:to="loc_sgmo_PfizerSB525Member_94f47401-6ce7-4aff-82ab-2939c71af4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember_57ed0f5c-92be-4783-927f-bdba1e14909f" xlink:href="sgmo-20240930.xsd#sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3bd0d86f-167c-445f-abd1-3e82a9b0c86c" xlink:to="loc_sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember_57ed0f5c-92be-4783-927f-bdba1e14909f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b310567b-4802-47ba-be5e-fca8a5a9c032" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3ec95d67-5c3c-4d4d-8e59-fc2d3b70201e" xlink:to="loc_srt_ProductOrServiceAxis_b310567b-4802-47ba-be5e-fca8a5a9c032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d4ddc9d8-a9d4-443e-82c0-ebdcaf2afcf6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b310567b-4802-47ba-be5e-fca8a5a9c032" xlink:to="loc_srt_ProductsAndServicesDomain_d4ddc9d8-a9d4-443e-82c0-ebdcaf2afcf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_dfd29300-43fe-411b-a7ae-992ee414cf3d" xlink:href="sgmo-20240930.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d4ddc9d8-a9d4-443e-82c0-ebdcaf2afcf6" xlink:to="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_dfd29300-43fe-411b-a7ae-992ee414cf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveMember_10807510-7f44-4ce7-abce-4f5fecc1b75c" xlink:href="sgmo-20240930.xsd#sgmo_SBFiveTwoFiveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_dfd29300-43fe-411b-a7ae-992ee414cf3d" xlink:to="loc_sgmo_SBFiveTwoFiveMember_10807510-7f44-4ce7-abce-4f5fecc1b75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_ec53bb98-c6b3-42d9-b806-8112aba59c49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d4ddc9d8-a9d4-443e-82c0-ebdcaf2afcf6" xlink:to="loc_us-gaap_LicenseMember_ec53bb98-c6b3-42d9-b806-8112aba59c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember_16e14e8e-0455-4340-9fc5-405942082ed8" xlink:href="sgmo-20240930.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d4ddc9d8-a9d4-443e-82c0-ebdcaf2afcf6" xlink:to="loc_sgmo_CNineORFSevenTwoMember_16e14e8e-0455-4340-9fc5-405942082ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_951785a8-27a0-426f-b216-63cec28915d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3ec95d67-5c3c-4d4d-8e59-fc2d3b70201e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_951785a8-27a0-426f-b216-63cec28915d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_42763e42-2ea2-41f7-8a0c-0da04b2fc59b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_951785a8-27a0-426f-b216-63cec28915d9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_42763e42-2ea2-41f7-8a0c-0da04b2fc59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_f6a98f91-9574-4025-8ecc-32cb5e0eb799" xlink:href="sgmo-20240930.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_42763e42-2ea2-41f7-8a0c-0da04b2fc59b" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_f6a98f91-9574-4025-8ecc-32cb5e0eb799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_cc824341-14f3-44dc-b79f-e006fd13ac49" xlink:href="sgmo-20240930.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_42763e42-2ea2-41f7-8a0c-0da04b2fc59b" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_cc824341-14f3-44dc-b79f-e006fd13ac49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_a842ace3-bdcc-4ac9-b326-e48002e95d5e" xlink:href="sgmo-20240930.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_42763e42-2ea2-41f7-8a0c-0da04b2fc59b" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_a842ace3-bdcc-4ac9-b326-e48002e95d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3dec3c9a-5cd2-4da1-bcbc-9d9e7a40f9c5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3ec95d67-5c3c-4d4d-8e59-fc2d3b70201e" xlink:to="loc_srt_RangeAxis_3dec3c9a-5cd2-4da1-bcbc-9d9e7a40f9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_893bd6f5-e272-4bb2-81da-0c495bd418ec" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3dec3c9a-5cd2-4da1-bcbc-9d9e7a40f9c5" xlink:to="loc_srt_RangeMember_893bd6f5-e272-4bb2-81da-0c495bd418ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f5e26096-6c30-4d1d-9d55-93fc1dc31743" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_893bd6f5-e272-4bb2-81da-0c495bd418ec" xlink:to="loc_srt_MinimumMember_f5e26096-6c30-4d1d-9d55-93fc1dc31743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c8a76cb3-25db-4283-a6d3-f2fcd65f6d2d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_893bd6f5-e272-4bb2-81da-0c495bd418ec" xlink:to="loc_srt_MaximumMember_c8a76cb3-25db-4283-a6d3-f2fcd65f6d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_3ec95d67-5c3c-4d4d-8e59-fc2d3b70201e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm_5ef861ff-718c-4984-97af-0fa71a67545f" xlink:href="sgmo-20240930.xsd#sgmo_AgreementTerminationTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_sgmo_AgreementTerminationTerm_5ef861ff-718c-4984-97af-0fa71a67545f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_fd5a75da-d698-4f48-b5ab-f0fc4cd6eca3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_fd5a75da-d698-4f48-b5ab-f0fc4cd6eca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_c9ac431e-b2e5-45a6-ae9c-3a5f2c72b2aa" xlink:href="sgmo-20240930.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_c9ac431e-b2e5-45a6-ae9c-3a5f2c72b2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_1109ea1b-a46d-4f36-a820-b8d332439bc7" xlink:href="sgmo-20240930.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_1109ea1b-a46d-4f36-a820-b8d332439bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_75bdde88-efc1-46f4-b325-8e46d03837a6" xlink:href="sgmo-20240930.xsd#sgmo_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_75bdde88-efc1-46f4-b325-8e46d03837a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_6ca3877f-1331-4ea8-8000-b856370b5efa" xlink:href="sgmo-20240930.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_sgmo_MilestonePaymentsReceived_6ca3877f-1331-4ea8-8000-b856370b5efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_8709ec15-79f5-4d14-8995-bbd195a9b1f6" xlink:href="sgmo-20240930.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_sgmo_MilestoneRevenueReceivable_8709ec15-79f5-4d14-8995-bbd195a9b1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_383fe03f-145d-47e9-be83-7b22bd1288e8" xlink:href="sgmo-20240930.xsd#sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_383fe03f-145d-47e9-be83-7b22bd1288e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_74a73f94-cafa-40a9-82bc-c8d28669c046" xlink:href="sgmo-20240930.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_74a73f94-cafa-40a9-82bc-c8d28669c046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_be95b4fd-c527-43ca-b7ed-0e8dda983b26" xlink:href="sgmo-20240930.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_be95b4fd-c527-43ca-b7ed-0e8dda983b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_b5365270-7542-4894-b384-acf79d74e692" xlink:href="sgmo-20240930.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_b5365270-7542-4894-b384-acf79d74e692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97e8a9e1-5322-4373-823f-9f6181efb05b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_88ec9afc-917a-494a-94ed-4fb229382e3f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97e8a9e1-5322-4373-823f-9f6181efb05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_429cf5d7-a518-4ff8-9772-41f87c4a6c33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d0c923f8-db04-4e69-8000-34eeca01b6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_429cf5d7-a518-4ff8-9772-41f87c4a6c33" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d0c923f8-db04-4e69-8000-34eeca01b6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_36961989-8fd2-4a5e-8c97-1eecc5da190f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d0c923f8-db04-4e69-8000-34eeca01b6d4" xlink:to="loc_srt_CounterpartyNameAxis_36961989-8fd2-4a5e-8c97-1eecc5da190f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b376f9b0-f073-4b7c-8820-003c5b2ecf39" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_36961989-8fd2-4a5e-8c97-1eecc5da190f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b376f9b0-f073-4b7c-8820-003c5b2ecf39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GenentechRocheGroupMember_d15c858d-94b8-4061-b934-36404734d42a" xlink:href="sgmo-20240930.xsd#sgmo_GenentechRocheGroupMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b376f9b0-f073-4b7c-8820-003c5b2ecf39" xlink:to="loc_sgmo_GenentechRocheGroupMember_d15c858d-94b8-4061-b934-36404734d42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherCollaborationAndLicenseAgreementsMember_e5d9a6db-3c07-4c7d-bbad-badff61ae723" xlink:href="sgmo-20240930.xsd#sgmo_OtherCollaborationAndLicenseAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b376f9b0-f073-4b7c-8820-003c5b2ecf39" xlink:to="loc_sgmo_OtherCollaborationAndLicenseAgreementsMember_e5d9a6db-3c07-4c7d-bbad-badff61ae723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_82a69e9e-f205-4971-9f42-fd46fe0c515d" xlink:href="sgmo-20240930.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OtherCollaborationAndLicenseAgreementsMember_e5d9a6db-3c07-4c7d-bbad-badff61ae723" xlink:to="loc_sgmo_KitePharmaIncMember_82a69e9e-f205-4971-9f42-fd46fe0c515d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_c7213637-86b4-414d-a563-7ca368775421" xlink:href="sgmo-20240930.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OtherCollaborationAndLicenseAgreementsMember_e5d9a6db-3c07-4c7d-bbad-badff61ae723" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_c7213637-86b4-414d-a563-7ca368775421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_3e8d2de2-a471-4764-b75a-1bc5192c303a" xlink:href="sgmo-20240930.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OtherCollaborationAndLicenseAgreementsMember_e5d9a6db-3c07-4c7d-bbad-badff61ae723" xlink:to="loc_sgmo_BiogenMAIncMember_3e8d2de2-a471-4764-b75a-1bc5192c303a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherLicensingAgreementsMember_6a817311-ee92-44be-aa7d-9b105da5ebd0" xlink:href="sgmo-20240930.xsd#sgmo_OtherLicensingAgreementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OtherCollaborationAndLicenseAgreementsMember_e5d9a6db-3c07-4c7d-bbad-badff61ae723" xlink:to="loc_sgmo_OtherLicensingAgreementsMember_6a817311-ee92-44be-aa7d-9b105da5ebd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4772ad3e-fd19-437f-b060-311cf07a28d9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d0c923f8-db04-4e69-8000-34eeca01b6d4" xlink:to="loc_srt_ProductOrServiceAxis_4772ad3e-fd19-437f-b060-311cf07a28d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_02ad990e-9a4a-429a-a766-e88bfe41a090" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4772ad3e-fd19-437f-b060-311cf07a28d9" xlink:to="loc_srt_ProductsAndServicesDomain_02ad990e-9a4a-429a-a766-e88bfe41a090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_d9564a4d-1acd-439c-9694-89e53ad7d5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_02ad990e-9a4a-429a-a766-e88bfe41a090" xlink:to="loc_us-gaap_LicenseMember_d9564a4d-1acd-439c-9694-89e53ad7d5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_3f937142-aac0-4e24-86cc-63f39678a151" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_02ad990e-9a4a-429a-a766-e88bfe41a090" xlink:to="loc_us-gaap_ServiceMember_3f937142-aac0-4e24-86cc-63f39678a151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_755001ad-e86d-4c76-bb55-604e611eda12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d0c923f8-db04-4e69-8000-34eeca01b6d4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_755001ad-e86d-4c76-bb55-604e611eda12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_db022127-fbe1-4d94-a7e4-72d4037647ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_755001ad-e86d-4c76-bb55-604e611eda12" xlink:to="loc_us-gaap_RevenuesAbstract_db022127-fbe1-4d94-a7e4-72d4037647ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8337433f-2a1e-48f2-aa3b-a3beb5086361" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_db022127-fbe1-4d94-a7e4-72d4037647ee" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8337433f-2a1e-48f2-aa3b-a3beb5086361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d79dc52f-2947-4344-a298-29affa700848" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_61d7c739-40b4-4d61-aa4f-73671da3e227" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d79dc52f-2947-4344-a298-29affa700848" xlink:to="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_61d7c739-40b4-4d61-aa4f-73671da3e227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5fd8f69-c655-450b-842f-443240b2d12f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_61d7c739-40b4-4d61-aa4f-73671da3e227" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5fd8f69-c655-450b-842f-443240b2d12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be2292d6-9de2-4c9c-bc3e-109ee1ca89cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5fd8f69-c655-450b-842f-443240b2d12f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be2292d6-9de2-4c9c-bc3e-109ee1ca89cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EquipmentFurnitureAndFixturesMember_418b6e3a-a9d9-4305-a0b9-4773b626fe6f" xlink:href="sgmo-20240930.xsd#sgmo_EquipmentFurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be2292d6-9de2-4c9c-bc3e-109ee1ca89cd" xlink:to="loc_sgmo_EquipmentFurnitureAndFixturesMember_418b6e3a-a9d9-4305-a0b9-4773b626fe6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_e69cf7de-3ddd-4ce1-a63f-8add755f0c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be2292d6-9de2-4c9c-bc3e-109ee1ca89cd" xlink:to="loc_us-gaap_ConstructionInProgressMember_e69cf7de-3ddd-4ce1-a63f-8add755f0c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LeaseholdImprovementsAndConstructionInProgressMember_1e10ee9e-48a0-457a-8d00-68d4e4e08073" xlink:href="sgmo-20240930.xsd#sgmo_LeaseholdImprovementsAndConstructionInProgressMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be2292d6-9de2-4c9c-bc3e-109ee1ca89cd" xlink:to="loc_sgmo_LeaseholdImprovementsAndConstructionInProgressMember_1e10ee9e-48a0-457a-8d00-68d4e4e08073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember_8dafe8ad-7bf4-450e-9c4f-cc404eeebea2" xlink:href="sgmo-20240930.xsd#sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be2292d6-9de2-4c9c-bc3e-109ee1ca89cd" xlink:to="loc_sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember_8dafe8ad-7bf4-450e-9c4f-cc404eeebea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a7c1785f-c3f8-402d-bfc4-16dbb5bbdbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_61d7c739-40b4-4d61-aa4f-73671da3e227" xlink:to="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a7c1785f-c3f8-402d-bfc4-16dbb5bbdbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2b95b2db-8397-4dc3-bba7-577bc44ecc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a7c1785f-c3f8-402d-bfc4-16dbb5bbdbbb" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2b95b2db-8397-4dc3-bba7-577bc44ecc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_cbe3459d-9520-4b59-8652-3d9995b00807" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a7c1785f-c3f8-402d-bfc4-16dbb5bbdbbb" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_cbe3459d-9520-4b59-8652-3d9995b00807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount_9aa83fbe-3447-4110-8b71-6dcab1580b47" xlink:href="sgmo-20240930.xsd#sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a7c1785f-c3f8-402d-bfc4-16dbb5bbdbbb" xlink:to="loc_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount_9aa83fbe-3447-4110-8b71-6dcab1580b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_7d846bdc-3007-4c29-b0b0-808507cccec8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a7c1785f-c3f8-402d-bfc4-16dbb5bbdbbb" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_7d846bdc-3007-4c29-b0b0-808507cccec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_2e015355-a6eb-43c9-8868-bded2c371bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a7c1785f-c3f8-402d-bfc4-16dbb5bbdbbb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_2e015355-a6eb-43c9-8868-bded2c371bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_6c851b99-0ad9-4787-b57a-dae08a73f0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a7c1785f-c3f8-402d-bfc4-16dbb5bbdbbb" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_6c851b99-0ad9-4787-b57a-dae08a73f0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLeasehold_090d5578-1512-40a1-8929-def58f2a434f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLeasehold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a7c1785f-c3f8-402d-bfc4-16dbb5bbdbbb" xlink:to="loc_us-gaap_ImpairmentOfLeasehold_090d5578-1512-40a1-8929-def58f2a434f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_8dad6019-1198-4e24-878b-351bd4b3dbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_a7c1785f-c3f8-402d-bfc4-16dbb5bbdbbb" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_8dad6019-1198-4e24-878b-351bd4b3dbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2c54c2c6-7c0b-4987-a7c8-76c00b42cf5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_05442794-e0dc-455b-becb-baf68d06b8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2c54c2c6-7c0b-4987-a7c8-76c00b42cf5c" xlink:to="loc_us-gaap_OtherCommitmentsTable_05442794-e0dc-455b-becb-baf68d06b8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4abd4c2d-7ca2-4e5b-b805-0a2c8ffd7262" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_05442794-e0dc-455b-becb-baf68d06b8fe" xlink:to="loc_srt_StatementGeographicalAxis_4abd4c2d-7ca2-4e5b-b805-0a2c8ffd7262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_51edebf7-1ebf-4324-a052-15afd0dc4374" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4abd4c2d-7ca2-4e5b-b805-0a2c8ffd7262" xlink:to="loc_srt_SegmentGeographicalDomain_51edebf7-1ebf-4324-a052-15afd0dc4374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember_b3615a19-c817-46ab-834e-1a450339adb5" xlink:href="sgmo-20240930.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_51edebf7-1ebf-4324-a052-15afd0dc4374" xlink:to="loc_sgmo_RichmondCaliforniaMember_b3615a19-c817-46ab-834e-1a450339adb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_1573ec5a-82f7-4701-b2c7-f0bedd3eabcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_05442794-e0dc-455b-becb-baf68d06b8fe" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_1573ec5a-82f7-4701-b2c7-f0bedd3eabcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OperatingLeaseRightOfUseAssetModificationReduction_1d57e408-b97a-4a6c-9cbd-277f16f2c1a3" xlink:href="sgmo-20240930.xsd#sgmo_OperatingLeaseRightOfUseAssetModificationReduction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1573ec5a-82f7-4701-b2c7-f0bedd3eabcd" xlink:to="loc_sgmo_OperatingLeaseRightOfUseAssetModificationReduction_1d57e408-b97a-4a6c-9cbd-277f16f2c1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_53368e10-4076-4dc0-8411-8e3e004aa2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1573ec5a-82f7-4701-b2c7-f0bedd3eabcd" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_53368e10-4076-4dc0-8411-8e3e004aa2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_3af4d6e0-59ca-4a01-b2a6-ed1b6ce2c37f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1573ec5a-82f7-4701-b2c7-f0bedd3eabcd" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_3af4d6e0-59ca-4a01-b2a6-ed1b6ce2c37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination_b3700ab2-c762-4882-ae16-4215813cac6a" xlink:href="sgmo-20240930.xsd#sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1573ec5a-82f7-4701-b2c7-f0bedd3eabcd" xlink:to="loc_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination_b3700ab2-c762-4882-ae16-4215813cac6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount_80e984af-bf1e-42b7-b086-c81ba6327258" xlink:href="sgmo-20240930.xsd#sgmo_LesseeRequiredLetterOfCreditOutstandingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1573ec5a-82f7-4701-b2c7-f0bedd3eabcd" xlink:to="loc_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount_80e984af-bf1e-42b7-b086-c81ba6327258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#STOCKBASEDCOMPENSATIONDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8cb1f3b8-0f7e-4460-8af5-5c7bf3a697b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_74369eb4-3236-4b55-89fe-57b5b93711a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8cb1f3b8-0f7e-4460-8af5-5c7bf3a697b0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_74369eb4-3236-4b55-89fe-57b5b93711a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d4cefd38-05bb-42f5-8076-e306e5e3f46a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_74369eb4-3236-4b55-89fe-57b5b93711a8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d4cefd38-05bb-42f5-8076-e306e5e3f46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4654b915-ecf1-47fc-b3e4-52fc5f78e1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d4cefd38-05bb-42f5-8076-e306e5e3f46a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4654b915-ecf1-47fc-b3e4-52fc5f78e1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_308a6d9f-0fdd-4886-bf11-5bcd5fccaae4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4654b915-ecf1-47fc-b3e4-52fc5f78e1c4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_308a6d9f-0fdd-4886-bf11-5bcd5fccaae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_89ebe3f8-b049-4778-bd0d-2493c9c281ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4654b915-ecf1-47fc-b3e4-52fc5f78e1c4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_89ebe3f8-b049-4778-bd0d-2493c9c281ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_46357525-a70b-4cf3-9823-647f88fac2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_74369eb4-3236-4b55-89fe-57b5b93711a8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_46357525-a70b-4cf3-9823-647f88fac2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d75c94d7-9394-42d6-9dec-4dfd22190ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_46357525-a70b-4cf3-9823-647f88fac2f8" xlink:to="loc_us-gaap_ClassOfStockDomain_d75c94d7-9394-42d6-9dec-4dfd22190ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreFundedCommonStockWarrantMember_215d9811-567d-47c6-91dd-2c2f5d607759" xlink:href="sgmo-20240930.xsd#sgmo_PreFundedCommonStockWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d75c94d7-9394-42d6-9dec-4dfd22190ad3" xlink:to="loc_sgmo_PreFundedCommonStockWarrantMember_215d9811-567d-47c6-91dd-2c2f5d607759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_869c7643-1fe4-4df2-9108-ad1a2d3dbe61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_74369eb4-3236-4b55-89fe-57b5b93711a8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_869c7643-1fe4-4df2-9108-ad1a2d3dbe61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f56ed8a4-e53d-4d5c-9d65-8e985e9cc4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_869c7643-1fe4-4df2-9108-ad1a2d3dbe61" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f56ed8a4-e53d-4d5c-9d65-8e985e9cc4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ddfba15f-ee34-4a51-8b37-e7d78475ec70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_869c7643-1fe4-4df2-9108-ad1a2d3dbe61" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ddfba15f-ee34-4a51-8b37-e7d78475ec70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#STOCKHOLDERSEQUITYDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9accf2f7-9d0b-49e0-a02e-a3da90be4b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd32be57-4962-4f33-b39f-ac0fdbc1c78a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9accf2f7-9d0b-49e0-a02e-a3da90be4b2f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd32be57-4962-4f33-b39f-ac0fdbc1c78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_db1223dc-91ea-4ba6-8493-15019da60b52" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd32be57-4962-4f33-b39f-ac0fdbc1c78a" xlink:to="loc_srt_CounterpartyNameAxis_db1223dc-91ea-4ba6-8493-15019da60b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d21cbd9c-6dcf-4442-8dbe-4f414545d5a8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_db1223dc-91ea-4ba6-8493-15019da60b52" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d21cbd9c-6dcf-4442-8dbe-4f414545d5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember_fa702eb9-4ac5-486d-a27f-fc06a56708a7" xlink:href="sgmo-20240930.xsd#sgmo_JefferiesLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d21cbd9c-6dcf-4442-8dbe-4f414545d5a8" xlink:to="loc_sgmo_JefferiesLLCMember_fa702eb9-4ac5-486d-a27f-fc06a56708a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_70cee94a-f617-4672-b7f3-8f1ba9f763b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd32be57-4962-4f33-b39f-ac0fdbc1c78a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_70cee94a-f617-4672-b7f3-8f1ba9f763b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbebf454-d69a-44fa-8f88-4c3f42bf02c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_70cee94a-f617-4672-b7f3-8f1ba9f763b1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbebf454-d69a-44fa-8f88-4c3f42bf02c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingProgramMember_c3702a0d-da96-4437-873b-af50468feddb" xlink:href="sgmo-20240930.xsd#sgmo_AtTheMarketOfferingProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbebf454-d69a-44fa-8f88-4c3f42bf02c0" xlink:to="loc_sgmo_AtTheMarketOfferingProgramMember_c3702a0d-da96-4437-873b-af50468feddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_3feadd08-a6e5-4b0d-baf8-d2219ceb0f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbebf454-d69a-44fa-8f88-4c3f42bf02c0" xlink:to="loc_us-gaap_PrivatePlacementMember_3feadd08-a6e5-4b0d-baf8-d2219ceb0f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3614340b-7a1c-4427-8098-9f9fe7a8b48d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd32be57-4962-4f33-b39f-ac0fdbc1c78a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3614340b-7a1c-4427-8098-9f9fe7a8b48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8cce2858-3e1f-464d-9fd8-a30f0e228899" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3614340b-7a1c-4427-8098-9f9fe7a8b48d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8cce2858-3e1f-464d-9fd8-a30f0e228899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommonWarrantMember_f181a1ba-a66e-4c6d-bd50-57e2f0ebb93f" xlink:href="sgmo-20240930.xsd#sgmo_CommonWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8cce2858-3e1f-464d-9fd8-a30f0e228899" xlink:to="loc_sgmo_CommonWarrantMember_f181a1ba-a66e-4c6d-bd50-57e2f0ebb93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreFundedCommonStockWarrantMember_e1bf7db9-4273-4b1d-a44d-008153b89fc3" xlink:href="sgmo-20240930.xsd#sgmo_PreFundedCommonStockWarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8cce2858-3e1f-464d-9fd8-a30f0e228899" xlink:to="loc_sgmo_PreFundedCommonStockWarrantMember_e1bf7db9-4273-4b1d-a44d-008153b89fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bf5a03fd-9c9a-4f9c-a547-c96ea1d07e20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd32be57-4962-4f33-b39f-ac0fdbc1c78a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bf5a03fd-9c9a-4f9c-a547-c96ea1d07e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ec7fa202-b831-4cbd-895a-e622c9eb37c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bf5a03fd-9c9a-4f9c-a547-c96ea1d07e20" xlink:to="loc_us-gaap_ClassOfStockDomain_ec7fa202-b831-4cbd-895a-e622c9eb37c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreFundedCommonStockWarrantMember_18f1052b-96de-42dd-b493-3fb498985610" xlink:href="sgmo-20240930.xsd#sgmo_PreFundedCommonStockWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ec7fa202-b831-4cbd-895a-e622c9eb37c9" xlink:to="loc_sgmo_PreFundedCommonStockWarrantMember_18f1052b-96de-42dd-b493-3fb498985610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_719d9a1c-6227-46c7-ac3f-f74f9df28529" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd32be57-4962-4f33-b39f-ac0fdbc1c78a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_719d9a1c-6227-46c7-ac3f-f74f9df28529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_97ccdc05-e287-42c2-8a4d-8bb11d242c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_719d9a1c-6227-46c7-ac3f-f74f9df28529" xlink:to="loc_us-gaap_EquityComponentDomain_97ccdc05-e287-42c2-8a4d-8bb11d242c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_23c56409-20f5-4d5d-9678-50e7faaebf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_97ccdc05-e287-42c2-8a4d-8bb11d242c5b" xlink:to="loc_us-gaap_CommonStockMember_23c56409-20f5-4d5d-9678-50e7faaebf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd32be57-4962-4f33-b39f-ac0fdbc1c78a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2011e3e3-2af9-4a6e-a3f8-0e27e9d84294" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2011e3e3-2af9-4a6e-a3f8-0e27e9d84294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue_af0dac09-20f4-4fbf-b990-84b12ca0403d" xlink:href="sgmo-20240930.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_sgmo_StockOfferingProgramMaximumValue_af0dac09-20f4-4fbf-b990-84b12ca0403d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_f233ef83-3ed6-4582-b93e-510792da7e16" xlink:href="sgmo-20240930.xsd#sgmo_SaleOfStockIncreaseToAggregateOfferingPrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_f233ef83-3ed6-4582-b93e-510792da7e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockOutstandingAmountAvailable_40dbd3a0-69b2-44fc-b60f-b89854a083c2" xlink:href="sgmo-20240930.xsd#sgmo_SaleOfStockOutstandingAmountAvailable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_sgmo_SaleOfStockOutstandingAmountAvailable_40dbd3a0-69b2-44fc-b60f-b89854a083c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1b6d5262-b253-4b91-b41a-87a896592cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1b6d5262-b253-4b91-b41a-87a896592cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e9ecc827-6506-4182-9623-cda7f5a4af72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e9ecc827-6506-4182-9623-cda7f5a4af72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_04538e73-a80e-439c-9356-8e2710712508" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_04538e73-a80e-439c-9356-8e2710712508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_04f63701-3ba9-4ed5-9597-c2732d8f0dad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_04f63701-3ba9-4ed5-9597-c2732d8f0dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_48573e20-2577-44c0-ba91-d1da06f0350d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_48573e20-2577-44c0-ba91-d1da06f0350d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_66803fb0-1629-4f09-96f7-53c352548fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_66803fb0-1629-4f09-96f7-53c352548fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit_27157c78-7f4e-4662-be1b-c6be6ef4a750" xlink:href="sgmo-20240930.xsd#sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit_27157c78-7f4e-4662-be1b-c6be6ef4a750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_caef4bb7-a379-4fca-8d40-14e11ea7cb79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_caef4bb7-a379-4fca-8d40-14e11ea7cb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_60b258e6-94b5-4be6-b3f8-125079d5da89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_SharePrice_60b258e6-94b5-4be6-b3f8-125079d5da89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance_38dc14bf-6ae3-4544-8fd1-3755d0af61d5" xlink:href="sgmo-20240930.xsd#sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance_38dc14bf-6ae3-4544-8fd1-3755d0af61d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_7bade6ff-b658-4267-a178-54a03cecacd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_7bade6ff-b658-4267-a178-54a03cecacd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3813e723-e030-4b34-9ebb-b93b7589fa92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3813e723-e030-4b34-9ebb-b93b7589fa92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds_e5d8fcc9-4323-444b-a8fa-776b67fbd5ef" xlink:href="sgmo-20240930.xsd#sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds_e5d8fcc9-4323-444b-a8fa-776b67fbd5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockAgentPlacementFees_1cd4313d-764d-4c60-853e-3dcfa6275ea7" xlink:href="sgmo-20240930.xsd#sgmo_SaleOfStockAgentPlacementFees"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_sgmo_SaleOfStockAgentPlacementFees_1cd4313d-764d-4c60-853e-3dcfa6275ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockOtherOfferingCosts_6f90333c-4a31-4c40-a547-ddbac304aea1" xlink:href="sgmo-20240930.xsd#sgmo_SaleOfStockOtherOfferingCosts"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_sgmo_SaleOfStockOtherOfferingCosts_6f90333c-4a31-4c40-a547-ddbac304aea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e80f5d86-ece1-47ef-b4fe-9874181034f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6ec555-e0bb-4c9c-9ce6-7e871ecd258b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e80f5d86-ece1-47ef-b4fe-9874181034f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#RESTRUCTURINGCHARGESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_8dfb15fe-0794-4424-9d16-08d29929419e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03f53d7b-f553-4061-aa7b-c93a949eded6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_8dfb15fe-0794-4424-9d16-08d29929419e" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03f53d7b-f553-4061-aa7b-c93a949eded6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_df468b48-8773-48b6-a2a0-6b6534eac242" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03f53d7b-f553-4061-aa7b-c93a949eded6" xlink:to="loc_us-gaap_RestructuringPlanAxis_df468b48-8773-48b6-a2a0-6b6534eac242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_0a7be46f-cfce-4b0c-9594-a3d316ca24a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_df468b48-8773-48b6-a2a0-6b6534eac242" xlink:to="loc_us-gaap_RestructuringPlanDomain_0a7be46f-cfce-4b0c-9594-a3d316ca24a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_April2023RestructuringPlanMember_e6a00c6b-b0bf-4cae-8e1e-dd17c556e9fd" xlink:href="sgmo-20240930.xsd#sgmo_April2023RestructuringPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_0a7be46f-cfce-4b0c-9594-a3d316ca24a9" xlink:to="loc_sgmo_April2023RestructuringPlanMember_e6a00c6b-b0bf-4cae-8e1e-dd17c556e9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_November2023RestructuringPlanMember_2492b6fe-a264-42f9-a639-39e2ffd3e31d" xlink:href="sgmo-20240930.xsd#sgmo_November2023RestructuringPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_0a7be46f-cfce-4b0c-9594-a3d316ca24a9" xlink:to="loc_sgmo_November2023RestructuringPlanMember_2492b6fe-a264-42f9-a639-39e2ffd3e31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FranceRestructuringPlanMember_a26d5475-9ff4-4de1-bb0d-f4488d50d7e0" xlink:href="sgmo-20240930.xsd#sgmo_FranceRestructuringPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_0a7be46f-cfce-4b0c-9594-a3d316ca24a9" xlink:to="loc_sgmo_FranceRestructuringPlanMember_a26d5475-9ff4-4de1-bb0d-f4488d50d7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_c0e96729-d4ee-45f8-bad8-766886122738" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03f53d7b-f553-4061-aa7b-c93a949eded6" xlink:to="loc_srt_TitleOfIndividualAxis_c0e96729-d4ee-45f8-bad8-766886122738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_035b197e-e24c-46c2-b337-2dd6def76957" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_c0e96729-d4ee-45f8-bad8-766886122738" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_035b197e-e24c-46c2-b337-2dd6def76957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FullTimeEmployeesMember_bd61057c-81ac-4ec4-8255-efc9480f1acc" xlink:href="sgmo-20240930.xsd#sgmo_FullTimeEmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_035b197e-e24c-46c2-b337-2dd6def76957" xlink:to="loc_sgmo_FullTimeEmployeesMember_bd61057c-81ac-4ec4-8255-efc9480f1acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractedEmployeesMember_7d5b4ad0-f1fb-4c7e-b4a9-fe8fac79398e" xlink:href="sgmo-20240930.xsd#sgmo_ContractedEmployeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_035b197e-e24c-46c2-b337-2dd6def76957" xlink:to="loc_sgmo_ContractedEmployeesMember_7d5b4ad0-f1fb-4c7e-b4a9-fe8fac79398e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0fd5a1c9-39cc-4d55-a621-d9a586c86f76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03f53d7b-f553-4061-aa7b-c93a949eded6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0fd5a1c9-39cc-4d55-a621-d9a586c86f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c6309507-6b02-4db0-9fdb-6392ba6f5fde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0fd5a1c9-39cc-4d55-a621-d9a586c86f76" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c6309507-6b02-4db0-9fdb-6392ba6f5fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_70f1bf77-2b91-470a-9ed6-963601527732" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c6309507-6b02-4db0-9fdb-6392ba6f5fde" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_70f1bf77-2b91-470a-9ed6-963601527732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ab86fea0-1363-4479-a27f-cd831b91c27d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c6309507-6b02-4db0-9fdb-6392ba6f5fde" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ab86fea0-1363-4479-a27f-cd831b91c27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0f89c2e3-e4e3-4fce-a63a-9d42215b4656" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03f53d7b-f553-4061-aa7b-c93a949eded6" xlink:to="loc_srt_RangeAxis_0f89c2e3-e4e3-4fce-a63a-9d42215b4656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c688261b-a9eb-433c-91c8-59955aeb20c7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0f89c2e3-e4e3-4fce-a63a-9d42215b4656" xlink:to="loc_srt_RangeMember_c688261b-a9eb-433c-91c8-59955aeb20c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2b729adf-4eac-42e2-9a53-547cf4b9336f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c688261b-a9eb-433c-91c8-59955aeb20c7" xlink:to="loc_srt_MinimumMember_2b729adf-4eac-42e2-9a53-547cf4b9336f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ca5bb2cc-7981-4438-95cb-0f25af4305fa" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c688261b-a9eb-433c-91c8-59955aeb20c7" xlink:to="loc_srt_MaximumMember_ca5bb2cc-7981-4438-95cb-0f25af4305fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_fdf9588e-dd18-4b14-bdc4-8e46d5c555e2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03f53d7b-f553-4061-aa7b-c93a949eded6" xlink:to="loc_srt_StatementScenarioAxis_fdf9588e-dd18-4b14-bdc4-8e46d5c555e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_84253d1f-833a-41fe-be85-ea6a77f0e8ed" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_fdf9588e-dd18-4b14-bdc4-8e46d5c555e2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_84253d1f-833a-41fe-be85-ea6a77f0e8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c404435b-1cca-42c4-a55f-07108ccb7678" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_84253d1f-833a-41fe-be85-ea6a77f0e8ed" xlink:to="loc_srt_ScenarioForecastMember_c404435b-1cca-42c4-a55f-07108ccb7678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_0e0c8591-1306-40cd-b09a-71da15784345" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_03f53d7b-f553-4061-aa7b-c93a949eded6" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_0e0c8591-1306-40cd-b09a-71da15784345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_61e4e272-9d5f-4380-89b2-a638b88d0589" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0e0c8591-1306-40cd-b09a-71da15784345" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_61e4e272-9d5f-4380-89b2-a638b88d0589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_19765bac-bb0a-4f95-89e3-ce0639ede054" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0e0c8591-1306-40cd-b09a-71da15784345" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_19765bac-bb0a-4f95-89e3-ce0639ede054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e3cb2742-1fbd-4342-a8c4-ea858522a05f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0e0c8591-1306-40cd-b09a-71da15784345" xlink:to="loc_us-gaap_RestructuringCharges_e3cb2742-1fbd-4342-a8c4-ea858522a05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_f591eb07-2ebb-4ffc-a094-4328e9a6c640" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0e0c8591-1306-40cd-b09a-71da15784345" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_f591eb07-2ebb-4ffc-a094-4328e9a6c640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_08e75284-24bc-489e-9366-a7dd3af509c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0e0c8591-1306-40cd-b09a-71da15784345" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_08e75284-24bc-489e-9366-a7dd3af509c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_4b9422dc-fa1a-4033-85e4-600c65f56f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0e0c8591-1306-40cd-b09a-71da15784345" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_4b9422dc-fa1a-4033-85e4-600c65f56f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails" xlink:type="simple" xlink:href="sgmo-20240930.xsd#RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ceba99f2-0cab-42b7-a9b3-69416b64543b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_254dc2a3-dff3-441f-9cd6-0052b5a68e62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ceba99f2-0cab-42b7-a9b3-69416b64543b" xlink:to="loc_us-gaap_RestructuringReserveRollForward_254dc2a3-dff3-441f-9cd6-0052b5a68e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_3fa5a943-4ae0-41e8-b7bc-cf8416b70af4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_254dc2a3-dff3-441f-9cd6-0052b5a68e62" xlink:to="loc_us-gaap_RestructuringReserve_3fa5a943-4ae0-41e8-b7bc-cf8416b70af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_90e19026-6027-4939-8558-67d048fa13e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_254dc2a3-dff3-441f-9cd6-0052b5a68e62" xlink:to="loc_us-gaap_RestructuringCharges_90e19026-6027-4939-8558-67d048fa13e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_b9efd1cf-d789-42b4-8052-1b6e4333fcac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_254dc2a3-dff3-441f-9cd6-0052b5a68e62" xlink:to="loc_us-gaap_PaymentsForRestructuring_b9efd1cf-d789-42b4-8052-1b6e4333fcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_db243ac3-2fa5-4fbe-bb94-9e51fcd9bded" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_254dc2a3-dff3-441f-9cd6-0052b5a68e62" xlink:to="loc_us-gaap_RestructuringReserve_db243ac3-2fa5-4fbe-bb94-9e51fcd9bded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>thirdamendmenttoleaseagr001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 thirdamendmenttoleaseagr001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOL4\\?SH/D/[PXZCR]Q_[9BLKQP+'3OCGX%M()8T@LX((L%Q\@$C@ GUZ=:
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M_BAJWA_5IHK>VLX&N!##"H93N3$98YS@.03WQ3K#Q;XCOOC%J_A!M62+3[.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@"+[-!@#R8\#H-@H^RV__/"+_O@5+10!&8(F?>8D+>I49I[*K## $=<$4M%
M#7C208=%8=<,,TB0Q1DF.-$)Z[5 I]% !4;6\#L6:&-F/4E0:DHH 0 *H50
M!T J":PL[B99IK2"25>CO&"P_$BK%% !4;P0R-N>)&/JR@U)10!$+: $$01@
MCH=@H-M S$M#&2>22HYJ6B@"-;>%#E88P2,<**5(8HP0D:+GKA0,T^B@"(6T
M"G*PQ@^H44U[&TDECE>U@:2,81S&"5^A[5/10 QX8I#F2-&([LH--^RVX.1!
M%_WP*EHH 0@,"" 0>"#35AB12J1HH;J H&:?10!&MO"C!DAC5AT(4 TVYL[:
M\0)=6T,ZCD"5 P'YU-10!'%;PP1>5#%'''_<10!^0I%MX%8,L,8(Z$**EHH
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MM)*(5G%O+Y9D) "[MN,Y(XSWJPWC7P^FO#0VOV&JGI:?9Y/,/&<XV],<Y]*
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M2BL&'R^9UXQUJO<_"JWU+X;6WA'4KZ.62R'^B7T=OL:)LDY*ECGK@C(S]<4
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M!<SZI-:PNPW".&$!8UQZ EFQZL?6NZKD/"NG'PQK6MZ3(-MM?7SZC8R'HPD
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M-O;1B.)+^+:H]PY/ZUZY7'_$7P5/X\T&/2%U*.QA699F<VYE8E00 /F7 YH
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M>X-OY91LL>H;!^\<\#\* .UHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-8OE'T.XG\:B^$OEOX LKFXVXLI;J""9S]R$2GOZ?*!]%H Z[0O$.E>)=/\
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M.VI2_%KQ)')J3/;06MH4A,0P$;S3M'ISSGJ?RKE/#&K:WX?^&?A_5;:ZM?L
MU$V\MHT!+2))=NA;?G@@MP .W.<\ 'LU%<1J.OZWJ-[KMKH*2K+I;""(I#&Z
MS3>6LF'W,"%^95XP>ISVKH[+[=JWAF,:E;MI]]<VVV>)&#&%RN#@@G.#TYH
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M0W/:RJT4RCUV. V/?%:]>(?'6232?%/@S6M.RFJ+/(BLGWG560A3ZCYF&/\
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MDLT:[EC-Y(D=L9;29%E9ONA690#G/K6[--%;023SRI%#&I9Y'8*J@=22>@H
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MN4 <2/ =TGQ#O_%R:Q$);NS-I]F-F2$&% .[S.3E0>GMQUKG1\&)1\/#X/\
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M0&!)/)X%>@S1>=!)$690ZE=RG!&1U'O7G]I\.]6M].\/V;>(X2NAW7FVS)8
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M"Y^4^8W'SGJ.U6OB)X*F\>: FD+J:6$(F69G-L96)4$ #YUQU]Z *?A6\O\
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M>,_10H_"K5OH]ZOB:[U2[OK>XMY8DA@M_LI5H%4L3A]YR26Y^49VCTH \Z^
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M[8$.4"S#C> JY!)SD\"NB/A^YU'6=/U/5KR&8Z>DGV9+:(H-[KM,A)8\[<@
M=,GD\8YVV^'.JV^D:'IW_"1Q&/1;];JU86'+*-_$GS_,WSGD8'J#V +&GZIX
MMUCQ-KFGV]_IEO!I5]#&6-HS&6)HPY7&_@X/7)R?3OSVGZ[XBT?X4:]K\6I0
M7%W;WET0;FWW9(G*D\,.W08P,8Q7=Z#X<NM'U_7-2FU&*Y359DF,2VQC,95
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MQ@&NZNM<U*/XAZ;HR26_]GWFGS7 !B/F*Z%0,G=@CYN@ ^M9LGP]O9?!^O:
M^MP?\3>\ENFG%B?W7F.&90OF\\C@Y_.M=_#-[+XNTO7I-3@_T*T>U:!;0CS-
MY4LP;S/E^Z,#!_&@#D/^$G\;W/A76-?MKC2?^)/=W226WV5_])CA8AN=_P G
MR@X^\2>XKTC2=035M&L=2B4K'=V\<ZJ>H#J& _6O.?!VEWNN^&/$NG1ZA!%I
M]YK%]%*RQ%I51I"'"G=CYE/!(XSGFO3;6VAL[2&UMT"0PHL<:#HJ@8 _(4 2
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%9VO:E_8WAW4]4VAS9VLMP%/?8A;'Z4 3
M/J=C'/<0O=1*]M'YL^6XB7U8]%XYY[<TV.ZL(YHQ'M2:[!D"B,AW '+$8SCH
M,GU [BO-O"^B:GXE^",?V34!!K6IS&_>\E&0\PGW@MP>,(J]#P.AZ5JZ?X4\
M9VOBK1]6N/$EO-$ME';ZK'Y7,[)O(V?+P,OU^7D9P>@ .FM?%^@WVL2:1;:@
MLNHQY\RV6-_,3& 2PQP.1R?6MNO%O!G_ "<KXP_Z\F_]"@KU;Q!?7VGZ%>W&
ME68OM1CA+P6I;'F-_AS_ $H TZ*\LT+X@ZK-\1M(\/7,UM=6^I:=]HEV1@&U
MG"N7C#*2K %"#UY[\&LJY^(7B^3_ (3Q;:YTV)/#<H\MVM69Y5WN,'YL X7K
M^G/ ![163!XFT:YU2[TN&^1[^SC,D]L%;S$48Y*XSW'UR*X/4_B3J3Z+X(BL
M(K>#5/$S1AY70NENORAV"YY.6X!/:L[PDEU%^T7XK2]FCGG72XPTD<>P,,08
M.,G!QC/O0!ZEHVO:7XALFO-(OHKRW60QM)$<@, "1^1'YUHU\Z^!/&;^!?@A
MJ6J00)-=R:T]O;I)G;O:-#EL<X 4FO3+/Q9J>G_$J+P9JLT5R;O3Q=6]TD6Q
MED&[<I ."/D8CN.ASUH [ZJNHZC::38RWM],(;:(;I)""0@]3CH/>O+?!WB_
MQ[XSM[I[/^QHEL-5$$\DL;KYD(QD* 3AL9.?<8QBJNK>+=8\8Z!\0C:S6MMI
M.DPS6J0M"6><!7#L6R-IXR,#OS0!Z1<>-?#5K8Z=>SZQ;1VVHOLM)2QVRG.#
MCVSW/ I\7C#P_/=ZC:Q:K;M-IK;;Q 3^YYP2W'0'J>@[XKA/"'A.Q\7?!WPS
M9WMK;R(B,WG2+EXAO.[9Z$@8SGCKSBNST[PCI]CXHU+74M+6&:\B,++"G^L!
M;<SN>[,<<=L=\F@#HE974,I#*1D$'((I:\X^$>IS/;>(?#TKL\>A:I+:VY8Y
M(AW-L7\-I'TP.U>CT %%%<_KVHZC9ZE9P0RVUI82QR&2[D DD,HQLC2/(+$Y
M8\ \+CB@#H**\U3QYKMSX)\-:U;P6(N=0U6/3[F-T<*<S-&2O.5SL[AL9]JT
M8_%NHZ)K7B&R\0RVMQ!IVG+J<<UI T1V$N&0J6;)RO!SWH ZC4]=T[1YK**_
MN/*DO9UMK<;&;?(QP%X''XUHUY=XGFUF^LO ^HWTUJ(KK7+*5K:.(@PELE0'
MS\V 2#D<GD8Z5ZC0 5FW^O:;IMW':7$[&ZD0R+!#$\LFP'!;:@)"YXR1BM*O
M'_'$'C'PGX\N/&?ANU75K&>WC@O;, LT80>@^8#'S C.,G(QU /5--U;3]8@
M>;3KR&ZBC?RW:)MP5\ E3[@$9':I3>6POEL3.GVIHC,(L_,4! +8],D"N1^'
M'BS1?%VDW^IZ9;O9W$ESYE_;2$?)*45<@CJ"$'/<@YKS3Q5XCFT3XD>'_'PO
MTFTV]+6DD".&,-MG"Y Y^93YF#T(Q0![=K7B#2O#MLMSJ]XEI S;1+(#MSZ9
M P#3CKFF_P!BKK"W:/IS1^:+B,%UV==W&>/4]JR_&FGV>N>&TL+M!-9W=U;1
MN ?O*TJ]"/YUX[9ZC?\ PBU'5?!FN2O-X?U&"9M-NV'",RD#Z9) 8=C@]#D@
M'O1U:P72O[4DNHX;'9YAGF/EJ%]26Q@5F1^-O#TD"7!U#RK5_N74\,D4#>F)
M74(<_7FO*_BW=37WBOP)X9G8KI5W-"\Z=%E)D5,'UP,_]]5ZSXCU70=(TAH]
M?EA@TZ=3 WG1DQD$8VD@8&1VH U;:XAO+6&YMW$D,R+)&XZ,I&0?RIMM>6UX
M9Q;SI*8)3#+L.=C@ E3[\BL3^UK#1_ \%WITGFVL5O'#9--E!*2 D620."2O
M/3!S7F'PYU*7PG\6=<\)WNI+?0:JQO+>ZW B24C<3QQDC<#[H* /5M7\8>']
M NX[75]4ALII.8Q."H?Z'&#UK4O;VVTZQFO;R=(;:!#))*YP%4=2:\[^+'A7
M_A+;62RCCWWD&FS7-KQSYB21G ^HW+^-8?AGQ0?'/PO@L)7WSV%K*=1SW\E/
MW6?=F*-[^6XH ]3T7Q'I'B*!Y]'O4O(4;:TL2DH&]-V,9Y'%5I/&.@1M<@:B
MLBVIVW$D,;RQPGN'=057'?)&*\0\*:I>:/\ LS:[=V#M'<?;&C$B'!17:)&(
M]#ACSVKU/X165O;?"K1$B1=LT+22<?>9F).?7T_"@#L[2[MKZUCNK2>*XMY5
MW1RQ.&5AZ@C@U-7BGP*N[B#7/&&A1LS:;9W>ZW7/$9+NI ^H4?E7M= %>^OK
M;3;&:]O9E@MH$+RROT51U)K#;Q]X72YAMFU>)9YU#11%'#2 ]U&,D<'I6[=V
MD%_:O;7,8DADX=&Z,,YP:\=\=?\ )Q7@O_KW7_T.6@#TMO&GAU-,FU)M4B%E
M!,8)IRK;8I!CY6./E/S#KZT]_%VA1Z(NM/J"KIC=+LQOY?7 .[&,9XSZURWQ
MBLX+;X4^)988PCW+0RRD?Q-YD2Y_)5'X5QNIWU^?V;$MVTB9;;^SX!]J,T>W
M'F+SMSN_2@#UIO&&@)HHUIM04:83@79C?RNN/O8QC/&?6H#X\\,"VBN6U:);
M>4@1S,CA')Z8;&#7F^I?\FJ)_P!>,/\ Z/6M7X<W%SJ_AK1/#U_I<D>DR:&S
M^<[*1<-YB#Y<$E=H/?!^8<<4 =YJGBS0M$OH;+4M02VN9R!#'(K9E/ PO'S<
MD#BI=/\ $VBZI?26-GJ5O)>QC<]L6VRJ/78<''X5Y7\:'*>/OAW(D;2E;XD(
MA&6_>P\#) R?<@5#87*_$7XYV^K6"OIB>'H?+N8KK"7,I#." @)XRVT\\#Z@
M4 >V32QP0R32NJ11J6=F. H R2:2">*ZMXKB"19(94#HZG(92,@C\*Y3X@'^
MT=&;PU%?Q64^J0RAII'"[(E7GKZL43'HS>E<W\"O$SZKX/DT2\;_ $_19/(9
M2<DQ'.S\L,O_  $4 =A+X\\,07EQ9RZO%'<VREIX61@T0&,EAC@<CD^M79?$
MVBQ:*-9.I0/IA&?M<1\R,#IRRY YXYKR.PN;BT_:.\7/:Z9-J,ITX*+>)XUS
M\D'4NP '8]3ST-+9^"M3\$_ CQ5;:M+']IND:?R(FW+",*,9[GCG'M0!Z:?'
M_A9; 7S:Q$+-NEP4?RSSC[V,=>*MZQXLT+P_-#%JVHQV;S_ZKS58"3I]TXP>
MHZ>M>;?"RYN=2\'Z!X<N]+D&CW6EWADG=E*SGS@NT $D8#MUQGMTJO\ 'H 7
MO@H#I]N;^<= 'K5[K>GZ=#;RWDSPI<.(XBT+_,Y. N,<$]@>35"[\;>'+"2Z
M2ZU2*)K0A;C<K8B)Q@,<8!Y'7UJ3Q/S:6'_82M?_ $:M<S\7;2"T^$WB0P1A
M#,8Y9"/XF,L>2?R _"@#I+/QEX>U">V@M-2CEENE9K=51OWP4%CLX^; !/%/
MTWQ;H6L:C-I^G:BES=P$B:%$;=$0<'=Q\O/'-8GPULX+GX;^%)I8PTEM;B2%
MCU1BK(3_ -\LP_&N%^&,S6_Q.^)<R(7:.YE<*/XB)9#B@#U?4_%.BZ1>Q6-Y
M?HM[*,I:Q*TLK#UV("V/?%2V/B'2-2G>WM+^&2>-"\L.</$!C[ZGE>HZ@5Y7
M\ '.L6_B/Q'?/Y^K7=Z$EF;E@NT-@>@R>G^R/2O1_$?AFUU>RU1TD%K?7FG2
M6!N1Q\K=-WK@_P S0 ]/&7A]T23^TD6&0[8IWC=(I3Z1R$!7/H%)S6[7@%AX
MTUCP7:6W@WXC:&QTE0D%OJ,*Y"JI&P@]'VX!XPPQR":]^5E=0RD%2,@CH10
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M.0O48QZ&@#O**\\\1>,-;T&*]NYS9(;:_BB2P5#*TEL[HGFNZM^[)+,1N '
M&"35I)]7D^,=S:#4(OLD6D1S)"T!(4-*0P!##YCL'S<_2@#K-.U:SU7[7]CD
M9_LEP]K-NC9=LBXW#D#/4<CBKC*KH590RL,$$9!%>?0^/+^V\.:Y>W\5K+>6
MFMOI-HD2LB.VY$0MDD]6+'GH*T[O7=6T+Q7I&E:A+;75KJZR1PSQPF,PSHN[
M##<<HPZ=P1R30!U%O96MGN^S6T,&[[WE1A<_7%3UY9+XV\51>#=0\2NVE>5I
MFH26\UNL#YN$681G:V_Y#@Y_BR?3I7J= !1110 4444 %%%% !1110 4444
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M.QT26\2[-HI59EB,>023TW'UZUKWEY;Z?9RW=U*L4$2[G=NW^)]N]3TA /4
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M[V+S/*7S=IDQ\VSIGVI]% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF95VAL@E_E_7.>V.?2?"&A^*=%TB#3M6U:QNXK*'R;7R(65I !A?-8D\ <8
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M#);':\2F8*J?/A!USD/G-;4?P_U)?''AGQ"]]:;-&T];%H0K9E^1U+ ]OOY
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MU\96NN6S^5!!9+;&U7HSIE8W/J51Y%_$>E3'0+T_$,>(_-M_LPTXV'D\[_\
M6;]^>G7C'XY[4 >;WMUJE_\  +7KS4[R*Z:2>;D0E&W"[(.3N(QQP !@<<UW
MT&NZU:^/+;1-46P:UO[.6YMS;*X>%HV4%&).'&&Z@+]*QY?A_J[>!-5\*KJ=
MD;>YN'>WE,+!D1IO-._GYCG@8P._/2M^YT'4;KQKI.O-):I'96LMN\(+$OYF
MTD@XXQM''?VH 3QWK^H^&M 34-.AMII/M,,+)/GD/(J<8(Y^;O52?Q!KFFWU
MMI.I-8F_O7GFAEL[6:98[:,)]Y!\Q?<X'4#'/L=#QIH%YXET)=.LYX(&^T13
MF28$@>6X<# ]2N*K>*O#.IZO<Z5K&CW\-AK>FE_+:1#)#(C@!XW'!(.!@]1C
M\@#G]>U?Q#J/PS\6K?6RV4UI#/&MPUK(BW<&PX9%9@R,>ASNQCOGC2BUBXTJ
MT\.Z?(;>34;VT9H[B*PD?R8$1"1L5F9B2RCJ!W[8-W4O#^NZOX-U/3+_ %"T
MDU'4H6A>2.-D@@4C&$7))ZDY)R2?0 56UCPCJ][9Z#>:?J-O9:[HJE(92A>&
M9&4*ZNO!PVT'OC'XT 9NI>-?$^E^$]5U"?2H%N+"]BABEF@DACNX9'5%=48[
ME;YN03V]ZU;GQ!KFEWMMIFIFP^V:A-*]L]G;33"*WC52=R#YF?<P'&!@Y[8I
MFN>%O$'B#PC<:=?:G9'4+J6%WDCB=8(5C=7"HF23DKR2<G/L!5OQ5X9U'6FT
MK5-+OXM/US3'9X7=3)"X< /&PX)4X'/48H P=3\:^)]+\)ZSJ$VEP+/I]U%'
M#/-;RPQW<4CJH=48[E8;N03CCWK67Q-JVF>,9-+UL6)LI--EU")[5'#0B-@&
M1BQ._@YW +TZ4S6_"WB#Q#X/N]-U#4[(ZA>/$7>*)U@A6-U<*BDDDDCDD]_8
M"K=]X9O-2\86NL7#6OV1-/EL9K<%BSB0@L0<=L8Q_*@"/3M8\3:G9Z'K%K:6
M4NGZBR236W*RVT#KN5]Y;#$#&5"]^.F:SKSQIK-SI]UJ6@V7VQ;>[>&.R^P3
MLURD<AC<B8?(IR&(X/ &>3@6?#'A;Q+H,-OH\VN6L^A6;@VY6!A=,@.5C9MV
MT*. 2!D@8XS4=EX1\2Z)JE]!HNN6D6A7UP]RT4]NSSVK.<N(B"%Y.2-P(&>A
MYR =A=/<2:9*]LX@G:(LC2Q[MAQW7(SCTS7GGA;Q3J5G\/?#4UU/!=ZCK=PD
M%N7C9=KNS,[R'<=V ">-N>!QG(]*\I?)\K)V[=N2<G&/4UY];?#O48_!VEZ1
M+JMN+W1;E+C3+F. @ H21Y@+?-N#8(&/QH V[;Q#?V?C=/#6K"WE^UVC75G=
M6\9C#;3AXV4LW(R""#C':J?Q$NM4M1X<33[V.W2YUNV@E5H2^_+%ADAA\N5&
M1U/J.^I:Z%<W'B6'7]6-N+JWM6MK>&W+,B;B"[EF ))P !@8&>N>#Q?X?NM?
ML].^Q7,,%U8:A#?1&9"R,8\_*V"#@@GI0!S<ZZN?B[=1Z?+9+>GP["'GGB8Q
M@^>^2(PV3D]MW'J<<SZ7X^N;_P .:#++!'%JFJ33P.(H9)DC,)<.X1?F8':,
M#/&[D\5JV_A_5(?&\OB&2>TE#Z:EB8P&0EE<OO[X!+$8YP.YK!B^'6JVWAK3
M+>UU:"WUG2;V:[L[M(RT;"5F+QNI_A(;''I0!T?A?5]8U"ZU2UU:Q:-+65?L
MUZ+9X$NHV&>$?+!E(P>?3%8OC4:DWCKP6EM=VT<;W<YC62W9]KBW?EL.-PP2
M .,>IZ5U&A6NLPQ23Z[>VUQ>28&RTC9(8U&?NAB22<G))]!CBJ'B#0=0U3Q)
MH&IVLMLD>E2R2F.7=F4NA0C('RX!)SS0!6MM6U'5=3URQT(Z?;G3)%BEEFMV
M87%RR!FX5QM49 S\QSGTYYK5_$:^*_"G@[5?LYMY6\26D<T!.?+D21E89[C(
MX]C740^&]2T?Q/JNJZ--:M!JP1[FVN=P$<RC;YB%0<@CJIQDCJ*HW/@*:'P]
MH.E:==0YTW4X]2FFG4@SR*Y=A@=-S,?7 P.: $FN(K3XS7ES,VV*'PPLCMZ*
M+AR3^50W7C76+3P5;>-6@M'TI]DTMD(V\Y+=V #"3=@N 02-H'49XR=B3PS=
M7/CFXUNX>V:RN-+&FO;Y;=MWERV<8_B(Q^.:R[?P-J*^$AX.NKZWFT17"K<8
M87#6X?<(BOW<\;=^>G\.: +I\1:HGC#4-&EET^*!M.^WZ=<-"^& ;#ASOYV\
M=,<-GC%5?#?B_4O$7AC1[N/[''J=W>/;W,)@?;#Y>XR#;OR" O!)ZLO S6KX
MF\)1>(;S1K@3& V$S>9M'^M@="LD7T;Y<^PI=(\)Q:3XMUC6HYB8[_:Z6_\
M#$Y $K#W?9&3_NT 9J^*=7-_XTM?(L=^B1126W#8<-$9#O.?8#C%4K'QAXA\
MKP=J%_%IIL->\J&2&%'\R.1XBX<,6QC(/RXX]36B/"NIC4_%UV)[3&NPQQ1J
M=W[G9&8P3Q\V0<]NF/>JY\&ZI_8WA"P%S9Y\/S0R,YW?O_+C,8 &/ER#GO0
MW4O&6J"T\6WFGI:1IX=8J8;E&+3[8Q(QR&&T$'"\'IGOBNLT2[N;_1+*\NTC
M2>XB65EC! 4,,@<\YP1GWKS.4W.LZ_KVH:?J7A:6 W?D20ZM&ZR((0%VN%<
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M,&O2R[?G! P!R<9;G'(QST&CQ:K#9NNL7-M<7!F<H]O&441D_*"">H'7_)H
MT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** $V+O#[1N P&QSCT_2EHHH ****
M "BBB@ HHHH **** "D5%0850HR3@#')Y-+10 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 9\^A:/=7HO;C2K&:[&")Y+=&<8_VB,UH444 %%%% !1110 4444 %%%%
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MZ(]D0GD_=L?*C/1WP/D!P>6QT/I0!KT5D:AXJT'2Y8H[W5K2%Y8FFC5I 2R
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M<C)QUP:HV&M6ND3>/=&UV9;?4[J[N+FV68<W5N\06(1_W\!<8&<5ZM2$ G)
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MUG4]2\/:I%=%]0C74/#MV S32910\)^\&("GN.#Z8KU; SG SZT8&0<#([T
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M@''3<!6-#X@TR\TCX8I;7(F:TN8([GRU+>2XMF4HV!PV>W7O7L@  P!@#L*
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M$601P1N(P2<C&.M<-I-]8M\/?AK#-+&&M]:C\U91C9M\W).>P)7GH"17NM%
M'FOBC4K+PY\1+:_UN2YM-$N]-%O#=P/(D<4XE9V5RG3<&!R>I'M75>#K32+3
M1&.AVTT.GSSO-&96<F7=C+@/R 3G'KU[UOD C! (]Z6@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *ANKNWL;62ZNYXX+>)=TDLK!54>I)Z5-5#6_\ D :C_P!>LO\
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ML:WW%V"X(=RP.>A ()';-<78W%G#\%/!R^;"DD>KVS,NX!E*W!+$CM@<GVH
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MU+&%3R0#@X/0X/!QG'>DG\3:-;7T=G-?(DLDOD*65MAE_P">>_&W?_LYS[4
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M(.J*^-I88/R@YXZ54NO'/A>S6X:;6[0"WD\J7:V[8V,D'&>F1D]!GG% '0$
MD$@'%+@>G2N<U7QGINE:YI&ENS2/J(>19$1F18U0MN! .23M&!V.?K;\4^(K
M7PKX<O-8NU=X[="51%)+MV''3)[G@4 ;%(0",$ CWK-77]/&GV]W).56<[8T
M$;%Y&QDJJ8W,>">!T&:GTW5+'5[8W%A<I/&KF-RO5''56!Y5AZ'F@"X0",$9
M%  '05Q'B34M6M?B/X5TFTU6:"QU1;HW$2Q1-_JHPR[2R$C)//\ 2NWZ#K0
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MNLVK?;MHMRK9#EN%&>@)/ !QS5S4]?TS1PWVZZ$>Q/,?",_EI_>;:#M7@\G
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M !1110 4444 %%%% !1110 4444 %%%% !67XEN%M?"VK3O8F_6.TE9K0?\
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M!(8V=S9L0JC)XP3Q]*ZVB@#S6ZUF!/''A?Q ]P&\/RZ?-9I=L"(H9V*L"6/
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MP\,_$[1KF79J4UY>7$=MM)=HGB3:X']W@\]!6PNNV(\0:3:,?L$DV@Q^7?+
M6GNAN_U$>01P1DC!8Y&,=:].P"<X%+0!X9I5]8MX"^&<4TL8-OK$?FK*,;-H
ME!)SV!*\] <5W_Q LY++3[+Q3IL0-YH,INBB#'FV[<3I^*Y;ZK7:5@:KHFIZ
MKJZ;]75-"*+Y^GK; O*RMGF3.0IX!&.0".] %CPW;30Z5]JND*7E](;NX4]5
M9\80_P"Z@1/^ USGQ1N8(='T=99D1O[:LWPS ':LH+'Z <DUW5% &3K'B;1]
M!6Q?4;Q84OIE@MW"EE=V&1R 0![GBK&KZO9:%I5QJ6H3"*U@7<[8R?8 #J3T
M J2_L(]1B2&=F\D.&>,8Q)@Y /MD=!C/3ID5:H X'P[XR\.:QX@2X6^^TZS>
MKY$-O'"Y^SQ#+%=Q4#MN9L\D #.!6)8@^'?AYXH\*RC.JB6[@LK8?ZRZ6?)B
M9!_$#OY(Z;6ST->LT8&<]Z /-/&]@-!^!$FCS2IYUOI\%L.?]8ZE =OKT)KK
MM?T_0_$7AORM4GB^P-ME2Y6<)Y;*<JZOG@@]ZW:0@'J <<\T >?^'-#N-1\<
M-XEGN+V>PL;4V>GR7I'F7!8Y>;: H"X 4<#=R?2I_&44D?Q!\!7S9^RQW=U
MY["22 A/_037=52U32[?5[$VMR& W+)'(AP\4BD,KJ>Q! (_PH Y'Q+=0Z=\
M4_"UU=,8X'L[R!7VDAI#Y9"C'<X.!WKG!=6+^'OBN?.@+RRW.SYAEQ]G"KCU
M^;('O7K4"RK"BSNLDH&&=5V@GUQDXJ2@#R#^V;+1M6\.:IK=Q<Q:)=^'X+6.
M]@ED5(KA3N97,9XW CKW7V.._P#!]II%KHKG0[6:#3YYWGC,K.3*6QF0;SN
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MX(';:V3VP?2O6A&@"@(H"_=&.GTH XR[\2ZAX<U/PZ-:93;:R$M9A@#[+=E
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M5'=)$*[4$TQW<C[H#+ST&10!ZBOCKPT\=TZZK&?LK!9DV/O!()&$QN8$ D$
MC )K1CU[2YM(@U6&]CELK@#R9(\MYA/0*!R3[ 9XZ5R=E=6:_&7693-"!_8\
M"[RP RKN6&?4#!/MBN)TJ[&G>"?"6K3)<R:5INI7HU 6C.)+=9'E"2$(0P #
M?DWO0!ZJ_C/P[%I5SJ4VJ0PVMK)Y4YE#(\3_ -UD(#!O;&:FM?%6B7NISZ;;
M:A'+>01F5XE#9* X)4XPP!X.W/->;^*V\.7?PX\7:IX?CGD&HQ0H]Y*\K?:Y
M%; 51(<G:.X'?'\)QT.I7=FWQ3\(-!/"8_L-VF488^81[!QZX.![4 ;_ (5\
M66GBNWN9[6.:-8KB2)1)"Z95&VY.1C)(/'4=Z=XL\46WA32DO+B.61I9HX(U
M2-F^9F"Y) X SGWZ#DUA?#&YC33=5TUPZW=OJMXTL;(PV!IF*Y.,<@Y'K4WQ
M3!7P8)MK&."_M)I2JD[469"S<=@* .CGU[3K>.!I)9-TZEXXD@D:5E'4^6%+
M8&1DXXR/6K&G:E9ZM8QWNGW,=S;29VR1G(.."/8@\$=JX8:K%IWQ2?5M0F$6
MD:GI4<5E>392)71R6C);&TMG<,]>V:T/A_82VTGB2]4%+#4-7EN+-2,!D(4&
M0#T9@2/48/>@!/BAJFJ:'X/?4M)U"2SN8[B&/*QQN&#R*IR'4]C7801M#"L;
MS23,HYDDQN;ZX 'Z5P/QFGC3P!+"7'FO=6Y2,<LP652<#J< $UT,OC70BT,-
MGJ$%Y=7$BQ0P0-N+,QQSC.T#J2>@!H M:AXGT;2I6CO;T0A'6.20HQCB9L8#
MN!M0G(^\1U'K2ZCXFT?299H[R\V-!&)9]D;N(4.<,Y4$(#@\MCH?2O-;:\T&
M"ZU_POXPAU(WEQJ-Q+#;(]P4OX9'+IL"':3R!CC&/8X=XCOX ?&.BBW?3+A-
M'18X8(3)+J'[AL$O@Y1,[>,'@DG'% 'I]UK5A9F(23,YEC,J+#&TI*#&7P@)
MV\CGIS3'U[34L;6\%P9(;N,2VXAC>1Y4(#95%!8C!!Z<9KSAGM[O3_#U[IGB
M,Z'K5OHT0BFNE M[J/\ BC=7QG#+G(YYR,XXADUQM/U'PUX@\3V-UIFE7>C?
M97:U:5$LY]X8!@AW*K*%P#Z#TS0!ZIIFJ6.LV$=]IUS'<VTF=LB'C(."#Z$'
M@@\BK,LB0Q/+*X2-%+,S'  '4FL#P?;:1!I5Q-H=I-!8W5R]PKRM(3.S ;I,
M2?, 2#]<9[U7\8WEO<K9^&C>+;S:M)Y4C9&4A +/UX^;&P9ZEN^#0!0\#^+;
M_6=<UK3-6A\B=&2^L4(P39RJ-GX@CYO=L=JZJ]U>QT^:.&XF;SY%9TACC:21
ME7&YMJ@G R.<8Y'K7GGC2&7PCXF\.^+I-3FNVCF^P74;QQAFMGSD@(H)V-AL
M58\3:_IGA_XAZ;KK7\*K<:1) 3.'\B1/-#*4D16^;.<C&,8Z<4 =4/&_A@V*
M7JZY9-;O(L2NL@;+MP%P.<U+:^+="OK-[JTU!;B)+AK;]RC.S2J,E54#<QQS
MP#QSTKS'46T.+X1VUKI^L6NIQ_VO#),\?W=S7 DD4(>0 &/![<]ZZ7QS?0Z/
MXE\/:]>BY.@"*X@N+FS=QY#R>64D8QG)4[",T =?:^(M(O=+?4K>^C>UC<Q.
MW(*2 XV%2-P;) VD9R1QS4*^+M!-M?7#ZC'"EAC[4MPK1/#D9&Y' 89'3CGM
M7G^MII<.A0^(?#FGZA-I2:U%?:A+')-YERFQE>5-QW$*64Y&,[3V&:LWUSX5
MU3POXJUK01/<//H\UO+?S23$2'8=D0\P_,V?3IP.] '9)XW\-/=Q6PU>W$LT
M)FCWY560+N.&(QD#DC.1W%6M+\2:/K-O=3V%]')':,5N-P*&(@9^8, 0,<Y/
M%>?WEQ9?9?A?^]@Q%+$S<CY +<KD^GS8'UJKK<5QJ.K_ !-M=*Q-=S6MB8HH
MVYFV*?,5<=3CY3CU H ](M_%&C7-X]HEZ$G6'S]DT;1;HO[Z[P-R^XR*J0^/
M/"]PUD(=9MW%[)Y5NRAMKON*XSC )((&<9[9KGO#VK^$/$NKZ?JM@E]-J-C'
M(9'NI9_] 5D(<.7.W).!CGU' S7(PS6R? G3XP\:SC5E<IT<8O2V<=?N<_3V
MH ]/@\7V5QXSNO#B1S^=;0H[R&%]I9B0 #C& %Z].<9X-=%7!V=W#:_&+4Q*
M6 O]+M?LI5"PEVO)NP0,<9!-=%XPMKZ\\&:U;:9N^W2V4J0A3@EBI  ]ST%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJL&4,,X(SR,'\J %HKD/B#XF'AW2;=?MTNGM=R[#?QVAN!:H!EG*@$'LO/\
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MG6OBDD7@70M8L+N\6SO]1%K>7[VRB2%!DN43!7)QQUX!ZF@#UNBN5T*XGO\
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M9EA=D61R J%P-H8[EX)SR/6FZGXETC1V<7]WY0CVF5Q&[+"#T,C*"$!]6(H
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M+&8,Z"UE<7,JG(Y5"-BD _[3 =A\W?VUO#:6L-M;QB.&%!'&B]%4#  _"I:
M.!N&2T^)&E>+9@T&EZCHS632SC8('WB5-^?N[@6'/<8ZD55T?4;;PVWBWQEJ
M7F)::G?J+1%0EYTC38C*.N&.XCV&>E>D44 <%X?\1Z1K-W=Q:;J+S>(-0B8O
M<+9R^7;*JG8!O5044GIU9F)P,G'.^)?#GBO38O"EI_;UC/''K,(A*:6P,<FV
M0^8Y\T[NY.<9+9S7K]% #(A(L*+*X>0* [*N Q[D#M7$^*8I(_BCX&O7!^S
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M54;023@KC'0J1UK3*#P[\;=1U?50+/2;S0MED\V%12HCS$#T##:QV^]>P44
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M\NLH.J@SNR\=L@@CZUF^)M4A/BO7=+>-[&=])7RI8;<O-J.0_P @;:<*F<$
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M< 2#UZXSWH Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:1K:WC^TV;./*M0"WS9QP3WY[46WCGPU>7%C!;ZM#(]\<6^%;:Y[+NQ@,<<
MD$]J .@;.T[2 V."1FLO2M!@TD7LL<C27U])YMU=N!OD?&!QT"J, +T '?DE
M;_Q%I6F231W=UM:",2S[8V?R4.<,Y4'8.#R<=#Z&K6GZE9:M:+=:?=17-NQP
MLL3!E/XT )IVG0:9:F"#<VZ1I9)'.6D=CEF)]23]!T&  *K>(]+FUOPYJ.E0
MSI U[;26YE="X0.I4G (R<'UK \&:I<M)XM.JZD\T-AJ\L237!51%$L<;8X
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M?:L91AQN)._@<\XP*Z2R\7:!J&B3:S:ZI ^GPL5EFR1L;@;6!Y!Y'!&3D>M
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M)/+B4#/N5;'KBLC1[C09-)N?!WBFTU*;6X[J7-@9+C;>$RF1)$VG:%)()8X
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M]>TFW,TU[&^DW"@9 W O#(W^RK@Y/HQJEX-T>^TK7KKPM,DKZ5HUP;ZTG?\
MY:+,IV)[[6,Q/N%H ETKQA;Z+KGBR/Q#K4C6]K?HEN95W&-#$K'A%X4%N3C'
M3)KI-3U#3FUG0HCKKVTTTC206T+ B\&P\-P?E YSQTKB8KBU*_%,F2+,VX(<
MC]X/LP7CU^;(X[\4P74'V;X4EIDS$$\W)^Y_HI0[O3YN.>_% 'H.H^)]&TF2
M1;V]$0A*B9_+9DA+8V^8X!5,Y'WB.HKF[KQ$='^*%U!J&JR_V5_8J7,<! 8+
M(9F7Y%4;F.%]SU[5CZ1K>FZ1>>)?"_BFSEDNKO4Y[FW@:U:87\,A!3;@$$C
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M%6 Q@>=&46X9, JNYF.2.C ]Z-32*\\6>)/$%C/&^D_\(V;26>-@8YK@LQ4
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M:75S?K]@A<I-*$8^2PZAQC*$=]P&*L6VNZ;=W,%O!<%Y)[<748$;8,1Z/G&
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M(P0-VQE!QDCMSSCH:\UO-5UM-&L=3U>..]M-(\1(]Y?6,)VW<"QX%QM'7:Q
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M-L)Z\CM5?2-.U)_!7Q"L=/M[S_A'GAE30X)T8,08WWB,-\VPG&W_ /77LE%
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M!A8#?.IA0!5'5SG(P,G)]ZK:&\OAN3PIH6KHUA=+HI!OT@,DSL7'^BH<$ @
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MN[^5%C:2.'RD5 20JKDD<DGEB: -&&5)X8YHR2DBAE)!'!&1P:?110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*@EB2 /O#'KS7)6MD]E\;8U-Y<7$;>'G*B=@Q3_2$R <9(/7GW[<#T#:-V[
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M/*C[P/ H [JBO)(=6\1KX2\$Z^/$%PUUJ5U:VMQ#)#&8667(+%0 VX'!SN_
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M96T$MS<6LEK=1W<$]OMW1R(?E.&!!ZG@BJ\/A5(/$SZ\NJ7K7362V)5_+*[
M2P/W<[MQ)SG\*T[S4?L=Y8VXLKN?[7(8_-@CW)#A2=TAS\H.,9]35V@#BC\-
M-,;PM%H;:AJ!%O=->6EXKJD]O*6+%E95 ZL>H[_2M[0M#;1XI#<:E>:E=RX$
MEU=L-Q49PH"@  9/0=SG-:]% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >7MK
MC>&]4^)NKHBO);2VK(K?=W&! ,^V2,UO6\/BM?$-IMGNSI,\,D=XUVUOOBDV
M_))#L![Y!!R.G%6D\$VCW/B)[VYDNX->"BZ@9 H7:FP;2.1\H'KR,TGASP?/
MH3PBZ\0ZEJEO:C;9PW6P"$8QDE0"YP2 2> 3Q0!YL\5[_P ,_P!]>'6=0+M=
M2;E+)\V;QE;)V[CNR2<GD^V17?W^I:@/$\?AFWN-0F,>G_;)9X3 LS[I"BC+
M * ,'HN>5]\B_#NT'A34O#;ZG>OI]W(SQ*=@-MF3S?E(7YOGY^;/''%2ZOX&
M;4Y].U&'7M0M-;LD:,:E$J;I48Y*NFW:5ST&.* ,#4=1\:Z9HWAZ._OX[>_N
M-=CL)'6.-_.@?<59P!A6P!D+COZUWVCV5[I^GBWO]3DU*<.Q^T21+&Q4DD A
M0!P.,]ZQ+[P4+ZSTR%]7NS+8WR:@UPZJTD\ZY +\8Q@XP .  ,8KJ1G R<GN
M: .0M]2O/$GBKQ#I4&H3Z?!I AA0VZH7>1T+EVW*>!P .G!SGC'&:_K&H^)?
MA+)<7]P\-[9:K'970@51'.Z74:[\$$CL< @9SU'%>A3^%MGB2XUW2[^2QN[N
M)8;M?+$D<X7[C$'HZC@'/3J#574? EG>>%(O#MO>3VMJLPGDE55:2602>9N8
MD8R7Y/'Y"@#I;6%[>W2*2YEN77.990H9N>^T ?D*Y(7VJ>)=4\366G:F^G/I
M;+;6VQ$.9C&'\R3<IRN6 P,< ]<C'81*ZQ*)'#N!RP7&?PKE=0\#F;Q+/KFE
M:Y?Z1<7B+'?);!&6X"C"G#J0K <;A_C0!EZI<^)V\6>']$&NI:M?:;.UT]M;
MHRK-&$!=-PSU8\'\J0ZAX@U.?6=(LKV]:[TA(K9+J!;=!+.8E<R2*_8E@-JC
M& >O;?D\)1_\)#I.K0WLL7]F0/;PP;0RLCXW;F/S$G:.<_G575/ YNO$DFNZ
M3KE_H]W<HL=X+8(RW"KPI*N" P' :@"G9ZUK>I>(]-\-7\JV%['I7V_47M"K
M;WW^6$0D$!<AF/?H,]:YJQN=3T3P5\1KNSU)Q?V>KW,J7+1(6;;%&1D8VYQU
MP*[2_P#!$$NI:;JFF:C<Z;J5C";<7" 2^=$3DK(&SNR<MGKDDU6'P^C&B^(-
M-;6KV1-<F>6Y=TCRI8 -MPHP2 /;T H R]56\O/'_@=O[5O(1<6-S(RQ[-H9
M8T^8 J1D[B#G/MBO0;JX2TLY[F0$I#&TC =< 9-8%YX0%Y<:%=#5+J"[TA'B
M2:%4!E1U"L&!! )"CD=*Z1E#*58 J1@@]Q0!YG<^(]='PRA\=P:@3.$%Y)8%
M$\AH2^#%]W<"%/WLYR/0XJU-=>(=:\=7^D6/B&73[,Z7!>PE;6-VB9W88^8<
MC"\Y_#%:EMX!MK;2'T$:A.WA]IO,%@R*2J[]_E;^OE[NW7'&<5I0^&_)\8W'
MB(7TADGMEM6M_+78$4EEP>N<D\_I0!K75REE8SW4N2D$;2/@<X49/\J\G\3W
M&HZ]\);7Q#<ZC*IO+BUG:S14\I8VN$VH/EW97Y3NSDD'L<#UUT26-HW4,C J
MRD9!![5P;?#!?^$?E\/1>(=1CT7SEE@M@D;-!B02;0Y4DKD<9Z>] $M_JVL:
MUK/B#3-*>\@?3/+AA>V,&/-:,2!G\SDK\P& ,<'KGBEJ+ZG)XB^'#:S'#'J7
MGW(N5A;*;Q;N"1['K6OJ7@5KCQ =;TO7]1TJ^FB2&\>!8V%TJC +*RE0P'&0
M./2K=YX1BN-0T*ZBOIH?[&9WA4@/YK.I5BY/))!//'))H SM-O-9U'Q9XTT8
MZM)&MHEK]BD6&/-N9(V8\%<-SCKG@55\-:]JFN>'=+LI;^:+75O)+?4G5(]T
M9A/[WC;MP?D P./,4UT>F>'/[-\3:OK8O9)9-4\H2PL@"IY:E5VXYZ$YSG/M
M3].\,V&F>(]5UN ,+G4MGFJ?NJ5&"5'8MA<^NT4 <I-JWB;Q%:ZQ<: ]S#=6
M=_+:VJ@P>03$VTB4-\YW8)XQ@$8Z9*W5QXGU/QW+H4.NMID;Z)'>_NK>.7R9
MC*5(4D?,/E[^^,9R-*7P#Y>OWNHZ7K^I:9;ZA)YM]9VY39*_=E)!*$]RO/N*
MT8/"Z6_BX:_%>.I%DM@+41KY8B5MPQWSD]<_A0!APZ]?^'?%>MZ=K^J3W5J;
M'[?IKF*-247(E0;5&7#8P.<@BNLT.&_@T6T35+EKB_\ +#3N0H^<\D#: , \
M#CM7+7K:3XW\4Z=!#;7$CZ!?/+<3R0/&J,H*B,,P ;<VUN,C"<]1GN: .1CU
M2[U_QIKVB07T]A!I$-N"UN$WR22JS[B64\* H QR2<YKBO$FL:CX@^#7B+^T
M+EDO=*O7T^Y:%%5+HQRH-Q!!P""#A2.<]N*]#NO"X/B5M?TV]>QOIH!;W(\L
M21SH/NEE./F7L0>G!S534? EG?>#[CPW'>3P6]U(9;FX 5I9G9_,9B2,9+>W
M3@8H Z2T@DMK<12W4UTP)_>S! Q_[Y51^E<3%!<O\;+Q?[3O!$NC13"+Y"@S
M,P* %>%.T'CGWKN8$ECA59I1+(!RX7;G\*Q;KPPLWBU/$4&H7-M<?91:2Q(%
M*2HKEUSD9&"3T(R.* /,[2\UC0_AWJOB#3]5D@%CK5PPM%A0QS*;K:P<L"W1
MCC:5Q[UV=_JVK:QX@UW2=,>]@.F)$B/:&#/FR)O#/YG5>5  '9LYXPY_AW%)
MX0O_  VVK7!M;VY:YDE\M/,#-)YA [8W#TJ?5/ \EWKRZYIVO7VDZE)"L%W)
M:HA6Y5>A9'!&X=CVH W/#[ZL^@69UR.%-4\O%R(6RF\'&1]>OMFL$W^H^(O$
M'B/2K'4I-._LI(HH6B5"6FDCW[WW*?E&5  QG#9SQCJ+&SCT^RBM8F=EC'WY
M&W,Y/)9CW))))]37-ZIX(-UXE?7M*UN^T>\N(UAO/LRHZW"K]TD.I 8#@-Z4
M 0W=QK<5SI%E?ZM&LKV3_:(=,3,]Q< J-RAE(6,<Y)VC) /'%8=EXOUV;X=>
M']<N8KRXC>>1-4EL(5,RQH9$#A,$8W*I;:.!G%=--X+B&N66JV&J7MC-;VAL
MI-FU_/BW;_F+@_-NR2W4YJ'1O!$GA_3;&ST[7+Q192RO%YR(ZE)"28V  )&3
MG.<YQSCB@#F/$&HKK'A/PO=V.M)J:R^)K;R;MHP"!YC;5=0%Y48!& 3CWKH]
M O=4M?'NLZ!>ZG-J-O'9P7D$D\:*\9=G5E^15!'R@CCBEF^']M)9V\$5]+"Z
M:M_;$CI&O[RX!R..@7M@<\=<Y)U+;PX;?Q=<^(3?.\MQ;):O#Y8"!%)(QWSD
MF@!?%UYJEAX=FN=(MIKBXCDC+QVZAI3%O'F>6#P7V;L ]ZY-/'$9\/7-]I6K
M2Z@9]0M[&*.XC5)K)I&5&5U(49'S$%N">"<"NYU;3I-2M$BAO9;.6.5)4FB
M)!4YP0>"#T(]":PKOP#INJ6NM)J;M-/K'E&XFA7RMAB'[LH.<$'G))R?;B@#
M,OM6\3>%_P"V=6NHY[G1(-->>-+UX?.6Y7HH\KJC#KGD'IQ6O967B![C2+Y=
M>$UG- QOXI(T +,@*-#A?EPW9B<CU/-&F^#FBLKBVUS6;W75FMVM1]K"J$B8
M8884#+'C+')XXQSEGASP7)H!@BEU_4=0L;,8LK6XV!81C R5 +X!P,G ].F
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MO9)I9=3TQXS.JD1DKP/E"D@>Y)]ZW7\4:KX9U/Q;;ZE>G5(=-TV/4;8O$D;
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO+ $A8C#,-N.?E/Z\5TJ^+[1-9M=+O+&^LKB]B>6S\]%(N @RRKM8D,!SM8
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M)G!:-6G(;.]\DMA@.<#/)&*Z2_\ &-K82W</]GWTT]E9K>WD40C+6\9SC.7
M)^5N%)Z?3/"V>BZQ!\)_"]LVDWAO=*U:"ZN;01_O-BSLQV@\-\K \&M;7CKN
MJZKK5G=:)J,EE/IBC34A*B/S"C;_ #R& + D84DC@X!- %CQ7=P:AJ?@'5+.
M:1H+O4D9"'8*\;0NXRO3T/(S712>*+<7$R0V5W<0P7B64T\(0I'*Q48(+!L
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MFNI\,A)+6:ZAT%=%AF8%('A2.9L#[T@0D#T ZX'/7  -VBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **YJ\\<Z59&[D>.Z>SLKM;*ZO$13%#*VT;3SN."Z@D*0,
M_6FZMXZTS2=7N-*>TU.YOH;871AM;1I&>/=MROKSGGIQUSQ0!T]%<[J?C+3]
M+MKF[DMKV6SLR%O+B&(%;<D _,"0QP&!.T'&>:WX9H[B".:%U>*10Z.IR&!&
M010 ^BN<\6WND6J:1'JPO,3:E EL;;>!YV[Y-[*0-N>H)Y]#3;OQOIUMJ]_I
M4=GJ5U?642RR0V]JS%E;/*YQD<'GITP23B@#I:*PK?Q;I5YHVFZG:/).FI\6
M<*+^\E;!)4 XP0%;)) &#DU';^--(EL=1N9FFM6TV?[/=03)^\20XVJ I(8M
MD8VDYS0!T-%8<'BBS?5FTJZMKNRO_(-Q'!.@)FC'4H4+!B.ZYW>U9-M\2]%N
MK+[=#::NUFL<\CW"V#E(_*)#!B,X/&0/3KB@#LJ*Y&U^(VB75_I=L8M0@CU1
M5^QW4]L4@E=AD1A_[W./3/0FK]]XNL;%;^46]W<VVG-MO;BWC#) 0 6!Y#-@
M$$[0V.] &_17-:CXYT?3KK3[<"[NY-1@>>T^R6[2"954-\I'#$@C@>O.!S4<
MGCS3DMKB=;+49/LEFE[>1B$*]K&X)&]68'.%8X7)X^F0#H;>RM[::>:*/$L[
M;I7)+,WH,GL.PZ#M5BN1U3QFUMXA\.6%C83W=MJT<DXGCVX>-8]P"@L#GYE)
MSCCUSQ=U;QAI^D0W=S+!=S6=DXCO+J",,EN>,[N0QQD9VAL=^] '0T5C7?B"
MS\];&UBN+^XEM_M!CLRN5B/ <L64#/..<G!QT-8/PGN&NO RS-+/)NO;K:T[
M,S[?.?&XMSG'K0!V]%8?C12?!&NLLDL;I83NCQ2,C*RH2""I!ZBL3PGXOLAI
MGA?2+B*^2>\T^(07,L)$,TBQ!F4.>2< GI@XX)H [>BN=U3QIIND0S75Q%=-
MIUO-Y%Q?1H&BA?(4AN=Q )P2H(!X)R#4&H>/M+L-4N]-6TU2[N[6))GCM+-I
M"48X#+Z@=R./K0!U-%<[JGC/3=(AGNIX;M]/MIA#<WL48:*!\@$-SN(!(!*@
M@'@\@XC_ +2T9_'QA7[:VJQZ4TN5#^2UOYB\J.C-N(Y )[9[4 =-17&I\3-#
MDL8;];?4OL,ES]EDN3:D1P/O\L;R>F6^I&1D#-=E0 445P9\37&OQ>,-.>PO
M;2+3U>%)5D","(M^2RMD$DC&.V,]Q0!WE%>?^"?&%G#X;\):;=QWPEO;*&*.
M\DA/DR3"/)3>>K<'M@X/.:W]6\8Z?I$-U<S07<ME9R".[NX(PT<#<9W<[CC(
MSM#8[]#0!T-1SPI<0/#(7".,'8Y4X^H((_"G1R)-$DL;AXW4,K*<@@]"*R-;
M\3Z?H%WI]M>K<F2_E\F'RH&<%L$X)'?@\#)/I0!JP016MO'!!&D4,:A$C085
M5'  '85)7)Q^/]/E;4($TS5VO[ CS[$6F9@I&0X&=NTCIS[=:MQ>--)GAT.>
M(SO;ZVP2TF5/E+;2VUN<@X![=J .AHKFK[QG:VL/B$165U-=Z'"LMQ  HW!E
M+*5;.,84D]QZ9XJ#2_&:/I'AV;4[.Z@GU@111OL78TK1[^,,2%/.,^E '645
MA-XMTN*YUN"Y:6W.BQ+/=M(GRB-@S!E()SPIXZT:?XHL]2U1-*:VN[2ZFM/M
MD*SJH\V$D#<I5C@@D<'!&>E &[17%?#5I#IVO(\TTHBUV\B1II&=@JN !N8D
MG KM'=8T9W8*BC+,3@ >M "T5SL7C339+S3(6BNHH=4)6PNI(P(K@@9XYW#(
MY&X#/:DO?&FFV4%U=M#=RZ=:3&&YOHHPT4+ X;/.XA3P2JD#GG@X .CHK%;Q
M/8KXCM-$\N<W%Y ;BWE"J8I(QC)#9YQD<=><].:>_B*TB%X9(IT%M<+:C*@^
M=*P&%CP3N^\/3'.<8. #7HKF7\<Z7 -66\@O;6YTJ$3W-M)#ND$1!(==A8,O
M!Y!X[XHL?'6EWVI:99K!?Q?VG$9+.>:W*Q2D)O*AL]0.?0XX)H Z:BN:D\<Z
M5'+DQW36@O\ ^S6O%13$MQG;M/.[&[C=MQGO1=^-]/MM7O\ 2H[/4[J^LHEE
MDAM[5F+*V<%<XR.#STZ8))Q0!TM%<5JGC^)=,\-W^D6<]Y;:U=Q0I*H4; <D
MJ02/G(5ACH,'GIG8NO%5M:F[Q97LPLE0W9A5#Y!90P5ANR3M()V@@ ]: -VB
MBLO4]=MM,OK.P,4UQ?7H<P6\(7<RH 6.6(4 9'4]Z -2BN6E^(&B0^'K;6W-
MU]EN+G[+@0$M'+OV%7[+AN.3],U<TOQ78:GK%WI7D7EI=VT*W&R[A,7F1$D"
M1<_PY&.<$>E &[17F7CCQ#%J>F^'[FQCU%+:;6K18+Q&*0SKYHSD!LE2 2"R
MX.,CJ,^FT %%9VH:S!874%FL4US>SJSQVT 7>47&YCN(4 9 R2.2!UK/M?&F
MCWNC0ZE \S":Y-FEN8\3&<$@Q[?[PP<\X !.<<T =#16!%XNT]I-2@GBN[:\
MTZ,37%I)%NE\L]'4(6#J?52<=\52LOB%H]\^D%(-0CM]6(2UNI;<K$9"I81E
ML_>(!Z9&01G(- '645RGBG7[9M'UVSMX;^X>TMF^TS61V_9V*;AE@RL2!@D+
MD@$9'/.+HFH:6OA7X>QZJ;Y[R>.W-H\1<*9?)_Y:," >,\'/TH ]%HKE-+\6
MSW_BW7M*DTRZCM],$2^8%5B2R,Y8A23@C;M !/KC. WP[KWA^T\$V=_I[7@T
MZ:X>&V2X+/-+*9F7: Q))+@X!/ ZX . #K:*P[?Q592W]YI\\%W:ZA:PBX>T
MEC#2/$> Z;"P<9XX)P>N*S+/XCZ+>Q:3<10:@+/5)5@@NWMB(A(Q(5&;/4D=
MLCL2#0!U]%8EQXGM8)[E([6[N([6=+:XF@52L4C;2%(+!C@.I) (&>O!QMT
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M"ZEY%I?R?;A)'(["4(N[:IY5<$>@K2LO&>FWNMVNEB"]AEO(6FM)9X"D=P%
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M*H!/ R<GG&<&N>UOX@6\'A2+6-(MYKOS;Q+)E*A6MY#($82*Q!##.,>N.W-
M':T5YWJ&IM9?%?3[EHM1(FT29OL2EI&+B5 ,(&*@X[C ]3736'B_2]1T)=6B
M\]4:<VOV>2/$PG#;?**_WL_AWSCF@#>HKF7\=:7 FKB\@O;6YTF(3W5M)#ND
M$9!(==A8,O!Y!X[XJWH/B>U\0N_V2TOXXEACF2>XMRD<JN,C8W1L8Y_3(YH
MVZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ(HWVB$CE2"!\RXYR3UK22U;6/B-:>(K>*YCL+'3)('ED@>-IG=@0@5@&(4
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M=)D6YM;UX3/#'=0F/SHQU92?3N#@CN*B7QCI)O;"!VGCCU!_+LKEXB(;AL9
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M1TV2\*&YBC6*6-RJA00)$;:< #CCVKI:* *FGZ?'I\#(LLLTDC>9+-,07E?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXK0TCQ1/J7BN[T:73UMUAL8;Q)/-+,PD)&"NT;2,'UK&\%?\E%^('_7W:_\
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MADUV2QTA;Z48F,4[HDW^^BD!NG((P>^:N2^#_'D_BB'Q));Z6=6A3RXYQ<2
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M936Q81A(G\XH.V3(V0H^N![5ZOJFJ6^D61N;C<<NL<<:#+2R,<*BCN22!_/
MK)'B.ZC\:6?AZXT^-/M%C)=^>D^[!5E4KC:/[W7]* .,T31/B/X>TF'3-,BT
M6&TA+%$'.-S%C^I-:&/BM_>T:NYU2^?3;%[P6[3Q0C?,J'YP@ZE1_$1UQWYQ
MS@&Q;7$-Y:Q7-O*LL$R"2.1#D,I&01[8H \>\2>"?''B[R!KEMI5TL!+1K]I
MD15/KA6 S[U-:^$O'EIJB:F+;29[]%V)<W<[W$D8]%:0L5[],=:]@H) !).
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MFUN)()GB,\1_@?:1N'Z]LU'JO@7QIK6F6&FWMAHQLK AK:"*9XEC(& 0$(Y
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M'0Y'&10!@> !=V6H^)]!EN[B]L-,O42TFN7,CA'C5S&6/)VY Y]:3X1RR/X
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MC^ULF]_TJ3]YD;?[WR\<<8XIC^#-%>RTJS,5SY&E.LEDHNY1Y3*,*<[LG )
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M@<Z )B5F<?,+@ =#T]NGM7H!&X$'//'!Q6/-X6TJXU6RU.6*8WEG%Y,<HN)
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MH ANI98;266&(2R(I98RVT,?3.#BLSPGKI\3^%=/UHVXMS>1^9Y0?=LY(QG
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MAI/FQ@E0?N@]<#CTP,"@#)\4>*]0\/07-Y!X=N+[3[-=]W<+.L95<98HIY?
MY/0>YP<7=2\36UG:Z6UO&US<ZJZI909V%R5W$L?X55023@X]"<"JWCG2M4UC
MPO=VVEZA%:2>66998!(DX'/EMGHK8P?8UR7]H7&L>+/A?K=U ($NK.Z)0#"I
M*]NI 'U ./I0!W>CZZFI7NH:=-"+?4=/=5N(0^]=KKN1U; RI&>P.01CBM>N
M$TE))/C5XBFC!\F+2[6*4CIYA+,OX[<UW= '$ZWX]O-$634)/#-Y+X?ADV3:
MBLR;@-VTN(OO%,]^,CG&.:V]0\1)!J=AI=A"MWJ%[&T\:&38B1+C,CM@D#)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)"4)1HG7[K*1RI'MVR.AJ]10!AW/AG3CH>I:<MO)*NH!C<DSL))V( RTF<]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLY[4 =31110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !115*;4%74HM/A427+)YKC.!''G&X_4\ =\'T- %VBBJ,.HJVIRZ=,HCN%
M3S8^<B2/.-P]P< CMD>M %ZBBB@ HHHH **S]7GU*"WA&EVL,]Q),$/GN51%
MP26) )[>G)(KE['Q/XEU#Q-KFA0V&DBXTE(&9WN) LGFJ6 'RY&,4 =Q17):
M9XFU2Y\:1Z+?V5O;1-HR:BP#,9$D+A2A)P, Y[>E;^K-J0TYFTC[&;O<FW[6
M6\O;N&[.WG.W./?% %ZBD+ $ D#/3)I: "BLS5;C5XY[6'2K6VE\S>9I+F1E
M6-1C&-H.22>GL:Y72O%OB?6+?7)+32=,=](OI;)XOM$FZ9HP"2OR]\\ ]Z .
M]HKFM#\07NH>*_$FDWD5M%%I;VXA:(DEQ(A?YB?P' ]>M:^H'4Q)9?V=]C\O
M[0OVO[26SY.#G9C^/.,9XZT 7J*0L <$BL'QKKEWX<\):CJUC';RW%I"91'.
M2%('7IR?T^M &_14-K*T]G!,P :2-6('3)&:FH **YBP\9VM]X\U'PP(RKVM
MNDT<QZ3')$@'^Z2@^N[TKI\@=30 44F]=I;<,#OFE) &2< =Z "BDW#;NR,=
M<T @D@$$CK[4 +17->-?$-YX<TB"\LHK:5FNX()!,3PLD@3( ZGGUKI"P7.2
M!@9.30 M%)N&0,C)Z>]!95QD@9.!DT +11D#O5+5=6LM%TFXU.^F6.UMT+N^
M>OH!ZDG@#N30!=HHHZ4 %%(&##(((]J9)/#%!)-)*B11@L[LP"J!U)/;% $E
M%5-.U&VU32K74K9\VUS$LT;-QE6&0?R-6\YZ4 %%%<EI&OZWX@2SU73(+%M'
MFNYH)8I=RS+&CM'YH;.#DIG;MZ$<T =;12!@V<$'!P<4V2:**-GDD1$0%F9F
M   ZDT /HKD-<\82V^E>'M3TB.">SU74+:V+S;LB.5L;E [X]3Z<&NN!!S@@
MXX- "T45CW6NQ-%K$6FM%/>Z;&#(CMA%<J6"DCG.!G\10!L45B^$M9FU_P )
MZ5JMRD4=Q>6R3.D>0H)'.,DG%;)900"0">@SUH 6BBB@ HI RLNX,"OJ#Q0&
M!. 1GTH 6BLR+55U6QU%M%E@FN+9Y+=&E)\KSE7H2.=H8@''/!JY9-<FQMC>
MF'[68U\[R"?+WX^;;GG&<XSSB@">BD+J%W%@%/?/%+0 444BLK#*D$=.#0 M
M%)N!8J",CJ,T%@.I H 6BDW*&"Y&3T&:"RKC) R<#)ZT +11D#O2;UP#N&#T
M.>M "T4C,%&6( ]2:7('4T %%137$-O;RW$TJ1PQ*6DD9@%4#J2>V*CTZ^@U
M33;74+8DP74*31EA@[6 (R/H: +-%97B74;K1_#.IZG9Q0RSV=M).J3$A3L4
MMCCGM4NAW[ZGH.G7TP19KFUBG=4Z LH)P#SC)H T**0LH8*2,GH,]:IIJMG)
MK,FDI*&O(H1/(@_@4DA<^F<'\J +M%%% !12!E)(!!(ZC/2C<N[;D;L9QGF@
M!:*0LHZD#\:6@ HJGJNJ6FBZ5=:E?RB*UMHS)(Y]!V'J3T [DUC:IX@O;'QK
MX=TB.&W-EJBW!>1BQD4QQ[ACL,DCU[T =+12 AAD$$>HH#*WW2#CC@T +111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT?S9'0GL2.,$\C JY-H>ESZQ#J\MA ^HPIY<=PR?.JYSC/XG\S0!X_>:._\
M8>L^!K*SBDU31[Y]1T]GCS_HW^N0_P"T2?W)^OM71W>K_P!K>"M<\<:/;B.<
M:5Y-C(J?/& NZ1@?4,Q7ZQ5Z,ME;)?27RP(+J2-8GEQ\S(I)49] 6;\Z2UL;
M6QLDL[6WCBMD!"Q*N% /)X_$T <)I^CV#WVA>)-*U2Q0F&1((K"U\O[>&3.R
M0[V+;<;LGD'.:QO#MA;>)_"6AZ_-K-I;:A;7"33W4-J1=&XSAXG8N2=Q.-N.
M1MP,8KT'1_!WAWP_?37NDZ/:6=S,,/)$F#C.<#T'L,"DA\&^&[?7VUR'1;--
M38EC<+'\VX]6] 3Z]: //)/#VEW\GQ-6[M%G6W??")"6$;_90V]03PV>_45Z
M+X.GENO!.@W$\C232Z=;N[L<EF,:DDU(/#&C+]NQ8J/[0_X^\.W[_M\_//''
M/;CI5ZQL;;3+**SLXA#;1+MCC4G" = /0>U '(?%V"&?X7:V98HY#'$KH74'
M8VX#(]#@GGWJCXBTO3F\=>!=/CMH8[,B_#00@(AS"I((7'![COGGK7?7ME;:
MC936=Y!'/;3(4DBD7*LIZ@BLZ/PKH<,EC)%IT4;V (M2F1Y.?O;<'C/?U[YH
M \OENO\ A&M$\6VED5M-*M_$=O'(JJ2EO;R>49 %!&%.2" 1PQQBNWT30+33
MO%PU2UU.S7[;8[38Z?;^5#,JL")B S<C<%W>A K=A\-Z/ +X)I\)6_S]K5\L
M)\\'>#G<<>M,T+PMH?AE)DT73+>R$Q!D,2\MCIDGG R>/>@#7HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** $+!1DD 8SS1D 9R,=<UYQ>Z#IFL?&.^L]0M_M%M)H
M44KP.[;';SW&2,\X ''3@'J!6%HB06NC1Z#=/<W5O#XIGMM'MVE CFCC!(25
MF!S&IW=B<J,"@#V0,"NX$$>H-4M3U>RTBT%S>3*B-*D*\\L[L%50.Y)(KR.Z
MA5?!7Q/LG\D);7+R116^5CC;R4)VC/ W'GW[5H^+O"NAV'A/2KV'3H3<W>HZ
M;]HFD^=I/G4$G=GJ"0<=>] 'I<YU,:O:"#['_9I1_M'F%O.W\;-F.,=<Y]L5
M=W*&"[AN/(&>:X+4;2TM/BUX4%I%'$AL+U-L8PH"^7@ #@8R:YW2[*'Q=X3F
MU"^UBTL-4M+Z22YNDM<WEK*DK87>7SC: H7&-I  H ]?+*#@L >N,TM>5>)C
M/HVJZIJ^H:=;:UX>ENXGFN8L"\TUT"+P"/F0$!L#'WCZ\]UXM\/P^*/"U_I,
MJKNGB80NP_U<F/E8>F#C]: -NJ.KG4QILATC[']M!79]L+>5C<-V=O/W<X]\
M5Y$-=BED\,>-WLH88=*V:=K3F/!C=_W;?3RF53]) !6QXWTJ&#X47U]):K#>
M7=W!>R #:5:2X3"G'4JA"_@?6@#T5]5M$UF/2!*IOI+=[D19Z1JRKD^F2PQZ
MX/I63X0\07FNP:LU_%;PRV6J3V*B$G#"/ !YZDY/I6'=:?I\GQQ@EGL[5F_L
M%YM[Q*3YBW" /DC[P' /45Q]_I-C<^ /B#J4T >]L]:O9+:8D[H'5E(9/[IS
MU(Y/>@#W"D#*3@$'OUK+U!%O?"MP)QN$EF2W.,_)GM7E=M96>A?!S2O$EM$8
MKZ:TL[>]O<NS"V:5-X(!'&..,$#H10![0K*V=K X.#@]Z RMT8'''!KSX^'K
M*TO[O5+7Q!:6(O=)EB*:=;B*(H!D7! <\ID8;CJ!WK.TE)++49M"\0:#;6>I
M_P!D3)!?:<V(+V%=FXD !E8';P?4^HH ]2W+G&1GKC-!95(!8 G@9/6O#/[
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MG.:DO_$WB#3+[1;:]T^QB^VZK]AD9)'<%"A<.F0.P(.>AS57Q/\ \EA\!_\
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M0 >8'D^;:..P.._XU#J=AI#>&/AWJEI'"\\NKV#-=C!DE9\ER[=6)89.>XH
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M3PTUY=FWR"724@R^[A2>>IK,TF.&S\4_#N>SBBM;:[M+H*Q<&XN(O(#AYV7
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ML_@WPY+KXUU]&LVU,,&%R8QNW#HWIN]^M;>]0I;<-HZG/2C<NW=N&W&<YXH
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M:=IZ6%G"(+5%V)$C$!%]%YX'TINEZG:ZSIT6H64GF6TV3&_9@"1D>QQD5<H
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M6.<D*0.O Y/Z4 367A/0-.N[>[M-(M(;BVC,4,JQC<BGJ,_UZUI"RMEOWOA
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MU8I(%/5=RD':?3I0!Y!Y$UUX5\/6][+-+%:^,18V<[2-O>V65U'S9R>A&?\
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MZ7>V8FL3H$#& R,%)$S@'@YR HQ52R\!B=/*U?P%I[ZFQ+3:G'?!(I9"23(
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MDU)"&%PT8W9'0GL2.,$\C H XVQ\-:5K7Q-\40:E;&YB6UT^8([,H\S]X=^
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MAAB/J.M:U%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444C,$4LQ 4#))/ %
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MY?49').>#C%;2?#GB32[768)8-(O(K[5Y+QX7=MDT,@^=""IVD8&.N3U('4
MU[CQ3-INDRWE_#;/ONH[:Q>WF)CNO,"[7S@[1DMG&[ 0XS2:'XHNK_Q)=:-=
M62XCMQ<PWMN',,BYVE#N VN#CC)R.>*YL_#:[CT;5(=)GCTIFU"'4=*M2YDB
MM98P,Y] YSD#( QUZ5UWA\^)YV,_B&+3[4HFQ8+*1I [$C+L6 QTP%&>IR>F
M !VIZ\T&O66@V,<<NH74,EP3*Q"0Q(0"QQR268 #COR,5D#Q7?7VG^)=/%K#
M;:YHRD3(928V1D+)*C;<\CG!'!&/>K&N^'[\^+]+\4:3Y,EQ:P/:7-M,Y030
M,<_*V#AE89Y&#ZBHX_#5^#XGU0QV_P#:FM1+"D/FGRXD2,H@+[<DY+,<#O@9
MQD@$7PZL1<>"?#5[?65FT]O81_9)U^>15>,;CD@;2>^":3Q/XUOO#UMJ]\^F
MPI9::R*GVF4QO>Y 9O*XQ\H..^2#TK9\'Z;>Z-X2TO2M06$7%E;1V[-#(75M
MJ@9!(![>E<CKW@[Q-J:>+K13ILZ:NO\ HEY/,_FPQ[0!!M"X"Y!.0>Y)!- &
M]J'BG4X_%]OH-AI=O,;K3WO(9Y;HH!AE7#@*2!\W;<3QTY(S)/'^IQ^";S71
MHT#W&F7DEIJ-N+AML?EOM=T.TE@/O8('&?2KL.AZ[_PFNEZW/#8>3;:6]G,L
M=PV[>S*V5RG(&W&3C/7 Z4[PQHLVBZ=K=MK_ -A6'4]2N;A56<LK),<[#N5>
M<9Z9S0!LG5YI-;L+&UC@GAFM6N9YA(?W:Y4)@8YW$G'(X4U1\::R=$L=/E;3
M;>^BGU"WMV$SX\HNX"N!M.2#SU&.*I?#;16TKPZ9'NGNUE<I:32=?L:,P@7Z
M;26'^_5OQQHFHZ]IEC;::ML7AOX+IS/*4&V-PV!A3R<8H @N?$^MOXOO_#NG
MZ39O-!9I=13SW;*C!F*_, A(/RG@9^HJ/2_'?]K:#H%S!9!-2UF22&*V>3Y8
MVBW>:Q;'*KL..,G('&<B>#1M7B^(5]KYAM#:3Z=':(HG;?O1F;)&S&#NQU[5
MS-IX#\2:?X8T VDMA'KVA7EQ/"#*S03QS.Y=&.T%20V,X[>_ !TEQXNO=(T_
M4I=:TEHIK:ZCMK0Q/^[OFD(";">5Y.#G.,'K4LGB6^TWQ-8:)JMI;JVIQR-9
M7$$K;#(@W-&^1D<<AN_H*HZUX:UWQ9X7GAU.>TL=3$L5Q9QV[-)%;R1MN4LQ
M +$G(. ,#&,XR;;Z-J>MZ[HNJZM:VUJ=)661(8IS)YL[KMSG:,(!G'<DC@8Y
M ,)OB-K"^&9_$3Z%:I86=\UM=K]L)DVB7RB8QLPV,YYV_3O6YJ?BV:+7K_1=
M.CLWU&TM5N([:YF,;W98,=L?';;C//)Q@=:YZ;P3XAE^&NL>'-FGB\O;Z2XC
M?[2_EJKS"7D[,Y&,=*T_%GA>^\4P7MM>Z3I\I:,'3KP7!66REVC)W!<[0PW#
M!YZ$=* -6?63'\1++1I--MSYVGRW$=[OS( K("F-O R0>IS@57\/^+KCQ'Y%
MQ8164ML\TD5Q$)B)K0J'V^8N.I*@'IC<,;NM-'A[5T\<:/JS/!/:66FO932R
M2D2R.Q4E]NTC^'U[U0M_!]_<>)-&URYLK/3]6M')O[VSF.+U"A&TJ%&23M)+
M=,8&: (/#WB_4K?0->U?7!;RK!JLUI&L,C F02+$B $<+G'/7DDBM2V\7ZB^
MNS:6VFPW&ZT:YM[F!Y!"64\Q.Q3Y3W!YSZ"LK_A!-8N/#_B+1)+FTMX[K4I=
M1T^\B=F=9#*)4W*5  4C!P3G/;'.[I(\9W-LYUR'2H7BB94CLYG(N)",;F)7
MY%Z\ $Y/;&" 8MA\0M5N-*\-ZS<:+;1:9K%S%:L5NBTL;R$A6"[<%<C'7//0
M5LW?B;4KA=9DT'38KY=)E,$B/(5>XE50SI'@'& P&3U.1CC-8$7@S7X? GA;
M1 E@UUI%_;W,S?:6".L3EOE.S.3GN.*NV^A>*_#_ (DU:70QIEQI>KW'VMUN
MY75[28@!R H.]3@'&1Z9'4@&F?%%[#XPTO1[O34MK34[5IH)Y)3O\Q0"T)7&
M P!SUQ@&M71M2N-3-]))!$EM#=/!;R(Y8RA#M9B"!CY@R]_NYKGO'=@MYX<M
M;6#4577;2YMY+"8X,GVC<%#%?1@6SVQD]!75Z;81:7IEM8P9,=O&L8+=6P.I
M]SU/N: .1^*OR^%K.01>8Z:K9E5&,D^<O SZU+!XRU"P\3-H_B;3+>P6:UDN
M[2YMK@S(Z1\NK952&4<],5H>-M"N_$&@):V#PK<PW4%T@F8JCF-P^TD D9QC
M.#56Z\-7'B368M1UJ&.VBM[*>T@MXI?,;,P"R.S8 ^ZH  SU)/I0!4A\>74E
MSHLJZ:LUCJDBQX@+M-:[QE&D&W;MZ!L'Y<]6JGHGB+Q/):>,+U[2SO9-.U":
M.*W6=UR(XX\1K\IZC)SW8G@9JYX6TSQMI5O::'J,VF/IMCM1-0B9_/FB3[J&
M,C )  )STSC)YJ_X8T35=$UK7_.%H^G7^H/?12K(QERZJ"A7;@8V]<G/I0!1
M_P"$\D,OA!Q;VAL_$*@";SSF%]@8+MV_-DG;GC!ZU?O?%CZ?'=S3V\/E?;UL
M+)A*?W\A'S%OE^4*=P.,GY&XZ"N>;X:W"^&M:TZ.[3S1<-+HAZ"S D\Y!GM^
M\)!/]T+Z5M>(/"-W?>$K"QTR]2'5=-N([VVN)5RCW"Y+%P.S%GS_ +U $$?C
MYK.;64U6R/DZ?:BZCN[4,8IU)QL&X##[B!C)SG/%36WB[4&\1VFER:=#,E[#
M(\5Q;/(4AD09V2L4X!'1NY'2H[G1/$7BSPSJ.G>)#9:>;FW,,4=B[2@/D$2,
M6 Z%1A1VSDG/%GP^OC8^4GB!=*5;52#):2LS7C8(&05 0<Y.,G('04 8<'Q&
MU>3PQ8^))=#MHM-DO?LMR/M9:1,SF$,@V88 XSD@GG@#D]UK%Q=6FC7MQ9+$
MUS%"SQB8G9D#/..?\]J\_'@GQ"/A?'X9V:?]M6^^T>9]I?R]OVGS^NS.?X>G
MO7HEU UYIL]NV(WFA9#@Y"DC'X]: /*;^_U+4?AQX'U+44CGNI-7TV961\O(
M2V>=P !)]\>]=?;>,KBSU77+'Q!9V]H=,LEU$26LS2J\!W9ZJIW H>W-8J^$
M?$Q\&>&=&DBTOSM&OK69BMR^V2. YSGR^K>F./4YP-+4/"-]K'BK6[F[6WCT
MS4]&&FDI,6E0Y<[MNT#^/U[4 2VWC2\?6M)MI=.22TU+(WVI=VM&QE1)E0"#
MTR.A]>M:/C'Q)<>%],MKR"P6\$MW%;,GF[&7S&"@@8P3ST)'UJAX8M/&UM':
MZ=KDFE_9+,!3>6SNTMTJC"@J0 F>-QR>X YR*_Q5,@\*V9A"&7^UK+8'.%+>
M<N,D=J )K/Q;K,?BP^'=8T:UMKJYMGN=/DANR\<P4_,C-L!5AG)(!']:&E_$
M34+CPHOBO4=&@M=#%K)*[)=;Y?,638J!=H!#'@'/7T&,[3:/?ZAXKM=?O+:&
M$Z=:RPVEN)MQ>23&]F8# &% '7J2<=*QM.\!7D_PB?P9J\D$,_ELBSVTAD4-
MYAD1N54\'&1[4 :]UXGU#1M5T>VUJQMXK?5I?L\4UO*6\B<C*QOD#<&P0&'<
M=.],TWQ?<S2^)K?4;."TN=$;)1)6?S8RF])/NCAAD8&>0:CDT/6?$#: FO0V
MD TFZ2]E>"8O]HF165"H*C:N6W'// 'O4VK^$I+[QOIVMP3B*W$)AU"+_GNJ
M.)(?R<<^W'>@!MSKMW!XI\*Z?J&CV8N-1CG;SUFWM;.D>YE7*CKD#.1GGBET
MSQ;/K-_/%81V<BVU^]G=6QE(N(%5ROF%<=#@$#T.<\$5)KFBZG?^-?#6K6J6
MQM-,-P9O,E*NWFIL&T!2..O)%9-[X/O]5UW3M4N+*SL]4LM0\[^U+68AYK8.
M2(V4*,DIA2#D#D@]B 6H?&%M8WWC&;4=/@LTT3RGGF@;>]R&CW*3\J\XPH!_
M.IKGQ9?Z1/HLFL:?!%8ZM,ELKPREFMIG&45\@!@>FX8P>QZUGS^"+W5KOQM%
MJ)MXK+7TA6!X92[QF.,("RE0.H#<'VJP?#VMZY8:%I^NQ6D::9<Q7,\\,Q?[
M2T0.S:I4;03@G/3&!G.0 5KCQQKWD>)I;70K)O[ E83>9>L!(BQB0[<)G<0>
MA  XY-:4WC6*2^T>SMFM;>75+$7L#7TA19,[<1J1U;YLGT]#GB@GA?7%M/&\
M1BL=VNM(UMBX;";HA'\_R<=,\9]*67PM?7GA[3M$UG1=-U.P@TZ*W>,SD/'.
M@V[T8H" 1CG((QP#S0!V6GS7%QIEK/=V_P!GN9(4>:'=GRW*@LN>^#D5R4WC
MF[/A>?Q79:=%<:) [DKYI$\D*.5:51C;V)"GJ!U!.*W_  QI5UHWA?3M,OKL
MWEQ;0+'),23N(]SR0.F3Z5R=CX/UO3?!NH^"H3:R:;-YT-K?-*=\4$I)8,FW
MEUW-C!P>.E !XCU&_N_'?@>33OLLMG<"ZN+?S)642?Z/PS84XPKG'7KVK?\
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MYG\V&/: (-@7 7()R#W)()K8AT/7?^$UTK6YX;#R;;2WLYECN&W;V96RN4Y
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MOK^QM&N+:S5K2X#%Y '3#DDJ-I/?!.?6I+;5M:N?BCJ6D21VK:;;V$,BIYK
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M<,K#//!]14</AV^6Y\2ZR\,/]I:O"D$5OYORQ(B%5#/CJ2Q)P.. ,XR>OHH
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M++PUP5$;*7/5CD]3DUS\"0:M\"[S7+C"^((?/N9+O&+B*[21L#=U!X50/[I
MZ4 >KG5[+^W5T83!KXV[7)C!^Z@8+D^F2W'T-76944LS!5 R23@"O-K"S@F^
M+MK<:G96HO6\-0W$I:)<K/Y^"PX^\#@9Z]*WO&TMBTN@V5RDDUQ<:BIM;?S
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MD4C;B6W,3NXYZ]*O>"_#6CW?B/Q1<3V,<DMCK[26I)/[EA%&<J.W)Y]<#T%
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M1U.Q^RO=VL#3)'<$X8#KP"":J3>(]1A\7>&M+\NV-IJMK--(V&\Q6C16P.<
M$M[]* -Z+1]/AL9;*.TC6WF),JC_ ):$]2QZL3@<FG:;I5AH]H+73K6.UMU^
M[%$,*OT'0=:LF6-9%C9U#M]U2>3]!2O(D8R[JO!/)QP.M %";0=)N-3_ +3F
MTZV>_P#*\G[28QYFSGC=U[G\S5?_ (1+P^-.BT\:1:_8HG\R.WV?NT;.=P7H
M#GFM*ZE:.W)BDA69AB+S3A2W;Z_A6+X&UVY\3>"],UF\CBCN+N,NZ1 A1\Q'
M&23T% %_^P-*_M![_P"PPF\>+R7G(R[1_P!TGN/:BPT#2M,D1[*RBA:-#''C
M)$2G&50'A0<#@8' J_YL?F^5YB>9C.S<,X^E#RQQAB\BJ%&3DXP* %DC6:-H
MW&588(SBJ.EZ'I>B1/%I=C#9QNVYDA7:I/K@<9]ZOEE52S, H&22>,5S6A>(
M+W4O&/B+29UM?LNGI;/;R0YRXE5R=Q)P?NCI0!?'A?0UAO(1IEN([TEKI-O$
MY/4O_>_&G?\ "-Z-YEE)_9T&^P&VT;;S /1/[OIQVXJAKFI^(+!=3N[.VL/L
M-E;&4-<%]\K!2S  < =!GUSZ55\-:[XBUJPT/5)K/3Q8:C&))1$S^9 #&64\
M\'D 'IUH W[#1-,TRYN+FQLHH)KD[IW08,A]6]3[FL^;P/X7GFN99=!L':Y<
M/-NA!#L"#DCIG(Y]>];@EC,IB$BF0#)7/('TH:6-?O2(/F"\L.IZ#ZT 0W&G
M6=UI[6$]M$]FR;# 5^0K_=QZ>U+;V-K:V*V5O"L=LJ[%C7@*OH/05+)+'"NZ
M61$7.,L<#-.+*H!) !.!DT 8B>#?#<5A/81Z+9K9SL'F@6,!)&'=EZ$_6K3>
M'])>\M;QK&)KFT7;;RD9:(>BGL*N2W=M!;2W,L\:00@M)(S *@'7)[8J/3-0
M@U;2K34;4DV]U"D\>X8.UE##(]<&@"M!X>T>V%X(=.MU%[G[4-@(GSUW@_>_
M&H-.\(^'M(L[FTT[2+2V@NN)TBCQY@]&/4CKQTY-:_FQ^88_,3>!DKGG\JYO
MPQXAO-4U#Q!;:D+6+^SM0^R1&+(#+L5AG)Y/S>U %\^%="-K:VITNV^SVCB2
MVBV_+"PZ,H_A(]127WA/0-2U W][I%I/=E/+:5XP69?0^N.V>E:TDL<*[I9%
M1<XRQP*YWQIKU_X?TVQN[%+=Q-?V]M+YP)PLCA25P1SSWH NQ^%= A-F8M(M
M(_L6?LNR,+Y.>I7'0GN>]2+X<T=)+R1=/A#WHQ=,!S,/]O\ O>G-9QUZ_7XD
MQ^'FCM_L+Z6]ZK@-YF\2*F"<XQR>U=(6"C+$#)QR>] &/<>$_#]WHR:/<:1:
M2:=&=T=LT8*(?51_#^%.;PMH3Z7;Z8=)M/L-LVZ&W$8"(W7('KGG/6M5)$DS
ML=6P<'!S@^E(LL;.R*ZEU^\H/(^M %)-#TR/5!J:V40OQ'Y0N,?/L_NYZX]J
M=IFBZ9HL<L>F6%O9I*YDD6",(&8]SBDL]8LK_4;ZQMIEDFL65)]I!"LPSM^H
M&,_6LG4->OK/Q]I&B[+;[!?6MQ,SD'S T>WOG 'S>G:@#1O/#>C7]ZUY=:;;
MR7+IY<DA7!D7^Z^/O#V.1537CX@WV]AHEC9_99XGCFNY9]IM>  RQ[3OXS@9
M'('05NHZR('1@RGD$'(-)'+'*"8Y%< X)4YP: (K&R@T[3[>QM4"6]O$L4:C
MLJC 'Y"J6I^&M%UFXBN-2TRVNYHO]6\R;BG^[GIT'2L^_P!?OK/Q]I&B[+;[
M!>VMQ,SD'S T>WOG 'S>G:NC1UD0.C!E/((.0: ,NR\,:'IUTUU9Z5:0SM&8
MFD6,;BAP2N?0X'%06_@OPQ:K"L&@Z?&()O/BVP+\C_WA^?X5M)+'(&*2(P4X
M)4YP:=O7&=PQ]: ,D>%M#6"[@&F6XBO&+7*;>)B>I<?Q'ZTEYX5T'4+2TM;O
M2K:6&S/^C*R?ZGV4]0/8>E:S2(F=[JN 6.3CCUI0RE=P(*D9SGC% &,OA'PZ
MEG<VB:+8K;W3;YXUA $I_P!KU'MTJQ<^'])O+6VMKBQB>*U.ZWR,&$],HW5>
M..#659>(;RY^(-YH3"U:QCTY+R&2+)<EI&3!.<?PGH*=JFO7]AXZT'1U2V-C
MJ45R[N0?,4Q*#P<X .X=CTH TI_#NCW6E_V7/IMM)8%MQMV0%&.<Y([G/.3W
MYI]]H>EZEI7]F7UC!<V6 !#*NY1CIC/0CUJ\LL;H'5U*'HP/!I=R\<CGISUH
M R]/\,Z'I5W]KL=*M(+G8(_.2(;]H[;NO?\ &I[W1M-U&[MKN\LXIKBV.Z"1
MQEHCZJ>Q^E&J:Q9:-%;R7LPC%Q<Q6L0SR\DC!5 '?KD^P)K'3Q!>CXC3:!,M
MJ+!=*%^DHSOSYNS!).,<$].] &DGAS1X[MKI+"$2M,;AL [3+G/F%>A?/\6,
MU9U+3+'6+)K/4;6*ZMG(+12KN5L=,CO4>K-J)TQGTB2S6ZW(5>[W&+;N&[.W
MG[N<>^*N/+'&5#R*I;[H8XS]* *!\/Z2;VUO#8Q&YM5VV\I&6B'HI["F?\(W
MHWV][[^S;?[1)()78+P\@Z.5Z%A_>(S5K4YKN#3+B73X$GNPA\F-R0K-VR1T
M'J:Y*;Q)XE@\9V?AMH-),US9O=B8&3:H5@NW'X]: .JN=%TR\U*VU&YL+>:]
MM@1!.\8+Q_0TFJZ+IFN6R6^J6,%Y"CB14F0,%8="/0US4GB3Q!9^(?#.FW]I
M8Q#4KBZAN/++L0(D=D9"<<, IY'K767+S2Z?.VGR0&X,;>2TF3'OP<;L<XSU
MQ0!FMX1\.LETAT6Q"W85;A1" )0HPH8#J  ..E3GP[I!N;.Y-A"9[(;;:0C+
M0CN%/;TXJU9//_9]J;Z2 W31KYK09\MGQ\VS/.,YQ[5(\\:P>;YL84CY69L*
M?3F@!E]86FIV4MG?6T5S;2C#Q2H&5A[@U#9:/I^GQRI:VRQ^: LC DLX P 6
M/)P.G/%9/@O7KWQ!IM_/?I DUMJ-Q9X@!"D1MM!Y)/.*T/$>L#0?#]YJ0B::
M6)/W,*C)EE)PB#ZL0/QH 2V\-Z-96=Q:6NG00VUP29HHUVK(3U) ZY[^M.3P
M[HT>COI"Z;;?V:XVM:F,&/'7&WH.>:;X;UR#Q)X;T_6;; CNX5DV@YVM_$OX
M'(_"M(RQJ<-(@^;;RPZ^GUH R+7PCX?L='ETFUTBTBT^8YEMUC 60_[7][\:
MT[2SM["TCM;2)88(EVI&O11Z#T%2B1#(8PZ[P,E<\@?2D,L8D$9D42,,A2>2
M/I0!4.BZ8VL+JYL+<ZBL?EBZ,8\P+Z;NO<_G4-OX;T:UO#=P:;;QS&0S95<
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M)>RZ;;M<2E3*Q7_6%?NEQT8CL3G%2RZ)ID^JQ:I+90O?Q#;'<%?G0>@/8>U
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M69-8M=&LH=1DR6N$B ;)ZGV)[D=:</"^AK!=P#2[817K%KE-G$Q/4N/XC]:
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MT0IX;TFUN)UD!%L\ODJP)^9MV#SU//6I-!TZ73[.62[$7VZ[F:YNC%]W>V
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MMY7"MU48)X'!SGK7;V=CIX^-6KRR6ML)!I=M*KM&N0YED&X'^\>!GKTKI_\
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MLIFN+"WF?&^2)7;'3) ->./)::Y\$_%=_J<<,FL"6Z-X9 "\4RR$1KSR-JA
M!Z5Z[IDBKHEG(3\@MD;(YXVB@"PMS T[0+-&9E&3&&&X#Z427$$6[S)HTVD
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M%#/8?P8QT<$[7]P.N* /2OM$(G$'G1^<1N\O<-V/7'6B2>&)T226-&D.$5F
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSOQ+OM3T_P ,12:;<QP&2]MX92T98E'E52 01CKS[9''6LW5/[43XL:2MO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAK;RK;PS+*9K=64&-9U)RI)((P>YS[4 >D5G:GK^DZ* =2OX+4$ DR-@*"<
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M*QS,9HY)%)5L8QMR,8R3C!XZ  ]"HHHH **** "BBB@ HHHH **** "BBB@
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M';(P V*2 <9!/0#+'ZG(\3^#K_Q/YT-U;Z<LB7*R:?JB2LMS:("I(P$Y((;
MW8.1GIFNJTS7](UEG73-3M+QD17<6\ROM5LX)P>^#^5:- '#2>'O%6B^*=2O
MO#=SI<FG:K(L]Q;ZAY@,$P4*738/F!"C(..G:KE[X<U<>+-$UFSN[:<VMG)9
MW376X,P<J?,4*,$Y4_+D#GK76TC,J*68A5 R23@ 4 97BC3[O5_"VJ:99>2)
M[VUEMU:9RJKO4KDX!/&>F*YVZ\(:K+IOA:Y@DLX]:\/;5C!D8PSH8Q'(I;;E
M=P'!P<8[UU]CJ-EJEN;BPNX+J$.4\R%PZ[AP1D<<4?VA9C4AIOVJ'[<8?/\
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MW]I%=VD\<]O,H>.6-MRNIZ$'N*9%J%G-?W%C%=0O=VZJTT*N"\8;.TD=LX-
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M0(PO[O.3GOTQWKT.B@ '3GK1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
@0 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>thirdamendmenttoleaseagr002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 thirdamendmenttoleaseagr002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[@XF;/SC8=NWGIG/MCGT:LVR\0:1J-^]C::C;S721B4Q*_S%,XW#^\N>XR*
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M$7S?N_;/'T]Z )-/\1?8-#\,Z1; ?;+C28[@R-"\JQ1JB+DJG))+ #D#@\]
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M8RW#D2IY7F8&%'S$>N /?M'?>)-7U'Q!X$DTUX(++5[>:[,,H8DL(-P#$=0
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M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;IHY88[B-W55EC5AGG=T)XQU-:]IKVNGQE=>'+Z+3HY9-.-_9S0!V5 'V%9
M2-V"0<C;GVH ZZBO+O#OC#4M-^&&GZ]J]U!*+N[*/<M Y%N'GD#22 -RH.
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MY(J]7EGBO4-7U?P_X2U6=+2*SO=:L)EMU5O-A5I R9?=AC@C(VC&>IQSZG0
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M-*O[2ZMU0":-D^SS8(,B#YL]00,@\?>YKI-+L?[,TFRL!,\PM8$A\V3[S[5
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M\@XI=1^'\6H:W;F6*U?1(=(.E"T9FW["RL&!QP5V#'TSF@#0O]=U30M)T_\
MM3[))J>H7*VT:VMO(R1L0S$E0Q9\*IZ8R?3.1DW/BSQ)8:?XEFDTZ.5--LS>
M6E[):2V\4P526C9&.=PQU!P1Z4Z;P7K^H>$++3+_ %N+^UM+N$N=/U.-"6W)
MD*)%/WOE)!.><Y(];MQH/B?5_"^JV.L:CI[WM]:/9H+6-XX(E=2"Y!)+-S[
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MV_B?PY?:+=.R17<6PNO5#G*L/H0#^%9.C:)XD>V%IXHU6RO;:.)H0MI"T;7
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M<9#\ZGD< '(]Z?I^M^)=6T_1=:L;.SET_4)4:6U.5E@MGR1)YA;#,!@E0O?
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M+7/#C75D)-3NY9Q.-V(Q))O(VXY(Z=><^W(!IKK^MV7C?3-*U)+!K+5;>>6
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M,BE6PP#XW$8&WZ\8.0_B_P 6CP=K>KB321-H%W/;W"_9W(O/*;DCYQY>5/\
MM<^E 'J%4]5U6ST32Y]2OY&CM8%W2.J,Y SCHH)/7TKEKSQ#KL_C2PT;3FL(
MK:^TM[Q))X6=XF#(.0& ;[W3Y>O7CG*N/&^O6_PTUS6-M@=5T:\FLY6,3>5+
MY<@3<%W97((/4\B@#T"]U&UT^W2:YD*K(P2,!2S.QZ*J@9)Z\ =C4.C:YI^O
MVCW.G3F6..5H9 T;(T<B_>5E8 @CT(KC_&PU"3QAX*%O=P1H][(45X"^UQ _
MS'#C(P2,<8]>U:-KKFHV'CV?0]6DL4L[BS-W9310&,RE3B56)<C*\'IT/M0!
MU]%97AR[OM0T6&^OS%ON"TL0CC*8B)S'N!)^;;@GW..U7-0EN8--NI;*W%Q=
M)$S0PLX02. =JECP,G S0!9HKA-*\5ZE+XKT_1Y[FSNUO=/DG:2"%@D,Z%=R
MJP8JZ_,1P<@CK6._C?Q5'X,O/$SMI7E:=J#V\]NL#YG19Q&=K;_D.#GHV?;I
M0!ZB[K'&SL<*H))]JI:/K6GZ_IXO],G\^V+O&'V,N65BK<$ ]0:R&UJ]U7Q7
MJ.AZ7-#;#3((GN9Y(O,)DE!*(!D<!5R3WR ,=:S?A+YO_"##SMGF_;[O?L^[
MN\]\X]LT =I--';PO-*=J(-S'!/'T%5=(U>QU[2H-3TV?S[.<$QR;2NX D'@
M@'J#5T]#7COA#6M;\/\ PY\)7T3V+:9+>)9RV[1,92LD[+O#[@ 03]W:?KV
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M%CO!#=<+SV%9@\8:S::GH45^;+S=0U!K.[L84+_9,ARG[U6*E\*"0>N> ,4
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M7"6L6V-FW2/]T< X^IXK#U_5M5LK\0P36MG9FS:2*=T\Z2:X!XC6($,0%Y)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML+<C(W[]V[?USVQTIOB[PL_B-+"YLM0;3M5TV?S[.[6,.%)&&5E.,JPX(_\
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M/((YS7'6&NZ]HGP1T[7H;Z">X98&;SX"QQ)*J-SNY;+YR0?I7::+HFMPH?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ.>>.VMY;B9PD42%W8]
M%4#)-8+^(6MO"<_B&ZVHCV[7%O;M@?+M+(I/]YAC/IT[9(!T5%<<FKW]IIL?
MB%M52]TP0H;RW\I<Q,<;F1EQPH.=K9X'6NP5E=0RD%2,@CN* %HHHH ****
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M@!_>+MW<$C&=O.WKCM0!NT5SNB>+[+7=;U73;=)E-A,(=SPNH=MH9CDC '(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,I&00<@BEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M) R.E! /4 TM% "$ C!&:7&*** $(!&" 1Z4M%% !1110 4@4#H!2T4 %)M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMT@(!WK&&:1L@[LEL 'C"],F@"['X]L)-'\/:FME>>1KEQ';VYPG[MG)QO\
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MJVN'*+-&7CD++N50,908P!C/%=-\/8&A^'WA\M/++YFG6SCS"#LS$ORC '%
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MQD@= >] %ZBL>/7C/INC7UOIUW/%J?E']V%/V=73=NDYZ#@'&>M;% !1110
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M;03P1B>6 QS@!PR,5.<$CJ/6@"77]&C\0Z'=Z3-<SV\%U&8I6@V[BA&"!N!
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MDC.>O(S6_=3-;VDTZPR3-'&SB*,#<Y SM&>YZ4RQN7O-/M[I[:6V>:-7:"8
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M(7L0,?-G.0<GM2:??:EXNM/$MU:ZG<6,UA?SV-DD.W;&8@/F<$'?N8DD'C&
M,'FKFD?#VRT2[(M-4U,:4)C/'I)E'V='SNXXW;<\[<XSUS5MO!T,6HZG=:?J
M-Y8)JAW7D$.PJ[XP77<I*,1U(Z]>O- ')6/BG6O$4_@"YBU"6PCUJ&Z^UPQ1
MH5W1Q'YEW D<Y(R2.G!QRZ Z[/'XSTT^)M05=$DWVDZK'YK;H1(%=MOS*#V
M!Y.3TQULG@VQ_M#0;JUN+BT30T>.TMX=GEA6380VY23\O'6FQ>#H89M?E74[
M[?K8'VC(B^3"; 4^3CY1CG- '+?VWKVK7'P^$6L2V8URPEDO!%%&1O6!7W+E
M>#ECC.0..#CF+[;J]KI_Q"\,ZGJ$NI1:?IC3VMW,JB0QRPN=C[0 2"O7'K]
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MV>6$4DKC"YR"3W[T_P 1^';?Q)8V]O-<W%L]M<QW<$]N5WQRH<J1N!!^A!H
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MF1&>*)A@J@V[03QDD$G ]!0!S-EJ6N6D7P_U6;6[FY_MD0P7=M(B"(A[<ON
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MDM?$4,VLQ:3/8WMG>RPO.B3HNTHI4$AU9E)RXX!SZ@<9Y'P&[2_$KX@/=_\
M'XMU;HH;J( C;,>Q'-=KK=U!IFE76KRPB1["WEG0?Q':A8@?4"@#1HKS'4]<
MUG2_AQIGCB/4II[DI;7-Y:G'DRQRLH:-5Q\I7>,$<_+SG-7!_;6K>-O%ND_\
M)%?6UI:V]K+;^2D0>,NLA(!V],CTR<#GKD [^26.$*9'5-S!5W'&2>@^M/KR
M!K^_\2:-\,]2O+^YCN+N["S&%@H9A%)\^,8W?+]!DX S6XD6N:KX^U_1D\37
MUK:6=O9SP^7'$64L7)7.WE3MY[].<#! /0ZQK_Q'!I_B;2=#EM;@RZF)3#,
MOECRTW,#SG.,=N]<E:ZKJOB3P?K?B*SU2>SN[:>Y%E$FWRXUA)"JZD?-NVY)
M/3=QC%1?VNVO^)?AAJ[Q>4]Y;W<S1CHI:V!('MGI0!Z760WB731]N82LT-BX
MBGF5<H)20!$O=GRP& #R0.O%'BO4)M)\(:SJ-O\ Z^UL9IH_9E0D?J*X7P?X
M7A\3_ K3-*DNY[9[I3<?:HC^\67SC('SW.10!Z&FJ1/?QV(CE^U&(321\$PH
M<@%R#@9((&"<X/8$C,N/&.G)XA?0+**YU'5(D\R>"T53Y"^KLS*J]1QG/M6+
MI_PU73_$>C:RGB#4WDT^T6VFC=^+O:&"L_/^T>.>@_'C/@ 97U3QG)?Y.IF[
MC^T;_O9S+G/_  +- 'J.C^+=,UC4[S2HS-;:K9\SV-RH250<888)#+R.5)'(
M]:S(/B+I]WXGO/#EMIFJ3:K9J7F@5(QM4;>=Q< _>7H>]<#XH,R?M.>&_P"S
M\^:UFGVC;W7][NS_ , Q^E5--;5U_:%\9'0TM'O_ + WEB[9@F<0_P!T9ZXH
M ]CT77X=;>]B2SO;2:SD$<L5W$$;) 8$8)!&#U%20Z[I]QXANM#CG!U"U@2X
MEC]$<D#\>!G_ 'E]:JZ9=KIW@^UU34@PG33XI+IR,NQ6,$Y]3G/'J:\2UC49
M/!GQ+T+QF[W7EZF/*U<2P2HL;,>5!=1D*I7:!_SRH ]ZUC6=.\/Z7-J6JW<=
MK:0C+R/^@ ZDGT'-8L/CB&32SJTFAZU!I6SS/M<ENI&SKO\ +5S)MQSG9TYK
MSGX^SR/?^#X9VSH\ETSS\_(Q!0<_\!+8^IKV[:I7;@;<8QVQ0!R$WQ+T"#7]
M+T:7[6EQJ5FMY"WDY0(RE@"<YW$*> #]:30OB9X?\0:(^L6QN8;&*Y^S3R3Q
MA?(8XVE\$X4Y'S=!WQ6Y)H-I)=:=(540:: ;6%5X5@I4$GJ0%) '3OR<8S]2
MT"TM_"?B&%P)'U"":2YD*@;V,6T8 Z *J@#VZDY) .E!R,BBN&^#^J7.K_"[
M1KB[9GFC1X"[=6".RK_XZ /PJS%J-QXA\<:_H?VRXL[;2(+< 6[!'DDE5GWE
ML9PH"@#IDG.>, '2ZIJ=IHVE76I7TOE6MM&9)'QG 'MW/M5/3=;FO=4N;"XT
MB_LGBC6599E4QR*W& ZDC<".5Z_45YCXBU34==^#7B5=3N9#>:1?26$LL0"+
M=>7*@#D8XR".F.1^%>O6ENUK;B)KB:X()/F3$%C^0% #I+A$+HO[R9$W^2A&
MXCMU(ZD8YK-\,^(+?Q1H%OK%K#-##.TBJDP <;'9#G!(ZKZUS&CVLC?&'Q*S
M7UV5CL[-Q&7!7!\WY<8X4=@,=3UKD=#N-4T;X7:)KEGJUQ&(=4,1LU5/)DC>
M\9&#9!8D[CSD8XP.Y /;**X*[OM:\1:KXDL-+GFMGTUTM[9HIUCVR&)7\QP5
M.X$MC!XPO3-==HIU$Z+9_P!KF ZB(@MR;<Y0R#AB/QH RI?&4$?B6?0(]*U*
M>_AA%PRQI'M\LG 8$N!C/X^U6M)\5:9J^HW&F1/-;ZE;J'EL[J(Q2JIZ, >&
M7W4D5S=G_P EXU+_ + $7_HXU4\;#;\6? +V7_'^SW*S;>IM]HSN]OO8]\T
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MUD,7ELOR\8$8(^XO0YXKL** ,O7-%_MRW@@:_N[1(ITG(MMG[PHP90V]6XR
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M5C>9YF48,CA0S?7: /R%<UK_ ([L/#\\ZS:=JUU#:X^UW-I:&2*VR ?G;(Z
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MKZAJ.FZC>:>VI ?;(X-A61@,"1=RG:^."1U],\UK1W\KZS-8&PN5BCA647;
M>4Y)(V YSN&,GCO5V@#FM0\$Z?>Z5I&F07%U86FDSQ7%M':E/OQ_<W%U;/OZ
M]ZZ-%*HJEBY P6.,GWXIU% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4V12\;*&9"P
M(W+U'N*=10!X@]O(GP%\4327ES.6N+I<3/NZ7)^;.,DGN2:[4W6IZ+\1-*LY
MM6N;RTU.PN))8)50)&\6P@Q@ $##$8)/N2>:L2_#FPET'5=$_M34UT_49GE:
M)7CQ%O?>RIE.A;UR1V(R<ZDWA>.X\0:7K4NHWK7.G1/%&O[L(X< -N&S.3M'
M0CI0!R>FWOBSQ%H6C^(]+G6.2>1;B:.:Y7[.T!)W1[ N00. V<Y')KTKK7&Z
M;\.K'2;^1K/5=4CTIYC/_9(F'V8.3G &-VW/.W.#WR.*[*@#@?B" OB3P(
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M9"RV8CV>6&W9QLSG<<]?TK);X:Z5)X;_ +%>^U!ECO&OK>ZWHLUO.6+;D95
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MO>/+!]0G,.GI;M:'Y=T): N<''/S>N:YWS[[7(_A=>W>I78N+O<TS1L%#/\
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M_* ^ W&?0XKMBH)!(!(.1[4 <K#X[@N-1U'3X=#UF2[TX(UU$L41:,.NY?\
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MJQC;8X!SM. <'WP1^=/K@OA?;21V6N2/>W4^W6KR+$TFX';)@,>,YP/6N]H
MY/5/'UEI%I/>76E:J+.&Y-J;@1)M9P_E_*"X)!;C.*=J7CB'2K#4+J\T75HO
ML5O]I=&CCRZ9P2I#X..XSD9%97QA4+\/W   ^W6IX_Z[+6K\2U'_  K;Q$V!
MD6$H!_"@#I;:<7-K#<*"%E17 /4 C-2UYY;3ZII'BWPE;'6+FXMM8LYTGMY%
M01Q&.)74Q@#([CDG/?-4]&OM;.G^(M>O-?O9X]!U+4%6T\N,+<1Q*=JOA?8=
M,?3F@#T^BN!TT>*[J3P_K%M=JUM.$?4%GN5,4T;J#F-0ORL"1@ \]#GK69?Z
M]JMG-I=W#JL]Y)-XA2RGF@ %GY+RE/)4-U91C+*#A@06[4 >G"6,S-"'4RJH
M=DSR 20#CT.#^1I]>:V;R:;\0_'FI/=WDRV-E:W A,@*L/+E;9C' '. ,=>]
M6=-;Q9J$7AW6[2[7RKGRI=06:Y4PRPR*"?+0+\K D;>>>A)H ]!HKR2>^\0R
M^%_&^HCQ+?)-HFHW(M-D<0W+&B,%?Y.5YQ@8ZDG/;U+3KEKS3+2Z< --"DA
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M*+M7;A01@<=:ET[7X-0U2YTTVMW:WEM$DLL5Q&!A6+ $,"5;[I^Z2/QXK6H
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M'RUVI@! 1@'UI\/B93JMGIMYI.HV-Q>%A!YZ1LC;5+'YHW8 X'0G/MC)K=H
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M,]U<R@R[><!< *H&21QU/.: ,UK^X3Q/H7A1+ZY6&:PDO9YRP\R0*558PP'
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M*5+X8#OD'(J33?$47AOQ/XY>Y34[V"VNH9-D2O<&&/R%9B2Q^5023C/K@<4
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MZ4PW<-U$5EB; (&T9SG(QC.<\4 ;]%<^GB^Q&J3:9=6U[9WL=L;I8)8=S31
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M!^[L]**RL.FZ23Y5_)2:ZFH+6TBM!)Y8)>5M\DC<L[8QDGZ #V  % $]%%%
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MKM0<<A1UKF;9M:NO@EJOAZ]TO4SJEK;R64 :SD!N4!Q&R\?W< YY&.:]=HH
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M&1&^8-ROW3UY/IC!-OX9PWFG^&WTF^T^ZM9[6ZN=S31[4?=,[*4/\0PPY'%
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MMX[L"/UZ47>CQ:AIVB"6'7-)U6RTF$6VIV5M*7C< AX9%"G(RH.",')P1GD
MZ"Y\;/\ \)'X?T^TTR[DM]4M7N_-VJ"4"J0H!;@C>"<].@SS@CU[2;/4/%U[
M8VVHW%]8I$]]"VY0Q$9*"-7( &T9)  /7FL81^(8]<\"ZOJVEW$]U'87$%Z+
M2,-Y4KK'MW <*#M.3T!]JGM;"]N/$WQ#VV5TB:C;PI:220LB3%;<HV&(QPQ
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MSFWN0N7B)P'4HS*1GCKD&@#:HJGJ.I0:9#&\P=WFD$4,48R\KG)"J/7 )YP
M 22 *QD\:V31ZLIL=06\TD!KNR\M3,B$;@X 8A@0"?E)/M0!/K7AA=5U*WU.
MWU2_TW4+>)H5GM'4AD8@E61U92,@'IGBKNF:2-/+2S7MS?W;J%:YN2NXJ.P"
M*JJ/H!GOFJ>D>*['7'LA80W$L=W:"[$H"[8T)(&\AN&)!&.O!]#B"_\ &VF:
M<B7-Q#=#3&N?LIU%44P+)NV<_-NQN^7=MVY[T =)17/ZKXNL=*74'-O=W46F
MJ&OI+95*VX(W?-E@20IW$+D@$<<BI;;Q387>MQ:5 D[S3V/]H0/M&R6'(&0<
M\'+#@@4 ;=%</K?Q!6#PG-JVEZ?<S.E^-/=9 B^3)Y@C8G+<X)P,9R<=!S70
MW&OK"R0)IU[/?&'SVLXO+,D:9(!8EPHR00!NR<''0X ->BN>M?&FCWVCZ?J-
MD\MR-0D,-M;HF)7D&=R[21@KM;)) &.O2L'P7=/<_$7QL&CO(0GV+]Q=/N:,
ME')Q\S#!ZC!QS0!W]%-D<1QLY#$*"2%4D_@!R:XC3/%WAO1/!<.J6D6HKIDM
M[)"HD1I'$C3%6+%B=HWD]3^% '<T5A:7XKL]3UVYT;[+?6EY#"+A4NX?+\V(
MMMWKSG&>,'!]JT=4U.VT?3Y+VZ8B)"JX4<LS,%51[EF YXYH S=9\+KJNJ6^
MJ6VJ:AIFH01&$36CH0T9()5D=64\C/3-7=,TD:>7EEO+F^NW 5[FY*[B!T "
MJJJ.3T ]\U6;Q+:6\&HS:C!<Z<FGQK+,;E5QM;."I1F#?=(X[\=:;#XHM6UF
MUTJ\M+NPNKR-I+472J!.%&6"E6;# <E3@X[4 ;E%-ED2&)Y975(T4LS,<!0.
MI)KGX?&>GRW^F6SV]Y#'JH;[!<2Q@1SX7=Q@EERO(W 9H Z*BN83QUI<DEHR
MPW?V.[OCI\%[L7RGG!*[?O;@"RL 2N,CKTK.TZ,_\+<\0VYEG,3Z5;/M,SG:
M6>0';S\O0=,4 =Q17G_P[U2/3_AW;37<LTSO?W,,2EC))*YN) JC)Y/'4G@
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MHOE23 L-OWMPR48 E0#CZ5GZC:2^)_$/A:>"SNH(M+F>[N);B!HMI\LJL8W
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M1RV"HR!DXZ TFGV$I\7>(/%+6US':SV<-K!&86$LVS)9_+QN')"C(!X)Z8-
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MF=\,BMPQ *D >OUKT;PL;>X6YO;7PV=$AFV +-;)!/*1G)=5Z 9 &>>O&,9
M-#4-:@L+VWL5BFNKZX1I([:#;O*+C<Q+$* "0,DCD@#-<UK_ ,08;3P/J^M:
M7:3S75@[6\UO*%1[6;('[P$] 2#\N<Y&..0NKVE]I7Q,LO$JVMQ=:;-IK:=<
M"WC,CV[>9YBOL7+$'H< X[US^O>%M3U'P[\0-0M+.;S=;>!K2T9=LC)"JC<5
M/(+$,<'G@9Y.* -+Q%J#6WQ$\&WKV^H1&:*_#V>[>S%47;A%8KGYCR.QY(QQ
MT>G>,M,U#2+O4"ES:BSN3:7%O<1XE2;( 3:"<DEEQ@G.X5BZE)=:EX]\&ZFF
ME:A%;6\=YYYDMSF+S$54W8SC)4\=N^*YZ[T+6+_3O%IM-,E>X_MV+4[2WNH2
MB7D<8CROS#'.QA@^U '<CQG8QW][I]Y:7UG?6EK]L-O+&KO)#G&]/+9@P!X(
MSD4[P[XPL_$SQ&QL=22WEM5N8[J:V*PL"<;0V<%AW'UK#TZXM]1L+V\M?!-Q
MH[I9R1N\]@L<[NPP(XPF69<Y)/ Z>^-CX?03VG@'1;.ZMYK>YMK5(98IHRC*
MRC!Z]1[B@"?6_%NG:#JECIUU%>27-\)# L%NSABB[B >YZ# ]1G YJC:?$30
M[G2-5U"87=D=)8)>VMU#LFB)^[\H)SN[8/-9_C*Y%G\1? LS132*LE\"(8R[
M & #.T<G'M6=JECKL5QXN\4:+I\QFO$M+>VA:'$LB1G$DHC<?>PQ"AA_#G'(
MR =A;^*K674+W3YK.]MKZSMUN7MY(U=GB8D!E\MF!Y!&,YS7/W/Q0M)/#5SK
M&E:-JMU"EC)>1S/;A(3M."I<G&1U(&3C.,D8JGI4-S:_$2XU1-%UA-/N-$2(
M3W"EW,BR.QW98MG! "]?8"FZ/H^I2_ .70C8W$6J+IDUO]FE0HQD(; &>#G(
MYZ<T =#!XR2"/08=1TZ_BN-6"QPN5CV-)MW$$A\+D9(!Z]N>*W(M4CFUJYTM
M8)O,MXDE>7"^7AR0HSG.?E/&.WN,\KJ>FR^(_ABD30SZ;?6D$<]J]TH1X9X5
M#*YY^49!!SVS6SX/CNWT)-3U&(1:CJ9%W<(/^6990%3_ ("@4?4'UH K>+/$
M]UH%_H=I;:=-<_VC>"!I$*?* I8J S#YB%^F,\YQ5VY\2PPW-Q;6]C>WMS:Q
M++<PVRH6@# E0V6 +$ G:I)_,9R?'=K>/=>&+^ULKB\CL-56:=+=-SJAC==V
M.X!854TE;[PWXT\0W%]87LMCK!AN[>:"!IRCJ@5XG"9VD8&#]W'>@#K](U:Q
MUW2K?4].G6>TN%W1R 8SV((/0@@@CL16!:^);G4O'&L>''TRZ2UM((<S+(BD
ME]^7R'W!2% &.>N<5)X T*Y\/^%DMKM/+N)KB:Z>'(/D^8Y8)D<< C..,YJE
M:QWFF?%#7+R73KN2SO[*V\JYBCW(ICW[@V.<_,,  DT 87P_\86ND>!="AU"
M+49%GNY;9KXQEXDD>XD"!W)SSP,@$#/)%=MJOB>VTL7I6SO+T6,8DNS:JI\A
M2-W.YAD[><+DXQQR,^<Q:9J:?!O2]*;2K\:A#J2RO;_9GW*HNS*3TQC8<_IU
MK3N8)=$\::S+J'A"XUW3=7>.YM;FWM$F>)O+5&CD#XVCY003Q^N #T;3[^UU
M73K>_LIA-:W,:RQ2#HRD9!K,A\46UQ-$(+2[DMI;IK1;M%0Q^8I96S\VX ,K
M#)7&1[C.AI4!MM+MHC:0695!_H\  2+OM&...F1UKSR'2+RV\36NI^'8-4TV
MXN-2/]JZ=+$_V.:+<=\P+#:&( 8%3DD@8ZT =1)XZTN*0DPW;68U#^S6O51?
M*6?=MVGYMV-WR[MN,]Z?<^-+*#6;_2(;#4[N_LXDF>&"VR75LXVDD ]#R<#T
M)-<%K<.OZMI-Q]MT'59=2M=;CFVQ)B!8%G!4Q $!R5Y+8+9SD@8KJM-%S'\3
MM8U*:PO8K6;3+>-9&MV(+H79E! ()&X=.#VS0!/'\2=%ET_3]1CM]1;3KV1(
MOMGV?$4#LVT+(2<@[N#@$ ]ZUM5\2V^F&["6=Y>FRC$MT+55/DJ02,[F&3@$
M[5R<=N1GSA=,U,?!*WT<Z5?_ -HK?JYMOLS[@HO/-STQC9S^G6M.\AET;QOJ
M]U?^$;G7=,UCRI[:>WLUFDA<1JC1NKX*@[0<G 'YX /1--U&TU?3+;4;&836
MMS&)(I!_$I''T^E8^K>,K#2(+NZEMKR:QLI!%=W<"*T<#<9R"P9L9&=H;'X'
M&KI,!MM*MXC9P66%S]F@ "19.=HQQQGDC@G-><6=I+H>MZSI6J^")=96\OYK
MJQOHK6.6-TE;=LE=ON;22,GMVZ9 .RN/&>FVFN0Z5.D\;SVSW<$[;!#+&B[F
M*N6Y(';KCGIS5#Q!XSN--T?1+VUT>])U._M[<+*$1HU=QG*EOO,N0!V/7&*H
M^+=!G\46JZ9%!]BDT>%+NWN5M"8VN /E2,$',8Q\P'7*@=#4&O7.K^(O!N@:
ME)H5]#?V6K6=W>V(A/F*(WRY0'[P[C';\: .LO/$<=KO1-.OKJYA@%Q/;0",
MO"ASC=EP"3M;A22<&L__ (6%H3C16MS=W*:PCO:-!;LP;8I)4_[7&,=0>N!S
M7.:C'<:3XXO=6O\ PC=:SIFKV\!0PVR3S6DJ*5*,I/ (P<@XS5N[L;B/Q/X'
MEAT-[.VM'NY)X;6WS':K)&0@;8-NXD\XR,Y/3F@"[J/Q"AC\'ZYK%CIMX;O2
M2\4]G<*L;Q.%!!;YL;<$'()R.E=1I-W+?:7;W$]O+!(Z LDNW)XZ_*2,'ZUY
MQ?:1J>H6'Q+MX-/NO,U+#V?F0L@G A53M)'7*D8KT/0;F2ZT2TDDM+BT;RE7
MRKA0KC  Y&>.<]: -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT"35RTT44=PUJ\+Q_O1.'V>5M&<L6P!@G.:YVUO9;CXV1(]M?VA_L*1FAN9
MRD^=& RA791Z''/'- 'H5%(3@$\\>@KEK#Q]INI7S6MK8ZHPBO)+.>8VI$=N
MZ+DF1L_*.HY].<9&0#JJ*YP>--/%[ID,UO>00:HVRQNY4413L1E0,,64L.1N
M49IM_P".-,T^)[J6&Z?3HKH6DM_&BF&.3=L(/S;B QVDA2 >,\&@#I:*PM6\
M4VNE)?.+.\O(]/4/>/:JK" ;=W.Y@2=OS$+D@$<<C-&?6O#]_P")_##C[5/=
MW<,TVFSQ;UA*&,%RW(!^7& 02">U '5T5A:9XKM-4_M<1VMU"^E2&*Y2<(I#
M!=W'S8QC!ST/K3_^$DB>&U\C3[Z>ZN+?[2MFBH)5C_O-N8*N<@ %LGGC@X -
MJBN=M?&VCWVC6>I6C33?;)C;06RIB9IAG='M)&"-I))(  SG%87A*Z>X^*'C
M -%>0;;>SS!=/N*,1(3M^9A@\'Y3B@#OZ*:[K%&TCL%1068GL!7.:?XWTW4+
MK2H4M[R*+5D=["XD1=DX0;CC#%E^7D;@,B@#I:*XV?XDZ3#:ZG<K8:M+#IEP
MT%XR6G^IV@$N<D?*-WUX/&.:Z^&6.>&.:)@\<BAD8="",@T /HK/U/6+;3)+
M6!UDFNKMS';V\(!>4@;CC)   &220!^(K+/C?2TL-7N)XKR&;1QNOK1HLS1#
M;N#84D%2H)# XXZT =)17!:WXTT'4O".ISZEIFMC2!;12O*MN\8F23D>6ZD=
M",$Y Z<D&NHN]<M;&_M-,CBFN;ZXB:6.WAV[O+7 +$L0 ,D#D\D_6@#5HKA]
M4\9>'=8\#ZO>WEOJATR#,-VJ0.D@8'#*"".01@G.!Z\UJWOB[3M*U2RT<VU_
M+=7-NTT"10%]ZJ!P"3R>1[#N10!T=%<S!X[TB?0)M69+J%8;O[#);2Q@3+<;
M@HCQG&26'?'.<U-#K=KK@UG2C#=VEY8HHN(9&".H=2497C8C! /0YXYH Z"B
MN1^%\CS?#/0))79W:U!9F.23D]371:GJEKI%G]INF(4NL2(HRTCL<*BCN22!
M0!<HKGX/&&FM=:I:WJSZ=/ID*W%REV%&V(@D.&5F4C@]#GCI1'XNL_[0L+2[
MM+VR.H@_8I+E%"3D#.T88E6QR P4_CQ0!T%%<V/&NGG1]9U/[->"+1IY(+R/
M8N]"BAF(^;! # \&BZ\;Z;;:AI]C]GOYKC4+8W-ND5N6WJ #@'U^8>P[D4 =
M)17"ZU\1(X? >I:]I>GW33VD[6<L$ZJCVTVX+^\&[H"RGC.<CW(Z.;7A$881
MIUY)?2QM*+)/+\U44X+$E]@&2,?-SGV. #7K"UOPQ#K%_;:A'J&H:=?VR-%'
M<64H!*,02K*RLK#*@\CL*SC\1]!&EZ?J %XT5[>?855;<EHI\D%''8C!XY)[
M9I/^%B:<EQ:VLVEZW!>72S-#:RV+"1_+." ,\YX(P2,')P* -[3-(73BTLMY
M=7UTR[6N+IE+[?0!0%4?0#/?.*T:Y2T^(>B7>A7NJ,+NW^Q3BVN+2>';/'*S
M!50KGJ21@YQ[\&K<7BZR:35H)[6]M[K2XDFN+=XP[[&!*LNPL&!P>AXQSB@#
MH**\]U;XH1)X1O-9TG1M4F5;$74-Q+;A(/F.T98GDJ2,@9/IFNZL;B2ZLXYI
M;:6W=AS'+MW#_ODD?K0!8HHJ.:%+B%HI-VQA@[6*G\QR* ,G7O#D6OR6AGU'
M4K:& N)(+2Y,27"L "L@')''8CJ:V418T5$4*JC 4#  KQ[P'JV@2_#JVN_$
M/B"X?4-TRR*VL2K,V)6"@*) <XV@?A72>(;62P\3_#^#[7<RLEP\$CO*V)=M
MNWS,N<%B1G/6@#OJ*YW5O&5AI$%W=2VUY-8V4@CN[N!%9(&XSD%@S8R,[0V/
MP.)[WQ19VSRI:P7&HR0VPNI5LPC>7$<E6)9E'.#@ DG'2@#;HKB;KQZ)=4\+
M1:387%[9:TLLRS)L!9$C)V@,P(8':3G' P,YXN?\)YI[ZS<Z5!I^K7%S:W,5
MO.(;,D1>8,J[<\)R.?RS@T =517-77C?3+2TDU!X;MM)BG,$NHHBF%&#;"3\
MVXJ&X+!2/>G7OC.PM->;14M-0NKX6GVM$MX-PD3<%^4D@'D]>G'7I0!T=%<1
MK/BKPYJ_@#^UKZ+4&TN:98Y(XE9)HY%E"[6VD;2' !YQ]:Z'4-?ALKQK*&UN
M;Z\2'[1)!:A2R1Y(#$LR@9(( SDX.!P: -:BJ&B:S9>(=&M=6TZ0R6ERF^-F
M4J>N""#T(((_"C4]6@TQK6-TDEGNY?)MX8MNZ1@K.<;B ,*K'DCIZX% %/4_
M#46J>(=*UE[Z[BFTPR&"./9L/F+M;=E23D>XK;KC_$FO:--X6EFUJRU..T6\
M2"2)%*R+(LB[<LC8 W;>=V#[UM7NOV]IJHTN*"XO+\VYNC!;A=RQ [=Q+,HY
M/ &<G!]#0!K45R ^)&A-HEIK"QZ@;*ZN5M8W^R,/G9MO.>P.0?H<9J]8^,M.
MN[_4;*>"\L)[" 74BWD.S="<_O%P3\ORGK@CTH FUKPS!KM[:S7.H:C';PJR
M26<%P4@N5..)5Q\PX]1P2.E;=<YI_C.QU"]TZV%I>P'4[9KJQ>9$VW"* 3C#
M$@X93A@.#61IGQ">32-?U?4M(O8+/3+R:%MGE,42/:I!P^2V<DXR.>"<4 =U
M16--XFLH-7TK39(K@2:I&\ELX0%2$3>P.#D'!';O6=8>/M,U*]:VMK'5&6.[
MEM)YS:D16[QC),C9^4=>OXXR,@'545SB^,]/%]IMO/;7EO#JAVV-U*BB*=L9
M &&+*2.1N49J>V\46UY/;""SNWM;FXDMXKM50Q,Z;]W\6X#*,,E>2/<4 ;E%
M%85]XIM;26_2&SO+X:> ;QK5%80Y7=@Y8%CMP<*"<$>HH W:*YJY\=:+ ^C"
M-KFZ36%9K.2V@9U<!2V,^O&,=<]0*N:!XEM/$(O4A@NK6YLIO(N+:Z0))&V
MPR 2,$$$$&@#9HJKJ-XVGZ;<WBV\EP88R_E1D!GP.@W$#\S7F&M>(+C7? WA
M+7KJ&ZLY)-7L9&VR81U:0$X5&.X8_O#/M0!ZS16!IGBVSU+4=0T_['?VMY91
MK,\-Q!AY(VSM= "<@D$>N>HK.\-Z]H5MX0TB71X;UK2]GDALK>5MTTCAI"W+
MMQ]QSRW08ZX% '8452TS4EU.&5Q;7%N\4K0O'.H#!ACT)!'/!!YIFKZ4NKP0
MV\ES<P1),))/L\SQ-( #\NY2"!D@G![8H T**\RT/2(K_P"(OC/2;B^U8V5D
MEE]FC&J7(\KS(B6((?/)YYIR3OX=^*/V=CJ6I.GAN+]W&6E>603%2P#-A20H
MR<@?B>0#TNBN)UCQ3X<U?P/:ZM>17\FF75Q&H6)621)5E"@/M(VX<8.3CZU?
MU;QSI^DZS/I!L-4N[Z*U^U^3:6I<O'NV_+R,\Y]N.N< @'3T5R7B/Q%;7&BZ
MU:VUKJ-P;:U8W,EK\AMV*;@"=RMN ()"Y('7K@V?A\[2?#OPZ[L69M.@)9CD
MD[!0!TE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!X[=1>(-3T_1[G4- U9]6LM?
MBN+M40"&.)96(\E=P!&TK\P&>NYNE:6N:3>OK-WK'AZVU72_$?VJ-&C6-FM-
M0CRHW2<%!A<C.0?E.,Y%>H44 %<;J4%RWQ7T6\2TN6M(=/N(9)UA8HKNR%03
MC'\)^E=E10!Q?A..XB\:>+YYK*[A@O;J&2VDE@95D580C$$CCE3UQ75:D672
M[LI;BY80N1 1GS3M/R_CT_&K5% 'G/A71KK2/$EM'H1U6'P[-;2-=:?J,;A;
M*3Y=BQ,XSR2V0I(X)SR*YVVL]:C^'?A_0/\ A'=4-[I.JV[7/[D!"J3ELHQ/
MS CG(X'<CC/M%% 'G5E=:OX3\7:]%-X?U/4;#6+A;VUGLHU?8Y15:.3+ )C:
M,$G%7;B&_;XEZ#?3V,WEPZ7-#<2PPNT4<KLA"AL<CY3S_*NXHH XWX?V]S:K
MXC%U:7%O]HUNYNH?.B9-\3D;6&1WP>.OK5KXD?\ )-?$?_8/E_\ 03745F^(
M-%B\0Z'=Z3/<300749BE:';N*GJ!N! _*@#D+BTE\4Q>#(K>SNH1IUS#?W,T
M\#1B,1Q$! 2 '+,P^[D8!.>F>>U*'Q!JFFVTM_H&K2:I9:_%<3+&@$"0K/D>
M2NX!LK@EL$YSDXQ7K5A:?8+"WM/.DF$*",228W, ,#. !^E6* .*T*.Z7XF^
M([R:PNX;>[M;1(99(2$9HP^\;NG&X<]#V)I?!MK>:?K7BJQO--N4CNM5EO([
MAE'DR1NB  '/)X.1CCO7:51UC3?[7TJ>P^VWEEYP ^T6<OERI@@Y5NW3'T)H
M XWP3H=YIVO:AILS*^D:'.Z:9@Y(\Y5DVGWC5MH]I#7H%4M*TN#1[!+2!I9
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M\IP.HZXJ_P"'[:ZL/&/BF[.BZI#97UE;-!+,#(S%%D!R=Q8L2PXY/KBO1Z*
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M:0E%>/<K(00Q![Y(QP:]&KG+[PC'<:U/JUEK&J:9=7"HMQ]DE0I+M&%)61&
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MQ2+/9-OE=)5VC/<#(S][GO7J]% ',>!H-9MM(NH-7NKB[2.[=;*XNDV3RVX
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M8!<EF4*,D 9/)/'0UP?A'Q59^'O"WB+5=074#:KXAN(E5U:26,%D558D\8)
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MT6J>'-;N-/\ !EQI+R:;-;CSK%(KB:1EX153)*YZDX&2/0U4>SOO[)^'$?\
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M4#X]2YL(\Z7K=L+?5_1?*(96/KO0M%]#GM4VNRZHWC2&TETR_N=%>Q_=M9
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MR+*L@"Y*-@+NQSNP1ZU/XVTVQU:UL;/4=/O;BW:<L+FQ#F:S<*=LB[/F'/'
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M(5'*!?E;KQR3@9/!-7O"WB'5]5AL[.\\-W^G7-N@6]FNXPL0(7!\H@Y?)QC
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M['&!@9.3QSR$\7B#4K#0;O4/#^K/JUEKT<]ZJH!%'&'?B%=P!7!7Y@.?XFH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7TH Z"BL*V\56-SXNN/#/E7,6HP6WVI@ZKL:/<%!!!/<CBMV@ HHHH ****
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MEN8PJ-E3D[D)/*CJ:ZTPJ]L8)SYRLNU]X'S@\'('% 'EW[/?_),S_P!?TO\
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M)!;'R[LDJN3GL*Q/%'PXT[Q5XAL-<N-2U"TO;#'V=[0QKMPVX9W(2>>>?4T
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K 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>thirdamendmenttoleaseagr003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 thirdamendmenttoleaseagr003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'0]4U"<>3I.HSB?3K;S VQ/FRW!.,Y48Z_+0!Z+_ ,)+H/\ T&]-_P# M/\
M&KUK>6M]#YUI<PW$6<;XG#KGZBOG7X<ZVF@ZEX[E_LZ:Z>2_BAC*0;TB+2RK
MN<]%49_'%>C_ !%G_P"%??#76)O#R_9)+JY&SR@%$#2$!RN.G0D>A:@#N+C7
M]&M+@V]SJ]A#.N,Q27**P_ G-7);F""W-Q+-''"!DR.P"@>N>E<5\+=$L8?A
M=ID;V\<O]H6_GW9D4,9VDR3OSUX..>PKCO@IJUW#KOBGPC)*\VG:=,YM YW>
M4HD9"H)['@X^OK0!ZO\ \)+H/_0;TW_P+3_&K]M<V]Y L]K/%/"V=LD3AE.#
MC@CBOG/X-Z]!HG@[5!)ID]X]QJ4,"L+<O$F_:N7;H!S^/'K7T'I&D6>AZ>+&
MPB6*V6221(U& F]RY  Z#+' H O5!=7MI8Q>;>74-O'G&^:0(,_4U/7*_$L!
MOAGXC! (^PR'GZ4 =):WEK?1>;:7,-Q'G&^)PXS]14U8_A)0O@W0U4  :?!@
M#_KFM4==\0ZCIUW>)!9V\-K:6@G^V7LA2*:0DXB4CO\ +R>V1P: .FHKA;CQ
M_='1O"FI6>D)+'KTT<.QKC:T3.I;'W<$?*><CZ5:L/&5Q!JFOV'B&UMK-M)M
MDO6FMIFE1H6#'NJG(VGMS0!TM]JEAI@B^W7MO;><XCB$T@4NQ. JYZG)' H3
M5+"34WTV.]MWODC\Q[=9 9%3(&2O4#)%>:^-]0U35O#/AO4IK&VAL[O5K&5$
M\PF:%6D!4MQ@DCJ!C!/4]:VSLC^.DCG:H_X1D%FZ?\O)Y- '=45P\OCB^;PD
M_BZSTV*?1DW2>5YA$[P*Q!E'&T' +;3V[@\4Z^\::E)XAL=+T32[6\34-,:_
MM+B6Z**P&W&X;?E'S=LYR.G) !VCNL:,[L%11EF8X 'J:@L-1LM4M1<Z?=PW
M5N6*B6%PZD@X(!''!KG[7Q#J6J:C<:5:6=HE[86\+Z@996:..:1=PA7 RW R
M6[9'!SQF_"$L? :EXQ$_VZ[W1@Y"GSGXSWQ0!W=%%<+K/CJ^T6%KZ\TZ&WMA
MJ(LTMIY=MQ-'O"><@Z$9.0/3G(H [JBN1O/$^L+XWF\,V.E6DD@TX7L5Q+=%
M5P9-GS@)D=#P,YXY'.*UE\0?-\*1ZA<V 34WU$Z2MFDN5>Z\PH '(X7C<3C@
M ]>X!UC:I8+J:::;VW%\Z%UMO,'F%1U.WKCWJW7G4_\ :'_"Z-!%_%:@_P!E
MW126W)^;E,@@^GKGG/:O1: ,Q_$6AQNR/K.GJZG#*UT@(/H>:L6>J:?J#,ME
M?VMRR#+"&97*_7!KSWXI:58Z;X+TV"TMHHT75[7D*,L3)DDGN2>377ZW-I7A
MBUNO$4EJBRQQ"$^4H4R[G 13_P "( /;<: -ZBN.M?%VH-XFMM)ET^*XBO(7
M>*ZMO,\N&11GRY2R< CHW?\ NUB_\+(UK_A#7\4MH5HEA:W+17:&[)DVB;RR
M8QLP<=?FQGGCN0#TNBN;UO7]1L+VXBM[2WAM;>T%P;Z]<I#(Y) B4COQDGMD
M<'-8\WQ"N6\/>%=7L](66/7;F*W,;7&&B9PQP/EPP^4\Y';B@#O**Y"Q\3ZS
M/K>M:%>6%C!J5G:I=VSQ3O)"Z/N W$J#D%?3GVI?AKJ>J:SX'T_4=4:)Y;E#
M*)%8EF)=B<@C ]@,\4 =->WUIIMJ]U?74-M;IRTLT@15^I/%2PS1W$$<\+J\
M4BAT=3D,",@BN=^(:JWPY\2;@#C39R,^NPUBZ/XFU/3#X1T^]TVW33M4MTMX
M)DN"TJ.L(8%UV[<'!Z$X_2@#OZ*X7Q#XZOO#]C?ZG<Z=##:6=X+9(+B4I/=Q
M[E4RQ]L?-P.<A3R*U;[Q)>:?XYTS0[BS@6RU**1H+OS3DR(,F,KC ..0<\X-
M '2T5R][XM;3K6^N[BWB,"WRV%D5D.;B0D*<\?*%;<#C/W&..@IFD>*KRZ\5
M/HMU8AXFMOM$-_;+)Y60<&-]P&&[CGD>E '5U5U#4K'2;1KO4;R"TMU^]+/(
M$4?B:LLP52S$  9)/:O*O'>NWOB3X1:SJUE:6W]DS1L(?,<^:\8D"^;TP.1D
M+Z<Y!XH ]55@ZAE.5(R".]0WE]::=:O=7UU#;6Z#+2S.$5?J3Q7/0>(KB+Q?
M8^'&M8C%/IAO$N!(=P*E5VE<>^<YK#U?Q!+XB^&_CQ;FTCADTW[;8_(Y</Y<
M0._D#&=W3VH ]!AFCN((YX762*10Z.IR&4C((I]<(/$EYX>TCP:ALX'TR_CM
M[66[>4@V[M&-N5QR"1C.1@UTUOJ=Q<^([VP2&(VEI%&7GWG=YKY/EXQCA=K$
MY_C6@#5HJ&ZN8;*SGN[A]D,$;22-Z*HR3^0KBAX^NR^CW2:8+BPU*5(VCMQ(
MT]JKC*R/\NT@<;L'C/!:@#NZ*X>]\;:GIOB6[T&[TF$7<D ETDI*Q6_;."N=
MOR%<Y;K@9/05K:MXD;2KC3M.D6 :E>1O(<LQBB5,;FX&3RR@# SGMB@#HJ*X
M>U^($JZ??&_TMX[VWOHK&W5-PBO'E.(RC,HP#SG@[<'K6LNJ>((M5NK&YTJ!
MHEL_M,-]%(?)+@X,3 C(;N".H["@#HJ*X3_A/[EO FA^)TTV+;J,\,,D!F/[
MOS)-@(.WG'7H*E@U?6Y?BQ>Z4QM?[/M].CF2/>P(#R$%CQRWR]. !^- ';4V
M21(8VDE=4C499F. !ZDUP-S\1IAID&M6&GB]TZ28+Y$(D:Y,1;;YJ@+M/KM]
M.^>*W?[?N]4UG4]-T:"VD_LP(MQ+<N0KRLNX1J .PQECTR!@\X -JQU"SU2T
M2[L+J&ZMG)"S0N'1L$@X(X/((_"K-<+\'<_\*OTK*;#YEQE?[O[^3BNY;=M.
MT MC@$X&: (;R]M=.M7NKVYAMK=!EY9G"*OU)XI\$\5U;Q7$$BR0RH'1U.0R
MD9!'MBO+8M4UC6OAWX_EU8VTBPMJ,"F-F^4QIM 52.%P,YSG/UK3T3Q-J>DV
MO@VRO--MUTS4[>*UBF6X+3)((0P++MVX.T]"<?I0!W46HV4]_<6$5U"]W;*K
M30*X+QAN5+#J,XJS7(6OB8KXG\5VTVDPQMI-K#.9K=M\ETK*[ 'Y1R N .>2
M>:L>&O$MQXA%I=VYT^YTZYMVE::UF+-!)\N(F!'7#-SQ]WH* .GK+/B30@2#
MK6G CJ#=)_C6I7F7Q%TFPTNQ\$6=G:Q10Q^)+&,*J 97YNOK0!W,GB70HK26
M[?6=/6VAQYDOVE-J9SC)SQG!_*M-6#*&4Y!&017 _%'2K&W^'?B>]AMHHYY[
M.-)&50-P1\KGW&YN:OVWB;4[/Q1HNC:CIMO%:ZK!*;26*X+R(T2!B)!M &5/
M\).".IZT =/;ZC97ES=6UM=0RSVK!)XT<%HF(R P[<59KB;3Q3<!_&+IHMG'
M=:,X+A)R/M.(M^6?9G.W '!],U#:^.]3C\,Q>)-5TB"#2Y[&&:W$-SNFDGD*
MA8]I  !+<')P,$]P #L9M4L+>_M[":]MX[RXSY-NT@$DF 2<+U. #5NO-]>.
MJ'XE^ SJ-O9J&ENRK6[L2C?9SE#D<CIAN,^@KTB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KS;XM^!=;\>6.G6>EM8Q+:S&5I+F9E)R,8 5#_.O2:3
M<-VW(W8SC/.* ,'4;?6KF^T2>&SLMMI.TUP'NF!YB>/"?N^?OYR<=,5C?$?X
M=VOCC3X98]D.K6;!K:<CAAG)C;_9/Z'GUSW%% !00",$9!HHH X;P#\.[;P5
M>:],A1UO[HM;J.1%!U"?7)(/J%6G_#WP!;^!CK1B*L;Z]:2+;_! /]6A]QEJ
M[:B@#S+Q;X&U_7/B=H7B:T_L];32]@,<MPX>0!V8XPA X/K77>,=+O\ 7?!V
MI:58I;BYO;=H<S2E43<,9R%)./I6_10!Q_PT\-ZGX1\&6VAZG]E:6W>0B2WE
M9E<,Y;NHQUQ6KHMMJEOJ>L2WUO:QP7=R)X3#.SL (HX\,"@_YYYX)ZXK;HH
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M5W?-M*@?Q=,]J[JB@#S*Y\,^-+_PGI6A7,.D&32[NV=;L73XG2%@1E/+^4X
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M:=8[MW$N^/82O[L8ZY .?K7>T44 %%%% !1110 4444 %%%% !1110 4444
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MB^4S,K*S;B/EX/3)]C6=8:7K$/\ PGIDTBY7^U)&>S&^+]Z#"(Q_'QR.^.*
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M$,ADC51C#G(S^)]*@L-'UJ+POX]M)-'N5GU6\O)K-/,B_>++&$7G?@<CG.*
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ML=)TZ:\G^V0S$(Z* J-N/+,/2@"1(O"5SK6G6EA:+!?^9]HB>&W:(@1X)R2
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M<].U &G1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !5'6-'L->TN73M2@\ZUEQN7<5.000000000""*O44
M8.G^$[.QE1Y+W5+[RV#1I?7TDR*1T.TG!(Z@G)!Y%;U%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHK-T+7]+\2Z6FI:/>1W=HY*ATR,$=00>0?8UI4 %%%% !1110 4444 %%%%
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M7$!88RAXYQ@<YS@4_P ,?#Q?"GA:^\/Z?J\S6UVSL9)85+QEU"G&,#H.X/-
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M,73:N]MY)"X8,HSQQM'7K7*?&[3;C2;C0_'NF)_I>DW"1SX_BC+97/MDE?\
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M!R?QH FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]FVEK?1W)M_+.[S-A"D !T/!!&?J:XKP]K'B7PO\(M$\1VUQ8RZ39H/M&GF
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M-&&_>"N6)7GKG/?&.U73_ 4]OX9MO"UYJ<5QH<$@.Q;<I-,@?>(W;<1C.,D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MATYM/U:TCNK5F#&-\XR#D'B@#E_A[H TK^TY$N3/8QW,MKI@(XBMU<LR@_\
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M'4Y-6_&=O9>*O#'V6VUBQM=0AFCN[9I+A2J2QMN4-@].HX]<UT'_  C>A?\
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M"/9M(=S@J,[P"20 1[D=M*U(A^),FLR7U@]@VE1V/FF\C\PNLC/N*CC!W?\
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M4?\ "-Z%_P! 73O_  %3_"@"7^VM*_Z"=E_W_7_&C^VM*_Z"=E_W_7_&HO\
MA&]"_P"@+IW_ ("I_A1_PC>A?] 73O\ P%3_  H E_MK2O\ H)V7_?\ 7_&C
M^VM*_P"@G9?]_P!?\:B_X1O0O^@+IW_@*G^%'_"-Z%_T!=._\!4_PH E_MK2
MO^@G9?\ ?]?\:/[:TK_H)V7_ '_7_&HO^$;T+_H"Z=_X"I_A1_PC>A?] 73O
M_ 5/\* )?[:TK_H)V7_?]?\ &C^VM*_Z"=E_W_7_ !J+_A&]"_Z NG?^ J?X
M4?\ "-Z%_P! 73O_  %3_"@"7^VM*_Z"=E_W_7_&G1ZKITTBQQ:A:O(QPJK,
MI)/L,U!_PC>A?] 73O\ P%3_  I\.A:/;S)-!I5C%*ARKI;HK*?4$#B@#0HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'VDA5   &2<\G'2@"[8^%DTO6=?U73]MO<:FB\>:[JTH#?O&!X!RP&!QA??
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI-SXWTV+0[^UDL2MN+R2Y$)=8I\?)&A(Y*D_,>X&!U.,O5O^$B\2>"=(OI]
M9M9TB^CN;K3IX]J7:JKHVS=Q\P8L >1TQTSZ=10!YIJ>DS>+O!VKPZ-X6.@S
MRP((C=V\<$TTB2+(%PI.$^3&6ZEO0<]-X>\1:IKK0BX\.WVE&-?]*:]55&_&
M-L6"2PSSNP!@>IXZ6B@#QB+3]<A^&VF^&QX=U)KW3-4B>9MBA'5;DONC8GY@
M5.<]!SDCC/96L-_8_%'4[Y],NFL]0T^V5)T"E(VC+[E<YZ_,, 9SVKM:* .&
M\$Z0\_AK7],U:PGABO=1O',<\97?#*Q((SZ@_44>#=!UA/#MS::ZQ6ZA@?2K
M:7J3 A95E]BV1GU"*:[FB@#R_P 'V]U;6>G^']2\!JFJ6&R)]2:VB-LR)@"4
M2?>+$#( &<]<<X[SQ+O/AG4XXH99I9;66...)"S,Q4@# ]^_2M2B@#@?">H:
MGHGP^TK34\/:E/JMM:+$;=HQ$F\#O(Q"A?<9/L:Q-1\%:EI'P@UC3/+?4-=U
M:Z%Y<K:H6#3-*C,%]%"KU.,X]\5ZS10!Q4Z7$OQ7TW4DLKPV0TF6W:<P,%21
MY$90<CCA3].]8K6EQH'BW6X=0\&RZ[9:I=?:[.[M[>*4H655:*3>1L *\$G'
M->GT4 ><2QZQX2\9IJZ:#-?:9?Z;#:SPZ5&&-I-&6("H2/W>&(S_ "JYXGBU
M>[;PIJQTB=VM-3,\]I;[7DBC:-U7/."1E=V#@$GJ!FN[HH X/2([_P ,^,/$
M,U[I]Y-8ZN\=Y;S6\1F*2! KQ.%SM(P,$_+CO6%#X:U+1='\'VS6-Q+-!KCZ
MC=I!&9%MHW\SC(X.W>H(&>^,UZS10 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSJVY< 'D(V2Q/3J*[2Z2P\1ZIIB3P":QO]'N6:*4?>1VMS@CMP: 'R^)7O\
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M33,A,T<FUMX/ '!SWXP?7MFNFLD@CL+=+9]]NL2B)MV[*XX.>_'>@">BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT3J+BQ#V]Q%GYHV#DC([9!!H ZCP]?ZM>C48]8LH;6>UNS GDN621/+1@X)
MZECQVZ=LULUS^K^-_#FAV"WVH:G'%:M<_95E56=3)W *@Y P<GH,$=14UCXM
MT/4?$=[X?M+])-4LEWSP!6&T<9P2,'&1G!XS0!M4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNCC&?O<\<<YXXK<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH7_@)-_\<H\KQC_S^:%_X"3?_'*CF\0W]OXXTO09;6V$%Y92W#3+(Q8.FT$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-[?7]+USP%=:@TM[#;ZGK2I%#%A9979T_<MG@ D%6[8S180/#KGQ!TUXXK2
M:?;S+:V<K+'$YCDR5("X)VKD@#.*[R\\,:)?Z;<:=<Z="]I<3&XDBP0#(3DN
M,<@YYR,?K4$?@OP[%-/-%I<22SP?9Y9$9@SISP2#G)R<GJ<G)H \V72K:'PC
M\-=5B:>/4+FZLK6:Y2=Q(T,D3;DSG@<#IT[<U>OFD\):UX\CT!&@2+1(KV.%
M265)OW@,@![X )]<<UWS>$=#:RL;,V;?9K!UDM(Q/(!"R_=*_-P1V].U68]
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M!"@$  @ 'CGO0!YS9M8Z;X=\6Z1-<7EOI\7B%;6T@M7^<[_*80J6X"L20<D
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M(R9X(RI!(.!D'@U4?P/X:>QN[(Z3"+:[G^T7$2,RB1\YR<'G!P0.@P,#B@#
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M%KTJU\(^'[*\DNX-*MUGE@^SR.5W;TYX;/4G)R3R<\FGZ=X7T?2I(7L[0KY
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8L?A?3HO$L
MGB%3<_VE)$('D,[%3&#D+MZ8S[5M44 <Z/!&BJFH)&EU&M]<"ZE$=U(H67>L
MFY!GY"752<8SBK)\,6#P:BDS7$TNHP^1<W#2D2M& 0%!&-H&YL8QR2>M;-%
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A** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085527455328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Nov. 07, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANGAMO THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0359556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">501 Canal Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Richmond<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">970-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGMO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,646,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001001233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085526250112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 39,201<span></span>
</td>
<td class="nump">$ 45,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">10,496<span></span>
</td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,434<span></span>
</td>
<td class="nump">12,403<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">58,131<span></span>
</td>
<td class="nump">94,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">19,146<span></span>
</td>
<td class="nump">26,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">17,766<span></span>
</td>
<td class="nump">25,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets', window );">Refundable research income tax credits and other non-current assets</a></td>
<td class="nump">14,720<span></span>
</td>
<td class="nump">16,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">111,263<span></span>
</td>
<td class="nump">165,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">19,791<span></span>
</td>
<td class="nump">15,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">10,961<span></span>
</td>
<td class="nump">8,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">11,635<span></span>
</td>
<td class="nump">23,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="nump">774<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">43,161<span></span>
</td>
<td class="nump">47,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">27,727<span></span>
</td>
<td class="nump">33,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1,241<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">72,129<span></span>
</td>
<td class="nump">82,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">2,086<span></span>
</td>
<td class="nump">1,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,522,192<span></span>
</td>
<td class="nump">1,492,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,480,921)<span></span>
</td>
<td class="num">(1,406,376)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,223)<span></span>
</td>
<td class="num">(4,595)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">39,134<span></span>
</td>
<td class="nump">82,887<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 111,263<span></span>
</td>
<td class="nump">$ 165,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax, Refundable Research Credits And Other Non-current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085526935680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 49,412<span></span>
</td>
<td class="nump">$ 9,398<span></span>
</td>
<td class="nump">$ 50,249<span></span>
</td>
<td class="nump">$ 174,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">27,732<span></span>
</td>
<td class="nump">57,089<span></span>
</td>
<td class="nump">87,846<span></span>
</td>
<td class="nump">183,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">11,049<span></span>
</td>
<td class="nump">13,918<span></span>
</td>
<td class="nump">34,861<span></span>
</td>
<td class="nump">48,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">44,799<span></span>
</td>
<td class="nump">5,521<span></span>
</td>
<td class="nump">65,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of goodwill and indefinite-lived intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">89,485<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">38,781<span></span>
</td>
<td class="nump">115,806<span></span>
</td>
<td class="nump">128,228<span></span>
</td>
<td class="nump">386,136<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">10,631<span></span>
</td>
<td class="num">(106,408)<span></span>
</td>
<td class="num">(77,979)<span></span>
</td>
<td class="num">(211,946)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">3,515<span></span>
</td>
<td class="nump">3,694<span></span>
</td>
<td class="nump">9,610<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">10,760<span></span>
</td>
<td class="num">(102,893)<span></span>
</td>
<td class="num">(74,285)<span></span>
</td>
<td class="num">(202,336)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="num">(4,800)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">10,672<span></span>
</td>
<td class="num">(104,163)<span></span>
</td>
<td class="num">(74,545)<span></span>
</td>
<td class="num">(197,536)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Net income allocated to participating securities</a></td>
<td class="nump">1,287<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) available to common stockholders</a></td>
<td class="nump">$ 9,385<span></span>
</td>
<td class="num">$ (104,163)<span></span>
</td>
<td class="num">$ (74,545)<span></span>
</td>
<td class="num">$ (197,536)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Shares used in computing net income (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing basic net loss per share (in shares)</a></td>
<td class="nump">208,345<span></span>
</td>
<td class="nump">177,171<span></span>
</td>
<td class="nump">198,849<span></span>
</td>
<td class="nump">173,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding - diluted (in shares)</a></td>
<td class="nump">214,325<span></span>
</td>
<td class="nump">177,171<span></span>
</td>
<td class="nump">198,849<span></span>
</td>
<td class="nump">173,375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 65<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-65<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085528669424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 10,672<span></span>
</td>
<td class="num">$ (104,163)<span></span>
</td>
<td class="num">$ (74,545)<span></span>
</td>
<td class="num">$ (197,536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">1,664<span></span>
</td>
<td class="num">(1,144)<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="nump">981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Net pension (loss) gain</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">494<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 12,332<span></span>
</td>
<td class="num">$ (104,808)<span></span>
</td>
<td class="num">$ (74,173)<span></span>
</td>
<td class="num">$ (195,713)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085525967056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,793,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 294,958<span></span>
</td>
<td class="nump">$ 1,668<span></span>
</td>
<td class="nump">$ 1,450,239<span></span>
</td>
<td class="num">$ (1,148,545)<span></span>
</td>
<td class="num">$ (8,404)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,249,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering expenses</a></td>
<td class="nump">15,106<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">15,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,481,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax</a></td>
<td class="num">(1,404)<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="num">(1,419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">755,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">719<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">21,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Net pension (loss) gain</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized (loss) gain on marketable securities, net of tax</a></td>
<td class="nump">840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(197,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(197,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,279,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">134,922<span></span>
</td>
<td class="nump">$ 1,773<span></span>
</td>
<td class="nump">1,485,811<span></span>
</td>
<td class="num">(1,346,081)<span></span>
</td>
<td class="num">(6,581)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,074,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2023</a></td>
<td class="nump">233,642<span></span>
</td>
<td class="nump">$ 1,771<span></span>
</td>
<td class="nump">1,479,725<span></span>
</td>
<td class="num">(1,241,918)<span></span>
</td>
<td class="num">(5,936)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax</a></td>
<td class="num">(101)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">6,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(1,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,144)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Net pension (loss) gain</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized (loss) gain on marketable securities, net of tax</a></td>
<td class="nump">494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(104,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,279,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">134,922<span></span>
</td>
<td class="nump">$ 1,773<span></span>
</td>
<td class="nump">1,485,811<span></span>
</td>
<td class="num">(1,346,081)<span></span>
</td>
<td class="num">(6,581)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178,133,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">82,887<span></span>
</td>
<td class="nump">$ 1,781<span></span>
</td>
<td class="nump">1,492,077<span></span>
</td>
<td class="num">(1,406,376)<span></span>
</td>
<td class="num">(4,595)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,761,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering expenses</a></td>
<td class="nump">21,788<span></span>
</td>
<td class="nump">$ 248<span></span>
</td>
<td class="nump">21,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,809,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon exercise of pre-funded warrants</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,535,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax</a></td>
<td class="num">(684)<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="num">(699)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">379,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">9,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Net pension (loss) gain</a></td>
<td class="nump">234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized (loss) gain on marketable securities, net of tax</a></td>
<td class="num">(233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(74,545)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74,545)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,619,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">39,134<span></span>
</td>
<td class="nump">$ 2,086<span></span>
</td>
<td class="nump">1,522,192<span></span>
</td>
<td class="num">(1,480,921)<span></span>
</td>
<td class="num">(4,223)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,201,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2024</a></td>
<td class="nump">23,690<span></span>
</td>
<td class="nump">$ 2,082<span></span>
</td>
<td class="nump">1,519,084<span></span>
</td>
<td class="num">(1,491,593)<span></span>
</td>
<td class="num">(5,883)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax</a></td>
<td class="num">(203)<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">(207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">1,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Net pension (loss) gain</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized (loss) gain on marketable securities, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">10,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,619,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">$ 39,134<span></span>
</td>
<td class="nump">$ 2,086<span></span>
</td>
<td class="nump">$ 1,522,192<span></span>
</td>
<td class="num">$ (1,480,921)<span></span>
</td>
<td class="num">$ (4,223)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085529092608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (74,545)<span></span>
</td>
<td class="num">$ (197,536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">5,521<span></span>
</td>
<td class="nump">65,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,866<span></span>
</td>
<td class="nump">13,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discount and impairment on marketable securities</a></td>
<td class="num">(273)<span></span>
</td>
<td class="num">(2,031)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization in operating lease right-of-use assets</a></td>
<td class="nump">3,360<span></span>
</td>
<td class="nump">5,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">9,099<span></span>
</td>
<td class="nump">21,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash adjustments</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">1,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of goodwill and indefinite-lived intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">89,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
<td class="nump">18<span></span>
</td>
<td class="num">(6,195)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest receivable</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(9,573)<span></span>
</td>
<td class="nump">2,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">6,403<span></span>
</td>
<td class="nump">5,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other accrued liabilities</a></td>
<td class="num">(6,851)<span></span>
</td>
<td class="num">(5,220)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">2,060<span></span>
</td>
<td class="num">(4,182)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(4,081)<span></span>
</td>
<td class="num">(3,737)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="nump">774<span></span>
</td>
<td class="num">(159,671)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(63,788)<span></span>
</td>
<td class="num">(174,304)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(59,551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">1,110<span></span>
</td>
<td class="nump">193,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">34,730<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from sale of assets classified as held for sale</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(115)<span></span>
</td>
<td class="num">(18,484)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">36,200<span></span>
</td>
<td class="nump">115,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock, net of offering expenses</a></td>
<td class="nump">21,924<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from at-the-market offering, net of offering expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(684)<span></span>
</td>
<td class="num">(1,404)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">719<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">21,386<span></span>
</td>
<td class="nump">14,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(6,003)<span></span>
</td>
<td class="num">(43,930)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">46,704<span></span>
</td>
<td class="nump">101,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">40,701<span></span>
</td>
<td class="nump">58,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment included in unpaid liabilities</a></td>
<td class="nump">$ 389<span></span>
</td>
<td class="nump">$ 2,757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the maturity, prepayments and calls (requests for early payments) of debt securities designated as held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085524689008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or &#8220;the Company&#8221;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. The Company believes its zinc finger (&#8220;ZF&#8221;) epigenetic regulators are ideally suited to potentially address devastating neurology disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system (&#8220;CNS&#8221;), in preclinical studies.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, the Company announced its strategic transformation into a neurology-focused genomic medicine company focused on developing epigenetic regulation therapies designed to address serious neurological diseases and novel adeno-associated virus (&#8220;AAV&#8221;) capsid delivery technology. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three and nine months ended September&#160;30, 2024 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024. The Condensed Consolidated Balance Sheet data at December&#160;31, 2023 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2023 (the &#8220;2023 Annual Report&#8221;) as filed with the SEC on March 13,&#160;2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2023, included in the 2023 Annual Report.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity, Going Concern, and Capital Resources</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects will require several years and substantial expenditures to complete and ultimately may be unsuccessful. In recent years, the Company&#8217;s operations have been funded primarily through collaborations and strategic partnerships, research grants and from the issuance of equity securities. As of September&#160;30, 2024, the Company had capital resources of $39.2&#160;million consisting of cash and cash equivalents. On August 2, 2024, the Company entered into a global epigenetic regulation and capsid delivery license agreement (the &#8220;Genentech Agreement&#8221;) with Genentech, Inc., a member of the Roche Group (&#8220;Genentech&#8221;), under which the Company received a $40.0&#160;million upfront license fee in August 2024 and a $10.0&#160;million milestone payment in October 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Accounting Standard Codification (&#8220;ASC&#8221;) Topic 205-40, Presentation of Financial Statements&#8212;Going Concern (&#8220;ASC Topic 205-40&#8221;), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the Condensed Consolidated Financial Statements are issued. As required under ASC Topic 205-40, management&#8217;s evaluation should initially not take into consideration the potential mitigating effects of management&#8217;s plans that have not been fully implemented as of the date the Condensed Consolidated Financial Statements are issued. When substantial doubt exists, management evaluates whether the mitigating effects of its plans sufficiently alleviates the substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effects of management&#8217;s plans, however, are only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (ii) it is probable that the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans must have been approved by the Company&#8217;s board of directors before the date that the financial statements are issued.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s history of significant losses, its negative cash flows from operations, its limited liquidity resources currently on hand, and its dependence on additional financing to fund its operations after the current resources are exhausted raise substantial doubt about its ability to continue to operate as a going concern within one year after the date that the Condensed Consolidated Financial Statements are issued. Based on the Company&#8217;s current operating plan, its cash and cash equivalents as of September&#160;30, 2024, together with the $10.0&#160;million milestone payment that the Company received from Genentech in October&#160;2024, is expected to allow the Company to meet its liquidity requirements only into the first quarter of 2025, which is less than one year following the date these Condensed Consolidated Financial Statements are issued. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company&#8217;s cost structure and operating plan. Management&#8217;s plans include, among other things, pursuing one or more of the following steps to raise additional capital, none of which can be guaranteed or are entirely within the Company&#8217;s control:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">raise funding through the sale of the Company&#8217;s common stock, including sales under the at-the-market offering program with Jefferies LLC;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">raise funding through debt or royalty financing; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish collaborations with potential partners to advance the Company&#8217;s product pipeline.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is unable to raise capital on acceptable terms, or at all, or if it is unable to procure collaboration arrangements or external direct investments to advance its programs, the Company would be required to discontinue some or all of its operations or develop and implement a plan to further extend payables, reduce overhead or scale back its current operating plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan would be successful. Additional capital may not be available to the Company on a timely basis, on terms that are acceptable or at all. In particular, the perception of the Company&#8217;s ability to continue to operate as a going concern may make it more difficult to obtain financing for the continuation of its operations, particularly in light of currently challenging macroeconomic and market conditions. Further, the Company may be unable to attract new investments as a result of the speculative nature of its newly reprioritized core neurology preclinical programs. If adequate funds are not available to the Company on a timely basis, or at all, the Company will be required to take additional actions to address its liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering its research and development activities, which would have a material adverse effect on its business and prospects, or the Company may be required to cease operations entirely, liquidate all or a portion of its assets, and/or seek protection under the U.S. Bankruptcy Code.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, useful lives and impairment of long-lived assets, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company recorded additional revenue related to a change in estimate in connection with the collaboration agreement with Kite Pharma, Inc., a Gilead Sciences, Inc. subsidiary (&#8220;Kite&#8221;). This adjustment was driven by a reduction in the estimated future level of the Company&#8217;s research and development services and as a result, future project costs. This resulted in an increase in proportional cumulative performance on this collaboration and an increase in revenue of </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$8.9&#160;million, a decrease in net loss of $8.9&#160;million, and a decrease in the Company&#8217;s basic and diluted net loss per share of $0.05 for the nine months ended September 30, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Company recorded additional revenue related to a change in estimate in connection with the collaboration agreement with Kite. This adjustment was driven by a further reduction in the estimated future level of the Company&#8217;s research and development services and as a result, future project costs. This resulted in an increase in proportional cumulative performance on this collaboration and an increase in revenue by $4.9&#160;million, a decrease in net loss by $4.9&#160;million, and a decrease in the Company&#8217;s basic and diluted net loss per share of $0.03 for the three and nine months ended September 30, 2023.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research services. Research and license agreements typically include nonrefundable upfront signing or license fees, payments at negotiated rates for time incurred by Company researchers, third-party cost reimbursements, additional target selection fees, sublicense fees, milestone payments tied to ongoing development and product commercialization, and royalties on future licensees&#8217; product sales. All funds received from the Company&#8217;s collaboration partners are generally not refundable. Non-refundable upfront fees are fixed at the commencement of the contract. All other fees represent variable consideration in contracts. For contracts that contain a provision where the Company reimburses its customer for certain costs they incur and where the Company does not acquire any distinct goods or services in exchange for such payments, the Company accounts for it as a reduction to the contract transaction price. Deferred revenue primarily represents the portion of nonrefundable upfront fees or milestone payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s performance obligations in its collaboration agreements frequently represent distinct bundles of licenses of intellectual property and research and development services, with these components being individually non-distinct as the customer cannot benefit from the licenses independently from the research and development activities. In some instances, the Company has determined that the customer can benefit from the licensed intellectual property separately from the research and development activities, and the licenses of intellectual property and research and development services are individual distinct performance obligations. Options to license the Company&#8217;s intellectual property and/or acquire research and development services also represent performance obligations when they grant customers a material right, e.g. a right to a discount the customer would not have received if they did not purchase the Company&#8217;s services under the existing contract. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from grants of licenses to intellectual property that are distinct and therefore separate performance obligations are recognized at the point in time when the license is effective and the Company has completed the transfer of a copy of the licensed intellectual property to the customer. Revenues from distinct research and development services as well as from distinct bundles of licenses of intellectual property and research and development services, are recognized over time using a proportional performance method. Under this method, revenue is recognized by measuring progress towards satisfaction of the relevant performance obligation using a measure that best depicts the progress towards satisfaction of the relevant performance obligation. For most of the Company&#8217;s agreements the measure of progress is an input measure based on a level of effort incurred, which includes the value of actual time by Company researchers plus third-party cost reimbursements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration allocated to options that include material rights is deferred until the options are exercised or expire. The exercise of such options is accounted for as contract continuation, with target selection fees and estimated variable consideration included in the transaction price at that time and allocated specifically to the respective target&#8217;s performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. For variable consideration, the amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. A cumulative catch-up is then recorded in the current period to reflect the updated transaction price and the updated measure of progress. The estimated period </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of performance and level of effort, including the value of Company researchers&#8217; time and third-party costs, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current expectations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, discount rates and probabilities of exercise of technical and regulatory success, and the expected level of effort for research and development services. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract modifications occur when the price and/or scope of an arrangement changes. If the modification consists of adding new distinct goods or services in exchange for consideration that reflects standalone selling prices of these goods and services, the modification is accounted for as a separate contract with the customer. Otherwise, if the remaining goods and services are distinct from those previously provided, the existing contract is considered terminated, and the remaining consideration is allocated to the remaining goods and services as if this was a newly signed contract. If the remaining goods and services are not distinct from those previously provided, the effects of the modification are accounted for in a manner similar to the effect of a change in the estimated measure of progress, with cumulative catch-up in revenue recorded at the time of the modification. If some of the remaining goods and services are distinct from those previously provided and others are not, to account for the effects of the modification the Company applies principles consistent with the objectives of the modification accounting.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from collaboration and license agreements as a percentage of total revenues were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.529%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genentech, Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other license agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable. If a change in circumstance occurs that indicates long-lived assets may be impaired, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. The long-lived asset evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. The Company reassesses the composition of its asset groups whenever there are changes in its operations that affect whether the cash flows associated with assets included in asset groups are largely independent. If the impairment review indicates that the carrying amount of an asset group is not recoverable, an impairment loss is measured as the amount by which the carrying amount of an asset group exceeds its fair value. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, general macroeconomic conditions, conditions specific to the industry and market, an adverse change in legal factors, business climate or operational performance of the business, and sustained decline in the stock price and market capitalization compared to the net book value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calculating the fair value of a reporting unit, an asset group and an individual asset involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During a portion of the nine months ended September 30, 2023, the Company had goodwill and indefinite-lived intangible assets (IPR&amp;D). These assets were written off in full as the Company recognized impairment losses during the nine months ended September&#160;30,&#160;2023, see&#160;Note&#160;6&#160;&#8211;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment and Write-Down of Assets Held For Sale</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo considers all highly liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in money market accounts and U.S. government-sponsored entity debt securities. Restricted cash consisted of a letter of credit for $1.5&#160;million, representing a deposit for the lease of office and research and development laboratory facilities in Brisbane, California.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,201&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,204&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,514&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,444&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,701&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,704&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,014&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,944&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. Right-of-use assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases, calculated as the sum of the amortization of the right of use asset and accretion of the lease liability, is recognized on a straight-line basis over the lease term, unless the right of use asset was previously written down due to impairment. The Company evaluates the lease arrangement for impairment whenever events or changes in circumstances indicate that the carrying amounts of the right-of-use asset may not be fully recoverable. To the extent an impairment of the right-of-use asset is identified, the Company will recognize the impairment expense and subsequently amortize the remaining right of use asset into rent expense on a straight-line basis (unless another systematic basis is more representative of the pattern in which the Company expects to consume the future economic benefits from the asset) from the date of impairment to the earlier of the end of the right-of-use asset&#8217;s useful life or the end of the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there is a change to the terms and conditions of a contract that results in a change in the scope of or the consideration for a lease, the Company determines if the lease modification results in a separate contract or a change in the accounting for the existing lease and not a separate contract. For lease modifications that result in a separate contract, the Company accounts for the new contract in the same manner as other new leases. For lease modifications that do not result in a separate contract, the Company reassesses the classification of the lease at the effective date of the modification, remeasures and reallocates the remaining consideration in the contract, and remeasures the lease liability using the discount rate determined at the effective date of the modification.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected not to apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants to Purchase Shares of Company Stock </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the accounting classification of warrants to purchase shares of its stock as either liability or equity by first assessing whether the warrants meet liability classification criteria in accordance with ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 480&#8221;). Under ASC 480, a financial instrument other than an outstanding share that embodies an obligation to repurchase the entity&#8217;s shares or is indexed to such an obligation, and that requires or may require the entity to settle it by transferring assets, is classified as a liability. In addition, a financial instrument that embodies an unconditional obligation, or </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares must be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception, (b) variations in something other than the fair value of the issuer&#8217;s equity shares, or (c) variations inversely related to changes in the fair value of the issuer&#8217;s equity shares. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If financial instruments, such as warrants, are not required to be classified as liabilities under ASC 480, the Company assesses whether such instruments are indexed to the Company&#8217;s own stock under ASC 815-40. In order for an instrument to be considered indexed to an entity&#8217;s own stock, its settlement amount must always equal the difference between the following: (a)&#160;the fair value of a fixed number of the Company&#8217;s equity shares, and (b) a fixed monetary amount or a fixed amount of a debt instrument issued by the Company. Certain adjustments to this amount are allowed, if they are based on non-levered inputs into the fair value of a fixed price/fixed consideration-option.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants are also required to meet equity classification criteria to be classified in stockholders&#8217; equity. Under these criteria, warrants have to provide for settlement in shares, or cash or shares at the entity&#8217;s option. With limited exceptions, a possibility of net cash settlement under any circumstances will result in the warrants being classified as liabilities. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants classified as equity are generally measured using the Black-Scholes valuation model on the date of issuance. Warrants classified as liabilities are remeasured at any reporting date using valuation models consistent with their terms, with changes recognized in earnings.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records employee severance costs based on whether the termination benefits are provided under an on-going benefit arrangement or under a one-time benefit arrangement. The Company accounts for on-going termination benefit arrangements, such as those arising from employment agreements, applicable regulations or past practices, in accordance with ASC Topic 712, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Nonretirement Postemployment Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 712&#8221;). Under ASC 712, liabilities for post-employment benefits related to past services and that vest or are accumulated over time are recorded at the time the obligations are probable of being incurred and can be reasonably estimated. The Company accounts for one-time employment benefit arrangements in accordance with ASC Topic 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 420&#8221;). One-time termination benefits are expensed at the date the entity notifies the employee, unless the employee must provide future service over a period extending past the minimum notification period, in which case the benefits are expensed ratably over the future service period. Other associated costs are recognized in the period in which the liability is incurred.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred to terminate contracts are recognized upon their termination, e.g., when notice of termination is provided to the counterparty. Costs related to contracts without future benefit are recognized at the cease-use date. Other exit-related costs are recognized as incurred.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2023-07&#8221;), which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2023-09&#8221;), which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085528610272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and marketable securities. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no cash equivalents or marketable securities as of September&#160;30, 2024. The fair value measurements of the Company&#8217;s cash equivalents and marketable securities as of December&#160;31, 2023 are identified at the following levels within the fair value hierarchy (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,798&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,798&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,306&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,798&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally classifies its marketable securities as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085528603520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">CASH EQUIVALENTS AND MARKETABLE SECURITIES</a></td>
<td class="text">CASH EQUIVALENTS AND MARKETABLE SECURITIES<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no cash equivalents or marketable securities as of September&#160;30, 2024. The table below summarizes the Company&#8217;s cash equivalents and marketable securities as of December&#160;31, 2023 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,072&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,306&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.687%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,798&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were not material during the three and nine months ended September&#160;30, 2024. There were no realized gains and losses on the sales of investments during the three and nine months ended September&#160;30, 2023. Total unrealized gains for securities with net gains in accumulated other comprehensive loss were not material during the three and nine months ended September&#160;30, 2024 and 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company did not record an allowance for credit losses related to its marketable securities for the three and nine months ended September&#160;30, 2024 and 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no unrealized losses related to its marketable securities for the three and nine months ended September&#160;30, 2024. The Company had no material unrealized losses related to its marketable securities for the three and nine months ended September&#160;30, 2023. The Company had no material unrealized losses, individually and in the aggregate, for marketable securities that were in a continuous unrealized loss position for greater than 12 months as of September&#160;30, 2024 and December&#160;31, 2023. These unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews its marketable securities for indications of credit losses. No significant facts or circumstances had arisen to indicate that there had been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#8217;s review of these securities, the Company determined that no allowance for credit losses related to its marketable securities was required at either September&#160;30, 2024 or December&#160;31, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods the Company had investment in debt securities, the Company also considered whether it was more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis. No impairment charges were recorded during the three and nine months ended September&#160;30, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085524213984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET INCOME (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">BASIC AND DILUTED NET INCOME (LOSS) PER SHARE</a></td>
<td class="text">BASIC AND DILUTED NET INCOME (LOSS) PER SHARE<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share has been computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is calculated by dividing net income </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(loss) by the weighted-average number of shares of common stock plus potentially dilutive securities outstanding during the period. Potential shares of common stock exercisable for little or no consideration are included in both basic and diluted weighted-average number of shares of common stock outstanding. During the three months ended September&#160;30, 2024, basic and diluted weighted-average number of shares outstanding were 208.3&#160;million and 214.3&#160;million shares, respectively. During the nine months ended September&#160;30, 2024, both basic and diluted weighted-average number of shares outstanding were 198.8&#160;million shares, and included pre-funded warrants to purchase 3,809,523 shares of common stock with an exercise price of $0.01 per share. These warrants were exercised during the three months ended June 30, 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of basic and diluted net income (loss) per share are as follows (in thousands, except per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197,536)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income allocated to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,385&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,163)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,545)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197,536)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of common stock pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - diluted</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,325</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,171</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,849</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,375</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.59)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.14)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase shares of common stock, with the exercise price of $1.00 per share, entitle holders to participate in dividends but are not required to absorb losses incurred. As a result, for the three months ended September&#160;30, 2024, the Company applied the two-class method to allocate net income to shares of common stock and these warrants for purposes of calculating basic and diluted net income per share. The warrants were excluded from basic net loss per share calculations during the nine months ended September&#160;30, 2024. No warrants were outstanding during the three and nine months ended September&#160;30, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computation of diluted net income per share for the three months ended September&#160;30, 2024 excluded 12.7&#160;million shares subject to stock options and restricted stock units outstanding because their inclusion would have had an anti-dilutive effect on diluted net income per share. The computation of diluted net loss per share for the nine months ended September&#160;30, 2024 excluded 51.6&#160;million shares subject to stock options, restricted stock units outstanding, warrants to purchase common stock, and the employee stock purchase plan shares reserved for issuance because their inclusion would have had an anti-dilutive effect on diluted net loss per share. The computation of diluted net loss per share for the three and nine months ended September&#160;30, 2023 excluded 22.1&#160;million shares subject to stock options, restricted stock units outstanding, and the employee stock purchase plan shares reserved for issuance because their inclusion would have had an anti-dilutive effect on diluted net loss per share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085524785424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</a></td>
<td class="text">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, the Company entered into a global epigenetic regulation and capsid delivery license agreement with Genentech to develop intravenously administered genomic medicines to treat certain neurodegenerative diseases. Under the terms of the agreement, the Company granted an exclusive license to Genentech for the Company&#8217;s proprietary zinc finger repressors (&#8220;ZFRs&#8221;) that are directed to tau and a second undisclosed neurology target. The Company also granted an exclusive license to Genentech to the Company&#8217;s proprietary, neurotropic adeno-associated virus capsid, STAC-BBB, for use with therapies directed to tau and to the second neurology target. The Company is prohibited from exploiting (for itself or with or for a third party) </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products directed to tau and to the second neurology target during the applicable exclusivity periods set forth in the agreement. The Company was responsible for completing the technology transfer and certain preclinical activities, and Genentech is solely responsible for all clinical development, regulatory interactions, manufacturing and global commercialization of resulting products. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, the Company received a $40.0&#160;million upfront license payment from Genentech. In October 2024, the Company received a $10.0&#160;million milestone payment related to the technology transfer which was completed in September 2024. Under the terms of the agreement, the Company is also eligible to earn up to $1.9&#160;billion in development and commercial milestones spread across multiple potential products. In addition, the Company is also entitled to receive escalating, tiered mid-single digit to sub-teen double digit royalty payments on the net sales of such products, subject to adjustments for patent expiration, entry of competitive products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will continue, on a product-by-product and country-by-country basis, until the date when there is no remaining royalty payment obligation in such country with respect to such product, at which time the agreement will expire with respect to such product in such country. Royalty obligations cease upon the later of expiry of the last valid patent claim covering the product in the country or 10 years from the date of the first commercial sale of the product in such country. Genentech has the right to terminate the agreement for convenience. Each party has the right to terminate the agreement on account of the other party&#8217;s uncured material breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Genentech in accordance with ASC Topic 606 and concluded that Genentech is a customer. The initial transaction price of $50.0&#160;million includes the upfront license fee of $40.0&#160;million and the $10.0&#160;million technology transfer milestone payment. None of the development milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price as uncertain events are resolved or other changes in circumstances occur. Potential sales-based milestones and royalty payments are not estimated as they meet the sales-or usage-based royalty exception under ASC 606 and are recognized in the period they are earned, provided the related performance obligations have been completed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified two performance obligations within the Genentech Agreement. All licenses were accounted for as a performance obligation to provide functional IP that is satisfied at a point in time that was satisfied upon completion of the technology transfer in September 2024. The preclinical activities represent research and development services and are satisfied over time as the Company conducts and Genentech benefits from the associated activities. Revenue related to the preclinical activities is recognized using an input method of cumulative actual costs incurred relative to total estimated costs. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the initial transaction price to the performance obligations based on the relative standalone selling price of each performance obligation. In the absence of an observable standalone selling price, the Company used a methodology that maximized the use of observable inputs. This included a cost plus margin approach for the preclinical activities, which required the estimation of total costs and an expected margin. The standalone selling price of the licenses was determined based on the analysis of the probability-adjusted discounted cash flows and potential sales of licensed products. Significant estimates and assumptions were used that include but are not limited to, expected market opportunity and pricing, timelines, and likelihood of success of clinical, regulatory and commercialization activities. The Company expects to allocate variable consideration payable upon achievement of future milestones and royalty payments to the specific performance obligation to which they relate, i.e. the license performance obligation, as such allocation would meet the allocation objective in ASC&#160;Topic&#160;606.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, the Company had a receivable of $10.0&#160;million related to the milestone payment which had been earned but not yet received, and deferred revenue of $0.8&#160;million related to this agreement which is expected to be recognized over approximately the next three months. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.103%"><tr><td style="width:1.0%"></td><td style="width:47.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.250%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Genentech agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer Inc. (&#8220;Pfizer&#8221;), pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia A, and closely related products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, the Company was responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty-free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#8217;s products that utilize the AAV delivery system.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i) the expiration of patent claims that cover the product in a country, (ii) the expiration of regulatory exclusivity for a product in a country, and (iii) 15 years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the agreement, the Company received an upfront fee of $70.0&#160;million and was eligible to receive up to $208.5&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $266.5&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and potentially other products. To date, two milestones of $55.0&#160;million in aggregate have been earned and received. The Company is eligible to earn from Pfizer up to $220.0&#160;million in remaining milestone payments for giroctocogene fitelparvovec, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are 14% - 20% of the annual worldwide net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer was a customer. The Company completed its performance obligations and recognized the amounts included in the transaction price of $134.0&#160;million during the periods through December 31, 2020. No revenue was recognized during the three and nine months ended September&#160;30, 2024 and 2023. The remaining development, intellectual property and regulatory milestone amounts have not been included in the transaction price and have not been recognized as their achievement is dependent on the progress and outcomes of Pfizer&#8217;s development activities and is therefore uncertain. If and when these milestones become probable of being achieved, they will be recognized in full at that time. Sales milestones and royalties are not recognized until triggered based on the contractual terms.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into an exclusive, global collaboration and license agreement with Pfizer, subsequently assigned to Alexion, AstraZeneca Rare Disease (&#8220;Alexion&#8221;) in September 2023, for the development and commercialization of potential gene therapy products that use zinc finger transcriptional regulators (&#8220;ZF-transcriptional regulators&#8221;) to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZF-transcriptional regulators that bind to and specifically reduce expression of the mutant form of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Pfizer (now Alexion) an exclusive, royalty-bearing, worldwide license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZF-transcriptional regulators that satisfy pre-agreed criteria. During a specified period, neither the Company nor Alexion are permitted to research, develop, manufacture or commercialize outside of the collaboration any zinc finger proteins (&#8220;ZFPs&#8221;) that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i) the expiration of patent claims that cover the licensed product in a country, (ii) the expiration of regulatory </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exclusivity for a licensed product in a country, and (iii) 15 years after the first commercial sale of a licensed product in a major market country. Alexion also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Alexion to develop, manufacture and commercialize licensed products under the agreement would automatically terminate. Upon termination by the Company for cause or by Alexion without cause for any licensed product or licensed products in any country or countries, the Company would have the right to negotiate with Alexion to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Alexion to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following any termination by the Company for Alexion&#8217;s material breach, Alexion would not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time. Following any termination by Alexion for the Company&#8217;s material breach, the Company would not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a $12.0&#160;million upfront payment from Pfizer and is eligible to receive up to $60.0&#160;million in development milestone payments from Alexion contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million in commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Alexion will pay the Company royalties of 14% - 20% of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party is responsible for the cost of its performance of the research program. Alexion is operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $5.0&#160;million has been earned and paid, however no products have been approved and therefore no royalty fees have been earned under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Alexion in accordance with ASC Topic 606 and concluded that Alexion was a customer. The Company completed its performance obligations and recognized the amounts included in the transaction price of $17.0&#160;million during the periods through December 31, 2020. No revenue was recognized during the three and nine months ended September&#160;30, 2024 and 2023. The remaining development milestone amounts have not been included in the transaction price and have not been recognized as their achievement is dependent on the progress and outcomes of Alexion&#8217;s development activities and is therefore uncertain. If and when these milestones become probable of being achieved, they would be recognized in full at that time. Sales related milestones and royalties are not recognized until triggered based on the contractual terms. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, Pfizer notified the Company of Pfizer&#8217;s assignment of the collaboration and license agreement to Alexion, AstraZeneca Rare Disease, pursuant to a definitive purchase and license agreement for preclinical gene therapy assets and enabling technologies that closed on September 20, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Collaboration and License Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, the Company had a collaboration and license agreement with Kite and certain other license agreements. In 2023, in addition to the agreement with Kite, the Company had collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc. (&#8220;Novartis&#8221;), and Biogen MA, Inc. (&#8220;Biogen&#8221;). These collaboration agreements were designed for the research, development, and commercialization of various potential therapy products, including potential engineered cell therapies for cancer and gene regulation therapies to treat neurodevelopmental disorders and diseases. The collaboration agreements with Novartis and Biogen were both terminated effective June 2023. The Company&#8217;s services under the Kite collaboration agreement were completed during the year ended December 31, 2023, and the agreement expired pursuant to its terms in April 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed each of these collaboration agreements in accordance with ASC Topic 606, concluding Kite, Novartis and Biogen were customers. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under these agreements were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.477%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.477%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.477%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license fee fixed consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services variable consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,496&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,035&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Novartis agreement:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront license fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Biogen agreement:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and other fixed consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost-sharing payments for research services, net variable consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,849&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from other license agreements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,190&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2024 and December&#160;31, 2023, the Company had no material receivables, no deferred revenue, and no amounts included in transaction price remaining to be recognized related to these license and collaboration agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085528721360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IMPAIRMENT AND WRITE-DOWN OF ASSETS HELD FOR SALE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesTextBlock', window );">IMPAIRMENT AND WRITE-DOWN OF ASSETS HELD FOR SALE</a></td>
<td class="text">IMPAIRMENT AND WRITE-DOWN OF ASSETS HELD FOR SALE<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company experienced a sustained decline in stock price and related market capitalization, the collaboration agreements with Biogen and Novartis were terminated, and actions were initiated including deferral and reprioritization of certain research and development programs, announcement and execution of restructuring of operations and reductions in force. As a result, throughout the year the Company tested various long-lived and indefinite-life intangible assets for impairment and recognized a pre-tax goodwill impairment charge of $38.1&#160;million, a pre-tax indefinite-lived intangible asset impairment charge of $51.4&#160;million along with the income tax benefit from the reduction of the associated deferred tax liability of $6.3&#160;million, and a pre-tax long-lived assets impairment charge of $65.5&#160;million during the year ended December 31, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nine months ended September 30, 2024</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024, the Company&#8217;s Board of Directors approved the wind-down of operations in France and corresponding reduction in workforce, including closure of the Company&#8217;s cell therapy manufacturing facility and research labs in Valbonne, France (the &#8220;France Restructuring&#8221;), and also initiated several actions aimed at reducing costs, including actions to commence the closure of its facility in Brisbane, California. As such, the Company reassessed its long-lived assets for impairment as of March 31, 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the France Restructuring, the Company concluded its equipment, furniture and fixtures located in France met the held for sale criteria as of March 31, 2024. The Company wrote down the carrying value of these assets to their estimated fair value of $1.0&#160;million, net of the estimated costs to sell, recognizing a loss of $1.8&#160;million. The fair value measurement represents a level 3 nonrecurring fair value measurement. The loss is included in impairment of long-lived assets in the accompanying Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also reassessed whether its remaining long-lived assets continued to represent a single asset group for purposes of impairment assessment. After considering changes in the manner in which the right-of-use assets and leasehold improvements related to the Company&#8217;s Brisbane and Valbonne, France, facilities are used, costs incurred to cease use of these assets, the France Restructuring, and the Company&#8217;s activities to market these facilities for sublease, the Company concluded the identifiable operations and cash flows of these assets are now largely independent of the operations and the cash flows of each other, as well as of the remainder of the Company. Accordingly, the Company assessed impairment of the resulting asset groups separately.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the changes in the use of assets related to the Brisbane and Valbonne facility leases, the Company concluded there were indicators of impairment for these asset groups, and further established that the carrying values of these asset groups were not recoverable. The Company proceeded to determine their fair values using a discounted cash flow method, which represents a level 3 nonrecurring fair value measurement. As a result, the Company recognized pre-tax long-lived asset impairment charges of $2.0&#160;million on the right-of-use assets and $0.5&#160;million on the related leasehold improvements during the three months ended March 31, 2024. No impairment was recognized on the remaining long-lived assets, as their carrying values were not in excess of their fair values.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2024, the Company faced a sustained decline in its stock price and related market capitalization, and continued the France Restructuring and activities related to the closure of its facility in Brisbane, California. There was also a decline in the market rates for facility subleases in Brisbane, California, indicating the carrying values of right of use and leasehold improvement assets could be impaired. As such, the Company reassessed its long-lived assets for impairment as of June 30, 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded there were indicators of impairment for the Brisbane and Valbonne facility lease asset groups, and further established that the carrying values of these asset groups were not recoverable. The Company proceeded to determine their fair values using a discounted cash flow method, which represents a level 3 nonrecurring fair value measurement. As a result, the Company recognized pre-tax long-lived asset impairment charges of $0.9&#160;million on the right-of-use assets and $0.1&#160;million on the related leasehold improvements during the three months ended June 30, 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also reassessed the fair value of assets held for sale as of June 30, 2024 and recorded an additional charge to write-down the carrying value of these assets by $0.1&#160;million. Assets held for sale are included within prepaid expenses and other current assets on the Company&#8217;s Condensed Consolidated Balance Sheet as of June 30, 2024. The fair value measurement represents a level 3 nonrecurring fair value measurement. The loss is included in impairment of long-lived assets in the accompanying Condensed Consolidated Statements of Operations. The sale of these assets is expected to occur within one year, either collectively or separately.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2024, no additional impairment was recorded.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will continue to assess whether its long-lived assets are impaired in future periods. As the Company finalizes the wind-down of its France operations and corresponding reduction in force of all France employees, as well as the closure of its Brisbane facility, it is reasonably possible that additional impairment charges will be recognized, for example, if sublease rates of leased facilities or selling prices of the assets held for sale are less than those estimated.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nine months ended September 30, 2023</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, as a result of the sustained decline in the Company&#8217;s stock price and related market capitalization, and termination of the collaboration agreements with Biogen and Novartis, the Company performed an impairment assessment of goodwill, indefinite-lived intangible assets, and other long-lived assets. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operated as a single reporting unit based on its business and reporting structure. For goodwill, a quantitative impairment assessment was performed using a market approach, whereby the Company&#8217;s fair value of equity was compared to its carrying value. The fair value of equity was derived using both the market capitalization of the Company and an estimate of a reasonable range of values of a control premium applied to the Company&#8217;s implied business enterprise value. The control premium was estimated based upon control premiums observed in comparable market transactions. This represented a level&#160;2 nonrecurring fair value measurement. Based on this analysis, the Company recognized a pre-tax goodwill impairment charge of $38.1&#160;million during the three months ended March 31, 2023. As a result, the goodwill was fully impaired as of March&#160;31, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before completing the goodwill impairment assessment, the Company also tested its indefinite-lived intangible assets and then its long-lived assets for impairment. Based on the qualitative assessment, the Company determined it was more likely than not that its indefinite-lived intangible assets were not impaired. The Company determined all of its long-lived assets represented one asset group for purposes of long-lived asset impairment assessment. The Company concluded that the carrying value of the asset group was not recoverable as it exceeded the future undiscounted cash flows the assets were expected to generate from the use and eventual disposition. To allocate and recognize the impairment loss, the Company determined individual fair values of its long-lived assets. The Company applied a discounted cash flow method to estimate fair values of its leasehold improvements and right-of-use assets, including leasehold improvements in the process of construction and a cost replacement method to estimate the fair value of its furniture, fixtures and laboratory and manufacturing equipment. These represented level&#160;3 nonrecurring fair value measurements. Based on this analysis, the Company recognized pre-tax long-lived asset impairment charges of $11.2&#160;million on the right-of-use assets, $5.0&#160;million on the related leasehold improvements, and $4.2&#160;million on construction-in-progress, during the three months ended March 31, 2023. No impairment was recognized on the remaining long-lived assets as their carrying values were not in excess of their fair values.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2023, the Company&#8217;s stock price and the related market capitalization continued to decline. In April 2023, the Company announced a restructuring of operations and a corresponding reduction in force. The Company also initiated discussions around several actions aimed at reducing costs, preserving liquidity and improving operational performance metrics, including deferral and reprioritization of certain research and development programs, further reduction in force, and closing or downsizing its facilities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reassessed its indefinite-lived and long-lived assets for impairment as of June 30, 2023. Given the actions contemplated above, the Company determined that it was more likely than not that its indefinite-lived intangible assets were impaired. Accordingly, the Company developed an estimate of the fair value of its indefinite-lived intangible assets using the multi-period excess earnings model (income approach) and concluded the carrying value of its indefinite-lived intangible assets were fully impaired. This represents a level 3 nonrecurring fair value measurement. As a result, an indefinite-lived intangible assets impairment charge of $51.3&#160;million, as well as the related income tax benefit of $6.3&#160;million due to the reversal of a deferred tax liability associated with the indefinite-lived intangible assets was recognized during the three and six months ended June 30, 2023. The impairment charge was primarily driven by a higher discount rate applied to future cash flows based on market participants&#8217; view of increased risk related to the asset.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that there were indicators of impairment in its long-lived asset group as of June 30, 2023, based on the same factors above as well as the impairment of its indefinite-lived intangible assets. As the estimated fair value of this asset group, based on a market approach, exceeded its carrying value, no impairment loss was recognized. This represented a level 3 nonrecurring fair value measurement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2023, the Company&#8217;s stock price and the related market capitalization continued to decline, and as such, the Company reassessed its long-lived assets for impairment as of September 30, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined all of its long-lived assets continued to represent one asset group for purposes of long-lived asset impairment assessment. The Company concluded that the carrying value of the asset group was not recoverable and the estimated fair value of this asset group was below its carrying value. The lower fair value of the asset group was mainly driven by the sustained decline in the Company&#8217;s stock price and the related market capitalization. To recognize the impairment loss, the Company determined individual fair values of its long-lived assets. The Company applied a discounted cash flow method to estimate fair values of its leasehold improvements and right-of-use assets, including leasehold improvements in the process of construction, and a market approach to estimate the fair value of its furniture, fixtures and laboratory and manufacturing equipment. These represented level 3 nonrecurring fair value measurements. Based on this analysis, the Company concluded the fair values of the long-lived assets were lower than their net book values due to declines in the market prices for leases, furniture, fixtures, and equipment. The Company recognized pre-tax long-lived asset impairment charges of $17.6&#160;million on the right-of-use assets, $13.7&#160;million on the related leasehold improvements and construction-in-progress, and $13.5&#160;million on furniture, fixtures, and laboratory and manufacturing equipment during the three months ended September 30, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the details of the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value. Disclosure may also include a description of the impaired asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired asset is reported.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085525078560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 5, 2024, the Company entered into an amendment to the operating lease of office and research and development laboratory facilities in Brisbane, California. The amendment established early termination rights for the landlord upon thirty days&#8217; notice to the Company, with the earliest date the landlord may terminate the lease being September 30, 2024. Additionally, the amendment authorized the landlord to draw on the existing letter of credit to satisfy the majority of the Company&#8217;s February 2024 through April 2024 rent payments and obligated the Company to provide a cash security deposit or replenish the letter of credit back to $1.5&#160;million by June 1, 2024. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the amendment represented a lease modification to be accounted for as a single contract with the existing lease under ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and remeasured its lease liability using the current incremental borrowing rate of 9.6%, and recorded an adjustment to reduce both the lease liability and the corresponding right-of-use asset by $1.9&#160;million as of the lease modification date.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2024, the Company entered into another amendment to extend the deadline for replenishing the letter of credit to September&#160;30,&#160;2024, the effect of which had no material impact to the Company&#8217;s financial statements. The letter of credit was replenished during the three months ended September 30, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085524761584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense recognized in the accompanying Condensed Consolidated Statements of Operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,315&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,099&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085524729344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s common stock authorized for issuance was 960,000,000 shares and 640,000,000 shares as of September&#160;30, 2024 and December 31, 2023, respectively.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Offering Program</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into an Open Market Sale Agreement&#8480; with Jefferies LLC (&#8220;Jefferies&#8221;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#8217;s common stock having an aggregate offering price of up to $150.0&#160;million through Jefferies as the Company&#8217;s sales agent or principal. The Company is not obligated to sell any shares under the sales agreement. In December 2022, the Company entered into an amendment to the Open Market Sale Agreement&#8480; which increased the aggregate offering price under the at-the-market offering program by an additional $175.0 million. No shares were sold under the sales agreement during the three months ended September&#160;30, 2023. During the nine months ended September&#160;30, 2023, the Company sold 8,249,261 shares of its common stock for net proceeds of approximately $15.1 million. No shares were sold under the sales agreement during the three and nine months ended September&#160;30, 2024. Approximately $194.5&#160;million remained available under the sales agreement as of September&#160;30, 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance and Sale of Common Stock and Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 21, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional investors (collectively, the &#8220;Investors&#8221;). On March 26, 2024 the Company issued and sold in a registered direct offering (the &#8220;Registered Direct Offering&#8221;) an aggregate of 24,761,905 shares of common stock of the Company, par value $0.01 per share, and pre-funded warrants to purchase up to an aggregate of 3,809,523 shares of common stock, together with accompanying warrants (&#8220;Common Warrants&#8221;) to purchase up to an aggregate of 28,571,428 shares of common stock. The combined offering price of a unit consisting of one share of common stock and the accompanying Common Warrant to purchase one share of common stock was $0.84. The combined offering price of a unit consisting of a pre-funded warrant to purchase one share of common stock and the accompanying Common Warrant to purchase one share of common stock was $0.83. The pre-funded warrants are immediately exercisable at any time, until exercised in full, at a price of $0.01 per share of common stock. The Common Warrants are exercisable six months from issuance, expire five and a half years from the issuance date and have an exercise price of $1.00 per share. Both pre-funded warrants and Common Warrants can be exercised net in limited circumstances and entitle holders to dividends if and when paid by the Company.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Barclays Capital Inc. and Cantor Fitzgerald &amp; Co. (the &#8220;Placement Agents&#8221;) acted as the placement agents for the offering, pursuant to a Placement Agency Agreement, dated March 21, 2024 (the &#8220;Placement Agreement&#8221;). Pursuant to the Placement Agreement, the Company paid the Placement Agents a cash placement fee equal to 6.0% of the aggregate gross proceeds raised in the Registered Direct Offering. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received aggregate net proceeds from the Registered Direct Offering of $21.9&#160;million, net of the Placement Agents&#8217; fees of $1.4&#160;million and other offering costs of $0.7&#160;million. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common Warrants and pre-funded warrants were determined to be equity-classified and proceeds received from their issuance were recorded as a component of stockholders&#8217; equity within additional paid-in capital. The Company determined that the warrants should be equity classified because they are freestanding financial instruments, do not embody an obligation for the Company to repurchase its shares, do not contain exercise contingencies tied to observable markets or indices, permit the holders to receive a fixed number of shares of common stock upon exercise in exchange for a fixed amount of consideration, subject only to adjustments that are inputs to the fair value of a fixed price/fixed consideration-option, and meet the equity classification criteria. The pre-funded warrants were exercised in full on April 8, 2024 and the Company issued an aggregate of 3,809,523 </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock at an exercise price of $0.01. The Common Warrants had not been exercised and remained outstanding as of September&#160;30, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085528649168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING CHARGES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">RESTRUCTURING CHARGES</a></td>
<td class="text">RESTRUCTURING CHARGES<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">April 2023 Restructuring</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2023, the Company executed a restructuring of operations and a corresponding reduction in workforce (the &#8220;April 2023 Restructuring&#8221;), designed to reduce costs and increase focus on certain strategic priorities. The April 2023 Restructuring resulted in the elimination of approximately 110 roles in the United States, or approximately 23% of the total United States workforce. The April 2023 Restructuring resulted in the incurrence of one-time severance payments and other employee-related costs, including additional vesting of service-based stock compensation awards. The Company had estimated that it will incur $5.0&#160;million in expenses related to employee severance and notice period payments, benefits and related restructuring charges for the April 2023 Restructuring. No expenses related to the April 2023 Restructuring were incurred during the three and nine months ended September&#160;30, 2024. No expenses related to the April 2023 Restructuring were incurred during the three months ended September 30, 2023.The Company incurred approximately $5.0&#160;million of expenses related to the April 2023 Restructuring during the nine months ended September&#160;30,&#160;2023, of which $3.8&#160;million is included in research and development expense and $1.2&#160;million is included in general and administrative expense in the accompanying Condensed Consolidated Statements of Operations. The April 2023 Restructuring and the cash payments related thereto are complete as of September 30, 2024.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">November 2023 Restructuring</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2023, the Company executed a restructuring of operations and a corresponding reduction in workforce (the &#8220;November 2023 Restructuring&#8221;), designed to reduce costs and advance its strategic transformation into a neurology-focused genomic medicine company. The November 2023 Restructuring resulted in the elimination of approximately 162 roles, including 108 full-time employees and 54 contracted employees and eliminated open positions, in the United States, or approximately 40% of the total United States workforce, and included one-time severance payments and other employee-related costs, including additional vesting of service-based stock compensation awards. The total restructuring expenses are estimated to be approximately $8.0 million to $9.0 million, related to employee severance and notice period payments, benefits, Brisbane facility close-out costs, and other related restructuring charges for the November 2023 Restructuring. The Company recorded $6.7 million of expenses relating to the November 2023 Restructuring in the fourth quarter of 2023. The expense adjustments recorded during the three and nine months ended September&#160;30, 2024 were not material. The cash payments relating to employee severance and notice period payments, benefits, other employee-related costs for the November 2023 Restructuring are complete as of September&#160;30, 2024. The Company expects the Brisbane facility close-out costs to be complete by second quarter of 2025, which were previously estimated to be complete by third quarter of 2024. The Company expects to incur estimated costs of $0.9&#160;million to $1.9&#160;million on Brisbane facility close-out costs through the second quarter of 2025.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">France Restructuring</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2024, the Company&#8217;s Board of Directors approved the France Restructuring which will result in the elimination of all 93 roles in France, or approximately 24% of the total global workforce. As a result, the Company has terminated its research and development activities in France and is in the process of disposing of its France-based assets and settling the associated liabilities. The Company is also making severance payments as required by French law and the terms of the applicable collective bargaining agreements, and incurring other employee-related costs. The total restructuring expenses are estimated to be approximately $5.3 million to $5.6 million, related to employee severance and notice period payments, benefits, contract termination costs, and other related restructuring charges for the France Restructuring. The Company had recorded $4.7 million of expenses relating to the France restructuring in the fourth quarter of 2023. The expenses incurred during the three and nine months ended September&#160;30, 2024 related to employee severance and notice period payments, benefits, other employee-related costs, and facility shutdown costs were not material. During the three months ended June 30, 2024, the Company recognized $2.4&#160;million as expense relating to a manufacturing agreement for costs that will be incurred without economic benefit to the Company, included in general and administrative expense in the accompanying Condensed Consolidated Statements of Operations. During the three months ended September&#160;30, 2024, the Company reached a settlement relating to the terminated manufacturing agreement and recognized $2.2&#160;million as a reduction to general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations. The Company expects to incur other additional estimated costs of $0.2 million to $0.5 million related to the France Restructuring through the fourth quarter of 2024. The Company expects the France Restructuring and its related cash payments to be substantially complete by the fourth quarter of 2024. See&#160;Note&#160;6&#160;&#8211;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment and Write-Down of Assets Held For Sale </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for impairment considerations related to the France Restructuring.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of accrued April 2023 Restructuring, November 2023 Restructuring and France Restructuring charges included within other accrued liabilities on the Company&#8217;s Condensed Consolidated Balance Sheet as of September&#160;30, 2024 (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo may also incur other cash expenses or charges not currently contemplated or estimable due to events that may occur as a result of, or associated with, the November 2023 Restructuring and France Restructuring.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085528602768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transfer to Nasdaq Capital Markets and Compliance with Bid Price Requirement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo&#8217;s common stock was transferred from Nasdaq Global Market to the Nasdaq Capital Market effective as of the opening of business on October 26, 2024 and has continued to trade under the symbol &#8220;SGMO.&#8221;  The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Select Market, and listed companies must meet certain financial requirements and comply with Nasdaq&#8217;s corporate governance requirements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the transfer, Sangamo was granted an additional 180-day grace period, or until April 21, 2025, or the Compliance Date, to regain compliance with the bid price requirement set forth in the continued listing requirements of Nasdaq Listing Rule 5450(a)(1) (the &#8220;Bid Price Requirement&#8221;). To regain compliance with the Bid Price Requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of Sangamo&#8217;s common stock must be at least $1.00 for at least ten consecutive business days during the additional 180-day compliance period. On November 5, 2024, Sangamo received a letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC that Sangamo has regained compliance with the Bid Price Requirement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085689707440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three and nine months ended September&#160;30, 2024 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024. The Condensed Consolidated Balance Sheet data at December&#160;31, 2023 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2023 (the &#8220;2023 Annual Report&#8221;) as filed with the SEC on March 13,&#160;2024.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, useful lives and impairment of long-lived assets, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research services. Research and license agreements typically include nonrefundable upfront signing or license fees, payments at negotiated rates for time incurred by Company researchers, third-party cost reimbursements, additional target selection fees, sublicense fees, milestone payments tied to ongoing development and product commercialization, and royalties on future licensees&#8217; product sales. All funds received from the Company&#8217;s collaboration partners are generally not refundable. Non-refundable upfront fees are fixed at the commencement of the contract. All other fees represent variable consideration in contracts. For contracts that contain a provision where the Company reimburses its customer for certain costs they incur and where the Company does not acquire any distinct goods or services in exchange for such payments, the Company accounts for it as a reduction to the contract transaction price. Deferred revenue primarily represents the portion of nonrefundable upfront fees or milestone payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s performance obligations in its collaboration agreements frequently represent distinct bundles of licenses of intellectual property and research and development services, with these components being individually non-distinct as the customer cannot benefit from the licenses independently from the research and development activities. In some instances, the Company has determined that the customer can benefit from the licensed intellectual property separately from the research and development activities, and the licenses of intellectual property and research and development services are individual distinct performance obligations. Options to license the Company&#8217;s intellectual property and/or acquire research and development services also represent performance obligations when they grant customers a material right, e.g. a right to a discount the customer would not have received if they did not purchase the Company&#8217;s services under the existing contract. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from grants of licenses to intellectual property that are distinct and therefore separate performance obligations are recognized at the point in time when the license is effective and the Company has completed the transfer of a copy of the licensed intellectual property to the customer. Revenues from distinct research and development services as well as from distinct bundles of licenses of intellectual property and research and development services, are recognized over time using a proportional performance method. Under this method, revenue is recognized by measuring progress towards satisfaction of the relevant performance obligation using a measure that best depicts the progress towards satisfaction of the relevant performance obligation. For most of the Company&#8217;s agreements the measure of progress is an input measure based on a level of effort incurred, which includes the value of actual time by Company researchers plus third-party cost reimbursements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration allocated to options that include material rights is deferred until the options are exercised or expire. The exercise of such options is accounted for as contract continuation, with target selection fees and estimated variable consideration included in the transaction price at that time and allocated specifically to the respective target&#8217;s performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. For variable consideration, the amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. A cumulative catch-up is then recorded in the current period to reflect the updated transaction price and the updated measure of progress. The estimated period </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of performance and level of effort, including the value of Company researchers&#8217; time and third-party costs, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current expectations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, discount rates and probabilities of exercise of technical and regulatory success, and the expected level of effort for research and development services. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract modifications occur when the price and/or scope of an arrangement changes. If the modification consists of adding new distinct goods or services in exchange for consideration that reflects standalone selling prices of these goods and services, the modification is accounted for as a separate contract with the customer. Otherwise, if the remaining goods and services are distinct from those previously provided, the existing contract is considered terminated, and the remaining consideration is allocated to the remaining goods and services as if this was a newly signed contract. If the remaining goods and services are not distinct from those previously provided, the effects of the modification are accounted for in a manner similar to the effect of a change in the estimated measure of progress, with cumulative catch-up in revenue recorded at the time of the modification. If some of the remaining goods and services are distinct from those previously provided and others are not, to account for the effects of the modification the Company applies principles consistent with the objectives of the modification accounting.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable. If a change in circumstance occurs that indicates long-lived assets may be impaired, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. The long-lived asset evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. The Company reassesses the composition of its asset groups whenever there are changes in its operations that affect whether the cash flows associated with assets included in asset groups are largely independent. If the impairment review indicates that the carrying amount of an asset group is not recoverable, an impairment loss is measured as the amount by which the carrying amount of an asset group exceeds its fair value. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, general macroeconomic conditions, conditions specific to the industry and market, an adverse change in legal factors, business climate or operational performance of the business, and sustained decline in the stock price and market capitalization compared to the net book value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calculating the fair value of a reporting unit, an asset group and an individual asset involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo considers all highly liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in money market accounts and U.S. government-sponsored entity debt securities. Restricted cash consisted of a letter of credit for $1.5&#160;million, representing a deposit for the lease of office and research and development laboratory facilities in Brisbane, California.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. Right-of-use assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases, calculated as the sum of the amortization of the right of use asset and accretion of the lease liability, is recognized on a straight-line basis over the lease term, unless the right of use asset was previously written down due to impairment. The Company evaluates the lease arrangement for impairment whenever events or changes in circumstances indicate that the carrying amounts of the right-of-use asset may not be fully recoverable. To the extent an impairment of the right-of-use asset is identified, the Company will recognize the impairment expense and subsequently amortize the remaining right of use asset into rent expense on a straight-line basis (unless another systematic basis is more representative of the pattern in which the Company expects to consume the future economic benefits from the asset) from the date of impairment to the earlier of the end of the right-of-use asset&#8217;s useful life or the end of the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there is a change to the terms and conditions of a contract that results in a change in the scope of or the consideration for a lease, the Company determines if the lease modification results in a separate contract or a change in the accounting for the existing lease and not a separate contract. For lease modifications that result in a separate contract, the Company accounts for the new contract in the same manner as other new leases. For lease modifications that do not result in a separate contract, the Company reassesses the classification of the lease at the effective date of the modification, remeasures and reallocates the remaining consideration in the contract, and remeasures the lease liability using the discount rate determined at the effective date of the modification.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected not to apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_WarrantOrRightPolicyPolicyTextBlock', window );">Warrants to Purchase Shares of Company Stock</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the accounting classification of warrants to purchase shares of its stock as either liability or equity by first assessing whether the warrants meet liability classification criteria in accordance with ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 480&#8221;). Under ASC 480, a financial instrument other than an outstanding share that embodies an obligation to repurchase the entity&#8217;s shares or is indexed to such an obligation, and that requires or may require the entity to settle it by transferring assets, is classified as a liability. In addition, a financial instrument that embodies an unconditional obligation, or </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares must be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception, (b) variations in something other than the fair value of the issuer&#8217;s equity shares, or (c) variations inversely related to changes in the fair value of the issuer&#8217;s equity shares. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If financial instruments, such as warrants, are not required to be classified as liabilities under ASC 480, the Company assesses whether such instruments are indexed to the Company&#8217;s own stock under ASC 815-40. In order for an instrument to be considered indexed to an entity&#8217;s own stock, its settlement amount must always equal the difference between the following: (a)&#160;the fair value of a fixed number of the Company&#8217;s equity shares, and (b) a fixed monetary amount or a fixed amount of a debt instrument issued by the Company. Certain adjustments to this amount are allowed, if they are based on non-levered inputs into the fair value of a fixed price/fixed consideration-option.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants are also required to meet equity classification criteria to be classified in stockholders&#8217; equity. Under these criteria, warrants have to provide for settlement in shares, or cash or shares at the entity&#8217;s option. With limited exceptions, a possibility of net cash settlement under any circumstances will result in the warrants being classified as liabilities. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants classified as equity are generally measured using the Black-Scholes valuation model on the date of issuance. Warrants classified as liabilities are remeasured at any reporting date using valuation models consistent with their terms, with changes recognized in earnings.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock', window );">Restructuring</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records employee severance costs based on whether the termination benefits are provided under an on-going benefit arrangement or under a one-time benefit arrangement. The Company accounts for on-going termination benefit arrangements, such as those arising from employment agreements, applicable regulations or past practices, in accordance with ASC Topic 712, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Nonretirement Postemployment Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 712&#8221;). Under ASC 712, liabilities for post-employment benefits related to past services and that vest or are accumulated over time are recorded at the time the obligations are probable of being incurred and can be reasonably estimated. The Company accounts for one-time employment benefit arrangements in accordance with ASC Topic 420, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exit or Disposal Cost Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 420&#8221;). One-time termination benefits are expensed at the date the entity notifies the employee, unless the employee must provide future service over a period extending past the minimum notification period, in which case the benefits are expensed ratably over the future service period. Other associated costs are recognized in the period in which the liability is incurred.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred to terminate contracts are recognized upon their termination, e.g., when notice of termination is provided to the counterparty. Costs related to contracts without future benefit are recognized at the cease-use date. Other exit-related costs are recognized as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2023-07&#8221;), which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2023-09&#8221;), which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and marketable securities. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_WarrantOrRightPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Or Right, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_WarrantOrRightPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 420<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085528619360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock', window );">Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from collaboration and license agreements as a percentage of total revenues were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.529%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genentech, Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other license agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,201&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,204&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,514&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,444&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,701&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,704&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,014&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,944&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,201&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,204&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,514&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,444&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,701&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,704&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,014&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,944&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085528712768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurements of Cash Equivalents and Marketable Securities</a></td>
<td class="text">The fair value measurements of the Company&#8217;s cash equivalents and marketable securities as of December&#160;31, 2023 are identified at the following levels within the fair value hierarchy (in thousands):<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,798&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,798&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,306&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,798&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085524195680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Cash Equivalents and Marketable Securities</a></td>
<td class="text">The table below summarizes the Company&#8217;s cash equivalents and marketable securities as of December&#160;31, 2023 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,072&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,306&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Fair Value of Marketable Securities by Contractual Maturity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.687%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,798&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085528779424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Components of Basic and Diluted Net Income (Loss) per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of basic and diluted net income (loss) per share are as follows (in thousands, except per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197,536)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income allocated to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,385&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,163)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,545)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197,536)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of common stock pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - diluted</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,325</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,171</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,849</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,375</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.59)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.14)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085524784656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span></div><div style="margin-top:6pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.103%"><tr><td style="width:1.0%"></td><td style="width:47.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.250%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Genentech agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under these agreements were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.477%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.477%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.477%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license fee fixed consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services variable consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,496&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,035&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Novartis agreement:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront license fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Biogen agreement:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and other fixed consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost-sharing payments for research services, net variable consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,849&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from other license agreements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,190&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085528611024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense recognized in the accompanying Condensed Consolidated Statements of Operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,315&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,099&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085528663392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING CHARGES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Accrued Restructuring Costs</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of accrued April 2023 Restructuring, November 2023 Restructuring and France Restructuring charges included within other accrued liabilities on the Company&#8217;s Condensed Consolidated Balance Sheet as of September&#160;30, 2024 (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085527252912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit established as a deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 56,514<span></span>
</td>
<td class="nump">$ 56,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,204<span></span>
</td>
<td class="nump">$ 100,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_GenentechRocheGroupMember', window );">Genentech, Inc. | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Variable consideration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_GenentechRocheGroupMember', window );">Genentech, Inc. | License | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc | Change In Agreement Estimate, March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax', window );">Increase in revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent', window );">Increase in net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInEarningsPerShareBasic', window );">Increased earnings per share, basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInEarningsPerShareDiluted', window );">Increased earnings per share, diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc | Change In Agreement Estimate, September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax', window );">Increase in revenue</a></td>
<td class="nump">4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent', window );">Increase in net income</a></td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInEarningsPerShareBasic', window );">Increased earnings per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInEarningsPerShareDiluted', window );">Increased earnings per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Earnings Per Share, Basic</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Earnings Per Share, Diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Net Income (Loss) Attributable To Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Revenue From Contract With Customer, Excluding Assessed Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_GenentechRocheGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_GenentechRocheGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInAgreementEstimateMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInAgreementEstimateMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInAgreementEstimateSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInAgreementEstimateSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085527706176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration And Licensing Agreements (Details) - Revenue from contract with customer - Customer concentration risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_GenentechRocheGroupMember', window );">Genentech, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes For BioMedical Research Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_OtherLicensingAgreementsMember', window );">Other license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_GenentechRocheGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_GenentechRocheGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_OtherLicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_OtherLicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085525159200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 39,201<span></span>
</td>
<td class="nump">$ 45,204<span></span>
</td>
<td class="nump">$ 56,514<span></span>
</td>
<td class="nump">$ 100,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Non-current restricted cash</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 40,701<span></span>
</td>
<td class="nump">$ 46,704<span></span>
</td>
<td class="nump">$ 58,014<span></span>
</td>
<td class="nump">$ 101,944<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085526694912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 35,798,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,508,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,566,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,826,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,377,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,593,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,031,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,508,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,798,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">38,306,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,508,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,566,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,826,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,377,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,593,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,031,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,508,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,508,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,508,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,798,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,798,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,566,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,826,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,377,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,593,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,031,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085526122560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">$ 39,201,000<span></span>
</td>
<td class="nump">$ 45,204,000<span></span>
</td>
<td class="nump">$ 56,514,000<span></span>
</td>
<td class="nump">$ 100,444,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,564,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,798,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent', window );">Total cash equivalents and marketable securities, amortized cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">38,072,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax', window );">Total cash equivalents and marketable securities, gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax', window );">Total cash equivalents and marketable securities, gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent', window );">Total cash equivalents and marketable securities, estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,306,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,347,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,566,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,826,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,399,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,377,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,599,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,593,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,026,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,031,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,508,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,508,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,508,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,508,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents accumulated gross unrealized gain before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents accumulated gross unrealized loss before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for Sale Securities Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities, gross unrealized gain, before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities, gross unrealized loss, before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085525476096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Available-for-Sale Securities by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,943<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 35,798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085527697376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Realized gain and losses on the sales of investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded', window );">Allowance for credit loss related to marketable securities, not previously recorded</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Allowance for credit loss related to marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding accrued interest, of credit loss expense on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) with no credit loss previously recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085524934608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Apr. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing basic net loss per share (in shares)</a></td>
<td class="nump">208,345,000<span></span>
</td>
<td class="nump">177,171,000<span></span>
</td>
<td class="nump">198,849,000<span></span>
</td>
<td class="nump">173,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding - diluted (in shares)</a></td>
<td class="nump">214,325,000<span></span>
</td>
<td class="nump">177,171,000<span></span>
</td>
<td class="nump">198,849,000<span></span>
</td>
<td class="nump">173,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">12,700,000<span></span>
</td>
<td class="nump">22,100,000<span></span>
</td>
<td class="nump">51,600,000<span></span>
</td>
<td class="nump">22,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sgmo_PreFundedCommonStockWarrantMember', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of new stock issued during the period (in shares)</a></td>
<td class="nump">3,809,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,809,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (USD) (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Offering price of each common stock (in dollars per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sgmo_PreFundedCommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sgmo_PreFundedCommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085525910080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET INCOME (LOSS) PER SHARE - Components of Basic and Diluted Net Income (Loss) per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 10,672<span></span>
</td>
<td class="num">$ (104,163)<span></span>
</td>
<td class="num">$ (74,545)<span></span>
</td>
<td class="num">$ (197,536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Net income allocated to participating securities</a></td>
<td class="nump">1,287<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) available to common stockholders</a></td>
<td class="nump">$ 9,385<span></span>
</td>
<td class="num">$ (104,163)<span></span>
</td>
<td class="num">$ (74,545)<span></span>
</td>
<td class="num">$ (197,536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Basic:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding - basic (in shares)</a></td>
<td class="nump">208,345<span></span>
</td>
<td class="nump">177,171<span></span>
</td>
<td class="nump">198,849<span></span>
</td>
<td class="nump">173,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding - basic (in shares)</a></td>
<td class="nump">208,345<span></span>
</td>
<td class="nump">177,171<span></span>
</td>
<td class="nump">198,849<span></span>
</td>
<td class="nump">173,375<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding - diluted (in shares)</a></td>
<td class="nump">214,325<span></span>
</td>
<td class="nump">177,171<span></span>
</td>
<td class="nump">198,849<span></span>
</td>
<td class="nump">173,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract', window );"><strong>Net income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of share-based payment arrangements (in shares)</a></td>
<td class="nump">5,823<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of share-based payment arrangements (in shares)</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic And Diluted EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_EarningsPerShareBasicAndDilutedEPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 65<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-65<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085525359664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Genentech, Inc. (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2024 </div>
<div>USD ($) </div>
<div>performance_obligation</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,412<span></span>
</td>
<td class="nump">$ 9,398<span></span>
</td>
<td class="nump">50,249<span></span>
</td>
<td class="nump">$ 174,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_GenentechRocheGroupMember', window );">Genentech, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_RoyaltyObligationTerm', window );">Royalty obligation, term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,226<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">49,226<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License | Genentech, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer liability</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Variable consideration amount</a></td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation amount</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations', window );">Number of performance obligations | performance_obligation</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,679<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 48,679<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License | Genentech, Inc. | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgmo_LicenseTechnologyTransferMember', window );">License, Technology Transfer | Genentech, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer liability</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customer, Number Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_RoyaltyObligationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_RoyaltyObligationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_GenentechRocheGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_GenentechRocheGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_LicenseTechnologyTransferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_LicenseTechnologyTransferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085523498864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">37 Months Ended</th>
<th class="th" colspan="1">82 Months Ended</th>
<th class="th" colspan="1">89 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>milestone </div>
<div>product</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,412,000<span></span>
</td>
<td class="nump">$ 9,398,000<span></span>
</td>
<td class="nump">$ 50,249,000<span></span>
</td>
<td class="nump">$ 174,190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | S B Five Two Five And Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive', window );">Potential amount to be funded for achievement of specified commercialized and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | S B Five Two Five And Other Products | Achievement of specified clinical development intellectual property and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | S B Five Two Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | License | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty', window );">Percentage of net sales per developed licensed product which will trigger royalties by counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | License | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty', window );">Percentage of net sales per developed licensed product which will trigger royalties by counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | S B Five Two Five And Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved', window );">Collaborative arrangement, number of milestones achieved | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember', window );">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember', window );">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | License | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty', window );">Percentage of net sales per developed licensed product which will trigger royalties by counterparty</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember', window );">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | License | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty', window );">Percentage of net sales per developed licensed product which will trigger royalties by counterparty</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember', window );">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember', window );">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | C9ORF72 | Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember', window );">Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | C9ORF72 | Achievement Of Commercial Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate additional revenue recognition milestone method revenue eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AgreementTerminationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Termination, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AgreementTerminationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements number of products approved under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Milestones Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNumberOfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Eligible Royalties, Triggered By Percentage Of Net Sales Per Developed Licensed Product By Counterparty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Customer contract liability milestone payment eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestoneRevenueReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone&#8203; revenue receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestoneRevenueReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of clinical or regulatory milestones included in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveAndOtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveAndOtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerSB525Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085527374160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 49,412<span></span>
</td>
<td class="nump">$ 9,398<span></span>
</td>
<td class="nump">$ 50,249<span></span>
</td>
<td class="nump">$ 174,190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_GenentechRocheGroupMember', window );">Genentech, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">49,226<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">49,226<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_GenentechRocheGroupMember', window );">Genentech, Inc. | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">48,679<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">48,679<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_GenentechRocheGroupMember', window );">Genentech, Inc. | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">547<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_OtherCollaborationAndLicenseAgreementsMember', window );">Other Collaboration And License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">9,398<span></span>
</td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">174,190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,496<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,388<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes For BioMedical Research Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes For BioMedical Research Inc. | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes For BioMedical Research Inc. | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">134,849<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">132,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_OtherLicensingAgreementsMember', window );">Other license agreements | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 186<span></span>
</td>
<td class="nump">$ 3,902<span></span>
</td>
<td class="nump">$ 1,023<span></span>
</td>
<td class="nump">$ 8,127<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_GenentechRocheGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_GenentechRocheGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_OtherCollaborationAndLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_OtherCollaborationAndLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_OtherLicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_OtherLicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085526658256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IMPAIRMENT AND WRITE-DOWN OF ASSETS HELD FOR SALE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets, indefinite-lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount', window );">Reduction in deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment on right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 17,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure', window );">Estimated fair value of equipment, furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,521<span></span>
</td>
<td class="nump">$ 65,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLeasehold', window );">Impairment of leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of assets to be disposed of</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_EquipmentFurnitureAndFixturesMember', window );">Equipment, Furniture, And Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_LeaseholdImprovementsAndConstructionInProgressMember', window );">Leasehold Improvements and Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember', window );">Furniture, Fixtures And Laboratory And Manufacturing Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Reduction In Deferred Tax Liabilities, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLeasehold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLeasehold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_EquipmentFurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_EquipmentFurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_LeaseholdImprovementsAndConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_LeaseholdImprovementsAndConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085524890544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 05, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 4,081<span></span>
</td>
<td class="nump">$ 3,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lessee, operating lease, discount rate</a></td>
<td class="nump">9.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination', window );">Lessee, operating lease, required notice of termination</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount', window );">Lessee, required letter of credit outstanding, amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sgmo_RichmondCaliforniaMember', window );">Richmond, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_OperatingLeaseRightOfUseAssetModificationReduction', window );">Reduction to right of use asset from lease modification</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Required Notice Of Termination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LesseeRequiredLetterOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Required Letter Of Credit Outstanding, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LesseeRequiredLetterOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OperatingLeaseRightOfUseAssetModificationReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset, Modification Reduction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_OperatingLeaseRightOfUseAssetModificationReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sgmo_RichmondCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sgmo_RichmondCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085681136912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,315<span></span>
</td>
<td class="nump">$ 6,189<span></span>
</td>
<td class="nump">$ 9,099<span></span>
</td>
<td class="nump">$ 21,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,478<span></span>
</td>
<td class="nump">3,236<span></span>
</td>
<td class="nump">4,186<span></span>
</td>
<td class="nump">11,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,837<span></span>
</td>
<td class="nump">$ 2,953<span></span>
</td>
<td class="nump">$ 4,913<span></span>
</td>
<td class="nump">$ 9,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085520557392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 08, 2024</div></th>
<th class="th"><div>Mar. 26, 2024</div></th>
<th class="th"><div>Mar. 21, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,761,905<span></span>
</td>
<td class="nump">8,249,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon exercise of pre-funded warrants (in shares)</a></td>
<td class="nump">3,809,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,809,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sgmo_PreFundedCommonStockWarrantMember', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of new stock issued during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,809,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,809,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (USD) (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Offering price of each common stock (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Direct offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,761,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds', window );">Cash placement fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_SaleOfStockAgentPlacementFees', window );">Net of placement fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_SaleOfStockOtherOfferingCosts', window );">Proceeds from other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Direct offering | Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of new stock issued during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,809,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Direct offering | Common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares of common stock for each Common warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit', window );">Sale of stock, number of shares issued in transaction, per unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance', window );">Warrants exercisable, period after issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Direct offering | Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,571,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares of common stock for each Common warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit', window );">Sale of stock, number of shares issued in transaction, per unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (USD) (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Offering price of each common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_JefferiesLLCMember', window );">Jefferies LLC | At-The-Market Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_StockOfferingProgramMaximumValue', window );">Stock offering program, maximum value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice', window );">Stock offering program, increase to aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_SaleOfStockOutstandingAmountAvailable', window );">Sale of stock agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 194.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 194.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,249,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockAgentPlacementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Agent Placement Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockAgentPlacementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Increase To Aggregate Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockIncreaseToAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Number of Shares Issued in Transaction, Per Unit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockOtherOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Other Offering Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockOtherOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockOutstandingAmountAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Outstanding Amount Available</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockOutstandingAmountAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Placement Fee, Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_StockOfferingProgramMaximumValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Offering Program, Maximum Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_StockOfferingProgramMaximumValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Or Right Outstanding, Exercisable, Period After Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sgmo_PreFundedCommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sgmo_PreFundedCommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sgmo_PreFundedCommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sgmo_PreFundedCommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sgmo_CommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sgmo_CommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085529137360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING CHARGES - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 01, 2024 </div>
<div>employee</div>
</th>
<th class="th">
<div>Nov. 01, 2023 </div>
<div>employee</div>
</th>
<th class="th">
<div>Apr. 26, 2023 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 603,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_April2023RestructuringPlanMember', window );">April 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees eliminated in restructuring | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_April2023RestructuringPlanMember', window );">April 2023 Restructuring Plan | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_April2023RestructuringPlanMember', window );">April 2023 Restructuring Plan | General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_November2023RestructuringPlanMember', window );">November 2023 Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees eliminated in restructuring | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of positions eliminated in restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_November2023RestructuringPlanMember', window );">November 2023 Restructuring Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_November2023RestructuringPlanMember', window );">November 2023 Restructuring Plan | Minimum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Expected cost remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_November2023RestructuringPlanMember', window );">November 2023 Restructuring Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_November2023RestructuringPlanMember', window );">November 2023 Restructuring Plan | Maximum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Expected cost remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_November2023RestructuringPlanMember', window );">November 2023 Restructuring Plan | Full-Time Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees eliminated in restructuring | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_November2023RestructuringPlanMember', window );">November 2023 Restructuring Plan | Contracted Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees eliminated in restructuring | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_FranceRestructuringPlanMember', window );">France Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees eliminated in restructuring | employee</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of positions eliminated in restructuring</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_FranceRestructuringPlanMember', window );">France Restructuring Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_FranceRestructuringPlanMember', window );">France Restructuring Plan | Minimum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Expected cost remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_FranceRestructuringPlanMember', window );">France Restructuring Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=sgmo_FranceRestructuringPlanMember', window );">France Restructuring Plan | Maximum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Expected cost remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected cost remaining for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=sgmo_April2023RestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=sgmo_April2023RestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=sgmo_November2023RestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=sgmo_November2023RestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=sgmo_FullTimeEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=sgmo_FullTimeEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=sgmo_ContractedEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=sgmo_ContractedEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=sgmo_FranceRestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=sgmo_FranceRestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46085528703424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING CHARGES - Accrued Restructuring Costs (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at December 31, 2023</a></td>
<td class="nump">$ 11,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(10,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at September 30, 2024</a></td>
<td class="nump">$ 1,653<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>59
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M(P?.9_O#='0KST>.UUD=Z?0ZG9Y5YU?,'HC =QD!G"052T5*C!J;,/[!Z,Y
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M=\(.#RN[@[!IFO(%E6J1DQQM:2&31;*MUP#!%KLBD4G/&  $& E\G103913
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ME%]E<P4E..$* -\7C,E]1TW0%/6C?P%02P,$%     @ 3H!L6<FVF:=N"P
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M^E<M/E1M6RW6+^<BFXFZ*R"_OZZJ]LN;[H<RMK_5<OY_4$L#!!0    ( $Z
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M>;&L7[J G8 ^9VM^G6_OMB]V7-6O,_3N?\7GU\WK&9V;YFV1'ZR ]5:BC"_
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M9+/ >48;^2!(?F$5Y$9M5,BK#,*44 3C!_ZMHA??;PSI\5C>^KFJX?5?Y*V
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M6?T^[7[TLXJNK5$#;OGK:Y8MPB-__Z]<V3:^X?-)<=?<8Y2#I<)6&L1R(F
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M<R]S:&5E=#@N>&ULG5C;;MLX$/T5PBV*%G!MQ\ZMS@5(TQ1;H%ETFUX>%OM
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MV!LP&Z^R<>%-$ZZ/&)]P&0V/%>@E+ G@^]* ?&E!!OK_)YS^#U!+ P04
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MPLF^QI;*6&SI5JFTQ">-NEMD?MM%N<ZQ=?G9+U0&7<XZ+C'K0XI)SE+FTZ=
MI"(2SG=Q7C$CO&>6=<2(. UXP.! E'$N2.  Z&*DE_7$^/FFH92W-4MB2B+>
M7VN#9$N<H2M%F^WA\7A9>*>$LG6P9GU]01!'-8X7VX/4_>'FLI*\$),'SV_
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;,U866_;.!#^*P.W*!)
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MH_M3%M0X.8U"(SKTXO=SFE5=MLN5^!8!:!&3*2,F$]HNZZ9M.V1U?$1T++I
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M8U5N).,0M+[E7M<<>;DHVL+>O7&]>X#=92:/(<O((1E CAR7.J4A8DS[JHG
MI*&H92S*8)( ,/.)F'OW0(!8Z*4*YQ<+U3OT[>A',X_+13O>^=J''W:*_A4
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M WY?E*B\[@LMT/W1L%?_ U!+ P04    " !.@&Q9K^Q$+^,-  !*-@  &0
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MZZYUL1 7VLQ5SK3>F6MI"XT'"@8OE$70$?$1/Y6,)>&ASG6A^6"=)UF9DJP
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M/C8CCQ^=//T^V#9SIH$+#G'-8! "4:*>P:+""\AR&%>XIF!Q:6'P;+DD'/0
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M&!P9.E)]QN=DTY+PU:*8<Q>KG7K<^F3MY!'6*: C5/+ +?/"E2]:",L0L#2
M>63BU9 )4-.7T2-<<F>,>)B\;]&,!_]BD  ?R'LP3>@^4H].80WA>9:2,M3-
MAJW'ZO[;7NO<4UEB3V#95:4QARJIT/!H#5C08%D#71&_:OZA0THT-KX@D,/$
MB2DSH:O!;S"L0-" %'$JU'^/%YU%3%CZ@!)_0!\;#8]]0<8["T!-?IG6G"!2
MR7:[P' [;%+S;H'8BG=KV)7T2VVY"$NH3D8OC[(N[9M#=$U:)U Z6$[28X4T
MD&<!O"^=BYL#.QCVR]D_4$L#!!0    ( $Z ;%F3P2$W[@(  &0&   9
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MOQ19NN A240-?.V&%>B0 ='3H+'G=<V63&8&2$.RP78'G%+C5,F&*NJ%K@U
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M 5 : ])OA-!'P02H_RJF_P!02P,$%     @ 3H!L6:.N!-D:!   ?@D  !D
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M:Z#./Z6I?-W)'&S^!X'!?U!+ P04    " !.@&Q9$.)--)$$  !K&@  &0
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MCCTT?QV-W-D?\MH\>!H'C\'0';\@=SB<O(Y?@O$3FDZ>@V'@S]%/: 9;R#;
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MV41[IX$56L-MSA=D_Q$U>M0"4Y(S]0OV#=;00+IEG!0-6:R@P&7]#W\W^W!
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MRP&FI<PK][RCQ2ZK-%="8]V:-;?XL0/23,#W:R'TL6,$RL\G]U]02P,$%
M  @ 3H!L66IT8.:!!   ZA0  !D   !X;"]W;W)K<VAE971S+W-H965T,S,N
M>&ULS5A;;Z,X%/XK1^QJ-97:<LM]DTAI $VD7J*FW7E8[8,+3H(*F+5-,_/O
MUS:420JA:8>'?4FP.=]W[.\<VP>/=X0^LRW&'+['4<(FVI;S=*3KS-_B&+%+
MDN)$O%D3&B,NFG2CLY1B%"A0'.F68?3T&(6)-AVKOB6=CDG&HS#!2PHLBV-$
M?USAB.PFFJF]=MR'FRV7'?ITG*(-7F'^F"ZI:.DE2Q#&.&$A28#B]42;F2//
M5 !E\5>(=VSO&>14G@AYEHU%,-$,.2(<89]+"B3^7O <1Y%D$N/XMR#52I\2
MN/_\RNZIR8O)/"&&YR3Z%@9\.]$&&@1XC;*(WY/=5UQ,J"OY?!(Q]0N[PM;0
MP,\8)W$!%B.(PR3_1]\+(?8 @J<>8!4 ZRV@<P1@%P#[5 ^= M YU4.W '1/
M!?0*0$]IGXNEE'801],Q)3N@TEJPR0<5+H46 H>)S*P5I^)M*'!\>C5;+>8P
MNW7 65P_/K@.W+H/L+B=W]VX\.7Z;K4Z@Z5[#ZNOLWO1X6".PHB=P07\#CJP
M+:*8C74N1B+Y=+_P>I5[M8YXM>&&)'S+P$T"'-3@G6;\L &O"P5*&:Q7&:ZL
M1L(53B_!-L[!,JQ.S7CFI\/MNNG\FG?WU[Q[S?!92B_!&-1Y/]#2+E/*5GSV
M$3X7T21,-@R6F,)*9L@Y.&&4<1R<P],/F),X%GO*/$*,G<,B\:,L$/;PL"-Y
M)]Q@OB4!_'TMF&'!<<S^J<NQ?!B=^F'(+7G$4N3CB2;V7(;I"]:F?_QF]HP_
MZP+<)IG3)IG;)IG7$ME!8G3*Q.@TL4]5+C#(& X@3, G<9IQ&7EQ-(0^).(<
MC8@(?RKR1NTL\$68Y7O,65T"Y.ZZRIT\0E^FEC&P.UW#,,;ZRWYTJY9FOV_V
MS8JE4V,Y' PZPXJE6\=IV_VJ=Z]1ED^*WBU%[S:*_DV=K4)Q](*IJ!4@R>(G
M(3!9%\J"J#<81XE:@Q<0Y"OU/>F[5>G-CFW52%^U/"9]C>41Z>LXZZ5O%.>3
MTO=*Z7N-TL\2'BHY1>T$#/L9#7DH!']'VEYU<E;?,*K*5@TMRZPQ=*J&73'%
MJJ%[*J/7./%/RMHO9>TWRKJD^&*=R8,?=HA2E/#:"J21Y*.G0YMD3IMD;IMD
M7DMD!V$=E&$=_#_*AD&;B=$FF=,FF=LFF=<2V4%B#,O$&#:N]]ORP$K$AZKX
M(O*?(60L$^L_$%NJ2 &^Q;)H",F[Q]:PLL'9 V/8E67SP=;:.**/AO5$IVZ;
M3KV6R XB9AH_ORJ-YE)/12FEH2^*N,>5<Z8"$Y H0G2OP*N-44'=W]/+N#3,
M-Q%J'L!'0W223[=5GUY;;(<AVOOP-QM#=+=>8[5Z\BB)Y861OY55N=QF\V7V
M@:#ESGK[5<O;B#6.Y\,1>]>AVZI#KV [FB)Y&/2]JY@8TXVZ-&-"U2SA^2=T
MV5M>S,W4==2;_BMS-#=K^AUSY.;7;C_I\UO &T0W8<(@PFOARKCLBQV'YA=K
M>8.35%T$/1'.2:P>MQ@%F$H#\7Y-"']M2 ?E]>;T/U!+ P04    " !.@&Q9
M:G-XBF4%  "I'   &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6S%65UO
MHS@4_2M6MEJUTK1@("'III':P&@J33M5T^X\N^ D5@&SMI-.__W:0$D EWZL
M1_N2@#GWF'M\?>V+IT^4/?(UQ@+\2I.,GPW60N2GEL6C-4X1/Z$YSN23)64I
M$O*6K2R>,XSBPBA-+,>V1U:*2#:838NV&S:;THU(2(9O&.";-$7L^0(G].EL
M  <O#;=DM1:JP9I-<[3""RSN\QLF[ZR:)28ISCBA&6!X>38XAZ>A8RN# O$W
MP4]\[QHH5QXH?50WE_'9P%9OA!,<"46!Y-\6SW&2*";Y'O]4I(.Z3V6X?_W"
M_K5P7CKS@#B>T^0GB<7Z;# >@!@OT281M_3I&ZX<&BJ^B":\^ 5/%=8>@&C#
M!4TK8_D&*<G*?_2K$F+/0/+H#9S*P&D;>*\8N)6!^]X>O,K >V\/P\J@<-TJ
M?2^$"Y! LRFC3X IM&13%X7ZA;74BV0J4!:"R:=$VHG9Q?GB<@[.KP,07'Z_
MOPL#<!W>@<OK^8^K$!Q^_[%8'(&;\!8LOIW?AN 8S&F:TPQG@@.Z!!>(DPB@
M+ 8!238"Q^!:QO9E%M$42VO*^1'(,0.+-6*R(< "D42V'8/[10 .#X[  ;
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M!/[](@S9ZTY20+Y4=O@?4$L#!!0    ( $Z ;%G_,)5<-0T  )&Z   9
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;,W=:T_CRAW'\;=BT:HZE?8LL>-P
M*R"Q\6WL91?!GE9JU0<F&< Z29S:9EFJOOB.$Q/'8";QGN]JV0=L+I[/..!_
M/(E_'A\_I-GO^9V4A?%M.IGE)SMW13$_VMW-1W=R&N?OT[F<J6=NTFP:%^IN
M=KN;SS,9CQ>-II-=J]?;VYW&R6SG]'CQV$5V>IS>%Y-D)B\R([^?3N/L\8.<
MI \G.^;.TP.7R>U=43ZP>WH\CV_EE2Q^FU]DZM[N2ADG4SG+DW1F9/+F9.?,
M/(H&_;+!8HF_)_(A7[MME"_E.DU_+^^(\<E.KUPC.9&CHB1B]=]7.92322FI
M]?A/A>ZL^BP;KM]^TKW%BU<OYCK.Y3"=_",9%W<G.P<[QEC>Q/>3XC)]"&3U
M@@:E-THG^>*G\5 MV]LQ1O=YD4ZKQFH-ILEL^7_\K?I%K#6PK%<:6%4#ZWD#
M\Y4&_:I!?]L>[*J!O6V#0=5@L&V#O:K!WK8-]JL&^]LV.*@:'&S;X+!J</BL
M@?WJ'Z[W])?K/6O2?ZT/<_7'7FYTRZUDL8DY<1&?'F?I@Y&5RRNOO+'83A?M
MU9:5S,J2NBHR]6RBVA6GYV?AYTMC^-O5E\_G[N75.^/B[/++)W4K$!=7QMDG
MQ[CZ<GGVQ?7%T#C[^%&<?1JZ5\:OQL5-\E^9&6(V>F_\XL@B3B;Y7X]W"[5*
M);P[JKK_L.S>>J5[TSA/9\5=;KBSL1RWM'?T[?N;VGOZ]H>;V@<;UM_:!(@-
M+V!_$Q#J@8.-:Q!M '2_@UVU.:VV*>MIF_I@:45'JHVB;[XSK)ZY;_QVY1B_
M_+EMVQCJF?/X<1O%T2M7<JY6IE<REJUAW.V9OH;QF+7QF;4)MOY#63T-(Q@F
M_([?C7K7FTCU/CB3QCQ+Q_>CHFT+_T.P9HOOK]Y%^XL>^J_T<"ES&6>C.R.>
MC0U'?E4CE;D:=Q3&69;%LUM9WGYG#%6996H,812I<2&S<CQDJ!_&Y^).9KGQ
MKX]*-40AI_F_V]Y)EZM@MZ]".?0ZRN?Q2)[LJ+%5+K.O<N?T+W\R]WI_:RL]
M$G-(S"4QC\1\$@M(3)!82&(1A#6JTEY5I:W3555^E;-[F;<5D[9EUV(B,6>)
M[2VP\@/1UU/[T#;51Z3>\>[7]4)YN>!A__#@Q7+>R^4&ZGWP\,6"_LL%S7W;
M+!=\MF1 OF!!8B&)11#6V'@'JXUWH-UXUP;8;=NOMG'7[9?$'!)S2<PC,9_$
M A(3)!:26 1AC7K:6]73WL\?HNV154EB#HFY).:1F$]B 8D)$@M)+(*P1E7N
MKZIR7[N7.[O-Y*+TC$)FTV06E]^SOEO<::LO+=:UOO1K9@Z,1_6&T39X=,C5
M<$G,(S&?Q (2$R06DE@$88UB.E@5T\&V0T;C?\:5\<'PDJ_2^/*0+F^<J3W?
M8D=F7"R_2FG]9*3MHVN-D9A#8BZ)>23FDUA 8H+$0A*+(*Q1=H>KLCO\^2/+
M0[(J2<PA,9?$/!+S22P@,4%B(8E%$-:H2K-7']GL;?7UGW$_&ZM]7OPTU&P]
M2JFENM97I:U_D[;?6_YK?I'FH/VZJ.:AFH]J :H)5 M1+:*T9A&MQ0-,_9@R
M+53))/'$B*?I_6RQ^[J6QDU94^/%#BP>W26JTA9[O/3&R.=RE-PDZLE1.IW*
M;*3:JF'I>+%WS..)JL?5D;?6\:=^A3J7XE(;K)6BM;<W:*U%LF,7U3Q4\U$M
M0#6!:B&J1936K$6KKD4+_GRG%CM[M3P5GXQ488_7AJS)K)"3,NYVKYZ89^E<
M9L7CHG0S>7L_B8LT>]Q4O]H7T;E^2<U!-1?5/%3S42U -8%J(:I%E-8L\3I'
M8KZ!((F))DE0S4$U%]4\5/-1+4 U@6HAJD64UJS0.E-BZD,EZT6Y&M+^6J:Z
MQ^M9M?BQ7"*OALN9'$FUAVY+9W[0]]>Y&NV7X]W>0?MXE^S8134/U7Q4"U!-
MH%J(:A&E-4NM3L"86T=@VL:[K<6$YF)0S4$U%]4\5/-1+4 U@6HAJD64UJRW
M.B%COH&(C(EF9%#-0347U3Q4\U$M0#6!:B&J1936K- Z+6/J0RGGJP%FMCRX
M48TLX^M)^^X0#<Q4VOIA#<MZY;@&&I%!-0_5?%0+4$V@6HAJ$:4U*ZF.RIA=
MLC(?DY&<Y5+=.D]FR?2^-7RF%SL7$QJ-0347U3Q4\U$M0#6!:B&J1936K+<Z
M(V.^@9",B:9D4,U!-1?5/%3S42U -8%J(:I%E-8\9[N.RUCZN(RJ-[43+.);
M61XGG,FB.EH_5[O)ZA"A'!N3Y9YR_'0VKO%PEZBJ?D@F$Z/(DMM;M726/L:3
M(E%MKQ^-49D:D-D\SHK'MIK5KU77FJVTP[4A:N^]:3\;G:)]NJCFH9J/:@&J
M"50+42VBM&8MUJD;:T/JYK71:?SMM=&I7NQ<1Z3FH)J+:AZJ^:@6H)I M1#5
M(DIKUEN=K+&LGS\ZM=!@#*HYJ.:BFH=J/JH%J"90+42UB-*:%5H'8RSM8?V?
M-CI%HS*5UAR=6L\'IV@"!M4\5/-1+4 U@6HAJD64UBS%.@%CZ1,PU>#TZL.O
M VO06C1HH@75'%1S4<U#-1_5 E03J!:B6D1IS>JJ0R_6X T,1=&8#*HYJ.:B
MFH=J/JH%J"90+42UB-*:%5K'9"SM0?[383J9Q-=I%I>3 1MQ799JB!G/\G@Y
M5_ \4V/1UMI# S"HYJ":BVH>JOFH%E1:8^JTOMV6C!!HQR&J1936+*PZW6+I
MTRVZ^?KT33M7#:DYE;:>N7X^5]_F1;S-B_B;%PG05R90+42UB-*:&VL=(+&V
M"I L/P7]@>E6]-UTWK#15 FJN:CFH9J/:@&J"50+42VBM&81UJD2ZPVD2BPT
M58)J#JJYJ.:AFH]J :H)5 M1+:*TYKSH=:JDKT^5O/IAZ9TQNY]>JYUC>K-V
M0OG3;!)CM4=]98+V95'JN^U:E*CFH)J+:AZJ^:@6H)I M1#5HDIKG*6Y&L@W
M*ZW.C/3UF9'SER>?ZDX[U6N="PC-BZ":BVH>JOFH%J":0+40U:)*:TQJ/WCV
M?4NSCNHL2%\_R\K91'XKO\"[N(NSJ5JA^Z*<)25_MTACO3/.<C66_*><R5%L
M7,:9-)Q$C4'S]IT4FOA -0?57%3S4,U'M0#5!*J%J!916K,.URZI\P:F0NFS
M%]5AKZK#7E:'O:X.>V$=]LHZ[*5UV&OKL!?7^1%!D'X=!.GK@R =)V_?H&DF
M7!_JFW8N+#0#@FH>JOFH%J":0+40U2)*:Q96G0'IZR<^^<XAZ+8GLNI[[[S3
M0],?J.:BFH=J/JH%J"90+42UB-*:M5FG/_IO8)*4/IH1034'U5Q4\U#-1[4
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MMGGQ?O-!IJORS?*'5,IT66XN1#@361&@OG],4_GRH3C ]M\?#/X%4$L#!!0
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;*U7;6_;-A#^*P>M&%K
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M,^O"@@@W)$O4/=__C65"0\,7\D3FO[ O;$=#"\),*IZ68!U!2EGQ3[Z70AP
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M66O\][\I_<X_JT*!Q'0D9B Q$XE92,Q&8A2).4C,!6%")+5=)#69/N8Q#'@
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M[CUX\#Z*-^^I>/OKUO@W4$L#!!0    ( $Z ;%F7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 3H!L69CY>V3K P
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MDN,>) <?HP1!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M
M(:M (:M (:M (:M (:M (:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$
M(:M$(6N"0M8$A:P)"EF3_R3KN]:KO_ZIT:YQK<KFZ,^Z/T?S3U!+ 0(4 Q0
M   ( $Z ;%D'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ 3H!L67N!<G+N    *P(  !$
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M970R+GAM;%!+ 0(4 Q0    ( $Z ;%G/.*[=608  /H<   8
M  " @184  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !.
M@&Q9S3*"7J4#  #@"P  &               @(&E&@  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ 3H!L6<FVF:=N"P  MV4  !@
M         ("!@!X  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( $Z ;%DCV-%@%@@  !(C   8              " @20J  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !.@&Q98EZ!=6LH  !OA0
M&               @(%P,@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ 3H!L611RK@>:!@  6Q   !@              ("!$5L  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( $Z ;%F/I[V_E08
M .H1   8              " @>%A  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " !.@&Q9TMIX&!8&  ""$P  &0              @(&L
M:   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( $Z ;%D"
MUQ$S$!4  $!,   9              " @?EN  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ 3H!L6:_L1"_C#0  2C8  !D
M     ("!0(0  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $Z ;%E%-)BA.00  ,D)   9              "
M@66K  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ 3H!L
M62$*N;*X'@  GV,  !D              ("!U:\  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " !.@&Q9[D;.I5($   9#0  &0
M        @('$S@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( $Z ;%FJP%C%B ,  &$(   9              " @4W3  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 3H!L6:.N!-D:!   ?@D
M !D              ("!#-<  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " !.@&Q9Y$:^P,H#  #G"   &0              @(%=VP
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( $Z ;%F 75VX
MT0,   L*   9              " @5[?  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ 3H!L63L=F20" P  : 8  !D
M ("!9N,  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !.
M@&Q9\M^;W/("  "+!@  &0              @(&?Y@  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( $Z ;%FYK&H2$ <  $U    9
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M970S,"YX;6Q02P$"% ,4    " !.@&Q9-U,/,,D"   >!P  &0
M    @(&A#0$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M $Z ;%FEST4R=0,  $H-   9              " @:$0 0!X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ 3H!L66IT8.:!!   ZA0  !D
M             ("!310! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " !.@&Q9:G-XBF4%  "I'   &0              @($%&0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( $Z ;%F)"J2HF 8
M #8[   9              " @:$> 0!X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ 3H!L6?\PE5PU#0  D;H  !D              ("!
M<"4! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !.@&Q9
M._U'H3,'   *00  &0              @('<,@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( $Z ;%E78P.0<P<  "5-   9
M      " @48Z 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ 3H!L61/\'XR9 P  _PT  !D              ("!\$$! 'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !.@&Q9S>&:+Z(#  #L$
M&0              @(' 10$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( $Z ;%EEZW/[W0L  &F<   9              " @9E) 0!X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ 3H!L60/(&0[[
M"P  O;X  !D              ("!K54! 'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    " !.@&Q98O>2I)X"  !.!@  &0
M@('?80$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( $Z
M;%G"<1-_, ,  .H2   -              "  ;1D 0!X;"]S='EL97,N>&UL
M4$L! A0#%     @ 3H!L69>*NQS     $P(   L              ( !#V@!
M %]R96QS+RYR96QS4$L! A0#%     @ 3H!L69CY>V3K P  0AT   \
M         ( !^&@! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $Z ;%GN
M2=W_G@$   @:   :              "  1!M 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( $Z ;%FHRH?9JP$  $$:   3
M      "  >9N 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     S #, W T
' ,)P 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>271</ContextCount>
  <ElementCount>229</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARE</Role>
      <ShortName>BASIC AND DILUTED NET INCOME (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - IMPAIRMENT AND WRITE-DOWN OF ASSETS HELD FOR SALE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALE</Role>
      <ShortName>IMPAIRMENT AND WRITE-DOWN OF ASSETS HELD FOR SALE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - RESTRUCTURING CHARGES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/RESTRUCTURINGCHARGES</Role>
      <ShortName>RESTRUCTURING CHARGES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARETables</Role>
      <ShortName>BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARE</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - RESTRUCTURING CHARGES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/RESTRUCTURINGCHARGESTables</Role>
      <ShortName>RESTRUCTURING CHARGES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/RESTRUCTURINGCHARGES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration And Licensing Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration And Licensing Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Available-for-Sale Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Available-for-Sale Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails</Role>
      <ShortName>BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARETables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE - Components of Basic and Diluted Net Income (Loss) per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails</Role>
      <ShortName>BASIC AND DILUTED NET INCOME (LOSS) PER SHARE - Components of Basic and Diluted Net Income (Loss) per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARETables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Genentech, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Genentech, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - IMPAIRMENT AND WRITE-DOWN OF ASSETS HELD FOR SALE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails</Role>
      <ShortName>IMPAIRMENT AND WRITE-DOWN OF ASSETS HELD FOR SALE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALE</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - STOCK-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - RESTRUCTURING CHARGES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails</Role>
      <ShortName>RESTRUCTURING CHARGES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sgmo-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - RESTRUCTURING CHARGES - Accrued Restructuring Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails</Role>
      <ShortName>RESTRUCTURING CHARGES - Accrued Restructuring Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="sgmo-20240930.htm">sgmo-20240930.htm</File>
    <File>sgmo-20240930.xsd</File>
    <File>sgmo-20240930_cal.xml</File>
    <File>sgmo-20240930_def.xml</File>
    <File>sgmo-20240930_lab.xml</File>
    <File>sgmo-20240930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="690">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sgmo-20240930.htm": {
   "nsprefix": "sgmo",
   "nsuri": "http://www.sangamo.com/20240930",
   "dts": {
    "inline": {
     "local": [
      "sgmo-20240930.htm"
     ]
    },
    "schema": {
     "local": [
      "sgmo-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sgmo-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sgmo-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sgmo-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgmo-20240930_pre.xml"
     ]
    }
   },
   "keyStandard": 191,
   "keyCustom": 38,
   "axisStandard": 23,
   "axisCustom": 0,
   "memberStandard": 29,
   "memberCustom": 32,
   "hidden": {
    "total": 6,
    "http://fasb.org/us-gaap/2024": 1,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 271,
   "entityCount": 1,
   "segmentCount": 62,
   "elementCount": 398,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 690,
    "http://xbrl.sec.gov/dei/2024": 29
   },
   "report": {
    "R1": {
     "role": "http://www.sangamo.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "longName": "9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-43",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-43",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "9952156 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS",
     "longName": "9952157 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES",
     "longName": "9952158 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARE",
     "longName": "9952159 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE",
     "shortName": "BASIC AND DILUTED NET INCOME (LOSS) PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES",
     "longName": "9952160 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALE",
     "longName": "9952161 - Disclosure - IMPAIRMENT AND WRITE-DOWN OF ASSETS HELD FOR SALE",
     "shortName": "IMPAIRMENT AND WRITE-DOWN OF ASSETS HELD FOR SALE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetImpairmentChargesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetImpairmentChargesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "9952162 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATION",
     "longName": "9952163 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.sangamo.com/role/STOCKHOLDERSEQUITY",
     "longName": "9952164 - Disclosure - STOCKHOLDERS' EQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.sangamo.com/role/RESTRUCTURINGCHARGES",
     "longName": "9952165 - Disclosure - RESTRUCTURING CHARGES",
     "shortName": "RESTRUCTURING CHARGES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.sangamo.com/role/SUBSEQUENTEVENTS",
     "longName": "9952166 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9954471 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "9954472 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables",
     "longName": "9954473 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables",
     "longName": "9954474 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARETables",
     "longName": "9954475 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Tables)",
     "shortName": "BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
     "longName": "9954476 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables",
     "longName": "9954477 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.sangamo.com/role/RESTRUCTURINGCHARGESTables",
     "longName": "9954478 - Disclosure - RESTRUCTURING CHARGES (Tables)",
     "shortName": "RESTRUCTURING CHARGES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "longName": "9954479 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails",
     "longName": "9954480 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration And Licensing Agreements (Details)",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration And Licensing Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-57",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-57",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails",
     "longName": "9954481 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Details)",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails",
     "longName": "9954482 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-82",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
     "longName": "9954483 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Details)",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails",
     "longName": "9954484 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Available-for-Sale Securities by Contractual Maturity (Details)",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Available-for-Sale Securities by Contractual Maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails",
     "longName": "9954485 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Narrative (Details)",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:GainLossOnSaleOfInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "us-gaap:GainLossOnSaleOfInvestments",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:GainLossOnSaleOfInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "us-gaap:GainLossOnSaleOfInvestments",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails",
     "longName": "9954486 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Details)",
     "shortName": "BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
     "longName": "9954487 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE - Components of Basic and Diluted Net Income (Loss) per Share (Details)",
     "shortName": "BASIC AND DILUTED NET INCOME (LOSS) PER SHARE - Components of Basic and Diluted Net Income (Loss) per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-119",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails",
     "longName": "9954488 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Genentech, Inc. (Details)",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Genentech, Inc. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-127",
      "name": "sgmo:RoyaltyObligationTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
     "longName": "9954489 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details)",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-142",
      "name": "sgmo:AgreementTerminationTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
     "longName": "9954490 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Details)",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-134",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails",
     "longName": "9954491 - Disclosure - IMPAIRMENT AND WRITE-DOWN OF ASSETS HELD FOR SALE (Details)",
     "shortName": "IMPAIRMENT AND WRITE-DOWN OF ASSETS HELD FOR SALE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-215",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-215",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "longName": "9954492 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-221",
      "name": "us-gaap:IncreaseDecreaseInOperatingLeaseLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "sgmo:OperatingLeaseRightOfUseAssetModificationReduction",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-221",
      "name": "us-gaap:IncreaseDecreaseInOperatingLeaseLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "sgmo:OperatingLeaseRightOfUseAssetModificationReduction",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONDetails",
     "longName": "9954493 - Disclosure - STOCK-BASED COMPENSATION (Details)",
     "shortName": "STOCK-BASED COMPENSATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails",
     "longName": "9954494 - Disclosure - STOCKHOLDERS' EQUITY (Details)",
     "shortName": "STOCKHOLDERS' EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails",
     "longName": "9954495 - Disclosure - RESTRUCTURING CHARGES - Narrative (Details)",
     "shortName": "RESTRUCTURING CHARGES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-249",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "employee",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-1",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.sangamo.com/role/RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails",
     "longName": "9954496 - Disclosure - RESTRUCTURING CHARGES - Accrued Restructuring Costs (Details)",
     "shortName": "RESTRUCTURING CHARGES - Accrued Restructuring Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20240930.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r696"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of discount and impairment on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and employee benefits",
        "label": "Accrued Employee Benefits, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r66",
      "r126",
      "r518",
      "r545",
      "r546"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13",
      "r19",
      "r387",
      "r390",
      "r436",
      "r541",
      "r542",
      "r745",
      "r746",
      "r747",
      "r755",
      "r756",
      "r757",
      "r759"
     ]
    },
    "sgmo_AchievementOfCommercialMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "AchievementOfCommercialMilestonesMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement Of Commercial Milestones",
        "label": "Achievement Of Commercial Milestones [Member]",
        "documentation": "Achievement of Commercial Milestones."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement of specified clinical development intellectual property and regulatory milestones",
        "label": "Achievement Of Specified Clinical Development Intellectual Property And Regulatory Milestones [Member]",
        "documentation": "Achievement of specified clinical development intellectual property and regulatory milestones."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones",
        "label": "Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones [Member]",
        "documentation": "Achievement of specified preclinical development clinical development and first commercial sale milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r755",
      "r756",
      "r757",
      "r759",
      "r794",
      "r851"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r331"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential amount to be funded for achievement of specified commercialized and sales milestones",
        "label": "Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive",
        "documentation": "Aggregate additional revenue recognition milestone method revenue eligible to receive."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_AgreementTerminationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "AgreementTerminationTerm",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement termination, term",
        "label": "Agreement Termination, Term",
        "documentation": "Agreement Termination, Term"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease",
        "label": "Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease [Member]",
        "documentation": "Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r365"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "sgmo_April2023RestructuringPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "April2023RestructuringPlanMember",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2023 Restructuring Plan",
        "label": "April 2023 Restructuring Plan [Member]",
        "documentation": "April 2023 Restructuring Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetBackedSecuritiesMember",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset-backed securities",
        "label": "Asset-Backed Securities [Member]",
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r697",
      "r770",
      "r771",
      "r772"
     ]
    },
    "us-gaap_AssetImpairmentChargesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentChargesTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IMPAIRMENT AND WRITE-DOWN OF ASSETS HELD FOR SALE",
        "label": "Asset Impairment Charges [Text Block]",
        "documentation": "The entire disclosure for the details of the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value. Disclosure may also include a description of the impaired asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired asset is reported."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r101",
      "r122",
      "r145",
      "r184",
      "r188",
      "r194",
      "r195",
      "r236",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r382",
      "r384",
      "r419",
      "r514",
      "r592",
      "r666",
      "r667",
      "r696",
      "r723",
      "r787",
      "r788",
      "r807"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r127",
      "r145",
      "r236",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r382",
      "r384",
      "r419",
      "r696",
      "r787",
      "r788",
      "r807"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash equivalents and marketable securities",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399",
      "r682"
     ]
    },
    "sgmo_AtTheMarketOfferingProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "AtTheMarketOfferingProgramMember",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market Offering Program",
        "label": "At The Market Offering Program [Member]",
        "documentation": "At the market offering agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails",
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "terseLabel": "Gross unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturing after one year through five years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r511"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturing in one year or less",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r510"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_BiogenMAIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "BiogenMAIncMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biogen MA, Inc.",
        "label": "Biogen MA, Inc. [Member]",
        "documentation": "Biogen MA, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_CNineORFSevenTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "CNineORFSevenTwoMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "C9ORF72",
        "label": "C Nine O R F Seven Two [Member]",
        "documentation": "C nine ORF seven two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment included in unpaid liabilities",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents:",
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Cash And Cash Equivalents Accumulated Gross Unrealized Gain Before Tax",
        "documentation": "Cash and cash equivalents accumulated gross unrealized gain before tax."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross Unrealized Losses",
        "label": "Cash And Cash Equivalents Accumulated Gross Unrealized Loss Before Tax",
        "documentation": "Cash and cash equivalents accumulated gross unrealized loss before tax."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Amortized Cost",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r121",
      "r657"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash equivalents",
        "verboseLabel": "Estimated Fair Value",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r72",
      "r143"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r72"
     ]
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash equivalents and marketable securities, amortized cost",
        "label": "Cash Equivalents And Available For Sale Securities Amortized Cost, Current",
        "documentation": "Cash equivalents and available for Sale Securities Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash equivalents and marketable securities, estimated fair value",
        "label": "Cash Equivalents And Available For Sale Securities, Current",
        "documentation": "Cash equivalents and available for sale securities."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash equivalents and marketable securities, gross unrealized gains",
        "label": "Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax",
        "documentation": "Cash equivalents and available for sale securities, gross unrealized gain, before tax."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Total cash equivalents and marketable securities, gross unrealized losses",
        "label": "Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax",
        "documentation": "Cash equivalents and available for sale securities, gross unrealized loss, before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents:",
        "label": "Cash Equivalents [Member]",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificates of deposit",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Estimate by Type [Axis]",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "documentation": "Information by type of change in accounting estimate."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r156"
     ]
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingEstimateLineItems",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Estimate [Line Items]",
        "label": "Change in Accounting Estimate [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Estimate, Type [Domain]",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r156"
     ]
    },
    "sgmo_ChangeInAgreementEstimateMarch2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "ChangeInAgreementEstimateMarch2023Member",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change In Agreement Estimate, March 2023",
        "label": "Change In Agreement Estimate, March 2023 [Member]",
        "documentation": "Change In Agreement Estimate, March 2023"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_ChangeInAgreementEstimateSeptember2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "ChangeInAgreementEstimateSeptember2023Member",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change In Agreement Estimate, September 2023",
        "label": "Change In Agreement Estimate, September 2023 [Member]",
        "documentation": "Change In Agreement Estimate, September 2023"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r123",
      "r124",
      "r125",
      "r145",
      "r167",
      "r171",
      "r175",
      "r179",
      "r186",
      "r187",
      "r236",
      "r275",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r289",
      "r290",
      "r293",
      "r296",
      "r303",
      "r419",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r580",
      "r601",
      "r619",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r730",
      "r752",
      "r760"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering price of each common stock (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of common stock for each Common warrant (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails",
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of new stock issued during the period (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of products approved",
        "label": "Collaboration And License Agreements Number Of Products Approved Under Agreement",
        "documentation": "Collaboration and license agreements number of products approved under agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r106",
      "r114"
     ]
    },
    "sgmo_CollaborativeArrangementNumberOfMilestonesAchieved": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "CollaborativeArrangementNumberOfMilestonesAchieved",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, number of milestones achieved",
        "label": "Collaborative Arrangement, Number Of Milestones Achieved",
        "documentation": "Collaborative Arrangement, Number Of Milestones Achieved"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_CollaborativeArrangementTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "CollaborativeArrangementTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement transaction price",
        "label": "Collaborative Arrangement Transaction Price",
        "documentation": "Collaborative arrangement transaction price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper securities",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r274",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r93",
      "r515",
      "r579"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r268",
      "r269",
      "r641",
      "r781",
      "r784"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r714",
      "r715",
      "r717",
      "r718",
      "r719",
      "r720",
      "r755",
      "r756",
      "r759",
      "r794",
      "r850",
      "r851"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r580"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r59",
      "r580",
      "r598",
      "r851",
      "r852"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r517",
      "r696"
     ]
    },
    "sgmo_CommonWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "CommonWarrantMember",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common warrants",
        "label": "Common Warrant [Member]",
        "documentation": "Common Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income (loss)",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r131",
      "r133",
      "r137",
      "r507",
      "r526",
      "r527"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r47",
      "r48",
      "r199",
      "r640"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r47",
      "r48",
      "r199",
      "r548",
      "r640"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r47",
      "r48",
      "r199",
      "r640",
      "r734"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of revenues",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r47",
      "r48",
      "r199"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r33",
      "r47",
      "r90",
      "r640"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r47",
      "r48",
      "r199",
      "r640"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r661"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in Progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r308",
      "r319"
     ]
    },
    "sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of net sales per developed licensed product which will trigger royalties by counterparty",
        "label": "Contract With Customer, Eligible Royalties, Triggered By Percentage Of Net Sales Per Developed Licensed Product By Counterparty",
        "documentation": "Contract With Customer, Eligible Royalties, Triggered By Percentage Of Net Sales Per Developed Licensed Product By Counterparty"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer liability",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r319"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenues",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r319"
     ]
    },
    "sgmo_ContractedEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "ContractedEmployeesMember",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contracted Employees",
        "label": "Contracted Employees [Member]",
        "documentation": "Contracted Employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r678",
      "r682",
      "r697",
      "r711",
      "r847"
     ]
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring",
        "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r82",
      "r83"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r284",
      "r291",
      "r437",
      "r457",
      "r513",
      "r658",
      "r660"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover page.",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "CustomerContractLiabilityMilestonePaymentEligibleToReceive",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and sales-based milestone payments to be received",
        "label": "Customer Contract Liability Milestone Payment Eligible To Receive",
        "documentation": "Customer contract liability milestone payment eligible to receive."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit loss related to marketable securities",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss, Current",
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrentAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities:",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit loss related to marketable securities, not previously recorded",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Allowance for Credit Loss, Not Previously Recorded",
        "documentation": "Amount, excluding accrued interest, of credit loss expense on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) with no credit loss previously recorded."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails",
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "verboseLabel": "Estimated Fair Value",
        "totalLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Table Text Block]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax benefit",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r111",
      "r754"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r184",
      "r191",
      "r195",
      "r666",
      "r667"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCK-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r334",
      "r362",
      "r363",
      "r364",
      "r680"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per share",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic net loss per share (in dollars per share)",
        "terseLabel": "Basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r164",
      "r167",
      "r175",
      "r178",
      "r179",
      "r183",
      "r378",
      "r381",
      "r395",
      "r396",
      "r508",
      "r528",
      "r663"
     ]
    },
    "sgmo_EarningsPerShareBasicAndDilutedEPSAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "EarningsPerShareBasicAndDilutedEPSAbstract",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income (loss) per share:",
        "label": "Earnings Per Share, Basic And Diluted EPS [Abstract]",
        "documentation": "Earnings Per Share, Basic And Diluted EPS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted net loss per share (in dollars per share)",
        "terseLabel": "Diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r167",
      "r175",
      "r178",
      "r179",
      "r183",
      "r378",
      "r381",
      "r395",
      "r396",
      "r508",
      "r528",
      "r663"
     ]
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDilutedLineItems",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r171",
      "r175"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BASIC AND DILUTED NET INCOME (LOSS) PER SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r180",
      "r181",
      "r182"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in deferred tax liabilities",
        "label": "Effective Income Tax Rate Reconciliation, Reduction In Deferred Tax Liabilities, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Reduction In Deferred Tax Liabilities, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "sgmo_EquipmentFurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "EquipmentFurnitureAndFixturesMember",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment, Furniture, And Fixtures",
        "label": "Equipment, Furniture, And Fixtures [Member]",
        "documentation": "Equipment, Furniture, And Fixtures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r117",
      "r134",
      "r135",
      "r136",
      "r148",
      "r149",
      "r150",
      "r152",
      "r157",
      "r159",
      "r161",
      "r185",
      "r237",
      "r238",
      "r253",
      "r305",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r394",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r430",
      "r431",
      "r436",
      "r524",
      "r541",
      "r542",
      "r543",
      "r555",
      "r619"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399",
      "r409",
      "r682"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399",
      "r409",
      "r682"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Value Measurements of Cash Equivalents and Marketable Securities",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r796",
      "r797",
      "r802"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r408",
      "r409",
      "r411",
      "r444",
      "r445",
      "r446",
      "r671",
      "r672",
      "r676",
      "r677",
      "r678",
      "r682",
      "r688"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399",
      "r400",
      "r402",
      "r682",
      "r799",
      "r803"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r406",
      "r407",
      "r408",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r506",
      "r682",
      "r689"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r321",
      "r326",
      "r399",
      "r409",
      "r444",
      "r676",
      "r677",
      "r678",
      "r682"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r321",
      "r326",
      "r399",
      "r400",
      "r409",
      "r445",
      "r671",
      "r672",
      "r676",
      "r677",
      "r678",
      "r682"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r399",
      "r400",
      "r401",
      "r402",
      "r409",
      "r446",
      "r671",
      "r672",
      "r676",
      "r677",
      "r678",
      "r682",
      "r688"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurement Frequency",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399",
      "r400",
      "r402",
      "r682",
      "r799",
      "r803"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r408",
      "r409",
      "r411",
      "r444",
      "r445",
      "r446",
      "r671",
      "r672",
      "r676",
      "r677",
      "r678",
      "r682",
      "r688"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value on recurring basis",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r803"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r287",
      "r301",
      "r392",
      "r416",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r525",
      "r669",
      "r682",
      "r686",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r697",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r773",
      "r774",
      "r775",
      "r776",
      "r795",
      "r798",
      "r799",
      "r800",
      "r801",
      "r803"
     ]
    },
    "sgmo_FranceRestructuringPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "FranceRestructuringPlanMember",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "France Restructuring Plan",
        "label": "France Restructuring Plan [Member]",
        "documentation": "France Restructuring Plan"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_FullTimeEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "FullTimeEmployeesMember",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Full-Time Employees",
        "label": "Full-Time Employees [Member]",
        "documentation": "Full-Time Employees"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture, Fixtures And Laboratory And Manufacturing Equipment",
        "label": "Furniture, Fixtures And Laboratory And Manufacturing Equipment [Member]",
        "documentation": "Furniture, Fixtures And Laboratory And Manufacturing Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized gain and losses on the sales of investments",
        "label": "Gain (Loss) on Sale of Investments",
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "sgmo_GenentechRocheGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "GenentechRocheGroupMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genentech, Inc.",
        "label": "Genentech, Roche Group [Member]",
        "documentation": "Genentech, Roche Group"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r603"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails",
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of goodwill and indefinite-lived intangible assets",
        "label": "Goodwill and Intangible Asset Impairment",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r249",
      "r250",
      "r251",
      "r670",
      "r684"
     ]
    },
    "us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairedLongLivedAssetsHeldAndUsedLineItems",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impaired Long-Lived Assets Held and Used [Line Items]",
        "label": "Impaired Long-Lived Assets Held and Used [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets, indefinite-lived",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r750",
      "r779",
      "r780"
     ]
    },
    "us-gaap_ImpairmentOfLeasehold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLeasehold",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of leasehold improvements",
        "label": "Impairment of Leasehold",
        "documentation": "The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r37"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r37",
      "r80",
      "r683"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of assets to be disposed of",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r78",
      "r685"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r81"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r95",
      "r100",
      "r509",
      "r522",
      "r665",
      "r666",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails",
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r260",
      "r403",
      "r405",
      "r410",
      "r538",
      "r540",
      "r604",
      "r653",
      "r687",
      "r820"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails",
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r260",
      "r403",
      "r405",
      "r410",
      "r538",
      "r540",
      "r604",
      "r653",
      "r687",
      "r820"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense (benefit)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r112",
      "r160",
      "r161",
      "r184",
      "r192",
      "r195",
      "r370",
      "r371",
      "r374",
      "r529",
      "r681"
     ]
    },
    "sgmo_IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refundable research income tax credits and other non-current assets",
        "label": "Income Tax, Refundable Research Credits And Other Non-current Assets",
        "documentation": "Income Tax, Refundable Research Credits And Other Non-current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and other accrued liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest receivable",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenues",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r749"
     ]
    },
    "sgmo_IncreaseDecreaseInEarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "IncreaseDecreaseInEarningsPerShareBasic",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Increased earnings per share, basic (in dollars per share)",
        "label": "Increase (Decrease) In Earnings Per Share, Basic",
        "documentation": "Increase (Decrease) In Earnings Per Share, Basic"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_IncreaseDecreaseInEarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "IncreaseDecreaseInEarningsPerShareDiluted",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Increased earnings per share, diluted (in dollars per share)",
        "label": "Increase (Decrease) In Earnings Per Share, Diluted",
        "documentation": "Increase (Decrease) In Earnings Per Share, Diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and employee benefits",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "IncreaseDecreaseInNetIncomeLossAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Increase in net income",
        "label": "Increase (Decrease) In Net Income (Loss) Attributable To Parent",
        "documentation": "Increase (Decrease) In Net Income (Loss) Attributable To Parent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "negatedTerseLabel": "Lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r749"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in revenue",
        "label": "Increase (Decrease) In Revenue From Contract With Customer, Excluding Assessed Tax",
        "documentation": "Increase (Decrease) In Revenue From Contract With Customer, Excluding Assessed Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive effect of share-based payment arrangements (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r179",
      "r333"
     ]
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and other income, net",
        "label": "Interest and Other Income",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Marketable Securities by Contractual Maturity",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH EQUIVALENTS AND MARKETABLE SECURITIES",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r116",
      "r201",
      "r203",
      "r417",
      "r418",
      "r816"
     ]
    },
    "sgmo_JefferiesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "JefferiesLLCMember",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jefferies LLC",
        "label": "Jefferies LLC [Member]",
        "documentation": "Jefferies LLC"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_KitePharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "KitePharmaIncMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kite Pharma Inc",
        "label": "Kite Pharma Inc [Member]",
        "documentation": "Kite Pharma Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_LeaseholdImprovementsAndConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "LeaseholdImprovementsAndConstructionInProgressMember",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements and Construction in Progress",
        "label": "Leasehold Improvements and Construction in Progress [Member]",
        "documentation": "Leasehold Improvements and Construction in Progress"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, discount rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "sgmo_LesseeOperatingLeaseRequiredNoticeOfTermination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "LesseeOperatingLeaseRequiredNoticeOfTermination",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, required notice of termination",
        "label": "Lessee, Operating Lease, Required Notice Of Termination",
        "documentation": "Lessee, Operating Lease, Required Notice Of Termination"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_LesseeRequiredLetterOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "LesseeRequiredLetterOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, required letter of credit outstanding, amount",
        "label": "Lessee, Required Letter Of Credit Outstanding, Amount",
        "documentation": "Lessee, Required Letter Of Credit Outstanding, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of credit established as a deposit",
        "label": "Letters of Credit Outstanding, Amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r51",
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r145",
      "r236",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r383",
      "r384",
      "r385",
      "r419",
      "r578",
      "r664",
      "r723",
      "r787",
      "r807",
      "r808"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r94",
      "r520",
      "r696",
      "r753",
      "r777",
      "r804"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r120",
      "r145",
      "r236",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r383",
      "r384",
      "r385",
      "r419",
      "r696",
      "r787",
      "r807",
      "r808"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "sgmo_LicenseTechnologyTransferMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "LicenseTechnologyTransferMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License, Technology Transfer",
        "label": "License, Technology Transfer [Member]",
        "documentation": "License, Technology Transfer"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash Equivalents and Marketable Securities",
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r327",
      "r366",
      "r402",
      "r473",
      "r537",
      "r539",
      "r547",
      "r570",
      "r571",
      "r624",
      "r626",
      "r628",
      "r629",
      "r631",
      "r651",
      "r652",
      "r668",
      "r673",
      "r679",
      "r688",
      "r689",
      "r693",
      "r694",
      "r707",
      "r789",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814"
     ]
    },
    "sgmo_MilestonePaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "MilestonePaymentsReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments received",
        "label": "Milestone Payments Received",
        "documentation": "Milestone payments received."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_MilestoneRevenueReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "MilestoneRevenueReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone revenue receivable",
        "label": "Milestone Revenue Receivable",
        "documentation": "Milestone\u200b revenue receivable."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r327",
      "r366",
      "r402",
      "r473",
      "r537",
      "r539",
      "r547",
      "r570",
      "r571",
      "r624",
      "r626",
      "r628",
      "r629",
      "r631",
      "r651",
      "r652",
      "r668",
      "r673",
      "r679",
      "r688",
      "r689",
      "r693",
      "r707",
      "r789",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing Activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "terseLabel": "Net income (loss)",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r74",
      "r96",
      "r118",
      "r130",
      "r132",
      "r136",
      "r145",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r160",
      "r161",
      "r172",
      "r236",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r378",
      "r381",
      "r396",
      "r419",
      "r523",
      "r600",
      "r617",
      "r618",
      "r721",
      "r787"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) available to common stockholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r153",
      "r154",
      "r155",
      "r156",
      "r164",
      "r165",
      "r174",
      "r179",
      "r381"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow disclosures:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_NovartisInstitutesForBioMedicalResearchIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "NovartisInstitutesForBioMedicalResearchIncMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novartis Institutes For BioMedical Research Inc.",
        "label": "Novartis Institutes For BioMedical Research Inc. [Member]",
        "documentation": "Novartis Institutes For BioMedical Research Inc."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_November2023RestructuringPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "November2023RestructuringPlanMember",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "November 2023 Restructuring Plan",
        "label": "November 2023 Restructuring Plan [Member]",
        "documentation": "November 2023 Restructuring Plan"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of milestones included in transaction price",
        "label": "Number Of Clinical Or Regulatory Milestones Included In Transaction Price",
        "documentation": "Number of clinical or regulatory milestones included in transaction price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r665",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment on right-of-use assets",
        "label": "Operating Lease, Impairment Loss",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-term portion of lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization in operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "sgmo_OperatingLeaseRightOfUseAssetModificationReduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "OperatingLeaseRightOfUseAssetModificationReduction",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction to right of use asset from lease modification",
        "label": "Operating Lease, Right-Of-Use Asset, Modification Reduction",
        "documentation": "Operating Lease, Right-Of-Use Asset, Modification Reduction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r75",
      "r76",
      "r88"
     ]
    },
    "sgmo_OtherCollaborationAndLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "OtherCollaborationAndLicenseAgreementsMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Collaboration And License Agreements",
        "label": "Other Collaboration And License Agreements [Member]",
        "documentation": "Other Collaboration And License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net pension (loss) gain",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r13",
      "r65",
      "r66",
      "r89"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r13",
      "r89"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r6",
      "r420",
      "r427"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on marketable securities, net of tax",
        "verboseLabel": "Net unrealized (loss) gain on marketable securities, net of tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r235"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "sgmo_OtherLicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "OtherLicensingAgreementsMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other license agreements",
        "label": "Other Licensing Agreements [Member]",
        "documentation": "Other Licensing Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non-cash adjustments",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash payments",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r748"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Taxes paid related to net share settlement of equity awards",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "sgmo_PfizerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "PfizerMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pfizer Inc.",
        "label": "Pfizer [Member]",
        "documentation": "Pfizer."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_PfizerSB525Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "PfizerSB525Member",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pfizer SB-525",
        "label": "Pfizer SB-525 [Member]",
        "documentation": "Pfizer SB-525 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_PreFundedCommonStockWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "PreFundedCommonStockWarrantMember",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails",
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrants",
        "label": "Pre Funded Common Stock Warrant [Member]",
        "documentation": "Pre Funded Common Stock Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r516",
      "r696"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Direct offering",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from at-the-market offering, net of offering expenses",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock, net of offering expenses",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of marketable securities",
        "label": "Proceeds from Maturities, Prepayments and Calls of Held-to-Maturity Securities",
        "documentation": "The cash inflow associated with the maturity, prepayments and calls (requests for early payments) of debt securities designated as held-to-maturity."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r769"
     ]
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of marketable securities",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r140",
      "r202",
      "r234"
     ]
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of assets classified as held for sale",
        "label": "Proceeds from Sale of Productive Assets",
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r196",
      "r475",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r655",
      "r674",
      "r706",
      "r707",
      "r708",
      "r710",
      "r712",
      "r785",
      "r786",
      "r790",
      "r819",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r848",
      "r849"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r196",
      "r475",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r655",
      "r674",
      "r706",
      "r707",
      "r708",
      "r710",
      "r712",
      "r785",
      "r786",
      "r790",
      "r819",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r848",
      "r849"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r435"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value of equipment, furniture and fixtures",
        "label": "Property, Plant, and Equipment, Fair Value Disclosure",
        "documentation": "Fair value portion of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r683",
      "r796",
      "r797",
      "r801"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r435",
      "r512",
      "r521",
      "r696"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r435"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r320",
      "r327",
      "r357",
      "r358",
      "r359",
      "r366",
      "r402",
      "r447",
      "r456",
      "r473",
      "r537",
      "r539",
      "r547",
      "r570",
      "r571",
      "r624",
      "r626",
      "r628",
      "r629",
      "r631",
      "r651",
      "r652",
      "r668",
      "r673",
      "r679",
      "r688",
      "r689",
      "r693",
      "r694",
      "r707",
      "r715",
      "r782",
      "r789",
      "r799",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r320",
      "r327",
      "r357",
      "r358",
      "r359",
      "r366",
      "r402",
      "r447",
      "r456",
      "r473",
      "r537",
      "r539",
      "r547",
      "r570",
      "r571",
      "r624",
      "r626",
      "r628",
      "r629",
      "r631",
      "r651",
      "r652",
      "r668",
      "r673",
      "r679",
      "r688",
      "r689",
      "r693",
      "r694",
      "r707",
      "r715",
      "r782",
      "r789",
      "r799",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r284",
      "r291",
      "r437",
      "r457",
      "r513",
      "r659",
      "r660"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r793"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues under agreement",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r793"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r793"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r653",
      "r666",
      "r815"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails",
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current restricted cash",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r103",
      "r143"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r743",
      "r751"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RESTRUCTURING CHARGES",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r259",
      "r262",
      "r267"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring expected cost",
        "label": "Restructuring and Related Cost, Expected Cost",
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r261",
      "r264",
      "r266"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostExpectedCostRemaining1",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected cost remaining",
        "label": "Restructuring and Related Cost, Expected Cost Remaining",
        "documentation": "Amount of expected cost remaining for the specified restructuring cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring costs incurred",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r261",
      "r264",
      "r266"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employees eliminated in restructuring",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of positions eliminated in restructuring",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails",
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restructuring charges",
        "terseLabel": "Restructuring charges",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r263",
      "r264",
      "r783"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r261",
      "r264",
      "r265",
      "r266"
     ]
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at December 31, 2023",
        "periodEndLabel": "Balance at September 30, 2024",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r265"
     ]
    },
    "us-gaap_RestructuringReserveRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveRollForward",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESAccruedRestructuringCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Reserve [Roll Forward]",
        "label": "Restructuring Reserve [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r87",
      "r519",
      "r544",
      "r546",
      "r554",
      "r581",
      "r696"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r148",
      "r149",
      "r150",
      "r152",
      "r157",
      "r159",
      "r161",
      "r237",
      "r238",
      "r253",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r386",
      "r388",
      "r389",
      "r391",
      "r394",
      "r430",
      "r431",
      "r541",
      "r543",
      "r555",
      "r851"
     ]
    },
    "sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer concentration risk",
        "label": "Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk [Member]",
        "documentation": "Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r184",
      "r189",
      "r190",
      "r193",
      "r195",
      "r196",
      "r197",
      "r199",
      "r317",
      "r318",
      "r475"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from contract with customer",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r733"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r654"
     ]
    },
    "sgmo_RevenueFromContractsWithCustomerNumberOfPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "RevenueFromContractsWithCustomerNumberOfPerformanceObligations",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of performance obligations",
        "label": "Revenue From Contracts With Customer, Number Of Performance Obligations",
        "documentation": "Revenue From Contracts With Customer, Number Of Performance Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining performance obligation amount",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "sgmo_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable consideration amount",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "verboseLabel": "Revenue related to agreements",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_RichmondCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "RichmondCaliforniaMember",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Richmond, California",
        "label": "Richmond, California [Member]",
        "documentation": "Richmond, California"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_RoyaltyObligationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "RoyaltyObligationTerm",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty obligation, term",
        "label": "Royalty Obligation, Term",
        "documentation": "Royalty Obligation, Term"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_SBFiveTwoFiveAndOtherProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "SBFiveTwoFiveAndOtherProductsMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "S B Five Two Five And Other Products",
        "label": "S B Five Two Five And Other Products [Member]",
        "documentation": "S B Five Two Five And Other Products"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_SBFiveTwoFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "SBFiveTwoFiveMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "S B Five Two Five",
        "label": "S B Five Two Five [Member]",
        "documentation": "S B Five Two Five"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_SaleOfStockAgentPlacementFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "SaleOfStockAgentPlacementFees",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net of placement fees",
        "label": "Sale Of Stock, Agent Placement Fees",
        "documentation": "Sale Of Stock, Agent Placement Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration received on transaction",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_SaleOfStockIncreaseToAggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "SaleOfStockIncreaseToAggregateOfferingPrice",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock offering program, increase to aggregate offering price",
        "label": "Sale Of Stock, Increase To Aggregate Offering Price",
        "documentation": "Sale Of Stock, Increase To Aggregate Offering Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_SaleOfStockNumberOfSharesIssuedInTransactionPerUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransactionPerUnit",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, number of shares issued in transaction, per unit (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction, Per Unit",
        "documentation": "Sale of Stock, Number of Shares Issued in Transaction, Per Unit"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_SaleOfStockOtherOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "SaleOfStockOtherOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from other offering expenses",
        "label": "Sale Of Stock, Other Offering Costs",
        "documentation": "Sale Of Stock, Other Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_SaleOfStockOutstandingAmountAvailable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "SaleOfStockOutstandingAmountAvailable",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock agreement",
        "label": "Sale Of Stock, Outstanding Amount Available",
        "documentation": "Sale Of Stock, Outstanding Amount Available"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_SaleOfStockPlacementFeePercentageOfGrossProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "SaleOfStockPlacementFeePercentageOfGrossProceeds",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash placement fees",
        "label": "Sale Of Stock, Placement Fee, Percentage Of Gross Proceeds",
        "documentation": "Sale Of Stock, Placement Fee, Percentage Of Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r328",
      "r758"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r328",
      "r731",
      "r758"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfChangeInAccountingEstimateTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfChangeInAccountingEstimateTable",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Change in Accounting Estimate [Table]",
        "label": "Change in Accounting Estimate [Table]",
        "documentation": "Disclosure of information about change in accounting estimate."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r156"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Basic and Diluted Net Income (Loss) per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]",
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about diluted earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r167",
      "r171",
      "r175"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTANDWRITEDOWNOFASSETSHELDFORSALEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Impaired Long-Lived Assets Held and Used [Table]",
        "label": "Impaired Long-Lived Asset, Held and Used [Table]",
        "documentation": "Disclosure of information about impairment of long-lived asset held and used. Includes, but is not limited to, description of impaired long-lived asset, facts and circumstances leading to impairment, amount of impairment loss, income statement caption that includes impairment loss, method of fair value determination, and segment in which impaired long-lived asset is reported."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "label": "Research and Development, Contract to Perform for Others [Table]",
        "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r793"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restrictions on Cash and Cash Equivalents",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r91",
      "r818"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r261",
      "r264",
      "r265",
      "r266"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Restructuring Costs",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r82",
      "r83"
     ]
    },
    "sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues",
        "label": "Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues [Table Text Block]",
        "documentation": "Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r332",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r567",
      "r568",
      "r569",
      "r625",
      "r627",
      "r630",
      "r632",
      "r639",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r656",
      "r675",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r709",
      "r715",
      "r790",
      "r819",
      "r821",
      "r822",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r848",
      "r849"
     ]
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r332",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock price (USD) (in dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r123",
      "r124",
      "r125",
      "r145",
      "r167",
      "r171",
      "r175",
      "r179",
      "r186",
      "r187",
      "r236",
      "r275",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r289",
      "r290",
      "r293",
      "r296",
      "r303",
      "r419",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r580",
      "r601",
      "r619",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r730",
      "r752",
      "r760"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r59",
      "r62",
      "r63",
      "r117",
      "r134",
      "r135",
      "r136",
      "r148",
      "r149",
      "r150",
      "r152",
      "r157",
      "r159",
      "r161",
      "r185",
      "r237",
      "r238",
      "r253",
      "r305",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r394",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r430",
      "r431",
      "r436",
      "r524",
      "r541",
      "r542",
      "r543",
      "r555",
      "r619"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r567",
      "r568",
      "r569",
      "r625",
      "r627",
      "r630",
      "r632",
      "r639",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r656",
      "r675",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r709",
      "r715",
      "r790",
      "r819",
      "r821",
      "r822",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r848",
      "r849"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r185",
      "r431",
      "r475",
      "r549",
      "r566",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r580",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r599",
      "r602",
      "r603",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r619",
      "r716"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r328",
      "r731",
      "r732",
      "r758"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r185",
      "r200",
      "r431",
      "r475",
      "r549",
      "r566",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r580",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r599",
      "r602",
      "r603",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r619",
      "r716"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of pre-funded warrants (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r40",
      "r59",
      "r62",
      "r87",
      "r286"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r58",
      "r59",
      "r87"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of offering expenses (in shares)",
        "verboseLabel": "Issuance of common stock (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r58",
      "r59",
      "r87",
      "r550",
      "r619",
      "r634"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r58",
      "r59",
      "r87"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of pre-funded warrants",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r59",
      "r62",
      "r63",
      "r87"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r58",
      "r59",
      "r87"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of offering expenses",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r58",
      "r59",
      "r87",
      "r555",
      "r619",
      "r634",
      "r722"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of stock options and vesting of restricted stock units, net of tax",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r58",
      "r59",
      "r87"
     ]
    },
    "sgmo_StockOfferingProgramMaximumValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "StockOfferingProgramMaximumValue",
     "crdr": "debit",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock offering program, maximum value",
        "label": "Stock Offering Program, Maximum Value",
        "documentation": "Stock Offering Program, Maximum Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r62",
      "r63",
      "r77",
      "r582",
      "r598",
      "r620",
      "r621",
      "r696",
      "r723",
      "r753",
      "r777",
      "r804",
      "r851"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r144",
      "r288",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r305",
      "r393",
      "r622",
      "r623",
      "r638"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r439"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r439"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESGenentechIncDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r439"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r440"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r767",
      "r806"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Domain]",
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r287",
      "r301",
      "r392",
      "r416",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r525",
      "r682",
      "r686",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r697",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r773",
      "r774",
      "r775",
      "r776",
      "r795",
      "r798",
      "r799",
      "r800",
      "r801",
      "r803"
     ]
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government-sponsored entity debt securities",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae)."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r817"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. treasury bills",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r676",
      "r678",
      "r682",
      "r817"
     ]
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "crdr": "debit",
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income allocated to participating securities",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r176",
      "r177"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r105",
      "r107",
      "r108",
      "r109"
     ]
    },
    "sgmo_WarrantOrRightOutstandingExercisablePeriodAfterIssuance": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "WarrantOrRightOutstandingExercisablePeriodAfterIssuance",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercisable, period after issuance",
        "label": "Warrant Or Right Outstanding, Exercisable, Period After Issuance",
        "documentation": "Warrant Or Right Outstanding, Exercisable, Period After Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "sgmo_WarrantOrRightPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.sangamo.com/20240930",
     "localname": "WarrantOrRightPolicyPolicyTextBlock",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to Purchase Shares of Company Stock",
        "label": "Warrant Or Right, Policy [Policy Text Block]",
        "documentation": "Warrant Or Right, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of warrants",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r798",
      "r799",
      "r800"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of shares outstanding - diluted (in shares)",
        "totalLabel": "Weighted average number of common shares outstanding - diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r179"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares used in computing basic net loss per share (in shares)",
        "verboseLabel": "Weighted average number of common shares outstanding - basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r179"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic:",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares used in computing net income (loss) per share",
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(j)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(k)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "420",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-14"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "65",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-65"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "66",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-66"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-5"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-21"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001628280-24-047102-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-047102-xbrl.zip
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MYZY^K55<[_E<;;?;Y^S7^%+K+3CSJ3'_:&I4GMV7<\N!*RF2\SSPB.,CM4@
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M-4+/ U!ES[G]'.O9%#<K1_PA* G\#[; >2$V7>I^\]UUZ.0[2!4-;D+'S$R
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M8D9;#AIF%UKS  4M:06XF.TUP$X/+'@BCTI1CYK*./3\$,-3@:O %6@T<HM
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M<!<^AM!<@ 9>@QX">R(LQX$71B9P9+X2@^O6N.Q2PF=?\$GZ*[&/PGB0Q Z
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M*;(NZ1N8%C'+T-9)$=R$HHW,%<FIO6K7*,TW%V6+JSV3K.3Q_RBNQRIX63
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M=)XQALYS+-Z!;#D#-*Y03D/L+,O+B-(>-=O&RI;Y]T*JJ4J&WQYMI9VK38B
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M*X_N2L6^)\6.#9IP>]W<7E+3#?L!WRZ\:/1LMKVPHOR=\FVJJ[:HA@XWTUP
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M);">\+G*_.09 .]SU'GVE2_-L]I/N,3RF08=>Q9SY5D6<79NTYCQG@5_F;P
MSZ-,!O.^L+^L%QVI@RZ^P_,WO+R"/Y6RMJZ\"K2B]%@"%H<492+G5_)H9'2:
M)&5BP1\W/]*H6SHK2L81 )R3+0#B6UFR<3 G6!+[!<3^/<N0H)N\V$4TQOX,
M1,F]Q7$[4G>^NI'&_<*G>4$&C=DS C>(R@CX[].J@&ELXAD1Q\ /%(KM3PF
M?0)@,0$,L@@JT>*=U0/ZG&A-[-$XPYJH"HF\%MY5!XNJ_)\6J"+@+G@X[H12
M?^'>.'/VDTZB0AHLS.2 B&^)5^TH2Y%,P#Y;:.*BFIF58DT26S/3J^<3S;Q3
M2GJV*MK!KU[!>L'_\D/WII74D1GLA&"5NJ&/6?HQ.D?$8)%VWI$#>!\+"#'P
MP"CP#2VP:*T@G)D^F!)ZL<P0C76F&OF15HRVOHS3[DTB?C@#\N)R(S7NJ1=O
MZIV>!>)'FBTJ+'+8NONR6+R?/+XDN50F4F[<+UHP23]4O38KP&06QG8E3^6T
M T_*R<J/Y%RFM5&16\9<0; ?C$2'VA'( 2\)DLI[CV60:ZD/0  M1"G'!ZL0
MM*V?E*489K "#?OB8BC>3I26<;"F%9=A<G%66Q:76DBF'S*/B*<G3IC"82XO
M:S#KNB;C,"_?-ND "P+H&3;"8KL<""R@K& IJCUD#_(PL&PNY"#Y<Y.]8YBK
M<>8.SK"6>U;L;;LX0/:"1$5C6K4D?\_<6Y*EI5''>XN_;>FQ<:XR+C&=3CSJ
MM!?E-PNV$:.;Z-]G^4;(F^]%#24V++,W*7;S[2.E^BY&D1/6";]R5>WZ='&(
MXK6SU0!W@_0Q@1RRF[ 4-=K1\ C/4F[XJ^.=#='I)/S<D.B(DN@0D6X,GZ[C
M8*1GQ4DC?YGFK-D)*GP_Q!4X)HD36E1V0DN-U1E;=KPO>N' ,ISD]"RR2U!(
M43]#^-]W5JRCUOA!+XQ,_O2,E-E6 $ZL&5$WG;UR.SV<I;OVB)7H?&6FDBFO
M$6,!452[3%2B,X^Y6Y0&DHKR-3:#_4VAPG?Z\)TJS+D;VV"7X@Q#&B40<!&)
M'_K>IHBN[;OEM==%7:.9%EFQ%VNZ=>?=;5FN@];1M./>[#P=BX$!WEI1_C&;
M&_B0YMS1>W%?O<CBFB*',1>S*-'VR_@8(1Z6G-]=DM+UDN^C65])]1I%B?@4
MIWP'*4,NS(RV9X +Z$4:Q978#I=5Q$U4^_.D/4L1X<:(_F3:X32*T[B\(/6=
M/5V<DP9A#@A&EA+,+IA.!?&G8SQL>+;ZP 398<*O$<?9I@C'36S*9ULLQAQ7
M7D(OO,\#7QF'\ @#(UR\G"+U&4RM4.*S?1>,L7/;H")#BV,FB:(H&<(,L+D>
MR6L%K\R@B8LI=AFQ'+8IBLV3+Z-^8G/)_ +*Q(A5F)LO $D3C 3W%8N%RI$K
MPD(Y?.\57XE1)T6GS/!]$C\IKQKG*4P_9.*^A<LJ"(Z>$OHCVN7E+ZS2D;95
M4FOBHS)+7N+"=PV]$,_"J$!*W<QT5Q]_0# 91R5BR(NIW0TP]K ;?]\U6=G@
M?(/ Y*M8O#8MN1=KL<1,4&E@A(0K3Q;M=K"%=<*\0F<!V!(KX(5AL!I1Y7;6
ML+6\,#)>=<2 P+H2,*CSZ#>@?8RAH3BRC$&@60H3MS%&C_ 7SF.+&QWSS0+Q
M#@/<2\-]7%P>V?8FI-L2)>9:=23;=\>!3W^(@T;-R;=2QE9MI%266B]'^0)
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MP/[O/9:CF788W*^WX1G#+^.6NBPY=/$ASB],>VOF[.O^/8BL>/PCT9%%!G[
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M1.RFA_WGD7MQRZC\1-YF+'B,.'#)J1['DN]<)PH*\ C!MG*%"5^]W-2J@EB
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MSNN&S'\*"*7UBC9#*-5PHU];E7T$#E@)R,I.2*1U$_ZAS'?NJ%Z_S6CY07'
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M]0-6LL%/]+487\N*0^46_0^6\49$[3K\=%4N*2F"H.*N+$T65!X7.M85YZY
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M FQW>S(S@#4SLR@EP,0$V,<LRLP ULK,II0 $Q-@'[,I,P-8.S.K,LN*H_,
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M %:*627$MN78FE[J-/5R7=_EX%T)("G?,J=1 %]A-U51%T=5''K7QF$=  :
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MJG*W1KO+#AAS> E\HPNT[5J_NW-)F IZSXZ!@ZM#9V,X=1; ^6@]>J^<_ Y
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M.>PV\"+?Y,?JWP E.[$RGSS_E] 3T B*\.212SB>^W *+&"J3!Q*LIKYWK]
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M9$GE.,E* CH,2QE\XMX9@E6]*@ISH(\A$)?$^>\9""WA.5(_4#T2M$C56WC
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MU018-C=@IB-K]/L)E2]T I)HIUX1Q40#F%<T20!]'X&HBF8&(:@(J8+[8E6
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MZF+,50)98TV0L"?K.0$T@<0X+ K7(HM&\12$:5J;9!*6._1<0#H !J@X1I8
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M=]:&C057Y$@)17H1UP6:ERT;^NNDO"A+J+CR'R/_PP6RY@T:8;Y&0/SI>T%
M0/CI@D7@Q##Y$Q23Y95TWBA0OL+W*XI7OFZH7 4A^74$*##ZQ"C\E &'=HWK
MF((&W%$\I0&G :<!=Q1/:<!IP&G '<53&G :<!IP1_&4!IP&G ;<43RE :<!
M5RG '=-5\6)WK@J1,A4=W<"MO2[W/Y_:G\[N7^,,?UX%.;VXRBRNI.)C52"9
M%<W,-@G_/*_.B7[_\.^76<RZ\@7S+A?2:,YW8?DOS9OT^_MAO\=1E_T;J&ES
ME<L^ADUM7LIFT]8%U=KPYG=JB_;W2B[&-IMK^LHAA\/$VH4$S?#2\/TY0(,2
M%K:^Y-XOJ41%11I\:,IX0Y01)RP7D(5I1M/(P90>RGA*DITP^>L3!RKA]\;O
M;2Z5#RK5J433BJ:5O=,*Y@0^AU9ZKZX]F::5-T0KJS6N$DH+]9H5TKK>E)O@
M^77UU[D-7W4UWF9S33OBO1@GO?W4SZM@?2V-@<_&P(,: ;WVGBI+:9Q\\SCY
M;&5[7]7.-$Z^)IS<OU+;/0II_:;:2'TKND?^O-#8QMT+7BK^J5>VUY6]J=;(
M/^MW=?;@P7I<K'ER&LP\-P#);#$LF1;.@<..PA6])K:14Z];&NW4D"U38&19
M3Y<AUGD:.H[W9+@FOGD)YV2'J$X]LQ%1[PPD6:O6[O2JT##RP&K3FT;'101<
M0,]-[<D\1O4 HYH#C4X:G39!IV>;@N4U]].H=ERH=M!.?;T!"<CN65E]B2IC
MT55>,[WTIE/NF[;AL)DQP[*QNRFAF\8OCYIVVD>HA/8;Z$[IM[I5B!&6:99J
M;'P9';2/06>-3)5'IG>5P*8%%32/3:V3BV8.F]YK1*H.(AU01I:L7_;;0O;M
MK%Y6+3_F"-1+U0Y!>S@W))R=6JB_E'+9 >Y=:P^T1^J-8>/>E,ONR44EG $:
MF:J/3,]U;_;/M'OSC:+:8=7/'DK'3F-GUXOV;CZG"L$I[HE;VK.Y =FLZ:9:
M3>63[IRVSRIQ^T'[$ Z'C7M3/@<G%SM;,AJ9W@8R/5?Y'+RZ.XT:U4J1HB4K
MGP.Z&]CN[9Q[IGV?STGZ#(%/!)$_9R/;<;37<RG)G!VAXCEHG5QT:UWM]7QK
MV%B2XKFYKE#Z-4&-:I4)N.\)U]8%W >=(@_[Y@%WC4C'Q;,.JW1VA61L5X%=
MO2F/)_9)ML>PE)!3=U>+4S]W[?%<1C:]8U0\SS"@T*A&/HOV'!P.&_?E\1ST
M@%]K9-+(M%>/9WFWB32J'1>J'5;Y')!T;.?3B:OG\7SYYAU5?4J7D=O&M'V;
MQ6F.,%6VVVB<7+3!-C[K5+NNC:ZN]/((O"=UO]O F&!G9_FH$;"2"+B5__DP
M*;EY#&R=7.0CTEM[GS7J50OU#B:\RS49NHTV">7>X&T4FZNX(LS,A>9+S' M
MV<!FH?;<MK:</)>1%X;>]+P-\+>\"(=46]N!%JL%R:U+LI<%FM?-GN)2K.D:
MK*ZUR)]2G"MM9CR7/76 /?5KC5Y9]^U+.NN7\+EI"M<47BT*W];XZI9B?&E*
MUI3\FBFY#"MV5U)>:\6>[6;%:AK6-/R::?@E2/BY*G:/5.QVHZR<FI<B:G(1
M?" [^8*V@F"VW<B@O?SQP;(?U;G<1%,X5W,QF+OHB;EV'WD08MWJX-(Q@L >
MV]SZ-+^$MQ!$D>%\,T*$_ORS$0*GA)GO8;A/CF?^2N#;/V$<H#Z#@4,_XH <
ML!(%1;#M'VQ7P**EJ-QV+9CSO'T&W.;@^-LB;\2$L[%A^^P16QE@.EVA$X*-
MY@1#"0UX2("#/7&?,R, 5,0(4L#>V2X+)UX$:[*"]W'=?#F>1"B!%K!%QY@%
M_%Q]^*@"I+9+"Z67/DK 22S#&.<B5B DQ<\?GVPKG"!IUAN"/*4G2<XL?Z[#
M3Q_RW_?/ZF?]7N%/C7KS/[8*_RY[>^'[;K._;KZ-EMYLU-N#[LJAUCC6-JR+
MOUFD>\/!5OCL3([NSL6C%J=<-JGT%RBE5\CI/W.33T?<9^UF[8^1_^&BU6BU
M,RSS3<7S!4-T'Q@0/. "FW/#9Y[/'!XLOP.V+1YM%8]XML/ZV:K8?M"Q=&UL
MZ_VO%<0ONO$]QOX2'0MC,U+FPU__M,.)[=ZZ_'\ R^/&/ULK8)BUU:CUNV55
M2=GX1#=7L>3)OKVN/Y*;&9@-DS"T< );?)BPL?THOMDG;WO1-,RW1M*4]@04
M?2].^ L<,!)W\&SJ;F+UZ4YMT-GY1M!.29D[$/ QJR.KTPNKH'<\PTQ^U3ZB
M\J'SNMU$+Y(UTFSN)VNDA./>T6U$3J(/&2_1,G_-677<-3^DVYX]&+8KDD8<
M+PCP(B3Z73@+X #I5J2=N+2$DV:KVPYI%&PL8B"&_S!N<.LBQMV.4]ZSM7=E
M&@EJM;8CB^XAUM0^N7"]'*KGO@C1 08G:#C,$GHCPAZ41<[I3%PX.#:%Y4\"
MQ@%I+';'9R&Y#P39M!LUUFJT.G5V/\'#V?J$,E>AKV^^/!<>@(@F\H$G(+N
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M#K'$4-_*A+TS)]R*,#MBT9@ERARZEJ2!)1?0VHT-+Z!5R)A$OS1:B9Y+>1B
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MO2APP$ZSIK9K!V+Z!VJ,98*99H%%Z7(2_J'/C9"9W \-,"]='OF>Q7%=@CJ
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MR=(2]D@B@("A UOD(/T7IS,<A\4#2(5!2&ZI@'@@:FWDD\)V@J'A$*(Q_"7
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M)501<VFV047/RT'S6DBZO?_@^J!_&#*ZHNR*LE\39>\U&V"P]6R ?5'U"A^
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MI+$4#XR@C8KY&:G&Y^2)ESI0>BK(2. UWB$%RM;RFPT..5GAW+6_(_I\F5I
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M?G/6:=3*:E %B P+L8J)$%$/" E,* ,A-K0]V%#$"8OXG4)H! Q^ '#S1TR
M2ASC+UW'&CJN$RVV!\'P?N:_NYQ,;'C'@WU%NP2S[BLLCBT>O1&L1[3W56[R
MROLH]@3/_2IVY-CA.>D'&T.S\^:L6RMS\R3XYNETI1,L4^0+X-@-<R'O_E?;
M"NUGDED73MVIE?7+D3@T7D_,9'2D]1399F^7TI/>^(Z$U6@=]0?EWPP>FX;B
MD$K--:2&N\XA#U-% '%D9X[WF22DN,!V2D\@);#W/C0^^%8P1CS^Z(!TB?P
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MBXEJQKFJ(Y%!AP365@Q*;T!Z3&H55)X"ZU$*0ON[$PHLB"+N"34"*#F$)R&
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M)H[,Z+J1*J3(5LGD> (=CV*>H!OHIZ11W\G$)?929R:6RCFAJ*X^^L$W4/*
MZ^D^NS(82L<=V!XVCOQDRT(,3F7K'%>4:<Z@/H[B$+5AF<A#O0CM>R B6,%G
M+9.Y5MF2>+S8C1*/EXW.8C%5/)?T6<JV;3$T+,^STTW:UJ5F= _(R-@7H6V&
MEV)K6"*3Y]K8[*]1X$P/?)>GK./I,+8H1VB!588V4^J S9;R$/(,K]0/DNO<
M$*AP8S3?EZ6?C_.UL*PAM,$H($L\/=N;W#(2I*<!@X01P,1WN3%+DL3XQFPL
M@9XASVT378=8#J=Z#UE@7HW#M'V.0@Q?,1,CQ:G@ HQ\U^6];^@2ZM27N_J6
MW#J6MH[$WXV-'43]-V=%2?%IUY>C^B^A?\25]0P2X-JU4!HJ3Z6?DV6G+LH$
M>>_9$T=<F7Q-FEF :1[<VTD H Q?EB0G%T)W51)3ZN47O(D-,GS;FPXL[JQ*
M_'GFACK%U0)Y6B^ZUF6 9P>#H,Z"N;8;IB$?U"UV&H=VB\T]W>+RZ<2M6JK0
M2;[E.=4.G9+"G_4!N9K5P1IKL#J0!QM#<[Q9A8R:2@TJE!I%O2&\VB\ +YPD
M42L;X:)$0RCD*\ONH&18D9K@B9]O>-85E3!;.2L6&-2:FYWUOK2SM3KM%H:4
MKE"<I".78\U2*5*8"WJ1C6[K@'+>YJZ-&2!I>[ILZ/@1FEK7_H,JF3QZ:TL=
MIO'R]M820*YI<EGC!U((*3ZDC*P(X]%,FKP^I7-X=@PVAW^_."7[#-X(I.7/
MX'E,5ALA2Q7TP\2P9'>[MLXZW:5E#ULSSCHXT*";9TALG.DVS1/.T-O)&>3.
MT:RL%^238R"*K3BYLQ5](LH/T'^A2T#C*)\60-L).(,I?11;O0UIT#-DV(<N
M;"US>M.TH$YQ6M#S0,$Q.9$^5)0LU,'NVTMRA99Z DSIDF%!>D"V/6\[S4Z5
M,D@IHXG!3ZD$SU)Y!]NR^'/:3!>LO_Z22O?-.S9TM^:>R&\6K*[!DLV:6_ X
MF,:'P F'EH?1^9'C<FC=#^U3/XXD*B7(MIYO8HD42KN*5+[(AC!O/$7OS<,7
M6X\6I  9I18/V3+^JC-*CC;QXR":&O^-K2#B3 QN&X 04$J_EC6AH/$\WP&;
ML!A&0NH+')D_4Z 'B_,\&7>6<:!UL&&I]IWUB-RE=#PD'<Z178G @B6I=88+
M."B@U#AS-1U36)P$P'E@/SA^'&(Y0(:YZ6^*IDZ0?5'99GWA $W>]\0TN6Y)
MFY@-F<Y7BBG"(QL[1[LMC&NNR(!\ C/=Q-FQDW.UT=I==2[XOS603G3-H0+[
M0G0[?JOR$S.+(S<G.2.^J%Q>=3;ZX(,NA/?&F<M8T$X:SH/H#U0$",E,,/#!
MME>9Y04/;*[J=]LOH^IW.Z"%%*2(J5@8GWT+&GMW>:W,CC3V+M7,K]+8[UU_
M"/_2@G;G(3L8X%[3_H<IUFY0ABJQ>(>$;8GOSU*9!@DDV0A0849*OPU)2(R=
M$.TFUM_QO?P#H<);86@+RP#^B%RI0L#G_LBAO;B.-41NI4*Y6D\N +H/&L,W
M_%F1P8&G^&_LH#\;Q-XGC$!.#==Z5'XV/+/JGP:8 "R$DJN2Q@_&$%@ <^:D
MVTBHK)XX8#?-$J5B#]9(=Q,GZX8*?@_][@6T]70!NJ(NXCF;I7AHOMOO=JT1
MZ4!0%$3)O4\S0XJ8<CY4_50;I+<=&P3]!4^U0<0!@R<:'^&VHI5;N?GEW@Q\
MAU*UPFD<C?U'@1A%]L['['E2Q_AK# >3FT\S;\2&>X^:SVZ(#R6MG]:@O"MQ
M"_CWI@HK-I9NKB[0"97!J>.0!1#S8@"KM,94YQ\D(:G&6B)Y8ZC%1;%D U5=
MU&O)'2WN46*F:B6SCZC0\LLOP>$L&EBC*8402)0R4++DIPGY,CAR/L=34>KI
M?K!GH50#46I5Q,]B]4?&2P DJZ\WW%[4K]2V9C:BN3R?;6SWMN/ATXW2/,RI
M&JT@J/%D3:"WB8_LJ;LF+T!!GZFDZUPJ3:#02M+MY$*AM<3U4_A"TB:U2&_:
M[\4*81@/,8DZ F$!"F':GU.^C5O;9B+ +O?\5Y?_189BXWUZ\L%+V^@EK9T!
M;$Z@N-$_L5#J]"-*3SC7.=L,?['=L?$)>#YUP]OQ_I?NECJ^)SM.U8/ETDX*
M%;RJ=&E)Z5*_*EVJ2I<.Z1!/+%T2-0^;#2M!C2[&$O(ELB_,UWGTVMF*CL/W
M:MZ1%'-=_Y%$+&$*^GA \,U@QPMR.XY& 5:VEB50F<LC-R!+"L6OM,*5YB_*
MNX5B)A;5/%&&[Q7Z7$OTP@^62ZO>3K$B>/D@BA/2-_T80#D.W[Y;MYH?+HU!
MIC@^31Y"1Y8U#^UW\H_WZ)!SK<4[QZ,KH!^]%^\28@)98W:2,.((?YUPS5J=
M.:<8:BQ6%E_7X*N?\Y_W>[5VO5/X5;W6*/R\[%6->JTU6/ZJ%3.7EP[NSC]6
M,)Z,1>/+C.'JKZHMH]NX1@_(9[8>+XM3?MNI.5=;FDM]N+.H)?5947["RQ,G
M?OWHP^Q^J%EUZ>SLW*RZE"B!_["#AXTGT_4P8[EA]EIYQ_JS)M/M</#<)AQC
M0O\K7+?1.O!)]H6:0O8Z%!2:FT&AD$L<-[6LF-JZ-,:@$43WS5FW_FQJ6()X
M.T7X8A%Y' A_H?N>GH3H!:<_$D0_V2*F?Q$@_.0'*:3?6#90"K;9+>@.^W93
ML;!C0I"V!>S1+E>GLT]M29P<+D5I"N@*77P-7O;TF;.O6C_=,G0.FTUMPJ5:
M+Z"]8B=?L]O9EKC>TB5N<:9R=H+R03O2;BWOWIKY-%N2,J3T*"-%EE1L$T/F
MPO=%O?ZH2T-$X27 H=F<0Q>^3/_%.QC'-)?2?DBZYM$0RQ&N824)9H8_X?RZ
M))4+O6KFZOSJ$B_=%GL#]3N'WANH\;39UO$PM/\;P\U<TO44.(8'^68\O4'!
M+.O?/MQ>_OVWR^L[X_(?\,_2YC\ESFY^9\%*S3T11>)'S>'-4J^]V/(1)CI3
MMV"<+ O4>FV%8^N_JO/W9]&A4S11G[L.]T/%:3H?@)52MS"@/LJ=1"7VR!*D
M!0<LGH2+$Q\B 9M =H85 /J%4V;%K%59-E,$/ ,'RW*&J*4R2+%,4*2Z#N,0
MMA52I.!F%/G$[+I:OTY,N57T04L%UC@UX6XQ&_JNK.&]_>7S34U4ZQI<-UNX
M+:X6YK25=,8 O1/8!2;^>'8@V[6G3WYK8]ZK>!FGL+G8 7LL:G8Q]C'#F<O4
MVU3V74KZT 8)SC!Z49X"]\L52VFW$LPQ%&<;]R . D\D!B8O.+8.^^<IZ<?Y
M5@+13$-*942_>VR=)QJT)ED_C7[]= RB%+Y5:8<D0GF"AXAYL>.Z0U_($)2@
MWX\ 2Y/KMS%EF6&OD38^/G1$]UH=TI@QACI?-)793@EFNF)N3NIFX70";WX5
M7W^-03?HM#OU$^OM2>-MJOZ\D*4D7?KOEFZX\,>$6MA\WYDL1.)?=K\B0E=(
M):R$8+K7+)YI($G-'5G*1(@&AF32N;8%?_\!1UEP%V+Y461[E R"I?V422Y9
MPABG,&CIJP4XH$&"$8$&#"JUJ2,3 "56)1WM8?$(,X!4#WMY0W\G<(GFPR'F
MJDTF$DT%E'B2I. D. *=U#NYQI3RZ>^YI>/:5U4EMRQ+;AF4)[>LK\X.VDJ=
MK3)B]K^7*B,FB]#E1M;[%&+UFAEA?MK;GR%V=7?YF?T71K,F4R:S__Q\?GW^
MR^5GL)"$G+@U/E[=7OQV>WMU<VV<7W^$_S__]7]OKVZ-FT_&IZOK\^N+J_-?
MC8N;ZX]7=_*9KY>WO_UZ1X_<?+G\>HY?W!Z9\H,JZ=@)1W$8BF8T0OI_MCQ@
M15+DDRC]F#R'@OP<)-\B=$BM^*142<RE<2+YS%=2JS)YU5(?%C,*4*^W,9-;
MO,]4B=1Z\PF0T=@EXM3U?2X<2Y*V1=H/*0>V)57Y6YN<6:+15^]<"DUM$/'Y
MB%42\2AH:9?RJ4LYH0">H:Q@:EQ:N@61@F2J<@4:7B7G%R3/B2-+%8(FCTF(
MH\H_<N;4E$2"2'PUM%W'?LA_+O6G@B]B=YS]4($U]P4G.F<_=I ]C',?SZQ%
M]J.Y"RB8_3"T[6_Y#Z=%.\.J#_59<N<,'NP@ M!T+<K7!757ZM >CDA %8WN
MS ]586" KC+0Z$/.XK^-1]-EEX>:HYPQ 6KX-P]3EG$7L<=_!TX()X'_%)83
M(D\)EEI<LJL<;#P'Q$<GVRB*+5F?R[,UR%]+[57QZRE>L2A6XB$<H*T&B^07
MG% N2X_ /!L[.)>&JFA0;<2<]4D<Q30>9?4J$DCL*G10,>2*RW YO&I($]I1
M#$(VL1E]>T*7Q8M)62HKWI]S1PZ!GM#/*0?"17YJJO=7N!WC$P->XM#8#D>!
M,^1JH"\6X,R5:5S! D;CG&[CW//P"%]M1B@/<]+AR_KIWU11'T[P$Y4\,@%)
M)/TUM/:!N-N)XPH_:9;#(&8H5H(]V!WFG[ZJ!6\E[VHKZY!>G-JBB>N$\7S.
M%4*V&FM'N*F=EST12T"C *)#! D(./G?N0X![BX/F+_7C/_U8SGVACS4H*:.
M11F#3  =IV6$Y.D&F8G>?X"$B-,2K/ >2E(O$WFB%>?0"_5Z'D *.]T.L/@4
MR:"5)RXA6_CI2^'N\_=4X/Q8TQKHK7!N+U7?=ZI2W3Q@ R=XUY'I-O^TB;5;
MI9WLR#G@1)'RY'FAJ+L3 2XRQ(@[C1SJ@TW-\N1K!)M7_?0(QUP02"2S0) [
M"J?H?,00)A/7&<FP"K;&PLXOJOL>1K>0AK!1.C!:.($0_81NOP/^H=?N'LM7
MYPZ6P8'*@-9]#/NF5A'84G9L$_L-8\$MC;F/>CXS95#< _)FV \6\EQ"<MG[
M#Y>F()V0:3%&GN:A@R,WX8)M,:89%J/SHFMA;,]\CYL+BD'%0RZ=Q6C3]SFW
M(4"@@"0;V@ML3I+$JZP'"^0ZI8QC,3;\G,XOG^>U4QW&I*/+QN==V'GP@/ +
M%R&0,/'/B^M;ZO0&LFT$.$$0#2/XM;V>9W)_=':A/*N_S9%'A4_IVK);>MNP
M(NPR0=*OC*12,%PP6GV45_VK,Z*R7#7AD^GC%QNGNMFCZ9&Q'AS4$-^CM[$I
M?7Z/MD$^*Y(>5!(M.GWD*5D"2=">H@=7 ,E*QJ *A4'!21^1FH:@29-C32S%
MMN6\-OSI5W^$+P"&-Z?7:3_ N;K<0H3I\P'X*+6IDD6W=)HL=^4A;, YDT@#
M,9BQS76[I+(G/.XW%3HI/H2M^]WM[\ (0GR!A 6LE?P.53=D6O/ GP>.'6']
MB<XT YLT7N"4=-3_^_05U6HY0FY,'7>$,+!BT;=5=%0"<< 36G#@G>*7$4;A
M(V+4I!&MOU4<OI?>J<GOC> 3@*8%*.R?:F'X!R>(0X$2IG%[=WYQ^N'#!Y/.
MC#:&5#\#:XZ")GL8/Y"!,7&@_"&2FT@U6"F[%C&'$5O:AC@B3GCTJ<"5,@(,
M_)$GUI!A3<)K@18ZBT[ZTW#\*ED5-#K0VK"=2G8Q;&>D7J UNS$3D8B]T>$T
MG-@"K\Z4S\-"@@I1%< I2,#9?E?]DM@((9D'^!N/T/@Y,DZTFKQH$'EZXF;R
MJ&7\H5VOU56==3R'![Q(X?3$EE//_]#0GX-_@WWL>ZJO3P&KDJF6->!,*II"
M6Z+..JYS3S>-BH05X-)4F]ZH#8QA,A,CU>.((Y?B'I,]  +-R5:Q1C0V>8:7
M"FB:*$;J?K5(;@&\V))PB.W-G/$I=DC"Y!K8*;D.PGAX&N%$+9'YQ%\$_L)R
M]?HS'-<;6B[KB60-R^5-W1&AYN/,[1'/%55=$-9690Y7-TCL+]E+RQ"U[<8O
MONC6 !#PCHS>/E"'+)_M0Z'IRF;@K#L#BK-B'4Z%E,?<KO_&S@.@A/!_E%<:
MHE0&;DWN,>EP(-)+-\W(T9]HKU).Z8[*>- =$D2)HDL#-7)!0Q_DC4%V$&8N
MP%%<!W8_1J4_'6[&>:VDZY"/P E '<HV)C1NX/=@M!.K)D_?O4?A3N0Q0*LH
M#I2?CR U@0V(6=])CW53.8?TO82PN1%<;6)P &2F[)= M6J.WAWRC/%U:::+
M/R32TV*\(EN"F[+@R%?ZB=;F7?#1I/7Y+.]"Q\YI89C<!SD62,(E21_$/(#5
M#-&/G-F6=/BRC^R>Z&3$=)*)8A.;^1X9C:9L2J-"RVA;B"N1))AW92]SI]"6
M<7PL7U_1_A"$G--2M%4G5-"/>#IPYIPTSSX%%.TFQ*SFLGN@MG3QG/U7<;!D
M' :L;SV0,I@8F&@N!_X]V<BLH&DZ"E*K_ ]ZRIH1N:;<C<6.(=%ZKABD->/<
MQ;C!_31%H<7BDO4C@M!8P>+!L<AIJ@;?L_Z7C$DG[U48.5$LH.AXV*(;G0:Y
M^9=9)YB:;.Q(MZ4R::A?$[S615L<NWLOOS($3S#F[+8U<87<)_EK)IV;2(Y&
M6)+ZB#HB1AVHI)R5@62)U!/FBHVF,$*TC=&>2H8I4('VT-=QCR,! OX,94E9
M4N4GQ#&-.2@)\ X?/P/N'ZF1T_#)V 8>H'B.*92(A<:&DK4$GR.08-!AB EI
MEM"=K(C;W'D@W_3=6/FT)U0T8D[;,#R+ @DXR0+V##\F_5L.Z/N=<DFP&9JR
M(G1"26B#.C3ET  WR=-'-1<0&KVC$4@]WKD,Y:!QYKJ@(T[0)@+Y 6!"?&!G
M%[XE>04<ET<+@NT!0AVV/+0HHJC>DR#M4.52"1OI6RJE1U@,/&]\K-A!(EX0
MW<N:WV/_IW)#X8?+EVG5JV8P5>K+(1WB::DO^[,JDO9W,U#O8IQ:378C!A^Q
M@QCYMN 1RGU0QD;2J9:]\-:"18E\DGC^")ZG,"OZMUA>TEO0O1*Q[K!4B](=
M-Z(/-44(239;*AZ,PXCL )0ZSL"6*K?*KL37@M@(.1,!EW]4PDSGTR.:(:NI
M>VC  _-<F((WDQH!_!T/8*!R)7PYI&%2$S+2#7Z&[U$3P$4C6Q9D2=O_M]IM
MS?A@>=^">!Z-%F"+CL7,E(4?T[;0$RC7F6,\%998X!J)C$U4%+@(P!-[S*\@
M\:.K)N)KA!];=A.'>BJC1C],-J'M-&G:/(3%V,>%?XASR@YV,H@3HG2;^BY&
M=@X_"&+#NZ16\477).ZD/]%9+S9R0&Z!&U*BE*[DS&U\!N]1CMM"W] C*NF>
M_\ JF(7SD@V2WS)>R)=9/,GKG7'BO$V1)G;T+0PN)&YB\M-S(^XED4B"_HF3
M?SWLU795<! =WX5N:Z+G\_-_F#*DQZ$%"FO0F;0-L;> <X\T7SOMASW5Y# <
MJY1HZ?1_! 1W%Z?^HY=RT2M=5!BV!JAO_MP".VQDA#.DX(F#X1#Z!7Z^X/2;
MVT_7&"R)%L0>C1%8 :#<)H_AN&K+\4S!N1"L EQ/\LTU6K7. 7GG$@HLCN%)
MNER7#%/J6"M+F*>-_MXHD_)BNKMNI;E,ITG!IM%F/)"B ^Q4D:)@>4*V./>6
ML#/0IAL'\3UA[-7U1U-VPY>=<I4L^^3[[/7Z"(\;YUK37'2YPZ\_?3SG6-+M
MW6FGWC*+EBO*.5#I4L1))%]PN+<ZJ8I();+^%*EJ[?J@"F<VQ)E;+7;@@K9F
MB='MY',"]$AAA\@?HWM'FYB4-G;U4B@C0J4&G_@R18VK\7.3TBC(2\LX(E60
MF3,>LTG )4Y:""/CUL.B&LS(T>WX?(UPA1%;PX@K3^M=H9QVY'<*N>LX!D31
M>3FGF3%#Q__Z'< ?.9&+ZJK((_Q"<3(Q\$..V!#!=*%>WUY<#\X1J31E ./K
MQ?PA)T63Q$V93L0&BA7Q6T8(3[FTRYHM1^_(+T6#3R,>.*!MZMIZ:-1Z1NB/
MG7B&-?.>9[M<9 F&$88<:",8/TA2&,&DY;">GI-DI3AF0@/$)T&S@6./?'8#
MX8:%IB*-+ 8.\LX*U7>%ZA?2^1BQN1E'4S\0L7Q.#+L#3F>C7Y2N*9F'D_(2
MBY&Y4JDLUI^%3IDDNJ3T/[!$:2+%O;2=64O6DU+T3 _$'I'I\V#!WC%6+G+0
M0RW/@VWK5+J=3!$'0%B$>T,7Q/SI,$").[0"6"V@H],+YGB.0 []A4UYTQAN
M O<^4Y-0K__R)44,6MY/A@8J3-ZAZH=,C-.\XSFG*\,_+<,2$IFPC6K2+WR/
M2@ H-S4I62=.'TY%4]ZIR'08+8HJ9)%=8:A3HJ\Q\V/Z)QAHN*+*EABCRP-1
MVQ6C$?"76L!6<>)QA@TS=<R^7I]+-T]D.Y[R8 1D1@%.L,7'RX=Q\( 1<5',
M+C+_*==<3JY&S<;_CA*$WF_=WV.=:X2!D'/EBT?'T*,.4,#PU<#4@8>!@Y1(
M*"0'&4/AO0!D3&G@DA%L:92LQXCGB61]=,:VR%-)B];DM<B*"&QH^#.DA0"K
MJ'%7U'B.@H/-,+X1J=#PE4A1X(1)GL2RP4@[TX\/W:% ,A!E73;U5WGU%A4.
M[TZBI/S-( #NB9$DS0TTOUY2P\.UE>1F2%+EDI W)@^PRX!9F\I%I;P\NMZ,
M#O&$W.$D^ZVX2.+ W=E2*]W$87;@I/S)&@+9?N0+J&AV=Z9[6IW#O%@/B,@;
M"4W(CZ.1/R/'"XY;&.'PSDGLZAG/28X@^7EPCJPCK%3R$.F)TFB./UHDA\[A
M7:[-1L8Y39_%!#CTBH=68+G(/;"*"O2SN14\ &<?D?$ )O&@6>?TQJSOD'[!
M;OY%L4^ T4KZT-?.LZX0:T/$NF-LH.HMJB09L_I_AY&.#RGL(>67E&65/.A[
MG)Z5> 6!^Y]_%;Y!=M,$W%Y+*$DT!83R<#A%4>)3$FTM1#?!,$TCICFTR7"U
M>Q>0/HBQ'GSBN%+]#JB+$I9^_X*Z=^AB6!MVWVD"X=C?0IG[C0&?I#0O9#<W
M)AN!!$*52^4P@3$RAY-&%2;N4BUA562<XE.4P(6Y!Q['005C"E.EC D>:9X[
MK2-%4A>20M]BM)7&'CKQ8N&X":V)';&CT9Z@@0O6,[Y+3_F"'8!5P'^)4=N
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MRLQ\N(']6S76-X=;:8Q2F<*B  F$7O*ESLC0[^./*QS:&0[]S5Z4,QJZ&CO
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MV#5U3!5=4ENU/F!H08_421QA@7;!MF@GN /9JCX-9DX+%2'2].1 "4G5]?3
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M=AP7=-9(:MCJ7C4O#\9F4L#_"A=J"9P%J2G$VS13]">@KX8A4)0USH!Y1QB
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M+L%P>E9MT/4%_A%7$E.2PEJQ< C2O:(ZSS$7V#S1_FJ_056/[#<U<&L"_^#
M,09(%*=>&;0%4+^/?PSU>[LC[O>/'0BSNZG@SLEN?48GAZ[:T\2<%LL<.'FQ
M::3CDVKW,.]%# JK7'<EUFB;/(<7/Q)7>F-"8S\65YHTK(M)%E3VHV_)E7#
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M(ZQ>V#*;I.]]F^3J7)6<S\\?I4+-ZG.YFB24JZ_[:5$SN1*S]='_P6TM;+L
MLZ?4,LYO/:<SD:5 />:F 04P&D61.S' J+^4IOO$H7NL=4Z2R@0+VD7E*4YF
M$KAK>L-T4G-577"'I+96VLN#N=UCWC\ZP ZV40W35<>I;.?6'=9DQ$8&&H];
ME8213IU[&0J]<56XW$]I=IL&$Q4*;+'@25A2]=%(+>%I[00=6MQ'-2N*6' Y
MY51-"S;S<%"$$S5=4C40%31$RS&*=FY!1;<&9YBRP*>IYW'QJ="U[2VGP_C>
MPF^E.IZV^)_+:&I0X;7"<&" FU/<KGU2NTEJ[^^3VO=)[8]I$;N6U#X)EXDD
M+!/_H6L2 8LMI)O.2 0.=9S$9#@1V/!_\Y@:,'6MBH4,BIK\H#2+<[#$;K@7
MMC02 CTJ!@FSY.9AQ+V+C,W @BJ*,!\E2Y*E-B'*VXR^A.F2"Y7!YPD_>;1R
M&Y6CKI&CW/+%=TU>@_@12>T*/I $C+FD(::IRZ(&?$8).!<<;-NT-HD_ =N?
M95GDA)BY&Y%NSG)O"M2=K'Q<-K4M$DT12^B,NJ/=N")60#>HROMTI?>/NQ=B
M(A?OE!T5M1EJBAD%TPRS(KEXEY0YR6HVT.+=X *7A?9PQ]%_*"6)X*1@O;J!
MG4-XVJ,<IY6VY:@X8&<,L?Y3*0G#E#*I*5YP^PK; 7:1)5C=Q@T/S#E8Q4IH
MJ%6K(D7LP)I-53T5+H73(E1#U^LK0]J1VZL*:TH98MPH08_;S#JU9W&N:?;4
MI5E;3W*I:7;';*WK>G##H<"[W58VIL94]HM]RTRP15=ZK@VT\.LT$QU>,16J
MBIMLA;ES]5?,F58"=>*_T+G;U/?H]%;-'+2KF7>()0SZ/^V5TQW5Z_[$RFG?
MQ+.^ZU5L%C\?AI?7P?DY*!+7OY]=!N?OWUQ<OAM>GU^\_^(0W^#H1PGQ!?W6
M&-_;L]^&;SFX=_;Z_/UO6T7W'I%,_D.97L:HI#/Z0[JR60<+2;=-U)0+;E!3
MY8:>;RBY ,--Z-TAW=.VZG(S?FOOPC<U3D9;&L.:KE7;TM_S'X?^AJT$B#D$
MP9OAZ?7%Y:[1WBN5D,N9*)#-+4I,15@33'0D71]]ZUD.!H!6%276B-Y T[%*
MTEPRZO78G-#R 4W0\TYPCG9J?ZCMD:;4G8OJ\%\VD'7[.OWB3)M0:_42C(>S
M7/)SFL;#*5X)+&W$3M+D*0TE  N[-EDFW,*7_-OL]_P&$R?4'G8.F);%)!K1
M'QU)=K'^&$_5PMEP(T;A'G)8C[@%W1V!GG2+[EE<P YCCBXUK!4[Q$7CJ6$A
MP1:,D2\B<H[!E[9X2EX++(93TM@MD0NGQ/7'V))1<><Y<@8\PIW=)'>D4R?O
MY(I+"'6+18TX[J?)UEM^W 6;C1MK_SPX?NX@7M*O^B>#!AQZ1J?BP70V8& 2
M ?%%^,>@VI);[BTMSC;&Y69WI<7YJ9+%+=K$TS!U6]7#G>V?G!P+WA6G'DML
M7CQ ,H1ID6I2_X'U3("F-?QWKNP%K?4TU^!=FVG,-*CGGG+I%/A2Q $50@O2
MV1[_@@'1])U2'^$\^-]OG%ZCJ^I%T(!4B'K5V.]><CF\VV5:DG)1D&W$[#;?
MA)W+@HA"2/I(G(.@;93&T54@QEIOV8X%P 8^2+CH]%);T:5&IK<=7W7CYUF\
MH*-%I','0L$O?))CMIO6"28J(M"T*3H6"-+,;@+U8I6VBO)/A#%@![%Y:I+!
M<J5).!ZE)0!WMYD8')G5".K6AN565+MGR]G4.G!7*O7=G3!=9EG,4:]KA;64
M2MH72Q-G:BAK4I[</"M]RA[)Z&()<Y#$@*7YO']AXH+Z$9!(Y2[O@B^'3A_+
MLC'G?Z(5F&6JFQ&:KUN<,]W:5NC*Z6>H>XD*F G[O=.HTOB6NL-'/V)O^#O*
M7_8AQH6'?!9ERU$I"M47HLG]L5V[;[?+MX=W2+B9 J*V[3>!>HU7'C]0&%,L
MO(&CM;TMJ1>[SG8;A47L=KOLN'TSW4M _8R=-4@9'C=>CW+*]/+ ^' #/'GK
M(LIEU*D&+Q RNCE0%\59=*=139;T"!&VV1H/69Y*IHFXS9.4X3:&YX'V.]Q-
MPB!+XBJ3DJ\]:?UM;-\"N&IQ<DL8,J)D&(54FK9*?I9NU6[RY751*C)&WF1[
M!]V]I=OERFI][SJRGW3F"5W/,"#/K\W=<]J>/,7KBT@Y\%$,4^!3%J3U8_<*
M4^#23PCK.%X%IUDD#='1&,!IH7*OOT-!-OC$BMW1ND+(("4R$CHEEHBD*QI%
MG>P<Q1L=H$GWONFN[J+>N\W@'R&+V4H1W4Z'9ZQ2QK1T_DJXD!/L -FHY=,'
MZ%ZSM(E\<>.D.5)*CT"9^LQ%.M2W(5%6\R$#FPKII[3]?-3K]GP=&DYWN0!M
MQK9S!V6#\FRGBBZU"?+]W*^]#/\+A):EV&F"("^-(<.](+2B9*$QX7,78)Z:
MH(PD;.;?#D&3T]1,TE$C!*C@0YGXC(Z>,+#F-Y<O%U_R&LHY!JC"-5/\O+&S
M]6844+-9SB91=X3E@BS^M;P5OQ_>5&&P,H/L4]/MB$#U#U:;P\44XSP>K2LQ
M,B"R8!<&?^<S@\/4OIES^0MG>EN]GBP2Y*0D6P3"UVQQ*.89\]KUV^5?&%;;
M%LL1W P.;<.-*TW7<XJ5 VT8A0[D6K8*D[4ZGNW/;:T#SXYP 8,C$"OCTJWX
MU'NG-[8;#!/)FW-O7=MMHKH!))O($,@--O'&+0537''2/'W4H(^365"48%7)
M7O%TT,54A1AGI5K2$BDQ-<S9)(%IOR/Z\BX\&>:7]M.O^=,7!@F=^HJITF*<
M8^X%E@-\)N3E9$4 _HY%C]$^.!5259AYCCF?!:Q5F(>4/R"+$X )Z184-:"M
MZ_8_8$8M'9 [>$-#W6VX>VXG^3M \3;<5SCF^O"H TB>@]49L]3KCLZ(#:8Y
M.EXAPG,?+Y,P-TC(6EYI'>7.O JG,D>5,R[9=1C%R*Y1?6AJY*Z-2!G=@_MT
ML9#M5(FE@X0"V4U49RRR\0S6I1ALQ\?_9NQL@M9WDV7>L++J&EC6>L,N5MB,
M*@7]PKUUE1YJI+6"FKB4A.*4$F?U"N#E!"WO!6;1P&?_1=V?*MATJL8C]S;!
MWB;X/C:!5GOWR2@F&>5PG_.\3RMY3(O8M9QG8.KP(<R?:W3CRY^1%[-9*4!@
MJ F,+$-SN%YLVF^,&%A%FFH(SSR5VA>=ZTM9TSOJA@"E; C*0B)-A-"GG*89
M!FTB5CO*?*FAFFR366TJA(X8CE/V%LL?_*")\Y"7M%C'@L(*6W1D@Q;E!!"R
M$DO>6)D_!:8-7TKCT"CS=@D(SVVG;%J#O,]NV#W1N$RK,*Q?;GVQ9@;>!ZJ3
M<+08Q_0BC#);ZXS6,@%@ZVJS0FL$+@2VT>,.Z&&8OEK$N%\E;1@A/L8,FVUC
M&</A/W0\ W0>D*,PD!,7(VTUNV'A37+>583]@NJ9"B/Q:!0=[8>[!!T'+#&X
M@/9L,!= O$P7V@#KNU6RHPP,:0+1)LL+;3K&;Q4;\A8NQP%6+M2U<]S^-YS7
MSB8_Y^3K&*5\&)_Z1YB,LC2%<Y+GI7"!L+<GOD4H3WAGI[/_UQ$9=>[2^0JF
MX+V<Q; \W_ES5(N!MGR6'EM#4E+3;Y(D9%63# FY^E%VN*!M4IW/<36(+ HF
MN6"ELQ('?70C;/$$NL%.,A(<HPB%QWS!!?LZ79XJ*2Q>J>3*>X8-6Q$^"E4G
M4"&0C4[Z<'>@('M2&P5FYHZSD\^9]AGCD4ZA)N>^M%D1U@52>0+]?85I7&VB
M<1$;0W&J/$/(JNM4A8#K-8:4L:+1,@,-??P)4[PEXL=3]KLEV8 ^&M@)V\(-
M!I,XH);<7!2H:EE\?>PN> ?3Q."O]7IY62CP:NR4VV"QC1><U@%HM[C%!,"E
M5-A98'3#P?!M?'O=X/?L5M'4X/-_7:9*&/PZ7.):"V>X:&CL%Z91M%8EMFKA
MC =&IABANH;L)$9*8P=([ C8(]<%0'Q%2"1&-2">K,CX;]F]VUFFBWK9^TF5
M5G(W#+L7)WBN!,"!BH-<HO?=?0577H=L?K\)1SFEKY%%J4'L<2>NKH>G!Z]>
MO1)9$:%?A*0X/,'=^R@R7E@2P9NXPHY]2DGJ!]U//"SX74>#2$^6Y*N*R*5#
M7,=Z%^;H7\=,CG5^)<-2B;$8,IH@G3N.:N/!W^ K,[O+^Z6I@!F"V67*%DUN
M.$M(WU2Z.Z8=159JERCEM>:*NI-E6O_QO*K\K6:_*FTFV:<JLJ$%ZV =&HIT
MZ<_"!&(A&QBYNC :%*I49_%X/@L?\+$671$'+LUFHZM7,V,Z;'<7-"/2@W+!
M&IDIS,_A&1(6'=-R;$-@W#T[EW4T-V38CN([3<D?NB7)^@O0T;%X2XDF;K\N
MRK9S9@.EG_#E:HK\;(Q?B,?;TR\Y4.R2,8G-QDZEACL1'_ZKHE_#VV_?GK)K
M&11'3GJJF6^FO9X;/K;8!1ACU@* /(HFZBR^-Y<BIXA=XYVK]#4%X8@7#"66
M JZ/4O9S.*=Z5PO>MSX <:L8E"$*0'%\_JS?.>D=<X_36O0#L9K4 =X)U)QT
MX /9F>ZO>MAYT3OI'(,BV3S"FOB).PPFFTRG& 0K2?8,7G2.G_<[1X,7K>.6
MU&0'MP.[Y'"/UNI#3XA"JBM@M[M:,I?()K^T3E(ZQ[XXLM^HZ(>DDFL,:60S
M*&D;4A!$'N.^T[_$9PN3FV#]*'(74C?8KF38AQPO1L%H23$:$YE60.P2R<.^
MS96IA?$*&\?SI7?'L25!$,:269$'#C V[L[457O8+*'@AG(YM31W1#T6,5]G
MIF":T$50>,@JY58V-5/R469%R$C6&\Y5A2RXC5UOY6G.^8,Z#Z"HM/YTPDT3
MC @3!N"V.UH-E%HONE:/L&V4 2RSH?DQ''5*5P#M'O,#51!+0(!LDI@#?I7P
M%84\9-BQ#GC8$"SG?50B&SA5!,@6=!!>AV=LX45!!DD/R!&Y8.<=(FYL+NN8
M#WJ6]0B;[7NG6HZ5J,^-OCWBG/I-GB[+#L)OW'"LJ0G-FB:"!AX5&Y4YUQOX
M6LZ)SZ"^8)F^.^X2E$*=%'P??<O^X'N!Y ;K1U9G(JDQETIS>UX#'&UBP=3?
MUQC[G\6WIXM!I"EN)H4%H)'96V"[#VNQ*#Q9#XH&(O"OG(*LHSASW%8L!F(Q
MV3GY-0G6QV"#$6RU_M3'-$;S_:HT'9Y &\S"J!:J;DQ^$?MJ71!>Z["NDFHB
M[";.)\Q(HH$8;89UC05E0[HIFU4Y2Q'D?&F]S+'4-&K8TC&00%Q6@)3T!K?N
MQ6V6)]%M'"E[6I@ISRGXAD8BTN_1\T,$-$:W*H-?:>;DEI?@,L40J07F#<=W
M;;V,TA^<) )*G@+;#D6+'<6$KJ41 >ZBMA#HPW9SG7;0=\\UT.:@\Z:;9U[Q
MJ1H$=GOS'R'3O&,B- M=8GJD,&3Y%"[AO]3&4+%3/N*ZU>LE(D1M9F#V@C"#
MHWP)QW$@06N;+)IF!%]*#F[D'%JY-YVJZ@J9GT)O!R?'EEY<<TH\M_$!(M%A
M=HFKLV.&(5.\,/LC//WUA9+WF1[Z7;,\R0VB?<$&QY6]HW.EJNWAO7Z=6R5U
M_N%7G^Q^XM\^0<,D:!SM$S3V"1J/:1&[EJ"Q-HE89X0]JBP.SO<6##@R%6.V
MRCC:-=E*VW&CZ&NTQI9NLQ6_<57L-JBB9KL:-%=;RV!<'NL*Z:OM@/P=UG :
MCN2""8%J-6494OQ:G9HLAD#B0(+.=:8\X<J7Y&'#0C:JQ785/T;9M3*SX^65
MF XYS=.3G T.16/:]<OJM,1\<,)#5HA6M 0R0A5K&\[GO)-RK3I:#SDN21RT
M'-A\ 3H"*T!*0^&[D'B"<HC2V\RLM@IS[O4LB0:0D]KKIB\!)[5R @F7"]/,
M_"@HE6/ 2'B;C!L1 _[92GG1<\_3V++S'>?C^&T.?W+'&*<)PAC='F,+Z^!5
MW+AH:;4P874_M2%9FX]D7\.$LI(5+B8>FMLGM;)+%)*45RFRZBR4359K_E+
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M>PZ"BZS%7EPG6M7D2,-3)H=7SO*VH4+,D%WF)QDTZ44X=>DH[_LX3"67AU<
M4GR,E56Q3@@J?9AV+\9HBYX$\]54!> T8S]SP2N8EZRJ'5-8Q46P6HC[RB]S
M\WH&Z%NDZ\JTGZC5G=5>A3/2Z<V"&*$?-T5;QDPJ.J[Z9^TD.P)#&9JP*Y>R
MBCGC.:0BQ^X?NJT\"^5\K]U?3?$T7:W40)<=6_NMS3&W,V"GJL<BP(J,5[D0
MYC+ _$?:V.RXK1-#[],"<%G8%X6Z5Y72$Z^LR.0JZW*A<25P) %A^QW-<R33
M6:/X50\==[[AT"G0RB;W1GB'VJ<K>KFVD,W*K5_!_,HFCWC)-7R-+?K*!L_%
MLF H%)W-1FX)KKQQ> BV(%*W#L@$A[\G@OG!M-@@*.D)FPO?2/\PH%03M>R8
M"!L70\-ET>28PVK9:F9@F'/=OV.9-K@GM O .Q!_ ERTQ,2#7=W%R\U-%RJT
MC;^EGO;5#:D2#$/^.RX#H3+%S9 ,8A&R(8Z6D/I"J"CJAL&OFDOX8H=+\+XV
M<0D#9$$GPVS0X8OZLC!/!.FF7#<.A1)UV4,58('B.V:C*=M-"@ETJ867,U++
M!:G=GD+W7L, IXMB;?KW4H\HJHY@A)XJ*H@IZD#6.*;DFBF&/RSJ;S'C)!Z,
MPF$GYXJ?QZA8B4GHL3IB U5)T$$RV8C$FI4?75H;8>8 D 38INPS]O*E6O$N
MW*359M\;*87^_A?.C/R9/$+Q_H7MK/A.H6I#KA#R\V19Q#5[5&(?*1 <<:D.
MDIB[^@%9,9J)AB[5F"09-9YQMYK'=;4 ](?*2 [R:9-+A@?TAG-]9P*(%;<,
MJ_M?:P(P*]QIOR+V[B$\@%*<MF&>D^@U >*&_64AH+$2,%%4Y=*A'K=;W(0)
M:N28Z(%;A2Q5P(^1+>$,#K+)@>CX-"I>6.=X;T$ZT>VSN7!NDW%J78\,:4R_
MB- =IFR.AUE'.$>'MF')]#$/?$#J DF)8!""-Z*V&)7=#&\YCS-1RB^%%4TI
M;N7^I>0B!=HF5+Y*DV] Z8!$E1U3YNSC3=L4YXZ;[FP$N40$86I+T!963FUT
MAR ]!(A8S!G3.5-4,E<53#AM+_.34>&?!&0H7:Q<4TI'"PH,Y*A(8Z+HB^#"
MI;@5VUP:9\L_L3)>H*2I Q0<1Y9]8L+K!J]MKB7V@UK;/*W<LFM;1ZH,LVE*
M MDY*@.'-PE^[A\?=WM^6[?C2K,X'V7/1O^_GOGA+IJ%T9B^*>J-76=2\#;5
MP[N-Y8XX#%8MO\$WBL(4WS2/AP3K<CI)@^$\)TY[P$?0$H"CU2=6 WH41,0*
M^":P8TF!Q1<;<$=1YX=9R]LF7]^S>.BV^W"1KT K 8-"&=Q(OY>>0P%:^;:4
M8.)$BQ N;WF+B2-"5Z!ND:;@5"?X2H,C31I(RX*HZ\\SS[,H0A/RQ)"'/F>@
MC@EST4BO1,RK0G' ABZ9S]N*8*88*Y!T43J=1% E=*J=:5/ QH\[[=2BEW)?
M#&O*UI?4P31<,)F >SP+R#SJOS2Q@^^ME;3$S7P^_4>.5^^U4.:0-^QWW##<
MB"O8L'N>_MK):M+S\)! 7$C\'/YRFJ'&@ 0!_RJRA P:F+PQQ GM0=,Q"9Z&
MAJU21U)OBH+>"-@(>*1W\/==4V7.&]3X-HV!4CP<4!U"L)(J .."$6 35$OX
M7%*P3O(,#/>;,(]15VBN<R S9N$$\N6Z%<%2^N<RZ]7<DBQ.N,HHA5D7<V*G
M#>K76"H]W+S$QJS<#0Q)$G);%3S^3F- EC]7^(#*CY!@[FC#5*!(R$#G+&(-
M+P?G"4S1L-SW81&%_P.W#E6>=ZSH$%X=$ W_K=/@_5*$V<Q#-N)8O#9_;CD#
MGI3&-F@J2-!ZD6A?K(XU/<A?T#FBC46-]9K*N[6&VCZ\81+D'6^#H_0\0@I;
MRY(N3-[/D:^!,LY%&* VB#LZ7KE1%*(L^='@2KT5B@">G=#]YOT%AC^9F+?H
M)SQF37PXZH3DR)(-FHYQKW.UU&&/BG8IU^#&"9=$X:J0"$H<K2&?6<AHW03(
MC+&8G_O=7L^"]G6X8G:THHLE628%3+Z0NB',2IPOYS0((T+ISSF0'0%:;>C1
M-DA/3D-KV1@?X4-O@=FWRR4(A>.CX]Z3\)<G_5_,EKV"[WV@[UW: ;A1,I\!
M+3'-@ @Q6Y* .TQW%Y<Y-.V./")3^8V3"*^HX$/8!?OP*M4<C5-_T>\]&?_R
MY/"7)\-?!)0W"OHOX/P0F 78DIP9^;U*(#H!30D&%J0]%RT"%$X"%PQ>4TMC
M<HY,N7K4_,G(L\8=0H<H:-/$%0U,)*Y_GSMB<D>>[7-']KDCCVD1NY8[XO%2
M@RL0KI$9Z#$HR6@NJY*(D\'-N_!DWY=]91Z2N8ML%(09 C8VL<N=2^X>%EI:
M<,[*E-UV=V+UC6)#0%0B<CC:E$1.]I9,_@8)><JGRDJST6_6R$AM_<HCIZ)Q
M:@%ZD5I1UZQGF9(>_;&*GK1IQAX=?O6,G1XW/"_&0/3KB=&S)3-RO*2-XXD^
M0A$J8YF DIW*"FP*C+-1SSJVD\B,NIUH?8KW(G+A_XK5?)0EY.(9]%Y>_?;N
MHDO_[K\,6%%JG);H^46EYW/"U%2$<V6*((M-&\IV"1Z+4"X70\VQ9(;,-%U7
MX!: .?J@Y"<;;!;^E GI V-=9&243#$.D!*1NP,T)>V;\[.%+@1Y+!?"FDB@
MI!T 4\&_CK7OU-'3Q$1@+>W8ZO+<W^5;*&L[:#>95CG'S993HDJL"VZ]T0)9
MPCZ6L&PV7.[."SNV8)=IH8X+7O>TCY2F7-\>J#"R'3ND]D1,+X#O;H1QJ+3L
MK43-.7O('N0:0Z]3";]*7:^78F'K3PI5>]EM:-XR*YD(M5&B>\=&M;:H35P!
M/\K\TZQ3*QN--BH'A(!)Z."K]0I)&20MITY?*M?/:K!,;>YK%:;=T4,]IE*,
MM-C0-;(\ZL@@Q3_::80A00R ,4)!GJ7Q&(1)0I5[TNS+!1K@C N9EH/ KY$J
M\5,?XO13<#532M!-X%<7UZ?!*SWJJXQZ<6.LM%Q/7\W7;N3T1A&<ETB@B'D:
M"4%9D[!4GR4Z:A)]W,;(E*5RQ]W?Z)6S !"UC-W.E[GK'JNK3L+B3@:LP!<U
MK(9 #28JHC#X I._3 /I N,9+C$EX:UMNSS/C(-)>TJQS@_WUV\9K,.*/ &,
M]$^IQ9HS< @[M"KD6G)$^K:@ MF0?C7*LT]P32(5)BHW$-^1*EE!(T(0F/]0
M'R.#H%D\"0WWA<T1I*Z6&MX(C&'##OF^>$Z*%N=="X%051X'Y&4+W'9?EL68
MKG!.0K+CX?<R4$5/Z@0W*HW<GXLEJOW*_$:0HR1.JW])LC@B_'D$]BB\I[!E
M&FQI@_2+H[_\M-FL[1_V?EHO,_L#]#BYCI'G@XH8/<#?W+L<;8'?OCY[Q\D%
MP:#+_ZC_]\?WEV>_G5]=GUV>O0ZNAF_/KH*+-\'9WS^>7_]W<'5V^O'R_/K\
M[*H3?+PZP[]\N+PX/3M[#;\8OG\=G%]=?3R[##Y\O#S]?7C5\NZ.J1_OL_1K
MB.;PAR&:PU:B>7WV9OCQ[?55\/'#Q7LXZ??G%Y>[?."E4RS\%4?_[(<Y^J/6
MHW]W_OX,^,2;,[CBK\^O3M]>7'V\_/,>^<D/<^3'K4=^<?T[\/CS]V\N+M\-
MK\\OWN_<83<R]#]M].AY>_3H#J1_-/CIOF-.L,+Q >P:XJ?\2O#/^>KE#@6B
MO/FKS[-X%)<O'WR"WR(Z]0.L[ XAJT8ZW$DF_ZR5R9_]U^_GK\ZOMQ+D=U@O
M VP;IHF=K0[( EP4ZE?]CY=8P)N$JU_CE&9/+^D-%DZ+? +!GK'J4[@H?8__
M+"SDY*1[-#A&+E+F\/^1_K PF"[LQM.&W\,?#E\T_JG7[3>_TC+4H/NBU_Q&
MVTCMOS\>#+[)G%X,NJ"GK!WJ*6T7;QD<"E+ 7WXZ_*D2^_]UL/@<]/5!NY*L
M>C)\*-^:W%]LHO;>>L9\QGP*LRU'*C>$7D:;UMW#5<O^??UC.[Z+KU4QSF/C
M1WN=C9?H=?:V\UO3$S"=[Z\LD3IRV.T_)D)!9MN\.<2NO[,BM(%2'EY=6#]!
M41=F9;DH?GWZ]/;VM@OS[$ZSFZ?#?#P#];]XJJ)IF#^-PC)\"J/U!X>'3V&^
M_6>#%X,7O<%A;]![=C)X6DSGV0%6QO2>]0:?U>?#P^ZLA)M[J<C-' 6G>&03
MKO6"2W.>ZK@PWJ(GL?F1B\UM ^$R"S37.NP>VF1]2N(W0>93:;=6R;5_<? W
M2:-@Y#LN;/JEVZ#Q.)>V8A<=LAC_CF1_U\=^)&8SV#.;/;-I839'O<&SD]ZA
M839'P&R.D=GTF=E4>,P0I'*DZYF):WP+'M3_.AXD.1=['O2(>=#AG@?M>5 +
M#QKT#N'_3PP/&O0'_9//Q(0F\:2<,2=Z@_]D!B3Q>J,(O5IAG/T[L!M3T-T_
M(9XSV/.<1\MS^KUN_]_OP'6VY!/W8S]ON2:DU.>'+[\]+]TSR>_")*V6=7+8
M P;7[XF:9:!R#9C42)6W2A"OW$ZA!D.^@\I6MQ-P3;6'Q_\XW.I?MR-'>\[Z
MB#GKX"Z<=:_/[2"KHEZ2H3;WRHR0/<)ISK?SFCI-6FL0%*JWA 2RF8%]^/ F
MN'CS)G@.*\1<\C@-@U?9$L'J8,BW'X2A_769K()#MNPVL((VBM$!H#2#9;72
MU7T^M9_@?H+[">XGN)_@?H+[">XGN)_@]YC@WC1\.$=__VY.M[UIN(.F8=5G
M<]@7GPTA__0/0T97'+P,^D=/PE^<&*&D]WP HV\<+\(D./NLX2PNL 10Y7NO
MSR.^VGNOSY_O:@^^]&I;E,_]U7[L5WMP+Z&RAUO0O^TC9#\* QK4$I&H//\#
M]JL/V?/<?Q%\[%YU3[L(0D.,J']XW-NSF\?*;C#&=_[^ZH=B. _-<1YBT>=4
M6!/\UZO+M\%YREC5)G4_.)".#_+[2/\^RF &*9?*8JL$074YURW-;P@Y*@3]
M 32.D6(0"6Q.3=\IPRG#_&,>3A0)D+49PTY(?Z_;5$.PO_P/>OFO3G_?7_X=
M7[1[UZ[#S]@'9@7F?*E2;#877(UG:AX&?R \V9F^JF_C]!-V+#1,HOA3W,Y'
MXQC=3W _P?T$]Q-\H GNE)9RM/NNSGO=H6OJ:H =[Q">@P'EKL)T&LXSDT^_
MMF&/Z>Q0SG+5U@R-801T1S3LF,,=GP0.<H,28MME(DH@8Z?"6[H2 %71-@?!
M4X(+<! +'@96Y?^M^T\KJH*'HG!\5$51P-\\$$S,OP5M4!%$3[Z/!XXY',^H
MT8\^,Z&'0;=OVTZM;P[%;Q#!+=;YC.2YP^,>]6L+HVQ!?=R==[PG3WK/= W<
M59AC_[;BX.)SHE;!<$S5<8->;R"]!V?8%DXZ.$:8'AEI<&HJ*]'@U )<?JFF
M,;943JF'",Y@D17<L<*?ZPLS 8L+>:910F46_9/#(UX0%\ZT0Q9M3S3_^1^C
M_.E_[A;U]0=DJ+517U,?M5$X_C3-LV4:'<@$)_2?E]]KNJZ/D^(O1[UGUWBH
ME]S1F>RL@^N.[GCG>%"PU(IJEMA9(D2'),B%3$A7V&0-&Q @KC01' U8Z)9L
M]$R>4=_(9=%&BD&_CP_V!PVT:$GP$)\Q;VQ+M]S<R<"1ZFZDQ7+T3^HJE05)
M+&"R=R#K]43\,(0I=3T[19VG F&/S);8M6[3)R$%+,?C1K14BR<,[__\V_\5
M=O<+PU"/,$<\F\=:I%>;"_6?!Z=O+DEL/'\9# 8GW6>]_I/1+_43O\.Y/N3F
M]0YA\_Z][:C?T/5$B&!<_1T767&<W#_Z7".&U:.!I'OQ;2#ICN\=DFZ'T.<>
M?"[[-DC;M4'J#YHL[ <"B[LZ_^W]\'I;2-=^%??M 0T65P=#E:7:MF\K]9M?
M-%H]-K")L+R)8EL12\V<K1;NOX%=4;G_!@:^1@H,B(DV#XB*Y '"DE^F"**.
MXX7+<I;EV*MYJ^X<_>^!'MB\K=@;)OK5M$T1@V8@9KZ>_/?%^0.^W.TQ;[X+
MT-_Q\V[OQ7HDO&V'.NIUG_?7(_IMZ6+;#=2X+5U-5\/WOPW?702(&#S\</;Q
M^OSTJA.<OS_=)GK4/[Z'\-&?\12>%D^#X=NS_QJ^?WUV&;SN!N^&IY?#LR^!
MZ-NP+W+3B44MP-[#QN$!+O#E(]FQC6B'?80+'2;J<TA-R7"SPG$>JGO8K%W9
M$J*A#[G"IN72WOYT%JM)/07\S[Y)3]:DQ_^R#<<;[#G>-^-X'RZ'U[__]\>K
MWX?!ZX^7P_-7PU<?]RRO_7Z'Y6RU+&9A\'J9A_$H'"W_[-?Y2J78N?P?V &I
MB?_5\N3_[!OVI*F& /=K.*:.;]@.JIT=U@)WZPV?#9ZTQK["C\7[]F@<;2?M
MCK:GHRQ:P?_,RGGRG_\?4$L#!!0    ( $Z ;%FT0']!?1   /RB   1
M<V=M;RTR,#(T,#DS,"YX<V3M7>MSVS@._]Z_@N<OMS=3-^\FZ33=41P[]:Y?
M9SGM[G[9823*YE26O)24QO?7'T!)?DD6)3]:M<[-S3:1"!# #P1!D%3>__H\
MMLD3$QYWG9O*R9OC"F&.X9K<&=Y4'@:-ZE7EUP^O7KW_5[7ZQVV_1>Y<(Q@S
MQR<UP:C/3/*5^R/BCQCY[(HO_(F2GDU]RQ7C:O6#)*NYDZG@PY%/3H]/S^-F
M\5OQ[O+$O+P^N;JLTE-V7CVW+D^KC^;;D^KIU1F]N+Z\-*^O+U\/W[UE%];;
M*WI5/;NZO*B>LV-:O;H\/:N:I]?';^D)M8[IA63Z[+WSC!$;4P*J.=Z[9^^F
M,O+]R;NCHZ]?O[[Y>O;&%<.CT^/CDZ,_VBU=-JU$;6WN?%EJ_?PH[+C]V1&^
M?J0>BYM[P[&[U-RCSI".W3>&.SY";8^OSX[CQLB*9S#GCN=3QY@Q-WU1]:<3
MYJ73P.LC?(W]G%:/SZIG)PG*$S7I<?483 VDU/<%?PQ\U@#L[IA% ]N_J03.
M/P&UN<69"8YA,X1^J<'":Y^*(?,[=,R\"368VC ?7A&"</'QQ!4^<1*4%O4>
MI<2>\"59A830MER#^M)CL:4'3:5RB?9'S/8]_*V*O[UY]LS*4?Y> Z\ZI'12
MJ.=%FK#WZ$D1";*<(TV,5!+\K1K35?%1]>04O&1C&>;>7TR&F&Y+&5*]=ATH
M*DKYN[>M&+-Q5UB,B+*0&)*1QXPW0_?IR&0\CU^N-L<?4CR1.H[K2WI\$CV;
M3+ACN>$#>(0POHNQ[#,K#FN)F!E%V)/KZ^LC^1;BDB2FPA"NS;(;'TV$.V'"
MY\Q;C+>2P4@PZZ:"4;<:!Y&_)X*] 4GB)HD.EAT27T,/S(,X)O5MS16*62 F
MT O@8+/01&76WV164?V!A#O\I]#>IH]%M0<29O_PBAO4+JHXD!B!O8G7(_D
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M*(@/,1 MF/'>!)IS[2N%-6#N).FJZ>TIU4R;:]X2Q-GQP 0WQ+N )F>V*"'
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M7-1..E@"94?-BYH*:N&J> &LV1QI JRMRAO+0&VG?$85U;U,APWDWD8UC*4
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M9B%P8EDJ!?"D4R%)AK;6CZ# 9ZY&Z^IO%8%5UMLGE-35]=7<+E; -2T=<:-
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M9K=MTCHZ:J%2[T)@LZG2!%J[X52+8&W'"JVDP":TV$#Z7:TN,X@V1N!662*
MH6.O94)T"==!03,%SJUU[D<GQ@L&9_>\6$7HM2W-FT"AAS%"F5GFT8;&W4\#
M;J,:=[^D*%$&. (*P8EF7=D6?/C6XJLVE_RPHMAJERQZ.? +6,@FE6,V;@2:
M-"P1+W&\E%JF1+ NQV85BEYO"%U=%=<5::=Q]R$K3T7&D<9B$6<7B5?2D.@T
M>)8H$K+ZZ<'KC;O?ZLEE%1VU4'U_0=1I$T0[&VN_DKI>#K=>1];=Q-I#--FC
M@DBP@N$N%A*Q3GD"FO/H( @36[( 7V^L?67EKR+B[F/MF<V,*AZ(TZD4MDEH
MQI3[6Y'QFW56:49_<$-A;66L9A^L(LDV;C;G?"Y=8";?R^8W'$Q;?4Y/SYE+
MKO@Q.,YR>AX-;F@BDVR0WRFCR<1KS_-G ?UA)]3150O-5AYAFE^F-0#5DKFP
M$-"6+8;-%3=L2^HM& Z+P3D38XI4$?2X$!R/G%B/#I$-@;'$\1>J=GAUAU1H
M:CYTQ(15A-V&Z7BWZ\U3RT14&FT 5%)6)>T'[25M+%$4<(OU$#*K7;GT"8@M
M9,)LKIPGC=LWD6P;"55W@*;[WWCO>G(Y')5DGG-.&0,!@G"?2PB7!N)+*0(*
MW(!+5G)7NV#(,W"V<#^YW7#_6JJI?1XY1?3XBMW_WKNZOIJV(3SWF28TC*:4
MEF@LA4R"<Z46<V \>BJI2(V\C)>>M#.4J"_WVK[GO;O\>;WNL^'>Q<4(+G#K
MO$/=BW">N1"0+3I+D#21RJ*#Y@00Q:AQ/'D#3#?C1_.'[AA56M)&[<+8]W ^
MJ<*[]\WW^E/G2]*$_I>G1+O 2Q!()$%3)'?QLZ6G5D2^*E^6/VYGF5)) RV$
M/=P0>3R^AO3^>LK<:9[QS:YX!+]-_X1""#HICOYYX*K<V3A&@F2>6..MT\KQ
MF&N7$FF&;&<HU:+"6K@GN<?]_2$Z@FE:,K[T(8E0VE@>#^X%I)V#@Q@M.GA:
M45PG&:Z33G-!(BZ167GILZG=^'HE@+M'LM;4U\(YV_U8QWGY@NELN)DEAP^P
M4JF$!2.(MQ2(%$4J0FEBT;K'79EQ1:O75EL!WRXSK:[R6FB8?,]K_.Q'QZ/I
MT56:.@BX"$]A(\2L16F>(()'[Q&2(DXY0R(W@B=;W(CJD:8OP]HY6M56U=*N
MR=NKMR-MZ=C!*>'*&#0<(R4X#D822Y[J3(6BG<0TO^9Z.]MF88<J?LI0VS%#
M#WR\?/C><ZTM%3E0PC3'*9:I0\L@&Z)$%(HK:7,TV^7H4]!_L+15-3_EJ:MU
MSO&B 8%+_Q=4YCE:"\I$8XG)$NT(7=PD8(%$'4!#EMZH9K$::SQ\9^C5B786
MG+5N'@!RAWEZC'=K,$2/3P_!$"],H7E$=SI)9+T$QL";&$SUV(\E6':&1565
MLH MFX<3%Q0WQ[V:!AP"#LC)4-+?\%4H-T?%+S$NJ>1M=7[</GWW&+&>X!=P
M8+.#]H=[X;V3WH/?811[XW+*>W-&MY<G,"H+GQ\@:&%39#)DHCT((I64Q.:$
MWHA1*E&?-4O-NERO"6!G"-.9EA90:^/S^;E/L#=(-T[!/>BEU>:Y"3Z!SID$
MK2R17.-*R$J0@_141(@^IMI)"R]AVAEFM:*D!2RJE;;P<!+,F'^SAM[^\=;[
M9,A])L!P@2(1%)=5(8D#%$YP(AAE7?:N]K'\6D!WCF_MJW,!"=<^IW_L"-Q6
M#?@ 9<F-^,I?X!]_'0W'X\^C801(XW-0"=W&B":=0,A2RD"\S9X8HX,V.20%
MS;(I5WWRSK"I?;TL8-':A_"/T>Y=(+[[D%$(,4G!1"*FI"O*J"FQ2@ 1*6:O
MN5'0L*+<LX_967YL*/$%9%C[#/U)?$5I:SV/O9G62#_7V5$A1"323Q-4T"6<
M)A^E%'P45'KP;%4R/'W,SI)A0XDO(,/&Q]7/1D;L#P??8#2>%M6_>3WIH<E_
M=[QY#I9F7-LT@0BEX1B@M28S$&>-9)91(7/MD-S-$.\,][:@X 7\=/4[%IP<
MG)Z=?-D_PS<>_;K_U[V37P].CXK=5IK5;="\H-'G;M['8'7XE5H:G,!X,KJ.
MD^OYXE,<+QC#Z!O<,8T"C58Y1I@H42DT)A*H0T.%)<^4L5)(57D^-\%5KRW!
M@Z=-G]0OE]SWVMU1D95()I"L2A 8U8QXCS]&)[R3#E 3NO:2UAQ>5ZT%JK-E
M>?. NBK9=GN A0)$ W#6\#=+76KW$&L,CL0&33PO<:Q!*R'!1RYKGPXL!++]
M#-C*6G_:^79#Z;?3%/DAJ'F%ZP:P6LIN70)I._FM%93V$@TVD'B'A*!(<Y Z
MDY@CE)*0L0192>)%$DQ'SZ6O?2?6*1%>R&[MC@>K"+IZW=VOHUX?]2">@)N7
M?-*>TJ@#[JDAH]7O@5A@N,PF9M ;T.!RL[2UEY[4O4]411_#MH19.T'Q:/AM
M"N(Y?%PZ'C0Z5I[KTH8S.^*U<$0XX#DG 8(U4W:#A[T!?=<6:>W)_6%4+D*7
M(4- 24FCB,LE,3*A9QU*W=\LI;5)T62@62C5LX]Y VJN)\::F8*CR?E9;U*,
MV,-!ZGWKI6O?GVY1D8+3ACN2). X5;8D^&2)T=I:S3@WHD:3GH4/?ZL6?1UI
MMZW^?_0FE]/QHJS&E[VO9\.#P:0W^3Z; $V@5NSUM2*\[CM^55#H<_1H01N5
M&W^M"ID*%9@S0(#+6$JZ<!*$,(2GI!&IT4XUB@G_$8CS3!.P[?)F%254-RBN
M^_TSE-&\&?)XM@>&I!E5)A++/&*"*(GEY:8@1R<MS?C;V,R46/R ;KN"M:J1
M865QUG83]H>#R<A'W#(?HS))!>D3)9GE<O^# \:?'<E@LX_&"6=?O-YX_A%O
M5,UU1-K"R<_A( ZOX+:,U\=9[_+I<D9S4I[%XJC$6"HP*?1;."/)>65UM!H'
M7/GTYQDX;]6NK*V)%LI,+($VGQ0-P+5T:OPLL.V<'5=38S-Z;*"#[E:3N;FK
M!76*&J(#Y0@RT%*5/A M' ]>9Y53[8Y.6R#("V?*V^''*J)OYWX!\ ,O<=%\
M#]^@/_PZK1GY>XE"@?E&B$9-R 8WTU+N1!KJB2N%EYP6FC+%C1$MW$B^!*O[
MLZN*BGQZ^5!5"RU47?P5!C!";VJ0]M(5BAHWW&D\RD.0/N!4 $\)$[I$L1IW
MTSTW)BL8XH[<U$Z>;P3L+9&EOB9JMRPO86NS9=.ZR$$0D"7+IQSM>BV0N$ER
MSM"\UJJ1G?I22_+Y ]^J);J^5"O6H+H%,6-8$Q@53RSO/;K[T\@UA?]8?1M(
MKHTY.N\RJJWEF@7B':"C6T*-<7VP1#FGE(? :;-J$MM6X#.G@G7UMXK *NOM
M$TKJZGK>'Y8'PYU/F93@!B(Y<((&J2!*FIAE<$+H1C6N7]#<@X=V>PZTMMB'
M-616\_RN +DI?3L?CE<A<'0GC+.L-/>UQ*D8",U<^2P%5=G74-[]A_Z REM;
M9I5GWJTI=QIAX$>]X70YR2D[9>TT2L26IFN2A%2.A$'JI$I$/C3RC5Y0XL*'
MOV5K9W-I5ZR(. 4TP_%E,/X*L9=[D.8-GQN JF@'+072O55404G#MB1<>_8O
M!6<E1X:S3*Q ,T*R#"2 502\]L9D"A8:N;RO2^W/V%)=:7T5P;:D[0_#$40_
MGG?0BI+BEJ,"83'ZTD9#$J]4)M0P:F,,1IL:P3N+G][MUEU)+0L4O8%,6SC6
M>F8'FQ?6^CP<3P4]/NCWKGJ#\N=SS=!]X 9-QX18T0RAQ)8ZX^A*V&!MHJIZ
M2:+UD&XYPJ^-M* .5-8MT<K!79R]9N?,&:T"NB8AT&EW1X4XT56-0+4H!A-5
MM?-EFV+;+3*MKY:V\T#V+_WHHF3>BABXD9RP'!)2&E]YBPLH>*NLXMRC.]0F
M568XWCHMUA%WQ6C2S=:]FUSN6=V1\XSR@$ -X:5"C<PY$D^=+$5'+#BOHY:U
MJUI5@/W6"=:!,EN(/6FX=)Y D3B^A9U3"T9Q*PF7(1*)ZR=Q0FOB34K"9T5=
MK-WM9&60N\6U"HIJH<O),X /!_%Z-+IY?2Z#DYRG2+)GN"=3(8A5((DN>5PJ
M*YUM[0:?#:'M%HO65LK2,[HEU4!FORY?@A_#?_S;_P-02P,$%     @ 3H!L
M69 $)$VOO   4!@' !4   !S9VUO+3(P,C0P.3,P7VQA8BYX;6S4O7MS&SFR
M)_K_?@K<.1$;W1%"=SU05<"<QX9LRSW>L"U=6Y[9O1TW&'A*=8<B=8J4VCZ?
M_@+U((LB601 5*DW8J8M457(S!^(1"*1CW_[']\?YN!95JMRN?CWO\2_1'\!
M<L&7HES<_?M?OMV^A_@O_^,__MM_^[?_"\+_]>;+1_!NR9\>Y&(-WE:2KJ4
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M/Q[EO_]E53X\SF7WV7TEU>%AYU6U,ZKADA@NX]QP^2_'B/UZ!ON!^%WO\QJ
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M.H:5Z80@NZG/AB<357H!>EAW?+7-&9N8XL:P_=P#^')"@!WB@Z<!VB\B>%3
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M<(+6]@ 0'"G?LJDU??!3Q\G/H%QLFH9OP-NR4_L 0]KX/D $L^J=B$]LQ_L
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M'']NA+B>]HLD"\9HAA!,8Z;/1%&A((LPA9(@F8F4JB(+%]TSB3J9(,;'J31
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M24 -2\!,$)C7^60//?8<CK4>D%N<\\<%TFUE;W@!-3,736  O%90,P1JCBY
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MX1&FBX*PDF0GX,'N#<\J%4+4FXLI7%^*#XNW]+%<TWF;#)T)Q3CG" HDM=&
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MQLD7O+LEM/>-;^GJWD0,MK7H*"DR$F49E'$>0R0QA3B-<A@K3'F",<E1Y-@
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M2=R8YY(AN\9+!H4V-D(23'"$$*$T:'Q2B/">E_VEE/-GN\60VT25;N.A6XV
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M,-_3B%F?:2;D%SRD?RHRP)U[#\O<=\BL/9J]@Q>=V5IS:Z[XXL>GR>S/Q?K
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M0)R)7#K^=>T&Q6D#J?T1XH+)+$>TK-R(4G^B1'_10<XTG$71U2;6#$9/K2I
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M90%)54C(B,:02Z4P+EBNJZ#LQMG 13BN!K;^,/)T9.=:'NC*6G&.?K8I@+\
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MP$SDE-/J-JBS[@76MTZ\'R$]CW7_L#TS^5[_M?PP<90U2&)4*J0@<EM60K6
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MT&-F'FP,/7IQ!(?'E_'$1DFSJ5Y5PWS74H]?M!JAJB"R9!0BZ4I7,%60&5'
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M/O"L)-:>P5&LWMX4_()N:I*.Y=A>Y)2(3-F0H NHA339"^OQ=]O=V#QXVVH
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M_(Z!^RNF0;9*XAZ-=I1:1#L+^)47BBC+@J::<2UJ)SP^0T:_.UJGX=R&LFX
M+G=73LNN3C><#)@,63F62([HY4E< "3HE GZ>!:X1EY8[9N5YRGI=X?J C05
M)-[ CG2/^-MSLN'X"E?"<DE,QK,WD"=3N.LG!K.#KR@\U-AP[*?7ARC1V?.W
MGX/L5<H:C2V/J02ORA"GM<%8-B3!>* IU:Z&ZY"=?G?);A#<ANZ;,)]+%I?N
MPK(#P\ $#XDAW?C2,F:(0NG]6C*!0^1@,[6N=O^G%TCI-Q^B._AM)_,&+.@Q
M!B3W;@,$=#&5M\1J"$0Z'4M%#NX!&*@8#'^ML;5S8;\AH-^\A2Y@LKE\&[ K
M'\:I'+^51*'[=,?"R-YH\8\A74Q._70^C,//"P_T?LS"&S\;Q@$%!31X#'IX
MZ:9H)'*>'"><29-E*+WU:I^8;DOS2A"L/H>P2PCN5(NMF;2[<1\7DP<YX\M,
MH1OV<KDT+=>D0B"/$F0F:+4=0LMKRJF@5M2>S[(FB2MALOH<Q)V9Q<HZ:L!P
MWJZR4Y@N)HG?R8QG%W6PB0"SY89>:V(5=\1Q)K*B6BA6^YS_)5I6NXZD/Q*J
MJHB] 0OVF(^;-<!MC")B;"X"TB^I0":HYR1E:PS72G->VSE[EI!^[['KZ/@[
MP%E?X$VT77G,QMOAJ.SY RZBX2GACBU\)%*A?'P*DB3MK$C"0=:U[WU>(*7?
M"^N=8&<3H3>!GK]!F=H :0\?ZC_"\=5E@.E)7C U.[F:S^9^7#+.E@R^'<[B
M:#*[FL+B).5.EHR&K&),I0&_PJU:\3+R&HCA@-ZBRL&XVIF"=2A?S:[]4)FJ
M/:CTAX+RC9T/2F,HKA4"*Y1JO8@K5<5 7(@F< M"^=H%YVL1V.^&VP>&-H3Q
M^NILP-E[@;FE.)_P. C!X+K7DL2L2GN': BZ)Q@/<2-!,&Y8K'VFLB:)_6[R
M[>*UBDJK(7;'I4K[)^]/SPY^Q\\<_O7@\!B_/3@Z.>^F;NFE=^VDB&DE1BM5
M-#V88W'C/BQZ;#VI\+TON,M&Y*PL88Y1(M''+;/< LD*K&6R1#>UVY^M26+=
M^PR: 3SSF;#2M*X,[B V)H5^/6=9>2U!U][9U[_/Z+!/47?H>/V>8QVY-[ %
MOU09_VXR14N^'# 6KR^F?CQ#017UC=/BN]&-,M/_=S6;+P<F+NKHGRVS/O4W
M$SDI2]I2@>&@<*1TS2'!9-Q99-86DHDA5<^#VB6#?3=/VAWHV\5-PXNJ]$@9
M0UK>EY>1H[/UY. -4SP 0^Z=1SGH1"R%B,;%*\:IA?I9#5WQTG>;I_Z7RD[1
ML/ZJ<#>K8@P?%_>DG2^.#^,I^-'POR']/AF5V. W/QR7+?5D?'\KNS<=SDH
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M9\2A^(16DH&M[BI^CZ@F3WAV"[Q-5=0"YI8N[S)9Z6)RX;^62]%/-PVGRQ'
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MAR92"-<AM*TTP8U%W%0JH#:*"6<9+D*)CJQ.BGB.N[A*EAGJ@I&Q]O%7&ZF
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ME5IMAM666'M,5R-@JP6&%<"VE69:0MN;Z[LO?Q_"M&1X7Q_!%QC=3$TI8E.
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ML*UP<DI+CV86\S$A.UPD3KN2#PM*^&222K6'8Z_?M'G/K=[7$NBK39O7X>X
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MK[KIS03NX&M<BHHCG)PL90,2X<N=Q;_ZG+VAU$I;^<RO16"]I+[CZ^]^5 Y
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MR21'JKW2IK2NZ14K?/K9[:"P(^EU]5@Y /_R["9,1VGD)S_/_%Q7WP;7#8T
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M?AMN Z?Z,F@.J+M']E4CYO/NX/)R,F^#?+?+482+S(6 ;-&UAJ2)5!;=>2>
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M!EK7QP,QA^7](-);L2F_\RX'[W+P+@?O<G#-Y="(N*=6L#Y<O/KE"G6LR]]
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M^*0 +9 PR!05%L$OW%,K-ECB+CNPCTY]"XH#57Q%++_9IXKZX&ZHI5N1X%C
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MI9C+B@M?26R_*R+T7M/.E;2_:AW<R]UNS\R/H9U8)+(2%LQ"G47R4:;)$KL
MP\;D,RT/?Z6%X+]TQ07:C[V2G:IZNPN9K&9U4:JZJ^C]CI(U>=&YVJPJ'XO-
MR:NZ0'\[K.Y&EI7^@6H>K4MPY042"3:!QF,%22<7^)\2.PZ#.$+)CN$9//+6
M>05SH6 F*$J5XQ3E.P@T6ED#H,G4L:#\I#_P I$8H;NQ)#\,T2$.U0Q2';&%
MP,F55:U^:5'L2FS88]D]ZOU0E23%< .2[%8L&9<F5<R@?;4FT-;G''0V&PH%
M,0&'7=-YS)+<--?>F*[R>SG/++^E,*;R7NMZS@K%1HX1X^S#.<U4AW$.BK0*
MHP"%W.8UW(TU1QN1CE? 0.72XIQ*E(QK@H$6?.DSM^H'HJ0 RQ@=M!&%0ZXK
M4R&ZK)!:C5%KI,D]TI$.0SE$J74ZU8Y&KS'^=R90S:C7,)$O1(E4AKJBK1>S
M_$:.]R+VU48&+N(U2T?01Q>%6+EP]?[Y-CR.TZ&O\[&%#NGF<M()O[7 +"M2
MB%U-HAH%?B-U6X4S0Z[W/ZSLH4FX]VF_57^K4]G^73/LA:G6*52S3)3A<"V:
M2RDW5?/YGJ 16+^SB]_:D3J337HZW?MHPLQO.=CW#RE2^/%[A+A&%(8+@PM<
M,<92#_=.]AM0$I[@T>'A]"_?GYS_^.*8_G-U27J**0H=DE817%_#*%DF/P77
MIN)5C2 %D>$EE92I4EU5Q72KWK[U-8$?N.TEJIG8H\'\ E8+MV[) 88;JNFO
ML;\&TVZ"I>HW"=SQI 6BZ&E-P]1:Y5I$NM+JG2/N;;CSG09)W'^F*/WLLD=6
M^.02*)7HY@,ZR$M5](A?F/7L]$_[:@(8.9&@X++:IP__5DG90LXEHZ(;71B[
M>+(. 3]:L2Y/E*-CZ]JF:%ST@O0:0\#SMBI1PK$QR(FJ0N$Y;1J7!E"["! $
M8 /_]) 8$[!JX*,*9]7'+[!ZFM;A%,Y!L-6$/VPZ/5#XH=G7[5"Q5ND[V&&E
M)M-D)6BMM 2]5;C!1_NHL:WKE,#?UG0X<M:5',^@@,J1K]<S=('U*,"=*TP$
M:DK*RM%_+3"&)F.^T5J0,FTY4>8$1E'0QQ 5DD:@GY'<VU9'&HQ%PD'2O2X[
M1:1#PXA&L+0X'YGN([!/C6V,D>E"AIMP<QQ![HL5FJ"$2?U$_VI?R)3<05)F
MM#SFBQ0]B,><8K+>_867K.8Q,7Q-^+H)'H@P B#"B0<B>"""*\-Z((('(CP_
M( (H?;XJ8%_ILZ[^Z^;J=T'M>Y"C>GHXWBJ51[Y"X  ]5DE6L_IYI8L$O*%F
MC..AR9/)V>1TK%1Y[&L&/HPJWTETC7BJ?!JJ]#6/AJC2D4I'%LKE1H!5SPG5
MW,/&9/6I^:;M;#Z-+MK7F+#!>&"V"=Z*BAP/_YWEMP?_R&]U1*F![*3(F34'
M_C 7=Q.0CLT()OKGO$X1V%3*DH)5%!E13:WGW3;6[(4UKET;SM*4VJ%1J5[)
MIW6:)U6P9[7P@.%Q'JTP5M<US*&C?8T&ZB_Q <M3;;B[FV:CN;2WI?S,S2CK
M]3K=F.A,?UQ3!DAE-^G$:2MB)A@31N#6@=31)@N4T6E9K,K\--),Q=GP>UV$
MZ";)T5VGDC/Y]VJKA4F7YL(7[;3N@>[A\ 0FTR[T6ABL5&R,]\MJ':[K&-U(
M[:KO93&&G;)>)OF1LFAAG%B%&!O&P$-H4D1?_,AH9@R;#IZ_Q79,.KQWFGSV
M.7<6Z2/566DJ]'W!U7B*X3(&M/BT23?&4^\MSTKD3?[<+,G?A[\WL\(<>?E'
M#<]2LIJJ'$1-.0AK5SZ'.-^QSQ;M7VDW;K3??M"%MO.=DB[T[@F=V0XX+0?V
M8UBKZ2.<_@E2* XN4Y&LZ"=)9H%%&+O>P)[>&BB3=:42\H3N6Y$J( M%<YH,
M&7JKC7&Q,G[WFS@+1X(I\MN.!-.0*A;<:>U-P"R--2$D;TCY+OC3IH".:L1$
MNEI/]^E=J_PXH7?QAIWCB4I^K;U;ZNZUH#YZ'@I['5-\:$Y+&.WMX/-:>DS^
M]B+X*2G&@Z)],7DYWOZTQQ[/W2/ =[^,AO:.QMLYY]@CN'N45\/E_19^F[N@
M\CW8X3A>X><QF-U->2UO?LYW27S!+E=_0=!KX82WU?9]C#5;[-@#,'L,1B!Y
ML(L^[)3-VJC+9T%K'O?1I[52.WC)&^X"P3U[O,>QQWL,T*%&40<?FD*:HR''
M<[#P1TJ-)Q[GT:=&+#F15&!LC84"&16-Z=JCM;5./+2CNRE79214^NO8L&^G
MX[V?3WQ MD>(O^_0%]>U1:Q*UO\-6Q7GJS#X61;PEDT8_%0@E"0,WJ^%@HA<
M5R*](T'1YW_Y_"]G\K].VS/T^5\^_\OG?_G\+Y__]47U.P^IZ.EWGQ"CZ8Z*
M)P)N]!/<+G-59L9JX5:!:K$W/=P/-E)P=S90UN0-Z@<2%Y(0=DK!@SK%H)(L
M!O)3=7%P9&Q8NL9*/*9*(@*EL$Y.*3,$PAK'E.JQ(X(4R+LWL"Z12*CD);7.
MFZ<(7=43N<H65-8P%=FBABL\A,F:@KY82H/ZIE*U#52]9!'(U3K--U+K.-AH
M3U4$4:T9&,$\5C/+ TL&V!"S!]SAPU[IVU 5C>'&2B)^2/V8T%2/T>5;J5:4
M2I48+?EZ=$JOG]OK"W=(M]_OZB<L!(LT^+JH%\%%#":2:9HU4,Q.-8TD+"JF
MT<@"Q3)YO%0%P'F=<=N_T=*PA[?T:#@I0 5HB@,'[T&2.4/50P#R 7@X:2G<
M\E!!HE42$BUNEF<B0$.G5SNP6Z"LA_9NLIBV5/SNE1^<4>D_55O=%"Z#<9OR
M?WN(+K<+#I:=BH-81MP@PI]#RL^)1[UT-^7G-U= 4UF-Y;!K:GEXO:(JEY00
M</W6&1:D6V+K3)%4F<M 88\DL&",Q>R!>3C-;UU0][4F=914(:QQ3ZD0S"W4
M3G$ITGF'3U1;27CBWWE".7$D#52FX+[-&:%)/[DC9;3DRRW)1LM''M$SP$??
M+#CS_8>+RX-7KUXY*SJ>P]7EP4O=3;D&M62%EH83>N+#PO/'XRWL?^H!2]LH
M,'<B:?KY4Z!'*@U08!(Y4S).!Q$*&>6+C"K\$Z( U.EE#6\QK7ABT+Y%J1WL
ML>ITU>ZUU(*^_X0!@;I8YZ4L>[T(G@5*_M2CGX:(&W,R@@_BDPOD_<"DXQ>C
ME:\^0-LGP0:.!2=<DQ?M.HL(KC :FIP> E&.%A=ZZ@.6 V1)Q3E68Z+"EY/S
M$1.A#SOVB1"]IZ"8O9.K.E.%]D9$C6= CV.E1A] W$:-F^"7I!R/4!QQG9!3
M'TWK$>%;"F$C^GX\3LD1%TDZ]8&H[J;\;PQ1.A5]X5;?*)T1LX.]"<N(Z@5B
M+\L($TNHNB,!.//B8XFUYS1 4U<I#0GGJ1"AY $"HZS".G6".W6JSW1XV*H1
M7-:S?Z,30?] %^U;4S%4RF,@-]1Z0\%9_4&64^5B+(U:: 2'#O]^5HQ9XV(9
MST2%=\F1U:K -Q"(IK0=A(70?@%#ZS:5/*95Q]?G6AGZ\[E6SN9:G;5GZ'.M
M?*Z5S[7RN58^U^K+B5B"I[5!V*SMJ-K^2M4)4G%;-MD!P453T?<7_$9I+*V!
MO@V VZE'VW0W16OB#MD5V0;4J^Q@38AE6YNS+8A85"(,/N+LEVA'W&^)A-H,
M 74LAHL7&T.CRH?8[V2NPNUDI8#"5D?J+^  3&# D7 >=2HD:(Y@:N0Q?UOE
M*#1A5!DML^2/&I^,90GD7J(9@5EF]"W8&3QGE>@&>[M L0G?Y9\2ZT_]_4?8
M)Q"L^!)Y$,&N48B=.%W_T=J;@AHGX8)H^F L':#A<H.A+;8(8$%8/9RG40+?
M@VJJ!A7IIDS@MZL\EFFI*J<W:G0A%Z+@?5=[NS$Y3)8RC0!VG&\2T3]B5'V3
M6<WSB_*RXGKH//[*!OU. L("1*G 4)S5JX63^N G=I.+2F2+!.69:90R5HET
MYM%7W4WY1=19M S^3PVVL1MM*QY8L^S%>"%89QZ"U2-#W=O'\CJX0(S-)?D,
MX,]G'AVUE>XNP?Y/G*A+SB1GT@&HZXB9IOFXE2[3::A"#5,*TUX,J;<_0#OO
M9[0D[=%6]Y"T4N7<H>RF#Z(N2H&WO9GU]5OVYT;8)N=99)V<>>C55AIU+<3V
M :U5M*Y*MN(X*-62H(JMT#+BH-P='IS!KHBFZ>>\FSDL#"S[:CY'3?=&!J]5
M[$*U%ZQ@_4',J9OXX =9K)H(6R;1?,9VC_ +,,7+/!.S=(-E+K!3)BQ%5>G0
M2=&M."%<%Z4TIE\*]B1'<JX^+9,9_ 9)>;1,Z*%G6YGPK=BDN7!(^;$4G@^B
MUO-C5>@Y7 @>>'8?+?HLV*](?AYR=B_YC5MI;DE)8P>V.W-BN2#EB]<JC4'[
MQ#)-T.L<W,@EXH*H]29YX1^B+F@?W04J,[;NT)H5ZD_ZR5>])_=P>0X0QM4G
M]-K#8@<O)+5V!\ADO :\!Q]N%T:J<)%KPHC8.!CY)>B#TUOI;LA'Z!CUJ4L$
M[@[,:2ZPU"E<:DV9,)%E>(.Q*3QD4H\VQ?G<QS"W$NYNB=209=>8M2FV#3;F
M$EA*"SJ>3"?'XZ5+']3<2I>6SNB.'$4+ #$L2'H@(H71:LF2 #LA1R"("/X#
M&C](U6R!</\BKR20L-7F$1<7WNT%3; 4=A(MR44Y[!)MB?#'.3_-3^6G=<+Y
MDUKDX[Y?(:2E9& .-Q_NVS"E_*-&P\BV8F@B#]'^[>%\\D!?&OKD =>2!\[;
M,_3) SYYP"</^.0!GSSPY40LNR\M;^=P//5\.FDC<>=-)?=E6R&S1R-/;@G6
M;[K1.I.ER=WYV_':%VZ"UVAK=VED_*\=&[WC=0&>>^Q8SV+-2Q>B&:AN.[(;
MTHG]>&A5TM%6ACKW&+GNIORZK4R_"P39N)"29F*4T&22NP)J0[-$/R>A.*@_
M1RL-2:=[645+27<9? AM^CVQWXLA[\WV*4TJS<NV2PG>U[0?&'"[MHM&=/0P
M7-GP-+Y2@X2PC05DK)/=S41'\5$,H)<#?DP8/RNF;UL6@5UT$</W.G<+?V@!
M$76,\;J=^&?CR<WA;-O<IKW);9*FY'"9R2#&C8UA%5L)N?GA:,661Q7VQ=9@
M;QUGA-90%R+-!(3IS8*F'G2(CF]@IG=R4:>""J-=K)%^X;.]QNVK<C #H;ZC
M^CB%A)?\42<@'_;-O_!]V&ZNVYFHX ^:-P]++-E)+V?'?:M9$G58 58K820<
M:+2LY4&2W4UY(Q<YR'8B#PYEN,!5#\S7?#E:0O1PR3XA5M1:S@G;2$EU\IRU
MF\A9S>76*O*'A KZ"TA*4&Y2_$XI9F4]JTA[ PJ>%_F*GJ0U#O214]*:!_W+
M]Z<O?GR45ZUUJ$?G@^3.'R49JG,_''^%.-XCZ'_B7&B_ER/\++?=.8]GR_)Z
MUEOOG&MP[ [\EG7]#)(HSCUNN:<5Y-G!:_;$8.U0XUIQ1DE@ PJFA,X,M/7>
M2:S+ W_\6A-PR7:@(%[(*BDJJUO$FN (JHQH(!N8DHSD:B:+8'H:!D>'1Z.M
M3'+N4='=3?F-,F*TW\NU,A'HI^0Y/0:#AU"KX;3DELOQ\T%YH4HDJI8BL[,Y
M>:ICY8X7'GI]-W<\)XSKG^>G+\\^:O8C50&!@9PS)'?.0 PBWBOWW6(:7=UB
M;=4!U-5/V0/=U)LG)E//)659*THN)/E16.]/5LI/GE/S+_JZRJE(9!K?@LZ%
MA1D77%.>?-TX*! NT#V]QW:V\S2P?+O]!,ZDK&%NI+!AW@\Q,KL?(P2^46!2
MEOOT:"$S>8OA,)I*/L<X'DY>4AW) P_D]D!N]X'<+]HS]$!N#^3V0&X/Y/9
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M)Z)F[F)*]ZU 5K7,RZ;X:!D:;;;$<-<-'&)>;$*C+<.GA8Q 1\$G)?PXID]
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M]-U=VJ[9=XUK]LIJ%\++4;4?Y$>X\XJ/7*19.V9Y&7,*R7"Q<37%5OL&+):
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MJ0YJ0QK'EZ[2-5+)XIB'ZTV>'0QJ".K0=RIN=AGUWJU:U(:Q#70B:$1DB?8
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M2OP*YZ<O2I-J1P6Z9)9082ZL6K12WFFE(7'#+UW[5-Z(M.8%,(">UMA-[!Z
MVV-.\SQ/$RQ'&A%._V E/E)MRZ&\A3LFA+Y S@!J5+=8;# )$?YC*X6F]MB
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M/\AB%=Y1-BO$JE0B>%OD<1U5![/-@?HG476$F?3%!C]6_PQFHDS*$'Y2J#?
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MO! L7.3P>6Q3HNKG;!H\E\&Z+LJ:(+TXFD4W.5!EP3IJZW,B9A'8%UTAY[)
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MAVD[%E$V-UV!D?3;(9*@FT,KBK-->ZNLW4G*@;.S>2"X;E[-EWE+=\5;'>G
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MAJ3ZM$PU)%D,!K:Z4^I88%\? 26%HHO5K51)V4I%"HFNZ=+4D/[\@?<4UT_
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M;6C9)X_$7Z^FC<9JV4&M?'PVZ@FR ZN24:.;7?"VE>I3]K9,RY>A_R=BXIG
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ME'*M."'SU +,@(@'Z@\2VA5Q86YE\@D , $ MA$ \&H" $P @+$T.P$ )@#
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M?TB&ZM9*K9^$PWX\'%/'(S>O]/2J-H/;TU[!AHS&NS]%41!.SGYDDA%^4>4
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M:U'%\;9V3_?$M0S]HWA@WZ;<Y\KL;J$-=ZH2T/-;.\M MLV3ABBGQ0RSK=?
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MV'P\,NG5P?.7(I3^QT7\GN>4V)&R5_I+KD:4UV+ *%H:#2-1,.Y,XH8N6SM
MO[H329J8)$2I&)_ PV?$N9?'HL63D$@B>D* +;QO/2!BRQZE@#=*I59OYN+V
M1RAD42)/"L()EY1HXY0Q?_@E*+OA9 G)/V-#<W4/8F2.6)%EM*)!]!'&/-![
MBV!'1A:DEHK29%A'F& 6$\QB-#"+5\\GF,4$LQA+LQ/,8H)9_(7<W:-1<F_&
MH^1J?^.Y:%A@X&*:RPA@U:BMQ4U9ZN1+@BV7WY'#X_C 1*WLB>;[Y(D(268U
M5O3/0+(O2>>SJ3KT_G1&2>-4ML]H&9JIDS5)G1'$R7\6LRVM2I*!;NLQOZ+
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M:LTFDZ M8PQ,W#))0%I6CB-*F>;A"XQUM?PQT+HQ78XL!EP<53A6G-7VT=
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M)Z]TT FY/BN#G)-$UK5F6OQ-'3F;N.W6HE)#DIK8Y^KD<J:6V;ZZ9;LXJN"
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MPKUX_N(Y]B%?F<A<:RCVW:9*J=,)IW0!OT8P:G!EI)4N 6*4..(30<XBC8_
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M7R%H.RJ3GOH<+1BW!QM _>;$L EE6);"[*8SJ^S4T5>8:S#86N,>!H1$R V
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M_>SD-5VCMH0W\?8"SP]'P\HEP8&&G'R@/XL3Z R7K,1LE> *9HQLD,V'GOH
M"P8*BLD73A)I[(PI9!"H\<FWS,X(;=04]DN4A0':Q$(H)=Q+Q0V;VO0KAY$8
MWZ;CKQ2<M>XA3#1QJ^]J>S<*YE%,/CI%;$IDJG U6E+KH[KFE,"#93+73SR$
M*:_T @6H*EF4?=>XGBEWK 3K=?B56EYDK*?[S"Z^9"RI/\GHQ7>;F6]W %:"
M^L\Z-?>#XAUFIC)U ^) PVD3[7L6&U3>H=C/QYVU+R$.ALKW%3OT"H<OC:?&
MZ;[G!B;C+'*Z3;JW .A)BKD;B7TI:&C>1IBF3__FS#7K3PFJU6(&%R'V*($>
MUSR\A>-BINZ&=HG%@=$R[&C\]O!9TX/ZB$[P%%,_TW\UIEBSQ$Z%*ZN]*7R/
M-!:AR>'(WFB$#KI*>"YU/JB_I5*;:*JHTG([:U/>#C\=>G6\[M4Q+ 5Z1*0'
MK(](%IXTW52ZY=XFG&2P9+\]?W8@\B*0+%_U7,,G/5.-2RAYA6!G\+R#*=?J
M:*(PS(V)7]H3-[!RUC[D38W'A7S60QV]]P(3W[5K?LS]^#WTES_)ONRGF"?C
M_\H33I(AQT&90Q (.HW?"$!ZBB -*%'(N8T793#+HOSKP7JZY"?,Q5,F]:WQ
MGJS_U>3<F9P[XW'NO)F<.Y-S9RS-3LZ=R;GSXRJ53E?Q=!5OTU7\=O@JQNZF
MR?_]7^G+E[,WT>$L?IT<Q:_>OGKW;A8=OHB.U)&:OU4O7ZG_[\U_3=?W='U/
MU_=T?>_^]?W$7SU.@!X^_Z\GO.IG.TO.+X+?SZ\OSJZN@M]_.[L\^_1^D^[^
M4!>*I1O<U,]F-[)Q/'<]UIPLX.'PJ6*HKKN!GKL&D= &11\ZC!.1H3LY,Y^=
M@CKP6#_:]VROGWM]O'YS<,BUYI]Z>[Q[>_#N^?#7?YT\YI*'/_MHH!2Z.K[X
M]?CCI^ :SL7QY[,OU^<G5V%P?G%RT!5'/ZL(]-M.<:9G+PX.7SYR Z[[Y<\^
MZK^L&.#_D'[U\_O&2Y2H6*JY_"^*A.!3__6_@X PCQ7]%X55L@H^1G$9J<=5
MM7[D8CQ1CK3*EKX]>-4MXB4OZ/'W\T<IL5+_KV<OGQ_\!>;D(R_^BXC8!6%;
MG)8'WO3^!T[&=5IG,AO!R=FG[R]U]A?&(#9_M1V].WCW\FBZVAYUM?UZ=G%V
M<7UV\AO?9\%TH?VX"VV<%]>P,\->9_\'5.+@MZ:.L0Y!]:T.D1]XT8UI>>W5
MM.,#=:Z=?WP.N9@&".M-<A&NU<B^\U[$#OP Q,.W8R=^6 W2)P8I_KH(Q6 G
MIF#PY$V>O,F3-WGKO<FCP+KQV"B+/CATL.6C['[_TNPAXI:@=Q+=W?\!@_B.
MRW=J9VIG:F=J9VIG:F?'VYFLP,D*G*S R0J<K,!=L@)?OWK\Q?&#KYN?;CN^
MDKQ3;3H^2'^SX;LN>3QD[.4$NAW1!?D&[HT7+Z;[<;H?I_OQK\?<CO!6?7,X
MZNX_UK<Z?$'NEE'YA(OV]731CNBBG2S1Z::=;MK=L$0/GQ]MXZ5Y^*WAR"VZ
M'Z>K;KKJIJMNNNJFJ^Y'777OMO&J>[%E_M/IVIJNK>G:FJZMZ=KZ$=?6BX.M
M=&H>OFW=6I.%-EUUTU4W777353===0-7W<N#PQ]RV8T_D#EP:;YYM*4W-I3J
MU,[4SM3.U,[4SM3.E!TQF8&3&3B9@9,9.)F!WV8&OMA&X^WQ8;JQ7:)3.U,[
M4SM3.U,[4SO;V,YD!$Y&X&0$3D;@9 3NCA%X^&-"@3_="GRY96#-_VM6)"OX
MWVV]R/[W_P]02P,$%     @ 3H!L6=J\UW+&!P  KR8  !<   !S9VUO+3(P
M,C0P.3,P>&5X,S$Q+FAT;>U:;6_C-A+^?K^"EZ#;!+ =R['SXF0#Y)(4"'"W
M[>4"]+X=:'$4$:%$E:3LN+_^9H92[,1)U]WM=KU!"S1KB3.<(>?A,T-2IWDH
MS-EI#E*=_>WT[]VNN+1I74 91.I !E"B]KJ\$S\K\/>BVVVD+FPU=_HN#V+0
M'PS%S];=ZZF,[4$' V=M/Z=[\?ETCXV<3JR:GYTJ/15:O=_2AP?':MB'P8$\
MVA\>IX?':7HDDR0;C2;9<9:I_R5;J(KB4<>'N8'W6X4NNSF0_?%PT#L<5>%D
MIE7(QTF__]T6BYZ=9K8,:,^A?OP9NUGI+,!#Z$JC[\HQ#VDKJK;-J376C;?[
M_-\)M70S66@S'W]_JPOPX@/,Q(TM9/E]Q\O2=STXG45!KW\%] G=X\=9=/D0
M^S&ZA'8(R8"<OGK(]40'L9_TDJ<>+P]<NCL<>[ 5:F&W2[ZG.-G@OHKST0T%
MJ74R:%N.ZU*!(ZFMLXNKF]OK'ZXOSF^O?_RP[KB^^"B&+X;@NB/.#3Q(\EY<
M]L2_9.HD=$0*+NAL+D(NP[OMT=').N,X0).55 I73]= %L:C81LPC0;*,.[2
MFZ\TU*37CN'/M_YT6H8'O1%-P[7(Y12$@ZF&&?).R+47O]32(:K-'-]7U@5A
M2_&#=85(^MU_"YN)_\CR3A96W.;@9 5UT*GOB.LR[6&@CM] H 8;%ZA_2(_A
MP4 4<W%?VID!=8>+A./51$E9=*&TF$30@M2ED.5<U&5P-> (,*UPAL'P25'@
MD]/2B$RF^,H)6R )!AOE5@1*2,%[Z>8D4LA[0+M+?7I\I] 9-&DX/:$-$DBU
MPW2$8B6J"Z8G,<MUF@M?TY^%_@P<-)W0  KM#>8M2H$S'7(<H*\@90>IWPI=
MLPJ'.44U)2;SY6EX(PC<_W80""+3)<:8X+*(:0?AA^+8[);:=9DAD7"^PM^I
MJ17VB;A9"F ',:>)?"H,.R&6D&S, I(-&OPSTXAZI:GC#DG4!@40AQ;!PN8\
M^Y-*GXO,V)EO0>K@3OO@)!J2]#+ZC5YVEK#F6V=6O'TC<!MN'-QNG\3FW?;1
M(#D\\0V@FMJ ",)FF<;'';_+@;L6T@%#!$.N)P8HE (0EQ.C?4X:)%8@/Q)'
MTK/2/C76UZA'S.FLB5BIG$U!X6LO=A :"A!K,?Y7#VF.*1#$.9+236U0(MF7
MW62T ]&+9*3B4WS45"26$:/4OR#F6H)NA!+YLK:A[(FA# W1.)\#&B4HOW]Z
M^93TCS8(I3MR=V-@.N@=)S01E^!Q(X#AXISV<2QU*-VFLO;KJU#>FP#BHK$4
M,ZFM'7: _#35GED/I:#D?JAD7O#E,N<Z,)*!UJ32!5@Z#1]3HT;N1%^\-5KQ
M=M37$Z^5ED[3 '1,^)P%2NJI]I2$>6EZSMC,D=8#.H0;45:JL*;4:6TD43L.
MBYU8)'/4B*7!<D6#OR9 @LB^J _JT]EVPX \V20@[P]7@;P^93V#\_J*:Z,:
M5\)4*P*K]+:41.K2(]"IKB0$2Z=:-"&^M9QHH\.<$OQ+9FEM,? 84W%9/!%=
MJDLY=SPT ZIJ5R&F/1<D*6Z[%3O %>H=E%AG&(0VMD!%:X9$L/J.\,6UI2ND
M[S<#X'23 !R9^&HJ3<UT1>&%+,,B44\Q,/Z%8N^QH%B#?N/CR_4? Q85D3I]
MK#(GM@ZO>[!.@I"/TD E=/;Q38^8M,4YKT&(,X'^,-[(P%O G-HDS#6D&<.Y
M"@O:>S>U&[>\B+W?P964T6V:UHZ"OY0^7^BUL#[@>SJ:Q+Y\BATU)SIBYQ65
M#%&,+/9,NG$<]TS QP9THE#6CW[M1J]RZ1]K#>(_1CTHKG-X/AK2G@NC[\$T
M9PC/Y#N?/46?A_2-VHR-WLYFC$\75;M(.@N>(MI<!NJ"L@AJ:T>]LUK(/GHG
ML9@-UOG'C,\OL,NBT"$ _$92F%BL*:A=:?2/.]E!.",'>^)X_)=*ZG8-PB^U
M1O=YO=5ERJ<-NW_MN;Y<IC\W6*5AU:@1;;3/I1USJ@&QT63KQ[W/#.0]I=]8
MM7$"YGJ3SSS;HZ'?A;AFFQ)/&5Z@-JE0T<,CL[V*SJ9*115'=SBX.+@&\%@
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M$&."RR*F+< /XF@V2^VJ2$ D/F'A=YQ5 F,"-TL!; %SBLBG1-@)L83D+%M
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MT 1\*QZI3+D9)?AUT]+:\L#SF K+8D5TJ2[UN>.^-JBL3 E,6U^0Q-AW"Z^
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M+3(P,C0P.3,P>&5X,S(Q+FAT;>U9;6_;-A#^OE]Q2[#4 6Q'\OM+&L!+4K3
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M^J\S2?5L;K&L&:Q@H8#&Q_(.A0O&XWI9@09I@QF%:V.A1; $7B8R2D%G8VE
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M;:?-'"WWH17W=&)WG4YL0L4?;?".C44L+)%H*0N)7(N4%C211;:2'**1-<U
M.%7IA6 =(C*Z(B^HE\5)9/F-R-#09,U)PB!!E05#K1LTB2D0ZM+5-LR@8AB5
MEIA=*,*I1>06Z)H5.)UH2T>U5IR30V^#;]J)8H88<0D$2LRUNI5$I"'L6X"F
M""YDDE#PM*CL)]7;ET2%SJ2)2_$[)@N"+ZTA5Z,(BAR?D*_"V,?)G0_> N7*
M.-IHXA(8(_/H>Z&*PO'NE[  ^Y["/K[D[[U*JK[+]UU'[CW;7U!+ P04
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ML)I:$798 //J;L+K+.>&Q&HPGLOL!CSR\]VN_;O%U8?%MB(0("^SI%:=;?^
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MGX+^ U!+ 0(4 Q0    ( $Z ;%G6^G,J*9<! !88$@ 1              "
M 0    !S9VUO+3(P,C0P.3,P+FAT;5!+ 0(4 Q0    ( $Z ;%FT0']!?1
M /RB   1              "  5B7 0!S9VUO+3(P,C0P.3,P+GAS9%!+ 0(4
M Q0    ( $Z ;%D] ;9K*!H  (GS   5              "  02H 0!S9VUO
M+3(P,C0P.3,P7V-A;"YX;6Q02P$"% ,4    " !.@&Q9)&@;64-*  "8+@,
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M,#(T,#DS,'AE>#$P,2YH=&U02P$"% ,4    " !.@&Q9VKS7<L8'  "O)@
M%P              @ '&'P0 <V=M;RTR,#(T,#DS,'AE>#,Q,2YH=&U02P$"
M% ,4    " !.@&Q9SN]+5M('   B)P  %P              @ '!)P0 <V=M
M;RTR,#(T,#DS,'AE>#,Q,BYH=&U02P$"% ,4    " !.@&Q9$&(>* P&  !N
M&P  %P              @ '(+P0 <V=M;RTR,#(T,#DS,'AE>#,R,2YH=&U0
M2P$"% ,4    " !.@&Q9/^AE@ZH)   1&@  '               @ $)-@0
M=&AI<F1A;65N9&UE;G1T;VQE87-E86=R+FAT;5!+!08     "P + .@"  #M
%/P0    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>sgmo-20240930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sgmo="http://www.sangamo.com/20240930"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sgmo-20240930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2024-11-07</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInAgreementEstimateMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInAgreementEstimateSeptember2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInAgreementEstimateSeptember2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:LicenseTechnologyTransferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:GenentechRocheGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherLicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherCollaborationAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherCollaborationAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherCollaborationAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:OtherCollaborationAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:EquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:LeaseholdImprovementsAndConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-26</startDate>
            <endDate>2024-03-26</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2024-03-26</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-26</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-26</startDate>
            <endDate>2024-03-26</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:CommonWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-26</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-26</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:CommonWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-21</startDate>
            <endDate>2024-03-21</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-21</startDate>
            <endDate>2024-03-21</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-08</startDate>
            <endDate>2024-04-08</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sgmo:PreFundedCommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-08</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-26</startDate>
            <endDate>2023-04-26</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-26</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:April2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-01</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sgmo:FullTimeEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-01</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sgmo:ContractedEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-01</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:November2023RestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-01</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sgmo:FranceRestructuringPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="performance_obligation">
        <measure>sgmo:performance_obligation</measure>
    </unit>
    <unit id="milestone">
        <measure>sgmo:milestone</measure>
    </unit>
    <unit id="product">
        <measure>sgmo:product</measure>
    </unit>
    <unit id="employee">
        <measure>sgmo:employee</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-25">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-26">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-27">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-28">0001001233</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-29">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-243" id="f-745">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-30171</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">SANGAMO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">68-0359556</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">501 Canal Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Richmond</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">94804</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">970-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">SGMO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">208646870</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-30" unitRef="usd">39201000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">45204000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">35798000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">10496000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">923000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">8434000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">12403000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">58131000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">94328000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">19146000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">26874000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">17766000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">25991000</us-gaap:OperatingLeaseRightOfUseAsset>
    <sgmo:IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">14720000</sgmo:IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets>
    <sgmo:IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">16627000</sgmo:IncomeTaxRefundableResearchCreditsAndOtherNonCurrentAssets>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">111263000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">165320000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">19791000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">15259000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">10961000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">8918000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">11635000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">23554000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">774000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">43161000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">47731000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">27727000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">33515000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">1241000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">1187000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-64" unitRef="usd">72129000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">82433000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-66" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-67" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-68" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-70" unitRef="usd">2086000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">1781000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-3" decimals="-3" id="f-72" unitRef="usd">1522192000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">1492077000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-74" unitRef="usd">-1480921000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">-1406376000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-76" unitRef="usd">-4223000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">-4595000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-78" unitRef="usd">39134000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">82887000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-80" unitRef="usd">111263000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">165320000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-82" unitRef="usd">49412000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-83" unitRef="usd">9398000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-84" unitRef="usd">50249000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-85" unitRef="usd">174190000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-86" unitRef="usd">27732000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-87" unitRef="usd">57089000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-88" unitRef="usd">87846000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-89" unitRef="usd">183351000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-90" unitRef="usd">11049000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-91" unitRef="usd">13918000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-92" unitRef="usd">34861000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-93" unitRef="usd">48068000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-5" decimals="-3" id="f-94" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-6" decimals="-3" id="f-95" unitRef="usd">44799000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="-3" id="f-96" unitRef="usd">5521000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-7" decimals="-3" id="f-97" unitRef="usd">65232000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-5" decimals="-3" id="f-98" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-6" decimals="-3" id="f-99" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-1" decimals="-3" id="f-100" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-7" decimals="-3" id="f-101" unitRef="usd">89485000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-102" unitRef="usd">38781000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-103" unitRef="usd">115806000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-104" unitRef="usd">128228000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-3" id="f-105" unitRef="usd">386136000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-106" unitRef="usd">10631000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-107" unitRef="usd">-106408000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-108" unitRef="usd">-77979000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-109" unitRef="usd">-211946000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome contextRef="c-5" decimals="-3" id="f-110" unitRef="usd">129000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="c-6" decimals="-3" id="f-111" unitRef="usd">3515000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="c-1" decimals="-3" id="f-112" unitRef="usd">3694000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="c-7" decimals="-3" id="f-113" unitRef="usd">9610000</us-gaap:InterestAndOtherIncome>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-114" unitRef="usd">10760000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-115" unitRef="usd">-102893000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-116" unitRef="usd">-74285000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-117" unitRef="usd">-202336000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-118" unitRef="usd">88000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-119" unitRef="usd">1270000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">260000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-121" unitRef="usd">-4800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-122" unitRef="usd">10672000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-123" unitRef="usd">-104163000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">-74545000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-125" unitRef="usd">-197536000</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-5" decimals="-3" id="f-126" unitRef="usd">1287000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-6" decimals="-3" id="f-127" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-7" decimals="-3" id="f-129" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-5" decimals="-3" id="f-130" unitRef="usd">9385000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-6" decimals="-3" id="f-131" unitRef="usd">-104163000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">-74545000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-7" decimals="-3" id="f-133" unitRef="usd">-197536000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-134"
      unitRef="usdPerShare">0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-135"
      unitRef="usdPerShare">-0.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-136"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-137"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-138"
      unitRef="usdPerShare">0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-139"
      unitRef="usdPerShare">-0.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-140"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-141"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-142" unitRef="shares">208345000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-3" id="f-143" unitRef="shares">177171000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-144" unitRef="shares">198849000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-3" id="f-145" unitRef="shares">173375000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-146" unitRef="shares">214325000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="-3" id="f-147" unitRef="shares">177171000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-148" unitRef="shares">198849000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-3" id="f-149" unitRef="shares">173375000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-150" unitRef="usd">10672000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-151" unitRef="usd">-104163000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-152" unitRef="usd">-74545000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-153" unitRef="usd">-197536000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-154" unitRef="usd">1664000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-3" id="f-155" unitRef="usd">-1144000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-156" unitRef="usd">371000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-3" id="f-157" unitRef="usd">981000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-158" unitRef="usd">4000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-3" id="f-159" unitRef="usd">-5000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-160" unitRef="usd">-234000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-3" id="f-161" unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-5" decimals="-3" id="f-162" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-6" decimals="-3" id="f-163" unitRef="usd">494000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-164" unitRef="usd">-233000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-7" decimals="-3" id="f-165" unitRef="usd">840000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-166" unitRef="usd">12332000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-6" decimals="-3" id="f-167" unitRef="usd">-104808000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-168" unitRef="usd">-74173000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-7" decimals="-3" id="f-169" unitRef="usd">-195713000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-170" unitRef="shares">208201140</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-171" unitRef="usd">2082000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-172" unitRef="usd">1519084000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-173" unitRef="usd">-1491593000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-174" unitRef="usd">-5883000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-175" unitRef="usd">23690000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-13"
      decimals="INF"
      id="f-176"
      unitRef="shares">418572</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-13" decimals="-3" id="f-177" unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-14" decimals="-3" id="f-178" unitRef="usd">-207000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-5" decimals="-3" id="f-179" unitRef="usd">-203000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-180" unitRef="usd">3315000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-181" unitRef="usd">3315000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c-15" decimals="-3" id="f-182" unitRef="usd">-1664000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c-5" decimals="-3" id="f-183" unitRef="usd">-1664000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-3" id="f-184" unitRef="usd">4000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-185" unitRef="usd">4000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-186" unitRef="usd">10672000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-187" unitRef="usd">10672000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-17"
      decimals="INF"
      id="f-188"
      unitRef="shares">208619712</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-189" unitRef="usd">2086000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-190" unitRef="usd">1522192000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-191" unitRef="usd">-1480921000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-192" unitRef="usd">-4223000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-193" unitRef="usd">39134000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-21"
      decimals="INF"
      id="f-194"
      unitRef="shares">178133548</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-195" unitRef="usd">1781000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-196" unitRef="usd">1492077000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-197" unitRef="usd">-1406376000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-198" unitRef="usd">-4595000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-199" unitRef="usd">82887000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-25"
      decimals="INF"
      id="f-200"
      unitRef="shares">24761905</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-25" decimals="-3" id="f-201" unitRef="usd">248000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-26" decimals="-3" id="f-202" unitRef="usd">21540000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">21788000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-25"
      decimals="INF"
      id="f-204"
      unitRef="shares">3809523</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-25" decimals="-3" id="f-205" unitRef="usd">38000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-26" decimals="-3" id="f-206" unitRef="usd">33000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">71000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-25"
      decimals="INF"
      id="f-208"
      unitRef="shares">1535250</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-25" decimals="-3" id="f-209" unitRef="usd">15000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-26" decimals="-3" id="f-210" unitRef="usd">-699000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">-684000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-25"
      decimals="INF"
      id="f-212"
      unitRef="shares">379486</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-25" decimals="-3" id="f-213" unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-26" decimals="-3" id="f-214" unitRef="usd">142000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">146000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-26" decimals="-3" id="f-216" unitRef="usd">9099000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">9099000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c-27" decimals="-3" id="f-218" unitRef="usd">-371000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">-371000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-27" decimals="-3" id="f-220" unitRef="usd">-234000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">-234000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-27" decimals="-3" id="f-222" unitRef="usd">-233000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">-233000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-28" decimals="-3" id="f-224" unitRef="usd">-74545000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">-74545000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-17"
      decimals="INF"
      id="f-226"
      unitRef="shares">208619712</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-227" unitRef="usd">2086000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-228" unitRef="usd">1522192000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-229" unitRef="usd">-1480921000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-230" unitRef="usd">-4223000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-231" unitRef="usd">39134000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-29"
      decimals="INF"
      id="f-232"
      unitRef="shares">177074546</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-233" unitRef="usd">1771000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-234" unitRef="usd">1479725000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-235" unitRef="usd">-1241918000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-236" unitRef="usd">-5936000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-237" unitRef="usd">233642000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-34"
      decimals="INF"
      id="f-238"
      unitRef="shares">205129</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-34" decimals="-3" id="f-239" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-35" decimals="-3" id="f-240" unitRef="usd">-103000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-6" decimals="-3" id="f-241" unitRef="usd">-101000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-35" decimals="-3" id="f-242" unitRef="usd">6189000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-243" unitRef="usd">6189000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c-36" decimals="-3" id="f-244" unitRef="usd">1144000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c-6" decimals="-3" id="f-245" unitRef="usd">1144000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-36" decimals="-3" id="f-246" unitRef="usd">-5000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-3" id="f-247" unitRef="usd">-5000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-36" decimals="-3" id="f-248" unitRef="usd">494000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-6" decimals="-3" id="f-249" unitRef="usd">494000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-37" decimals="-3" id="f-250" unitRef="usd">-104163000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-251" unitRef="usd">-104163000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-38"
      decimals="INF"
      id="f-252"
      unitRef="shares">177279675</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-253" unitRef="usd">1773000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-254" unitRef="usd">1485811000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-255" unitRef="usd">-1346081000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-256" unitRef="usd">-6581000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-257" unitRef="usd">134922000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-43"
      decimals="INF"
      id="f-258"
      unitRef="shares">166793320</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-259" unitRef="usd">1668000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-260" unitRef="usd">1450239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-261" unitRef="usd">-1148545000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-262" unitRef="usd">-8404000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-263" unitRef="usd">294958000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-48"
      decimals="INF"
      id="f-264"
      unitRef="shares">8249261</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-48" decimals="-3" id="f-265" unitRef="usd">83000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-49" decimals="-3" id="f-266" unitRef="usd">15023000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-7" decimals="-3" id="f-267" unitRef="usd">15106000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-48"
      decimals="INF"
      id="f-268"
      unitRef="shares">1481508</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-48" decimals="-3" id="f-269" unitRef="usd">15000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-49" decimals="-3" id="f-270" unitRef="usd">-1419000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-7" decimals="-3" id="f-271" unitRef="usd">-1404000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-48"
      decimals="INF"
      id="f-272"
      unitRef="shares">755586</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-48" decimals="-3" id="f-273" unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-49" decimals="-3" id="f-274" unitRef="usd">712000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-7" decimals="-3" id="f-275" unitRef="usd">719000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-49" decimals="-3" id="f-276" unitRef="usd">21256000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-7" decimals="-3" id="f-277" unitRef="usd">21256000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c-50" decimals="-3" id="f-278" unitRef="usd">-981000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c-7" decimals="-3" id="f-279" unitRef="usd">-981000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-50" decimals="-3" id="f-280" unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-3" id="f-281" unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-50" decimals="-3" id="f-282" unitRef="usd">840000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-7" decimals="-3" id="f-283" unitRef="usd">840000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-51" decimals="-3" id="f-284" unitRef="usd">-197536000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-285" unitRef="usd">-197536000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-38"
      decimals="INF"
      id="f-286"
      unitRef="shares">177279675</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-287" unitRef="usd">1773000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-288" unitRef="usd">1485811000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-289" unitRef="usd">-1346081000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-290" unitRef="usd">-6581000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-291" unitRef="usd">134922000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-292" unitRef="usd">-74545000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-293" unitRef="usd">-197536000</us-gaap:NetIncomeLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="-3" id="f-294" unitRef="usd">5521000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-7" decimals="-3" id="f-295" unitRef="usd">65232000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-296" unitRef="usd">3866000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-7" decimals="-3" id="f-297" unitRef="usd">13238000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-298" unitRef="usd">273000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-7" decimals="-3" id="f-299" unitRef="usd">2031000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-300" unitRef="usd">3360000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-7" decimals="-3" id="f-301" unitRef="usd">5945000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-302" unitRef="usd">9099000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-3" id="f-303" unitRef="usd">21256000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-304" unitRef="usd">4000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-7" decimals="-3" id="f-305" unitRef="usd">-1119000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-1" decimals="-3" id="f-306" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-7" decimals="-3" id="f-307" unitRef="usd">89485000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">18000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-309" unitRef="usd">-6195000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="c-1" decimals="-3" id="f-310" unitRef="usd">-402000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="c-7" decimals="-3" id="f-311" unitRef="usd">-192000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-312" unitRef="usd">9573000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-7" decimals="-3" id="f-313" unitRef="usd">-2530000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-314" unitRef="usd">-6403000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-7" decimals="-3" id="f-315" unitRef="usd">-5159000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-316" unitRef="usd">-6851000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-7" decimals="-3" id="f-317" unitRef="usd">-5220000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-1" decimals="-3" id="f-318" unitRef="usd">2060000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-7" decimals="-3" id="f-319" unitRef="usd">-4182000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-320" unitRef="usd">-4081000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-321" unitRef="usd">-3737000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-1" decimals="-3" id="f-322" unitRef="usd">36000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-7" decimals="-3" id="f-323" unitRef="usd">112000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-324" unitRef="usd">774000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-7" decimals="-3" id="f-325" unitRef="usd">-159671000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-326" unitRef="usd">-63788000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-327" unitRef="usd">-174304000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-3" id="f-328" unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-7" decimals="-3" id="f-329" unitRef="usd">59551000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities contextRef="c-1" decimals="-3" id="f-330" unitRef="usd">1110000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities contextRef="c-7" decimals="-3" id="f-331" unitRef="usd">193858000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-332" unitRef="usd">34730000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-7" decimals="-3" id="f-333" unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c-1" decimals="-3" id="f-334" unitRef="usd">475000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c-7" decimals="-3" id="f-335" unitRef="usd">0</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-336" unitRef="usd">115000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-337" unitRef="usd">18484000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">36200000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-339" unitRef="usd">115823000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-1" decimals="-3" id="f-340" unitRef="usd">21924000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-7" decimals="-3" id="f-341" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-7" decimals="-3" id="f-343" unitRef="usd">15106000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">684000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-7" decimals="-3" id="f-345" unitRef="usd">1404000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockPlans contextRef="c-1" decimals="-3" id="f-346" unitRef="usd">146000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans contextRef="c-7" decimals="-3" id="f-347" unitRef="usd">719000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-348" unitRef="usd">21386000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-349" unitRef="usd">14421000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-350" unitRef="usd">199000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-351" unitRef="usd">130000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-352" unitRef="usd">-6003000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-353" unitRef="usd">-43930000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-354" unitRef="usd">46704000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-47" decimals="-3" id="f-355" unitRef="usd">101944000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-356" unitRef="usd">40701000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-42" decimals="-3" id="f-357" unitRef="usd">58014000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-358" unitRef="usd">389000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-7" decimals="-3" id="f-359" unitRef="usd">2757000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-360">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organization and Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo Therapeutics, Inc. (&#x201c;Sangamo&#x201d; or &#x201c;the Company&#x201d;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. The Company believes its zinc finger (&#x201c;ZF&#x201d;) epigenetic regulators are ideally suited to potentially address devastating neurology disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system (&#x201c;CNS&#x201d;), in preclinical studies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2023, the Company announced its strategic transformation into a neurology-focused genomic medicine company focused on developing epigenetic regulation therapies designed to address serious neurological diseases and novel adeno-associated virus (&#x201c;AAV&#x201d;) capsid delivery technology. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three and nine months ended September&#160;30, 2024 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024. The Condensed Consolidated Balance Sheet data at December&#160;31, 2023 was derived from the audited Consolidated Financial Statements included in Sangamo&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2023 (the &#x201c;2023 Annual Report&#x201d;) as filed with the SEC on March 13,&#160;2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2023, included in the 2023 Annual Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity, Going Concern, and Capital Resources&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects will require several years and substantial expenditures to complete and ultimately may be unsuccessful. In recent years, the Company&#x2019;s operations have been funded primarily through collaborations and strategic partnerships, research grants and from the issuance of equity securities. As of September&#160;30, 2024, the Company had capital resources of $39.2&#160;million consisting of cash and cash equivalents. On August 2, 2024, the Company entered into a global epigenetic regulation and capsid delivery license agreement (the &#x201c;Genentech Agreement&#x201d;) with Genentech, Inc., a member of the Roche Group (&#x201c;Genentech&#x201d;), under which the Company received a $40.0&#160;million upfront license fee in August 2024 and a $10.0&#160;million milestone payment in October 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Accounting Standard Codification (&#x201c;ASC&#x201d;) Topic 205-40, Presentation of Financial Statements&#x2014;Going Concern (&#x201c;ASC Topic 205-40&#x201d;), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the Condensed Consolidated Financial Statements are issued. As required under ASC Topic 205-40, management&#x2019;s evaluation should initially not take into consideration the potential mitigating effects of management&#x2019;s plans that have not been fully implemented as of the date the Condensed Consolidated Financial Statements are issued. When substantial doubt exists, management evaluates whether the mitigating effects of its plans sufficiently alleviates the substantial doubt about the Company&#x2019;s ability to continue as a going concern. The mitigating effects of management&#x2019;s plans, however, are only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (ii) it is probable that the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans must have been approved by the Company&#x2019;s board of directors before the date that the financial statements are issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s history of significant losses, its negative cash flows from operations, its limited liquidity resources currently on hand, and its dependence on additional financing to fund its operations after the current resources are exhausted raise substantial doubt about its ability to continue to operate as a going concern within one year after the date that the Condensed Consolidated Financial Statements are issued. Based on the Company&#x2019;s current operating plan, its cash and cash equivalents as of September&#160;30, 2024, together with the $10.0&#160;million milestone payment that the Company received from Genentech in October&#160;2024, is expected to allow the Company to meet its liquidity requirements only into the first quarter of 2025, which is less than one year following the date these Condensed Consolidated Financial Statements are issued. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Successful completion of the Company&#x2019;s development programs and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company&#x2019;s cost structure and operating plan. Management&#x2019;s plans include, among other things, pursuing one or more of the following steps to raise additional capital, none of which can be guaranteed or are entirely within the Company&#x2019;s control:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;raise funding through the sale of the Company&#x2019;s common stock, including sales under the at-the-market offering program with Jefferies LLC;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;raise funding through debt or royalty financing; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;establish collaborations with potential partners to advance the Company&#x2019;s product pipeline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company is unable to raise capital on acceptable terms, or at all, or if it is unable to procure collaboration arrangements or external direct investments to advance its programs, the Company would be required to discontinue some or all of its operations or develop and implement a plan to further extend payables, reduce overhead or scale back its current operating plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan would be successful. Additional capital may not be available to the Company on a timely basis, on terms that are acceptable or at all. In particular, the perception of the Company&#x2019;s ability to continue to operate as a going concern may make it more difficult to obtain financing for the continuation of its operations, particularly in light of currently challenging macroeconomic and market conditions. Further, the Company may be unable to attract new investments as a result of the speculative nature of its newly reprioritized core neurology preclinical programs. If adequate funds are not available to the Company on a timely basis, or at all, the Company will be required to take additional actions to address its liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering its research and development activities, which would have a material adverse effect on its business and prospects, or the Company may be required to cease operations entirely, liquidate all or a portion of its assets, and/or seek protection under the U.S. Bankruptcy Code.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, useful lives and impairment of long-lived assets, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, the Company recorded additional revenue related to a change in estimate in connection with the collaboration agreement with Kite Pharma, Inc., a Gilead Sciences, Inc. subsidiary (&#x201c;Kite&#x201d;). This adjustment was driven by a reduction in the estimated future level of the Company&#x2019;s research and development services and as a result, future project costs. This resulted in an increase in proportional cumulative performance on this collaboration and an increase in revenue of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$8.9&#160;million, a decrease in net loss of $8.9&#160;million, and a decrease in the Company&#x2019;s basic and diluted net loss per share of $0.05 for the nine months ended September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2023, the Company recorded additional revenue related to a change in estimate in connection with the collaboration agreement with Kite. This adjustment was driven by a further reduction in the estimated future level of the Company&#x2019;s research and development services and as a result, future project costs. This resulted in an increase in proportional cumulative performance on this collaboration and an increase in revenue by $4.9&#160;million, a decrease in net loss by $4.9&#160;million, and a decrease in the Company&#x2019;s basic and diluted net loss per share of $0.03 for the three and nine months ended September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its revenues pursuant to the provisions of ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 606&#x201d;). The Company&#x2019;s contract revenues are derived from collaboration agreements including licensing arrangements and research services. Research and license agreements typically include nonrefundable upfront signing or license fees, payments at negotiated rates for time incurred by Company researchers, third-party cost reimbursements, additional target selection fees, sublicense fees, milestone payments tied to ongoing development and product commercialization, and royalties on future licensees&#x2019; product sales. All funds received from the Company&#x2019;s collaboration partners are generally not refundable. Non-refundable upfront fees are fixed at the commencement of the contract. All other fees represent variable consideration in contracts. For contracts that contain a provision where the Company reimburses its customer for certain costs they incur and where the Company does not acquire any distinct goods or services in exchange for such payments, the Company accounts for it as a reduction to the contract transaction price. Deferred revenue primarily represents the portion of nonrefundable upfront fees or milestone payments received but not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s performance obligations in its collaboration agreements frequently represent distinct bundles of licenses of intellectual property and research and development services, with these components being individually non-distinct as the customer cannot benefit from the licenses independently from the research and development activities. In some instances, the Company has determined that the customer can benefit from the licensed intellectual property separately from the research and development activities, and the licenses of intellectual property and research and development services are individual distinct performance obligations. Options to license the Company&#x2019;s intellectual property and/or acquire research and development services also represent performance obligations when they grant customers a material right, e.g. a right to a discount the customer would not have received if they did not purchase the Company&#x2019;s services under the existing contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from grants of licenses to intellectual property that are distinct and therefore separate performance obligations are recognized at the point in time when the license is effective and the Company has completed the transfer of a copy of the licensed intellectual property to the customer. Revenues from distinct research and development services as well as from distinct bundles of licenses of intellectual property and research and development services, are recognized over time using a proportional performance method. Under this method, revenue is recognized by measuring progress towards satisfaction of the relevant performance obligation using a measure that best depicts the progress towards satisfaction of the relevant performance obligation. For most of the Company&#x2019;s agreements the measure of progress is an input measure based on a level of effort incurred, which includes the value of actual time by Company researchers plus third-party cost reimbursements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration allocated to options that include material rights is deferred until the options are exercised or expire. The exercise of such options is accounted for as contract continuation, with target selection fees and estimated variable consideration included in the transaction price at that time and allocated specifically to the respective target&#x2019;s performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. For variable consideration, the amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. A cumulative catch-up is then recorded in the current period to reflect the updated transaction price and the updated measure of progress. The estimated period &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of performance and level of effort, including the value of Company researchers&#x2019; time and third-party costs, are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current expectations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, discount rates and probabilities of exercise of technical and regulatory success, and the expected level of effort for research and development services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract modifications occur when the price and/or scope of an arrangement changes. If the modification consists of adding new distinct goods or services in exchange for consideration that reflects standalone selling prices of these goods and services, the modification is accounted for as a separate contract with the customer. Otherwise, if the remaining goods and services are distinct from those previously provided, the existing contract is considered terminated, and the remaining consideration is allocated to the remaining goods and services as if this was a newly signed contract. If the remaining goods and services are not distinct from those previously provided, the effects of the modification are accounted for in a manner similar to the effect of a change in the estimated measure of progress, with cumulative catch-up in revenue recorded at the time of the modification. If some of the remaining goods and services are distinct from those previously provided and others are not, to account for the effects of the modification the Company applies principles consistent with the objectives of the modification accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from collaboration and license agreements as a percentage of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Genentech, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other license agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the carrying value of long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable. If a change in circumstance occurs that indicates long-lived assets may be impaired, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. The long-lived asset evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. The Company reassesses the composition of its asset groups whenever there are changes in its operations that affect whether the cash flows associated with assets included in asset groups are largely independent. If the impairment review indicates that the carrying amount of an asset group is not recoverable, an impairment loss is measured as the amount by which the carrying amount of an asset group exceeds its fair value. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, general macroeconomic conditions, conditions specific to the industry and market, an adverse change in legal factors, business climate or operational performance of the business, and sustained decline in the stock price and market capitalization compared to the net book value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Calculating the fair value of a reporting unit, an asset group and an individual asset involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During a portion of the nine months ended September 30, 2023, the Company had goodwill and indefinite-lived intangible assets (IPR&amp;amp;D). These assets were written off in full as the Company recognized impairment losses during the nine months ended September&#160;30,&#160;2023, see&#160;Note&#160;6&#160;&#x2013;&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment and Write-Down of Assets Held For Sale&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo considers all highly liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in money market accounts and U.S. government-sponsored entity debt securities. Restricted cash consisted of a letter of credit for $1.5&#160;million, representing a deposit for the lease of office and research and development laboratory facilities in Brisbane, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. Right-of-use assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the implicit rate in the Company&#x2019;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases, calculated as the sum of the amortization of the right of use asset and accretion of the lease liability, is recognized on a straight-line basis over the lease term, unless the right of use asset was previously written down due to impairment. The Company evaluates the lease arrangement for impairment whenever events or changes in circumstances indicate that the carrying amounts of the right-of-use asset may not be fully recoverable. To the extent an impairment of the right-of-use asset is identified, the Company will recognize the impairment expense and subsequently amortize the remaining right of use asset into rent expense on a straight-line basis (unless another systematic basis is more representative of the pattern in which the Company expects to consume the future economic benefits from the asset) from the date of impairment to the earlier of the end of the right-of-use asset&#x2019;s useful life or the end of the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If there is a change to the terms and conditions of a contract that results in a change in the scope of or the consideration for a lease, the Company determines if the lease modification results in a separate contract or a change in the accounting for the existing lease and not a separate contract. For lease modifications that result in a separate contract, the Company accounts for the new contract in the same manner as other new leases. For lease modifications that do not result in a separate contract, the Company reassesses the classification of the lease at the effective date of the modification, remeasures and reallocates the remaining consideration in the contract, and remeasures the lease liability using the discount rate determined at the effective date of the modification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected not to separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected not to apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants to Purchase Shares of Company Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the accounting classification of warrants to purchase shares of its stock as either liability or equity by first assessing whether the warrants meet liability classification criteria in accordance with ASC 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 480&#x201d;). Under ASC 480, a financial instrument other than an outstanding share that embodies an obligation to repurchase the entity&#x2019;s shares or is indexed to such an obligation, and that requires or may require the entity to settle it by transferring assets, is classified as a liability. In addition, a financial instrument that embodies an unconditional obligation, or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares must be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception, (b) variations in something other than the fair value of the issuer&#x2019;s equity shares, or (c) variations inversely related to changes in the fair value of the issuer&#x2019;s equity shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If financial instruments, such as warrants, are not required to be classified as liabilities under ASC 480, the Company assesses whether such instruments are indexed to the Company&#x2019;s own stock under ASC 815-40. In order for an instrument to be considered indexed to an entity&#x2019;s own stock, its settlement amount must always equal the difference between the following: (a)&#160;the fair value of a fixed number of the Company&#x2019;s equity shares, and (b) a fixed monetary amount or a fixed amount of a debt instrument issued by the Company. Certain adjustments to this amount are allowed, if they are based on non-levered inputs into the fair value of a fixed price/fixed consideration-option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants are also required to meet equity classification criteria to be classified in stockholders&#x2019; equity. Under these criteria, warrants have to provide for settlement in shares, or cash or shares at the entity&#x2019;s option. With limited exceptions, a possibility of net cash settlement under any circumstances will result in the warrants being classified as liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants classified as equity are generally measured using the Black-Scholes valuation model on the date of issuance. Warrants classified as liabilities are remeasured at any reporting date using valuation models consistent with their terms, with changes recognized in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records employee severance costs based on whether the termination benefits are provided under an on-going benefit arrangement or under a one-time benefit arrangement. The Company accounts for on-going termination benefit arrangements, such as those arising from employment agreements, applicable regulations or past practices, in accordance with ASC Topic 712, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Nonretirement Postemployment Benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 712&#x201d;). Under ASC 712, liabilities for post-employment benefits related to past services and that vest or are accumulated over time are recorded at the time the obligations are probable of being incurred and can be reasonably estimated. The Company accounts for one-time employment benefit arrangements in accordance with ASC Topic 420, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exit or Disposal Cost Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 420&#x201d;). One-time termination benefits are expensed at the date the entity notifies the employee, unless the employee must provide future service over a period extending past the minimum notification period, in which case the benefits are expensed ratably over the future service period. Other associated costs are recognized in the period in which the liability is incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred to terminate contracts are recognized upon their termination, e.g., when notice of termination is provided to the counterparty. Costs related to contracts without future benefit are recognized at the cease-use date. Other exit-related costs are recognized as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2023-07&#x201d;), which requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC Topic 280, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2023-09&#x201d;), which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-361">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three and nine months ended September&#160;30, 2024 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2024. The Condensed Consolidated Balance Sheet data at December&#160;31, 2023 was derived from the audited Consolidated Financial Statements included in Sangamo&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2023 (the &#x201c;2023 Annual Report&#x201d;) as filed with the SEC on March 13,&#160;2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-362">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-5" id="f-363" unitRef="usd">39200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ContractWithCustomerLiability contextRef="c-52" decimals="-5" id="f-364" unitRef="usd">40000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-53" decimals="-5" id="f-365" unitRef="usd">10000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-53" decimals="-5" id="f-366" unitRef="usd">10000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-367">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, useful lives and impairment of long-lived assets, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <sgmo:IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-54" decimals="-5" id="f-368" unitRef="usd">8900000</sgmo:IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:IncreaseDecreaseInNetIncomeLossAttributableToParent contextRef="c-54" decimals="-5" id="f-369" unitRef="usd">-8900000</sgmo:IncreaseDecreaseInNetIncomeLossAttributableToParent>
    <sgmo:IncreaseDecreaseInEarningsPerShareDiluted
      contextRef="c-54"
      decimals="2"
      id="f-370"
      unitRef="usdPerShare">-0.05</sgmo:IncreaseDecreaseInEarningsPerShareDiluted>
    <sgmo:IncreaseDecreaseInEarningsPerShareBasic
      contextRef="c-54"
      decimals="2"
      id="f-371"
      unitRef="usdPerShare">-0.05</sgmo:IncreaseDecreaseInEarningsPerShareBasic>
    <sgmo:IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-55" decimals="-5" id="f-372" unitRef="usd">4900000</sgmo:IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:IncreaseDecreaseInNetIncomeLossAttributableToParent contextRef="c-55" decimals="-5" id="f-373" unitRef="usd">-4900000</sgmo:IncreaseDecreaseInNetIncomeLossAttributableToParent>
    <sgmo:IncreaseDecreaseInEarningsPerShareDiluted
      contextRef="c-55"
      decimals="2"
      id="f-374"
      unitRef="usdPerShare">-0.03</sgmo:IncreaseDecreaseInEarningsPerShareDiluted>
    <sgmo:IncreaseDecreaseInEarningsPerShareDiluted
      contextRef="c-56"
      decimals="2"
      id="f-375"
      unitRef="usdPerShare">-0.03</sgmo:IncreaseDecreaseInEarningsPerShareDiluted>
    <sgmo:IncreaseDecreaseInEarningsPerShareBasic
      contextRef="c-56"
      decimals="2"
      id="f-376"
      unitRef="usdPerShare">-0.03</sgmo:IncreaseDecreaseInEarningsPerShareBasic>
    <sgmo:IncreaseDecreaseInEarningsPerShareBasic
      contextRef="c-55"
      decimals="2"
      id="f-377"
      unitRef="usdPerShare">-0.03</sgmo:IncreaseDecreaseInEarningsPerShareBasic>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-378">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its revenues pursuant to the provisions of ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 606&#x201d;). The Company&#x2019;s contract revenues are derived from collaboration agreements including licensing arrangements and research services. Research and license agreements typically include nonrefundable upfront signing or license fees, payments at negotiated rates for time incurred by Company researchers, third-party cost reimbursements, additional target selection fees, sublicense fees, milestone payments tied to ongoing development and product commercialization, and royalties on future licensees&#x2019; product sales. All funds received from the Company&#x2019;s collaboration partners are generally not refundable. Non-refundable upfront fees are fixed at the commencement of the contract. All other fees represent variable consideration in contracts. For contracts that contain a provision where the Company reimburses its customer for certain costs they incur and where the Company does not acquire any distinct goods or services in exchange for such payments, the Company accounts for it as a reduction to the contract transaction price. Deferred revenue primarily represents the portion of nonrefundable upfront fees or milestone payments received but not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s performance obligations in its collaboration agreements frequently represent distinct bundles of licenses of intellectual property and research and development services, with these components being individually non-distinct as the customer cannot benefit from the licenses independently from the research and development activities. In some instances, the Company has determined that the customer can benefit from the licensed intellectual property separately from the research and development activities, and the licenses of intellectual property and research and development services are individual distinct performance obligations. Options to license the Company&#x2019;s intellectual property and/or acquire research and development services also represent performance obligations when they grant customers a material right, e.g. a right to a discount the customer would not have received if they did not purchase the Company&#x2019;s services under the existing contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from grants of licenses to intellectual property that are distinct and therefore separate performance obligations are recognized at the point in time when the license is effective and the Company has completed the transfer of a copy of the licensed intellectual property to the customer. Revenues from distinct research and development services as well as from distinct bundles of licenses of intellectual property and research and development services, are recognized over time using a proportional performance method. Under this method, revenue is recognized by measuring progress towards satisfaction of the relevant performance obligation using a measure that best depicts the progress towards satisfaction of the relevant performance obligation. For most of the Company&#x2019;s agreements the measure of progress is an input measure based on a level of effort incurred, which includes the value of actual time by Company researchers plus third-party cost reimbursements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration allocated to options that include material rights is deferred until the options are exercised or expire. The exercise of such options is accounted for as contract continuation, with target selection fees and estimated variable consideration included in the transaction price at that time and allocated specifically to the respective target&#x2019;s performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. For variable consideration, the amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. A cumulative catch-up is then recorded in the current period to reflect the updated transaction price and the updated measure of progress. The estimated period &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of performance and level of effort, including the value of Company researchers&#x2019; time and third-party costs, are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current expectations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, discount rates and probabilities of exercise of technical and regulatory success, and the expected level of effort for research and development services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract modifications occur when the price and/or scope of an arrangement changes. If the modification consists of adding new distinct goods or services in exchange for consideration that reflects standalone selling prices of these goods and services, the modification is accounted for as a separate contract with the customer. Otherwise, if the remaining goods and services are distinct from those previously provided, the existing contract is considered terminated, and the remaining consideration is allocated to the remaining goods and services as if this was a newly signed contract. If the remaining goods and services are not distinct from those previously provided, the effects of the modification are accounted for in a manner similar to the effect of a change in the estimated measure of progress, with cumulative catch-up in revenue recorded at the time of the modification. If some of the remaining goods and services are distinct from those previously provided and others are not, to account for the effects of the modification the Company applies principles consistent with the objectives of the modification accounting.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock contextRef="c-1" id="f-379">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from collaboration and license agreements as a percentage of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Genentech, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other license agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-57" decimals="2" id="f-380" unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-58" decimals="2" id="f-381" unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-59" decimals="2" id="f-382" unitRef="number">0.98</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-60" decimals="2" id="f-383" unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-61" decimals="2" id="f-384" unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-62" decimals="2" id="f-385" unitRef="number">0.58</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-63" decimals="2" id="f-386" unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-64" decimals="2" id="f-387" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-65" decimals="2" id="f-388" unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-66" decimals="2" id="f-389" unitRef="number">0.04</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-67" decimals="2" id="f-390" unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-68" decimals="2" id="f-391" unitRef="number">0.77</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-69" decimals="2" id="f-392" unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-70" decimals="2" id="f-393" unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-71" decimals="2" id="f-394" unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-72" decimals="2" id="f-395" unitRef="number">0.07</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-73" decimals="2" id="f-396" unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-74" decimals="2" id="f-397" unitRef="number">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-75" decimals="2" id="f-398" unitRef="number">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-76" decimals="2" id="f-399" unitRef="number">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-400">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the carrying value of long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable. If a change in circumstance occurs that indicates long-lived assets may be impaired, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. The long-lived asset evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. The Company reassesses the composition of its asset groups whenever there are changes in its operations that affect whether the cash flows associated with assets included in asset groups are largely independent. If the impairment review indicates that the carrying amount of an asset group is not recoverable, an impairment loss is measured as the amount by which the carrying amount of an asset group exceeds its fair value. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, general macroeconomic conditions, conditions specific to the industry and market, an adverse change in legal factors, business climate or operational performance of the business, and sustained decline in the stock price and market capitalization compared to the net book value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Calculating the fair value of a reporting unit, an asset group and an individual asset involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-401">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo considers all highly liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in money market accounts and U.S. government-sponsored entity debt securities. Restricted cash consisted of a letter of credit for $1.5&#160;million, representing a deposit for the lease of office and research and development laboratory facilities in Brisbane, California.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-3" decimals="-5" id="f-402" unitRef="usd">1500000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c-1" id="f-404">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c-1" id="f-403">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-405" unitRef="usd">39201000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-406" unitRef="usd">45204000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-42" decimals="-3" id="f-407" unitRef="usd">56514000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-47" decimals="-3" id="f-408" unitRef="usd">100444000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-3" decimals="-3" id="f-409" unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-4" decimals="-3" id="f-410" unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-42" decimals="-3" id="f-411" unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-47" decimals="-3" id="f-412" unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-413" unitRef="usd">40701000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-414" unitRef="usd">46704000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-42" decimals="-3" id="f-415" unitRef="usd">58014000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-47" decimals="-3" id="f-416" unitRef="usd">101944000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-417">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. Right-of-use assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the implicit rate in the Company&#x2019;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases, calculated as the sum of the amortization of the right of use asset and accretion of the lease liability, is recognized on a straight-line basis over the lease term, unless the right of use asset was previously written down due to impairment. The Company evaluates the lease arrangement for impairment whenever events or changes in circumstances indicate that the carrying amounts of the right-of-use asset may not be fully recoverable. To the extent an impairment of the right-of-use asset is identified, the Company will recognize the impairment expense and subsequently amortize the remaining right of use asset into rent expense on a straight-line basis (unless another systematic basis is more representative of the pattern in which the Company expects to consume the future economic benefits from the asset) from the date of impairment to the earlier of the end of the right-of-use asset&#x2019;s useful life or the end of the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If there is a change to the terms and conditions of a contract that results in a change in the scope of or the consideration for a lease, the Company determines if the lease modification results in a separate contract or a change in the accounting for the existing lease and not a separate contract. For lease modifications that result in a separate contract, the Company accounts for the new contract in the same manner as other new leases. For lease modifications that do not result in a separate contract, the Company reassesses the classification of the lease at the effective date of the modification, remeasures and reallocates the remaining consideration in the contract, and remeasures the lease liability using the discount rate determined at the effective date of the modification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected not to separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected not to apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <sgmo:WarrantOrRightPolicyPolicyTextBlock contextRef="c-1" id="f-418">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the accounting classification of warrants to purchase shares of its stock as either liability or equity by first assessing whether the warrants meet liability classification criteria in accordance with ASC 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 480&#x201d;). Under ASC 480, a financial instrument other than an outstanding share that embodies an obligation to repurchase the entity&#x2019;s shares or is indexed to such an obligation, and that requires or may require the entity to settle it by transferring assets, is classified as a liability. In addition, a financial instrument that embodies an unconditional obligation, or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares must be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception, (b) variations in something other than the fair value of the issuer&#x2019;s equity shares, or (c) variations inversely related to changes in the fair value of the issuer&#x2019;s equity shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If financial instruments, such as warrants, are not required to be classified as liabilities under ASC 480, the Company assesses whether such instruments are indexed to the Company&#x2019;s own stock under ASC 815-40. In order for an instrument to be considered indexed to an entity&#x2019;s own stock, its settlement amount must always equal the difference between the following: (a)&#160;the fair value of a fixed number of the Company&#x2019;s equity shares, and (b) a fixed monetary amount or a fixed amount of a debt instrument issued by the Company. Certain adjustments to this amount are allowed, if they are based on non-levered inputs into the fair value of a fixed price/fixed consideration-option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants are also required to meet equity classification criteria to be classified in stockholders&#x2019; equity. Under these criteria, warrants have to provide for settlement in shares, or cash or shares at the entity&#x2019;s option. With limited exceptions, a possibility of net cash settlement under any circumstances will result in the warrants being classified as liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants classified as equity are generally measured using the Black-Scholes valuation model on the date of issuance. Warrants classified as liabilities are remeasured at any reporting date using valuation models consistent with their terms, with changes recognized in earnings.&lt;/span&gt;&lt;/div&gt;</sgmo:WarrantOrRightPolicyPolicyTextBlock>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock contextRef="c-1" id="f-419">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records employee severance costs based on whether the termination benefits are provided under an on-going benefit arrangement or under a one-time benefit arrangement. The Company accounts for on-going termination benefit arrangements, such as those arising from employment agreements, applicable regulations or past practices, in accordance with ASC Topic 712, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Nonretirement Postemployment Benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 712&#x201d;). Under ASC 712, liabilities for post-employment benefits related to past services and that vest or are accumulated over time are recorded at the time the obligations are probable of being incurred and can be reasonably estimated. The Company accounts for one-time employment benefit arrangements in accordance with ASC Topic 420, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exit or Disposal Cost Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 420&#x201d;). One-time termination benefits are expensed at the date the entity notifies the employee, unless the employee must provide future service over a period extending past the minimum notification period, in which case the benefits are expensed ratably over the future service period. Other associated costs are recognized in the period in which the liability is incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred to terminate contracts are recognized upon their termination, e.g., when notice of termination is provided to the counterparty. Costs related to contracts without future benefit are recognized at the cease-use date. Other exit-related costs are recognized as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-420">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2023-07&#x201d;), which requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC Topic 280, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2023-09&#x201d;), which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-421">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and marketable securities. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no cash equivalents or marketable securities as of September&#160;30, 2024. The fair value measurements of the Company&#x2019;s cash equivalents and marketable securities as of December&#160;31, 2023 are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally classifies its marketable securities as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-422">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and marketable securities. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-77" decimals="INF" id="f-423" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="c-1" id="f-424">The fair value measurements of the Company&#x2019;s cash equivalents and marketable securities as of December&#160;31, 2023 are identified at the following levels within the fair value hierarchy (in thousands):&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-78" decimals="-3" id="f-425" unitRef="usd">2508000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-79" decimals="-3" id="f-426" unitRef="usd">2508000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-80" decimals="-3" id="f-427" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-81" decimals="-3" id="f-428" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-82" decimals="-3" id="f-429" unitRef="usd">2508000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-83" decimals="-3" id="f-430" unitRef="usd">2508000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-84" decimals="-3" id="f-431" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-85" decimals="-3" id="f-432" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-86" decimals="-3" id="f-433" unitRef="usd">22566000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-87" decimals="-3" id="f-434" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-88" decimals="-3" id="f-435" unitRef="usd">22566000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-89" decimals="-3" id="f-436" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-90" decimals="-3" id="f-437" unitRef="usd">2826000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-91" decimals="-3" id="f-438" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-92" decimals="-3" id="f-439" unitRef="usd">2826000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-93" decimals="-3" id="f-440" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-94" decimals="-3" id="f-441" unitRef="usd">1405000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-95" decimals="-3" id="f-442" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-96" decimals="-3" id="f-443" unitRef="usd">1405000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-97" decimals="-3" id="f-444" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-98" decimals="-3" id="f-445" unitRef="usd">2377000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-99" decimals="-3" id="f-446" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-100" decimals="-3" id="f-447" unitRef="usd">2377000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-101" decimals="-3" id="f-448" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-102" decimals="-3" id="f-449" unitRef="usd">5593000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-103" decimals="-3" id="f-450" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-104" decimals="-3" id="f-451" unitRef="usd">5593000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-105" decimals="-3" id="f-452" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-106" decimals="-3" id="f-453" unitRef="usd">1031000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-107" decimals="-3" id="f-454" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-108" decimals="-3" id="f-455" unitRef="usd">1031000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-109" decimals="-3" id="f-456" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-82" decimals="-3" id="f-457" unitRef="usd">35798000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-83" decimals="-3" id="f-458" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-84" decimals="-3" id="f-459" unitRef="usd">35798000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-85" decimals="-3" id="f-460" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-82" decimals="-3" id="f-461" unitRef="usd">38306000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-83" decimals="-3" id="f-462" unitRef="usd">2508000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-84" decimals="-3" id="f-463" unitRef="usd">35798000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-85" decimals="-3" id="f-464" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-465">CASH EQUIVALENTS AND MARKETABLE SECURITIES&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no cash equivalents or marketable securities as of September&#160;30, 2024. The table below summarizes the Company&#x2019;s cash equivalents and marketable securities as of December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of marketable securities by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on the sales of investments were not material during the three and nine months ended September&#160;30, 2024. There were no realized gains and losses on the sales of investments during the three and nine months ended September&#160;30, 2023. Total unrealized gains for securities with net gains in accumulated other comprehensive loss were not material during the three and nine months ended September&#160;30, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company did not record an allowance for credit losses related to its marketable securities for the three and nine months ended September&#160;30, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no unrealized losses related to its marketable securities for the three and nine months ended September&#160;30, 2024. The Company had no material unrealized losses related to its marketable securities for the three and nine months ended September&#160;30, 2023. The Company had no material unrealized losses, individually and in the aggregate, for marketable securities that were in a continuous unrealized loss position for greater than 12 months as of September&#160;30, 2024 and December&#160;31, 2023. These unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews its marketable securities for indications of credit losses. No significant facts or circumstances had arisen to indicate that there had been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#x2019;s review of these securities, the Company determined that no allowance for credit losses related to its marketable securities was required at either September&#160;30, 2024 or December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the periods the Company had investment in debt securities, the Company also considered whether it was more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis. No impairment charges were recorded during the three and nine months ended September&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent contextRef="c-3" decimals="INF" id="f-466" unitRef="usd">0</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="c-1" id="f-467">The table below summarizes the Company&#x2019;s cash equivalents and marketable securities as of December&#160;31, 2023 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-110" decimals="-3" id="f-468" unitRef="usd">2508000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-110" decimals="-3" id="f-469" unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-110" decimals="-3" id="f-470" unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-110" decimals="-3" id="f-471" unitRef="usd">2508000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-111" decimals="-3" id="f-472" unitRef="usd">2508000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-111" decimals="-3" id="f-473" unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-111" decimals="-3" id="f-474" unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-111" decimals="-3" id="f-475" unitRef="usd">2508000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent contextRef="c-112" decimals="-3" id="f-476" unitRef="usd">22347000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-112" decimals="-3" id="f-477" unitRef="usd">219000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-112" decimals="-3" id="f-478" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-112" decimals="-3" id="f-479" unitRef="usd">22566000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent contextRef="c-113" decimals="-3" id="f-480" unitRef="usd">2825000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-113" decimals="-3" id="f-481" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-113" decimals="-3" id="f-482" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-113" decimals="-3" id="f-483" unitRef="usd">2826000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent contextRef="c-114" decimals="-3" id="f-484" unitRef="usd">1399000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-114" decimals="-3" id="f-485" unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-114" decimals="-3" id="f-486" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-114" decimals="-3" id="f-487" unitRef="usd">1405000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent contextRef="c-115" decimals="-3" id="f-488" unitRef="usd">2368000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-115" decimals="-3" id="f-489" unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-115" decimals="-3" id="f-490" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-115" decimals="-3" id="f-491" unitRef="usd">2377000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent contextRef="c-116" decimals="-3" id="f-492" unitRef="usd">5599000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-116" decimals="-3" id="f-493" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-116" decimals="-3" id="f-494" unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-116" decimals="-3" id="f-495" unitRef="usd">5593000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent contextRef="c-117" decimals="-3" id="f-496" unitRef="usd">1026000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-117" decimals="-3" id="f-497" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-117" decimals="-3" id="f-498" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-117" decimals="-3" id="f-499" unitRef="usd">1031000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent contextRef="c-4" decimals="-3" id="f-500" unitRef="usd">35564000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-501" unitRef="usd">241000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-502" unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-4" decimals="-3" id="f-503" unitRef="usd">35798000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent contextRef="c-4" decimals="-3" id="f-504" unitRef="usd">38072000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCostCurrent>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-505" unitRef="usd">241000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-506" unitRef="usd">7000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-507" unitRef="usd">38306000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesCurrent>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c-1" id="f-508">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of marketable securities by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-4" decimals="-3" id="f-509" unitRef="usd">10855000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-4" decimals="-3" id="f-510" unitRef="usd">24943000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent contextRef="c-4" decimals="-3" id="f-511" unitRef="usd">35798000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:GainLossOnSaleOfInvestments contextRef="c-1" decimals="0" id="f-512" unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments contextRef="c-5" decimals="0" id="f-513" unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments contextRef="c-6" decimals="INF" id="f-514" unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments contextRef="c-7" decimals="INF" id="f-515" unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded contextRef="c-5" decimals="INF" id="f-516" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded contextRef="c-7" decimals="INF" id="f-517" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded contextRef="c-6" decimals="INF" id="f-518" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded contextRef="c-1" decimals="INF" id="f-519" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="INF" id="f-520" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-4" decimals="0" id="f-521" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-3" decimals="0" id="f-522" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-523">BASIC AND DILUTED NET INCOME (LOSS) PER SHARE&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per share has been computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is calculated by dividing net income &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(loss) by the weighted-average number of shares of common stock plus potentially dilutive securities outstanding during the period. Potential shares of common stock exercisable for little or no consideration are included in both basic and diluted weighted-average number of shares of common stock outstanding. During the three months ended September&#160;30, 2024, basic and diluted weighted-average number of shares outstanding were 208.3&#160;million and 214.3&#160;million shares, respectively. During the nine months ended September&#160;30, 2024, both basic and diluted weighted-average number of shares outstanding were 198.8&#160;million shares, and included pre-funded warrants to purchase 3,809,523 shares of common stock with an exercise price of $0.01 per share. These warrants were exercised during the three months ended June 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of basic and diluted net income (loss) per share are as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104,163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(197,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) available to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104,163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(197,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of common stock pursuant to employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,325&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,171&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,849&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,375&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants to purchase shares of common stock, with the exercise price of $1.00 per share, entitle holders to participate in dividends but are not required to absorb losses incurred. As a result, for the three months ended September&#160;30, 2024, the Company applied the two-class method to allocate net income to shares of common stock and these warrants for purposes of calculating basic and diluted net income per share. The warrants were excluded from basic net loss per share calculations during the nine months ended September&#160;30, 2024. No warrants were outstanding during the three and nine months ended September&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The computation of diluted net income per share for the three months ended September&#160;30, 2024 excluded 12.7&#160;million shares subject to stock options and restricted stock units outstanding because their inclusion would have had an anti-dilutive effect on diluted net income per share. The computation of diluted net loss per share for the nine months ended September&#160;30, 2024 excluded 51.6&#160;million shares subject to stock options, restricted stock units outstanding, warrants to purchase common stock, and the employee stock purchase plan shares reserved for issuance because their inclusion would have had an anti-dilutive effect on diluted net loss per share. The computation of diluted net loss per share for the three and nine months ended September&#160;30, 2023 excluded 22.1&#160;million shares subject to stock options, restricted stock units outstanding, and the employee stock purchase plan shares reserved for issuance because their inclusion would have had an anti-dilutive effect on diluted net loss per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-5" id="f-524" unitRef="shares">208300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-5" id="f-525" unitRef="shares">214300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-526" unitRef="shares">198800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-527" unitRef="shares">198800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-118"
      decimals="INF"
      id="f-528"
      unitRef="shares">3809523</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="c-118"
      decimals="2"
      id="f-529"
      unitRef="usdPerShare">0.01</us-gaap:SharePrice>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-530">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of basic and diluted net income (loss) per share are as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104,163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(197,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) available to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104,163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(197,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of common stock pursuant to employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,325&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,171&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,849&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,375&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-531" unitRef="usd">10672000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-532" unitRef="usd">-104163000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-533" unitRef="usd">-74545000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-534" unitRef="usd">-197536000</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-5" decimals="-3" id="f-535" unitRef="usd">1287000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-6" decimals="-3" id="f-536" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-1" decimals="-3" id="f-537" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-7" decimals="-3" id="f-538" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-5" decimals="-3" id="f-539" unitRef="usd">9385000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-6" decimals="-3" id="f-540" unitRef="usd">-104163000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-541" unitRef="usd">-74545000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-7" decimals="-3" id="f-542" unitRef="usd">-197536000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-543" unitRef="shares">208345000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-3" id="f-544" unitRef="shares">177171000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-545" unitRef="shares">198849000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-3" id="f-546" unitRef="shares">173375000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-547" unitRef="shares">208345000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-3" id="f-548" unitRef="shares">177171000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-549" unitRef="shares">198849000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-3" id="f-550" unitRef="shares">173375000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-119"
      decimals="-3"
      id="f-551"
      unitRef="shares">5823000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-120"
      decimals="-3"
      id="f-552"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-121"
      decimals="-3"
      id="f-553"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-122"
      decimals="-3"
      id="f-554"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-123"
      decimals="-3"
      id="f-555"
      unitRef="shares">157000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-124"
      decimals="-3"
      id="f-556"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-125"
      decimals="-3"
      id="f-557"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-126"
      decimals="-3"
      id="f-558"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-559" unitRef="shares">214325000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="-3" id="f-560" unitRef="shares">177171000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-561" unitRef="shares">198849000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-3" id="f-562" unitRef="shares">173375000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-563"
      unitRef="usdPerShare">0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-564"
      unitRef="usdPerShare">-0.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-565"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-566"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-567"
      unitRef="usdPerShare">0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-568"
      unitRef="usdPerShare">-0.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-569"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-570"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-118"
      decimals="2"
      id="f-571"
      unitRef="usdPerShare">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-5" decimals="-5" id="f-572" unitRef="shares">12700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-5" id="f-573" unitRef="shares">51600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-6" decimals="-5" id="f-574" unitRef="shares">22100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-7" decimals="-5" id="f-575" unitRef="shares">22100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-576">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Genentech, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2024, the Company entered into a global epigenetic regulation and capsid delivery license agreement with Genentech to develop intravenously administered genomic medicines to treat certain neurodegenerative diseases. Under the terms of the agreement, the Company granted an exclusive license to Genentech for the Company&#x2019;s proprietary zinc finger repressors (&#x201c;ZFRs&#x201d;) that are directed to tau and a second undisclosed neurology target. The Company also granted an exclusive license to Genentech to the Company&#x2019;s proprietary, neurotropic adeno-associated virus capsid, STAC-BBB, for use with therapies directed to tau and to the second neurology target. The Company is prohibited from exploiting (for itself or with or for a third party) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;products directed to tau and to the second neurology target during the applicable exclusivity periods set forth in the agreement. The Company was responsible for completing the technology transfer and certain preclinical activities, and Genentech is solely responsible for all clinical development, regulatory interactions, manufacturing and global commercialization of resulting products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2024, the Company received a $40.0&#160;million upfront license payment from Genentech. In October 2024, the Company received a $10.0&#160;million milestone payment related to the technology transfer which was completed in September 2024. Under the terms of the agreement, the Company is also eligible to earn up to $1.9&#160;billion in development and commercial milestones spread across multiple potential products. In addition, the Company is also entitled to receive escalating, tiered mid-single digit to sub-teen double digit royalty payments on the net sales of such products, subject to adjustments for patent expiration, entry of competitive products to the market and payments made under certain licenses for third-party intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement will continue, on a product-by-product and country-by-country basis, until the date when there is no remaining royalty payment obligation in such country with respect to such product, at which time the agreement will expire with respect to such product in such country. Royalty obligations cease upon the later of expiry of the last valid patent claim covering the product in the country or 10 years from the date of the first commercial sale of the product in such country. Genentech has the right to terminate the agreement for convenience. Each party has the right to terminate the agreement on account of the other party&#x2019;s uncured material breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Genentech in accordance with ASC Topic 606 and concluded that Genentech is a customer. The initial transaction price of $50.0&#160;million includes the upfront license fee of $40.0&#160;million and the $10.0&#160;million technology transfer milestone payment. None of the development milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price as uncertain events are resolved or other changes in circumstances occur. Potential sales-based milestones and royalty payments are not estimated as they meet the sales-or usage-based royalty exception under ASC 606 and are recognized in the period they are earned, provided the related performance obligations have been completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified two performance obligations within the Genentech Agreement. All licenses were accounted for as a performance obligation to provide functional IP that is satisfied at a point in time that was satisfied upon completion of the technology transfer in September 2024. The preclinical activities represent research and development services and are satisfied over time as the Company conducts and Genentech benefits from the associated activities. Revenue related to the preclinical activities is recognized using an input method of cumulative actual costs incurred relative to total estimated costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated the initial transaction price to the performance obligations based on the relative standalone selling price of each performance obligation. In the absence of an observable standalone selling price, the Company used a methodology that maximized the use of observable inputs. This included a cost plus margin approach for the preclinical activities, which required the estimation of total costs and an expected margin. The standalone selling price of the licenses was determined based on the analysis of the probability-adjusted discounted cash flows and potential sales of licensed products. Significant estimates and assumptions were used that include but are not limited to, expected market opportunity and pricing, timelines, and likelihood of success of clinical, regulatory and commercialization activities. The Company expects to allocate variable consideration payable upon achievement of future milestones and royalty payments to the specific performance obligation to which they relate, i.e. the license performance obligation, as such allocation would meet the allocation objective in ASC&#160;Topic&#160;606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2024, the Company had a receivable of $10.0&#160;million related to the milestone payment which had been earned but not yet received, and deferred revenue of $0.8&#160;million related to this agreement which is expected to be recognized over approximately the next three months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.103%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Genentech agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pfizer Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer Inc. (&#x201c;Pfizer&#x201d;), pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia A, and closely related products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this agreement, the Company was responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty-free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#x2019;s products that utilize the AAV delivery system.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i) the expiration of patent claims that cover the product in a country, (ii) the expiration of regulatory exclusivity for a product in a country, and (iii) 15 years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon execution of the agreement, the Company received an upfront fee of $70.0&#160;million and was eligible to receive up to $208.5&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $266.5&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and potentially other products. To date, two milestones of $55.0&#160;million in aggregate have been earned and received. The Company is eligible to earn from Pfizer up to $220.0&#160;million in remaining milestone payments for giroctocogene fitelparvovec, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are 14% - 20% of the annual worldwide net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer was a customer. The Company completed its performance obligations and recognized the amounts included in the transaction price of $134.0&#160;million during the periods through December 31, 2020. No revenue was recognized during the three and nine months ended September&#160;30, 2024 and 2023. The remaining development, intellectual property and regulatory milestone amounts have not been included in the transaction price and have not been recognized as their achievement is dependent on the progress and outcomes of Pfizer&#x2019;s development activities and is therefore uncertain. If and when these milestones become probable of being achieved, they will be recognized in full at that time. Sales milestones and royalties are not recognized until triggered based on the contractual terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Company entered into an exclusive, global collaboration and license agreement with Pfizer, subsequently assigned to Alexion, AstraZeneca Rare Disease (&#x201c;Alexion&#x201d;) in September 2023, for the development and commercialization of potential gene therapy products that use zinc finger transcriptional regulators (&#x201c;ZF-transcriptional regulators&#x201d;) to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZF-transcriptional regulators that bind to and specifically reduce expression of the mutant form of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of this agreement, the Company granted Pfizer (now Alexion) an exclusive, royalty-bearing, worldwide license under the Company&#x2019;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZF-transcriptional regulators that satisfy pre-agreed criteria. During a specified period, neither the Company nor Alexion are permitted to research, develop, manufacture or commercialize outside of the collaboration any zinc finger proteins (&#x201c;ZFPs&#x201d;) that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i) the expiration of patent claims that cover the licensed product in a country, (ii) the expiration of regulatory &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;exclusivity for a licensed product in a country, and (iii) 15 years after the first commercial sale of a licensed product in a major market country. Alexion also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Alexion to develop, manufacture and commercialize licensed products under the agreement would automatically terminate. Upon termination by the Company for cause or by Alexion without cause for any licensed product or licensed products in any country or countries, the Company would have the right to negotiate with Alexion to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Alexion to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following any termination by the Company for Alexion&#x2019;s material breach, Alexion would not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene for a period of time. Following any termination by Alexion for the Company&#x2019;s material breach, the Company would not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene for a period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received a $12.0&#160;million upfront payment from Pfizer and is eligible to receive up to $60.0&#160;million in development milestone payments from Alexion contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million in commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Alexion will pay the Company royalties of 14% - 20% of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party is responsible for the cost of its performance of the research program. Alexion is operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $5.0&#160;million has been earned and paid, however no products have been approved and therefore no royalty fees have been earned under the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Alexion in accordance with ASC Topic 606 and concluded that Alexion was a customer. The Company completed its performance obligations and recognized the amounts included in the transaction price of $17.0&#160;million during the periods through December 31, 2020. No revenue was recognized during the three and nine months ended September&#160;30, 2024 and 2023. The remaining development milestone amounts have not been included in the transaction price and have not been recognized as their achievement is dependent on the progress and outcomes of Alexion&#x2019;s development activities and is therefore uncertain. If and when these milestones become probable of being achieved, they would be recognized in full at that time. Sales related milestones and royalties are not recognized until triggered based on the contractual terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2023, Pfizer notified the Company of Pfizer&#x2019;s assignment of the collaboration and license agreement to Alexion, AstraZeneca Rare Disease, pursuant to a definitive purchase and license agreement for preclinical gene therapy assets and enabling technologies that closed on September 20, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Collaboration and License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2024, the Company had a collaboration and license agreement with Kite and certain other license agreements. In 2023, in addition to the agreement with Kite, the Company had collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc. (&#x201c;Novartis&#x201d;), and Biogen MA, Inc. (&#x201c;Biogen&#x201d;). These collaboration agreements were designed for the research, development, and commercialization of various potential therapy products, including potential engineered cell therapies for cancer and gene regulation therapies to treat neurodevelopmental disorders and diseases. The collaboration agreements with Novartis and Biogen were both terminated effective June 2023. The Company&#x2019;s services under the Kite collaboration agreement were completed during the year ended December 31, 2023, and the agreement expired pursuant to its terms in April 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed each of these collaboration agreements in accordance with ASC Topic 606, concluding Kite, Novartis and Biogen were customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under these agreements were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.740%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.477%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.740%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.477%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.740%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.477%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Kite agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license fee fixed consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services variable consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Novartis agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront license fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Biogen agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license and other fixed consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost-sharing payments for research services, net variable consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from other license agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2024 and December&#160;31, 2023, the Company had no material receivables, no deferred revenue, and no amounts included in transaction price remaining to be recognized related to these license and collaboration agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ContractWithCustomerLiability contextRef="c-52" decimals="-5" id="f-577" unitRef="usd">40000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-53" decimals="-5" id="f-578" unitRef="usd">10000000</us-gaap:ContractWithCustomerLiability>
    <sgmo:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-52" decimals="-8" id="f-579" unitRef="usd">1900000000</sgmo:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <sgmo:RoyaltyObligationTerm contextRef="c-127" id="f-580">P10Y</sgmo:RoyaltyObligationTerm>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-52" decimals="-5" id="f-581" unitRef="usd">50000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability contextRef="c-52" decimals="-5" id="f-582" unitRef="usd">40000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-128" decimals="-5" id="f-583" unitRef="usd">10000000</us-gaap:ContractWithCustomerLiability>
    <sgmo:RevenueFromContractsWithCustomerNumberOfPerformanceObligations
      contextRef="c-52"
      decimals="0"
      id="f-584"
      unitRef="performance_obligation">2</sgmo:RevenueFromContractsWithCustomerNumberOfPerformanceObligations>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-129" decimals="-5" id="f-585" unitRef="usd">10000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-129" decimals="-5" id="f-586" unitRef="usd">800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-587">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.103%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.571%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Genentech agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under these agreements were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.507%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.740%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.477%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.740%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.477%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.740%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.477%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Kite agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license fee fixed consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services variable consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Novartis agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront license fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Biogen agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license and other fixed consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost-sharing payments for research services, net variable consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from other license agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-130" decimals="-3" id="f-588" unitRef="usd">48679000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-131" decimals="-3" id="f-589" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-132" decimals="-3" id="f-590" unitRef="usd">48679000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-133" decimals="-3" id="f-591" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-134" decimals="-3" id="f-592" unitRef="usd">547000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-135" decimals="-3" id="f-593" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-136" decimals="-3" id="f-594" unitRef="usd">547000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-137" decimals="-3" id="f-595" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-138" decimals="-3" id="f-596" unitRef="usd">49226000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-139" decimals="-3" id="f-597" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-140" decimals="-3" id="f-598" unitRef="usd">49226000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-141" decimals="-3" id="f-599" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:AgreementTerminationTerm contextRef="c-142" id="f-600">P15Y</sgmo:AgreementTerminationTerm>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="c-143" decimals="-5" id="f-601" unitRef="usd">70000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive contextRef="c-144" decimals="-5" id="f-602" unitRef="usd">208500000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive contextRef="c-143" decimals="-5" id="f-603" unitRef="usd">266500000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive>
    <sgmo:CollaborativeArrangementNumberOfMilestonesAchieved
      contextRef="c-145"
      decimals="INF"
      id="f-604"
      unitRef="milestone">2</sgmo:CollaborativeArrangementNumberOfMilestonesAchieved>
    <sgmo:MilestonePaymentsReceived contextRef="c-145" decimals="-5" id="f-605" unitRef="usd">55000000</sgmo:MilestonePaymentsReceived>
    <sgmo:MilestoneRevenueReceivable contextRef="c-146" decimals="-5" id="f-606" unitRef="usd">220000000</sgmo:MilestoneRevenueReceivable>
    <sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty contextRef="c-147" decimals="2" id="f-607" unitRef="number">0.14</sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty>
    <sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty contextRef="c-148" decimals="2" id="f-608" unitRef="number">0.20</sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty>
    <sgmo:CollaborativeArrangementTransactionPrice contextRef="c-149" decimals="-5" id="f-609" unitRef="usd">134000000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-150" decimals="INF" id="f-610" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-151" decimals="INF" id="f-611" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-152" decimals="INF" id="f-612" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-153" decimals="INF" id="f-613" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:AgreementTerminationTerm contextRef="c-154" id="f-614">P15Y</sgmo:AgreementTerminationTerm>
    <sgmo:MilestonePaymentsReceived contextRef="c-155" decimals="-5" id="f-615" unitRef="usd">12000000</sgmo:MilestonePaymentsReceived>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive contextRef="c-156" decimals="-5" id="f-616" unitRef="usd">60000000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive contextRef="c-157" decimals="-5" id="f-617" unitRef="usd">90000000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty contextRef="c-158" decimals="2" id="f-618" unitRef="number">0.14</sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty>
    <sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty contextRef="c-159" decimals="2" id="f-619" unitRef="number">0.20</sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty>
    <sgmo:MilestonePaymentsReceived contextRef="c-160" decimals="-5" id="f-620" unitRef="usd">5000000</sgmo:MilestonePaymentsReceived>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="c-160"
      decimals="INF"
      id="f-621"
      unitRef="product">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="c-160"
      decimals="INF"
      id="f-622"
      unitRef="milestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:CollaborativeArrangementTransactionPrice contextRef="c-161" decimals="-5" id="f-623" unitRef="usd">17000000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-162" decimals="INF" id="f-624" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-163" decimals="INF" id="f-625" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-164" decimals="INF" id="f-626" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-165" decimals="INF" id="f-627" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-166" decimals="-3" id="f-628" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-167" decimals="-3" id="f-629" unitRef="usd">5388000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-168" decimals="-3" id="f-630" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-169" decimals="-3" id="f-631" unitRef="usd">17938000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-170" decimals="-3" id="f-632" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-171" decimals="-3" id="f-633" unitRef="usd">108000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-172" decimals="-3" id="f-634" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-173" decimals="-3" id="f-635" unitRef="usd">1097000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-174" decimals="-3" id="f-636" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-175" decimals="-3" id="f-637" unitRef="usd">5496000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-176" decimals="-3" id="f-638" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-177" decimals="-3" id="f-639" unitRef="usd">19035000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-178" decimals="-3" id="f-640" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-179" decimals="-3" id="f-641" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-180" decimals="-3" id="f-642" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-181" decimals="-3" id="f-643" unitRef="usd">9568000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-182" decimals="-3" id="f-644" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-183" decimals="-3" id="f-645" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-184" decimals="-3" id="f-646" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-185" decimals="-3" id="f-647" unitRef="usd">2611000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-186" decimals="-3" id="f-648" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-187" decimals="-3" id="f-649" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-188" decimals="-3" id="f-650" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-189" decimals="-3" id="f-651" unitRef="usd">12179000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-190" decimals="-3" id="f-652" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-191" decimals="-3" id="f-653" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-192" decimals="-3" id="f-654" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-193" decimals="-3" id="f-655" unitRef="usd">132165000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-194" decimals="-3" id="f-656" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-195" decimals="-3" id="f-657" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-196" decimals="-3" id="f-658" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-197" decimals="-3" id="f-659" unitRef="usd">2684000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-198" decimals="-3" id="f-660" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-199" decimals="-3" id="f-661" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-200" decimals="-3" id="f-662" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-201" decimals="-3" id="f-663" unitRef="usd">134849000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-202" decimals="-3" id="f-664" unitRef="usd">186000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-203" decimals="-3" id="f-665" unitRef="usd">3902000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-204" decimals="-3" id="f-666" unitRef="usd">1023000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-205" decimals="-3" id="f-667" unitRef="usd">8127000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-206" decimals="-3" id="f-668" unitRef="usd">186000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-207" decimals="-3" id="f-669" unitRef="usd">9398000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-208" decimals="-3" id="f-670" unitRef="usd">1023000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-209" decimals="-3" id="f-671" unitRef="usd">174190000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AssetImpairmentChargesTextBlock contextRef="c-1" id="f-672">IMPAIRMENT AND WRITE-DOWN OF ASSETS HELD FOR SALE&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, the Company experienced a sustained decline in stock price and related market capitalization, the collaboration agreements with Biogen and Novartis were terminated, and actions were initiated including deferral and reprioritization of certain research and development programs, announcement and execution of restructuring of operations and reductions in force. As a result, throughout the year the Company tested various long-lived and indefinite-life intangible assets for impairment and recognized a pre-tax goodwill impairment charge of $38.1&#160;million, a pre-tax indefinite-lived intangible asset impairment charge of $51.4&#160;million along with the income tax benefit from the reduction of the associated deferred tax liability of $6.3&#160;million, and a pre-tax long-lived assets impairment charge of $65.5&#160;million during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nine months ended September 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2024, the Company&#x2019;s Board of Directors approved the wind-down of operations in France and corresponding reduction in workforce, including closure of the Company&#x2019;s cell therapy manufacturing facility and research labs in Valbonne, France (the &#x201c;France Restructuring&#x201d;), and also initiated several actions aimed at reducing costs, including actions to commence the closure of its facility in Brisbane, California. As such, the Company reassessed its long-lived assets for impairment as of March 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the France Restructuring, the Company concluded its equipment, furniture and fixtures located in France met the held for sale criteria as of March 31, 2024. The Company wrote down the carrying value of these assets to their estimated fair value of $1.0&#160;million, net of the estimated costs to sell, recognizing a loss of $1.8&#160;million. The fair value measurement represents a level 3 nonrecurring fair value measurement. The loss is included in impairment of long-lived assets in the accompanying Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also reassessed whether its remaining long-lived assets continued to represent a single asset group for purposes of impairment assessment. After considering changes in the manner in which the right-of-use assets and leasehold improvements related to the Company&#x2019;s Brisbane and Valbonne, France, facilities are used, costs incurred to cease use of these assets, the France Restructuring, and the Company&#x2019;s activities to market these facilities for sublease, the Company concluded the identifiable operations and cash flows of these assets are now largely independent of the operations and the cash flows of each other, as well as of the remainder of the Company. Accordingly, the Company assessed impairment of the resulting asset groups separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the changes in the use of assets related to the Brisbane and Valbonne facility leases, the Company concluded there were indicators of impairment for these asset groups, and further established that the carrying values of these asset groups were not recoverable. The Company proceeded to determine their fair values using a discounted cash flow method, which represents a level 3 nonrecurring fair value measurement. As a result, the Company recognized pre-tax long-lived asset impairment charges of $2.0&#160;million on the right-of-use assets and $0.5&#160;million on the related leasehold improvements during the three months ended March 31, 2024. No impairment was recognized on the remaining long-lived assets, as their carrying values were not in excess of their fair values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June 30, 2024, the Company faced a sustained decline in its stock price and related market capitalization, and continued the France Restructuring and activities related to the closure of its facility in Brisbane, California. There was also a decline in the market rates for facility subleases in Brisbane, California, indicating the carrying values of right of use and leasehold improvement assets could be impaired. As such, the Company reassessed its long-lived assets for impairment as of June 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded there were indicators of impairment for the Brisbane and Valbonne facility lease asset groups, and further established that the carrying values of these asset groups were not recoverable. The Company proceeded to determine their fair values using a discounted cash flow method, which represents a level 3 nonrecurring fair value measurement. As a result, the Company recognized pre-tax long-lived asset impairment charges of $0.9&#160;million on the right-of-use assets and $0.1&#160;million on the related leasehold improvements during the three months ended June 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also reassessed the fair value of assets held for sale as of June 30, 2024 and recorded an additional charge to write-down the carrying value of these assets by $0.1&#160;million. Assets held for sale are included within prepaid expenses and other current assets on the Company&#x2019;s Condensed Consolidated Balance Sheet as of June 30, 2024. The fair value measurement represents a level 3 nonrecurring fair value measurement. The loss is included in impairment of long-lived assets in the accompanying Condensed Consolidated Statements of Operations. The sale of these assets is expected to occur within one year, either collectively or separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2024, no additional impairment was recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will continue to assess whether its long-lived assets are impaired in future periods. As the Company finalizes the wind-down of its France operations and corresponding reduction in force of all France employees, as well as the closure of its Brisbane facility, it is reasonably possible that additional impairment charges will be recognized, for example, if sublease rates of leased facilities or selling prices of the assets held for sale are less than those estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nine months ended September 30, 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023, as a result of the sustained decline in the Company&#x2019;s stock price and related market capitalization, and termination of the collaboration agreements with Biogen and Novartis, the Company performed an impairment assessment of goodwill, indefinite-lived intangible assets, and other long-lived assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operated as a single reporting unit based on its business and reporting structure. For goodwill, a quantitative impairment assessment was performed using a market approach, whereby the Company&#x2019;s fair value of equity was compared to its carrying value. The fair value of equity was derived using both the market capitalization of the Company and an estimate of a reasonable range of values of a control premium applied to the Company&#x2019;s implied business enterprise value. The control premium was estimated based upon control premiums observed in comparable market transactions. This represented a level&#160;2 nonrecurring fair value measurement. Based on this analysis, the Company recognized a pre-tax goodwill impairment charge of $38.1&#160;million during the three months ended March 31, 2023. As a result, the goodwill was fully impaired as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Before completing the goodwill impairment assessment, the Company also tested its indefinite-lived intangible assets and then its long-lived assets for impairment. Based on the qualitative assessment, the Company determined it was more likely than not that its indefinite-lived intangible assets were not impaired. The Company determined all of its long-lived assets represented one asset group for purposes of long-lived asset impairment assessment. The Company concluded that the carrying value of the asset group was not recoverable as it exceeded the future undiscounted cash flows the assets were expected to generate from the use and eventual disposition. To allocate and recognize the impairment loss, the Company determined individual fair values of its long-lived assets. The Company applied a discounted cash flow method to estimate fair values of its leasehold improvements and right-of-use assets, including leasehold improvements in the process of construction and a cost replacement method to estimate the fair value of its furniture, fixtures and laboratory and manufacturing equipment. These represented level&#160;3 nonrecurring fair value measurements. Based on this analysis, the Company recognized pre-tax long-lived asset impairment charges of $11.2&#160;million on the right-of-use assets, $5.0&#160;million on the related leasehold improvements, and $4.2&#160;million on construction-in-progress, during the three months ended March 31, 2023. No impairment was recognized on the remaining long-lived assets as their carrying values were not in excess of their fair values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June 30, 2023, the Company&#x2019;s stock price and the related market capitalization continued to decline. In April 2023, the Company announced a restructuring of operations and a corresponding reduction in force. The Company also initiated discussions around several actions aimed at reducing costs, preserving liquidity and improving operational performance metrics, including deferral and reprioritization of certain research and development programs, further reduction in force, and closing or downsizing its facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reassessed its indefinite-lived and long-lived assets for impairment as of June 30, 2023. Given the actions contemplated above, the Company determined that it was more likely than not that its indefinite-lived intangible assets were impaired. Accordingly, the Company developed an estimate of the fair value of its indefinite-lived intangible assets using the multi-period excess earnings model (income approach) and concluded the carrying value of its indefinite-lived intangible assets were fully impaired. This represents a level 3 nonrecurring fair value measurement. As a result, an indefinite-lived intangible assets impairment charge of $51.3&#160;million, as well as the related income tax benefit of $6.3&#160;million due to the reversal of a deferred tax liability associated with the indefinite-lived intangible assets was recognized during the three and six months ended June 30, 2023. The impairment charge was primarily driven by a higher discount rate applied to future cash flows based on market participants&#x2019; view of increased risk related to the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that there were indicators of impairment in its long-lived asset group as of June 30, 2023, based on the same factors above as well as the impairment of its indefinite-lived intangible assets. As the estimated fair value of this asset group, based on a market approach, exceeded its carrying value, no impairment loss was recognized. This represented a level 3 nonrecurring fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2023, the Company&#x2019;s stock price and the related market capitalization continued to decline, and as such, the Company reassessed its long-lived assets for impairment as of September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined all of its long-lived assets continued to represent one asset group for purposes of long-lived asset impairment assessment. The Company concluded that the carrying value of the asset group was not recoverable and the estimated fair value of this asset group was below its carrying value. The lower fair value of the asset group was mainly driven by the sustained decline in the Company&#x2019;s stock price and the related market capitalization. To recognize the impairment loss, the Company determined individual fair values of its long-lived assets. The Company applied a discounted cash flow method to estimate fair values of its leasehold improvements and right-of-use assets, including leasehold improvements in the process of construction, and a market approach to estimate the fair value of its furniture, fixtures and laboratory and manufacturing equipment. These represented level 3 nonrecurring fair value measurements. Based on this analysis, the Company concluded the fair values of the long-lived assets were lower than their net book values due to declines in the market prices for leases, furniture, fixtures, and equipment. The Company recognized pre-tax long-lived asset impairment charges of $17.6&#160;million on the right-of-use assets, $13.7&#160;million on the related leasehold improvements and construction-in-progress, and $13.5&#160;million on furniture, fixtures, and laboratory and manufacturing equipment during the three months ended September 30, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:AssetImpairmentChargesTextBlock>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-210" decimals="-5" id="f-673" unitRef="usd">38100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-210" decimals="-5" id="f-674" unitRef="usd">51400000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <sgmo:EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount contextRef="c-210" decimals="-5" id="f-675" unitRef="usd">6300000</sgmo:EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-210" decimals="-5" id="f-676" unitRef="usd">65500000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:PropertyPlantAndEquipmentFairValueDisclosure contextRef="c-211" decimals="-5" id="f-677" unitRef="usd">1000000</us-gaap:PropertyPlantAndEquipmentFairValueDisclosure>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-212" decimals="-5" id="f-678" unitRef="usd">1800000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-213" decimals="-5" id="f-679" unitRef="usd">2000000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ImpairmentOfLeasehold contextRef="c-213" decimals="-5" id="f-680" unitRef="usd">500000</us-gaap:ImpairmentOfLeasehold>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-214" decimals="-5" id="f-681" unitRef="usd">900000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ImpairmentOfLeasehold contextRef="c-214" decimals="-5" id="f-682" unitRef="usd">100000</us-gaap:ImpairmentOfLeasehold>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="c-214" decimals="-5" id="f-683" unitRef="usd">100000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-215" decimals="-5" id="f-684" unitRef="usd">38100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-215" decimals="-5" id="f-685" unitRef="usd">11200000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ImpairmentOfLeasehold contextRef="c-215" decimals="-5" id="f-686" unitRef="usd">5000000</us-gaap:ImpairmentOfLeasehold>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-216" decimals="-5" id="f-687" unitRef="usd">4200000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-217" decimals="-5" id="f-688" unitRef="usd">51300000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-218" decimals="-5" id="f-689" unitRef="usd">51300000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <sgmo:EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount contextRef="c-217" decimals="-5" id="f-690" unitRef="usd">6300000</sgmo:EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount>
    <sgmo:EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount contextRef="c-218" decimals="-5" id="f-691" unitRef="usd">6300000</sgmo:EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-6" decimals="-5" id="f-692" unitRef="usd">17600000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-219" decimals="-5" id="f-693" unitRef="usd">13700000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-220" decimals="-5" id="f-694" unitRef="usd">13500000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-695">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 5, 2024, the Company entered into an amendment to the operating lease of office and research and development laboratory facilities in Brisbane, California. The amendment established early termination rights for the landlord upon thirty days&#x2019; notice to the Company, with the earliest date the landlord may terminate the lease being September 30, 2024. Additionally, the amendment authorized the landlord to draw on the existing letter of credit to satisfy the majority of the Company&#x2019;s February 2024 through April 2024 rent payments and obligated the Company to provide a cash security deposit or replenish the letter of credit back to $1.5&#160;million by June 1, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the amendment represented a lease modification to be accounted for as a single contract with the existing lease under ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and remeasured its lease liability using the current incremental borrowing rate of 9.6%, and recorded an adjustment to reduce both the lease liability and the corresponding right-of-use asset by $1.9&#160;million as of the lease modification date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 3, 2024, the Company entered into another amendment to extend the deadline for replenishing the letter of credit to September&#160;30,&#160;2024, the effect of which had no material impact to the Company&#x2019;s financial statements. The letter of credit was replenished during the three months ended September 30, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sgmo:LesseeOperatingLeaseRequiredNoticeOfTermination contextRef="c-221" id="f-696">P30D</sgmo:LesseeOperatingLeaseRequiredNoticeOfTermination>
    <sgmo:LesseeRequiredLetterOfCreditOutstandingAmount contextRef="c-222" decimals="-5" id="f-697" unitRef="usd">1500000</sgmo:LesseeRequiredLetterOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c-222" decimals="3" id="f-698" unitRef="number">0.096</us-gaap:LesseeOperatingLeaseDiscountRate>
    <sgmo:OperatingLeaseRightOfUseAssetModificationReduction contextRef="c-223" decimals="-5" id="f-699" unitRef="usd">1900000</sgmo:OperatingLeaseRightOfUseAssetModificationReduction>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-221" decimals="-5" id="f-700" unitRef="usd">-1900000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-701">STOCK-BASED COMPENSATION&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows total stock-based compensation expense recognized in the accompanying Condensed Consolidated Statements of Operations (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-702">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows total stock-based compensation expense recognized in the accompanying Condensed Consolidated Statements of Operations (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-224" decimals="-3" id="f-703" unitRef="usd">1478000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-225" decimals="-3" id="f-704" unitRef="usd">3236000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-226" decimals="-3" id="f-705" unitRef="usd">4186000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-227" decimals="-3" id="f-706" unitRef="usd">11996000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-228" decimals="-3" id="f-707" unitRef="usd">1837000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-229" decimals="-3" id="f-708" unitRef="usd">2953000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-230" decimals="-3" id="f-709" unitRef="usd">4913000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-231" decimals="-3" id="f-710" unitRef="usd">9260000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-711" unitRef="usd">3315000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-712" unitRef="usd">6189000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-713" unitRef="usd">9099000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-3" id="f-714" unitRef="usd">21256000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-715">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s common stock authorized for issuance was 960,000,000 shares and 640,000,000 shares as of September&#160;30, 2024 and December 31, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At-the-Market Offering Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company entered into an Open Market Sale Agreement&#x2120; with Jefferies LLC (&#x201c;Jefferies&#x201d;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#x2019;s common stock having an aggregate offering price of up to $150.0&#160;million through Jefferies as the Company&#x2019;s sales agent or principal. The Company is not obligated to sell any shares under the sales agreement. In December 2022, the Company entered into an amendment to the Open Market Sale Agreement&#x2120; which increased the aggregate offering price under the at-the-market offering program by an additional $175.0 million. No shares were sold under the sales agreement during the three months ended September&#160;30, 2023. During the nine months ended September&#160;30, 2023, the Company sold 8,249,261 shares of its common stock for net proceeds of approximately $15.1 million. No shares were sold under the sales agreement during the three and nine months ended September&#160;30, 2024. Approximately $194.5&#160;million remained available under the sales agreement as of September&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Issuance and Sale of Common Stock and Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 21, 2024, the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain institutional investors (collectively, the &#x201c;Investors&#x201d;). On March 26, 2024 the Company issued and sold in a registered direct offering (the &#x201c;Registered Direct Offering&#x201d;) an aggregate of 24,761,905 shares of common stock of the Company, par value $0.01 per share, and pre-funded warrants to purchase up to an aggregate of 3,809,523 shares of common stock, together with accompanying warrants (&#x201c;Common Warrants&#x201d;) to purchase up to an aggregate of 28,571,428 shares of common stock. The combined offering price of a unit consisting of one share of common stock and the accompanying Common Warrant to purchase one share of common stock was $0.84. The combined offering price of a unit consisting of a pre-funded warrant to purchase one share of common stock and the accompanying Common Warrant to purchase one share of common stock was $0.83. The pre-funded warrants are immediately exercisable at any time, until exercised in full, at a price of $0.01 per share of common stock. The Common Warrants are exercisable six months from issuance, expire five and a half years from the issuance date and have an exercise price of $1.00 per share. Both pre-funded warrants and Common Warrants can be exercised net in limited circumstances and entitle holders to dividends if and when paid by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Barclays Capital Inc. and Cantor Fitzgerald &amp;amp; Co. (the &#x201c;Placement Agents&#x201d;) acted as the placement agents for the offering, pursuant to a Placement Agency Agreement, dated March 21, 2024 (the &#x201c;Placement Agreement&#x201d;). Pursuant to the Placement Agreement, the Company paid the Placement Agents a cash placement fee equal to 6.0% of the aggregate gross proceeds raised in the Registered Direct Offering. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received aggregate net proceeds from the Registered Direct Offering of $21.9&#160;million, net of the Placement Agents&#x2019; fees of $1.4&#160;million and other offering costs of $0.7&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common Warrants and pre-funded warrants were determined to be equity-classified and proceeds received from their issuance were recorded as a component of stockholders&#x2019; equity within additional paid-in capital. The Company determined that the warrants should be equity classified because they are freestanding financial instruments, do not embody an obligation for the Company to repurchase its shares, do not contain exercise contingencies tied to observable markets or indices, permit the holders to receive a fixed number of shares of common stock upon exercise in exchange for a fixed amount of consideration, subject only to adjustments that are inputs to the fair value of a fixed price/fixed consideration-option, and meet the equity classification criteria. The pre-funded warrants were exercised in full on April 8, 2024 and the Company issued an aggregate of 3,809,523 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares of common stock at an exercise price of $0.01. The Common Warrants had not been exercised and remained outstanding as of September&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-716" unitRef="shares">960000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-717" unitRef="shares">640000000</us-gaap:CommonStockSharesAuthorized>
    <sgmo:StockOfferingProgramMaximumValue contextRef="c-232" decimals="-5" id="f-718" unitRef="usd">150000000</sgmo:StockOfferingProgramMaximumValue>
    <sgmo:SaleOfStockIncreaseToAggregateOfferingPrice contextRef="c-233" decimals="-5" id="f-719" unitRef="usd">175000000.0</sgmo:SaleOfStockIncreaseToAggregateOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-234"
      decimals="INF"
      id="f-720"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-235" decimals="0" id="f-721" unitRef="shares">8249261</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-235" decimals="-5" id="f-722" unitRef="usd">15100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-236"
      decimals="INF"
      id="f-723"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-237"
      decimals="INF"
      id="f-724"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <sgmo:SaleOfStockOutstandingAmountAvailable contextRef="c-238" decimals="-5" id="f-725" unitRef="usd">194500000</sgmo:SaleOfStockOutstandingAmountAvailable>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-239" decimals="0" id="f-726" unitRef="shares">24761905</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-240"
      decimals="INF"
      id="f-727"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-241"
      decimals="INF"
      id="f-728"
      unitRef="shares">3809523</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-242"
      decimals="INF"
      id="f-729"
      unitRef="shares">28571428</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sgmo:SaleOfStockNumberOfSharesIssuedInTransactionPerUnit
      contextRef="c-243"
      decimals="INF"
      id="f-730"
      unitRef="shares">1</sgmo:SaleOfStockNumberOfSharesIssuedInTransactionPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-243"
      decimals="INF"
      id="f-731"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-243"
      decimals="INF"
      id="f-732"
      unitRef="usdPerShare">0.84</us-gaap:SaleOfStockPricePerShare>
    <sgmo:SaleOfStockNumberOfSharesIssuedInTransactionPerUnit
      contextRef="c-244"
      decimals="INF"
      id="f-733"
      unitRef="shares">1</sgmo:SaleOfStockNumberOfSharesIssuedInTransactionPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-244"
      decimals="INF"
      id="f-734"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-244"
      decimals="INF"
      id="f-735"
      unitRef="usdPerShare">0.83</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SharePrice
      contextRef="c-244"
      decimals="2"
      id="f-736"
      unitRef="usdPerShare">0.01</us-gaap:SharePrice>
    <sgmo:WarrantOrRightOutstandingExercisablePeriodAfterIssuance contextRef="c-245" id="f-737">P6M</sgmo:WarrantOrRightOutstandingExercisablePeriodAfterIssuance>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-244"
      decimals="2"
      id="f-738"
      unitRef="usdPerShare">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sgmo:SaleOfStockPlacementFeePercentageOfGrossProceeds contextRef="c-246" decimals="2" id="f-739" unitRef="number">0.060</sgmo:SaleOfStockPlacementFeePercentageOfGrossProceeds>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-246" decimals="-5" id="f-740" unitRef="usd">21900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <sgmo:SaleOfStockAgentPlacementFees contextRef="c-246" decimals="-5" id="f-741" unitRef="usd">1400000</sgmo:SaleOfStockAgentPlacementFees>
    <sgmo:SaleOfStockOtherOfferingCosts contextRef="c-246" decimals="-5" id="f-742" unitRef="usd">700000</sgmo:SaleOfStockOtherOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-247"
      decimals="INF"
      id="f-743"
      unitRef="shares">3809523</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-248"
      decimals="2"
      id="f-744"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-746">RESTRUCTURING CHARGES&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;April 2023 Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 26, 2023, the Company executed a restructuring of operations and a corresponding reduction in workforce (the &#x201c;April 2023 Restructuring&#x201d;), designed to reduce costs and increase focus on certain strategic priorities. The April 2023 Restructuring resulted in the elimination of approximately 110 roles in the United States, or approximately 23% of the total United States workforce. The April 2023 Restructuring resulted in the incurrence of one-time severance payments and other employee-related costs, including additional vesting of service-based stock compensation awards. The Company had estimated that it will incur $5.0&#160;million in expenses related to employee severance and notice period payments, benefits and related restructuring charges for the April 2023 Restructuring. No expenses related to the April 2023 Restructuring were incurred during the three and nine months ended September&#160;30, 2024. No expenses related to the April 2023 Restructuring were incurred during the three months ended September 30, 2023.The Company incurred approximately $5.0&#160;million of expenses related to the April 2023 Restructuring during the nine months ended September&#160;30,&#160;2023, of which $3.8&#160;million is included in research and development expense and $1.2&#160;million is included in general and administrative expense in the accompanying Condensed Consolidated Statements of Operations. The April 2023 Restructuring and the cash payments related thereto are complete as of September 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;November 2023 Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 1, 2023, the Company executed a restructuring of operations and a corresponding reduction in workforce (the &#x201c;November 2023 Restructuring&#x201d;), designed to reduce costs and advance its strategic transformation into a neurology-focused genomic medicine company. The November 2023 Restructuring resulted in the elimination of approximately 162 roles, including 108 full-time employees and 54 contracted employees and eliminated open positions, in the United States, or approximately 40% of the total United States workforce, and included one-time severance payments and other employee-related costs, including additional vesting of service-based stock compensation awards. The total restructuring expenses are estimated to be approximately $8.0 million to $9.0 million, related to employee severance and notice period payments, benefits, Brisbane facility close-out costs, and other related restructuring charges for the November 2023 Restructuring. The Company recorded $6.7 million of expenses relating to the November 2023 Restructuring in the fourth quarter of 2023. The expense adjustments recorded during the three and nine months ended September&#160;30, 2024 were not material. The cash payments relating to employee severance and notice period payments, benefits, other employee-related costs for the November 2023 Restructuring are complete as of September&#160;30, 2024. The Company expects the Brisbane facility close-out costs to be complete by second quarter of 2025, which were previously estimated to be complete by third quarter of 2024. The Company expects to incur estimated costs of $0.9&#160;million to $1.9&#160;million on Brisbane facility close-out costs through the second quarter of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;France Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 1, 2024, the Company&#x2019;s Board of Directors approved the France Restructuring which will result in the elimination of all 93 roles in France, or approximately 24% of the total global workforce. As a result, the Company has terminated its research and development activities in France and is in the process of disposing of its France-based assets and settling the associated liabilities. The Company is also making severance payments as required by French law and the terms of the applicable collective bargaining agreements, and incurring other employee-related costs. The total restructuring expenses are estimated to be approximately $5.3 million to $5.6 million, related to employee severance and notice period payments, benefits, contract termination costs, and other related restructuring charges for the France Restructuring. The Company had recorded $4.7 million of expenses relating to the France restructuring in the fourth quarter of 2023. The expenses incurred during the three and nine months ended September&#160;30, 2024 related to employee severance and notice period payments, benefits, other employee-related costs, and facility shutdown costs were not material. During the three months ended June 30, 2024, the Company recognized $2.4&#160;million as expense relating to a manufacturing agreement for costs that will be incurred without economic benefit to the Company, included in general and administrative expense in the accompanying Condensed Consolidated Statements of Operations. During the three months ended September&#160;30, 2024, the Company reached a settlement relating to the terminated manufacturing agreement and recognized $2.2&#160;million as a reduction to general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations. The Company expects to incur other additional estimated costs of $0.2 million to $0.5 million related to the France Restructuring through the fourth quarter of 2024. The Company expects the France Restructuring and its related cash payments to be substantially complete by the fourth quarter of 2024. See&#160;Note&#160;6&#160;&#x2013;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment and Write-Down of Assets Held For Sale &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for impairment considerations related to the France Restructuring.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of accrued April 2023 Restructuring, November 2023 Restructuring and France Restructuring charges included within other accrued liabilities on the Company&#x2019;s Condensed Consolidated Balance Sheet as of September&#160;30, 2024 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.405%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo may also incur other cash expenses or charges not currently contemplated or estimable due to events that may occur as a result of, or associated with, the November 2023 Restructuring and France Restructuring.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-249"
      decimals="-1"
      id="f-747"
      unitRef="employee">110</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-250" decimals="-5" id="f-748" unitRef="usd">5000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringCharges contextRef="c-251" decimals="INF" id="f-749" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-252" decimals="INF" id="f-750" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-251" decimals="INF" id="f-751" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-252" decimals="INF" id="f-752" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-253" decimals="-5" id="f-753" unitRef="usd">5000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-254" decimals="-5" id="f-754" unitRef="usd">3800000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-255" decimals="-5" id="f-755" unitRef="usd">1200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-256"
      decimals="0"
      id="f-756"
      unitRef="employee">162</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-257"
      decimals="0"
      id="f-757"
      unitRef="employee">108</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-258"
      decimals="0"
      id="f-758"
      unitRef="employee">54</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="c-256" decimals="2" id="f-759" unitRef="number">0.40</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-259" decimals="-5" id="f-760" unitRef="usd">8000000.0</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-260" decimals="-5" id="f-761" unitRef="usd">9000000.0</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringCharges contextRef="c-261" decimals="-5" id="f-762" unitRef="usd">6700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-262" decimals="-5" id="f-763" unitRef="usd">900000</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-263" decimals="-5" id="f-764" unitRef="usd">1900000</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-264"
      decimals="0"
      id="f-765"
      unitRef="employee">93</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="c-264" decimals="2" id="f-766" unitRef="number">0.24</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-265" decimals="-5" id="f-767" unitRef="usd">5300000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-266" decimals="-5" id="f-768" unitRef="usd">5600000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringCharges contextRef="c-267" decimals="-5" id="f-769" unitRef="usd">4700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-268" decimals="-5" id="f-770" unitRef="usd">2400000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-269" decimals="-5" id="f-771" unitRef="usd">2200000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-270" decimals="-5" id="f-772" unitRef="usd">200000</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-271" decimals="-5" id="f-773" unitRef="usd">500000</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-774">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of accrued April 2023 Restructuring, November 2023 Restructuring and France Restructuring charges included within other accrued liabilities on the Company&#x2019;s Condensed Consolidated Balance Sheet as of September&#160;30, 2024 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.405%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringReserve contextRef="c-4" decimals="-3" id="f-775" unitRef="usd">11733000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-3" id="f-776" unitRef="usd">603000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-1" decimals="-3" id="f-777" unitRef="usd">10683000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-3" decimals="-3" id="f-778" unitRef="usd">1653000</us-gaap:RestructuringReserve>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-779">SUBSEQUENT EVENTS&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Transfer to Nasdaq Capital Markets and Compliance with Bid Price Requirement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo&#x2019;s common stock was transferred from Nasdaq Global Market to the Nasdaq Capital Market effective as of the opening of business on October 26, 2024 and has continued to trade under the symbol &#x201c;SGMO.&#x201d;  The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Select Market, and listed companies must meet certain financial requirements and comply with Nasdaq&#x2019;s corporate governance requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the transfer, Sangamo was granted an additional 180-day grace period, or until April 21, 2025, or the Compliance Date, to regain compliance with the bid price requirement set forth in the continued listing requirements of Nasdaq Listing Rule 5450(a)(1) (the &#x201c;Bid Price Requirement&#x201d;). To regain compliance with the Bid Price Requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of Sangamo&#x2019;s common stock must be at least $1.00 for at least ten consecutive business days during the additional 180-day compliance period. On November 5, 2024, Sangamo received a letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC that Sangamo has regained compliance with the Bid Price Requirement.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
